<?xml version="1.0" encoding="UTF-8"?>
<projectSnippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7141330\results\search\drugs\results.xml">
   <result pre="(Peg-IFN-α) and ribavirin. Peg-IFN-α induces a cellular antiviral state and" exact="ribavirin" post="acts in a synergistic manner through different mechanisms. Two"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7142690\results\search\drugs\results.xml">
   <result pre="patients had baseline immunosuppression withdrawn. In 19 of 20 cases," exact="methylprednisolone" post="16 mg daily was added and antiviral therapy (lopinavir"/>
   <result pre="mg daily was added and antiviral therapy (lopinavir plus ritonavir," exact="darunavir" post="plus ritonavir, or darunavir plus cobicistat) and hydroxychloroquine commenced."/>
   <result pre="and antiviral therapy (lopinavir plus ritonavir, darunavir plus ritonavir, or" exact="darunavir" post="plus cobicistat) and hydroxychloroquine commenced. In a subgroup of"/>
   <result pre="plus ritonavir, darunavir plus ritonavir, or darunavir plus cobicistat) and" exact="hydroxychloroquine" post="commenced. In a subgroup of 6 patients, the humanized"/>
   <result pre="subgroup of 6 patients, the humanized anti–interleukin-6 receptor monoclonal antibody" exact="tocilizumab" post="was also added (see their Table 2 and Supplementary"/>
   <result pre="(see their Table 2 and Supplementary Material2). The choice of" exact="lopinavir" post="+ ritonavir was made to target viral replication in"/>
   <result pre="Table 2 and Supplementary Material2). The choice of lopinavir +" exact="ritonavir" post="was made to target viral replication in combination with"/>
   <result pre="logical therapeutic interventions and use of supportive antibiotics (noting that" exact="azithromycin" post="was not given as has been suggested by others"/>
   <result pre="risks because prolongation of the cardiac QTc interval by both" exact="hydroxychloroquine" post="and lopinavir plus ritonavir have been reported. More importantly,"/>
   <result pre="prolongation of the cardiac QTc interval by both hydroxychloroquine and" exact="lopinavir" post="plus ritonavir have been reported. More importantly, a recently"/>
   <result pre="the cardiac QTc interval by both hydroxychloroquine and lopinavir plus" exact="ritonavir" post="have been reported. More importantly, a recently published trial"/>
   <result pre="have been reported. More importantly, a recently published trial of" exact="lopinavir" post="plus ritonavir found no significant benefits in terms of"/>
   <result pre="reported. More importantly, a recently published trial of lopinavir plus" exact="ritonavir" post="found no significant benefits in terms of viral clearance"/>
   <result pre="managed in the community with this approach. The use of" exact="hydroxychloroquine" post="in the patients in Italy did not seem to"/>
   <result pre="these fascinating first experiences. Other strategies including switch therapies from" exact="tacrolimus" post="to cyclosporine (with its known in vitro antiviral effect)"/>
   <result pre="first experiences. Other strategies including switch therapies from tacrolimus to" exact="cyclosporine" post="(with its known in vitro antiviral effect) are potential"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7143200\results\search\drugs\results.xml">
   <result pre="recovered and have been discharged from hospital. The efficacy of" exact="tocilizumab" post="in treating patients with COVID-19 who develop ARDS needs"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7143239\results\search\drugs\results.xml">
   <result pre="23-dihydroavermectin B1a; Abcam, Cambridge, UK) stock solution was prepared in" exact="dimethyl sulfoxide" post="(DMSO) at 50 mM and stored in aliquots at"/>
   <result pre="virus in vitro and vivoAntivir. Res.2018159556210.1016/j.antiviral.2018.09.01030266338 23.YangS.N.Y.AtkinsonS.C.WangC.LeeA.BogoyevitchM.A.BorgN.A.JansD.A.The broad spectrum antiviral" exact="ivermectin" post="targets the host nuclear transport importin alpha/beta1 heterodimerAntivir. Res.202010476010.1016/j.antiviral.2020.10476032135219"/>
   <result pre="lifecycle and innate immunityAnim. Health Res. Rev.2013148810210.1017/S146625231300004223800429 32.XuT.L.HanY.LiuW.PangX.Y.ZhengB.ZhangY.ZhouX.N.Antivirus effectiveness of" exact="ivermectin" post="on dengue virus type 2 in Aedes albopictusPLoS Negl."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7144238\results\search\drugs\results.xml">
   <result pre="at Institut Pasteur of Shanghai. Mice were anesthetized with 80 mg/Kg" exact="pentobarbital" post="sodium dissolved in phosphate-buffered saline (PBS) by intraperitoneal injection."/>
   <result pre="GCCCTTTGCGTTATATTGTAT. Histology After mice were anesthetized and sacrificed with 80 mg/Kg" exact="pentobarbital" post="sodium, the chest and abdomen were rapidly opened. The"/>
   <result pre="applying autophagy inhibitors, LY294002 (Figure 6(A)), 3-MA (Figure 6(B)) and" exact="chloroquine" post="(CQ) (Figure 6(C)). As previously reported, our results also"/>
   <result pre="an increasing dose of LY294002 (A) or 3-MA (B) or" exact="chloroquine" post="(C) or Rapamycin (D) for 30 min and then mock-infected"/>
   <result pre="by the US Food and Drug Administration (FDA); oseltamivir, zanamivir," exact="amantadine" post="and rimantadine, these drugs mainly target two of the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7144376\results\search\drugs\results.xml">
   <result pre="assays. Cytotoxicity and antiviral activity were evaluated in parallel, using" exact="ribavirin" post="as a reference inhibitor. The inhibitory activities of all"/>
   <result pre="were comparable or better than those of the control compound," exact="ribavirin" post="(Table 1). Notably, compounds W2, W6, W9, W10, W13,"/>
   <result pre="comparison, the maximum inhibition values of CVB3 and ADV7 by" exact="ribavirin" post="were 63.0% and 72.4%, respectively, indicating that the compounds"/>
   <result pre="of compounds W9, W13, and W15 were further investigated, using" exact="ribavirin" post="as a positive control drug. To this end, confluent"/>
   <result pre="W-9, 160 μM W-13, 160 μM W-15, or 160 μM" exact="ribavirin" post="for 2 h at 37 °C. Subsequently, viral titers"/>
   <result pre="CVB3 infection were further investigated by three different approaches, using" exact="ribavirin" post="as a positive control. Antiviral effects against CVB3 were"/>
   <result pre="which were comparable or superior therapeutic effects to those of" exact="ribavirin" post="(8.3 for CVB3 and 7.1 for ADV7), suggesting that"/>
   <result pre="in experiments to determine their antiviral mechanisms of action. Although" exact="ribavirin" post="was discovered in 1972, its mechanism of action has"/>
   <result pre="action have been proposed for ribavirin, including: (a) inhibition of" exact="inosine" post="monophosphate dehydrogenase [39]; (b) inhibition of proinflammatory mediators induced"/>
   <result pre="whole viral RNA genomes [41]. All these theories indicate that" exact="ribavirin" post="plays a role in the process of virus replication"/>
   <result pre="our laboratory [25]. Stock solutions of drugs were prepared in" exact="dimethyl sulfoxide" post="at a final concentration of 0.1% and diluted with"/>
   <result pre="W-9, 160 μM W-13, 160 μM W-15, or 160 μM" exact="ribavirin" post="after infection with 100 TCID50 of CVB3. Supernatants and"/>
   <result pre="W-9, 160 μM W-13, 160 μM W-15, or 160 μM" exact="ribavirin" post="were added for different time periods (−1–0, 0–10, 2–10,"/>
   <result pre="Cell Death in Coxsackievirus-B3 InfectionJ. Microbiol. Biotechnol.20182810911410.4014/jmb.1708.0800929032641 7.ZhangY.Y.LiJ.Y.XiaH.H.X.ZhangS.L.ZhongJ.WuY.Y.MiaoS.K.ZhouL.M.Protective effects of" exact="losartan" post="in mice with chronic viral myocarditis induced by coxsackievirus"/>
   <result pre="antiviral activity of the IMP dehydrogenase inhibitor VX-497—a comparison with" exact="ribavirin" post="and demonstration of antiviral additivity with alpha interferonAntimicrob. Agents"/>
   <result pre="W-9, 160 μM W-13, 160 μM W-15, or 160 μM" exact="ribavirin" post="for 36 h, and the culture media and cell"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7145936\results\search\drugs\results.xml">
   <result pre="pneumocytes; dysbalance in ACE2 as caused by ACE inhibitors or" exact="ibuprofen" post="may predispose to severe disease. Preliminary evidence suggests potential"/>
   <result pre="predispose to severe disease. Preliminary evidence suggests potential benefit with" exact="chloroquine" post="or hydroxychloroquine. Antiviral drugs like lopinavir/ritonavir, favipiravir and remdesivir"/>
   <result pre="understand the role of drugs commonly used in rheumatology like" exact="hydroxychloroquine" post="and tocilizumab in COVID-19. • Until further evidence emerges,"/>
   <result pre="role of drugs commonly used in rheumatology like hydroxychloroquine and" exact="tocilizumab" post="in COVID-19. • Until further evidence emerges, it may"/>
   <result pre="subjects contracting the virus [19]. Also, angiotensin II receptor antagonist" exact="losartan" post="is postulated to exert a protective action [19]. At"/>
   <result pre="school of thought that the commonly used non-steroidal anti-inflammatory drug" exact="ibuprofen" post="is believed to increase the expression of ACE2 [6]"/>
   <result pre="Such a belief is based on anecdotal reports, pointing to" exact="paracetamol" post="as a safer option for those in need of"/>
   <result pre="to rely on specific circumstances and, if possible, avoid using" exact="ibuprofen" post="during this pandemic. Fig. 1 Potential therapeutic targets for"/>
   <result pre="such as remdesivir [24] and favipiravir [25] and protease inhibitors" exact="lopinavir" post="and ritonavir [26] affect intracellular virion assembly, and there"/>
   <result pre="remdesivir [24] and favipiravir [25] and protease inhibitors lopinavir and" exact="ritonavir" post="[26] affect intracellular virion assembly, and there remains a"/>
   <result pre="A recent open-label, randomized, controlled trial evaluated the role of" exact="lopinavir" post="and ritonavir in 199 COVID-19 patients with hypoxemia (99"/>
   <result pre="open-label, randomized, controlled trial evaluated the role of lopinavir and" exact="ritonavir" post="in 199 COVID-19 patients with hypoxemia (99 treated with"/>
   <result pre="interacts with toll-like receptors (TLR) to stimulate downstream inflammatory pathways;" exact="chloroquine" post="and hydroxychloroquine use interferes with endosomal acidification and inhibits"/>
   <result pre="toll-like receptors (TLR) to stimulate downstream inflammatory pathways; chloroquine and" exact="hydroxychloroquine" post="use interferes with endosomal acidification and inhibits such TLR"/>
   <result pre="and 23 ongoing trials in China supported the notion that" exact="chloroquine" post="limits the replication of SARS-CoV-2 [34]. Preliminary reports suggest"/>
   <result pre="limits the replication of SARS-CoV-2 [34]. Preliminary reports suggest that" exact="chloroquine" post="and hydroxychloroquine are probably equally beneficial in COVID-19 and"/>
   <result pre="replication of SARS-CoV-2 [34]. Preliminary reports suggest that chloroquine and" exact="hydroxychloroquine" post="are probably equally beneficial in COVID-19 and that a"/>
   <result pre="for a long period [35]. A recent clinical trial evaluated" exact="hydroxychloroquine" post="(with or without azathioprine) versus placebo in severe COVID-19"/>
   <result pre="Also, concerns exist regarding the potential for cardiac arrhythmias with" exact="chloroquine" post="(and its analogs) as well as with azithromycin and"/>
   <result pre="arrhythmias with chloroquine (and its analogs) as well as with" exact="azithromycin" post="and protease inhibitors; hence, due care and careful monitoring"/>
   <result pre="combination [37]. Nevertheless, the rationale driving the potential benefits with" exact="hydroxychloroquine" post="merits its exploration as a therapeutic agent in COVID-19."/>
   <result pre="in COVID-19. Another suggestion has been to provide prophylaxis with" exact="hydroxychloroquine" post="(400 mg twice daily for a day, followed by"/>
   <result pre="such prophylactic therapy in COVID-19. The exact clinical scenarios where" exact="chloroquine" post="or hydroxychloroquine may be useful in COVID-19 remain to"/>
   <result pre="therapy in COVID-19. The exact clinical scenarios where chloroquine or" exact="hydroxychloroquine" post="may be useful in COVID-19 remain to be ascertained,"/>
   <result pre="may respond to immunosuppressive agents used for HLH such as" exact="tocilizumab" post="(IL-6 blockade) and anakinra (IL-1 blockade) [15]. A recent"/>
   <result pre="agents used for HLH such as tocilizumab (IL-6 blockade) and" exact="anakinra" post="(IL-1 blockade) [15]. A recent pre-print retrospectively evaluated the"/>
   <result pre="retrospectively evaluated the use of a single dose of intravenous" exact="tocilizumab" post="400 mg in 21 patients with COVID-19 from China"/>
   <result pre="trials are further evaluating the role of IL-6 blockade with" exact="tocilizumab" post="and sarilumab in severe COVID-19; the former drug is"/>
   <result pre="in China for this indication [42, 43]. Cepharanthine, selamectine and" exact="mefloquine" post="hydrochloride are other drugs that have been demonstrated to"/>
   <result pre="vitamin C. Viremic phase Antiviral drugs (lopinavir/ritonavir, favipiravir, remdesivir), chloroquine," exact="hydroxychloroquine" post="Cytokine storm phase Tocilizumab, sarilumab, baricitinib. Considerations for patients"/>
   <result pre="drugs agency to review safety of ibuprofen. 368:m1168. 10.1136/bmj.m1168 22.DayMCovid-19:" exact="ibuprofen" post="should not be used for managing symptoms, say doctors"/>
   <result pre="by a clinically proven protease inhibitor. Cell. 10.1016/j.cell.2020.02.052 24.WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="Antimicrob Agents20205510592310.1016/j.ijantimicag.2020.10592332070753 32.Gao J, Tian Z, Yang X (2020) Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="in clinical studies. Biosci Trends. 10.5582/bst.2020.01047 33.SchrezenmeierEDörnerTMechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatologyNat Rev Rheumatol20201615516610.1038/s41584-020-0372-x32034323 34.Cortegiani A,"/>
   <result pre="(2020) A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19. J Crit Care. 10.1016/j.jcrc.2020.03.005"/>
   <result pre="JM, Lagier JC, Brouqui P, Raoult D (2020) Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19. Int J Antimicrob"/>
   <result pre="P, Lagier J-C, Parola P et al (2020) Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="05 March 2020. Accesed on 29 Mar 2020 42.Approval for" exact="tocilizumab" post="use in severe Covid-19 in China. https://www.pharmaceutical-technology.com/news/roche-actemra-coronavirus-complications/. Updated 05"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7146685\results\search\drugs\results.xml">
   <result pre="(%)a COVID-19 western medicine treatment Antiviral drugs Abidol hydrochloride tablets," exact="oseltamivir" post="phosphate capsules 2 (4) Antibacterial drugs Moxifloxacin tablets (2"/>
   <result pre="phosphate capsules 2 (4) Antibacterial drugs Moxifloxacin tablets (2 brands)," exact="levofloxacin" post="tablets, cefdinir capsules 4 (8) Antipyretic and analgesic drugs"/>
   <result pre="2 (4) Antibacterial drugs Moxifloxacin tablets (2 brands), levofloxacin tablets," exact="cefdinir" post="capsules 4 (8) Antipyretic and analgesic drugs Ibuprofen tablets,"/>
   <result pre="cefdinir capsules 4 (8) Antipyretic and analgesic drugs Ibuprofen tablets," exact="diclofenac" post="sodium sustained release tablets 2 (4) Antitussive, antiasthmatic, and"/>
   <result pre="(4) Antitussive, antiasthmatic, and expectorant drugs Aminophylline sustained release tablets," exact="aminophylline" post="injection, acetylcysteine tablets, fudosteine tablets 4 (8) Digestive system"/>
   <result pre="antiasthmatic, and expectorant drugs Aminophylline sustained release tablets, aminophylline injection," exact="acetylcysteine" post="tablets, fudosteine tablets 4 (8) Digestive system drugs Esomeprazole"/>
   <result pre="disease drugs Cardiovascular and cerebrovascular drugs Nifedipine sustained release tablets," exact="nifedipine" post="controlled release tablets, nitroglycerin injection, amlodipine besylate tablets, levamlodipine"/>
   <result pre="cerebrovascular drugs Nifedipine sustained release tablets, nifedipine controlled release tablets," exact="nitroglycerin" post="injection, amlodipine besylate tablets, levamlodipine besylate tablets, perindopril tablets,"/>
   <result pre="Nifedipine sustained release tablets, nifedipine controlled release tablets, nitroglycerin injection," exact="amlodipine" post="besylate tablets, levamlodipine besylate tablets, perindopril tablets, clopidogrel bisulfate"/>
   <result pre="tablets, nifedipine controlled release tablets, nitroglycerin injection, amlodipine besylate tablets," exact="levamlodipine" post="besylate tablets, perindopril tablets, clopidogrel bisulfate tablets, metoprolol succinate"/>
   <result pre="release tablets, nitroglycerin injection, amlodipine besylate tablets, levamlodipine besylate tablets," exact="perindopril" post="tablets, clopidogrel bisulfate tablets, metoprolol succinate sustained release tablets,"/>
   <result pre="nitroglycerin injection, amlodipine besylate tablets, levamlodipine besylate tablets, perindopril tablets," exact="clopidogrel" post="bisulfate tablets, metoprolol succinate sustained release tablets, amiodarone injection,"/>
   <result pre="besylate tablets, levamlodipine besylate tablets, perindopril tablets, clopidogrel bisulfate tablets," exact="metoprolol" post="succinate sustained release tablets, amiodarone injection, furosemide injection 10"/>
   <result pre="perindopril tablets, clopidogrel bisulfate tablets, metoprolol succinate sustained release tablets," exact="amiodarone" post="injection, furosemide injection 10 (20) Lipid-lowering drugs Atorvastatin calcium"/>
   <result pre="clopidogrel bisulfate tablets, metoprolol succinate sustained release tablets, amiodarone injection," exact="furosemide" post="injection 10 (20) Lipid-lowering drugs Atorvastatin calcium tablets 1"/>
   <result pre="hypnotic drugs Estazolam tablets 1 (2) Antiallergic drugs Desloratadine tablet," exact="chlorphenamine" post="tablet, promethazine injection 3 (6) Chinese patent drugs Jinhua"/>
   <result pre="Estazolam tablets 1 (2) Antiallergic drugs Desloratadine tablet, chlorphenamine tablet," exact="promethazine" post="injection 3 (6) Chinese patent drugs Jinhua qinggan granule,"/>
   <result pre="(14) Critical care drugs Dopamine hydrochloride injection, adrenaline hydrochloride injection," exact="isoprenaline" post="hydrochloride injection, atropine sulfate injection, deacetylated hairy anthocyanin injection,"/>
   <result pre="drugs Dopamine hydrochloride injection, adrenaline hydrochloride injection, isoprenaline hydrochloride injection," exact="atropine" post="sulfate injection, deacetylated hairy anthocyanin injection, pedicel alkaloid injection,"/>
   <result pre="pedicel alkaloid injection, Nikethamide injection, hydroxyethyl starch 130/0.4 electrolyte injection," exact="dexamethasone" post="injection 9 (18) Abbreviation used: COVID-19, coronavirus disease 2019."/>
   <result pre="with antipyretic and analgesic drugs in Western medicine, such as" exact="paracetamol" post="and aspirin, which may cause excessive sweating or even"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7146719\results\search\drugs\results.xml">
   <result pre="by dermatologists are being examined in the fight against COVID-19:" exact="hydroxychloroquine" post="(HCQ), and, very recently, ivermectin. We hypothesize that HCQ"/>
   <result pre="(HCQ), and, very recently, ivermectin. We hypothesize that HCQ and" exact="ivermectin" post="may show a consequential and synergistic action if administered"/>
   <result pre="of COVID-19. HCQ is an antimalarial drug, an analog of" exact="chloroquine" post="(CQ), considered as an immunomodulator rather than immunosuppressant.1 HCQ"/>
   <result pre="in vitro, with HCQ found to be more potent than" exact="chloroquine" post="(CQ).2 HCQ has shown antiviral effects at both preinfection"/>
   <result pre="larva migrans. Interestingly, it also displayed an antiviral activity. Indeed," exact="ivermectin" post="acts as a specific inhibitor of importin-α/β–mediated nuclear import."/>
   <result pre="Thus, by impacting on importin-α/β–dependent nuclear transport of viral proteins," exact="ivermectin" post="suppresses the replication of several RNA viruses, including HIV,"/>
   <result pre="virus.3 Very recently, Caly et al4 demonstrated antiviral action of" exact="ivermectin" post="against the SARS-CoV-2 clinical isolate in vitro, with a"/>
   <result pre="as shown for other RNA viruses.4 However, no study with" exact="ivermectin" post="in vivo has been conducted. Based on all such"/>
   <result pre="Based on all such evidence, we hypothesize that HCQ and" exact="ivermectin" post="could act in a consequential and synergistic manner. Indeed,"/>
   <result pre="the entry of the virus into the host cell, while" exact="ivermectin" post="could reduce viral replication if the virus did get"/>
   <result pre="have been conducted on the combined effect of HCQ and" exact="ivermectin" post="on SARS-CoV-2 infection. Ours is only a hypothesis and"/>
   <result pre="References References 1ZhouD.DaiS.M.TongQ.COVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progressionJ Antimicrob Chemother2020dkaa11432196083 2YaoX.YeF.ZhangM.In vitro"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="the virus in vitro and vivoAntiviral Res1592018556230266338 4CalyL.DruceJ.D.CattonM.G.JansD.A.WagstaffK.M.The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntiviral Res202010.1016/j.antiviral.2020.104787 5Sanz-NavarroJ.FealC.DaudenE.Treatment"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7147535\results\search\drugs\results.xml">
   <result pre="are being studied in clinical trials, including antiviral agents and" exact="hydroxychloroquine" post="[12–14]; widespread uptake of the latter has resulted in"/>
   <result pre="Janus kinase inhibitors, anti-IL-1 agents, and anti-IL-6 drugs such as" exact="tocilizumab" post="[17, 18]. Several cutaneous immune-mediated diseases, including psoriasis, atopic"/>
   <result pre="that modulate T helper (Th)-1 responses, such as TNFα inhibitors" exact="abatacept" post="and ustekinumab, might specifically require more stringent precautions [28]."/>
   <result pre="penetration of SARS-CoV2 into the cell [36]. A study evaluating" exact="adalimumab" post="in COVID-19 infection has recently been registered in the"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="Infect Dis.202010.1093/cid/ciaa23732161968 14.ZhouDDaiS-MTongQCOVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progressionJ Antimicrob Chemother.202010.1093/jac/dkaa11432196083 15.KimAHJSparksJALiewJWet al.A"/>
   <result pre="dissemination of results and its consequences regarding the use of" exact="hydroxychloroquine" post="for COVID-19Ann Intern Med202010.7326/M20-122332271869 16.ZhangWZhaoYZhangFet al.The use of anti-inflammatory"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7148001\results\search\drugs\results.xml">
   <result pre="Results We treated and cured our &quot;particularly difficult-to-cure�? patient with" exact="sofosbuvir" post="plus glecaprevir/pibrentasvir plus ribavirin for 24 weeks. We discuss"/>
   <result pre="cured our &quot;particularly difficult-to-cure�? patient with sofosbuvir plus glecaprevir/pibrentasvir plus" exact="ribavirin" post="for 24 weeks. We discuss the literature on potential"/>
   <result pre="either the addition of active agents (other DAA classes and/or" exact="ribavirin" post="[RBV]), using longer treatment courses, or both. With these"/>
   <result pre="sharing of injection equipment. Treatment with pegylated interferon (IFN) plus" exact="ribavirin" post="(RBV) was attempted in 2007, but was stopped after"/>
   <result pre="treatment to 24 weeks of SOF/VEL with the addition of" exact="ribavirin" post="was more effective, curing 36/37 (97%) of those with"/>
   <result pre="Hepat2014; 21:229–40.24597691 9.NaggieS, CooperC, SaagM, et al.collab: ION-4 InvestigatorsLedipasvir and" exact="sofosbuvir" post="for HCV in patients coinfected with HIV-1. N Engl"/>
   <result pre="Abstract O005. 12.GaneEJ, ShiffmanML, EtzkornK, et al.collab: GS-US-342-1553 InvestigatorsSofosbuvir-velpatasvir with" exact="ribavirin" post="for 24 weeks in hepatitis C virus patients previously"/>
   <result pre="al.collab: AIDS Clinical Trials Group A5071 Study TeamPeginterferon Alfa-2a plus" exact="ribavirin" post="versus interferon alfa-2a plus ribavirin for chronic hepatitis C"/>
   <result pre="A5071 Study TeamPeginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus" exact="ribavirin" post="for chronic hepatitis C in HIV-coinfected persons. N Engl"/>
   <result pre="29.TorrianiFJ, Rodriguez-TorresM, RockstrohJK, et al.collab: APRICOT Study GroupPeginterferon Alfa-2a plus" exact="ribavirin" post="for chronic hepatitis C virus infection in HIV-infected patients."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7148677\results\search\drugs\results.xml">
   <result pre="times per day)�? are added as trial drugs. Combinations of" exact="ribavirin" post="and interferon or lopinavir/ritonavir are recommended. The course of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7148789\results\search\drugs\results.xml">
   <result pre="against cytomegalovirus, has been associated with bronchiolitis obliterans. Aciclovir and" exact="valaciclovir" post="has been reported with renal insufficiency. Adefovir , a"/>
   <result pre="and protease inhibitors. In a randomized controlled trial of indinavir," exact="saquinavir" post="and lopinavir in combination with low-dose ritonavir in 656"/>
   <result pre="inhibitors. In a randomized controlled trial of indinavir, saquinavir and" exact="lopinavir" post="in combination with low-dose ritonavir in 656 patients, median"/>
   <result pre="trial of indinavir, saquinavir and lopinavir in combination with low-dose" exact="ritonavir" post="in 656 patients, median total cholesterol increased by 0.5"/>
   <result pre="dementia complex taking optimal stable background antiretroviral therapy including either" exact="abacavir" post="or placebo, there was significantly more nausea in those"/>
   <result pre="Of six hemopoietic stem cell transplant recipients, who were given" exact="cidofovir" post="5 mg/kg/week for 2 weeks, then on alternate weeks"/>
   <result pre="under 100 × 106/l. The patients were pre-hydrated and given" exact="probenecid" post="and intravenous immunoglobulin 1–2 g/kg/week followed by 0.5 mg/kg"/>
   <result pre="given a mean of 4.5 (range 3–6) weekly doses of" exact="cidofovir" post="1 mg/kg without probenecid for BK virus-associated hemorrhagic cystitis,"/>
   <result pre="4.5 (range 3–6) weekly doses of cidofovir 1 mg/kg without" exact="probenecid" post="for BK virus-associated hemorrhagic cystitis, 84% had graft-versus-host disease"/>
   <result pre="there were other potential causes. In only 3 cases could" exact="cidofovir" post="have played a role. In those with normal renal"/>
   <result pre="role. In those with normal renal function, 80–100% of the" exact="cidofovir" post="was recovered from the urine, raising the possibility of"/>
   <result pre="Reports of renal insufficiency associated with the use of intravenous" exact="aciclovir" post="continue to appear (6A). In a retrospective review of"/>
   <result pre="kilogram, age, or sex on nephrotoxicity (7c). The predictors of" exact="aciclovir" post="nephrotoxicity were the concomitant use of nephrotoxic drugs and"/>
   <result pre="baseline. Fetotoxicity It has been suggested that maternal use of" exact="aciclovir" post="may be associated with necrotizing enterocolitis in the neonate"/>
   <result pre="the neonate (8A). Valaciclovir Immunologic An acute allergic reaction to" exact="valaciclovir" post="has been described (9A). •A 50-year-old woman developed general"/>
   <result pre="and reduced consciousness and faintness within 5 minutes of taking" exact="valaciclovir" post="500 mg for genital herpes. Skin prick tests for"/>
   <result pre="valaciclovir 500 mg for genital herpes. Skin prick tests for" exact="aciclovir" post="were positive. Urinary tract As with aciclovir, renal insufficiency"/>
   <result pre="tract As with aciclovir, renal insufficiency has been reported with" exact="valaciclovir" post="(10A) •A 73-year-old Japanese man with cardiomyopathy and chronic"/>
   <result pre="admitted with anuria, systemic edema, and renal dysfunction after taking" exact="valaciclovir" post="1 g tds 5 days for Herpes zoster infection"/>
   <result pre="10 mg alone (n = 14) or in combination with" exact="lamivudine" post="(n = 28) caused a fall in creatinine clearance"/>
   <result pre="was not statistically significant. Adefovir 10 mg/day in combination with" exact="lamivudine" post="300 mg/day has been used in 11 patients with"/>
   <result pre="underwent a period of preoperative treatment and peri-operative prophylaxis with" exact="lamivudine" post="and hepatitis B immunoglobulin with or without adefovir if"/>
   <result pre="in nine subjects and dysmenorrhea in two when they took" exact="entecavir" post="alone. Amantadine See ‘Drugs active against influenza viruses: ion"/>
   <result pre="in nine subjects and dysmenorrhea in two when they took" exact="entecavir" post="alone. Lamivudine (SED-15, 1989, SEDA-30, 344; SEDA-31, 480) Observational"/>
   <result pre="480) Observational studies In 33 treatment-naive HBeAg-positive children who took" exact="lamivudine" post="and high-dose interferon alpha 2a combination therapy, flu-like symptoms"/>
   <result pre="noted (14c). In an open study of the pharmacokinetics of" exact="lamivudine" post="in 12 patients receiving peritoneal dialysis, eye redness (n"/>
   <result pre="studies In a double-blind, Phase III, randomized, controlled trial of" exact="lamivudine" post="100 mg/day (n = 687) versus telbivudine 600 mg/day"/>
   <result pre="controlled trial of lamivudine 100 mg/day (n = 687) versus" exact="telbivudine" post="600 mg/day (n = 680), creatine kinase activity was"/>
   <result pre="= 680), creatine kinase activity was raised in patients receiving" exact="lamivudine" post="(3.1%) and telbivudine (7.5%) and fell spontaneously during drug"/>
   <result pre="kinase activity was raised in patients receiving lamivudine (3.1%) and" exact="telbivudine" post="(7.5%) and fell spontaneously during drug treatment to grade"/>
   <result pre="to grade 2 or lower in 74% of those taking" exact="lamivudine" post="and 67% of those taking telbivudine (16C). Grade 3"/>
   <result pre="74% of those taking lamivudine and 67% of those taking" exact="telbivudine" post="(16C). Grade 3 or 4 rises in transaminases during"/>
   <result pre="4 rises in transaminases during treatment were more frequent with" exact="lamivudine" post="than with telbivudine. Ribavirin Observational studies High-dose ribavirin during"/>
   <result pre="frequent with lamivudine than with telbivudine. Ribavirin Observational studies High-dose" exact="ribavirin" post="during an outbreak of severe acute respiratory syndrome in"/>
   <result pre="(17c). The risks of anemia, hypomagnesemia, and bradycardia attributable to" exact="ribavirin" post="were 27%, 45%, and 17% respectively. The authors concluded"/>
   <result pre="17% respectively. The authors concluded that the use of high-dose" exact="ribavirin" post="is appropriate only for the treatment of infectious diseases"/>
   <result pre="appropriate only for the treatment of infectious diseases for which" exact="ribavirin" post="has proven clinical efficacy, or in the context of"/>
   <result pre="the context of a clinical trial. They further stated that" exact="ribavirin" post="should not be used empirically for the treatment of"/>
   <result pre="areas of drug contact and conjunctival irritation occurred when aerosolized" exact="ribavirin" post="was used for 10 months in an infant with"/>
   <result pre="Musculoskeletal In a double-blind, Phase III, randomized, controlled trial of" exact="lamivudine" post="100 mg/day (n = 687) versus telbivudine 600 mg/day"/>
   <result pre="controlled trial of lamivudine 100 mg/day (n = 687) versus" exact="telbivudine" post="600 mg/day (n = 680), raised creatine kinase activity"/>
   <result pre="creatine kinase activity was more common in patients who took" exact="telbivudine" post="and it fell spontaneously during drug treatment to grade"/>
   <result pre="grade 2 or lower in 67% of those who took" exact="telbivudine" post="and 74% of those who took lamivudine. Myopathy (characterized"/>
   <result pre="before and during treatment) was reported in one patient after" exact="telbivudine" post="therapy for 11 months. When telbivudine was withdrawn, the"/>
   <result pre="in one patient after telbivudine therapy for 11 months. When" exact="telbivudine" post="was withdrawn, the creatine kinase activity normalized within 1"/>
   <result pre="Syncope occurred in a young man after he took tenofovir," exact="emtricitabine" post="and nevirapine for primary human immunodeficiency virus-1 (HIV-1) infection"/>
   <result pre="in a young man after he took tenofovir, emtricitabine and" exact="nevirapine" post="for primary human immunodeficiency virus-1 (HIV-1) infection for 6"/>
   <result pre="in a trial in which 96 patients were randomized to" exact="didanosine" post="+ stavudine or zidovudine + lamivudine, combined with efavirenz"/>
   <result pre="trial in which 96 patients were randomized to didanosine +" exact="stavudine" post="or zidovudine + lamivudine, combined with efavirenz and/or nelfinavir"/>
   <result pre="which 96 patients were randomized to didanosine + stavudine or" exact="zidovudine" post="+ lamivudine, combined with efavirenz and/or nelfinavir in AIDS"/>
   <result pre="to didanosine + stavudine or zidovudine + lamivudine, combined with" exact="efavirenz" post="and/or nelfinavir in AIDS Clinical Trials Group (ACTG) 384"/>
   <result pre="+ stavudine or zidovudine + lamivudine, combined with efavirenz and/or" exact="nelfinavir" post="in AIDS Clinical Trials Group (ACTG) 384 sub-study A5005s"/>
   <result pre="favorable effect on lipid profile and caused more lipoatrophy than" exact="abacavir" post="(38% versus 4.8%) in a randomized, open trial, stratified"/>
   <result pre="in which 237 adults with HIV infection were assigned to" exact="stavudine" post="(n = 122) or abacavir (n = 115), both"/>
   <result pre="HIV infection were assigned to stavudine (n = 122) or" exact="abacavir" post="(n = 115), both combined with lamivudine and efavirenz"/>
   <result pre="= 122) or abacavir (n = 115), both combined with" exact="lamivudine" post="and efavirenz (21C). There were dose-related increases in total"/>
   <result pre="or abacavir (n = 115), both combined with lamivudine and" exact="efavirenz" post="(21C). There were dose-related increases in total cholesterol, LDL"/>
   <result pre="after withdrawal (22c). In a randomized controlled trial of indinavir," exact="saquinavir" post="and lopinavir in combination with low-dose ritonavir in 656"/>
   <result pre="(22c). In a randomized controlled trial of indinavir, saquinavir and" exact="lopinavir" post="in combination with low-dose ritonavir in 656 patients, median"/>
   <result pre="trial of indinavir, saquinavir and lopinavir in combination with low-dose" exact="ritonavir" post="in 656 patients, median total cholesterol increased by 0.5"/>
   <result pre="active antiretroviral therapy (HAART), 27 of 50 patients who took" exact="indinavir" post="in combination with zidovudine and lamivudine developed nausea and"/>
   <result pre="27 of 50 patients who took indinavir in combination with" exact="zidovudine" post="and lamivudine developed nausea and were significantly more likely"/>
   <result pre="50 patients who took indinavir in combination with zidovudine and" exact="lamivudine" post="developed nausea and were significantly more likely to stop"/>
   <result pre="to stop taking the treatment than those who were taking" exact="zidovudine" post="+ lamivudine + tenofovir (24c). In a long-term follow-up"/>
   <result pre="taking the treatment than those who were taking zidovudine +" exact="lamivudine" post="+ tenofovir (24c). In a long-term follow-up study of"/>
   <result pre="treatment than those who were taking zidovudine + lamivudine +" exact="tenofovir" post="(24c). In a long-term follow-up study of 200 asymptomatic"/>
   <result pre="21 of 151 patients in a prospective study of once-daily" exact="saquinavir" post="+ ritonavir and two nucleoside reverse transcriptase inhibitors (NRTIs)"/>
   <result pre="151 patients in a prospective study of once-daily saquinavir +" exact="ritonavir" post="and two nucleoside reverse transcriptase inhibitors (NRTIs) were abdominal"/>
   <result pre="to achieve a sustained viral response, NRTI therapy, didanosine, and" exact="stavudine" post="were significantly associated with worsening of hepatic fibrosis in"/>
   <result pre="of hepatic fibrosis in 34 (17%) (28c). After multivariate analysis," exact="didanosine" post="(OR = 3.34; 95% CI = 1.39, 7.96) and"/>
   <result pre="efavirenz, lamivudine, and zidovudine; women of child-bearing potential were given" exact="nevirapine" post="instead of efavirenz. An efavirenz-based regimen was used in"/>
   <result pre="nevirapine-based regimen (29C). During the first year 48 subjects took" exact="isoniazid" post="prophylaxis and 214 received antituberculosis therapy (2 months of"/>
   <result pre="received antituberculosis therapy (2 months of rifampicin, isoniazid, pyrazinamide, and" exact="ethambutol" post="followed by 4 months of rifampicin and isoniazid). Of"/>
   <result pre="rifampicin, isoniazid, pyrazinamide, and ethambutol followed by 4 months of" exact="rifampicin" post="and isoniazid). Of a random sample of 133 tested,"/>
   <result pre="for a change in antiretroviral drug regimen. The use of" exact="isoniazid" post="preventive therapy during antiretroviral drug therapy did not increase"/>
   <result pre="the liver while taking HAART regimens containing atazanavir, fosamprenavir, and" exact="indinavir" post="(30A). Pancreas In the large EuroSIDA study there was"/>
   <result pre="pancreatitis and cumulative exposure to antiretroviral drugs generally, or to" exact="didanosine" post="and stavudine in particular (31C). There were 43 (9"/>
   <result pre="cumulative exposure to antiretroviral drugs generally, or to didanosine and" exact="stavudine" post="in particular (31C). There were 43 (9 presumptive) pancreatic"/>
   <result pre="and over 2 years of exposure to antiretroviral drugs, including" exact="stavudine" post="and didanosine, were 1.24, 1.73, and 0.78 per 1000"/>
   <result pre="significant association between reduced renal function and concurrent use of" exact="amprenavir" post="and didanosine, age over 50 years and lower baseline"/>
   <result pre="baseline weight. There was an association between concomitant use of" exact="tenofovir" post="and amprenavir and reduced kidney function in 441 patients"/>
   <result pre="There was an association between concomitant use of tenofovir and" exact="amprenavir" post="and reduced kidney function in 441 patients (OR ="/>
   <result pre="was seen on renal biopsy in three HIV-positive patients taking" exact="amprenavir" post="+ tenofovir; it resolved after drug withdrawal (33A). In"/>
   <result pre="(33A). In a randomized controlled trial of indinavir, saquinavir, and" exact="lopinavir" post="in combination with low-dose ritonavir in 656 patients, there"/>
   <result pre="trial of indinavir, saquinavir, and lopinavir in combination with low-dose" exact="ritonavir" post="in 656 patients, there was no apparent dose-related association"/>
   <result pre="events (23C). Immunologic An allergic reaction with possible cross-reactivity to" exact="didanosine" post="and tenofovir has been reported (34A). •A 25-year-old woman"/>
   <result pre="Immunologic An allergic reaction with possible cross-reactivity to didanosine and" exact="tenofovir" post="has been reported (34A). •A 25-year-old woman tested positive"/>
   <result pre="positive for HIV-1 and was given a once-a-day regimen including" exact="tenofovir" post="plus emtricitabine and efavirenz. After 10 days she developed"/>
   <result pre="HIV-1 and was given a once-a-day regimen including tenofovir plus" exact="emtricitabine" post="and efavirenz. After 10 days she developed a diffuse"/>
   <result pre="her conditions worsened over the next 3 days, so both" exact="tenofovir" post="and emtricitabine were withdrawn, with dramatic resolution of symptoms"/>
   <result pre="worsened over the next 3 days, so both tenofovir and" exact="emtricitabine" post="were withdrawn, with dramatic resolution of symptoms within 24"/>
   <result pre="symptoms within 24 hours. After 10 days she was given" exact="zidovudine" post="plus didanosine and ritonavir-boosted fosamprenavir. After 1 week she"/>
   <result pre="24 hours. After 10 days she was given zidovudine plus" exact="didanosine" post="and ritonavir-boosted fosamprenavir. After 1 week she again developed"/>
   <result pre="a diffuse rash and the treatment was withdrawn. She restarted" exact="zidovudine" post="and didanosine 7 days later and within a few"/>
   <result pre="rash and the treatment was withdrawn. She restarted zidovudine and" exact="didanosine" post="7 days later and within a few days the"/>
   <result pre="days the rash appeared again. Under observation she was given" exact="zidovudine" post="and atazanavir and after 8 days lamivudine and low-dose"/>
   <result pre="rash appeared again. Under observation she was given zidovudine and" exact="atazanavir" post="and after 8 days lamivudine and low-dose ritonavir. She"/>
   <result pre="she was given zidovudine and atazanavir and after 8 days" exact="lamivudine" post="and low-dose ritonavir. She remained well, except for mild"/>
   <result pre="of first in utero exposure in the third trimester to" exact="lamivudine" post="(OR = 3.76 versus unexposed; 95% CI = 1.09,"/>
   <result pre="3.76 versus unexposed; 95% CI = 1.09, 12) and to" exact="zidovudine" post="+ lamivudine (OR = 3.29 versus unexposed; 95% CI"/>
   <result pre="unexposed; 95% CI = 1.09, 12) and to zidovudine +" exact="lamivudine" post="(OR = 3.29 versus unexposed; 95% CI = 0.96,"/>
   <result pre="the odds of first exposure in the third trimester to" exact="lamivudine" post="(OR = 11; 95% CI = 1.9, 76) and"/>
   <result pre="lamivudine (OR = 11; 95% CI = 1.9, 76) and" exact="zidovudine" post="+ lamivudine (OR = 9.8; 95% CI = 1.7,"/>
   <result pre="= 11; 95% CI = 1.9, 76) and zidovudine +" exact="lamivudine" post="(OR = 9.8; 95% CI = 1.7, 72) were"/>
   <result pre="antiretroviral drugs Reports of renal toxicity with the combination of" exact="tenofovir" post="and didanosine in children suggest that this combination should"/>
   <result pre="Reports of renal toxicity with the combination of tenofovir and" exact="didanosine" post="in children suggest that this combination should be avoided"/>
   <result pre="suggest that this combination should be avoided (36A). Combination of" exact="saquinavir" post="with darunavir + ritonavir is currently not recommended as"/>
   <result pre="this combination should be avoided (36A). Combination of saquinavir with" exact="darunavir" post="+ ritonavir is currently not recommended as plasma concentrations"/>
   <result pre="should be avoided (36A). Combination of saquinavir with darunavir +" exact="ritonavir" post="is currently not recommended as plasma concentrations of darunavir"/>
   <result pre="+ ritonavir is currently not recommended as plasma concentrations of" exact="darunavir" post="are increased (37c). Buprenorphine Atazanavir and atazanavir + ritonavir"/>
   <result pre="plasma concentrations of darunavir are increased (37c). Buprenorphine Atazanavir and" exact="atazanavir" post="+ ritonavir both resulted in increased metabolite concentrations of"/>
   <result pre="of darunavir are increased (37c). Buprenorphine Atazanavir and atazanavir +" exact="ritonavir" post="both resulted in increased metabolite concentrations of buprenorphine, and"/>
   <result pre="in increased metabolite concentrations of buprenorphine, and dosage reduction of" exact="buprenorphine" post="is recommended; there was no change in the concentrations"/>
   <result pre="non-nucleoside reverse transcriptase inhibitor (NNRTI), nevirapine, or a protease inhibitor," exact="nelfinavir" post="or lopinavir + ritonavir, and two nucleoside analogues, high"/>
   <result pre="transcriptase inhibitor (NNRTI), nevirapine, or a protease inhibitor, nelfinavir or" exact="lopinavir" post="+ ritonavir, and two nucleoside analogues, high doses of"/>
   <result pre="lopinavir + ritonavir, and two nucleoside analogues, high doses of" exact="warfarin" post="were required to maintain therapeutic INRs (39A). Warfarin has"/>
   <result pre="effects on CYPs: induction, inhibition, or mixed effects. The increased" exact="warfarin" post="doses required in these two patients may have been"/>
   <result pre="by nevirapine, of CYP2C9 by nelfinavir, or of CYP2C9 by" exact="lopinavir" post="+ ritonavir. Drugs Active Against HIV: Nucleoside Analogue Reverse"/>
   <result pre="dementia ADC taking optimal stable background antiretroviral therapy including either" exact="abacavir" post="or placebo there was significantly more nausea in those"/>
   <result pre="placebo there was significantly more nausea in those who took" exact="abacavir" post="(40c). Immunologic Three patients developed painful lymphadenopathy shortly after"/>
   <result pre="twice-daily to a once-daily regimen (42A). In a 52-year-old woman," exact="abacavir" post="hypersensitivity presented as acute fibrinous and organizing pneumonia, with"/>
   <result pre="and the relation between the codon 245 variation and premature" exact="abacavir" post="withdrawal was investigated in 982 treated individuals (44C). Only"/>
   <result pre="method to identify individuals who could be safely treated with" exact="abacavir" post="when detection of HLA-B∗5701 is not rapidly and easily"/>
   <result pre="Alcohol Three patients had possible reactions to alcohol while taking" exact="abacavir" post="(45A). One had a disulfiram-like reaction (nausea, facial flushing,"/>
   <result pre="malaise after increasing his alcohol intake. The authors suggested that" exact="abacavir" post="might inhibit alcohol dehydrogenase. Didanosine (SED-15, 1113; SEDA-29, 303;"/>
   <result pre="Urinary tract Fanconi syndrome and nephrogenic diabetes insipidus associated with" exact="didanosine" post="have been reported (46A). •A 40-year-old man developed polydipsia,"/>
   <result pre="developed polydipsia, polyuria, fatigue, and weight loss after taking didanosine," exact="lamivudine" post="and boosted atazanavir for 2 years. He had hypophosphatemia,"/>
   <result pre="fatigue, and weight loss after taking didanosine, lamivudine and boosted" exact="atazanavir" post="for 2 years. He had hypophosphatemia, hypouricemia, hyperchloremic metabolic"/>
   <result pre="was high at 4.8 pg/ml (reference range 1.4–4.4 pmol/l). The" exact="didanosine" post="was replaced with another protease inhibitor and the other"/>
   <result pre="improved slowly. Drug–drug interactions Ganciclovir It has been suggested that" exact="ganciclovir" post="and its prodrug valganciclovir inhibit purine nucleoside phosphorylase (PNP)"/>
   <result pre="Ganciclovir It has been suggested that ganciclovir and its prodrug" exact="valganciclovir" post="inhibit purine nucleoside phosphorylase (PNP) in a similar manner"/>
   <result pre="inhibit purine nucleoside phosphorylase (PNP) in a similar manner to" exact="tenofovir" post="and increase didanosine concentrations, reducing its efficacy (47A). •A"/>
   <result pre="phosphorylase (PNP) in a similar manner to tenofovir and increase" exact="didanosine" post="concentrations, reducing its efficacy (47A). •A 68-year-old woman with"/>
   <result pre="HIV and cytomegalovirus enteritis was given valganciclovir, lamivudine, didanosine, and" exact="lopinavir" post="+ ritonavir. After 3 months, her viral load fell"/>
   <result pre="fell to 83 × 106/l and she had symptoms of" exact="didanosine" post="toxicity. Didanosine was replaced with abacavir, leading to complete"/>
   <result pre="count and resolution of symptoms. Reduction of the dosage of" exact="didanosine" post="or substitution with an alternative antiretroviral drug may be"/>
   <result pre="substitution with an alternative antiretroviral drug may be necessary when" exact="ganciclovir" post="is used. Stavudine Metabolism Lipodystrophy tended to occur more"/>
   <result pre="another study patients with lipoatrophy had higher drug exposure to" exact="stavudine" post="than controls (49c). This was reflected in the higher"/>
   <result pre="population curve (46% versus 23%). In addition, the duration of" exact="stavudine" post="therapy was independently associated with lipoatrophy. In a multivariate"/>
   <result pre="associated with lipoatrophy. In a multivariate analysis, both duration of" exact="stavudine" post="therapy and a concentration ratio over 1.0 independently correlated"/>
   <result pre="independently correlated with lipoatrophy. Changes in body habitus occur when" exact="stavudine" post="is withdrawn. In 574 HIV-positive women who stopped taking"/>
   <result pre="stavudine is withdrawn. In 574 HIV-positive women who stopped taking" exact="stavudine" post="for over 2.25 years, there were significantly smaller reductions"/>
   <result pre="compared with the reductions that occurred at 1–2.25 years after" exact="stavudine" post="withdrawal (50c). Stavudine reduces insulin sensitivity and causes mitochondrial"/>
   <result pre="personal or family history of diabetes who were randomized to" exact="stavudine" post="30–40 mg bd or placebo for 1 month, insulin"/>
   <result pre="placebo for 1 month, insulin sensitivity was significantly reduced by" exact="stavudine" post="(51c). In addition, muscle biopsies in those who took"/>
   <result pre="stavudine (51c). In addition, muscle biopsies in those who took" exact="stavudine" post="showed significant reductions in mtDNA/nuclear DNA, but there were"/>
   <result pre="retrospective study, symptomatic hyperlactatemia in 114 (91%) was associated with" exact="stavudine" post="median duration 13 months (52C). Nine patients (7.2%) died;"/>
   <result pre="of clinical trials conducted before and after regulatory approval of" exact="stavudine" post="has shown that a dosage of 30 mg bd"/>
   <result pre="appropriate dose in resource-limited settings (54M). Reducing the dosage of" exact="stavudine" post="by one-half increased fat mtDNA and bone density and"/>
   <result pre="HIV-infected mother–infant pairs, of whom 13 women had taken prenatal" exact="zidovudine" post="and 3 antiretroviral drugs without zidovudine (57c). All the"/>
   <result pre="women had taken prenatal zidovudine and 3 antiretroviral drugs without" exact="zidovudine" post="(57c). All the infants received zidovudine for 6 weeks."/>
   <result pre="3 antiretroviral drugs without zidovudine (57c). All the infants received" exact="zidovudine" post="for 6 weeks. Venous blood was obtained from women"/>
   <result pre="comparable to cord blood controls. The authors concluded that transplacental" exact="zidovudine" post="exposure is genotoxic in humans and they recommended long-term"/>
   <result pre="infants. Teratogenicity A possible association between first trimester exposure to" exact="zidovudine" post="and an increased risk of hypospadias based on one"/>
   <result pre="892 male live births). Logistic regression suggested that use of" exact="zidovudine" post="in the first trimester was associated with hypospadias (adjusted"/>
   <result pre="54). Pregnancy In a pharmacokinetic study of three doses of" exact="zidovudine" post="300 mg 3-hourly in pregnancy in six subjects, plasma"/>
   <result pre="zidovudine 300 mg 3-hourly in pregnancy in six subjects, plasma" exact="zidovudine" post="concentrations were substantially lower than previously reported during continuous"/>
   <result pre="mg dose followed by two 400 mg doses 3-hourly, the" exact="zidovudine" post="AUC and concentrations increased approximately in proportion to the"/>
   <result pre="results suggested erratic absorption. Drug–drug interactions Co-trimoxazole Combined exposure to" exact="zidovudine" post="plus co-trimoxazole caused a clinically significant suppression of humoral"/>
   <result pre="106/l (61c). Ribavirin Ribavirin did not inhibit the formation of" exact="zidovudine" post="triphosphate in peripheral blood monocytes in 14 patients over"/>
   <result pre="treatment with at least two thymidine-associated resistance mutations were given" exact="tenofovir" post="600 mg/day for 4 weeks in addition to their"/>
   <result pre="733 HIV-positive patients taking tenofovir, 85 patients (11.6%) stopped taking" exact="tenofovir" post="because of adverse events, including nausea, vomiting, diarrhea, and"/>
   <result pre="marker of proximal renal tubule damage in 92 HIV-infected children," exact="tenofovir" post="was significantly associated with very high abnormal values (65C)."/>
   <result pre="The efficacy, resistance profile, adverse effects, and drug interactions of" exact="efavirenz" post="have been reviewed (66R). Psychiatric Neuropsychiatric symptoms provoked by"/>
   <result pre="efavirenz have been reviewed (66R). Psychiatric Neuropsychiatric symptoms provoked by" exact="efavirenz" post="have been reviewed (67R). Of 103 patients who took"/>
   <result pre="reviewed (67R). Of 103 patients who took didanosine, lamivudine, and" exact="efavirenz" post="for 48 weeks, 19 had neuropsychiatric adverse effects related"/>
   <result pre="for 48 weeks, 19 had neuropsychiatric adverse effects related to" exact="efavirenz" post="(68c). In an evaluation of the effectiveness and adverse"/>
   <result pre="adverse effects of a simplification regimen with tenofovir, lamivudine, and" exact="efavirenz" post="in 154 HAART-experienced HIV-1-infected subjects with sustained viral suppression,"/>
   <result pre="to compare three protease inhibitor-sparing antiretroviral drug regimens (zidovudine +" exact="lamivudine" post="+ abacavir; zidovudine + lamivudine + efavirenz; zidovudine +"/>
   <result pre="protease inhibitor-sparing antiretroviral drug regimens (zidovudine + lamivudine + abacavir;" exact="zidovudine" post="+ lamivudine + efavirenz; zidovudine + lamivudine + abacavir"/>
   <result pre="antiretroviral drug regimens (zidovudine + lamivudine + abacavir; zidovudine +" exact="lamivudine" post="+ efavirenz; zidovudine + lamivudine + abacavir + efavirenz)"/>
   <result pre="(zidovudine + lamivudine + abacavir; zidovudine + lamivudine + efavirenz;" exact="zidovudine" post="+ lamivudine + abacavir + efavirenz) in the initial"/>
   <result pre="lamivudine + abacavir; zidovudine + lamivudine + efavirenz; zidovudine +" exact="lamivudine" post="+ abacavir + efavirenz) in the initial treatment of"/>
   <result pre="abacavir; zidovudine + lamivudine + efavirenz; zidovudine + lamivudine +" exact="abacavir" post="+ efavirenz) in the initial treatment of HIV-1 infection"/>
   <result pre="A renal calculus that occurred in a 47-year-old man taking" exact="efavirenz" post="contained efavirenz metabolites (60%) and about 40% of unspecified"/>
   <result pre="calculus that occurred in a 47-year-old man taking efavirenz contained" exact="efavirenz" post="metabolites (60%) and about 40% of unspecified proteins (71A)."/>
   <result pre="was a between-the-eyes adverse effect of type 1a, definitively implicating" exact="efavirenz" post="(72H). Breasts In cohort study from Cambodia, 2 of"/>
   <result pre="of 343 patients developed gynecomastia while taking a regimen containing" exact="efavirenz" post="(73c). Susceptibility factors Genetic Efavirenz is metabolized by CYP2B6."/>
   <result pre="factors Genetic Efavirenz is metabolized by CYP2B6. The pharmacokinetics of" exact="efavirenz" post="have been studied in 71 children with a G-to-T"/>
   <result pre="reported in a child (75A). •A 12-year-old HIV-positive girl taking" exact="lopinavir" post="400 mg bd, ritonavir 100 mg bd, stavudine 30"/>
   <result pre="(75A). •A 12-year-old HIV-positive girl taking lopinavir 400 mg bd," exact="ritonavir" post="100 mg bd, stavudine 30 mg bd, didanosine 250"/>
   <result pre="girl taking lopinavir 400 mg bd, ritonavir 100 mg bd," exact="stavudine" post="30 mg bd, didanosine 250 mg/day, and efavirenz 600"/>
   <result pre="mg bd, ritonavir 100 mg bd, stavudine 30 mg bd," exact="didanosine" post="250 mg/day, and efavirenz 600 mg/day developed an overt"/>
   <result pre="mg bd, stavudine 30 mg bd, didanosine 250 mg/day, and" exact="efavirenz" post="600 mg/day developed an overt psychosis. Her serum efavirenz"/>
   <result pre="and efavirenz 600 mg/day developed an overt psychosis. Her serum" exact="efavirenz" post="concentration was 7–8 times higher than expected and she"/>
   <result pre="efavirenz. Drug–drug interactions Antimalarial drugs Two healthy volunteers who took" exact="amodiaquine" post="plus artesunate and efavirenz had significant asymptomatic rises in"/>
   <result pre="interactions Antimalarial drugs Two healthy volunteers who took amodiaquine plus" exact="artesunate" post="and efavirenz had significant asymptomatic rises in liver transaminases,"/>
   <result pre="drugs Two healthy volunteers who took amodiaquine plus artesunate and" exact="efavirenz" post="had significant asymptomatic rises in liver transaminases, which did"/>
   <result pre="liver transaminases, which did not occur in the absence of" exact="efavirenz" post="(76c). Voriconazole In a randomized, placebo-controlled, two-period, multiple-dose within-group,"/>
   <result pre="two-period, multiple-dose within-group, fixed-dose sequence study of the interaction of" exact="voriconazole" post="200 mg bd with efavirenz 400 mg/day in healthy"/>
   <result pre="study of the interaction of voriconazole 200 mg bd with" exact="efavirenz" post="400 mg/day in healthy men, repeated doses of efavirenz"/>
   <result pre="with efavirenz 400 mg/day in healthy men, repeated doses of" exact="efavirenz" post="substantially reduced the steady-state mean AUC and Cmax of"/>
   <result pre="efavirenz substantially reduced the steady-state mean AUC and Cmax of" exact="voriconazole" post="by 80% and 66% respectively (77C). Repeated therapeutic doses"/>
   <result pre="by 80% and 66% respectively (77C). Repeated therapeutic doses of" exact="voriconazole" post="moderately increased the steady-state mean AUC and Cmax of"/>
   <result pre="voriconazole moderately increased the steady-state mean AUC and Cmax of" exact="efavirenz" post="by 43% and 37% respectively. When voriconazole was co-administered"/>
   <result pre="and Cmax of efavirenz by 43% and 37% respectively. When" exact="voriconazole" post="was co-administered with efavirenz, the incidence of adverse events"/>
   <result pre="the incidence of adverse events was similar to that with" exact="efavirenz" post="alone. Nevirapine Liver Hepatotoxicity is a major problem with"/>
   <result pre="efavirenz alone. Nevirapine Liver Hepatotoxicity is a major problem with" exact="nevirapine" post="(78R). The frequency of large increases in liver enzymes"/>
   <result pre="frequency of large increases in liver enzymes in patients taking" exact="efavirenz" post="is 1–8%, whereas in patients taking nevirapine it is"/>
   <result pre="in patients taking efavirenz is 1–8%, whereas in patients taking" exact="nevirapine" post="it is 4–18%. A warning about the increased risk"/>
   <result pre="The authors concluded that virologically suppressed patients who switch to" exact="nevirapine" post="do not have a significantly higher risk of hepatotoxicity"/>
   <result pre="(80c). Drug-naive patients (n = 142) who started treatment with" exact="nevirapine" post="were divided into two groups: those with high or"/>
   <result pre="respectively. The authors concluded that the advice not to use" exact="nevirapine" post="in drug-naive patients at increased risk of toxicity on"/>
   <result pre="1000 pregnant women taking nevirapine-containing regimens, 93% started or continued" exact="nevirapine" post="during the first and second trimesters (82cA). Concurrent chronic"/>
   <result pre="disease. Skin Widespread vitiligo after erythroderma has been attributed to" exact="nevirapine" post="(83A). •A 34-year-old man developed erythroderma, a high fever"/>
   <result pre="man developed erythroderma, a high fever and hepatitis after taking" exact="nevirapine" post="for 1 month. There was jaundice and a confluent"/>
   <result pre="in the upper dermis. The lesions faded on withdrawal of" exact="nevirapine" post="and administration of oral glucocorticoids, but took around 6"/>
   <result pre="with eosinophilia and systemic symptoms (DRESS) has been associated with" exact="nevirapine" post="in a child (84A) •A 12-year-old girl took a"/>
   <result pre="Immunologic In a retrospective study of trough plasma concentrations of" exact="nevirapine" post="and five oxidative metabolites in 1357 patients with rashes"/>
   <result pre="studied (86c). Women had significantly greater exposure than men to" exact="nevirapine" post="and four of the five metabolites at week 2,"/>
   <result pre="4. There were no strong relationships between plasma concentrations of" exact="nevirapine" post="or any of its five metabolites and case-defining events."/>
   <result pre="the cases and controls and were comparable in proportion to" exact="nevirapine" post="exposure. Pregnancy In a retrospective, five-center comparison in HIV-1-infected"/>
   <result pre="In a retrospective, five-center comparison in HIV-1-infected women who took" exact="nevirapine" post="as part of combination antiretroviral therapy during pregnancy, 15"/>
   <result pre="rash, giving a combined incidence of 19 potential cases of" exact="nevirapine" post="toxicity during pregnancy (8.1%) (87c). Alternative causes of rash"/>
   <result pre="stopped taking nevirapine. Of the 170 women who started taking" exact="nevirapine" post="during pregnancy, 13 (7.6%) developed a rash and 8"/>
   <result pre="8 (4.7%) hepatotoxicity. Only 2 of 65 women (3.1%) with" exact="nevirapine" post="exposure before pregnancy had had a rash. Susceptibility factors"/>
   <result pre="typing and demographic and immunological susceptibility factors for reactions to" exact="nevirapine" post="and efavirenz have been studied in 21 HIV-positive patients"/>
   <result pre="demographic and immunological susceptibility factors for reactions to nevirapine and" exact="efavirenz" post="have been studied in 21 HIV-positive patients with rashes"/>
   <result pre="were Japanese, 42% of those who had hypersensitivity reactions to" exact="nevirapine" post="had HLA-Cw8, compared with only 10% of the others"/>
   <result pre="use of once-daily dosing. However, tolerance to high concentrations of" exact="nevirapine" post="can develop when doses are increased slowly during the"/>
   <result pre="could be achieved without excess toxicity by switching to once-daily" exact="nevirapine" post="after several months of twice-daily administration (90R). However, in"/>
   <result pre="(90R). However, in the DAUFIN study, a twice-daily regimen of" exact="zidovudine" post="300 mg + lamivudine 150 mg + nevirapine 200"/>
   <result pre="DAUFIN study, a twice-daily regimen of zidovudine 300 mg +" exact="lamivudine" post="150 mg + nevirapine 200 mg was compared with"/>
   <result pre="regimen of zidovudine 300 mg + lamivudine 150 mg +" exact="nevirapine" post="200 mg was compared with a once-daily regimen of"/>
   <result pre="nevirapine 200 mg was compared with a once-daily regimen of" exact="lamivudine" post="300 mg + tenofovir 245 mg + nevirapine 400"/>
   <result pre="compared with a once-daily regimen of lamivudine 300 mg +" exact="tenofovir" post="245 mg + nevirapine 400 mg (91C). The study"/>
   <result pre="regimen of lamivudine 300 mg + tenofovir 245 mg +" exact="nevirapine" post="400 mg (91C). The study was stopped after early"/>
   <result pre="resistance profiles indicative of continuing viral replication caused by suboptimal" exact="nevirapine" post="plasma trough concentrations, possibly due to non-adherence. Non-B-subtype infection"/>
   <result pre="achieved with a twice-daily regimen. Drug–drug interactions Fluconazole Co-administration of" exact="nevirapine" post="200 mg/day with fluconazole 400 mg/day results in markedly"/>
   <result pre="regimen. Drug–drug interactions Fluconazole Co-administration of nevirapine 200 mg/day with" exact="fluconazole" post="400 mg/day results in markedly increased trough plasma nevirapine"/>
   <result pre="with fluconazole 400 mg/day results in markedly increased trough plasma" exact="nevirapine" post="concentrations compared with nevirapine alone (92c). In a retrospective"/>
   <result pre="results in markedly increased trough plasma nevirapine concentrations compared with" exact="nevirapine" post="alone (92c). In a retrospective study in 112 patients"/>
   <result pre="112 patients who were given nevirapine-based therapy with or without" exact="fluconazole" post="200 or 400 mg/day, mean nevirapine concentrations were 6.5"/>
   <result pre="therapy with or without fluconazole 200 or 400 mg/day, mean" exact="nevirapine" post="concentrations were 6.5 mg/l without fluconazole and 11.4 with"/>
   <result pre="or 400 mg/day, mean nevirapine concentrations were 6.5 mg/l without" exact="fluconazole" post="and 11.4 with fluconazole. One patient taking fluconazole developed"/>
   <result pre="mg/l without fluconazole and 11.4 with fluconazole. One patient taking" exact="fluconazole" post="developed hepatitis. Six of those who did not take"/>
   <result pre="fluconazole developed hepatitis. Six of those who did not take" exact="fluconazole" post="developed nevirapine-related rashes. There were no differences in 36-week"/>
   <result pre="487) Atazanavir Liver Hyperbilirubinemia and jaundice occurred during administration of" exact="atazanavir" post="in all 23 healthy volunteers taking part in a"/>
   <result pre="was a 52% increased minimum plasma concentration with co-administration of" exact="darunavir" post="(93c). Hair Alopecia has been reported with ritonavir-boosted atazanavir"/>
   <result pre="of darunavir (93c). Hair Alopecia has been reported with ritonavir-boosted" exact="atazanavir" post="(94A). Drug–drug interactions Rifampicin Concomitant usage of rifampicin with"/>
   <result pre="with ritonavir-boosted atazanavir (94A). Drug–drug interactions Rifampicin Concomitant usage of" exact="rifampicin" post="with regimens including atazanavir should be avoided, as they"/>
   <result pre="Drug–drug interactions Rifampicin Concomitant usage of rifampicin with regimens including" exact="atazanavir" post="should be avoided, as they result in subtherapeutic concentrations"/>
   <result pre="should be avoided, as they result in subtherapeutic concentrations of" exact="atazanavir" post="(95A). Tenofovir Atazanavir increased tenofovir concentrations in an open,"/>
   <result pre="result in subtherapeutic concentrations of atazanavir (95A). Tenofovir Atazanavir increased" exact="tenofovir" post="concentrations in an open, crossover study in 30 healthy"/>
   <result pre="frequently reported adverse effects in a randomized controlled trial of" exact="fosamprenavir" post="+ ritonavir in treatment-naive HIV-infected patients (97C). Indinavir Gastrointestinal"/>
   <result pre="adverse effects in a randomized controlled trial of fosamprenavir +" exact="ritonavir" post="in treatment-naive HIV-infected patients (97C). Indinavir Gastrointestinal Of 30"/>
   <result pre="treatment-naive HIV-infected patients (97C). Indinavir Gastrointestinal Of 30 patients taking" exact="ritonavir" post="+ indinavir 400/100 mg in an open pilot study"/>
   <result pre="patients (97C). Indinavir Gastrointestinal Of 30 patients taking ritonavir +" exact="indinavir" post="400/100 mg in an open pilot study in Mali,"/>
   <result pre="co-trimoxazole therapy and environmental temperature increase the risk (100R). Using" exact="indinavir" post="+ ritonavir at the lower doses of 400 and"/>
   <result pre="and environmental temperature increase the risk (100R). Using indinavir +" exact="ritonavir" post="at the lower doses of 400 and 100 mg"/>
   <result pre="patients in a study of asymptomatic HIV-infected individuals who took" exact="indinavir" post="in a long-term follow-up study over 157 weeks (25c)."/>
   <result pre="straight hair, and ingrowing toenails have all been attributed to" exact="indinavir" post="(102R). Pregnancy In a study of 16 pregnant women"/>
   <result pre="pregnancy (103A). Nelfinavir Metabolism Of 111 pregnant women 15 taking" exact="nelfinavir" post="developed gestational diabetes compared with none taking zidovudine monotherapy"/>
   <result pre="15 taking nelfinavir developed gestational diabetes compared with none taking" exact="zidovudine" post="monotherapy and two of 43 taking NRTIs and NNRTIs;"/>
   <result pre="Paronychia has been reported in a case report occurring during" exact="nelfinavir" post="treatment (105A). Ritonavir Drug–drug interactions Fluticasone Cushing’s syndrome and"/>
   <result pre="systemic glucocorticoid concentrations. Iatrogenic Cushing’s syndrome has been attributed to" exact="ritonavir" post="by an interaction with fluticasone (106A). •A 16-year-old girl"/>
   <result pre="syndrome has been attributed to ritonavir by an interaction with" exact="fluticasone" post="(106A). •A 16-year-old girl who had taken various antiretroviral"/>
   <result pre="had taken various antiretroviral drugs eventually took stavudine, lamivudine, and" exact="ritonavir" post="and then used inhaled fluticasone + salmeterol for bronchiectasis."/>
   <result pre="eventually took stavudine, lamivudine, and ritonavir and then used inhaled" exact="fluticasone" post="+ salmeterol for bronchiectasis. After 3 months she had"/>
   <result pre="stavudine, lamivudine, and ritonavir and then used inhaled fluticasone +" exact="salmeterol" post="for bronchiectasis. After 3 months she had excessive weight"/>
   <result pre="and amenorrhea. Cushing’s syndrome was attributed to an interaction of" exact="fluticasone" post="with ritonavir, which was changed to efavirenz. There was"/>
   <result pre="ASPIRE 1 study, 7 of 17 healthy volunteers who took" exact="saquinavir" post="+ ritonavir for 3 months developed grade 3 gastrointestinal"/>
   <result pre="study, 7 of 17 healthy volunteers who took saquinavir +" exact="ritonavir" post="for 3 months developed grade 3 gastrointestinal adverse effects"/>
   <result pre="In a 24-week multi-center, double-blind, randomized, dose-finding trial of ritonavir-boosted" exact="tipranavir" post="in 216 patients, the most common adverse events were"/>
   <result pre="nausea, vomiting, fatigue, and headache (113C). Hematologic Tipranavir boosted with" exact="ritonavir" post="caused an increased risk of bleeding in 3 of"/>
   <result pre="(114c). Intracranial hemorrhage has been reported in a patient taking" exact="tipranavir" post="(115A). Liver Tipranavir is associated with an excess of"/>
   <result pre="associated with hypertriglyceridemia has been reported in a patient taking" exact="tipranavir" post="+ ritonavir (117A). •A 42-year-old man taking tenofovir 300"/>
   <result pre="hypertriglyceridemia has been reported in a patient taking tipranavir +" exact="ritonavir" post="(117A). •A 42-year-old man taking tenofovir 300 mg/day, trizivir"/>
   <result pre="patient taking tipranavir + ritonavir (117A). •A 42-year-old man taking" exact="tenofovir" post="300 mg/day, trizivir (zidovudine, lamivudine, and abacavir) one tablet"/>
   <result pre="mg/day, trizivir (zidovudine, lamivudine, and abacavir) one tablet bd, and" exact="tipranavir" post="500 mg bd + ritonavir 200 mg bd drank"/>
   <result pre="abacavir) one tablet bd, and tipranavir 500 mg bd +" exact="ritonavir" post="200 mg bd drank six standard alcoholic drinks 2"/>
   <result pre="during the earlier illness also showed marked hypertriglyceridemia. Tipranavir +" exact="ritonavir" post="was withdrawn, efavirenz given, and tenofovir and trizivir continued."/>
   <result pre="illness also showed marked hypertriglyceridemia. Tipranavir + ritonavir was withdrawn," exact="efavirenz" post="given, and tenofovir and trizivir continued. His triglyceride concentrations"/>
   <result pre="marked hypertriglyceridemia. Tipranavir + ritonavir was withdrawn, efavirenz given, and" exact="tenofovir" post="and trizivir continued. His triglyceride concentrations fell to 10.3"/>
   <result pre="Porphyria cutanea tarda has been reported after the introduction of" exact="tipranavir" post="+ ritonavir to a backbone of tenofovir and lamivudine"/>
   <result pre="tarda has been reported after the introduction of tipranavir +" exact="ritonavir" post="to a backbone of tenofovir and lamivudine (118A). •A"/>
   <result pre="the introduction of tipranavir + ritonavir to a backbone of" exact="tenofovir" post="and lamivudine (118A). •A 59-year-old heterosexual woman switched to"/>
   <result pre="of tipranavir + ritonavir to a backbone of tenofovir and" exact="lamivudine" post="(118A). •A 59-year-old heterosexual woman switched to tipranavir-containing therapy"/>
   <result pre="present at baseline (119C). In addition, virological response rates to" exact="tipranavir" post="were reduced when the number of baseline protease inhibitor"/>
   <result pre="protease inhibitor mutations was five or more. Individuals who took" exact="tipranavir" post="without concomitant enfuvirtide and had five or more baseline"/>
   <result pre="was five or more. Individuals who took tipranavir without concomitant" exact="enfuvirtide" post="and had five or more baseline protease inhibitor mutations"/>
   <result pre="to lose antiviral response at weeks 4–8. However, individuals taking" exact="enfuvirtide" post="with tipranavir achieved more than 1.5 log10 reductions in"/>
   <result pre="antiviral response at weeks 4–8. However, individuals taking enfuvirtide with" exact="tipranavir" post="achieved more than 1.5 log10 reductions in viral load"/>
   <result pre="or more baseline protease inhibitor mutations. Virological response rates to" exact="tipranavir" post="were reduced when the baseline phenotype for tipranavir had"/>
   <result pre="rates to tipranavir were reduced when the baseline phenotype for" exact="tipranavir" post="had a greater than threefold shift in the 50%"/>
   <result pre="L33V/I/F, M36V/I/L V82T, V82L, and I84V. Drug–drug interactions Interactions with" exact="tipranavir" post="+ ritonavir have been reviewed (120R). Tipranavir is metabolized"/>
   <result pre="V82T, V82L, and I84V. Drug–drug interactions Interactions with tipranavir +" exact="ritonavir" post="have been reviewed (120R). Tipranavir is metabolized by CYP3A"/>
   <result pre="have been reviewed (120R). Tipranavir is metabolized by CYP3A and" exact="tipranavir" post="+ ritonavir in vitro inhibits CYP1A2, CYP2C9, CYP2C19, CYP2D6,"/>
   <result pre="reviewed (120R). Tipranavir is metabolized by CYP3A and tipranavir +" exact="ritonavir" post="in vitro inhibits CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A"/>
   <result pre="been studied in 315 HIV-infected patients (121C). The addition of" exact="tipranavir" post="+ ritonavir 2 weeks after single protease inhibitor therapy"/>
   <result pre="in 315 HIV-infected patients (121C). The addition of tipranavir +" exact="ritonavir" post="2 weeks after single protease inhibitor therapy reduced plasma"/>
   <result pre="inhibitor therapy reduced plasma trough concentrations of lopinavir, saquinavir, and" exact="amprenavir" post="by 52%, 80%, and 56% respectively. The efficacy of"/>
   <result pre="2 days after withdrawal (122A). Japanese authorities advised against using" exact="oseltamivir" post="in adolescents aged 10–19 years after two suicides during"/>
   <result pre="(123r). Gastrointestinal Acute hemorrhagic colitis has been associated with oral" exact="oseltamivir" post="in a 61-year-old man, who developed abdominal pain, diarrhea"/>
   <result pre="abdominal pain, diarrhea and hematochezia after taking two doses of" exact="oseltamivir" post="(126A). In a systematic review of three trials of"/>
   <result pre="children, 977 of whom had laboratory-confirmed influenza, those who took" exact="oseltamivir" post="had vomiting more often than untreated children but withdrawal"/>
   <result pre="There was no evidence of a difference in AUC1→20 of" exact="oseltamivir" post="or its active metabolite oseltamivir carboxylate between 14 Japanese"/>
   <result pre="a difference in AUC1→20 of oseltamivir or its active metabolite" exact="oseltamivir" post="carboxylate between 14 Japanese subjects and 14 Caucasian subjects,"/>
   <result pre="Zanamivir Systematic reviews A meta-analysis of the adverse effects of" exact="zanamivir" post="in children showed that it was no worse than"/>
   <result pre="C treated with interferon-alfa 2a alone (n = 53), with" exact="amantadine" post="100 mg bd (n = 111), with ribavirin (n"/>
   <result pre="53), with amantadine 100 mg bd (n = 111), with" exact="ribavirin" post="(n = 106) or with amantadine + ribavirin (n"/>
   <result pre="(n = 111), with ribavirin (n = 106) or with" exact="amantadine" post="+ ribavirin (n = 108), there was a sustained"/>
   <result pre="111), with ribavirin (n = 106) or with amantadine +" exact="ribavirin" post="(n = 108), there was a sustained virological response"/>
   <result pre="22% respectively (130C). This was statistically different between interferon +" exact="amantadine" post="and triple therapy but not between interferon + ribavirin"/>
   <result pre="+ amantadine and triple therapy but not between interferon +" exact="ribavirin" post="and triple therapy. The spectra and frequencies of adverse"/>
   <result pre="1 chronic infection taking interferon and ribavirin, with or without" exact="amantadine" post="200 mg/day, viral load fell more markedly in the"/>
   <result pre="specific residues appeared to be linked to the effect of" exact="amantadine" post="on the virus. The authors suggested that this implied"/>
   <result pre="authors suggested that this implied that the antiviral effect of" exact="amantadine" post="is non-specific and related to reduced endosomal acidification and"/>
   <result pre="randomized to interferon monotherapy (n = 26), dual therapy with" exact="ribavirin" post="(n = 24) and triple therapy with additional amantadine"/>
   <result pre="with ribavirin (n = 24) and triple therapy with additional" exact="amantadine" post="200 mg/day (n = 25), amantadine did not increase"/>
   <result pre="triple therapy with additional amantadine 200 mg/day (n = 25)," exact="amantadine" post="did not increase the frequency or severity of adverse"/>
   <result pre="interferon-beta for 4 weeks followed by interferon-alfa 2b, ribavirin, and" exact="amantadine" post="150 mg/day for 22 weeks, there was a sustained"/>
   <result pre="15 renal transplant recipients with chronic hepatitis C, doses of" exact="ribavirin" post="monotherapy (n = 7) or ribavirin + amantadine (n"/>
   <result pre="hepatitis C, doses of ribavirin monotherapy (n = 7) or" exact="ribavirin" post="+ amantadine (n = 8) were adjusted according to"/>
   <result pre="doses of ribavirin monotherapy (n = 7) or ribavirin +" exact="amantadine" post="(n = 8) were adjusted according to creatinine clearance"/>
   <result pre="one of those who received combination therapy were still taking" exact="amantadine" post="after 12 months; two completed treatment but with ribavirin"/>
   <result pre="taking amantadine after 12 months; two completed treatment but with" exact="ribavirin" post="alone. Four of those taking monotherapy completed treatment. Neither"/>
   <result pre="a new diagnosis of corneal disease and new prescriptions for" exact="amantadine" post="over 2 years, 36 (0.27%) of 13 137 patients"/>
   <result pre="most H5N1 subtypes, but some seasonal H1N1 remains sensitive to" exact="amantadine" post="(128R). However, in 2009, a novel pandemic strain vH1N1"/>
   <result pre="resistant to amantadine. References References 1.DoanM.L.MalloryG.B.KaplanS.L.DishopM.K.SchecterM.G.McKenzieE.D.HeinleJ.S.ElidemirO.Treatment of adenovirus pneumonia with" exact="cidofovir" post="in pediatric lung transplant recipientsJ Heart Lung Transplant269200788388917845926 2.NeofytosD.OjhaA.MookerjeeB.WagnerJ.FilickoJ.FerberA.DessainS.GrossoD.BrunnerJ.FlomenbergN.FlomenbergP.Treatment"/>
   <result pre="high mortality in the era of cidofovirTranspl Infect Dis92200710811317461995 4.SavonaM.R.NewtonD.FrameD.LevineJ.E.MineishiS.KaulD.R.Low-dose" exact="cidofovir" post="treatment of BK virus-associated hemorrhagic cystitis in recipients of"/>
   <result pre="transplant recipients for recurrence of hepatitis B virus infection despite" exact="lamivudine" post="plus hepatitis B immunoglobulin prophylaxisJ Gastroenterol Hepatol221220072130213418031370 13.BifanoM.YanJ.H.SmithR.A.ZhangD.GraselaD.M.LaCretaF.Absence of"/>
   <result pre="immunoglobulin prophylaxisJ Gastroenterol Hepatol221220072130213418031370 13.BifanoM.YanJ.H.SmithR.A.ZhangD.GraselaD.M.LaCretaF.Absence of a pharmacokinetic interaction between" exact="entecavir" post="and adefovirJ Clin Pharmacol471020071327133417675455 14.YilmazA.AkcamM.GelenT.ArtanR.Lamivudine and high-dose interferon alpha"/>
   <result pre="children: an East Mediterranean center’s experienceEur J Pediatr1663200719519916944240 15.AsariA.Iles-SmithH.ChenY.C.NadererO.J.JohnsonM.A.YuenG.J.OttoV.DunnJ.A.GokalR.Pharmacokinetics of" exact="lamivudine" post="in subjects receiving peritoneal dialysis in end-stage renal failureBr"/>
   <result pre="failureBr J Clin Pharmacol646200773874417662093 16.LaiC.L.GaneE.LiawY.F.HsuC.W.ThongsawatS.WangY.ChenY.HeathcoteE.J.RasenackJ.BzowejN.NaoumovN.V.Di BisceglieA.M.ZeuzemS.MoonY.M.GoodmanZ.ChaoG.ConstanceB.F.BrownN.A.collab: Globe Study GroupTelbivudine versus" exact="lamivudine" post="in patients with chronic hepatitis BN Engl J Med3572520072576258818094378"/>
   <result pre="outbreak of severe acute respiratory syndromePharmacotherapy274200749450317381375 18.StankovaJ.CarretA.S.MooreD.McCuskerC.MitchellD.DavisM.MazerB.JabadoN.Long-term therapy with aerosolized" exact="ribavirin" post="for parainfluenza 3 virus respiratory tract infection in an"/>
   <result pre="plus efavirenz) Study TeamLess lipoatrophy and better lipid profile with" exact="abacavir" post="as compared to stavudine: 96-week results of a randomized"/>
   <result pre="two randomized trials evaluating the safety and efficacy of indinavir," exact="saquinavir" post="and lopinavir in combination with low-dose ritonavir: the MaxCmin1"/>
   <result pre="trials evaluating the safety and efficacy of indinavir, saquinavir and" exact="lopinavir" post="in combination with low-dose ritonavir: the MaxCmin1 and 2"/>
   <result pre="Clin Trials85200726928117956828 26.Marin-NieblaA.Lopez-CortesL.F.Ruiz-ValderasR.VicianaP.MataR.GutierrezA.PascualR.RodriguezM.Clinical and pharmacokinetic data support once-daily low-dose boosted" exact="saquinavir" post="(1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive"/>
   <result pre="and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams" exact="saquinavir" post="with 100 milligrams ritonavir) in treatment-naive or limited protease"/>
   <result pre="Agents Chemother51620072035204217371813 27.StephanC.CarlebachA.RottmannC.HaberlA.DauerB.von HentigN.KurowskiM.StaszewskiS.Dose reduction effective in alleviating symptoms of" exact="saquinavir" post="toxicityInt J STD AIDS1822007818417331276 28.Bani-SadrF.LapidusN.BedossaP.De BoeverC.M.PerronneC.HalfonP.PolS.CarratF.CacoubP.collab: French National Agency"/>
   <result pre="pancreatitis in HIV-positive individuals in the EuroSIDA studyAIDS2212008475618090391 32.CraneH.M.KestenbaumB.HarringtonR.D.KitahataM.M.Amprenavir and" exact="didanosine" post="are associated with declining kidney function among patients receiving"/>
   <result pre="patients receiving tenofovirAIDS211120071431143917589189 33.SchmidS.OpravilM.ModdelM.HuberM.PfammatterR.KeuschG.AmbuhlP.WuthrichR.P.MochH.VargaZ.Acute interstitial nephritis of HIV-positive patients under" exact="atazanavir" post="and tenofovir therapy in a retrospective analysis of kidney"/>
   <result pre="tenofovirAIDS211120071431143917589189 33.SchmidS.OpravilM.ModdelM.HuberM.PfammatterR.KeuschG.AmbuhlP.WuthrichR.P.MochH.VargaZ.Acute interstitial nephritis of HIV-positive patients under atazanavir and" exact="tenofovir" post="therapy in a retrospective analysis of kidney biopsiesVirchows Arch4506200766567017464512"/>
   <result pre="retrospective analysis of kidney biopsiesVirchows Arch4506200766567017464512 34.RipamontiD.MaggioloF.SuterF.Possible allergic cross-reaction to" exact="didanosine" post="and tenofovir in an HIV-1-infected womanAIDS21820071059106017457107 35.BroglyS.B.YlitaloN.MofensonL.M.OleskeJ.Van DykeR.CrainM.J.AbzugM.J.BradyM.Jean-PhilippeP.HughesM.D.SeageG.R.3rdIn utero"/>
   <result pre="of kidney biopsiesVirchows Arch4506200766567017464512 34.RipamontiD.MaggioloF.SuterF.Possible allergic cross-reaction to didanosine and" exact="tenofovir" post="in an HIV-1-infected womanAIDS21820071059106017457107 35.BroglyS.B.YlitaloN.MofensonL.M.OleskeJ.Van DykeR.CrainM.J.AbzugM.J.BradyM.Jean-PhilippeP.HughesM.D.SeageG.R.3rdIn utero nucleoside reverse"/>
   <result pre="in HIV-uninfected childrenAIDS218200792993817457086 36.HawkinsS.BallC.Adverse events experienced by three children taking" exact="tenofovir" post="and didanosine in combinationHIV Med86200741117661851 37.SekarV.J.LefebvreE.MariënK.De PauwM.VangeneugdenT.HoetelmansR.M.Pharmacokinetic interaction between"/>
   <result pre="childrenAIDS218200792993817457086 36.HawkinsS.BallC.Adverse events experienced by three children taking tenofovir and" exact="didanosine" post="in combinationHIV Med86200741117661851 37.SekarV.J.LefebvreE.MariënK.De PauwM.VangeneugdenT.HoetelmansR.M.Pharmacokinetic interaction between darunavir and"/>
   <result pre="tenofovir and didanosine in combinationHIV Med86200741117661851 37.SekarV.J.LefebvreE.MariënK.De PauwM.VangeneugdenT.HoetelmansR.M.Pharmacokinetic interaction between" exact="darunavir" post="and saquinavir in HIV-negative volunteersTher Drug Monit296200779580118043478 38.McCance-KatzE.F.MoodyD.E.MorseG.D.MaQ.DiFrancescoR.FriedlandG.PadeP.RaineyP.M.Interaction between"/>
   <result pre="didanosine in combinationHIV Med86200741117661851 37.SekarV.J.LefebvreE.MariënK.De PauwM.VangeneugdenT.HoetelmansR.M.Pharmacokinetic interaction between darunavir and" exact="saquinavir" post="in HIV-negative volunteersTher Drug Monit296200779580118043478 38.McCance-KatzE.F.MoodyD.E.MorseG.D.MaQ.DiFrancescoR.FriedlandG.PadeP.RaineyP.M.Interaction between buprenorphine and"/>
   <result pre="darunavir and saquinavir in HIV-negative volunteersTher Drug Monit296200779580118043478 38.McCance-KatzE.F.MoodyD.E.MorseG.D.MaQ.DiFrancescoR.FriedlandG.PadeP.RaineyP.M.Interaction between" exact="buprenorphine" post="and atazanavir or atazanavir/ritonavirDrug Alcohol Depend912–3200726927817643869 39.FulcoP.P.ZingoneM.M.HigginsonR.T.Possible antiretroviral therapy–warfarin"/>
   <result pre="saquinavir in HIV-negative volunteersTher Drug Monit296200779580118043478 38.McCance-KatzE.F.MoodyD.E.MorseG.D.MaQ.DiFrancescoR.FriedlandG.PadeP.RaineyP.M.Interaction between buprenorphine and" exact="atazanavir" post="or atazanavir/ritonavirDrug Alcohol Depend912–3200726927817643869 39.FulcoP.P.ZingoneM.M.HigginsonR.T.Possible antiretroviral therapy–warfarin drug interactionPharmacotherapy287200894594918576910"/>
   <result pre="AIDS dementia complex trial design: results and lessons from the" exact="abacavir" post="trialPLoS Clin Trials232007e1317401456 41.GarcíaJ.T.GonzálezP.R.Hernández-MoraM.G.NovoaS.R.QuintanaF.B.LahozJ.G.VázquezV.S.Large lymphadenopathies complicating the abacavir hypersensitivity"/>
   <result pre="from the abacavir trialPLoS Clin Trials232007e1317401456 41.GarcíaJ.T.GonzálezP.R.Hernández-MoraM.G.NovoaS.R.QuintanaF.B.LahozJ.G.VázquezV.S.Large lymphadenopathies complicating the" exact="abacavir" post="hypersensitivity reactionAIDS211620072254225618090059 42.GervasoniC.ViganoO.GrinelliE.OrtuM.GalliM.RusconiS.Abacavir hypersensitivity reaction after switching from the"/>
   <result pre="43.YokogawaN.AlcidD.V.Acute fibrinous and organizing pneumonia as a rare presentation of" exact="abacavir" post="hypersensitivity reactionAIDS211520072116211717885309 44.ChuiC.K.BrummeZ.L.BrummeC.J.YipB.PhillipsE.J.MontanerJ.S.HarriganP.R.A simple screening approach to reduce B∗5701-associated"/>
   <result pre="abacavir hypersensitivity reactionAIDS211520072116211717885309 44.ChuiC.K.BrummeZ.L.BrummeC.J.YipB.PhillipsE.J.MontanerJ.S.HarriganP.R.A simple screening approach to reduce B∗5701-associated" exact="abacavir" post="hypersensitivity on the basis of sequence variation in HIV"/>
   <result pre="clinical practice?AIDS211320071823182417690585 46.D’YthurbideG.GoujardC.MéchaF.BlancA.CharpentierB.SnanoudjR.Fanconi syndrome and nephrogenic diabetes insipidus associated with" exact="didanosine" post="therapy in HIV infection: a case report and literature"/>
   <result pre="49.ter HofstedeH.J.KoopmansP.P.BurgerD.M.Stavudine plasma concentrations and lipoatrophyJ Antimicrob Chemother614200893393818281306 50.TienP.C.SchneiderM.F.ColeS.R.JustmanJ.E.FrenchA.L.YoungM.DeHovitzJ.NathwaniN.BrownT.T.Relation of" exact="stavudine" post="discontinuation to anthropometric changes among HIV-infected womenJ Acquir Immune"/>
   <result pre="Dis126200858258618337140 53.HillA.RuxrungthamK.HanvanichM.KatlamaC.WolfE.SorianoV.MilinkovicA.GatellJ.RiberaE.Systematic review of clinical trials evaluating low doses of" exact="stavudine" post="as part of antiretroviral treatmentExpert Opin Pharmacother85200767968817376022 54.MakinsonA.MoingV.L.KouanfackC.LaurentC.DelaporteE.Safety of"/>
   <result pre="stavudine as part of antiretroviral treatmentExpert Opin Pharmacother85200767968817376022 54.MakinsonA.MoingV.L.KouanfackC.LaurentC.DelaporteE.Safety of" exact="stavudine" post="in the treatment of HIV infection with a special"/>
   <result pre="Opin Drug Saf73200828329318462186 55.McComseyG.A.Lo ReV.3rdO’RiordanM.WalkerU.A.LebrechtD.BaronE.MounzerK.FrankI.Effect of reducing the dose of" exact="stavudine" post="on body composition, bone density, and markers of mitochondrial"/>
   <result pre="treatment?AIDS21920071207120817502732 57.WittK.L.CunninghamC.K.PattersonK.B.KisslingG.E.DertingerS.D.LivingstonE.BishopJ.B.Elevated frequencies of micronucleated erythrocytes in infants exposed to" exact="zidovudine" post="in utero and postpartum to prevent mother-to-child transmission of"/>
   <result pre="Transmission StudyJ Acquir Immune Defic Syndr443200729930517159659 59.MirochnickM.RodmanJ.H.RobbinsB.L.FridlandA.GandíaJ.HittiJ.BardeguezA.RathoreM.H.Gonzalez GarciaA.CababasayM.SamsonP.MofensonL.BrysonY.J.DorenbaumA.Pharmacokinetics of oral" exact="zidovudine" post="administered during labour: a preliminary studyHIV Med87200745145617760737 60.WattsD.H.Teratogenicity risk"/>
   <result pre="61.FeolaD.J.GarvyB.A.RappR.P.ThorntonA.C.Blunted humoral response to influenza vaccination in patients exposed to" exact="zidovudine" post="plus trimethoprim–sulfamethoxazolePharmacotherapy277200793794717594199 62.AweekaF.T.KangM.YuJ.Y.LizakP.AlstonB.ChungR.T.collab: AIDS Clinical Trials Group 5092s Study"/>
   <result pre="Trials Group 5092s Study TeamPharmacokinetic evaluation of the effects of" exact="ribavirin" post="on zidovudine triphosphate formation: ACTG 5092s Study TeamHIV Med85200728829417561874"/>
   <result pre="5092s Study TeamPharmacokinetic evaluation of the effects of ribavirin on" exact="zidovudine" post="triphosphate formation: ACTG 5092s Study TeamHIV Med85200728829417561874 63.DominguezS.GhosnJ.PeytavinG.IzzedineH.WirdenM.KtorzaN.MillerM.Aubron-OlivierC.TrylesinskiA.CalvezV.DerayG.KatlamaC.Efficacy and"/>
   <result pre="formation: ACTG 5092s Study TeamHIV Med85200728829417561874 63.DominguezS.GhosnJ.PeytavinG.IzzedineH.WirdenM.KtorzaN.MillerM.Aubron-OlivierC.TrylesinskiA.CalvezV.DerayG.KatlamaC.Efficacy and safety of" exact="tenofovir" post="double-dose in treatment-experienced HIV-infected patients: the TENOPLUS studyJ Med"/>
   <result pre="las causas y factores predictivos de discontinuacion del tratamiento con" exact="tenofovir" post="en pacientes VIH pretratados. [Analysis of the causes and"/>
   <result pre="of the causes and predictive factors for discontinuing treatment with" exact="tenofovir" post="in pretreated HIV patients.]Farm Hosp314200720020518052613 65.PapaleoA.WarszawskiJ.SalomonR.JullienV.VeberF.DechauxM.BlancheS.Increased beta-2 microglobulinuria in"/>
   <result pre="66.MaggioloF.Efavirenz Expert Opin Pharmacother8820071137114517516877 67.ArendtG.de NockerD.von GiesenH.J.NoltingT.Neuropsychiatric side effects of" exact="efavirenz" post="therapyExpert Opin Drug Saf62200714715417367260 68.Sánchez-CondeM.PalaciosR.SanzJ.Rodríguez-NovoaS.RivasP.SantosJ.SolaJ.AsensiV.de MendozaC.EstradaV.BarreiroP.González-LahozJ.Jiménez-NacherI.SorianoV.Efficacy and safety of"/>
   <result pre="and safety of simplification therapy with once-daily tenofovir, lamivudine, and" exact="efavirenz" post="in HIV-1-infected patients with undetectable plasma viral load on"/>
   <result pre="efavirenzClin Infect Dis45102007e128e13017968817 76.GermanP.GreenhouseB.CoatesC.DorseyG.RosenthalP.J.CharleboisE.LindegardhN.HavlirD.AweekaF.T.Hepatotoxicity due to a drug interaction between" exact="amodiaquine" post="plus artesunate and efavirenzClin Infect Dis446200788989117304470 77.LiuP.FosterG.LaBadieR.R.GutierrezM.J.SharmaA.Pharmacokinetic interaction between"/>
   <result pre="Dis45102007e128e13017968817 76.GermanP.GreenhouseB.CoatesC.DorseyG.RosenthalP.J.CharleboisE.LindegardhN.HavlirD.AweekaF.T.Hepatotoxicity due to a drug interaction between amodiaquine plus" exact="artesunate" post="and efavirenzClin Infect Dis446200788989117304470 77.LiuP.FosterG.LaBadieR.R.GutierrezM.J.SharmaA.Pharmacokinetic interaction between voriconazole and"/>
   <result pre="amodiaquine plus artesunate and efavirenzClin Infect Dis446200788989117304470 77.LiuP.FosterG.LaBadieR.R.GutierrezM.J.SharmaA.Pharmacokinetic interaction between" exact="voriconazole" post="and efavirenz at steady state in healthy male subjectsJ"/>
   <result pre="artesunate and efavirenzClin Infect Dis446200788989117304470 77.LiuP.FosterG.LaBadieR.R.GutierrezM.J.SharmaA.Pharmacokinetic interaction between voriconazole and" exact="efavirenz" post="at steady state in healthy male subjectsJ Clin Pharmacol4812008738418025525"/>
   <result pre="by non-nucleoside reverse transcrptase inhibitorsJ Antimicrob Chemother593200734234617255142 79.De LazzariE.LeónA.ArnaizJ.A.MartinezE.KnobelH.NegredoE.ClotetB.MontanerJ.StorferS.AsenjoM.A.MallolasJ.MirJ.M.GatellJ.M.Hepatotoxicity of" exact="nevirapine" post="in virologically suppressed patients according to gender and CD4"/>
   <result pre="Med94200822122618366445 80.KnobelH.GuelarA.MonteroM.CarmonaA.LuqueS.BerenguerN.GonzálezA.Risk of side effects associated with the use of" exact="nevirapine" post="in treatment-naive patients, with respect to gender and CD4"/>
   <result pre="of a large clinical cohortJ Antimicrob Chemother593200756957217255141 82.ManfrediR.CalzaL.Safety issues about" exact="nevirapine" post="administration in HIV-infected pregnant womenJ Acquir Immune Defic Syndr4532007365368"/>
   <result pre="Acquir Immune Defic Syndr4532007365368 83.Ramirez-HernandezM.Sanchez-SierraB.Martinez-EscribanoJ.A.Widespread vitiligo after erythroderma caused by" exact="nevirapine" post="in a patient with AIDSActa Derm Venereol875200744244317721659 84.SantosR.P.RamiloO.BartonT.Nevirapine-associated rash"/>
   <result pre="between early rash or liver toxicity and plasma concentrations of" exact="nevirapine" post="and primary metabolitesHIV Clin Trials86200739139918042504 87.NatarajanU.PymA.McDonaldC.VelisettyP.EdwardsS.G.HayP.WelchJ.de RuiterA.TaylorG.P.AndersonJ.Safety of nevirapine"/>
   <result pre="of nevirapine and primary metabolitesHIV Clin Trials86200739139918042504 87.NatarajanU.PymA.McDonaldC.VelisettyP.EdwardsS.G.HayP.WelchJ.de RuiterA.TaylorG.P.AndersonJ.Safety of" exact="nevirapine" post="in pregnancyHIV Med812007646917305934 88.VitezicaZ.G.MilpiedB.LonjouC.BorotN.LedgerT.N.LefebvreA.HovnanianA.HLA-DRB1∗01 associated with cutaneous hypersensitivity induced"/>
   <result pre="in pregnancyHIV Med812007646917305934 88.VitezicaZ.G.MilpiedB.LonjouC.BorotN.LedgerT.N.LefebvreA.HovnanianA.HLA-DRB1∗01 associated with cutaneous hypersensitivity induced by" exact="nevirapine" post="and efavirenzAIDS224200854054118301070 89.GatanagaH.YazakiH.TanumaJ.HondaM.GenkaI.TeruyaK.TachikawaN.KikuchiY.OkaS.HLA-Cw8 primarily associated with hypersensitivity to nevirapineAIDS212200726426517197830"/>
   <result pre="efavirenzAIDS224200854054118301070 89.GatanagaH.YazakiH.TanumaJ.HondaM.GenkaI.TeruyaK.TachikawaN.KikuchiY.OkaS.HLA-Cw8 primarily associated with hypersensitivity to nevirapineAIDS212200726426517197830 90.CooperC.L.van HeeswijkR.P.Once-daily" exact="nevirapine" post="dosing: a pharmacokinetics, efficacy and safety reviewHIV Med81200717 91.ClotetB.Once-daily"/>
   <result pre="a pharmacokinetics, efficacy and safety reviewHIV Med81200717 91.ClotetB.Once-daily dosing of" exact="nevirapine" post="in HAARTJ Antimicrob Chemother6112008131618006524 92.ManosuthiW.AthichathanabadiC.UttayamakulS.PhoorisriT.SungkanuparphS.Plasma nevirapine levels, adverse events"/>
   <result pre="Med81200717 91.ClotetB.Once-daily dosing of nevirapine in HAARTJ Antimicrob Chemother6112008131618006524 92.ManosuthiW.AthichathanabadiC.UttayamakulS.PhoorisriT.SungkanuparphS.Plasma" exact="nevirapine" post="levels, adverse events and efficacy of antiretroviral therapy among"/>
   <result pre="therapy and fluconazoleBMC Infect Dis720071417352798 93.SekarV.J.LefebvreE.De MarezT.Spinosa-GuzmanS.De PauwM.De PaepeE.VangeneugdenT.HoetelmansR.M.Pharmacokinetics of" exact="darunavir" post="(TMC114) and atazanavir during coadministration in HIV-negative, healthy volunteersDrugs"/>
   <result pre="Infect Dis720071417352798 93.SekarV.J.LefebvreE.De MarezT.Spinosa-GuzmanS.De PauwM.De PaepeE.VangeneugdenT.HoetelmansR.M.Pharmacokinetics of darunavir (TMC114) and" exact="atazanavir" post="during coadministration in HIV-negative, healthy volunteersDrugs R D84200724124817596110 94.TorresH.A.BarnettB.J.ArduinoR.C.Alopecia"/>
   <result pre="in HIV-negative, healthy volunteersDrugs R D84200724124817596110 94.TorresH.A.BarnettB.J.ArduinoR.C.Alopecia associated with ritonavir-boosted" exact="atazanavir" post="therapyAIDS211020071391139217545728 95.MallolasJ.SarasaM.NomdedeuM.SorianoA.López-PúaY.BlancoJ.L.MartínezE.GatellJ.M.Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in"/>
   <result pre="D84200724124817596110 94.TorresH.A.BarnettB.J.ArduinoR.C.Alopecia associated with ritonavir-boosted atazanavir therapyAIDS211020071391139217545728 95.MallolasJ.SarasaM.NomdedeuM.SorianoA.López-PúaY.BlancoJ.L.MartínezE.GatellJ.M.Pharmacokinetic interaction between" exact="rifampicin" post="and ritonavir-boosted atazanavir in HIV-infected patientsHIV Med82200713113417352770 96.NacherM.VantilckeV.MahamatA.El GuedjM.VazT.RandrianjohanyA.ClytiE.AznarC.CarmeB.CouppiP.Increased"/>
   <result pre="with ritonavir-boosted atazanavir therapyAIDS211020071391139217545728 95.MallolasJ.SarasaM.NomdedeuM.SorianoA.López-PúaY.BlancoJ.L.MartínezE.GatellJ.M.Pharmacokinetic interaction between rifampicin and ritonavir-boosted" exact="atazanavir" post="in HIV-infected patientsHIV Med82200713113417352770 96.NacherM.VantilckeV.MahamatA.El GuedjM.VazT.RandrianjohanyA.ClytiE.AznarC.CarmeB.CouppiP.Increased incidence of cutaneous"/>
   <result pre="a benign form of immune reconstitution disease?AIDS211620072248225018090055 97.TorresH.A.ArduinoR.C.Fosamprenavir calcium plus" exact="ritonavir" post="for HIV infectionExpert Rev Anti Infect Ther53200734936317547501 98.CanestriA.CisseM.MarcelinA.G.PeytavinG.TraoreE.AssoumouL.TraoreO.KoitaV.DialloF.SangareA.T.SidibM.K.CalvezV.SyllaA.KatlamaC.TubianaR.Experience of"/>
   <result pre="indinavir-associated nephrological complications in HIV-infected adults (predominantly women) with high" exact="indinavir" post="plasma concentration in Abidjan, Côte d’IvoireAIDS Res Hum Retroviruses2312007626617263634"/>
   <result pre="recognition and managementAm J Clin Dermatol84200722123317645377 103.UnadkatJ.D.WaraD.W.HughesM.D.MathiasA.A.HollandD.T.PaulM.E.ConnorJ.HuangS.NguyenB.Y.WattsD.H.MofensonL.M.SmithE.DeutschP.KaiserK.A.TuomalaR.E.Pharmacokinetics and safety of" exact="indinavir" post="in human immunodeficiency virus-infected pregnant womenAntimicrob Agents Chemother512200778378617158945 104.MartC.PeñaJ.M.BatesI.MaderoR.de"/>
   <result pre="2003Acta Obstet Gynecol Scand864200740941517486461 105.DomínguezM.V.CeballosV.C.CostaR.V.LaraT.E.FlorencioV.D.Paronychia in an HIV-infected patient under" exact="nelfinavir" post="therapyJ Eur Acad Dermatol Venereol215200771071117448006 106.PessanhaT.M.CamposJ.M.BarrosA.C.PoneM.V.GarridoJ.R.PoneS.M.Iatrogenic Cushing’s syndrome in"/>
   <result pre="Venereol215200771071117448006 106.PessanhaT.M.CamposJ.M.BarrosA.C.PoneM.V.GarridoJ.R.PoneS.M.Iatrogenic Cushing’s syndrome in a adolescent with AIDSs on" exact="ritonavir" post="and inhaled fluticasone. Case report and literature reviewAIDS2142007529532 107.St"/>
   <result pre="reviewAIDS2142007529532 107.St GermainR.M.YigitS.WellsL.GirottoJ.E.SalazarJ.C.Cushing syndrome and severe adrenal suppression caused by" exact="fluticasone" post="and protease inhibitor combination in an HIV-infected adolescentAIDS Patient"/>
   <result pre="combination in an HIV-infected adolescentAIDS Patient Care STDS216200737337717594245 108.KingJ.R.KakudaT.N.PaulS.TseM.M.AcostaE.P.BeckerS.L.Pharmacokinetics of" exact="saquinavir" post="with atazanavir or low-dose ritonavir administered once daily (ASPIRE"/>
   <result pre="an HIV-infected adolescentAIDS Patient Care STDS216200737337717594245 108.KingJ.R.KakudaT.N.PaulS.TseM.M.AcostaE.P.BeckerS.L.Pharmacokinetics of saquinavir with" exact="atazanavir" post="or low-dose ritonavir administered once daily (ASPIRE I) or"/>
   <result pre="Patient Care STDS216200737337717594245 108.KingJ.R.KakudaT.N.PaulS.TseM.M.AcostaE.P.BeckerS.L.Pharmacokinetics of saquinavir with atazanavir or low-dose" exact="ritonavir" post="administered once daily (ASPIRE I) or twice daily (ASPIRE"/>
   <result pre="Anti Infect Ther66200879780319053893 113.GatheJ.C.Jr.PieroneG.PilieroP.ArastehK.RubioR.LalondeR.G.CooperD.LazzarinA.KohlbrennerV.M.DohnanyiC.SaboJ.MayersD.Efficacy and safety of three doses of" exact="tipranavir" post="boosted with ritonavir in treatment-experienced HIV type-1 infected patientsAIDS"/>
   <result pre="113.GatheJ.C.Jr.PieroneG.PilieroP.ArastehK.RubioR.LalondeR.G.CooperD.LazzarinA.KohlbrennerV.M.DohnanyiC.SaboJ.MayersD.Efficacy and safety of three doses of tipranavir boosted with" exact="ritonavir" post="in treatment-experienced HIV type-1 infected patientsAIDS Res Hum Retroviruses232200721622317263650"/>
   <result pre="Hum Retroviruses232200721622317263650 114.ArbuthnotC.WildeJ.T.Increased risk of bleeding with the use of" exact="tipranavir" post="boosted with ritonavir in haemophilic patientsHaemophilia141200814014118184260 115.ChrysosG.GerakariS.StasiniF.KokkorisS.KourousisD.VelegrakiA.Intracranial haemorrhage possibly"/>
   <result pre="risk of bleeding with the use of tipranavir boosted with" exact="ritonavir" post="in haemophilic patientsHaemophilia141200814014118184260 115.ChrysosG.GerakariS.StasiniF.KokkorisS.KourousisD.VelegrakiA.Intracranial haemorrhage possibly related to tipranavir"/>
   <result pre="with ritonavir in haemophilic patientsHaemophilia141200814014118184260 115.ChrysosG.GerakariS.StasiniF.KokkorisS.KourousisD.VelegrakiA.Intracranial haemorrhage possibly related to" exact="tipranavir" post="in an HIV-1 patient with cryptococcal meningitisJ Infect5712008858718314196 116.de"/>
   <result pre="of tipranavir/ritonavir: case reportAIDS211120071495149617589203 119.NaegerL.K.StrubleK.A.Food and Drug Administration analysis of" exact="tipranavir" post="clinical resistance in HIV-1-infected treatment-experienced patientsAIDS212200717918517197808 120.VourvahisM.KashubaA.D.Mechanisms of pharmacokinetic"/>
   <result pre="interactions associated with ritonavir-enhanced tipranavirPharmacotherapy276200788890917542771 121.WalmsleyS.L.KatlamaC.LazzarinA.ArestéhK.PieroneG.BlickG.JohnsonM.MeierU.MacGregorT.R.LeithJ.G.Pharmacokinetics, safety, and efficacy of" exact="tipranavir" post="boosted with ritonavir alone or in combination with other"/>
   <result pre="ritonavir-enhanced tipranavirPharmacotherapy276200788890917542771 121.WalmsleyS.L.KatlamaC.LazzarinA.ArestéhK.PieroneG.BlickG.JohnsonM.MeierU.MacGregorT.R.LeithJ.G.Pharmacokinetics, safety, and efficacy of tipranavir boosted with" exact="ritonavir" post="alone or in combination with other boosted protease inhibitors"/>
   <result pre="Psychiatry229200793593617721896 123.MaxwellS.R.Tamiflu and neuropsychiatric disturbance in adolescentsBMJ334760620071232123317569896 124.WhitleyR.J.The role of" exact="oseltamivir" post="in the treatment and prevention of influenza in childrenExpert"/>
   <result pre="Opin Drug Metab Toxicol35200775576717916060 125.KawaiN.IkematsuH.IwakiN.MaedaT.KanazawaH.KawashimaT.TanakaO.YamauchiS.KawamuraK.NagaiT.HoriiS.HirotsuN.KashiwagiS.A comparison of the effectiveness of" exact="zanamivir" post="and oseltamivir for the treatment of influenza A and"/>
   <result pre="Metab Toxicol35200775576717916060 125.KawaiN.IkematsuH.IwakiN.MaedaT.KanazawaH.KawashimaT.TanakaO.YamauchiS.KawamuraK.NagaiT.HoriiS.HirotsuN.KashiwagiS.A comparison of the effectiveness of zanamivir and" exact="oseltamivir" post="for the treatment of influenza A and BJ Infect5612008515717936910"/>
   <result pre="BJ Infect5612008515717936910 126.MatsushitaM.NishiharaH.NishiyamaR.KobayashiY.Acute hemorrhagic colitis associated with oral administration of" exact="oseltamivir" post="for the treatment of influenza AJ Infect Chemother134200726726917721691 127.MathesonN.J.HarndenA.R.PereraR.SheikhA.Symmonds-AbrahamsM.Neuraminidase"/>
   <result pre="Lecture 2006Antivirals for influenzaJ Infect Dis1962200718119017570104 129.SchentagJ.J.HillG.ChuT.RaynerC.R.Similarity in pharmacokinetics of" exact="oseltamivir" post="and oseltamivir carboxylate in Japanese and Caucasian subjectsJ Clin"/>
   <result pre="for influenzaJ Infect Dis1962200718119017570104 129.SchentagJ.J.HillG.ChuT.RaynerC.R.Similarity in pharmacokinetics of oseltamivir and" exact="oseltamivir" post="carboxylate in Japanese and Caucasian subjectsJ Clin Pharmacol476200768969617456583 130.SalmerónJ.DiagoM.AndradeR.PérezR.SolR.RomeroM.de"/>
   <result pre="la MataM.GranadosR.Ruiz-ExtremeraA.Muñoz de RuedaP.Induction doses of interferon-alpha-2a in combination with" exact="ribavirin" post="and/or amantadine for the treatment of chronic hepatitis C"/>
   <result pre="de RuedaP.Induction doses of interferon-alpha-2a in combination with ribavirin and/or" exact="amantadine" post="for the treatment of chronic hepatitis C in non-responders"/>
   <result pre="of induction doses of interferon alone or in combination with" exact="ribavirin" post="or ribavirin plus amantadine for treatment of nonresponder patients"/>
   <result pre="doses of interferon alone or in combination with ribavirin or" exact="ribavirin" post="plus amantadine for treatment of nonresponder patients with chronic"/>
   <result pre="interferon alone or in combination with ribavirin or ribavirin plus" exact="amantadine" post="for treatment of nonresponder patients with chronic hepatitis CJ"/>
   <result pre="hepatitis CJ Gastroenterol425200736236717530360 133.UyamaH.NakamuraH.HayashiE.OgawaH.EnomotoH.YoshidaK.OkudaY.YamamotoM.HadaT.HayashiN.Triple therapy of initial high-dose interferon with" exact="ribavirin" post="and amantadine for patients with chronic hepatitis CHepatol Res375200732533017441804"/>
   <result pre="Gastroenterol425200736236717530360 133.UyamaH.NakamuraH.HayashiE.OgawaH.EnomotoH.YoshidaK.OkudaY.YamamotoM.HadaT.HayashiN.Triple therapy of initial high-dose interferon with ribavirin and" exact="amantadine" post="for patients with chronic hepatitis CHepatol Res375200732533017441804 134.CalancaL.N.FehrT.JochumW.Fischer-VetterJ.MüllhauptB.WüthrichR.P.AmbühlP.M.Combination therapy"/>
   <result pre="for patients with chronic hepatitis CHepatol Res375200732533017441804 134.CalancaL.N.FehrT.JochumW.Fischer-VetterJ.MüllhauptB.WüthrichR.P.AmbühlP.M.Combination therapy with" exact="ribavirin" post="and amantadine in renal transplant patients with chronic hepatitis"/>
   <result pre="with chronic hepatitis CHepatol Res375200732533017441804 134.CalancaL.N.FehrT.JochumW.Fischer-VetterJ.MüllhauptB.WüthrichR.P.AmbühlP.M.Combination therapy with ribavirin and" exact="amantadine" post="in renal transplant patients with chronic hepatitis C virus"/>
   <result pre="with chronic hepatitis C virus infection is not superior to" exact="ribavirin" post="aloneJ Clin Virol3912007545817409018 135.FrenchD.D.MargoC.E.Postmarketing surveillance of corneal edema, Fuchs"/>
   <result pre="Clin Virol3912007545817409018 135.FrenchD.D.MargoC.E.Postmarketing surveillance of corneal edema, Fuchs dystrophy, and" exact="amantadine" post="use in the Veterans Health AdministrationCornea26920071087108917893540"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7149589\results\search\drugs\results.xml">
   <result pre="al. (2000) 11 Influenza virus protein NA Zanamivir, oseltamivir, and" exact="peramivir" post="New strategies in small-molecule drug development to overcome influenza"/>
   <result pre="crystal structure of mutant viral polymerases with less sensitivity to" exact="ribavirin" post="was reported (Ferrer-Orta et al, 2010). 19.2.2 Herpesviruses Herpesviruses"/>
   <result pre="nucleoside analogs except foscarnet and cidofovir, while acyclovir, famciclovir, and" exact="valaciclovir" post="are used to treat the majority of cases of"/>
   <result pre="al., 2003). Other medications such as foscarnet, valganciclovir, ganciclovir, and" exact="cidofovir" post="have activity against the alpha herpesviruses and are recommended"/>
   <result pre="et al., 2004). Moreover, the inhibition of nsP4 RdRp by" exact="ribavirin" post="through its interaction with Cys483 residue increases the replication"/>
   <result pre="inhibitor of VEEV. It can serve as a substitute for" exact="ribavirin" post="because it cannot develop NHC resistant mutants. Favipiravir is"/>
   <result pre="al., 2018). Various inhibitors such as sinefungin, aurintricarboxylic acid, and" exact="ribavirin" post="were assessed and their inhibitory effect against nsP1 was"/>
   <result pre="three inhibitors against protein NA were approved by FDA namely" exact="zanamivir" post="(Relenza, Glaxo Smith Kline), oseltamivir (Tamiflu, Roche), and peramivir"/>
   <result pre="were approved by FDA namely zanamivir (Relenza, Glaxo Smith Kline)," exact="oseltamivir" post="(Tamiflu, Roche), and peramivir (Rapivab, BioCryst). Zanamivir was the"/>
   <result pre="namely zanamivir (Relenza, Glaxo Smith Kline), oseltamivir (Tamiflu, Roche), and" exact="peramivir" post="(Rapivab, BioCryst). Zanamivir was the first approved inhibitor among"/>
   <result pre="Johns Hopkins University BaconT.H.LevinM.J.LearyJ.J.SariskyR.T.SuttonD.Herpes simplex virus resistance to acyclovir and" exact="penciclovir" post="after two decades of antiviral therapyClin. Microbiol. Rev.161200311412812525428 BakailM.OchsenbeinF.Targeting"/>
   <result pre="viruses replication by antiviral compounds: synergistic effect of interferon-α and" exact="ribavirin" post="combinationAntiviral Res.612200411111714670584 BritoA.F.PinneyJ.W.Protein–protein interactions in virus–host systemsFront. Microbiol.82017155728861068 CaoY.LuZ.LiuZ.Foot-and-mouth"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7149606\results\search\drugs\results.xml">
   <result pre="early discovery efforts using phenotypic cellular screens for antiinfluenza activity," exact="amantadine" post="was discovered to have potent inhibitory effects. At the"/>
   <result pre="the drug was shown to have modest efficacy. Analogs of" exact="amantadine" post="were synthesized and found to have a slightly improved"/>
   <result pre="(NA) inhibitors and the development of widespread resistance to both" exact="amantadine" post="and rimantadine in the clinic, the interest in this"/>
   <result pre="and the development of widespread resistance to both amantadine and" exact="rimantadine" post="in the clinic, the interest in this target has"/>
   <result pre="through a new lead discovery exercise. Fig. 4 Arbidol (9)," exact="zanamivir" post="(10), oseltamivir (11), peramivir (12), and laninamivir octanoate (13)."/>
   <result pre="new lead discovery exercise. Fig. 4 Arbidol (9), zanamivir (10)," exact="oseltamivir" post="(11), peramivir (12), and laninamivir octanoate (13). 5.20.4.2.3 Neuraminidase"/>
   <result pre="discovery exercise. Fig. 4 Arbidol (9), zanamivir (10), oseltamivir (11)," exact="peramivir" post="(12), and laninamivir octanoate (13). 5.20.4.2.3 Neuraminidase inhibitors By"/>
   <result pre="of the viral receptor, sialic acid. The approved NA inhibitors" exact="zanamivir" post="(Fig. 4 (10)) (Relenza) and oseltamivir (Fig. 4 (11))"/>
   <result pre="The approved NA inhibitors zanamivir (Fig. 4 (10)) (Relenza) and" exact="oseltamivir" post="(Fig. 4 (11)) (Tamiflu) are potent inhibitors of the"/>
   <result pre="poor physicochemical characteristics and was formulated for intranasal dosing, while" exact="oseltamivir" post="is an oral prodrug that has seen more widespread"/>
   <result pre="during the 2007–08 influenza season that carried a mutation for" exact="oseltamivir" post="resistance and that spread rapidly.32 Together with the mutation"/>
   <result pre="resistance and that spread rapidly.32 Together with the mutation for" exact="oseltamivir" post="resistance, this virus carried compensatory mutations that allowed it"/>
   <result pre="drug, but subsequent seasons have not seen a rise in" exact="oseltamivir" post="resistance rates above the background level of about 3%"/>
   <result pre="is orally available and avoids some of the issues with" exact="cidofovir" post="therapy. During its development, the compound became the target"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7149618\results\search\drugs\results.xml">
   <result pre="aspecific binding of virus to cells, polyanionic compounds (polysulfates, i.e.," exact="dextran" post="sulfate, polysulfonates, polycarboxylates, polyoxometalates, and negatively charged albumins) have"/>
   <result pre="treatment of influenza. Several neuraminidase inhibitors have been developed, including" exact="oseltamivir" post="(Tamiflu) (34.1.3) and zanamivir (34.1.4), which were first used"/>
   <result pre="neuraminidase inhibitors have been developed, including oseltamivir (Tamiflu) (34.1.3) and" exact="zanamivir" post="(34.1.4), which were first used clinically as antiflu therapies"/>
   <result pre="first used clinically as antiflu therapies [65]. Laninamivir (34.1.5) and" exact="peramivir" post="(34.1.6) were also approved in northeast Asia (China, Japan"/>
   <result pre="receptors CCR5 and CXCR4. The CC-chemokine receptor 5 (CCR5) antagonist" exact="maraviroc" post="(34.1.11) is the only approved drug of the novel"/>
   <result pre="in the virus. Amantadine (34.1.12) 76., 77., 78., 79. and" exact="rimantadine" post="(34.1.13) 78., 79., 80. are representatives of uncoating inhibitors"/>
   <result pre="created on principles of structure- and fragment-based drug design, include:" exact="nelfinavir" post="(34.1.14), amprenavir (34.1.15), fosamprenavir (34.1.16), darunavir (34.1.17), saquinavir (34.1.18),"/>
   <result pre="principles of structure- and fragment-based drug design, include: nelfinavir (34.1.14)," exact="amprenavir" post="(34.1.15), fosamprenavir (34.1.16), darunavir (34.1.17), saquinavir (34.1.18), atazanavir (34.1.19),"/>
   <result pre="structure- and fragment-based drug design, include: nelfinavir (34.1.14), amprenavir (34.1.15)," exact="fosamprenavir" post="(34.1.16), darunavir (34.1.17), saquinavir (34.1.18), atazanavir (34.1.19), indinavir (34.1.20),"/>
   <result pre="fragment-based drug design, include: nelfinavir (34.1.14), amprenavir (34.1.15), fosamprenavir (34.1.16)," exact="darunavir" post="(34.1.17), saquinavir (34.1.18), atazanavir (34.1.19), indinavir (34.1.20), lopinavir (34.1.21),"/>
   <result pre="design, include: nelfinavir (34.1.14), amprenavir (34.1.15), fosamprenavir (34.1.16), darunavir (34.1.17)," exact="saquinavir" post="(34.1.18), atazanavir (34.1.19), indinavir (34.1.20), lopinavir (34.1.21), ritonavir (34.1.22),"/>
   <result pre="nelfinavir (34.1.14), amprenavir (34.1.15), fosamprenavir (34.1.16), darunavir (34.1.17), saquinavir (34.1.18)," exact="atazanavir" post="(34.1.19), indinavir (34.1.20), lopinavir (34.1.21), ritonavir (34.1.22), tipranavir (34.1.23),"/>
   <result pre="amprenavir (34.1.15), fosamprenavir (34.1.16), darunavir (34.1.17), saquinavir (34.1.18), atazanavir (34.1.19)," exact="indinavir" post="(34.1.20), lopinavir (34.1.21), ritonavir (34.1.22), tipranavir (34.1.23), simeprevir (34.1.24)."/>
   <result pre="fosamprenavir (34.1.16), darunavir (34.1.17), saquinavir (34.1.18), atazanavir (34.1.19), indinavir (34.1.20)," exact="lopinavir" post="(34.1.21), ritonavir (34.1.22), tipranavir (34.1.23), simeprevir (34.1.24). They share"/>
   <result pre="darunavir (34.1.17), saquinavir (34.1.18), atazanavir (34.1.19), indinavir (34.1.20), lopinavir (34.1.21)," exact="ritonavir" post="(34.1.22), tipranavir (34.1.23), simeprevir (34.1.24). They share relative similarity"/>
   <result pre="saquinavir (34.1.18), atazanavir (34.1.19), indinavir (34.1.20), lopinavir (34.1.21), ritonavir (34.1.22)," exact="tipranavir" post="(34.1.23), simeprevir (34.1.24). They share relative similarity in chemical"/>
   <result pre="atazanavir (34.1.19), indinavir (34.1.20), lopinavir (34.1.21), ritonavir (34.1.22), tipranavir (34.1.23)," exact="simeprevir" post="(34.1.24). They share relative similarity in chemical structures and"/>
   <result pre="Fig. 34.5 Protease inhibitors that act as antivirals. Darunavir (34.1.17)," exact="atazanavir" post="(34.1.19), and ritonavir (34.1.22) are drugs included in the"/>
   <result pre="inhibitors that act as antivirals. Darunavir (34.1.17), atazanavir (34.1.19), and" exact="ritonavir" post="(34.1.22) are drugs included in the list of Top"/>
   <result pre="Drugs by sales for the 2010s. Darunavir–Prezista The synthesis of" exact="darunavir" post="(34.1.17) 81., 82. was carried out via coupling mixed"/>
   <result pre="the mixed carbonate (34.1.27) in the presence of triethylamine provided" exact="darunavir" post="(34.1.17) in high yield (Scheme 34.1 .). Slight modifications"/>
   <result pre="86.. Scheme 34.1 The synthesis of darunavir. A series of" exact="darunavir" post="analogues have displayed impressive enzymatic and antiviral properties and"/>
   <result pre="treat HIV infection. Darunavir usually is used in combination with" exact="ritonavir" post="and other medicines. It maintains antiretroviral activity against a"/>
   <result pre="severe skin reactions or rash. Atazanavir–Reyataz The original synthesis of" exact="atazanavir" post="(34.1.19) 98., 99. was carried out through the reaction"/>
   <result pre="deprotection by coupling with N-methoxycarbonyl-L-tert-leucine (34.1.42) to produce the desired" exact="atazanavir" post="(34.1.19) (Scheme 34.2.). The required benzylhydrazine (34.1.39) was prepared"/>
   <result pre="racemization suppressor hydroxybenzotriazole [HOBt] base-triethylamine) to produce the target compound," exact="atazanavir" post="(34.1.19) (Scheme 34.2 .) The improved approach of the"/>
   <result pre="original synthesis of atazanavir. Another efficient and practical synthesis of" exact="atazanavir" post="was developed by employing the diastereoselective reduction of ketomethylene"/>
   <result pre="was employed, which allowed synthesis of the desired syn-1,2-amino alcohol" exact="atazanavir" post="(34.1.19) exclusively (Scheme 34.3 .) Other minor modifications of"/>
   <result pre="Ritonavir–Norvir The first publications 120., 121. describing the synthesis of" exact="ritonavir" post="(34.1.22) started from methyl N-(benzyloxycarbonyl)-L-phenylalanine methyl ester (34.1.48), which"/>
   <result pre="N-[N-(2-isopropylthiazol-4-ylmethyl)-N-methylaminocarbonyl]-L-valine (34.1.58) (EDCl, HOBt) in THF to produce the desired" exact="ritonavir" post="(34.1.22) (Scheme 34.4 .). Scheme 34.4 The synthesis of"/>
   <result pre="product (34.1.56) (Scheme 34.5 .). Scheme 34.5 The synthesis of" exact="ritonavir" post="(5-thiazolylmethyl)(4-nitrophenyl)carbonate. The second thiazoly moiety-N-[N-(2-isopropylthiazol-4-ylmethyl)-N-methylaminocarbonyl]-L-valine (34.1.58) was synthesized by"/>
   <result pre="methanol/water to provide the target chiral diaminoalcohol (34.1.55) transformed to" exact="ritonavir" post="(34.1.22) (Scheme 34.7 .). Scheme 34.7 The synthesis of"/>
   <result pre="the bioavailability of other protease inhibitors, including saquinavir, nelfinavir, and" exact="indinavir" post="128., 129., 130., 131., 132., 133.. Ritonavir, can cause"/>
   <result pre="Lopinavir–Kaletra The first report of a new protease inhibitor candidate" exact="lopinavir" post="(34.1.21) seems to be Abbott’s patent [134]. The core"/>
   <result pre="(34.1.21) seems to be Abbott’s patent [134]. The core of" exact="lopinavir" post="is identical to that of ritonavir. The 5-thiazolyl end"/>
   <result pre="identical to that of ritonavir. The 5-thiazolyl end group in" exact="ritonavir" post="was replaced by the phenoxyacetyl group, and the 2-isopropylthiazolyl"/>
   <result pre="replaced by the phenoxyacetyl group, and the 2-isopropylthiazolyl group in" exact="ritonavir" post="was replaced by a modified valine in which the"/>
   <result pre="Synthetic strategy employed for the synthesis of multikilogram quantities of" exact="lopinavir" post="is very similar to that implemented for ritonavir (34.1.22),"/>
   <result pre="quantities of lopinavir is very similar to that implemented for" exact="ritonavir" post="(34.1.22), but using the protected version (34.1.79) of the"/>
   <result pre="of NaHCO3 for liberation of free amine, produced the desired" exact="lopinavir" post="(34.1.21) in high yield and purity (Scheme 34.10 .)."/>
   <result pre="Lopinavir is a novel and strong protease inhibitor developed from" exact="ritonavir" post="with high specificity for HIV-1 protease 139., 140., 141.."/>
   <result pre="elongation. The DNA polymerase inhibitors are acyclovir (34.1.93), valacyclovir (34.1.94)," exact="penciclovir" post="(34.1.95), famciclovir (34.1.96), ganciclovir (34.1.97), and valganciclovir (34.1.98) (Fig."/>
   <result pre="DNA polymerase inhibitors are acyclovir (34.1.93), valacyclovir (34.1.94), penciclovir (34.1.95)," exact="famciclovir" post="(34.1.96), ganciclovir (34.1.97), and valganciclovir (34.1.98) (Fig. 34.6 .)."/>
   <result pre="inhibitors are acyclovir (34.1.93), valacyclovir (34.1.94), penciclovir (34.1.95), famciclovir (34.1.96)," exact="ganciclovir" post="(34.1.97), and valganciclovir (34.1.98) (Fig. 34.6 .). Fig. 34.6"/>
   <result pre="(34.1.93), valacyclovir (34.1.94), penciclovir (34.1.95), famciclovir (34.1.96), ganciclovir (34.1.97), and" exact="valganciclovir" post="(34.1.98) (Fig. 34.6 .). Fig. 34.6 Structure of DNA"/>
   <result pre="Viral RNA polymerase inhibitors are represented by the single drug" exact="ribavirin" post="(34.1.100) (Fig. 34.8 .). Fig. 34.8 Structure of ribavirin."/>
   <result pre="inhibitors. The viral DNA polymerase inhibitors acyclovir, valacyclovir, valganciclovir, and" exact="tenofovir" post="are included in the list of Top 200 Drugs"/>
   <result pre="mentioned compound (34.1.118) was transformed to a hydroxyl group with" exact="sodium nitrite" post="in acetic acid, which yielded (34.1.119). Subsequent amination with"/>
   <result pre="ganciclovir. Most of the known literature on the synthesis of" exact="valganciclovir" post="involves the coupling of the protected form of ganciclovir"/>
   <result pre="of valganciclovir involves the coupling of the protected form of" exact="ganciclovir" post="(34.1.97) with N-protected L-valine derivatives followed by deprotection. The"/>
   <result pre="with N-protected L-valine derivatives followed by deprotection. The synthesis of" exact="ganciclovir" post="for the synthesis of valganciclovir started from epichlorohydrin (34.1.122),"/>
   <result pre="by deprotection. The synthesis of ganciclovir for the synthesis of" exact="valganciclovir" post="started from epichlorohydrin (34.1.122), which on reaction with benzyl"/>
   <result pre="of valganciclovir started from epichlorohydrin (34.1.122), which on reaction with" exact="benzyl alcohol" post="in presence of 50% aqueous NaOH (at room temperature)"/>
   <result pre="which was deacetylated with a concentrated NH4OH/methanol solution to produce" exact="ganciclovir" post="(34.1.97) 167., 168. (Scheme 34.16 .). Scheme 34.16 The"/>
   <result pre="Scheme 34.16 The synthesis of ganciclovir. Other synthetic approaches of" exact="ganciclovir" post="(34.1.100) have been reported 169., 170., 171., 172.. Valganciclovir"/>
   <result pre="for ganciclovir. For this purpose, epichlorohydrin (34.1.122) was reacted with" exact="benzyl alcohol" post="in the presence of powdered KOH in toluene at"/>
   <result pre="over palladium hydroxide in refluxing ethanol to produce the desired" exact="valganciclovir" post="(34.1.98) 173., 174. (Scheme 34.17 .). Scheme 34.17 The"/>
   <result pre="of either of the two hydroxy groups of optionally amino-protected" exact="ganciclovir" post="and treating the monohydroxy-protected ganciclovir with protected L-valine (34.1.120)."/>
   <result pre="hydroxy groups of optionally amino-protected ganciclovir and treating the monohydroxy-protected" exact="ganciclovir" post="with protected L-valine (34.1.120). Most of the syntheses involve"/>
   <result pre="of the syntheses involve the use of key starting material" exact="ganciclovir" post="(34.1.97). In one approach, ganciclovir reacted with trimethyl orthoformate"/>
   <result pre="use of key starting material ganciclovir (34.1.97). In one approach," exact="ganciclovir" post="reacted with trimethyl orthoformate (or any other orthoformate) to"/>
   <result pre="which was treated with formic acid in DMF/H2O to yield" exact="ganciclovir" post="O-monoformate (34.1.136). The condensation of the ganciclovir O-monoformate (34.1.136)"/>
   <result pre="DMF/H2O to yield ganciclovir O-monoformate (34.1.136). The condensation of the" exact="ganciclovir" post="O-monoformate (34.1.136) with N-benzyloxycarbonyl-L-valine- (34.1.120) produced the monovalinate (34.1.137),"/>
   <result pre="by hydrogenation with Pd/C catalyst [175] to produce the desired" exact="valganciclovir" post="(34.1.98) (Scheme 34.18 .). Scheme 34.18 The synthesis of"/>
   <result pre=".). Scheme 34.18 The synthesis of valganciclovir. In another strategy," exact="ganciclovir" post="(34.1.97) was protected with tritylchloride or its derivatives in"/>
   <result pre="followed by benzyloxycarbonyl removal by hydrogenation with Pd/C to obtain" exact="valganciclovir" post="(34.1.98) 173., 176., 177., 178. (Scheme 34.19 .). Scheme"/>
   <result pre="or indwelling catheter access associated with the use of intravenous" exact="ganciclovir" post="185., 186., 187., 188., 189., 190., 191., 192.. Nucleoside"/>
   <result pre="point they can be represented as cytidine, guanosine, thymidine, and" exact="adenosine" post="derivatives. They all are inactive in their parent forms"/>
   <result pre="nucleoside reverse transcriptase inhibitors was synthesized, starting with azidothymidine (34.1.142)," exact="zalcitabine" post="(34.1.143), stavudine (34.1.144), lamivudine (34.1.145), emtricitabine (34.1.146), didanosine (34.1.147),"/>
   <result pre="transcriptase inhibitors was synthesized, starting with azidothymidine (34.1.142), zalcitabine (34.1.143)," exact="stavudine" post="(34.1.144), lamivudine (34.1.145), emtricitabine (34.1.146), didanosine (34.1.147), and abacavir"/>
   <result pre="was synthesized, starting with azidothymidine (34.1.142), zalcitabine (34.1.143), stavudine (34.1.144)," exact="lamivudine" post="(34.1.145), emtricitabine (34.1.146), didanosine (34.1.147), and abacavir (34.1.148), and,"/>
   <result pre="starting with azidothymidine (34.1.142), zalcitabine (34.1.143), stavudine (34.1.144), lamivudine (34.1.145)," exact="emtricitabine" post="(34.1.146), didanosine (34.1.147), and abacavir (34.1.148), and, later, some"/>
   <result pre="azidothymidine (34.1.142), zalcitabine (34.1.143), stavudine (34.1.144), lamivudine (34.1.145), emtricitabine (34.1.146)," exact="didanosine" post="(34.1.147), and abacavir (34.1.148), and, later, some nucleotide reverse"/>
   <result pre="(34.1.143), stavudine (34.1.144), lamivudine (34.1.145), emtricitabine (34.1.146), didanosine (34.1.147), and" exact="abacavir" post="(34.1.148), and, later, some nucleotide reverse transcriptase inhibitors, namely,"/>
   <result pre="abacavir (34.1.148), and, later, some nucleotide reverse transcriptase inhibitors, namely," exact="cidofovir" post="(34.1.149), adefovir (34.1.150), and tenofovir (34.1.151) appeared on the"/>
   <result pre="nucleotide reverse transcriptase inhibitors, namely, cidofovir (34.1.149), adefovir (34.1.150), and" exact="tenofovir" post="(34.1.151) appeared on the pharmaceutical market. Tenofovir (34.1.151) is"/>
   <result pre="appeared on the pharmaceutical market. Tenofovir (34.1.151) is used as" exact="tenofovir" post="disoproxil fumarate, a prodrug for oral delivery, and is"/>
   <result pre="reverse transcriptase inhibitors. Tenofovir–Viread Two approaches for the synthesis of" exact="tenofovir" post="(34.1.151) have been reported, both of which employ readily"/>
   <result pre="standard deprotection/cleavage procedure with trimethylsilyl bromide to reflux acetonitrile produces" exact="tenofovir" post="(34.1.151) [201] (Scheme 34.20 .). Scheme 34.20 The synthesis"/>
   <result pre="was deprotected using trimethylsilyl bromide in reflux acetonitrile, which produced" exact="tenofovir" post="(34.1.151) (Scheme 34.21 .) Scheme 34.21 The synthesis of"/>
   <result pre="the prepared adenine (34.1.161) with tosylated hydroxymethylphosphonate diester (34.1.162) using" exact="lithium" post="tert-butoxide in THF, and after quenching obtained product with"/>
   <result pre="subjected to excess bromotrimethylsilane in refluxing acetonitrile produced the desired" exact="tenofovir" post="(34.1.151) [203] (Scheme 34.22 .). Scheme 34.22 The synthesis"/>
   <result pre="it to a manufacturing process for the large-scale synthesis of" exact="tenofovir" post="disoproxil fumarate 204., 205.. Tenofovir became available in 2001"/>
   <result pre="and availability as a component of several fixed-dose formulations make" exact="tenofovir" post="an attractive choice for treatment-naïve and treatment-experienced HIV-infected patients."/>
   <result pre="215., 216., 217., 218., 219.. Since its approval in 2001," exact="tenofovir" post="has become one of the most frequently prescribed agents"/>
   <result pre="discovery of 1-(2-hydroxyethoxymethyl)-6-(phenylthio)thymine (HEPT) (34.1.164) followed by the synthesis of" exact="emivirine" post="(34.1.165) and compounds of the IQP-0410 (34.1.166) series [225],"/>
   <result pre="as the first generation of nonnucleoside reverse-transcriptase inhibitors, which include" exact="efavirenz" post="(34.1.171), the first nonnucleoside reverse transcriptase inhibitor (approved in"/>
   <result pre="reverse transcriptase inhibitor (approved in 1998) 229., 230., 231., 232.," exact="delavirdine" post="(34.1.172) 233., 234., 235., which is rarely used nowadays,"/>
   <result pre="(34.1.172) 233., 234., 235., which is rarely used nowadays, and" exact="nevirapine" post="(34.1.173) 236., 237., 238, 239.; all were commercialized as"/>
   <result pre="leads, and candidates, yielding the second-generation of nonnucleoside reverse-transcriptase inhibitors:" exact="etravirine" post="(34.1.174), which was approved in 2008 240., 241., and"/>
   <result pre="etravirine (34.1.174), which was approved in 2008 240., 241., and" exact="rilpivirine" post="(34.1.175) 242., 243., 244., 245., 246., 247., 248., 249.,"/>
   <result pre="inhibitors. The nonnucleoside reverse-transcriptase inhibitors in clinical use today are" exact="efavirenz" post="(34.1.171), delavirdine (34.1.172), nevirapine (34.1.173), etravirine (34.1.174), and rilpivirine"/>
   <result pre="nonnucleoside reverse-transcriptase inhibitors in clinical use today are efavirenz (34.1.171)," exact="delavirdine" post="(34.1.172), nevirapine (34.1.173), etravirine (34.1.174), and rilpivirine (34.1.175). Lersivirine"/>
   <result pre="inhibitors in clinical use today are efavirenz (34.1.171), delavirdine (34.1.172)," exact="nevirapine" post="(34.1.173), etravirine (34.1.174), and rilpivirine (34.1.175). Lersivirine (34.1.176) is"/>
   <result pre="clinical use today are efavirenz (34.1.171), delavirdine (34.1.172), nevirapine (34.1.173)," exact="etravirine" post="(34.1.174), and rilpivirine (34.1.175). Lersivirine (34.1.176) is a novel"/>
   <result pre="are efavirenz (34.1.171), delavirdine (34.1.172), nevirapine (34.1.173), etravirine (34.1.174), and" exact="rilpivirine" post="(34.1.175). Lersivirine (34.1.176) is a novel second-generation nonnucleoside reverse"/>
   <result pre="and dihydroxypyrimidine carboxamides [263], which finally led to discovery of" exact="raltegravir" post="(34.1.178) 264., 265.. Raltegravir (34.1.178) was the first integrase"/>
   <result pre="another potent inhibitor of viral integrase 282., 283., 284.. Both" exact="raltegravir" post="and elvitegravir are considered first-generation integrase inhibitors and are"/>
   <result pre="inhibitor of viral integrase 282., 283., 284.. Both raltegravir and" exact="elvitegravir" post="are considered first-generation integrase inhibitors and are highly efficacious"/>
   <result pre="chromatography and then N-methylated with dimethyl sulfate in dioxane using" exact="lithium" post="hydride as a base, which provided the compound (34.1.189)."/>
   <result pre="prepared (34.1.192) overnight with p-fluorobenzylamine in methanol produced the desired" exact="raltegravir" post="(34.1.178) 265., 267., 290. (Scheme 34.23 .). Further developments"/>
   <result pre="290. (Scheme 34.23 .). Further developments for efficient manufacturing of" exact="raltegravir" post="are published 291., 292., 293., 294., 295.. Scheme 34.23"/>
   <result pre="Biomol. Sci.21Structural Virology2011319337 72.ZhangG.ZhouF.GuB.DingC.FengD.XieF.WangJ.ZhangC.CaoQ.DengY.HuW.YaoK.In vitro and in vivo evaluation of" exact="ribavirin" post="and pleconaril antiviral activity against enterovirus 71 infectionArch. Virol.1574201266967922245989"/>
   <result pre="flu to treating Parkinson diseaseNeurology781420121096109922474298 77.SaitoR.LiD.SatoM.SuzukiH.AmantadineVirus Rep.3120064047 78.FlemingD.M.Managing influenza: amantadine," exact="rimantadine" post="and beyondInt. J. Clin. Pract.553200118919511351773 79.HaydenF.G.Amantadine and rimantadine—clinical aspectsRichmanD.D.Antiviral"/>
   <result pre="reduced resistance, WO 9967417 (1999). 85.GhoshA.K.SridharP.R.KumaragurubaranN.KohY.WeberI.T.MitsuyaH.Bis-tetrahydrofuran: a privileged ligand for" exact="darunavir" post="and a new generation of HIV protease inhibitors that"/>
   <result pre="review of its properties, use and drug interactionsPharmacology901-2201210210922797653 89.de BethuneM.-P.PeetersA.WigerinckP.From" exact="saquinavir" post="to darunavir: the impact of 10 years of medicinal"/>
   <result pre="103.FanX.SongY.-L.LongY.-Q.An efficient and practical synthesis of the HIV protease inhibitor" exact="atazanavir" post="via a highly diastereoselective reduction approachOrg. Process Res. Dev.12120086975"/>
   <result pre="Y.; Indukuri, V. S. K.; Gorantla, S. R., Preparation of" exact="atazanavir" post="bisulfate, WO 2014030173 (2014). 107.FarajallahA.BunchR.T.MeanwellN.A.Discovery and development of atazanavirKazmierskiW.M.Antiviral"/>
   <result pre="in HIV therapyDrugs Today442200810313218389089 116.GianottiN.SoriaA.LazzarinA.Antiviral activity and clinical efficacy of" exact="atazanavir" post="in HIV-1-infected patients: a reviewNew Microbiol.3022007798817619250 117.HarrisonT.S.ScottL.J.Atazanavir: a review"/>
   <result pre="treatment of HIV-1 infectionAIDS Rev.101200841418385776 133.CooperC.L.van HeeswijkR.P.G.GallicanoK.CameronD.W.A review of low-dose" exact="ritonavir" post="in protease inhibitor combination therapyClin. Infect. Dis.361220031585159212802760 134.Sham, H."/>
   <result pre="synthesis of acyclovir prodrugs. N2-acetylacyclovir and 6-deoxyacyclovirSynthesis61990461464 151.GaoH.MitraA.K.Synthesis of acyclovir" exact="ganciclovir" post="and their prodrugs: a reviewSynthesis32000329351 152.ChuC.K.CutlerS.J.Chemistry and antiviral activities"/>
   <result pre="Panda, A. K.; Kumar, Y.; Khanduri, C. H. Preparation of" exact="ganciclovir" post="mono-N-benzyloxycarbonyl-L-valinate ester, WO 2005092891 (2005). 179.SorberaL.A.CastanerR.CastanerJ.Valganciclovir hydrochlorideDrugs Future2552000474480 180.Arzeno,"/>
   <result pre="Fisher, L. E.; Prince, A. Preparation of L-monovaline ester of" exact="ganciclovir" post="purine acyclic nucleosides as virucides, WO 9727194 (1970). 181.Arzeno,"/>
   <result pre="9727194 (1970). 181.Arzeno, H. B. Preparation of L-monovaline ester of" exact="ganciclovir" post="purine acyclic nucleosides as virucides, WO 9727195 (1997). 182.Arzeno,"/>
   <result pre="Wong, J-W.; Roberts, C. R. Preparation of L-monovaline ester of" exact="ganciclovir" post="purine acyclic nucleosides as virucides, WO 9727197 (1997). 183.Arzeno,"/>
   <result pre="and (r)-9-[2-(phosphonomethoxy)propyl]adenineJ. Med. Chem.492620067799780617181162 205.RipinD.H.B.TeagerD.S.FortunakJ.BashaS.M.BivinsN.BoddyC.N.ByrnS.CatlinK.K.HoughtonS.R.JagadeeshS.T.KumarK.A.MeltonJ.MuneerS.RaoL.N.RaoR.V.RayP.C.ReddyN.G.ReddyR.M.ShekarK.C.SilvertonT.SmithD.T.StringhamR.W.SubbarajuG.V.TalleyF.WilliamsA.Process improvements for the manufacture of" exact="tenofovir" post="disoproxil fumarate at commercial scaleOrg. Process Res. Dev.145201011941201 206.De"/>
   <result pre="commercial scaleOrg. Process Res. Dev.145201011941201 206.De ClercqE.Discovery and development of" exact="tenofovir" post="disoproxil fumarateKazmierskiW.M.Antiviral Drugs: From Basic Discovery Through Clinical Trials2011Wiley85101"/>
   <result pre="233.AdamsW.J.AristoffP.A.JensenR.K.MorozowichW.RomeroD.L.SchinzerW.C.TarpleyW.G.ThomasR.C.Discovery and development of the BHAP nonnucleoside reverse transcriptase inhibitor" exact="delavirdine" post="mesylatePharm. Biotechnol.1119982853129760685 234.FreimuthW.W.Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse"/>
   <result pre="the treatment of HIVExpert Rev. Anti-Infect. Ther.23200436737315482202 239.PodzamczerD.FumeroE.The role of" exact="nevirapine" post="in the treatment of HIV-1 diseaseExpert Opin. Pharmacother.21220012065207811825335 240.SchillerD.S.Youssef-BesslerM.Etravirine:"/>
   <result pre="Med. Chem.5120085843585518763751 266.BeareK.D.CosterM.J.RutledgeP.J.Diketoacid inhibitors of HIV-1 integrase: from L-708,906 to" exact="raltegravir" post="and beyondCurr. Med. Chem.19820121177119222214459 267.SummaV.PaceP.Discovery and development of HIV"/>
   <result pre="HIV integrase inhibitorTher. Clin. Risk Manage422008493500 274.CroxtallJ.D.Lyseng-WilliamsonK.A.PerryC.M.RaltegravirDrugs681200813113818081377 275.CalinR.KatlamaC.The place of" exact="raltegravir" post="in the clinical management of HIV-1 infectionClin. Pract. (London,"/>
   <result pre="management of HIV-1 infectionClin. Pract. (London, U. K.)1042013427438 276.RokasK.E.E.BrandonB.P.ShamroeC.L.ScottS.S.MillisorV.E.BryantJ.E.WeissmanS.B.Role of" exact="raltegravir" post="in HIV-1 managementAnn. Pharmacother.464201257858922496475 277.BrainardD.M.WenningL.A.StoneJ.A.WagnerJ.A.IwamotoM.Clinical pharmacology profile of raltegravir,"/>
   <result pre="an HIV-1 integrase strand transfer inhibitorJ. Clin. Pharmacol.5110201113751402 278.OkekeN.L.HicksC.Role of" exact="raltegravir" post="in the management of HIV-1 infectionHIV/AIDS32011819222096410 279.NunesE.P.Santini de OliveiraM.GrinsztejnB.Clinical"/>
   <result pre="second-generation, highly efficient manufacturing route for the HIV integrase inhibitor" exact="raltegravir" post="potassiumOrg. Process Res. Dev.15120117383 292.HuntJ.A.Raltegravir (Isentress): the first-in-class HIV-1"/>
   <result pre="synthesis, and strategy for minimization of potential impurities observed in" exact="raltegravir" post="potassium drug substanceOrg. Process Res. Dev.168201214221429 295.Gurjar, M. K.;"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7149824\results\search\drugs\results.xml">
   <result pre="nonpolar plant extracts, prepared and evaporated, are reasonably soluble in" exact="dimethyl sulfoxide" post="(DMSO), especially if little or no water is present"/>
   <result pre="at 30% confluence (300 mL) with virus dilution and DEAE" exact="dextran" post="at a final concentration of 20 mg/mL. After adsorption"/>
   <result pre="the &quot;virus only�? control (cells not treated with compound or" exact="tetracycline" post="during the experiment) and multiply this number by 100"/>
   <result pre="positive patients and normal volunteersPhytother. Res.14200033333810925397 ChamorroC.de LatorreF.J.MonteroA.Sa’nchez-IzquierdoJ.A.JarenoA.MorenoJ.A.Comparative study of" exact="propofol" post="versus midazolam in the sedation of critically ill patients:"/>
   <result pre="and normal volunteersPhytother. Res.14200033333810925397 ChamorroC.de LatorreF.J.MonteroA.Sa’nchez-IzquierdoJ.A.JarenoA.MorenoJ.A.Comparative study of propofol versus" exact="midazolam" post="in the sedation of critically ill patients: results of"/>
   <result pre="active constituents from Piper longumBioorg. Med. Chem. Lett.2320132123212723434420 KangE.H.KownT.W.OhG.T.ParkW.F.ParkS.ParkS.K.The flavonoid" exact="ellagic acid" post="from a medicinal herb inhibits host immune tolerance induced"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7150227\results\search\drugs\results.xml">
   <result pre="ThielH.J.PlagemannP.G.W.MoennigV.PestivirusesFieldsB.N.KnipeD.M.HowleyP.M.Virology1996Lippincott-Raven PublishersPhiladelphia, New York10591073 TundisR.BonesiM.DeguinB.LoizzoM.R.MenichiniF.ConfortiF.Cytotoxic activity and inhibitory effect on" exact="nitric oxide" post="production of triterpene saponins from the roots of Physospermum"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7150462\results\search\drugs\results.xml">
   <result pre="The use of the prophylactic antiviral agent entecavir, compared with" exact="lamivudine" post="and telbivudine, was associated with the decreased risk of"/>
   <result pre="patients were positive for HBeAg. Most patients were treated with" exact="entecavir" post="(ETV) (n=304; 68.2%), lamivudine (LAM) (n=117; 26.2%), or telbivudine"/>
   <result pre="HBeAg. Most patients were treated with entecavir (ETV) (n=304; 68.2%)," exact="lamivudine" post="(LAM) (n=117; 26.2%), or telbivudine (LDT) (n=25; 5.6%) for"/>
   <result pre="with entecavir (ETV) (n=304; 68.2%), lamivudine (LAM) (n=117; 26.2%), or" exact="telbivudine" post="(LDT) (n=25; 5.6%) for HBV prophylaxis. The median duration"/>
   <result pre="tumors and hematological malignancies and between the groups treated with" exact="rituximab" post="and those who were not (P = 0.068 and"/>
   <result pre="large B-cell lymphoma who were receiving rituximab-cyclophosphamide, doxorubicin, vincristine, and" exact="prednisone" post="(R-CHOP) chemotherapy, and the result of such study showed"/>
   <result pre="anti-HBc hepatitis B core antibody CHB chronic hepatitis B ETV" exact="entecavir" post="HBV Hepatitis B virus HBsAg hepatitis B surface antigen"/>
   <result pre="B virus PreS1-Ag HR hazard ratio IQR interquartile range LAM" exact="lamivudine" post="LDT telbivudine R-CHOP rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone References"/>
   <result pre="PreS1-Ag HR hazard ratio IQR interquartile range LAM lamivudine LDT" exact="telbivudine" post="R-CHOP rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone References 1PaulSSaxenaATerrinNet al.Hepatitis"/>
   <result pre="range LAM lamivudine LDT telbivudine R-CHOP rituximab-cyclophosphamide, doxorubicin, vincristine, and" exact="prednisone" post="References 1PaulSSaxenaATerrinNet al.Hepatitis B virus reactivation and prophylaxis during"/>
   <result pre="gastroenterology and hepatology2013281313723020594 4LoombaRRowleyAWesleyRet al.Systematic review: the effect of preventive" exact="lamivudine" post="on hepatitis B reactivation during chemotherapyAnnals of Internal Medicine2008148751952818378948"/>
   <result pre="hematopoietic cell transplantationBlood20029972324233011895763 15JangJWChoiJYBaeSHet al.A randomized controlled study of preemptive" exact="lamivudine" post="in patients receiving transarterial chemo-lipiodolizationHepatology200643223324016440357 16LauGKYiuHHFongDYet al.Early is superior"/>
   <result pre="receiving transarterial chemo-lipiodolizationHepatology200643223324016440357 16LauGKYiuHHFongDYet al.Early is superior to deferred preemptive" exact="lamivudine" post="therapy for hepatitis B patients undergoing chemotherapyGastroenterology200312561742174914724827 17HsuCHsiungCASuIJet al.A"/>
   <result pre="hepatitis B patients undergoing chemotherapyGastroenterology200312561742174914724827 17HsuCHsiungCASuIJet al.A revisit of prophylactic" exact="lamivudine" post="for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a"/>
   <result pre="journal of haematology2002116116616911841412 20LauGKYiuHHFongDYet al.Early is superior to deferred preemptive" exact="lamivudine" post="therapy for hepatitis B patients undergoing chemotherapyGastroenterology200312561742174914724827 21ZhangMZhuGShiKet al.Systematic"/>
   <result pre="in adults: a systematic review and meta-analysisHepatology201663128430626566246 27HuangHLiXZhuJet al.Entecavir vs" exact="lamivudine" post="for prevention of hepatitis B virus reactivation among patients"/>
   <result pre="and anthracycline 25 (5.6) Combined regimen with steroids, anthracycline, and" exact="rituximab" post="17 (3.9) Combined regimen with steroid and rituximab 0"/>
   <result pre="anthracycline, and rituximab 17 (3.9) Combined regimen with steroid and" exact="rituximab" post="0 (0.0) Other chemotherapy regimen 324 (72.6) Duration of"/>
   <result pre="(21.8) Chemotherapy regimen 0.242 Rituximab-containing 13 (76.5) 4 (23.5) Without" exact="rituximab" post="381 (88.8) 48 (11.2) Prophylactic antiviral regimen 0.014 Lamivudine"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7150782\results\search\drugs\results.xml">
   <result pre="with plasmids ptetHBV and pUHD15-1neo under the influence of a" exact="tetracycline" post="responsive promoter. The successful establishment of this system has"/>
   <result pre="HBV/HDV infection after differentiation by the addition of DMSO and" exact="hydrocortisone" post="[72,73,77,106]. Although HepRG can support HBV infection, cccDNA formation,"/>
   <result pre="HBV replicationAntimicrob. Agents Chemother.1997411715172010.1128/AAC.41.8.17159257747 75.LiG.Q.XuW.Z.WangJ.X.DengW.W.LiD.GuH.X.Combination of small interfering RNA and" exact="lamivudine" post="on inhibition of human B virus replication in HepG2.2.15"/>
   <result pre="consToxicol. Appl. Pharmacol.200318923324610.1016/S0041-008X(03)00128-512791308 93.ChoiS.SainzB.Jr.CorcoranP.UprichardS.JeongH.Characterization of increased drug metabolism activity in" exact="dimethyl sulfoxide" post="(DMSO)-treated Huh7 hepatoma cellsXenobiotica20093920521710.1080/0049825080261362019280519 94.ClaytonR.F.RinaldiA.KandybaE.E.EdwardM.WillbergC.KlenermanP.PatelA.H.Liver cell lines for the"/>
   <result pre="the case of HepG2.2.15 and AD38 cells;Requires the addition of" exact="dimethyl sulfoxide" post="(DMSO) to promote differentiation (HepaRG) and supplementation of PEG"/>
   <result pre="A Modelling of HBV-host interactions and anti-HBV drug testing of" exact="entecavir" post="and interferon-β (IFN-β) [89]/2014 Genotypes C and D iPPSC"/>
   <result pre="expression in PHHs and HepG2-NTCP-C4 cells. Testing of antiviral agents" exact="entecavir" post="and myrcludex [87]/2017 Genotypes C and D iPPSC derived"/>
   <result pre="expression in PHHs and HepG2-NTCP-C4 cells. Testing of antiviral agents" exact="entecavir" post="and myrcludex [87]/2017 Genotype D Liver organoids Infection with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7150793\results\search\drugs\results.xml">
   <result pre="did not select for resistant variants after nine passages, whereas" exact="oseltamivir" post="selected for resistant variants after five passages. Our data"/>
   <result pre="have been reported to inhibit various NP functions; for example," exact="naproxen" post="prevents RNA binding to NP [17], a dichlorophenyl thiourea"/>
   <result pre="units/mL penicillin (Nacalai Tesque Inc, Kyoto, Japan), and 100 µg/mL" exact="streptomycin" post="(Nacalai Tesque). Human embryo kidney 293T cells were obtained"/>
   <result pre="phosphate (F. Hoffmann-La Roche, Basel, Switzerland) and its active form" exact="oseltamivir" post="acid (MedChem Express, Monmouth Junction, NJ, USA) were dissolved"/>
   <result pre="USA) were dissolved in phosphate-buffered saline (PBS). Oseltamivir refers to" exact="oseltamivir" post="phosphate unless otherwise stated. Naproxen was purchased from Sigma–Aldrich"/>
   <result pre="serially passaged in the presence of increasing concentrations of either" exact="oseltamivir" post="acid or NUD-1, as described [31]. In the first"/>
   <result pre="infected at a MOI of 0.001 in the presence of" exact="oseltamivir" post="acid (0.001–0.1 µM) or NUD-1 (1–8 µM). These concentrations"/>
   <result pre="on the basis of the 50% inhibitory concentrations (IC50) of" exact="oseltamivir" post="acid (0.02 µM) and NUD-1 (2.2 µM). Cells were"/>
   <result pre="the hemagglutination assay [22]. After identifying the highest concentration of" exact="oseltamivir" post="acid or NUD-1 that permitted detectable viral growth, the"/>
   <result pre="1000-fold and used to infect new cells. The concentrations of" exact="oseltamivir" post="acid and NUD-1 were increased by 10- and 2-fold,"/>
   <result pre="in subsequent passages. The 10-fold increase in the concentration of" exact="oseltamivir" post="acid was attributable to the rapid increase in viral"/>
   <result pre="After the fifth and ninth passages of the virus in" exact="oseltamivir" post="acid and NUD-1, the culture supernatant was harvested. Viral"/>
   <result pre="clone by plaque assay in the presence of 100 µM" exact="oseltamivir" post="was performed after the fifth passage. 2.8. Statistical Analysis"/>
   <result pre="formation of high-molecular-weight structures [35]. The effect of NUD-1 and" exact="naproxen" post="on RNA-induced NP oligomerization was assessed. In the absence"/>
   <result pre="1C, lanes 2–5). The effects of NUD-1 (lanes 6–9) and" exact="naproxen" post="(lanes 10–13) were analyzed by quantifying the intensity of"/>
   <result pre="absence of the compounds (lanes 2–5).The presence of NUD-1 or" exact="naproxen" post="significantly decreased (p &amp;lt; 0.05) the intensity of the"/>
   <result pre="band was suppressed in a dose-dependent manner by NUD-1 or" exact="naproxen" post="treatment (Figure S2A,B). Oseltamivir does not bind to NP,"/>
   <result pre="(Figure S2A, lane 12). These results indicate that NUD-1 and" exact="naproxen" post="interfered with the formation of high-molecular-weight NP oligomers. We"/>
   <result pre="NP (Figure S2E). Also, treatment of NP with NUD-1 and" exact="naproxen" post="in the absence of RNA did not affect NP"/>
   <result pre="results in Figure S1C. The cells treated with DMSO and" exact="oseltamivir" post="expressed GFP at comparable levels, indicating successful transcription activity"/>
   <result pre="proteins. The expression of viral proteins in cells treated with" exact="oseltamivir" post="or DMSO was not inhibited (Figure 3). Oseltamivir inhibits"/>
   <result pre="in the absence of a drug retained similar sensitivity to" exact="oseltamivir" post="acid and NUD-1 as the unpassaged virus. The passage"/>
   <result pre="virus. The passage of the virus in the presence of" exact="oseltamivir" post="acid resulted in the loss of drug sensitivity after"/>
   <result pre="not affect its sensitivity even after nine passages. Notably, the" exact="oseltamivir" post="acid-resistant virus was sensitive to NUD-1. Thus, in our"/>
   <result pre="NUD-1 interferes with NP oligomerization. In clinical studies, resistance to" exact="oseltamivir" post="[51] and reduced susceptibility to baloxavir [9] have been"/>
   <result pre="of IAV with a nucleozin analog. Another group reported that" exact="naproxen" post="could inhibit NP–RNA binding [17,52], the nuclear export of"/>
   <result pre="and cytotoxicity of NUD-1; Figure S2. Effect of NUD-1 and" exact="naproxen" post="on NP oligomerization; Figure S3. In silico analysis of"/>
   <result pre="Serial passage of influenza A virus in the presence of" exact="oseltamivir" post="acid and NUD-1. LINK Click here for additional data"/>
   <result pre="Virol.2012864970498010.1128/JVI.06159-1122345439 17.LejalN.TarusB.BouguyonE.ChenavasS.BerthoN.DelmasB.RuigrokR.W.H.Di PrimoC.Slama-SchwokA.Structure-based discovery of the novel antiviral properties of" exact="naproxen" post="against the nucleoprotein of influenza A virusAntimicrob. Agents Chemother.2013572231224210.1128/AAC.02335-1223459490"/>
   <result pre="activitiesJ. Virol.2010847337734510.1128/JVI.02474-0920463064 51.LinaB.BoucherC.OsterhausA.MontoA.S.SchuttenM.WhitleyR.J.Nguyen-Van-TamJ.S.Five years of monitoring for the emergence of" exact="oseltamivir" post="resistance in patients with influenza A infections in the"/>
   <result pre="Information StudyInfluenza Other Respir. Viruses20181226727810.1111/irv.1253429265727 52.TarusB.BertrandH.ZeddaG.Di PrimoC.QuideauS.Slama-SchwokA.Structure-based design of novel" exact="naproxen" post="derivatives targeting monomeric nucleoprotein of Influenza A virusJ. Biomol."/>
   <result pre="prostate cancerClin. Cancer Res.2013196891690110.1158/1078-0432.CCR-13-158124255071 Figure 1 Effects of NUD-1 and" exact="naproxen" post="on nucleoprotein (NP) oligomerization. (A) Purified recombinant NP was"/>
   <result pre="compound or in the presence of 100 μM NUD-1 or" exact="naproxen" post="and incubated at room temperature overnight before analysis via"/>
   <result pre="The relative band intensity in the presence of NUD-1 or" exact="naproxen" post="was calculated in reference to that in the absence"/>
   <result pre="pDsRed2-monomer-N1. Two hours post-transfection, the cells were treated with DMSO," exact="oseltamivir" post="(10 μM), or NUD-1 (10 μM) and further incubated"/>
   <result pre="number of GFP- and DsRed-positive cells in the presence of" exact="oseltamivir" post="or NUD-1 in reference to the ratio of GFP-"/>
   <result pre="virus (multiplicity of infection = 1) in the presence of" exact="oseltamivir" post="(100 μM), NUD-1 (12.5 μM), or DMSO. Nine hours"/>
   <result pre="Relative band intensity (%) in the presence of NUD-1 and" exact="oseltamivir" post="was calculated in reference to DMSO (control). The level"/>
   <result pre="(multiplicity of infection = 5) in the presence of DMSO," exact="oseltamivir" post="(16 μM), or NUD-1 (16 μM) and incubated for"/>
   <result pre="viruses-12-00337-t001_Table 1Table 1 Sensitivity of the passaged A/California/7/2009 virus to" exact="oseltamivir" post="acid and NUD-1. 50% Inhibitory Concentration (µM) Oseltamivir acid"/>
   <result pre="0.00 1.90 ± 0.28 Passage 5 in the presence of" exact="oseltamivir" post="acid &amp;gt;100 1.75 ± 0.07 Passage 9 in the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7150796\results\search\drugs\results.xml">
   <result pre="The next day, compounds were two-fold serially-diluted nine steps in" exact="dimethyl sulfoxide" post="(DMSO) to final concentrations from 100 µM to 0.19"/>
   <result pre="(EC90 of 1.2 ± 0.3 µM). The EC50 value of" exact="ribavirin" post="was 45.5 ± 13.5 µM (EC90 of 114.5 ±"/>
   <result pre="manner by using benzavir-2 (from 20 to 0.6 µM) and" exact="ribavirin" post="(from 200 to 6.3 µM) to observe plaque forming"/>
   <result pre="significant reduction of plaque formation at all applied concentrations, while" exact="ribavirin" post="only showed inhibition of plaque formation at 200 µM"/>
   <result pre="or DENV2) in the presence of benzavir-2 (2.5 µM) or" exact="ribavirin" post="(50 µM). The supernatant was harvested 24 h or"/>
   <result pre="1.2 ± 0.3 µM), whereas the two commercial antiviral drugs," exact="ribavirin" post="and favipiravir, that were included as positive controls, had"/>
   <result pre="consistent with previous reports displaying a variable efficacy range of" exact="ribavirin" post="against ZIKV (EC50 between 20 and 48 µM) [37,38,39]."/>
   <result pre="dose-dependent manner, using benzavir-2 (from 20 to 0.6 µM) and" exact="ribavirin" post="(from 200 to 6.3 µM) against the Brazilian ZIKV"/>
   <result pre="significant reduction of plaque formation at all applied concentrations, while" exact="ribavirin" post="showed a significant inhibition at 200 µM (Figure 3A)."/>
   <result pre="of the flavivirus genus. The antiviral effect of benzavir-2 and" exact="ribavirin" post="was assessed by focus forming assay on six different"/>
   <result pre="bioavailability of benzavir-2, a broad-acting antiviral compoundSci. Rep.20188192510.1038/s41598-018-20362-929386590 20.KimJ.A.SeongR.K.KumarM.ShinO.S.Favipiravir and" exact="ribavirin" post="inhibit replication of Asian and African strains of zika"/>
   <result pre="the respective compound. Figure 3 Antiviral activity of benzavir-2 and" exact="ribavirin" post="against wild-type Zika virus (wt ZIKV) infection by plaque"/>
   <result pre="per well) and viruses (300 PFUs), together with benzavir-2 or" exact="ribavirin" post="in Dulbecco’s modified Eagle medium (DMEM) with 1% carboxymethylcellulose"/>
   <result pre="benzavir-2 (from 20 to 0.62 µM) or 2-fold serial diluted" exact="ribavirin" post="(200 to 6.25 µM). (B) Plaque forming assay at"/>
   <result pre="(MOI) of 0.1 in the presence of benzavir-2 (2.5 µM)," exact="ribavirin" post="(50 µM), or DMSO in the virus control. After"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7150839\results\search\drugs\results.xml">
   <result pre="[62], antiviral [63], and antibacterial [64,65] activities. Ivermectin (IVN) and" exact="abamectin" post="(ABN) are chemically modified derivatives of avermectin. The activity"/>
   <result pre="from nature. From the natural compounds cited in this review," exact="chloroquine" post="was the only compound tested in vivo, in non-human"/>
   <result pre="treatment of malaria [70]. However, despite the in vitro results," exact="chloroquine" post="demonstrated no relevant results in vivo in decreasing viremia"/>
   <result pre="not correlated with the in vivo analysis that showed that" exact="chloroquine" post="was not suitable for patients with CHIKV. Additionally, the"/>
   <result pre="representing a delay in anti-CHIKV drug development. Apart from the" exact="chloroquine" post="case, all compounds that demonstrated antiviral activity have the"/>
   <result pre="65.LaingR.GillanV.DevaneyE.Ivermectin – Old Drug, New Tricks?Trends Parasitol.20173346347210.1016/j.pt.2017.02.00428285851 66.VargheseF.S.KaukinenP.GläskerS.BespalovM.HanskiL.WennerbergK.KümmererB.M.AholaT.Discovery of berberine," exact="abamectin" post="and ivermectin as antivirals against chikungunya and other alphavirusesAntivir."/>
   <result pre="Old Drug, New Tricks?Trends Parasitol.20173346347210.1016/j.pt.2017.02.00428285851 66.VargheseF.S.KaukinenP.GläskerS.BespalovM.HanskiL.WennerbergK.KümmererB.M.AholaT.Discovery of berberine, abamectin and" exact="ivermectin" post="as antivirals against chikungunya and other alphavirusesAntivir. Res.201611712410.1016/j.antiviral.2015.12.01226752081 67.collab:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7150924\results\search\drugs\results.xml">
   <result pre="broth (Sigma, St. Louis, MO, USA) supplemented with 100 μg/mL" exact="ampicillin" post="at 37 °C until the optical density at 600"/>
   <result pre="therapeutic agents, such as chemotherapeutic agents [50], IFN-α [51], and" exact="ribavirin" post="[6], suggesting this is an attractive strategy to use"/>
   <result pre="virusesAntivir. Res.20077311812510.1016/j.antiviral.2006.08.00516987555 31.BuckwoldV.E.WeiJ.Wenzel-MathersM.RussellJ.Synergistic In Vitro interactions between alpha interferon and" exact="ribavirin" post="against bovine viral diarrhea virus and yellow fever virus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7151241\results\search\drugs\results.xml">
   <result pre="long as the COVID-19 resource centre remains active. Hydroxychloroquine and" exact="azithromycin" post="have been touted for potential prophylaxis or treatment for"/>
   <result pre="are required for viral entry (5). The widely used antibiotic" exact="azithromycin" post="is increasingly recognized as a rare cause of QT"/>
   <result pre="and female sex have been implicated as risk factors. Interestingly," exact="azithromycin" post="can also provoke non-pause-dependent polymorphic ventricular tachycardia (11,12). A"/>
   <result pre="U.S. Food and Drug Administration perspective supported the observations that" exact="azithromycin" post="administration leaves the patient vulnerable to corrected QT (QTc)"/>
   <result pre="agents (5) whenever feasible Safety considerations for the use of" exact="hydroxychloroquine" post="and azithromycin in clinical practice have been described (18)."/>
   <result pre="whenever feasible Safety considerations for the use of hydroxychloroquine and" exact="azithromycin" post="in clinical practice have been described (18). Some of"/>
   <result pre="with permission from Giudicessi et al. (5). References References 1ChenC.Y.WangF.L.LinC.C.Chronic" exact="hydroxychloroquine" post="use associated with QT prolongation and refractory ventricular arrhythmiaClin"/>
   <result pre="erythematosus due to hydroxychloroquineCase Reports in Cardiology20162016462627927478650 4de OlanoJ.HowlandM.A.SuM.K.HoffmanR.S.BiaryR.Toxicokinetics of" exact="hydroxychloroquine" post="following a massive overdoseAm J Emerg Med3720192264.e5–8 5GiudicessiJ.R.NoseworthyP.A.FriedmanP.A.AckermanM.J.Urgent guidance"/>
   <result pre="causes a novel proarrhythmic syndromeCirc Arrhythm Electrophysiol102017e003560 13MosholderA.D.MathewJ.AlexanderJ.J.SmithH.NambiarS.Cardiovascular risks with" exact="azithromycin" post="and other antibacterial drugsN Engl J Med36820131665166823635046 14ZhangM.XieM.LiS.Electrophysiologic studies"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7151266\results\search\drugs\results.xml">
   <result pre="been found that neuraminidase inhibitors (oseltamivir, peramivir, zanamivir), ganciclovir, acyclovir," exact="ribavirin" post="are ineffectual and not recommended for clinical application [3]."/>
   <result pre="onset), without adverse reactions. Vancomycin was discontinued that night and" exact="cefepime" post="was discontinued the following day. On the eighth day"/>
   <result pre="for severe acute respiratory infections caused by 2019-nCoVChembiochem215202073073832022370 2WM.CR.ZL.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7151298\results\search\drugs\results.xml">
   <result pre="experimental model used, Madin-Darby dog kidney cells were treated with" exact="atorvastatin" post="(ATV, 5microM) before inducing the infection. Pretreatment reduced the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7151328\results\search\drugs\results.xml">
   <result pre="of Dermatology, Inc. pmcid: 7151328S0190-9622(20)30607-1 doi: 10.1016/j.jaad.2020.04.031 : Article Does" exact="hydroxychloroquine" post="combat COVID-19? A timeline of evidence AliaErisaMDGrant-KelsJane M.MDgrant@uchc.edu∗[], ∗Correspondence"/>
   <result pre="resource centre remains active. To the Editor: Chloroquine (CQ) and" exact="hydroxychloroquine" post="(HCQ) garnered scientific attention in early February after publication"/>
   <result pre="State Council of China held a news conference indicating that" exact="chloroquine" post="(CQ) had demonstrated efficacy in treating COVID-19–associated pneumonia in"/>
   <result pre="of HCQ 3 times a day for 10 days, plus" exact="azithromycin" post="if deemed necessary. A higher frequency of SARS-CoV-2 clearance"/>
   <result pre="6 days of treatment with HCQ alone or HCQ plus" exact="azithromycin" post="vs the untreated control group (70% vs 12.5%; P"/>
   <result pre="Summary of the findings on the first randomized trial using" exact="hydroxychloroquine" post="against COVID-1913 End points Treatment arm Control arm Body"/>
   <result pre="Table II Summary of the antiviral mechanism of action of" exact="chloroquine" post="and hydroxychloroquine14,15 Mechanism Effect Halts the glycosylation of ACE2R"/>
   <result pre="TNF-α) ACE2R, Angiotensin-converting enzyme 2 receptor; cGAS, cyclic guanosine monophosphate-" exact="adenosine" post="monophosphate synthase; IL, interleukin; MHC, major histocompatibility complex; TLR,"/>
   <result pre="TNF, tumor necrosis factor. ∗Hydroxychloroquine only. References References 1WangM.CaoR.ZhangL.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="Commission of the People's Republic of ChinaAvailable at:http://www.nhc.gov.cn/xcs/yqfkdt/202002/f12a62d10c2a4 8c6895cedf2faea6e1f.shtml 3GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="the 2019 novel coronavirus SARS-CoV-2Int J Antimicrob Agents553202010592332070753 9ColsonP.RolainJ.M.LagierJ.C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int J Antimicrob Agents202010.1016/j.ijantimicag.2020.105932[Epub"/>
   <result pre="fight COVID-19Int J Antimicrob Agents202010.1016/j.ijantimicag.2020.105932[Epub ahead of print] 10GautretP.LagierJ.C.ParolaP.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="Antimicrob Agents202010.1016/j.ijantimicag.2020.105949[Epub ahead of print] 11MahaseE.Covid-19: six million doses of" exact="hydroxychloroquine" post="donated to US despite lack of evidenceBMJ3682020m116632205321 12KimA.H.J.SparksJ.A.LiewJ.W.A rush"/>
   <result pre="dissemination of results and its consequences regarding the use of" exact="hydroxychloroquine" post="for COVID-19Ann Intern Med202010.7326/M20-1223[Epub ahead of print] 13ChenZ.HuJ.ZhangZ.Efficacy of"/>
   <result pre="hydroxychloroquine for COVID-19Ann Intern Med202010.7326/M20-1223[Epub ahead of print] 13ChenZ.HuJ.ZhangZ.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
   <result pre="Available at:10.1101/2020.03.22.20040758 14ZhouD.DaiS.M.TongQ.COVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progressionJ Antimicrob Chemother202010.1093/jac/dkaa114[Epub ahead of"/>
   <result pre="ahead of print] 15DevauxC.A.RolainJ.M.ColsonP.RaoultD.New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int J Antimicrob"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7151655\results\search\drugs\results.xml">
   <result pre="the treatment of both intestinal and extraintestinal amoebiasis [5,6,7,8] until" exact="metronidazole" post="became available [5]. Emetine is structurally unrelated to metronidazole."/>
   <result pre="significantly reduced by the use of 5-HT3 antagonists, such as" exact="ondansetron" post="[10], which may enable higher blood levels to be"/>
   <result pre="be of use. This would include agents such as lopinavir," exact="hydroxychloroquine" post="and mycophenolate with or without interferon beta-1b. In the"/>
   <result pre="agents such as lopinavir, hydroxychloroquine and mycophenolate with or without" exact="interferon beta-1b." post="In the case of mycophenolate with interferon beta-1b, it"/>
   <result pre="or without interferon beta-1b. In the case of mycophenolate with" exact="interferon beta-1b," post="it appears to have been therapeutically effective in treating"/>
   <result pre="ratio of ~30, calculated on trough levels for mycophenolate with" exact="interferon beta-1b," post="sub-therapeutic immunosuppressive doses may still have antiviral efficacy, especially"/>
   <result pre="especially if used in combination with other drugs such as" exact="hydroxychloroquine" post="or lopinavir. From animal studies, interferon beta-1b appears to"/>
   <result pre="other drugs such as hydroxychloroquine or lopinavir. From animal studies," exact="interferon beta-1b" post="appears to exhibit antiviral activity against the coronavirus on"/>
   <result pre="μg/L peak, 300 mg single oral dose. Blood level was" exact="astemizole" post="+ hydroxylated (active) metabolites. Large volume of distribution. Triflupromazine"/>
   <result pre="a trough of 2 μg/mL Mycophenolic acid + 12.5 IU/mL" exact="interferon beta-1b" post="(d) (e) 0.187 320.34 6.24 33.39 [46,47] The blood"/>
   <result pre="Mycophenolic acid is the active metabolite of mycophenolate. Mycophenolate with" exact="interferon beta-1b" post="appears to have been therapeutically effective in treating patients"/>
   <result pre="6.GilmanA.GoodmanL.GoodmanA.Pharmacological Basis Therapeutics6th ed.MacmillanNew York, NY, USA1980978-0-02-344720-4 7.ScraggJ.N.PowellS.J.Emetine hydrochloride and" exact="chloroquine" post="in the treatment of children with amoebic liver abscessArch."/>
   <result pre="lopinavir/ritonavir in HIV type-1-infected individualsAntivir. Ther.2009141001100410.3851/IMP141019918104 34.KamaliF.HuangM.L.Increased systemic availability of" exact="loperamide" post="after oral administration of loperamide and loperamide oxide with"/>
   <result pre="Ther.2009141001100410.3851/IMP141019918104 34.KamaliF.HuangM.L.Increased systemic availability of loperamide after oral administration of" exact="loperamide" post="and loperamide oxide with cotrimoxazoleBr. J. Clin. Pharmacol.19964112512810.1111/j.1365-2125.1996.tb00169.x8838438 35.KarunajeewaH.A.SalmanS.MuellerI.BaiwogF.GomorraiS.LawI.Page-SharpM.RogersonS.J.SibaP.IlettK.F.et"/>
   <result pre="systemic availability of loperamide after oral administration of loperamide and" exact="loperamide" post="oxide with cotrimoxazoleBr. J. Clin. Pharmacol.19964112512810.1111/j.1365-2125.1996.tb00169.x8838438 35.KarunajeewaH.A.SalmanS.MuellerI.BaiwogF.GomorraiS.LawI.Page-SharpM.RogersonS.J.SibaP.IlettK.F.et al.Pharmacokinetics of"/>
   <result pre="loperamide oxide with cotrimoxazoleBr. J. Clin. Pharmacol.19964112512810.1111/j.1365-2125.1996.tb00169.x8838438 35.KarunajeewaH.A.SalmanS.MuellerI.BaiwogF.GomorraiS.LawI.Page-SharpM.RogersonS.J.SibaP.IlettK.F.et al.Pharmacokinetics of" exact="chloroquine" post="and monodesethylchloroquine in pregnancyAntimicrob. Agents Chemother.2010541186119210.1128/AAC.01269-0920086162 36.DurcanL.ClarkeW.MagderL.PetriM.OP0187 Hydroxychloroquine blood"/>
   <result pre="controversies and improving adherenceAnn. Rheum. Dis.20157414214310.1136/annrheumdis-2015-eular.389524107981 37.OrrellC.LittleF.SmithP.FolbP.TaylorW.OlliaroP.BarnesK.I.Pharmacokinetics and tolerability of" exact="artesunate" post="and amodiaquine alone and in combination in healthy volunteersEur."/>
   <result pre="improving adherenceAnn. Rheum. Dis.20157414214310.1136/annrheumdis-2015-eular.389524107981 37.OrrellC.LittleF.SmithP.FolbP.TaylorW.OlliaroP.BarnesK.I.Pharmacokinetics and tolerability of artesunate and" exact="amodiaquine" post="alone and in combination in healthy volunteersEur. J. Clin."/>
   <result pre="for Therapeutic Drug Monitoring in Psychiatry: Update 2011Pharmacopsychiatry20114419523510.1055/s-0031-1286287 39.TaylorG.HoustonJ.ShafferJ.MawerG.Pharmacokinetics of" exact="promethazine" post="and its sulphoxide metabolite after intravenous and oral administration"/>
   <result pre="and oral administration to manBr. J. Clin. Pharmacol.19831528729310.1111/j.1365-2125.1983.tb01501.x6849764 40.YesavageJ.A.HolmanC.A.CohnR.Correlation of" exact="thiothixene" post="serum levels and agePsychopharmacology19817417017210.1007/BF004326876791222 41.SimonsF.E.SimonsK.J.ChungM.YehJ.The comparative pharmacokinetics of H1-receptor"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7152365\results\search\drugs\results.xml">
   <result pre="as long as the COVID-19 resource centre remains active. Keywords" exact="amantadine" post="chemoprophylaxis chemotherapy DAS181 (Fludase) influenza inhaled laninamivir oseltamivir outbreak"/>
   <result pre="active. Keywords amantadine chemoprophylaxis chemotherapy DAS181 (Fludase) influenza inhaled laninamivir" exact="oseltamivir" post="outbreak (control) peramivir pharmacokinetics postexposure resistance respiratory syncytial virus"/>
   <result pre="chemoprophylaxis chemotherapy DAS181 (Fludase) influenza inhaled laninamivir oseltamivir outbreak (control)" exact="peramivir" post="pharmacokinetics postexposure resistance respiratory syncytial virus ribavirin rimantadine RSV604"/>
   <result pre="oseltamivir outbreak (control) peramivir pharmacokinetics postexposure resistance respiratory syncytial virus" exact="ribavirin" post="rimantadine RSV604 seasonal zanamivir In this chapter, antiviral agents"/>
   <result pre="outbreak (control) peramivir pharmacokinetics postexposure resistance respiratory syncytial virus ribavirin" exact="rimantadine" post="RSV604 seasonal zanamivir In this chapter, antiviral agents against"/>
   <result pre="pharmacokinetics postexposure resistance respiratory syncytial virus ribavirin rimantadine RSV604 seasonal" exact="zanamivir" post="In this chapter, antiviral agents against influenza viruses and"/>
   <result pre="alternative. Amantadine and Rimantadine Spectrum Amantadine (1-adamantanamine hydrochloride; Symmetrel) and" exact="rimantadine" post="(α-methyl-1-adamantane methylamine hydrochloride; Flumadine) are symmetrical tricyclic amines (Fig."/>
   <result pre="highly pathogenic avian H5N1, and A (H1N1)pdm09 are resistant to" exact="amantadine" post="and rimantadine (see later discussion).3 By plaque assay, inhibitory"/>
   <result pre="avian H5N1, and A (H1N1)pdm09 are resistant to amantadine and" exact="rimantadine" post="(see later discussion).3 By plaque assay, inhibitory con­centrations of"/>
   <result pre="viruses. Rimantadine is 4 to 10 times more active than" exact="amantadine" post="in some assay systems. Both drugs are inhibitory for"/>
   <result pre="from the 1918 pandemic strain.4 FIGURE 44-1 Chemical structures of" exact="amantadine" post="hydrochloride (A) and rimantadine hydrochloride (B). Higher concentrations (10"/>
   <result pre="strain.4 FIGURE 44-1 Chemical structures of amantadine hydrochloride (A) and" exact="rimantadine" post="hydrochloride (B). Higher concentrations (10 to 50 µg/mL) inhibit other"/>
   <result pre="Rimantadine has pH-dependent trypanocidal activity at concentrations of approximately 1 µg/mL6;" exact="amantadine" post="at the same concentration in combination with doxycycline inhibits"/>
   <result pre="approximately 1 µg/mL6; amantadine at the same concentration in combination with" exact="doxycycline" post="inhibits Coxiella burnetii.7 Amantadine may transiently inhibit hepatitis C"/>
   <result pre="parenteral dosing. Combinations of M2 inhibitors and neuraminidase inhibitors and" exact="ribavirin" post="show enhanced antiviral and therapeutic effects in vitro or"/>
   <result pre="of influenza.9, 10, 11, 12 Mechanism of Action Amantadine and" exact="rimantadine" post="share two concentration-dependent mechanisms of anti-influenza action. Low concentrations"/>
   <result pre="through altered pH regulation of the trans-Golgi network. Amantadine and" exact="rimantadine" post="block proton permeation and prevent M2-mediated changes in pH."/>
   <result pre="the hemagglutinin during its transport late in infection. Amantadine and" exact="rimantadine" post="are also concentrated in the lysosomal fraction of mammalian"/>
   <result pre="in the trans-membrane region of the M2 protein.13 Amantadine and" exact="rimantadine" post="share cross-resistance. In avian models, resistant viruses are virulent,"/>
   <result pre="strains were M2 inhibitor sensitive. Since 2003, the prevalence of" exact="amantadine" post="resistance has increased progressively, although rates vary by virus"/>
   <result pre="vary by virus type and geography.25, 26 Among H3N2 isolates," exact="amantadine" post="resistance increased from 12% worldwide in 200325 to 91%"/>
   <result pre="A (H1N1)pdm09 virus.27 Among nonpandemic H1N1 isolates, the prevalence of" exact="amantadine" post="resistance was 4% in 2004-2005 worldwide and 16% in"/>
   <result pre="may have been contributing factors. Ribavirin and the neuraminidase inhibitors" exact="zanamivir" post="and oseltamivir carboxylate are active in vitro against M2"/>
   <result pre="been contributing factors. Ribavirin and the neuraminidase inhibitors zanamivir and" exact="oseltamivir" post="carboxylate are active in vitro against M2 inhibitor–resistant strains."/>
   <result pre="M2 inhibitor–resistant strains. The triple combination of amantadine, oseltamivir, and" exact="ribavirin" post="impedes the selection of drug-resistant influenza A virus in"/>
   <result pre="activity as single agents.32 Pharmacokinetics The clinical pharmacokinetic characteristics of" exact="amantadine" post="and rimantadine are shown in Table 44-2 . TABLE"/>
   <result pre="single agents.32 Pharmacokinetics The clinical pharmacokinetic characteristics of amantadine and" exact="rimantadine" post="are shown in Table 44-2 . TABLE 44-2 Clinical"/>
   <result pre="equivalent trough plasma levels of 0.3 µg/mL. Plasma protein binding of" exact="amantadine" post="is about 67%, and amantadine's volume of distribution (Vd)"/>
   <result pre="large (4 to 5 L/kg). Nasal secretion and salivary levels of" exact="amantadine" post="approximate those found in the serum. Cerebrospinal fluid levels"/>
   <result pre="levels are 52% to 96% of those in plasma, and" exact="amantadine" post="is excreted in breast milk. Amantadine is eliminated largely"/>
   <result pre="Nephrol. 1982;17:19-23. Amantadine pharmacokinetics remained unaffected by concurrent administration of" exact="oseltamivir" post="and ribavirin in healthy adult volunteers or stable immunocompromised"/>
   <result pre="Amantadine pharmacokinetics remained unaffected by concurrent administration of oseltamivir and" exact="ribavirin" post="in healthy adult volunteers or stable immunocompromised patients.34 Rimantadine"/>
   <result pre="50% higher than those in plasma. In contrast to amantadine," exact="rimantadine" post="undergoes extensive metabolism by hydroxylation, conjugation, and glucuronidation before"/>
   <result pre="hydroxylation, conjugation, and glucuronidation before renal excretion.5 The plasma of" exact="rimantadine" post="averages 24 to 36 hours. No clinically important differences"/>
   <result pre="In hemodialysis patients with severe renal failure, the clearance of" exact="rimantadine" post="is decreased by 40% and the is about 55%"/>
   <result pre="The risks for central nervous system (CNS) adverse effects with" exact="amantadine" post="and possibly with rimantadine are increased by concomitant ingestion"/>
   <result pre="nervous system (CNS) adverse effects with amantadine and possibly with" exact="rimantadine" post="are increased by concomitant ingestion of antihistamines, antidepressants, anticholinergic"/>
   <result pre="is associated with 15% to 20% increases, and aspirin or" exact="acetaminophen" post="is associated with 10% decreases in plasma rimantadine concentrations,"/>
   <result pre="aspirin or acetaminophen is associated with 10% decreases in plasma" exact="rimantadine" post="concentrations, but such changes are unlikely to be significant."/>
   <result pre="Neither adverse clinical nor adverse pharmacokinetic effects are observed when" exact="amantadine" post="and oseltamivir are co-administered.35 Concurrent administration of recommended doses"/>
   <result pre="clinical nor adverse pharmacokinetic effects are observed when amantadine and" exact="oseltamivir" post="are co-administered.35 Concurrent administration of recommended doses of amantadine,"/>
   <result pre="co-administered.35 Concurrent administration of recommended doses of amantadine, oseltamivir, and" exact="ribavirin" post="for 10 days was well tolerated.34 Toxicity Amantadine or"/>
   <result pre="ribavirin for 10 days was well tolerated.34 Toxicity Amantadine or" exact="rimantadine" post="given in treatment courses of 5 days is generally"/>
   <result pre="demonstrated that in children younger than 12 months of age," exact="amantadine" post="and rimantadine were well tolerated, as was oseltamivir.38 No"/>
   <result pre="in children younger than 12 months of age, amantadine and" exact="rimantadine" post="were well tolerated, as was oseltamivir.38 No evidence of"/>
   <result pre="adamantane antiviral agents.39 The most common side effects related to" exact="amantadine" post="ingestion are minor, dose-related gastrointestinal and CNS complaints, including"/>
   <result pre="discontinuation. CNS side effects occur in 5% to 33% of" exact="amantadine" post="recipients at dosages of 200 mg/day but are significantly less"/>
   <result pre="cardiac arrhythmias; and death can occur in association with elevated" exact="amantadine" post="plasma concentrations (1 to 5 µg/mL).45 Neurotoxic reactions may be"/>
   <result pre="(1 to 5 µg/mL).45 Neurotoxic reactions may be transiently reversed by" exact="physostigmine" post="administration, and lidocaine has been used to treat ventricular"/>
   <result pre="Neurotoxic reactions may be transiently reversed by physostigmine administration, and" exact="lidocaine" post="has been used to treat ventricular arrhythmias. Long-term amantadine"/>
   <result pre="and lidocaine has been used to treat ventricular arrhythmias. Long-term" exact="amantadine" post="ingestion has been associated with livedo reticularis, peripheral edema,"/>
   <result pre="and livedo reticularis may improve if treatment is switched from" exact="amantadine" post="to rimantadine.46 Patients with preexisting seizure disorders have an"/>
   <result pre="disorders have an increased frequency of major motor seizures during" exact="amantadine" post="use, and dosage reductions are advised. Psychiatric side effects"/>
   <result pre="although the risk for CNS side effects is lower with" exact="rimantadine" post="at dosages of 200 mg/day or 300 mg/day in ambulatory adults.5"/>
   <result pre="mouth, pupillary dilation, toxic psychosis, and urinary retention in acute" exact="amantadine" post="overdose suggest that anticholinergic activity is present in humans."/>
   <result pre="and in the peripheral nervous system. Malignant ventricular arrhythmia after" exact="amantadine" post="overdose has been described in humans. Amantadine and rimantadine"/>
   <result pre="after amantadine overdose has been described in humans. Amantadine and" exact="rimantadine" post="lack mutagenicity in vitro; carcinogenicity studies have not been"/>
   <result pre="for either. Amantadine is teratogenic and embryotoxic in rats, and" exact="rimantadine" post="may cause teratogenic effects in rabbits and maternal toxicity"/>
   <result pre="in pregnancy category C. Birth defects have been reported after" exact="amantadine" post="exposure during pregnancy.48 The safety of neither amantadine nor"/>
   <result pre="reported after amantadine exposure during pregnancy.48 The safety of neither" exact="amantadine" post="nor rimantadine has been established in pregnancy. Because of"/>
   <result pre="amantadine exposure during pregnancy.48 The safety of neither amantadine nor" exact="rimantadine" post="has been established in pregnancy. Because of excretion in"/>
   <result pre="recommended in nursing mothers. Clinical Studies Influenza A Amantadine and" exact="rimantadine" post="have been efficacious for the prevention and treatment of"/>
   <result pre="and the elderly concluded that available data only demonstrate that" exact="amantadine" post="has prophylactic efficacy and a modest therapeutic effect in"/>
   <result pre="of either adamantane. The emergence of widespread and nearly complete" exact="amantadine" post="resistance among influenza A/H3N2 isolates,26 as well as the"/>
   <result pre="amantadine resistance among influenza A/H3N2 isolates,26 as well as the" exact="amantadine" post="resistance of the pandemic A (H1N1)pdm09 strains, precludes the"/>
   <result pre="to that provided by vaccine.52 Rimantadine was less effective than" exact="zanamivir" post="in reducing cases of influenza A illness in adults"/>
   <result pre="largely due to the emergence of rimantadine-resistant viruses that caused" exact="rimantadine" post="prophylactic failure; no zanamivir-resistant viruses were isolated. Rimantadine administration"/>
   <result pre="A illness and are well tolerated in adults.54 Amantadine and" exact="rimantadine" post="are also effective therapies for uncomplicated adamantane-susceptible influenza A"/>
   <result pre="airway hyperreactivity, resolve more quickly in amantadine-treated patients. Amantadine or" exact="rimantadine" post="treatment in adults with leukemia or stem cell transplantation"/>
   <result pre="in index patients and nosocomial transmission to others.56 In children," exact="rimantadine" post="treatment is associated with lower symptom burden, fever, and"/>
   <result pre="titers during the first 2 days of treatment compared with" exact="acetaminophen" post="administration, but rimantadine-treated children have more prolonged shedding of"/>
   <result pre="but may blunt secretory antibody levels.57 Intermittent aerosol administration of" exact="amantadine" post="or rimantadine seems to be therapeutically useful in uncomplicated"/>
   <result pre="blunt secretory antibody levels.57 Intermittent aerosol administration of amantadine or" exact="rimantadine" post="seems to be therapeutically useful in uncomplicated influenza. No"/>
   <result pre="sustained viral response (SVR). In treatment-naïve patients, the addition of" exact="amantadine" post="(200 mg daily in single or divided doses) to interferon58,"/>
   <result pre="In re-treatment of interferon nonresponders, the combination of interferon plus" exact="amantadine" post="is ineffective61 but the addition of amantadine to the"/>
   <result pre="of interferon plus amantadine is ineffective61 but the addition of" exact="amantadine" post="to the combination of interferon plus ribavirin may be"/>
   <result pre="the addition of amantadine to the combination of interferon plus" exact="ribavirin" post="may be associated with SVR in 10% to 25%.62"/>
   <result pre="in 10% to 25%.62 Amantadine plus combined pegylated interferon and" exact="ribavirin" post="may increase SVR modestly in treatment-experienced patients compared with"/>
   <result pre="(2R,3R,4S)-3-acetamido-2-[CIR,2R-2,3-dihydroxy-1-methoxypropyl]-4-quanidino-3,4-dihydro-2-H-pyram-6-carboxylic acid (Fig. 44-3D ). Laninamivir octanoate consists of an" exact="octanoic acid" post="ester side chain attached at the C3 position of"/>
   <result pre="at the C3 position of laninamivir. Laninamivir octanoate, like polymeric" exact="zanamivir" post="conjugates, shares the pharmacokinetic characteristic of persisting for a"/>
   <result pre="influenza in patients as well. FIGURE 44-3 Chemical structures of" exact="oseltamivir" post="carboxylate (A), zanamivir (B), peramivir (C) and laninamivir (D)."/>
   <result pre="as well. FIGURE 44-3 Chemical structures of oseltamivir carboxylate (A)," exact="zanamivir" post="(B), peramivir (C) and laninamivir (D). Spectrum Laninamivir octanoate"/>
   <result pre="FIGURE 44-3 Chemical structures of oseltamivir carboxylate (A), zanamivir (B)," exact="peramivir" post="(C) and laninamivir (D). Spectrum Laninamivir octanoate exhibits little"/>
   <result pre="and in general appear to be intermediate between those of" exact="oseltamivir" post="carboxylate (lower) and zanamivir (higher), but the clinical importance"/>
   <result pre="to be intermediate between those of oseltamivir carboxylate (lower) and" exact="zanamivir" post="(higher), but the clinical importance of these differences is"/>
   <result pre="either as or more efficacious than multiple doses of oral" exact="oseltamivir" post="or intranasal zanamivir. The results of these studies in"/>
   <result pre="20 mg in children younger than 10 years old, or inhaled" exact="zanamivir" post="as the control neuraminidase inhibitor treatments. Laninamivir octanoate inhaled"/>
   <result pre="Laninamivir octanoate inhaled once was as well tolerated as inhaled" exact="zanamivir" post="20 mg twice daily for 5 days.87 In a double-blind"/>
   <result pre="octanoate of 20 or 40 mg was as well tolerated as" exact="oseltamivir" post="at 2 mg/kg body weight twice daily for 5 days.88"/>
   <result pre="of 20 or 40 mg was as well tolerated as oral" exact="oseltamivir" post="at 75 mg twice daily for 5 days.89 Notwithstanding the"/>
   <result pre="laninamivir octanoate tolerance plus those from studies of orally inhaled" exact="zanamivir" post="collectively suggest that orally inhaled laninamivir octanoate will likely"/>
   <result pre="= 61) or 20 mg (N = 61) laninamivir octanoate or" exact="oseltamivir" post="2 mg/kg (N = 62) ingested twice daily for 5"/>
   <result pre="of which all but 4 possessed the H274Y mutation, mediating" exact="oseltamivir" post="resistance. Oseltamivir therapy was likely not to have been"/>
   <result pre="octanoate 40-mg (28%) and 20-mg (32%) groups than in the" exact="oseltamivir" post="group, which might be con­sidered analogous to a placebo-treated"/>
   <result pre="between those treated with laninamivir octanoate 40 mg (73.5 hours) and" exact="oseltamivir" post="(67.5 hours) but significantly longer in the group treated"/>
   <result pre="their guardians.92 Of the 256 children, 119 were treated with" exact="oseltamivir" post="in weight-appropriate doses, zanamivir (124 cases), one dose of"/>
   <result pre="256 children, 119 were treated with oseltamivir in weight-appropriate doses," exact="zanamivir" post="(124 cases), one dose of intravenous peramivir (4 children),79"/>
   <result pre="in weight-appropriate doses, zanamivir (124 cases), one dose of intravenous" exact="peramivir" post="(4 children),79 or a single dose of orally inhaled"/>
   <result pre="groups. The median time to resolution of fever in the" exact="peramivir" post="group (17.0 hours) was significantly less than in the"/>
   <result pre="Spectrum Oseltamivir phosphate (Tamiflu) is the ethyl ester prodrug of" exact="oseltamivir" post="carboxylate, a sialic acid analogue (see Fig. 44-3A) that"/>
   <result pre="neuraminidases of influenza A and B viruses.93, 94 The metabolite," exact="oseltamivir" post="carboxylate, is approximately 50-fold more potent than the phosphate"/>
   <result pre="the recently circulating (2009) pandemic A/H1N1 viruses (S-OIV).27 Resistance to" exact="oseltamivir" post="has been recently reported in an H7N9 isolate.100 Influenza"/>
   <result pre="Influenza B viruses are 10-fold to 20-fold less susceptible to" exact="oseltamivir" post="carboxylate than influenza A viruses, and influenza B virus"/>
   <result pre="B virus illness responds less well clinically and virologically to" exact="oseltamivir" post="than influenza A illness.101, 102, 103 The carboxylate is"/>
   <result pre="sources or other pathogens only at 106-fold higher concentrations. Oral" exact="oseltamivir" post="is active in murine and ferret models of influenza.94,"/>
   <result pre="subsequent H5N1 infection.104 Neuraminidase inhibitors combined with M2 inhibitors or" exact="ribavirin" post="show enhanced antiviral activity in vitro and in animal"/>
   <result pre="A virus infection,105 including H5N1 virus.106, 107 Amantadine combined with" exact="oseltamivir" post="prevented the emergence of amantadine resistance in cell culture.108"/>
   <result pre="virus.106, 107 Amantadine combined with oseltamivir prevented the emergence of" exact="amantadine" post="resistance in cell culture.108 Mechanism of Action The neuraminidase"/>
   <result pre="replication. Resistance Resistant variants selected by in vitro passage with" exact="oseltamivir" post="carboxylate or zanamivir have point mutations in the viral"/>
   <result pre="variants selected by in vitro passage with oseltamivir carboxylate or" exact="zanamivir" post="have point mutations in the viral hemagglutinin or neuraminidase"/>
   <result pre="susceptibility in enzyme inhibition assays.96 Influenza A variants selected by" exact="oseltamivir" post="carboxylate are subtype specific, most commonly Arg292Lys in N2"/>
   <result pre="(H1N1)pdm09 pandemic, there was no linkage between prevalent use of" exact="oseltamivir" post="in immunocompetent patients and the appearance of oseltamivir-resistant A"/>
   <result pre="strains retained replicative fitness,116 transmissibility,122 and pathogenicity comparable with wild-type" exact="oseltamivir" post="strains in murine and ferret models of influenza infection.123"/>
   <result pre="patients with oseltamivir-resistant H1N1 compared with oseltamivir-sensitive strains.126 Pharmacokinetics Oral" exact="oseltamivir" post="is rapidly absorbed and metabolized by esterases in the"/>
   <result pre="plasma concentrations averages 2 to 4 hours. Dose proportionality of" exact="oseltamivir" post="has been reported over the dose range from 75"/>
   <result pre="carboxylesterase 1, the enzyme that normally catalyzes the conversion of" exact="oseltamivir" post="phosphate to carboxylate, can markedly impair the hydrolysis of"/>
   <result pre="resulting in the potential for a compromised antiviral effect after" exact="oseltamivir" post="administration.128, 129 Ingestion with food delays absorption slightly but"/>
   <result pre="failure requiring mechanical ventilation was well absorbed and converted to" exact="oseltamivir" post="carboxylate.130, 131 In healthy adults, peak and trough plasma"/>
   <result pre="carboxylate exhibits decreasing variability while clearance increases.121 Recommended doses of" exact="oseltamivir" post="are 3.0 mg/kg twice daily for infants from birth to"/>
   <result pre="elimination. Morbid obesity (body mass index ≥40 kg/m2) does not alter" exact="oseltamivir" post="pharmacokinetics.134 The effects of pregnancy on the pharmacokinetics of"/>
   <result pre="oseltamivir pharmacokinetics.134 The effects of pregnancy on the pharmacokinetics of" exact="oseltamivir" post="are unclear. One study reported no differences among women"/>
   <result pre="suggesting a need for 75 mg three times a day of" exact="oseltamivir" post="for treatment.136 Plasma protein binding of the prodrug (42%)"/>
   <result pre="in breast milk.139 In the ex vivo human placenta model," exact="oseltamivir" post="was extensively metabolized to the carboxylate moiety, but transplacental"/>
   <result pre="extensively metabolized to the carboxylate moiety, but transplacental passage of" exact="oseltamivir" post="carboxylate occurred at a low rate, inferring that fetal"/>
   <result pre="low rate, inferring that fetal exposure during maternal treatment with" exact="oseltamivir" post="may be minimal.140 No carboxylate was detected in cerebrospinal"/>
   <result pre="fluid were 2.1% and 3.5% for corresponding plasma concentrations for" exact="oseltamivir" post="and oseltamivir carboxylate in eight healthy adults after ingestion"/>
   <result pre="2.1% and 3.5% for corresponding plasma concentrations for oseltamivir and" exact="oseltamivir" post="carboxylate in eight healthy adults after ingestion of 150 mg"/>
   <result pre="therapies (peritoneal, hemodialysis, and continuous renal replacement therapies). Doses of" exact="oseltamivir" post="for patients with renal impairment receiving renal replacement therapy"/>
   <result pre="the pharmacokinetics of oseltamivir.127 Cystic fibrosis patients appear to clear" exact="oseltamivir" post="carboxylate more rapidly than patients who do not have"/>
   <result pre="not have the disease.144 Interactions Probenecid reduces renal clearance of" exact="oseltamivir" post="by about 50%.145 Few other clinically important drug interactions"/>
   <result pre="appeared to induce a torsades de pointes cardiac arrhythmia during" exact="oseltamivir" post="therapy for influenza.146 Specific studies have found no interactions"/>
   <result pre="found no evidence of mutagenic, teratogenic, or oncogenic effects. High-dose" exact="oseltamivir" post="causes renal tubular mineralization in mice and maternal toxicity"/>
   <result pre="Analyses of neuropsychiatric reactions among patients with influenza treated with" exact="oseltamivir" post="in three large U.S. administrative databases did not demonstrate"/>
   <result pre="in cases in Japan after a regulatory recommendation to restrict" exact="oseltamivir" post="use in children 10 to 19 years of age"/>
   <result pre="latter fact raises further doubts about a causal association between" exact="oseltamivir" post="therapy and neuropsychiatric and behavioral adverse reactions in patients"/>
   <result pre="anaphylaxis, and thrombocytopenia have been reported, but their relationship to" exact="oseltamivir" post="is uncertain. Clinical Studies Oseltamivir is efficacious for the"/>
   <result pre="in volunteers with induced influenza it was demonstrated that oral" exact="oseltamivir" post="is highly protective against experimental human influenza, and early"/>
   <result pre="children with naturally acquired seasonal influenza A infection—demonstrated that early" exact="oseltamivir" post="treatment of acute influenza reduces the time to illness"/>
   <result pre="observational studies of high-risk patients with seasonal influenza concluded that" exact="oseltamivir" post="treatment may reduce hospitalization, whereas treatment of hospitalized patients"/>
   <result pre="large number of observational data from individual cases suggested that" exact="oseltamivir" post="treatment may be associated with a reduction in mortality"/>
   <result pre="Cochrane analysis did not conclude that the evidence indicated that" exact="oseltamivir" post="treatment reduced complications or hospitaliza­tions.169b In hospitalized patients with"/>
   <result pre="hospitaliza­tions.169b In hospitalized patients with infection with influenza A (H1N1)pdm09," exact="oseltamivir" post="provides similar benefits even if treatment is started more"/>
   <result pre="has begun.170, 171, 172 It is uncertain to what extent" exact="oseltamivir" post="treatment may reduce transmission, although a review of four"/>
   <result pre="although a review of four trials of prophylaxis suggests that" exact="oseltamivir" post="may have reduced transmission.173, 174 Oseltamivir is less efficacious"/>
   <result pre="that crude mortality was significantly less in those treated with" exact="oseltamivir" post="(40%) than in those not treated (76%) when started"/>
   <result pre="8 who were not treated.179 Prophylactic administration of once-daily oral" exact="oseltamivir" post="(75 mg) is highly effective in reducing the risk for"/>
   <result pre="influenza may reduce secondary complications in institutionalized older adults.181 Once-daily" exact="oseltamivir" post="for 7 to 10 days is also effective for"/>
   <result pre="a sialic acid analogue designed to be structurally distinct from" exact="oseltamivir" post="and zanamivir such that cross-resistance to it among oseltamivir-resistant"/>
   <result pre="acid analogue designed to be structurally distinct from oseltamivir and" exact="zanamivir" post="such that cross-resistance to it among oseltamivir-resistant and zanamivir-resistant"/>
   <result pre="oseltamivir-resistant and zanamivir-resistant strains is not consistently observed.187, 188 Like" exact="oseltamivir" post="and zanamivir, peramivir inhibits influenza neuraminidase in enzyme assays"/>
   <result pre="strains is not consistently observed.187, 188 Like oseltamivir and zanamivir," exact="peramivir" post="inhibits influenza neuraminidase in enzyme assays at nanomolar concentrations189"/>
   <result pre="of influenza A than B viruses in vitro than is" exact="oseltamivir" post="or zanamivir.190 The clinical relevance of this difference has"/>
   <result pre="A virus infection in cell culture and in mice with" exact="peramivir" post="and ribavirin yields additive or synergistic interactions with no"/>
   <result pre="infection in cell culture and in mice with peramivir and" exact="ribavirin" post="yields additive or synergistic interactions with no increase in"/>
   <result pre="no increase in toxicity.191 The antiviral effect of combinations of" exact="peramivir" post="plus rimantadine in vitro is variable, ranging from additive"/>
   <result pre="in toxicity.191 The antiviral effect of combinations of peramivir plus" exact="rimantadine" post="in vitro is variable, ranging from additive to synergistic.192"/>
   <result pre="synergistic.192 In mice with experimental influenza infections, the combination of" exact="peramivir" post="and rimantadine is synergistic.193 In murine and ferret models"/>
   <result pre="mice with experimental influenza infections, the combination of peramivir and" exact="rimantadine" post="is synergistic.193 In murine and ferret models of influenza"/>
   <result pre="is synergistic.193 In murine and ferret models of influenza infection," exact="peramivir" post="is effective when administered intranasally,194 orally,195 and intramuscularly.196 Mechanism"/>
   <result pre="from peramivir-treated mice with experimental influenza infection,199 healthy volunteers given" exact="peramivir" post="for prevention or treatment of experimentally induced influenza A"/>
   <result pre="with an alteration in the hemagglutinin gene conferred cross-resistance to" exact="oseltamivir" post="and zanamivir and could cause lethal disease in mice."/>
   <result pre="alteration in the hemagglutinin gene conferred cross-resistance to oseltamivir and" exact="zanamivir" post="and could cause lethal disease in mice. Infection with"/>
   <result pre="with the resistant virus in mice was still amenable to" exact="peramivir" post="therapy, however.198 Naturally occurring oseltamivir-resistant influenza viruses possessing the"/>
   <result pre="to 661-fold202 reduced susceptibility to peramivir, less than that of" exact="oseltamivir" post="(982-fold). Studies suggest that infection due to viruses possessing"/>
   <result pre="may be successfully treated with higher dose regimens of injected" exact="peramivir" post="in mice203 and high-risk patients.204 However, intravenous peramivir was"/>
   <result pre="of injected peramivir in mice203 and high-risk patients.204 However, intravenous" exact="peramivir" post="was not more effective than oseltamivir in a case"/>
   <result pre="high-risk patients.204 However, intravenous peramivir was not more effective than" exact="oseltamivir" post="in a case report201 and in an observational study"/>
   <result pre="to influenza A (H1N1)pdm-09 strains possessing the H275Y mutation, intravenous" exact="peramivir" post="is likely to be suboptimal and intravenous zanamivir is"/>
   <result pre="mutation, intravenous peramivir is likely to be suboptimal and intravenous" exact="zanamivir" post="is preferred.205 Pharmacokinetics The absolute oral bioavailability of peramivir"/>
   <result pre="intravenous zanamivir is preferred.205 Pharmacokinetics The absolute oral bioavailability of" exact="peramivir" post="is 2%.206 As a result, clinical development has focused"/>
   <result pre="to those seen in young healthy adults (see earlier): median" exact="peramivir" post="plasma concentrations were 33,150 ng/mL at the end of the"/>
   <result pre="data to efficacy is unclear. In mice, plasma AUC of" exact="peramivir" post="is the pharmacokinetic characteristic related to efficacy.209 Data on"/>
   <result pre="peramivir is the pharmacokinetic characteristic related to efficacy.209 Data on" exact="peramivir" post="distribution into breast milk in humans are unavailable.206 Less"/>
   <result pre="milk in humans are unavailable.206 Less than 5% of 14C-labeled" exact="peramivir" post="administered to rats is recovered in breast milk. Peramivir"/>
   <result pre="Peramivir is eliminated unchanged into urine by glomerular filtration, and" exact="probenecid" post="does not affect its excretion. In patients with renal"/>
   <result pre="an Emergency Use Authorization (EUA) for the administration of intravenous" exact="peramivir" post="for the treatment of hospitalized patients with suspected or"/>
   <result pre="have been suggested.210 The EUA was terminated in 2010, and" exact="peramivir" post="was to be available only through clinical trials (see"/>
   <result pre="individuals exposed is still modest. No pharmacokinetic interaction of intravenous" exact="peramivir" post="and oral oseltamivir or rimantadine was observed in healthy"/>
   <result pre="still modest. No pharmacokinetic interaction of intravenous peramivir and oral" exact="oseltamivir" post="or rimantadine was observed in healthy volunteers.211 Drug-drug interactions"/>
   <result pre="No pharmacokinetic interaction of intravenous peramivir and oral oseltamivir or" exact="rimantadine" post="was observed in healthy volunteers.211 Drug-drug interactions in individuals"/>
   <result pre="was observed in healthy volunteers.211 Drug-drug interactions in individuals receiving" exact="peramivir" post="are unlikely because it neither induces nor inhibits important"/>
   <result pre="laboratory abnormalities compared with placebo.208 In placebo-controlled clinical trials of" exact="peramivir" post="orally up to 800 mg/day for 4 to 5 days,200"/>
   <result pre="intravenously once,208 adverse symptoms were not reported more frequently in" exact="peramivir" post="recipients than in placebo recipients. In controlled, blinded trials"/>
   <result pre="In a randomized, double-blind study comparing a single dose of" exact="peramivir" post="of 300 or 600 mg and a matching placebo given"/>
   <result pre="and 3.6%) all tended to be lowest in the 300-mg" exact="peramivir" post="group.213 In a randomized, unblinded study in hospitalized patients"/>
   <result pre="unblinded study in hospitalized patients treated for influenza with intravenous" exact="peramivir" post="at 200 or 400 mg once daily, or oseltamivir at"/>
   <result pre="with intravenous peramivir at 200 or 400 mg once daily, or" exact="oseltamivir" post="at 75 mg orally twice daily, all for 5 days,"/>
   <result pre="similar among treatment groups.�?214 Assessment of side effects of intravenous" exact="peramivir" post="in uncontrolled studies in hospitalized adults with high-risk comorbid"/>
   <result pre="infected with an influenza B challenge virus and treated with" exact="peramivir" post="has been reported.200 The relationship of the cardiac disorder"/>
   <result pre="is unknown. Clinical Studies In a study in serosusceptible volunteers," exact="peramivir" post="prophylaxis with 50 to 800 mg orally daily or placebo,"/>
   <result pre="of peramivir.200 In early studies in patients with influenza, oral" exact="peramivir" post="therapy with doses of 400 to 800 mg daily for"/>
   <result pre="from controls. Subsequently, controlled trials with an intravenous formulation demonstrated" exact="peramivir" post="therapeutic efficacy and tolerance in patients with influenza due"/>
   <result pre="placebo group to 59 hours and 60 hours in the" exact="peramivir" post="300-mg and 600-mg groups in the outpatient setting.208 Peramivir"/>
   <result pre="peramivir, 200 or 400 g/day, compared with historical reports with oral" exact="oseltamivir" post="at 75 mg twice daily, the reduction in virus concentration"/>
   <result pre="three treatments.211 An additional study utilizing a higher dose of" exact="peramivir" post="(300 mg twice daily or 600 mg four times a day)"/>
   <result pre="treated with oseltamivir.215 A randomized controlled study of intravenously administered" exact="peramivir" post="plus standard of care versus standard of care alone"/>
   <result pre="terminated because of futility to show a difference between the" exact="peramivir" post="and control groups.215, 216 As noted earlier, intravenous peramivir"/>
   <result pre="the peramivir and control groups.215, 216 As noted earlier, intravenous" exact="peramivir" post="is probably not effective for treatment of patients with"/>
   <result pre="peramivir is probably not effective for treatment of patients with" exact="oseltamivir" post="resistance due to possession of the H275Y mutation; intravenous"/>
   <result pre="oseltamivir resistance due to possession of the H275Y mutation; intravenous" exact="zanamivir" post="has been recommended. Ribavirin Spectrum Ribavirin (1-β- d-ribofuranosyl-1,2,4-thiazole-3-carboxamide; Virazole,"/>
   <result pre="virus (SARS) coronavirus in vitro.218 FIGURE 44-4 Chemical structure of" exact="ribavirin" post="(A) and the nucleoside guanosine (B). Low concentrations of"/>
   <result pre="ribavirin (A) and the nucleoside guanosine (B). Low concentrations of" exact="ribavirin" post="(1 to 10 µg/mL) reversibly inhibit macromolecular synthesis and the"/>
   <result pre="dosing in animal models of influenza and RSV infection. Parenteral" exact="ribavirin" post="has antiviral and therapeutic activity in animal models of"/>
   <result pre="Chapters 47, 168, and 169Chapter 47Chapter 168Chapter 169). Combinations of" exact="ribavirin" post="with immunoglobulin in RSV infection and with M2 or"/>
   <result pre="influenza B infection show enhanced antiviral activity.12 The use of" exact="ribavirin" post="in treatment of hepatitis B and C is discussed"/>
   <result pre="46. Mechanism of Action The antiviral mechanisms of action of" exact="ribavirin" post="are complex and most likely vary for different viruses."/>
   <result pre="intracellular of less than 2 hours. Ribavirin monophosphate competitively inhibits" exact="inosine" post="monophosphate dehydrogenase and interferes with the synthesis of guanosine"/>
   <result pre="mutagenesis and contribute to antiviral activity.222 HCV RNA polymerase incorporates" exact="ribavirin" post="monophosphate into viral RNA, which causes mutations and inhibits"/>
   <result pre="from patients with chronic hepatitis C.223 Resistance Antiviral resistance to" exact="ribavirin" post="has been documented only in Sindbis virus and HCV"/>
   <result pre="selected in genotype 1a–infected, ribavirin-treated patients has been associated with" exact="ribavirin" post="resistance in vitro.226 No ribavirin-resistant RSVs have been detected"/>
   <result pre="have been detected during aerosol therapy of children. Pharmacokinetics Oral" exact="ribavirin" post="is well absorbed, but bioavailability averages 45% to 65%"/>
   <result pre="of sustained viral responses.231 Plasma protein binding is negligible, and" exact="ribavirin" post="has a large Vd (&amp;gt;2000 L). At steady state, cerebrospinal"/>
   <result pre="are about 70% of those in plasma.229 The disposition of" exact="ribavirin" post="is complex, involving renal elimination and metabolism. After rapid"/>
   <result pre="(CrCl ≤30 mL/min). Dosage adjustments are needed for renal insufficiency, and" exact="ribavirin" post="should be used with caution in patients with CrCl"/>
   <result pre="as high in infants (1.8 mg/kg/hr) than in adults. Toxicity Systemic" exact="ribavirin" post="causes dose-related anemia because of extravascular hemolysis and, at"/>
   <result pre="concentrations occur during short-term oral administration. Long-term use of oral" exact="ribavirin" post="at dosages greater than 800 mg daily causes hemoglobin decreases"/>
   <result pre="nausea, depression, nervousness, and cough or respiratory symptoms.234 High-dose intravenous" exact="ribavirin" post="is associated with headache, hypomagnesemia, and hypocalcemia.235 Bolus intravenous"/>
   <result pre="and infusion over 10 to 15 minutes is advised. Aerosolized" exact="ribavirin" post="may cause conjunctival irritation, rash, bronchospasm, reversible deterioration in"/>
   <result pre="and use of personal protective equipment have been recommended.236 When" exact="ribavirin" post="is used in conjunction with mechanical ventilation, in-line filters,"/>
   <result pre="to the lower respiratory tract are undefined. In preclinical studies," exact="ribavirin" post="is mutagenic, gonadotoxic, and teratogenic.232 Low oral dosages have"/>
   <result pre="have been teratogenic or embryotoxic in multiple species. Use of" exact="ribavirin" post="is relatively contraindicated during pregnancy, and pregnant women should"/>
   <result pre="and pregnant women should not directly care for patients receiving" exact="ribavirin" post="aerosol. Ribavirin is categorized as pregnancy category X, and"/>
   <result pre="oral bioavailability of ribavirin. During co-administration clinically, ribavirin, amantadine, and" exact="oseltamivir" post="do not interact pharmacokinetically.34 Ribavirin antagonizes the anti-HIV-1 effects"/>
   <result pre="do not interact pharmacokinetically.34 Ribavirin antagonizes the anti-HIV-1 effects of" exact="zidovudine" post="but enhances the activity of purine dideoxynucleosides. Ribavirin use"/>
   <result pre="treatment of RSV bronchiolitis and pneumonia in hospitalized children. Oral" exact="ribavirin" post="in combination with various interferons is approved for treatment"/>
   <result pre="119, and 156Chapter 46Chapter 119Chapter 156). Respiratory Syncytial Virus Aerosolized" exact="ribavirin" post="(18-hour exposure daily for 3 to 6 days) variably"/>
   <result pre="may be as effective as prolonged exposure.240 Use of aerosolized" exact="ribavirin" post="is limited by concerns regarding its efficacy, ease of"/>
   <result pre="in ribavirin-treated children. No long-term adverse or beneficial effects of" exact="ribavirin" post="therapy have been documented in children.242 Combinations of aerosolized"/>
   <result pre="ribavirin therapy have been documented in children.242 Combinations of aerosolized" exact="ribavirin" post="and intravenous immunoglobulin or palivizumab may be beneficial in"/>
   <result pre="in children.242 Combinations of aerosolized ribavirin and intravenous immunoglobulin or" exact="palivizumab" post="may be beneficial in treating RSV pneumonia in hematopoietic"/>
   <result pre="hematopoietic stem cell transplant recipients,243, 244, 245, 246 whereas intravenous" exact="ribavirin" post="alone is ineffective.247 Therapy with either aerosolized248, 249, 250"/>
   <result pre="ineffective.247 Therapy with either aerosolized248, 249, 250 or oral251, 252" exact="ribavirin" post="appears to prevent progression from upper to lower respiratory"/>
   <result pre="tract infection in lung transplant recipients with oral and inhaled" exact="ribavirin" post="has been reported.253, 254 Other Respiratory Viruses Intravenous and"/>
   <result pre="reported.253, 254 Other Respiratory Viruses Intravenous and aerosolized forms of" exact="ribavirin" post="have been used to treat severe influenza virus infections.255,"/>
   <result pre="been used to treat severe influenza virus infections.255, 256 Aerosolized" exact="ribavirin" post="inconsistently reduces viral titers and illness measures in adults"/>
   <result pre="has modest efficacy in children hospitalized with influenza.257 However, oral" exact="ribavirin" post="300 mg three times per day combined with amantadine and"/>
   <result pre="However, oral ribavirin 300 mg three times per day combined with" exact="amantadine" post="and oseltamivir may possibly be effective for treatment of"/>
   <result pre="ribavirin 300 mg three times per day combined with amantadine and" exact="oseltamivir" post="may possibly be effective for treatment of influenza A"/>
   <result pre="treatment of influenza A (H1N1)pdm09 disease and more so than" exact="oseltamivir" post="alone.258 Oral, intravenous, and aerosolized ribavirin have been used"/>
   <result pre="and more so than oseltamivir alone.258 Oral, intravenous, and aerosolized" exact="ribavirin" post="have been used in immunosuppressed patients with severe parainfluenza"/>
   <result pre="and adenovirus infections with inconsistent clinical benefits.255, 259, 260 Intravenous" exact="ribavirin" post="has been used to treat adenovirus-associated hemorrhagic cystitis, pneumonia,"/>
   <result pre="in severe disease.261, 262 Treatment with intravenous263, 264 and oral265" exact="ribavirin" post="of human metapneumovirus pneumonia in immunocompromised patients has been"/>
   <result pre="pneumonia in immunocompromised patients has been associated with resolution. Aerosolized" exact="ribavirin" post="has been used in treating parainfluenza virus infections in"/>
   <result pre="parainfluenza virus pneumonia in hematopoietic stem cell transplant recipients.259 Oral" exact="ribavirin" post="was effective in accelerating functional graft recovery and reducing"/>
   <result pre="a bone marrow transplant recipient267 with paramyxovirus respiratory infection. Intravenous" exact="ribavirin" post="therapy was associated with successful treatment of paramyxovirus type"/>
   <result pre="patients270 and has been associated with frequent adverse effects.235 Intravenous" exact="ribavirin" post="seems to be ineffective in treatment of hantavirus cardiopulmonary"/>
   <result pre="range of inhibitory concentrations in cell culture.277, 278 Compared with" exact="oseltamivir" post="carboxylate, zanamivir is more active against influenza B, and"/>
   <result pre="inhibitory concentrations in cell culture.277, 278 Compared with oseltamivir carboxylate," exact="zanamivir" post="is more active against influenza B, and data from"/>
   <result pre="inhibits certain influenza A neuraminidase variants that are resistant to" exact="oseltamivir" post="carboxylate.96 Combinations of zanamivir plus rimantadine inhibit strains of"/>
   <result pre="neuraminidase variants that are resistant to oseltamivir carboxylate.96 Combinations of" exact="zanamivir" post="plus rimantadine inhibit strains of influenza A/H1N1 and H3N2"/>
   <result pre="that are resistant to oseltamivir carboxylate.96 Combinations of zanamivir plus" exact="rimantadine" post="inhibit strains of influenza A/H1N1 and H3N2 viruses synergistically,"/>
   <result pre="3 in cell culture, most likely by blocking attachment.283 Topical" exact="zanamivir" post="in the respiratory tract is active in murine and"/>
   <result pre="frequently than to the adamantane compounds and less frequently to" exact="zanamivir" post="than to oseltamivir. A recent systematic review of the"/>
   <result pre="immunocompetent ambulatory adults enrolled in prophylactic and therapeutic trials of" exact="zanamivir" post="found no reports of zanamivir resistance.284 In surveys of"/>
   <result pre="prophylactic and therapeutic trials of zanamivir found no reports of" exact="zanamivir" post="resistance.284 In surveys of other collections of influenza isolates,"/>
   <result pre="collections of influenza isolates, a similar absence or dearth of" exact="zanamivir" post="resistance was reported: influenza A H1N1 viruses circulating in"/>
   <result pre="prior to emergence of the 2009 pandemic were resistant to" exact="oseltamivir" post="but susceptible to zanamivir.285 Among 391 nonpandemic A/H1N1 isolates"/>
   <result pre="Q136K in an A (H1N1) seasonal virus (300-fold reduction in" exact="zanamivir" post="susceptibility)286 and S274N291 in nonpandemic A/H1N1 virus and I223R"/>
   <result pre="isolate. The relationship of these virus resistance mutations and prior" exact="zanamivir" post="therapy and immune competence was not consistently apparent. An"/>
   <result pre="influenza B virus with an Arg152Lys mutation resistant to both" exact="zanamivir" post="and oseltamivir was recovered from an immunocompromised child with"/>
   <result pre="virus with an Arg152Lys mutation resistant to both zanamivir and" exact="oseltamivir" post="was recovered from an immunocompromised child with prolonged virus"/>
   <result pre="An observational study in pediatric patients with influenza treated with" exact="oseltamivir" post="or zanamivir suggested that the lower prevalence of zanamivir"/>
   <result pre="study in pediatric patients with influenza treated with oseltamivir or" exact="zanamivir" post="suggested that the lower prevalence of zanamivir than oseltamivir"/>
   <result pre="with oseltamivir or zanamivir suggested that the lower prevalence of" exact="zanamivir" post="than oseltamivir resistance is more related to the intrinsic"/>
   <result pre="or zanamivir suggested that the lower prevalence of zanamivir than" exact="oseltamivir" post="resistance is more related to the intrinsic properties of"/>
   <result pre="of use of the drugs.296 Pharmacokinetics The oral bioavailability of" exact="zanamivir" post="is low (&amp;lt;5%). The approved formulation is a dry"/>
   <result pre="a proprietary Diskhaler device. The proprietary inhaler device for delivering" exact="zanamivir" post="is breath activated and requires a cooperative, trained patient."/>
   <result pre="approximate concentrations in alveoli. Median epithelial lining fluid concentrations of" exact="zanamivir" post="12 hours after oral inhalation of the recommended 10-mg"/>
   <result pre="ranged from 0.3 to 0.9 µg/mL.299 In other uninfected individuals, median" exact="zanamivir" post="levels in induced sputum were 1.34 µg/mL, 0.30 µg/mL, and 0.05 µg/mL"/>
   <result pre="averaging 0.04 to 0.05 µg/mL.277 Because of the low bioavailability of" exact="zanamivir" post="inhaled orally, dosage adjustments are not indicated in renal"/>
   <result pre="indicated in renal insufficiency. After intravenous dosing, the plasma of" exact="zanamivir" post="ranges from 1.6 to 2.9 hours,277, 299 with about"/>
   <result pre="eliminated unchanged in the urine.277 After intravenous administration of 600 mg" exact="zanamivir" post="to healthy adults, the median serum Cmax is 39.4 µg/mL,"/>
   <result pre="for influenza A and B neuraminidases, respectively.280 The pharmacokinetics of" exact="zanamivir" post="in 103 adults with influenza receiving 600 mg intravenously twice"/>
   <result pre="administration of an attenuated influenza vaccine.305 Toxicity Preclinical studies of" exact="zanamivir" post="found no evidence of mutagenic, teratogenic, or oncogenic effects."/>
   <result pre="or oncogenic effects. In cell culture, the inhibitory effect of" exact="zanamivir" post="on influenza virus replication was not impaired by analgesics,"/>
   <result pre="is classified as a pregnancy category C agent. Orally inhaled" exact="zanamivir" post="is generally well tolerated, and the frequencies of complaints"/>
   <result pre="result of the underlying illness. Similarly, in high-risk patients receiving" exact="zanamivir" post="or placebo, no differences in adverse reactions have been"/>
   <result pre="to moderate asthma or chronic obstructive pulmonary disease, orally inhaled" exact="zanamivir" post="is associated with fewer bronchitis episodes, similar measurements of"/>
   <result pre="of chronic obstructive pulmonary disease accompanied by pulmonary edema after" exact="zanamivir" post="inhalation, particularly in patients with underlying airway disease.311 Apparent"/>
   <result pre="other countries.312 If used in patients with obstructive airway disease," exact="zanamivir" post="should be administered cautiously under close observation and with"/>
   <result pre="a nebulized solution, and by intravenous injections. Intranasal and intravenous" exact="zanamivir" post="are highly protective against experimental human influenza, and early"/>
   <result pre="symptoms, and middle ear pressure abnormalities.163, 277, 317 Orally inhaled" exact="zanamivir" post="powder is approved in the United States for prevention"/>
   <result pre="patients older than 50 years, and in higher-risk patients.320 Inhaled" exact="zanamivir" post="treatment in adults is associated with a 40% reduction"/>
   <result pre="and B infection.319, 322 In individuals with influenza B illness," exact="zanamivir" post="reduces the median duration of fever by 32%, from"/>
   <result pre="to moderate asthma or other chronic cardiopulmonary conditions, orally inhaled" exact="zanamivir" post="treatment reduces illness duration and the incidence of complications"/>
   <result pre="and B infections,324 including a child to whom an aqueous" exact="zanamivir" post="solution (16 mg/mL) was administered by aerosol and nebulizer via"/>
   <result pre="endotracheal tube.325 More recently, in an observational study, orally inhaled" exact="zanamivir" post="was more efficacious for treatment of oseltamivir-resistant influenza A/H1N1"/>
   <result pre="oseltamivir-resistant influenza A/H1N1 than oseltamivir.326 Prophylactic administration of once-daily inhaled" exact="zanamivir" post="(10 mg) prevents febrile influenza illness during influenza season (84%"/>
   <result pre="an observational study with limited numbers of patients, orally inhaled" exact="zanamivir" post="and oral oseltamivir were not different for prevention of"/>
   <result pre="with limited numbers of patients, orally inhaled zanamivir and oral" exact="oseltamivir" post="were not different for prevention of secondary cases during"/>
   <result pre="pediatric wards.330 In nursing home residents, 2 weeks of inhaled" exact="zanamivir" post="was superior to oral rimantadine in preventing influenza A"/>
   <result pre="residents, 2 weeks of inhaled zanamivir was superior to oral" exact="rimantadine" post="in preventing influenza A infection, in part because of"/>
   <result pre="A infection, in part because of a high frequency of" exact="rimantadine" post="resistance,331 and inhaled zanamivir has been used to curtail"/>
   <result pre="because of a high frequency of rimantadine resistance,331 and inhaled" exact="zanamivir" post="has been used to curtail transmission of amantadine-resistant influenza"/>
   <result pre="transmission of amantadine-resistant influenza A in nursing homes.297 Orally inhaled" exact="zanamivir" post="has been administered in combination with oral oseltamivir. For"/>
   <result pre="24 hours of exposure to the index case compared with" exact="oseltamivir" post="or zanamivir alone. For treatment of adults with mainly"/>
   <result pre="of exposure to the index case compared with oseltamivir or" exact="zanamivir" post="alone. For treatment of adults with mainly A/H3N2 influenza,"/>
   <result pre="A/H3N2 influenza, zanamivir-oseltamivir combination treatment was not more efficacious than" exact="zanamivir" post="alone and was less efficacious than oseltamivir monotherapy.333 Zanamivir"/>
   <result pre="more efficacious than zanamivir alone and was less efficacious than" exact="oseltamivir" post="monotherapy.333 Zanamivir has been administered intravenously to treat patients"/>
   <result pre="influenza who could not receive or who had failed oral" exact="oseltamivir" post="therapy. Immunocompetent334 and immunocompromised335, 336 patients who were infected"/>
   <result pre="treated with intravenous zanamivir. There is a sense that intravenous" exact="zanamivir" post="may be lifesaving.341 However, an apparent lack of a"/>
   <result pre="lifesaving.341 However, an apparent lack of a relationship between intravenous" exact="zanamivir" post="treatment–associated reductions in pandemic virus load in upper and"/>
   <result pre="in seriously ill patients.342 A phase III study comparing intravenous" exact="zanamivir" post="and oseltamivir in hospitalized patients is underway. Polymeric Zanamivir"/>
   <result pre="ill patients.342 A phase III study comparing intravenous zanamivir and" exact="oseltamivir" post="in hospitalized patients is underway. Polymeric Zanamivir Conjugates Polymeric"/>
   <result pre="oseltamivir in hospitalized patients is underway. Polymeric Zanamivir Conjugates Polymeric" exact="zanamivir" post="conjugates are experimental, high-molecular-weight anti-influenza compounds comprising multiple zanamivir"/>
   <result pre="Polymeric zanamivir conjugates are experimental, high-molecular-weight anti-influenza compounds comprising multiple" exact="zanamivir" post="monomers connected at the 7-0 position to backbone or"/>
   <result pre="for 7 days after a single intranasal administration. Spectrum Polymeric" exact="zanamivir" post="conjugates exhibit broad-spectrum anti-influenza activity, inhibiting human influenza A"/>
   <result pre="length345 and type of linker molecule344 and the number of" exact="zanamivir" post="derivatives, whether dimeric,343 trimeric, or tetrameric.346 The most potent"/>
   <result pre="derivatives, whether dimeric,343 trimeric, or tetrameric.346 The most potent polymeric" exact="zanamivir" post="conjugate is a dimer with a 14-carbon linker, which"/>
   <result pre="mice, this dimeric conjugate is 100 times more potent than" exact="zanamivir" post="in preventing influenza virus replication in the lung for"/>
   <result pre="discussed in the section on pharmacokinetics. The specificity of polymeric" exact="zanamivir" post="conjugates for influenza A and B neuraminidase is presumed"/>
   <result pre="and B neuraminidase is presumed but not yet reported. A" exact="zanamivir" post="polymer can overcome zanamivir resistance. A zanamivir polymer bound"/>
   <result pre="presumed but not yet reported. A zanamivir polymer can overcome" exact="zanamivir" post="resistance. A zanamivir polymer bound to the neuraminidase of"/>
   <result pre="yet reported. A zanamivir polymer can overcome zanamivir resistance. A" exact="zanamivir" post="polymer bound to the neuraminidase of zanamivir-resistant avian influenza"/>
   <result pre="zanamivir.350 Mechanism of Action The synthesis of polymeric conjugates of" exact="zanamivir" post="that retain neuraminidase inhibitory activity is possible because of"/>
   <result pre="micrographs show influenza virus clumping in the presence of dimeric" exact="zanamivir" post="conjugates. The marked potency of some conjugates is postulated"/>
   <result pre="the marked enhancement of potency observed by synthesis of polymer-attached" exact="zanamivir" post="is postulated to be the result of interference with"/>
   <result pre="drug have not been reported. Pharmacokinetics Prolonged retention of polymeric" exact="zanamivir" post="compared with monomeric zanamivir in lung tissue accounts for"/>
   <result pre="reported. Pharmacokinetics Prolonged retention of polymeric zanamivir compared with monomeric" exact="zanamivir" post="in lung tissue accounts for the enhanced antiviral effect"/>
   <result pre="intratracheal instillation of the same single dose of a polymeric" exact="zanamivir" post="conjugate or monomeric zanamivir solution to rats, lung homogenate"/>
   <result pre="same single dose of a polymeric zanamivir conjugate or monomeric" exact="zanamivir" post="solution to rats, lung homogenate drug concentrations of the"/>
   <result pre="168 hours are 35 times and 160 times greater than" exact="zanamivir" post="concentrations.343 Generally, lung retention time is directly related to"/>
   <result pre="cells. Prolonged retention of high-molecular-weight polymeric conjugates compared with monomeric" exact="zanamivir" post="is expected. However, the prolonged lung retention time of"/>
   <result pre="may also play a role in the prolonged retention of" exact="zanamivir" post="polymeric conjugates in the lung after inhalation.343 Interactions and"/>
   <result pre="31HoopesJDDriebeEMKelleyETriple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and" exact="ribavirin" post="impedes the selection of drug-resistant influenza A virusPLoS One62011E2977822220216"/>
   <result pre="influenza A virusPLoS One62011E2977822220216 34SeoSEnglundJANguyenJTCombination therapy with amantadine, oseltamivir, and" exact="ribavirin" post="for influenza A infection: safety and pharmacokineticsAntivir Ther18201337738623264438 36JeffersonTDemicheliVDiPietrantorjCAmantadine"/>
   <result pre="for influenza A infection: safety and pharmacokineticsAntivir Ther18201337738623264438 36JeffersonTDemicheliVDiPietrantorjCAmantadine and" exact="rimantadine" post="for influenza A in adultsCochrane Database Syst Rev22006 38KimberlinDWShalabiMAbzugMJSafety"/>
   <result pre="for influenza A in adultsCochrane Database Syst Rev22006 38KimberlinDWShalabiMAbzugMJSafety of" exact="oseltamivir" post="compared with the adamantanes in children less than 12"/>
   <result pre="Infect Dis J29201019519819949363 50Alves GalvaoMGRocha Crispino SantosMAAlves da CunhaAJAmantadine and" exact="rimantadine" post="for influenza A in children and the elderlyCochrane Database"/>
   <result pre="A in children and the elderlyCochrane Database Syst Rev12012 53GravensteinSDrinkaPOsterweilDInhaled" exact="zanamivir" post="versus rimantadine for the control of influenza in a"/>
   <result pre="children and the elderlyCochrane Database Syst Rev12012 53GravensteinSDrinkaPOsterweilDInhaled zanamivir versus" exact="rimantadine" post="for the control of influenza in a highly-vaccinated long-term"/>
   <result pre="in children with influenzaPediatrics1292012e1431e143622614774 102KawaiNIkematsuHIwakiNA comparison of the effectiveness of" exact="oseltamivir" post="for the treatment of influenza A and influenza B:"/>
   <result pre="of the 2003-2004 and 2004-2005 influenza seasonsClin Infect Dis43200643944416838232 112WhitleyRJHaydenFGReisingerKOral" exact="oseltamivir" post="treatment of influenza in childrenPediatr Infect Dis J20200112713311224828 121KimberlinDWAcostaEPPritchardMNOseltamivir"/>
   <result pre="years with influenzaJ Infect Dis207201370972023230059 127HeGMassarellaJWardPClinical pharmacokinetics of the prodrug" exact="oseltamivir" post="and its active metabolite Ro 64-0802Clin Pharmacokinet37199947148410628898 135GreerLGLeffRDRogersVLPharmacokinetics of"/>
   <result pre="oseltamivir and its active metabolite Ro 64-0802Clin Pharmacokinet37199947148410628898 135GreerLGLeffRDRogersVLPharmacokinetics of" exact="oseltamivir" post="according to trimester of pregnancyAm J Obstet Gynecol204suppl 62011S89S9321492824"/>
   <result pre="to trimester of pregnancyAm J Obstet Gynecol204suppl 62011S89S9321492824 136BeigiRHHanKVenkataramananRPharmacokinetics of" exact="oseltamivir" post="among pregnant and nonpregnant womenAm J Obstet Gynecol204suppl 12011S84S8821492826"/>
   <result pre="therapyClin Infect Dis3920041300130615494906 180HaydenFGAtmarRLSchillingMUse of the selective oral neuraminidase inhibitor" exact="oseltamivir" post="to prevent influenzaN Engl J Med34119991336134310536125 182WelliverRMontoASCarewiczOEffectiveness of oseltamivir"/>
   <result pre="inhibitor oseltamivir to prevent influenzaN Engl J Med34119991336134310536125 182WelliverRMontoASCarewiczOEffectiveness of" exact="oseltamivir" post="in preventing influenza in household contacts: a randomized controlled"/>
   <result pre="randomized controlled trialJAMA285200174875411176912 185GovorkovaEAIenevaIAGoloubevaOGComparison of efficacies of RWJ-270201, zanamivir, and" exact="oseltamivir" post="against H5N1, H9N2, and other avian influenza virusesAntimicrob Agents"/>
   <result pre="Agents Chemother452001272311557461 200BarrosaLTreanorJGubarevaLEfficacy and tolerability of the oral neuraminidase inhibitor" exact="peramivir" post="in experimental human influenza: randomised, controlled trials for prophylaxis"/>
   <result pre="prophylaxis and treatmentAntivir Ther10200590116430195 207SugayaNKohnoSIshibashiTEfficacy, safety and pharmacokinetics of intravenous" exact="peramivir" post="in children with 2009 pandemic H1N1 influenza virus infectionAntimicrob"/>
   <result pre="overviewArch Pediatr Adolesc Med15019969429478790125 248BoeckhMEnglundJLiYRandomized controlled multicenter trial of aerosolized" exact="ribavirin" post="for respiratory syncytial virus upper respiratory tract infection in"/>
   <result pre="response to antiviral therapy, and effect on transplant outcomeBlood98200157357811468152 261SouzaILASchnertLGotoJMOral" exact="ribavirin" post="in treatment of adenovirus infection in hematologic patients: experience"/>
   <result pre="patients: experience from a Brazilian university hospitalClin Microbiol Infect162010S24 262GavinPJKatzBZIntravenous" exact="ribavirin" post="treatment for severe adenovirus disease in immunocompromised childrenPediatrics1102002E912093990 263BonneyDRazatiHTurnerASuccessful"/>
   <result pre="treatment of human metapneumovirus pneumonia using combination therapy with intravenous" exact="ribavirin" post="and immune globulinBr J Haematol452009667679 266FuehnerTDierichMDuesbertCSingle-centre experience with oral"/>
   <result pre="ribavirin and immune globulinBr J Haematol452009667679 266FuehnerTDierichMDuesbertCSingle-centre experience with oral" exact="ribavirin" post="in lung transplant recipients with paramyxovirus infectionsAntivir Ther16201117331740 275ChapmanJAbbottEAlberDRSV604,"/>
   <result pre="syncytial virus replicationAntimicrob Agents Chemother5120073346335317576833 279KawaiNIkematsuHIwakiNComparison of the effectiveness of" exact="zanamivir" post="and oseltamivir for the treatment of influenza A and"/>
   <result pre="replicationAntimicrob Agents Chemother5120073346335317576833 279KawaiNIkematsuHIwakiNComparison of the effectiveness of zanamivir and" exact="oseltamivir" post="for the treatment of influenza A and BJ Infect3620085157"/>
   <result pre="influenza A(H1N1) virus drug susceptibility in vitroAntivir Ther1520101151115921149922 293GubarevaLVMatrosovichMNBrennerMKEvidence for" exact="zanamivir" post="resistance in an immunocompromised child infected with influenza B"/>
   <result pre="inhibitorsClin Infect Dis522011e56e9321258094 318HaydenFGOsterhausADMETreanorJJEfficacy and safety of the neuraminidase inhibitor" exact="zanamivir" post="in the treatment of influenza virus infectionsN Engl J"/>
   <result pre="treatment of influenza virus infectionsN Engl J Med33719978748799302301 325GukarevaLVMatrosovichMNBrennerMKEvidence for" exact="zanamivir" post="resistance in an immunocompromised child infected with influenza B"/>
   <result pre="intravenous zanamivir: efficiency and complicationsTransplantation90201022322420644456 References References 1NeumayerEMHaffRFHoffmanCEAntiviral activity of" exact="amantadine" post="hydrochloride in tissue cultureProc Soc Exp Med Biol1191965393396 2WebsterRGKawaokaYBeanWJChemotherapy"/>
   <result pre="agentsYuVLMeriganTCWhiteNJAntimicrobial Therapy and Vaccines1999Williams &amp;amp; WilkinsBaltimore13441365 6KellyJMMilesMASkinnerACThe anti-influenza virus drug" exact="rimantadine" post="has trypanocidal activityAntimicrob Agents Chemother43199998598710103219 7MaurinMBenolielAMBongrandPPhagolysosomal alkalinization and the"/>
   <result pre="Dis Sci47200243844211855564 9SmeeDFHurstBLWongMHEffects of double combinations of amantadine, oseltamivir, and" exact="ribavirin" post="on influenza A (H5N1) virus infections in cell culture"/>
   <result pre="in cell culture and in miceAntimicrob Agents Chemother5320092120212819273672 10BantiaSKelloggDParkerCCombination of" exact="peramivir" post="and rimantadine demonstrate synergistic antiviral effects in sub-lethal influenza"/>
   <result pre="culture and in miceAntimicrob Agents Chemother5320092120212819273672 10BantiaSKelloggDParkerCCombination of peramivir and" exact="rimantadine" post="demonstrate synergistic antiviral effects in sub-lethal influenza A (H3N2)"/>
   <result pre="virus mouse modelAntiviral Res88201027628020943201 11SimeonovaLGegovaGGalabovASProphylactic and therapeutic combination effects of" exact="rimantadine" post="and oseltamivir against influenza virus A (H3N2) infection in"/>
   <result pre="modelAntiviral Res88201027628020943201 11SimeonovaLGegovaGGalabovASProphylactic and therapeutic combination effects of rimantadine and" exact="oseltamivir" post="against influenza virus A (H3N2) infection in miceAntiviral Res95201217218122617756"/>
   <result pre="is blocked by the antiviral drug, amantadineFEBS Lett5352003343812560074 17JubinRMurrayMGHoweAYAmantadine and" exact="rimantadine" post="have no direct inhibitory effects against hepatitis C viral"/>
   <result pre="internal ribosomal entry site-mediated translationJ Infect Dis181200033133410608783 18ZieglerTHemphillMLZieglerMLLow incidence of" exact="rimantadine" post="resistance in field isolates of influenza A virusesJ Infect"/>
   <result pre="and rimantadine: clinical aspectsRichmanDDAntiviral Drug Resistance1996WileyChichester, UK5977 20EnglundJAChamplinREWydePRCommon emergence of" exact="amantadine" post="and rimantadine resistant influenza A viruses in symptomatic immunocompromised"/>
   <result pre="clinical aspectsRichmanDDAntiviral Drug Resistance1996WileyChichester, UK5977 20EnglundJAChamplinREWydePRCommon emergence of amantadine and" exact="rimantadine" post="resistant influenza A viruses in symptomatic immunocompromised adultsClin Infect"/>
   <result pre="31HoopesJDDriebeEMKelleyETriple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and" exact="ribavirin" post="impedes the selection of drug-resistant influenza A virusPLoS One62011E2977822220216"/>
   <result pre="influenza A virusPLoS One62011E2977822220216 32NguyenJTHoopesJDLeMHTriple combination of amantadine, ribavirin, and" exact="oseltamivir" post="is highly active and synergistic against drug resistant influenza"/>
   <result pre="influenza virus strains in vitroPLoS One52010e933220179772 33GoralskiKBBoseRSitarDSNH4+ modulates renal tubule" exact="amantadine" post="transport independently of intracellular pH changesEur J Pharmacol5412006879416750190 34SeoSEnglundJANguyenJTCombination"/>
   <result pre="pH changesEur J Pharmacol5412006879416750190 34SeoSEnglundJANguyenJTCombination therapy with amantadine, oseltamivir, and" exact="ribavirin" post="for influenza A infection: safety and pharmacokineticsAntivir Ther18201337738623264438 35MorrisonDRoySRaynerCA"/>
   <result pre="Ther18201337738623264438 35MorrisonDRoySRaynerCA randomized, crossover study to evaluate the pharmacokinetics of" exact="amantadine" post="and oseltamivir administered alone and in combinationPLoS One22007e130518074029 36JeffersonTDemicheliVDiPietrantorjCAmantadine"/>
   <result pre="randomized, crossover study to evaluate the pharmacokinetics of amantadine and" exact="oseltamivir" post="administered alone and in combinationPLoS One22007e130518074029 36JeffersonTDemicheliVDiPietrantorjCAmantadine and rimantadine"/>
   <result pre="and oseltamivir administered alone and in combinationPLoS One22007e130518074029 36JeffersonTDemicheliVDiPietrantorjCAmantadine and" exact="rimantadine" post="for influenza A in adultsCochrane Database Syst Rev22006 37StrangeKCLittleDWBlatnikBAdverse"/>
   <result pre="influenza A in adultsCochrane Database Syst Rev22006 37StrangeKCLittleDWBlatnikBAdverse reactions to" exact="amantadine" post="prophylaxis in a retirement homeJ Am Geriatr Soc3919917007052061537 38KimberlinDWShalabiMAbzugMJSafety"/>
   <result pre="prophylaxis in a retirement homeJ Am Geriatr Soc3919917007052061537 38KimberlinDWShalabiMAbzugMJSafety of" exact="oseltamivir" post="compared with the adamantanes in children less than 12"/>
   <result pre="J Med32219904434502405270 41KeyserLAKarlMNafzigerANComparison of central nervous system adverse effects of" exact="amantadine" post="and rimantadine used as sequential prophylaxis of influenza A"/>
   <result pre="41KeyserLAKarlMNafzigerANComparison of central nervous system adverse effects of amantadine and" exact="rimantadine" post="used as sequential prophylaxis of influenza A in elderly"/>
   <result pre="home patientsArch Intern Med16020001485148810826462 42DegelauJSomaniSKCooperSLOccurrence of adverse effects and high" exact="amantadine" post="concentrations with influenza prophylaxis in the nursing homeJ Am"/>
   <result pre="in the nursing homeJ Am Geriatr Soc3819904282329251 43StangeKCLittleDWBlatnikBAdverse reactions to" exact="amantadine" post="prophylaxis of influenza in a retirement homeJ Am Geriatr"/>
   <result pre="of influenza in a retirement homeJ Am Geriatr Soc3919917007052061537 44KolbeFSitarDSPapaioannouAAn" exact="amantadine" post="hydrochloride dosing program adjusted for renal function during an"/>
   <result pre="case seriesMov Disord20200587387715809995 47MontoASOhmitSEHornbuckleKSafety and efficacy of long-term use of" exact="rimantadine" post="for prophylaxis of type A influenza in nursing homesAntimicrob"/>
   <result pre="clinical perspectiveAnn Pharmacother2919952993107606077 50Alves GalvaoMGRocha Crispino SantosMAAlves da CunhaAJAmantadine and" exact="rimantadine" post="for influenza A in children and the elderlyCochrane Database"/>
   <result pre="home: efficacy of vaccine and amantadineJ Am Geriatr Soc441996115311578855992 53GravensteinSDrinkaPOsterweilDInhaled" exact="zanamivir" post="versus rimantadine for the control of influenza in a"/>
   <result pre="of vaccine and amantadineJ Am Geriatr Soc441996115311578855992 53GravensteinSDrinkaPOsterweilDInhaled zanamivir versus" exact="rimantadine" post="for the control of influenza in a highly-vaccinated long-term"/>
   <result pre="Am Med Dir Assoc6200535936616286056 54BradyMTSearsSDPaciniDLSafety and prophylactic efficacy of low-dose" exact="rimantadine" post="in adults during an influenza A epidemicAntimicrob Agents Chemother341990163316362285274"/>
   <result pre="and the effect of antiviral therapyClin Infect Dis3920041300130615494906 57CloverRDWanerJLBeckerLEffect of" exact="rimantadine" post="on the immune response to influenza A infectionsJ Med"/>
   <result pre="58ZeuzemSTeuberGNaumannURandomized, double-blind, placebo-controlled trial of interferon alfa2a with and without" exact="amantadine" post="as initial treatment for chronic hepatitis CHepatology32200083584111003631 59HelblingBStamenicIVianiFInterferon and"/>
   <result pre="amantadine as initial treatment for chronic hepatitis CHepatology32200083584111003631 59HelblingBStamenicIVianiFInterferon and" exact="amantadine" post="in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled"/>
   <result pre="hepatitis C: a double-blind, randomized, placebo-controlled trialHepatology35200244745411826422 60BergTKronenbergerBHinrichsenHTriple therapy with" exact="amantadine" post="in treatment-naive patients with chronic hepatitis C: a placebo-controlled"/>
   <result pre="trialHepatology3720031359136712774015 61YounossiZMMullenKDZakkoWA randomized, double-blind controlled trial of interferon alpha-2b and" exact="ribavirin" post="vs. interferon alpha-2b and amantadine for treatment of chronic"/>
   <result pre="trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and" exact="amantadine" post="for treatment of chronic hepatitis C non-responder to interferon"/>
   <result pre="to interferon monotherapyJ Hepatol34200112813311211889 62AdinolfiLEUtiliRTonzielloAEffects of alpha interferon induction plus" exact="ribavirin" post="with or without amantadine in the treatment of interferon"/>
   <result pre="62AdinolfiLEUtiliRTonzielloAEffects of alpha interferon induction plus ribavirin with or without" exact="amantadine" post="in the treatment of interferon non-responsive chronic hepatitis C:"/>
   <result pre="children with influenzaPediatrics1292012e1431e143622614774 88SugayaNOhashiYLong-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus" exact="oseltamivir" post="as treatment for children with influenza virus infectionAntimicrob Agents"/>
   <result pre="virus infectionAntimicrob Agents Chemother5420102575258220368393 89WatanabeAChangSCKimMJLong-acting neuraminidase inhibitor laninamivir octanoate versus" exact="oseltamivir" post="for treatment of influenza: a double-blind, randomized, noninferiority clinical"/>
   <result pre="treated with oseltamivirJ Infect55200726727217604839 102KawaiNIkematsuHIwakiNA comparison of the effectiveness of" exact="oseltamivir" post="for the treatment of influenza A and influenza B:"/>
   <result pre="the 2003-2004 and 2004-2005 influenza seasonsClin Infect Dis43200643944416838232 103SatoMSaitoRSatoIEffectiveness of" exact="oseltamivir" post="treatment among children with influenza A or B virus"/>
   <result pre="and mortality in a ferret modelJ Infect Dis19720081315132318422444 105SmeeDFWongMHBaileyKWActivities of" exact="oseltamivir" post="and ribavirin used alone and in combination against infection"/>
   <result pre="in a ferret modelJ Infect Dis19720081315132318422444 105SmeeDFWongMHBaileyKWActivities of oseltamivir and" exact="ribavirin" post="used alone and in combination against infection in mice"/>
   <result pre="in miceAntimicrob Agents Chemother5220083889389718725448 107SmeeDFHurstBLWongMHEffects of double combinations of amantadine," exact="oseltamivir" post="and ribavirin on influenza A (H5N1) virus infections in"/>
   <result pre="Agents Chemother5220083889389718725448 107SmeeDFHurstBLWongMHEffects of double combinations of amantadine, oseltamivir and" exact="ribavirin" post="on influenza A (H5N1) virus infections in cell culture"/>
   <result pre="networkAntiviral Res49200114715611428241 111CarrJIvesJKellyLInfluenza virus carrying neuraminidase with reduced sensitivity to" exact="oseltamivir" post="carboxylate has altered properties in vitro and is compromised"/>
   <result pre="compromised for infectivity and replicative ability in vivoAntiviral Res542002798812062393 112WhitleyRJHaydenFGReisingerKOral" exact="oseltamivir" post="treatment of influenza in childrenPediatr Infect Dis J20200112713311224828 113JacksonHCRobertsNWangZManagement"/>
   <result pre="H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in AustraliaJ Infect Dis206201214815722561367 117HaugeSHBlixHSBorgenKSales of" exact="oseltamivir" post="in Norway prior to the emergence of oseltamivir resistant"/>
   <result pre="117HaugeSHBlixHSBorgenKSales of oseltamivir in Norway prior to the emergence of" exact="oseltamivir" post="resistant influenza A(H1N1) viruses in 2007-2008Virol J620095419435505 118LongtinJPatelSEshaghiANeuraminidase-inhibitor resistance"/>
   <result pre="wild-type counterpart in mice and ferretsPLoS Pathog62010 124SaitoRSatoISuzukiYReduced effectiveness of" exact="oseltamivir" post="in children infected with oseltamivir-resistant influenza A(H1N1) viruses with"/>
   <result pre="viruses with His275Tyr mutationPediatr Infect Dis292010898904 125StephensonIDemocratisJLackenbyANeuraminidase inhibitor resistance after" exact="oseltamivir" post="treatment of acute influenza A and B in childrenClin"/>
   <result pre="Infect Dis48200938939619133796 126RathBvon KleistMTiefFVirus load kinetics and resistance development during" exact="oseltamivir" post="treatment in infants and children infected with influenza A(H1N1)"/>
   <result pre="B virusesPediatr Infect Dis J31201289990522581220 127HeGMassarellaJWardPClinical pharmacokinetics of the prodrug" exact="oseltamivir" post="and its active metabolite Ro 64-0802Clin Pharmacokinet37199947148410628898 128WattanagoonYStepniewskaKLindegardlNPharmacokinetics of"/>
   <result pre="and its active metabolite Ro 64-0802Clin Pharmacokinet37199947148410628898 128WattanagoonYStepniewskaKLindegardlNPharmacokinetics of high-dose" exact="oseltamivir" post="in healthy volunteersAntimicrob Agents Chemother53200994595219104028 129ZhuHJMarkowitzJSActivation of the antiviral"/>
   <result pre="in healthy volunteersAntimicrob Agents Chemother53200994595219104028 129ZhuHJMarkowitzJSActivation of the antiviral prodrug" exact="oseltamivir" post="is impaired by two newly identified carboxylesterase 1 variantsDrug"/>
   <result pre="with severe H5N1 influenzaPLoS One320083410 131ArianoRESitarDSZelenitskySAEnteric absorption and pharmacokinetics of" exact="oseltamivir" post="in critically ill patients with pandemic (H1N1) influenzaCan Med"/>
   <result pre="influenzaCan Med Assoc J182201035736320159892 132OoCBarrettJHillGPharmacokinetics and dosage recommendations for an" exact="oseltamivir" post="oral suspension for the treatment of influenza in childrenPaediatr"/>
   <result pre="pharmacokinetics in morbid obesity (OPTIMO trial)J Antimicrob Chemother6620112083209121700623 135GreerLGLeffRDRogersVLPharmacokinetics of" exact="oseltamivir" post="according to trimester of pregnancyAm J Obstet Gynecol204suppl 62011S89S9321492824"/>
   <result pre="to trimester of pregnancyAm J Obstet Gynecol204suppl 62011S89S9321492824 136BeigiRHHanKVenkataramananRPharmacokinetics of" exact="oseltamivir" post="among pregnant and nonpregnant womenAm J Obstet Gynecol204suppl 12011S84S8821492826"/>
   <result pre="[letter]Int J Infect Dis12200845145218243025 140WorleyKCRobertsSWBawdonREThe metabolism and transplacental transfer of" exact="oseltamivir" post="in the ex vivo human modelInfect Dis Obstet Gynecol2008200892757418551180"/>
   <result pre="encephalitis: treatment with oseltamivirPediatr Infect Dis J212003173175 142JheeSSYenMEreshefskyLLow penetration of" exact="oseltamivir" post="and its carboxylate into cerebrospinal fluid in healthy Japanese"/>
   <result pre="Infect Dis Med Microbiol232012e79e9224294283 144JullienVHubertDLaunayGPharmacokinetics and diffusion into sputum of" exact="oseltamivir" post="and oseltamivir carboxylate in adults with cystic fibrosisAntimicrob Agents"/>
   <result pre="Med Microbiol232012e79e9224294283 144JullienVHubertDLaunayGPharmacokinetics and diffusion into sputum of oseltamivir and" exact="oseltamivir" post="carboxylate in adults with cystic fibrosisAntimicrob Agents Chemother5520114183418721670188 145HolodniyMPenzakSRStraightTMPharmacokinetics"/>
   <result pre="adults with cystic fibrosisAntimicrob Agents Chemother5520114183418721670188 145HolodniyMPenzakSRStraightTMPharmacokinetics and tolerability of" exact="oseltamivir" post="combined with probenecidAntimicrob Agents Chemother5220083013302118559644 146WellsQHardinBRajSRSotalol-induced torsades de pointes"/>
   <result pre="Agents Chemother5220083013302118559644 146WellsQHardinBRajSRSotalol-induced torsades de pointes precipitated during treatment with" exact="oseltamivir" post="for H1N1 influenzaHeart Rhythm720101454145720656063 147LamHJefferyJRSitarDSOseltamivir, an influenza neuraminidase inhibitor"/>
   <result pre="not affect the steady-state pharmacokinetic characterstics of cyclosporine, mycophenolate or" exact="tacrolimus" post="in adult renal transplant patientsTher Drug Monit33201169970422105586 148DaviesBEAceves BaldoPLennon-ChrimesSEffect"/>
   <result pre="in adult renal transplant patientsTher Drug Monit33201169970422105586 148DaviesBEAceves BaldoPLennon-ChrimesSEffect of" exact="oseltamivir" post="treatment on anticoagulation: a cross-over study in warfarinized patientsBr"/>
   <result pre="patientsBr J Clin Pharmacol70201083484321175439 149AtieeGLasseterKBaughmanSAbsence of pharmacokinetic interaction between intravenous" exact="peramivir" post="and oral oseltamivir or rimantadine in humansJ Clin Pharmacol5220121410141921960669"/>
   <result pre="Pharmacol70201083484321175439 149AtieeGLasseterKBaughmanSAbsence of pharmacokinetic interaction between intravenous peramivir and oral" exact="oseltamivir" post="or rimantadine in humansJ Clin Pharmacol5220121410141921960669 150DonnerBNiranjanVHoffmannGSafety of oseltamivir"/>
   <result pre="of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or" exact="rimantadine" post="in humansJ Clin Pharmacol5220121410141921960669 150DonnerBNiranjanVHoffmannGSafety of oseltamivir in pregnancy:"/>
   <result pre="oral oseltamivir or rimantadine in humansJ Clin Pharmacol5220121410141921960669 150DonnerBNiranjanVHoffmannGSafety of" exact="oseltamivir" post="in pregnancy: a review of preclinical and clinical dataDrug"/>
   <result pre="outcomes among patients receiving oseltamivirPharmacoepidemiol Drug Saf12200311112622055 153DonnerBBader-WederSSchwarzRSafety profile of" exact="oseltamivir" post="during the 2009 influenza pandemicPharmacoepidemiol Drug Saf20201153254321448900 154KaraAKaradag-OncelEOzkaya-OParlakayAOseltamivir use"/>
   <result pre="there still unanswered questions?Turk J Pediatr542012252922397038 155DutkowskiRSmithJRDaviesBESafety and pharmacokinetics of" exact="oseltamivir" post="at standard and high dosagesInt J Antimicrob Agents35201046146720189775 156IsonMGSzakalyPShapiraMYEfficacy"/>
   <result pre="high dosagesInt J Antimicrob Agents35201046146720189775 156IsonMGSzakalyPShapiraMYEfficacy and safety of oral" exact="oseltamivir" post="for influenza prophylaxis in transplant recipientsAntivir Ther17201295596422728756 157Tamiflu 2006"/>
   <result pre="transplant recipientsAntivir Ther17201295596422728756 157Tamiflu 2006 Product Monograph. 158CasscellsSWGrangerEKressAMThe association between" exact="oseltamivir" post="use and adverse neuropsychiatric outcomes among TRICARE beneficiaries, ages"/>
   <result pre="of neuropsychiatric and adverse events in influenza patients treated with" exact="oseltamivir" post="or no antiviral treatmentInt J Clin Pract63200959660519335705 160GreeneSKLiLShayDKRisk of"/>
   <result pre="antiviral treatmentInt J Clin Pract63200959660519335705 160GreeneSKLiLShayDKRisk of adverse events following" exact="oseltamivir" post="treatment in influenza outpatients, Vaccine Safety Datalink Project, 2007-2010Pharmacoepidemiol"/>
   <result pre="databasePLoS One62011e2848322163021 162TreanorJJHaydenFGVroomanPSEfficacy and safety of the oral neuraminidase inhibitor" exact="oseltamivir" post="in treating acute influenzaJAMA28320001016102410697061 163CooperNJSuttonAJAbramsKREffectiveness of neuraminidase inhibitors in"/>
   <result pre="patients treated with oseltamivirJ Infect Dis188200357858012898446 165AokiFYMacleodMDPaggiaroPEarly administration of oral" exact="oseltamivir" post="increases the benefits of influenza treatmentJ Antimicrob Chemother51200312312912493796 166KaiserLWatCMillsTImpact"/>
   <result pre="increases the benefits of influenza treatmentJ Antimicrob Chemother51200312312912493796 166KaiserLWatCMillsTImpact of" exact="oseltamivir" post="treatment on influenza-related lower respiratory tract complications and hospitalizationsArch"/>
   <result pre="pathogenicity: observations from household based trialsAm J Epidemiol165200621222117088311 174NgSCowlingBJFangVJEffects of" exact="oseltamivir" post="treatment on duration of clinical illness and viral shedding"/>
   <result pre="transmission of influenza virusClin Infect Dis502009707714 175SugayaNMitamuraKYamazakiMLower clinical effectiveness of" exact="oseltamivir" post="against influenza B contrasted with influenza A infection in"/>
   <result pre="in childrenClin Infect Dis44200719720217173216 176KawaiNIkematsuHIwakiNA comparison of the effectiveness of" exact="oseltamivir" post="for the treatment of influenza A and influenza B:"/>
   <result pre="studyClin Infect Dis44200796496717342649 180HaydenFGAtmarRLSchillingMUse of the selective oral neuraminidase inhibitor" exact="oseltamivir" post="to prevent influenzaN Engl J Med34119991336134310536125 181PetersPHGravensteinSNorwoodPLong-term use of"/>
   <result pre="oseltamivir to prevent influenzaN Engl J Med34119991336134310536125 181PetersPHGravensteinSNorwoodPLong-term use of" exact="oseltamivir" post="for the prophylaxis of influenza in a vaccinated frail"/>
   <result pre="a vaccinated frail older populationJ Am Geriatr Soc4920011711207834 182WelliverRMontoASCarewiczOEffectiveness of" exact="oseltamivir" post="in preventing influenza in household contacts: a randomized controlled"/>
   <result pre="183HaydenFGBelsheRVillanuevaCManagement of influenza in households: a prospective, randomized comparison of" exact="oseltamivir" post="treatment with or without post-exposure prophylaxisJ Infect Dis189200444044914745701 184BowlesSKLeeWSimorAEUse"/>
   <result pre="treatment with or without post-exposure prophylaxisJ Infect Dis189200444044914745701 184BowlesSKLeeWSimorAEUse of" exact="oseltamivir" post="during influenza outbreaks in Ontario nursing homes, 1999-2000J Am"/>
   <result pre="Am Geriatr Soc50200260861611982659 185GovorkovaEAIenevaIAGoloubevaOGComparison of efficacies of RWJ-270201, zanamivir, and" exact="oseltamivir" post="against H5N1, H9N2, and other avian influenza virusesAntimicrob Agents"/>
   <result pre="susceptibility in vitroAntivir Ther14201011511159 187GubarevaLGWebsterRGHaydenFGComparison of the activities of zanamivir," exact="oseltamivir" post="and RWJ-270201 against clinical isolates of influenza virus and"/>
   <result pre="of the anti-influenza virus activity of RWJ-270201 with those of" exact="oseltamivir" post="and zanamivirAntimicrob Agents Chemother4520011162116711257030 190SmeeDFHuffmanJHMorrisonACCyclopentane neuraminidase inhibitors with potent"/>
   <result pre="anti-influenza virus effects in MDCK cellsAntimicrob Agents Chermother4820044855 193BantiaSKelloggDParkerCDCombination of" exact="peramivir" post="and rimantadine demonstrate synergistic antiviral effects in sub-lethal influenza"/>
   <result pre="effects in MDCK cellsAntimicrob Agents Chermother4820044855 193BantiaSKelloggDParkerCDCombination of peramivir and" exact="rimantadine" post="demonstrate synergistic antiviral effects in sub-lethal influenza A (H3N2)"/>
   <result pre="Res88201027628020943201 194ChandPBantiaSKotianPLComparison of the anti-influenza activity of cyclopentane derivatives with" exact="oseltamivir" post="and zanamivir in vivoBioorg Med Chem1320054071407715911320 195SidwellRWSmeeDFHoffmanDHIn vivo influenza"/>
   <result pre="of the anti-influenza activity of cyclopentane derivatives with oseltamivir and" exact="zanamivir" post="in vivoBioorg Med Chem1320054071407715911320 195SidwellRWSmeeDFHoffmanDHIn vivo influenza virus inhibitory"/>
   <result pre="cyclopentane neuraminidase inhibitor RWJ-270201Antimicrob Agents Chemother45200174975711181355 196BantiaSArnoldCSParkerCDAnti-influenza virus activity of" exact="peramivir" post="in mice with single intramuscular injectionAntivir Res692006394516325932 197BantiaSAnanthSLHornLGeneration and"/>
   <result pre="Windward Islands2000 200BarrosaLTreanorJGubarevaLEfficacy and tolerability of the oral neuraminidase inhibitor" exact="peramivir" post="in experimental human influenza: randomised, controlled trials for prophylaxis"/>
   <result pre="2009 pandemic influenza virusAntimicrob Agents Chemother5620121208121422203589 203AbedYPizzornoABoivinGTherapeutic activity of intramuscular" exact="peramivir" post="in mice infected with a recombinant influenza A/WSN/33 (H1N1)"/>
   <result pre="(H1N1) virus containing the H27Y neuraminidase mutationAntimicrob Agents Chemother5620124375437922664977 204KohnoSKidaHMizugichiMIntravenous" exact="peramivir" post="for treatment of influenza A and B virus infection"/>
   <result pre="Investigator Brochure2007Biocryst PharmaceuticalsCary, NC 207SugayaNKohnoSIshibashiTEfficacy, safety and pharmacokinetics of intravenous" exact="peramivir" post="in children with 2009 pandemic H1N1 influenza virus infectionAntimicrob"/>
   <result pre="influenza virus infectionAntimicrob Agents Chemother56201236937722024821 208KohnoSKidaHMizuguchiMEfficacy and safety of intravenous" exact="peramivir" post="for treatment of seasonal influenza virus infectionAntimicrob Agents Chemother5420104568457420713668"/>
   <result pre="Chemother4520012115211811408232 210PeramivirClinical Pharmacology2009Elsevier/Gold StandardTampa, FLhttp://download.thelancet.com/flatcontentassets/H1N1-flu/treatment/treatment-53.pdf 211IsonMGHuiDSClezyKA clinical trial of intravenous" exact="peramivir" post="compared with oral oseltamivir for the treatment of seasonal"/>
   <result pre="FLhttp://download.thelancet.com/flatcontentassets/H1N1-flu/treatment/treatment-53.pdf 211IsonMGHuiDSClezyKA clinical trial of intravenous peramivir compared with oral" exact="oseltamivir" post="for the treatment of seasonal influenza in hospitalized adultsAntivir"/>
   <result pre="28-March 22008 213KohnoSYenM-YCheongM-JPhase III randomized, double-blind study comparing single-dose intravenous" exact="peramivir" post="with oral oseltamivir in patients with seasonal influenza virus"/>
   <result pre="III randomized, double-blind study comparing single-dose intravenous peramivir with oral" exact="oseltamivir" post="in patients with seasonal influenza virus infectionAntimicrob Agents Chemother5520115267527621825298"/>
   <result pre="Conference on Antimicrobial Agents and Chemotherapy. Chicago, September 14-172003 215IsonMGFraizJHellerBIntravenous" exact="peramivir" post="for treatment of influenza in hospitalized patientsAntivir Ther2013 216BioCryst"/>
   <result pre="with chronic HCV infectionJ Med Virol692003505812436477 221TamRCLauJYHongZMechanisms of action of" exact="ribavirin" post="in antiviral therapiesAntivir Chem Chemother122002261272 222GraciJDCameronCEQuasispecies, error catastrophe, and"/>
   <result pre="catastrophe, and the antiviral activity of ribavirinVirology298200217518012127780 223HongZCameronCEPleiotropic mechanisms of" exact="ribavirin" post="antiviral activitiesProg Drug Res592002416912458963 224VoNVYoungKCLaiMMMutagenic and inhibitory effects of"/>
   <result pre="ribavirin antiviral activitiesProg Drug Res592002416912458963 224VoNVYoungKCLaiMMMutagenic and inhibitory effects of" exact="ribavirin" post="on hepatitis C virus RNA polymeraseBiochemistry422003104621047112950173 225Fernandez-LarssonRPattersonJLRibavirin is an"/>
   <result pre="of a ribavirin-resistant NS5B mutation of hepatitis C virus during" exact="ribavirin" post="monotherapyHepatology38200386987814512874 227GluePThe clinical pharmacology of ribavirinSemin Liver Dis19suppl 11999172410349689"/>
   <result pre="of ribavirinSemin Liver Dis19suppl 11999172410349689 228PrestonSLDrusanoGLGluePPharmacokinetics and absolute bioavailability of" exact="ribavirin" post="in healthy volunteers as determined by stable-isotope methodologyAntimicrob Agents"/>
   <result pre="acquired immunodeficiency syndromeClin Pharmacol Ther4119875465553568539 230GluePSchenkerSGuptaSThe single dose pharmacokinetics of" exact="ribavirin" post="in subjects with chronic liver diseaseJ Clin Pharmacol492000417421 231JenJFGluePGuptaSPopulation"/>
   <result pre="liver diseaseJ Clin Pharmacol492000417421 231JenJFGluePGuptaSPopulation pharmacokinetic and pharmacodynamic analysis of" exact="ribavirin" post="in patients with chronic hepatitis CTher Drug Monit22200055556511034261 232ICN"/>
   <result pre="Intern Med12319958979037486483 235KnowlesSRPhillipsEJDresserLCommon adverse events associated with the use of" exact="ribavirin" post="for severe acute respiratory syndrome in CanadaClin Infect Dis3720031139114214523782"/>
   <result pre="in CanadaClin Infect Dis3720031139114214523782 236BradleyJSConnorJDCompogiannisLSExposure of health care workers to" exact="ribavirin" post="during therapy for respiratory syncytial virus infectionsAntimicrob Agents Chemother3419906686702344173"/>
   <result pre="randomized, placebo-controlled trialAm J Respir Crit Care Med160199982983410471604 240EnglundJAPiedraPAJeffersonLSHigh-dose, short-duration" exact="ribavirin" post="aerosol therapy in children with suspected respiratory syncytial virus"/>
   <result pre="syncytial virus lower respiratory tract infection and randomly treated with" exact="ribavirin" post="or placeboPediatr Infect Dis J161997102310289384333 243SmallTNCassonAMalakSFRespiratory syncytial virus infection"/>
   <result pre="244BoeckhMBerreyMMBowdenRAPhase 1 evaluation of the respiratory syncytial virus–specific monoclonal antibody" exact="palivizumab" post="in recipients of hematopoietic stem cell transplantsJ Infect Dis184200135035411443562"/>
   <result pre="and Marrow TransplantationBone Marrow Transplant28200147948411593321 247LewinsohnDMBowdenRAMattsonDPhase I study of intravenous" exact="ribavirin" post="treatment of respiratory syncytial virus pneumonia after marrow transplantationAntimicrob"/>
   <result pre="marrow transplantationAntimicrob Agents Chemother401996255525578913463 248BoeckhMEnglundJLiYRandomized controlled multicenter trial of aerosolized" exact="ribavirin" post="for respiratory syncytial virus upper respiratory tract infection in"/>
   <result pre="adaptive randomized trial of an intermittent dosing schedule of aerosolized" exact="ribavirin" post="in patients with cancer and respiratory syncytial virus infectionJ"/>
   <result pre="safely treated with high-dose ribavirinBone Marrow Transpl452010S215 253LiLAveryRBudevMOral versus inhaled" exact="ribavirin" post="therapy for respiratory syncytial virus infection after lung transplantationJ"/>
   <result pre="infection after lung transplantationJ Heart Lung Transpl312012839844 254PelaezALyonGMForceSDEfficacy of oral" exact="ribavirin" post="in lung transplant patients with respiratory syncytial virus lower"/>
   <result pre="syncytial virus lower respiratory tract infectionJ Heart Lung Transpl2820096771 255HaydenFGSableCAConnorJDIntravenous" exact="ribavirin" post="by constant infusion for serious influenza and parainfluenzavirus infectionAntiviral"/>
   <result pre="infusion for serious influenza and parainfluenzavirus infectionAntiviral Ther119965156 256Chan-TackKMMurrayJSBirnkrantDBUse of" exact="ribavirin" post="to treat influenzaN Engl J Med36120091713171419846864 257RodriguezWJHallCBWelliverREfficacy and safety"/>
   <result pre="treat influenzaN Engl J Med36120091713171419846864 257RodriguezWJHallCBWelliverREfficacy and safety of aerosolized" exact="ribavirin" post="in young children hospitalized with influenza: a double-blind, multicenter,"/>
   <result pre="to antiviral therapy, and effect on transplant outcomeBlood98200157357811468152 260ChakrabartiSCollinghamKEHolderKPre-emptive oral" exact="ribavirin" post="therapy of paramyxovirus infections after haematopoietic stem cell transplantation:"/>
   <result pre="haematopoietic stem cell transplantation: a pilot studyBone Marrow Transplant28200175976311781627 261SouzaILASchnertLGotoJMOral" exact="ribavirin" post="in treatment of adenovirus infection in hematologic patients: experience"/>
   <result pre="patients: experience from a Brazilian university hospitalClin Microbiol Infect162010S24 262GavinPJKatzBZIntravenous" exact="ribavirin" post="treatment for severe adenovirus disease in immunocompromised childrenPediatrics1102002E912093990 263BonneyDRazatiHTurnerASuccessful"/>
   <result pre="treatment of human metapneumovirus pneumonia using combination therapy with intravenous" exact="ribavirin" post="and immune globulinBr J Haematol452009667679 264RazaKIsmailjeeSBCrespoMSuccessful outcome of human"/>
   <result pre="treated with intravenous ribavirinJ Heart Lung Transpl262007862864 265Schachor-MeyouhasYBen-BarakAKassisITreatment with oral" exact="ribavirin" post="and IVIG of severe human metapneumovirus pneumonia in immune"/>
   <result pre="in immune compromised childPediatr Blood Cancer57201135035121671370 266FuehnerTDierichMDuesbertCSingle-centre experience with oral" exact="ribavirin" post="in lung transplant recipients with paramyxovirus infectionsAntivir Ther16201117331740 267ShimaTYoshimotoGNonamiASuccessful"/>
   <result pre="Ther16201117331740 267ShimaTYoshimotoGNonamiASuccessful treatment of parainfluenza virus 3 pneumonia with oral" exact="ribavirin" post="and methylprednisolone in a bone marrow transplant recipientInt J"/>
   <result pre="treatment of parainfluenza virus 3 pneumonia with oral ribavirin and" exact="methylprednisolone" post="in a bone marrow transplant recipientInt J Hematol88200833634018712461 268WrightJJO'DriscollGTreatment"/>
   <result pre="virus 3 pneumonia in a cardiac transplant recipient with intravenous" exact="ribavirin" post="and methylprednisoneJ Heart Lung Transpl242005343346 269KanjiJVaudryWSuccessful cardiac transplantation in"/>
   <result pre="a 4-year-old child with active parainfluenza-3 infection: experience with systemic" exact="ribavirin" post="therapyCan J Infect Dis Med Microbiol22201116A 270MazzulliTFarcasGAPoutanenSMSevere acute respiratory"/>
   <result pre="acute respiratory syndrome–associated coronavirus in lung tissueEmerg Infect Dis102004202415078592 271ChapmanLEMertzGJPetersCJIntravenous" exact="ribavirin" post="for hantavirus pulmonary syndrome: safety and tolerance during 1"/>
   <result pre="viruses in vitroAntimicrob Agents Chemother371993147314798363379 279KawaiNIkematsuHIwakiNComparison of the effectiveness of" exact="zanamivir" post="and oseltamivir for the treatment of influenza A and"/>
   <result pre="vitroAntimicrob Agents Chemother371993147314798363379 279KawaiNIkematsuHIwakiNComparison of the effectiveness of zanamivir and" exact="oseltamivir" post="for the treatment of influenza A and BJ Infect3620085157"/>
   <result pre="sequence analysis and susceptibilities of influenza virus clinical isolates to" exact="zanamivir" post="and oseltamivirAntimicrob Agents Chemother4720032264227212821478 281GovorkovaFAFangH-BTamMNeuraminidase inhibitor-rimantadine combinations exert additive"/>
   <result pre="effects in MDCK cellsAntimicrob Agents Chemother482004485515561867 282HataKKosekiKYamaguchiKLimited inhibitory effect of" exact="oseltamivir" post="and zanamivir on human sialadasesAntimicrob Agents Chemother5220083484349118694948 283MurrellMPorottoMWeberTMutations in"/>
   <result pre="MDCK cellsAntimicrob Agents Chemother482004485515561867 282HataKKosekiKYamaguchiKLimited inhibitory effect of oseltamivir and" exact="zanamivir" post="on human sialadasesAntimicrob Agents Chemother5220083484349118694948 283MurrellMPorottoMWeberTMutations in human parainfluenza"/>
   <result pre="drug susceptibility in vitroAntivir Ther1520101151115921149922 288World Health OrganizationWeekly update on" exact="oseltamivir" post="resistance to influenza A (H1N1) 2009 virusesAvailable athttp://www.who.int/csr/disease/swineflu/oseltamivirresistant20/00820pdfAccessed December"/>
   <result pre="during 2010 and 2011 identifies viruses with reduced susceptibility to" exact="oseltamivir" post="and zanamivirAntiviral Res97201324024423267831 291HurtACLeeRTLeangSKIncreased detection in Australia and Singapore"/>
   <result pre="of a novel influenza A (H1N1) 2009 variant with reduced" exact="oseltamivir" post="and zanamivir sensitivity due to a S274N neuraminidase mutationEuro"/>
   <result pre="novel influenza A (H1N1) 2009 variant with reduced oseltamivir and" exact="zanamivir" post="sensitivity due to a S274N neuraminidase mutationEuro Surveill1620111988421679678 292LeGoffJRoussetDAbou-JaoudeGI223R"/>
   <result pre="292LeGoffJRoussetDAbou-JaoudeGI223R mutation in influenza A(H1N1)pdm09 neuraminidase confers reduced susceptibility to" exact="oseltamivir" post="and zanamivir and enhanced resistance with H275YPLoS One72012e3709522936969 293GubarevaLVMatrosovichMNBrennerMKEvidence"/>
   <result pre="in influenza A(H1N1)pdm09 neuraminidase confers reduced susceptibility to oseltamivir and" exact="zanamivir" post="and enhanced resistance with H275YPLoS One72012e3709522936969 293GubarevaLVMatrosovichMNBrennerMKEvidence for zanamivir"/>
   <result pre="and zanamivir and enhanced resistance with H275YPLoS One72012e3709522936969 293GubarevaLVMatrosovichMNBrennerMKEvidence for" exact="zanamivir" post="resistance in an immunocompromised child infected with influenza B"/>
   <result pre="adult subjectsAntimicrob Agents Chemother5520115178518421896909 300PengAWMilleriSSteinDSDirect measurement of the anti-influenza agent" exact="zanamivir" post="in the respiratory tract following inhalationAntimicrob Agents Chemother4420001974197610858364 301WellerSThamlikitkulVFrancoisBPharmacokinetics"/>
   <result pre="the respiratory tract following inhalationAntimicrob Agents Chemother4420001974197610858364 301WellerSThamlikitkulVFrancoisBPharmacokinetics of intravenous" exact="zanamivir" post="in hospitalized adults with influenza: interim results from open-label"/>
   <result pre="op-label crossover study to evaluate potential pharmacokinetic interactions between oral" exact="oseltamivir" post="and intravenous zanamivir in healthy Thai adultsAntimicrob Agents Chemother5520114050405721690287"/>
   <result pre="to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous" exact="zanamivir" post="in healthy Thai adultsAntimicrob Agents Chemother5520114050405721690287 305Centers for Disease"/>
   <result pre="a randomized controlled trialPediatr Infect Dis J19200041041710819336 308AnekthananonTPukritayakameeSRatanasuwanWOseltamivir and inhaled" exact="zanamivir" post="as influenza prophylaxis in Thai health workers: a randomized,"/>
   <result pre="of developing influenza-related complicationsDrug Saf2420011113112511772145 310MurphyKEivindsonAPauksensKEfficacy and safety of inhaled" exact="zanamivir" post="for the treatment of influenza in patients with asthma"/>
   <result pre="treatment of influenzaExpert Opin Pharmacother4200379980512740002 313IsonMGGnannJWJrNagy-AgrenSSafety and efficacy of nebulized" exact="zanamivir" post="in hospitalized patients with serious influenzaAntivir Ther8200318319012924534 314KiatboonsriSKiatboonsriCTheerawitPFatal respiratory"/>
   <result pre="patients with serious influenzaAntivir Ther8200318319012924534 314KiatboonsriSKiatboonsriCTheerawitPFatal respiratory events caused by" exact="zanamivir" post="nebulizationClin Infect Dis50201062020095840 315CassLMREfthymiopoulasCByeAPharmacokinetics of zanamivir after intravenous, oral,"/>
   <result pre="respiratory events caused by zanamivir nebulizationClin Infect Dis50201062020095840 315CassLMREfthymiopoulasCByeAPharmacokinetics of" exact="zanamivir" post="after intravenous, oral, inhaled or intranasal administration in healthy"/>
   <result pre="CA, October 17-21Poster 1626: Safety, tolerability and pharmacokinetics of intravenous" exact="zanamivir" post="treatment in hospitalized adults with influenza: a phase 2"/>
   <result pre="2 open-label, multicenter, single-arm study2012 317WalkerJBHusseyEKTreanorJJEffects of the neuraminidase inhibitor" exact="zanamivir" post="on otologic manifestations of experimental human influenzaJ Infect Dis1761997141714229395349"/>
   <result pre="influenzaJ Infect Dis1761997141714229395349 318HaydenFGOsterhausADMETreanorJJEfficacy and safety of the neuraminidase inhibitor" exact="zanamivir" post="in the treatment of influenza virus infectionsN Engl J"/>
   <result pre="Trialists) Study GroupRandomized trial of efficacy and safety of inhaled" exact="zanamivir" post="in treatment of influenza A and B virus infectionsLancet3521998187718819863784"/>
   <result pre="A and B virus infectionsLancet3521998187718819863784 320MontoASWebsterAKeeneORandomized, placebo-controlled studies of inhaled" exact="zanamivir" post="in the treatment of influenza A and B: pooled"/>
   <result pre="A and B: pooled efficacy analysisJ Antimicrob Chemother441999232910877459 321KaiserLKeeneONHammondJImpact of" exact="zanamivir" post="on antibiotics use for respiratory events following acute influenza"/>
   <result pre="infection in high-risk patients [abstract]Arch Intern Med161200121221711176734 324JohnyAAClarkAPriceNThe use of" exact="zanamivir" post="to treat influenza A and B infection after allogeneic"/>
   <result pre="infection after allogeneic stem cell transplantationBone Marrow Transplant29200211311511850704 325GukarevaLVMatrosovichMNBrennerMKEvidence for" exact="zanamivir" post="resistance in an immunocompromised child infected with influenza B"/>
   <result pre="infected with influenza B virusJ Infect Dis1781998125712629780244 326KawaiNIkematsuHHirotsuNClinical effectiveness of" exact="oseltamivir" post="and zanamivir for treatment of influenza A virus subtype"/>
   <result pre="influenza B virusJ Infect Dis1781998125712629780244 326KawaiNIkematsuHHirotsuNClinical effectiveness of oseltamivir and" exact="zanamivir" post="for treatment of influenza A virus subtype H1N1 with"/>
   <result pre="327MontoASRobinsonDPHerlocherLZanamivir in the prevention of influenza among healthy adultsJAMA2821999313610404908 328HaydenFGGubarevaLVMontoASInhaled" exact="zanamivir" post="for preventing influenza in familiesN Engl J Med34320001282128911058672 329MontoASPichicheroMEBlanckenbergSJZanamivir"/>
   <result pre="householdsJ Infect Dis18620021582158812447733 330ShinjohMTakanoYTakahashiTPostexposure prophylaxis for influenza in pediatric wards:" exact="oseltamivir" post="or zanamivir after rapid antigen detectionPediatr Infect Dis J3120121119112322634596"/>
   <result pre="Dis18620021582158812447733 330ShinjohMTakanoYTakahashiTPostexposure prophylaxis for influenza in pediatric wards: oseltamivir or" exact="zanamivir" post="after rapid antigen detectionPediatr Infect Dis J3120121119112322634596 331GravensteinSDrinkaPOsterweilDA multicenter"/>
   <result pre="randomized controlled trial comparing the relative safety and efficacy of" exact="zanamivir" post="to rimantadine for nursing home influenza outbreak control [abstract"/>
   <result pre="trial comparing the relative safety and efficacy of zanamivir to" exact="rimantadine" post="for nursing home influenza outbreak control [abstract 1155]Presented at"/>
   <result pre="placebo-controlled trialPLoS Med72010 334BiattoJFCostaELPastoreLProne position ventilation, recruitment maneuver and intravenous" exact="zanamivir" post="in severe refractory hypoxemia caused by influenza A (H1N1)Clinics"/>
   <result pre="335GhoshSAdamsOSchusterFREfficient control of pandemic 2009 H1N1 virus infection with intravenous" exact="zanamivir" post="despite the lack of immune functionTranspl Infect Dis14201265765923013415 336Dohna-SchwakeCSchweigerBFelderhoff-MuserUSevere"/>
   <result pre="transplant recipient treated with intravenous zanamivir: efficiency and complicationsTransplantation90201022322420644456 337GuarAHBaggaBBarmanSIntravenous" exact="zanamivir" post="for oseltamivir-resistant 2009 H1N1 influenzaN Engl J Med3622010888920032317 338KiddIMDownJNastouliEH1N1"/>
   <result pre="Med3622010888920032317 338KiddIMDownJNastouliEH1N1 pneumonitis treated with intravenous zanamivirLancet3742009103619733390 339DulekDEWilliamsJVCreechCBUse of intravenous" exact="zanamivir" post="after development of oseltamivir resistance in a critically ill"/>
   <result pre="with intravenous zanamivirLancet3742009103619733390 339DulekDEWilliamsJVCreechCBUse of intravenous zanamivir after development of" exact="oseltamivir" post="resistance in a critically ill immune-suppressed child infected with"/>
   <result pre="with 2009 pandemic influenza A (H1N1) virusClin Infect Dis5020101493149620415572 340HarterGZimmermannOMaierLIntravenous" exact="zanamivir" post="for patients with pneumonitis due to pandemic (H1N1) 2009"/>
   <result pre="to pandemic (H1N1) 2009 influenza virusClin Infect Dis5020101249125120367227 341UhlDNew influenza:" exact="zanamivir" post="intravenous administration seems life-savingDtsch Apoth Ztg149200947 342FryAMPerezAFinelliLUse of intravenous"/>
   <result pre="inhibitors during the 2009 pandemic: results from population-based surveillanceJAMA306201116016221750292 343MacdonaldSJFCameronRDemaineDADimeric" exact="zanamivir" post="conjugates with various linking groups are potent long-lasting inhibitors"/>
   <result pre="derivatives related to zanamivirBioorg Med Chem Lett1220021925192812113810 350WeightAKHaldarJAlvarez de CienfuegosLAttaching" exact="zanamivir" post="to a polymer markedly enhances its activity against drug-resistant"/>
   <result pre="against drug-resistant strains of influenza A virusJ Pharm Sci100201183183520740680 351LeeCMWeightAKHaldarJPolymer-attached" exact="zanamivir" post="inhibits synergistically both early and late stages of influenza"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7152529\results\search\drugs\results.xml">
   <result pre="two patients in KoreaJ Korean Med Sci2020357e8632080991 13WangMCaoRZhangLYangXLiuJXuMet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7152756\results\search\drugs\results.xml">
   <result pre="drugs revealed that the HIV type 1 (HIV-1) protease inhibitor" exact="lopinavir" post="is active against MERS–CoV (21). This drug is currently"/>
   <result pre="for the treatment of MERS–CoV in combination with interferon-β and" exact="ritonavir" post="(22), which is used for pharmacological boosting. A recent"/>
   <result pre="ImbertI. (2018) Structural and molecular basis of mismatch correction and" exact="ribavirin" post="excision from coronavirus RNA. Proc. Natl. Acad. Sci. U.S.A."/>
   <result pre="(2008) Delayed chain termination protects the anti-hepatitis B virus drug" exact="entecavir" post="from excision by HIV-1 reverse transcriptase. J. Biol. Chem."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7152897\results\search\drugs\results.xml">
   <result pre="as the COVID-19 resource centre remains active. Highlights •Efficacy of" exact="chloroquine" post="and hydroxychloroquine in COVID-19 treatment is discussed. •Prophylactic use"/>
   <result pre="COVID-19 resource centre remains active. Highlights •Efficacy of chloroquine and" exact="hydroxychloroquine" post="in COVID-19 treatment is discussed. •Prophylactic use of chloroquine"/>
   <result pre="and hydroxychloroquine in COVID-19 treatment is discussed. •Prophylactic use of" exact="chloroquine" post="or hydroxychloroquine in COVID-19 is considered. The opinions expressed"/>
   <result pre="in COVID-19 treatment is discussed. •Prophylactic use of chloroquine or" exact="hydroxychloroquine" post="in COVID-19 is considered. The opinions expressed in this"/>
   <result pre="not those of the Ministry of Armies. The antimalarial drug" exact="chloroquine" post="has been shown to be effective in vitro against"/>
   <result pre="µM [2]. Hydroxychloroquine was found to be more potent than" exact="chloroquine" post="phosphate (EC50 5.47 µM) [2]. Chloroquine and hydroxychloroquine appear"/>
   <result pre="potent than chloroquine phosphate (EC50 5.47 µM) [2]. Chloroquine and" exact="hydroxychloroquine" post="appear to inhibit fusion of the virus to the"/>
   <result pre="conducted in China to investigate the efficacy and safety of" exact="chloroquine" post="and hydroxychloroquine in the treatment of COVID-19 [4], [5],"/>
   <result pre="China to investigate the efficacy and safety of chloroquine and" exact="hydroxychloroquine" post="in the treatment of COVID-19 [4], [5], [6]. Chloroquine"/>
   <result pre="patients with mild, moderate and severe COVID-19 who had no" exact="chloroquine" post="contraindications should be treated with chloroquine phosphate at a"/>
   <result pre="COVID-19 who had no chloroquine contraindications should be treated with" exact="chloroquine" post="phosphate at a dose of 500 mg twice per"/>
   <result pre="day for 10 days [7]. Preliminary clinical data showed that" exact="hydroxychloroquine" post="at 600 mg daily cured 70% of patients (n=20)"/>
   <result pre="6 after the first drug intake [8]. The efficacy of" exact="hydroxychloroquine" post="was improved by combining this drug with azithromycin, an"/>
   <result pre="such as Zika virus [9,10]. The 6 patients treated with" exact="hydroxychloroquine" post="combined with azithromycin (500 mg at day 1 followed"/>
   <result pre="virus [9,10]. The 6 patients treated with hydroxychloroquine combined with" exact="azithromycin" post="(500 mg at day 1 followed by 250 mg"/>
   <result pre="at day 6 (100%) compared with patients treated with only" exact="hydroxychloroquine" post="(57.1%) or without treatment (12.5%) [8]. These results are"/>
   <result pre="should be supplemented by larger studies. Importantly, therapeutic interventions using" exact="chloroquine" post="at high dose and/or in combination with macrolides may"/>
   <result pre="000 French soldiers deployed in malaria transmission areas. After 1990," exact="chloroquine" post="in combination with 200 mg of proguanil chlorhydrate was"/>
   <result pre="areas. After 1990, chloroquine in combination with 200 mg of" exact="proguanil" post="chlorhydrate was recommended, and this was replaced by doxycycline"/>
   <result pre="of proguanil chlorhydrate was recommended, and this was replaced by" exact="doxycycline" post="in 2006. Chloroquine is usually well tolerated. The more"/>
   <result pre="long-term chemoprophylaxis (duration &amp;gt;5 months) in non-immune soldiers [11]. Combining" exact="chloroquine" post="with an antibiotic such as doxycycline in daily prophylaxis"/>
   <result pre="non-immune soldiers [11]. Combining chloroquine with an antibiotic such as" exact="doxycycline" post="in daily prophylaxis did not increase the risk of"/>
   <result pre="effects [12]. Some European countries also recommended 300 mg of" exact="chloroquine" post="once weekly alone or in combination with proguanil 200"/>
   <result pre="mg of chloroquine once weekly alone or in combination with" exact="proguanil" post="200 mg daily. Some gastrointestinal side effects were observed"/>
   <result pre="duration of 5.5 years for continuous use of 300 mg" exact="chloroquine" post="base weekly or 3 years of 100 mg daily"/>
   <result pre="100 mg daily [14]. If the dose of 100 g" exact="chloroquine" post="base is exceeded, annual ophthalmological examinations are recommended. In"/>
   <result pre="base is exceeded, annual ophthalmological examinations are recommended. In addition," exact="chloroquine" post="is rapidly dealkylated into antiplasmodial active desethylchloroquine via cytochrome"/>
   <result pre="of 20 to 60 days [15]. The promising results of" exact="chloroquine" post="in treatment of COVID-19 and the low prevalence of"/>
   <result pre="of side-effects in long-term use indicate a possible use of" exact="chloroquine" post="at 100 mg daily or hydroxychloroquine at 300 mg"/>
   <result pre="a possible use of chloroquine at 100 mg daily or" exact="hydroxychloroquine" post="at 300 mg weekly in mass prophylaxis in individuals"/>
   <result pre="help protect frontline healthcare workers combating COVID-19 [16]. Chemoprophylaxis with" exact="chloroquine" post="or hydroxychloroquine could prevent COVID-19-associated pneumonia and block transmission"/>
   <result pre="frontline healthcare workers combating COVID-19 [16]. Chemoprophylaxis with chloroquine or" exact="hydroxychloroquine" post="could prevent COVID-19-associated pneumonia and block transmission by reducing"/>
   <result pre="the number of asymptomatic carriers. We propose the use of" exact="chloroquine" post="with a loading dose of 300 mg followed by"/>
   <result pre="May 2020 to evaluate the potential prevention of COVID-19 by" exact="chloroquine" post="at a loading dose of 10 mg base/kg, followed"/>
   <result pre="dose of 10 mg base/kg, followed by 150 mg of" exact="chloroquine" post="base (250 mg chloroquine phosphate salt) daily for 3"/>
   <result pre="base/kg, followed by 150 mg of chloroquine base (250 mg" exact="chloroquine" post="phosphate salt) daily for 3 months in 10 000"/>
   <result pre="will be recorded and compared in the subjects randomised to" exact="chloroquine" post="or placebo during 5 months of follow-up. Declarations Funding:"/>
   <result pre="to declare. Ethical Approval: Not required. References References 1WangMCaoRZhangLYangXLiuJXuMRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCov) in"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020 Mar 910.1093/cid/ciaa237pii: ciaa237 3RolainJMColsonPRaoultDRecycling of" exact="chloroquine" post="and its hydroxyl analogue to face bacterial, fungal and"/>
   <result pre="Agents30200729730817629679 4CortegianiAIngogliaGIppolitoMGiarratanoAEinavSA systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J Crit Care2020 Mar 1010.1016/j.jcrc.2020.03.005pii:"/>
   <result pre="treatment of COVID-19J Crit Care2020 Mar 1010.1016/j.jcrc.2020.03.005pii: S0883-9441(20)30390-7. doi.org/ 5GaoJTianZYangXBreakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in the treatment of"/>
   <result pre="of COVID-19 associated pneumonia in clinical studiesBiosci Trends1412020727310.5582/bst.2020.0104732074550 6TouretFde LamballerieXOf" exact="chloroquine" post="and COVID-19Antiviral Res177202010476210.1016/j.antiviral.2020.104762 7collab: Multicenter collaboration group of Department"/>
   <result pre="of Guandong Province and Health Commission of Guangdong Province for" exact="chloroquine" post="in the treatment of novel coronavirus pneumoniaExpert consensus on"/>
   <result pre="chloroquine in the treatment of novel coronavirus pneumoniaExpert consensus on" exact="chloroquine" post="phosphate for the treatment of novel coronavirus pneumoniaZhonghua Jie"/>
   <result pre="pneumoniaZhonghua Jie He He Hu Xi Za Zhi43202018518810.3760/cma.j.issn.1001-0939.2020.03.00932164085 8GautretPLagierJCParolaPHoangVTMeddebLMailheMHydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="type I and III interferon responsesAntimicrob Agents Chemother6312201910.1128/AAC.00394-19e00394–19 11PagèsFBoutinJPMeynardJBKeundjianARyferSGiuratoLTolerability of" exact="doxycycline" post="monohydrate salt vs. chloroquine-proguanil in malaria prophylaxisTrop Med Int"/>
   <result pre="vs. chloroquine-proguanil in malaria prophylaxisTrop Med Int Healh72002919924 12MichelRBardotSQueyriauxBBoutinJPTouzeJEDoxycycline-chloroquine vs." exact="doxycycline" post="placebo for malaria prophylaxis in nonimmune soldiers: a double-blind"/>
   <result pre="AfricaTrans R Soc Trop Med Hyg104201029029710.1016/j.trstmh.2009.10.00120129634 13PeragalloMSSabatinelliGSarnicolaGCompliance and tolerability of" exact="mefloquine" post="and chloroquine and chloroquine plus proguanil for long-term malaria"/>
   <result pre="Soc Trop Med Hyg104201029029710.1016/j.trstmh.2009.10.00120129634 13PeragalloMSSabatinelliGSarnicolaGCompliance and tolerability of mefloquine and" exact="chloroquine" post="and chloroquine plus proguanil for long-term malaria prophylaxis in"/>
   <result pre="Med Hyg104201029029710.1016/j.trstmh.2009.10.00120129634 13PeragalloMSSabatinelliGSarnicolaGCompliance and tolerability of mefloquine and chloroquine and" exact="chloroquine" post="plus proguanil for long-term malaria prophylaxis in groups at"/>
   <result pre="13PeragalloMSSabatinelliGSarnicolaGCompliance and tolerability of mefloquine and chloroquine and chloroquine plus" exact="proguanil" post="for long-term malaria prophylaxis in groups at particular risk"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7152904\results\search\drugs\results.xml">
   <result pre="of Ebola virus RNA-dependent RNA polymerase by remdesivirViruses1142019326 15WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7152908\results\search\drugs\results.xml">
   <result pre="coronavirus (COVID-19) outbreak: a call for actionChest2020 13https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-march-30-2020 14GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="Case Rep83202057857932185066 17ZhouD.DaiS.M.TongQ.COVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progressionJ Antimicrob Chemother2020 18ZhaiP.DingY.WuX.LongJ.ZhongY.LiY.The epidemiology,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7152910\results\search\drugs\results.xml">
   <result pre="and pandemic. M2-ion channel inhibitor amantadine, the neuraminidase (NA) inhibitors" exact="zanamivir" post="and oseltamivir are the FDA-approved antiviral drugs. However, both"/>
   <result pre="M2-ion channel inhibitor amantadine, the neuraminidase (NA) inhibitors zanamivir and" exact="oseltamivir" post="are the FDA-approved antiviral drugs. However, both classes of"/>
   <result pre="Bidepharm (Shanghai, China) with a purity of 99.35%. Zanamivir and" exact="peramivir" post="were purchased from Sigma-Aldrich (St. Louis, MO, USA). D715-2441"/>
   <result pre="microscopy. (f) The expression of viral NP and PB2 protein," exact="peramivir" post="as a positive control. (g) The production load of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7153035\results\search\drugs\results.xml">
   <result pre="early evidence of selection of Mycobacterium tuberculosis mutants resistant to" exact="streptomycin" post="(Mitchison, 1950). Antibiotic resistance in bacteria has similarities and"/>
   <result pre="the genetic barrier to resistance to the NS3/4A protease inhibitor" exact="telaprevir" post="[formula (20) in Fig. 8.3]. One of the amino"/>
   <result pre="One of the amino acid substitutions that confer resistance to" exact="telaprevir" post="is R155K in NS3. In genotype 1a, the triplet"/>
   <result pre="Amino acid substitution S282T in NS5B has been associated with" exact="sofosbuvir" post="resistance, and the substitution has been detected in patients"/>
   <result pre="isolates of HCV. In one of several clinical studies on" exact="sofosbuvir" post="efficacy, the mutant spectrum composition of HCV genotype 2b"/>
   <result pre="to the drug (Section 8.6). Two days after initiation of" exact="sofosbuvir" post="treatment, the level of S282T decreased to 0.03%, and"/>
   <result pre="that confer resistance of picornaviruses to the mutagenic purine analog" exact="ribavirin" post="illustrates how alternative amino acid substitutions in the viral"/>
   <result pre="in Fig. 8.3 with the structures of nevirapine, efavirenz, and" exact="delavirdine" post="[formulae (15), (16), and (17), respectively]. Several mechanisms have"/>
   <result pre="target for the development of specific antiviral inhibitors. Examples are" exact="saquinavir" post="and ritonavir for the HIV-1 [formulae (18) and (19),"/>
   <result pre="the development of specific antiviral inhibitors. Examples are saquinavir and" exact="ritonavir" post="for the HIV-1 [formulae (18) and (19), respectively, in"/>
   <result pre="dependence to HBB independence Eggers and Tamm (1965) Amantadine and" exact="rimantadine" post="IV 1 × 10−3 to 4 × 10−4 Measurements"/>
   <result pre="al., 1978 Rimantadinea IV 27% Percentage of children treated with" exact="rimantadine" post="that shed resistant IV Belshe et al. (1988) Disoxarila"/>
   <result pre="included in Figure 8.2 with the following number in parenthesis:" exact="amantadine" post="(6); rimantadine (7); disoxaril (2). bThe virus abbreviations are"/>
   <result pre="Figure 8.2 with the following number in parenthesis: amantadine (6);" exact="rimantadine" post="(7); disoxaril (2). bThe virus abbreviations are CAV9, coxsackievirus"/>
   <result pre="important issue of HCV resistance to interferon-alpha (IFN-α). IFN-α and" exact="ribavirin" post="were the two components of the standard of care"/>
   <result pre="resistance to other inhibitors of HCV replication: the protease inhibitor" exact="telaprevir" post="[formula (20) in Fig. 8.3], the NS5A inhibitor daclatasvir,"/>
   <result pre="the mutagenic purine nucleoside ribavirin, and the high barrier inhibitor" exact="sofosbuvir" post="[formula (21) in Fig. 8.3]. HCVp45 and HCVp100 displayed"/>
   <result pre="of any drug (No drug) or the presence of IFN-α," exact="ribavirin" post="(Rib), telaprevir (TPV), daclatasvir (DCV), or cyclosporin A (CsA)."/>
   <result pre="drug (No drug) or the presence of IFN-α, ribavirin (Rib)," exact="telaprevir" post="(TPV), daclatasvir (DCV), or cyclosporin A (CsA). Note the"/>
   <result pre="drug) or the presence of IFN-α, ribavirin (Rib), telaprevir (TPV)," exact="daclatasvir" post="(DCV), or cyclosporin A (CsA). Note the resistance of"/>
   <result pre="to drug resistanceJ. Infect. Dis.19120051953196015871130 BelsheR.B.SmithM.H.HallC.B.BettsR.HayA.J.Genetic basis of resistance to" exact="rimantadine" post="emerging during treatment of influenza virus infectionJ. Virol.621988150815123282079 BeveridgeW.I.B.Influenza:"/>
   <result pre="gag and protease: partners in resistanceRetrovirology920126322867298 GallegoI.SheldonJ.MorenoE.GregoriJ.QuerJ.Barrier-independent, fitness-associated differences in" exact="sofosbuvir" post="efficacy against hepatitis C virusAntimicrob. Agents Chemother.6020163786379327067341 GandonS.MackinnonM.NeeS.ReadA.Imperfect vaccination:"/>
   <result pre="population from a patient with S282T detected at relapse after" exact="sofosbuvir" post="monotherapyJ. Viral Hepat.22201587188125784085 HeinzB.A.RueckertR.R.ShepardD.A.DutkoF.J.McKinlayM.A.Genetic and molecular analyses of spontaneous"/>
   <result pre="dynamics in vivoPLoS Pathog.42008e1218225952 LubeckM.D.SchulmanJ.L.PaleseP.Susceptibility of influenza A viruses to" exact="amantadine" post="is influenced by the gene coding for M proteinJ."/>
   <result pre="and resistance: advances and challenges aheadCurr. Opin. Virol.82014ivvii25155454 MitchisonD.A.Development of" exact="streptomycin" post="resistant strains of tubercle bacilli in pulmonary tuberculosis; results"/>
   <result pre="accumulation in the single-stranded DNA bacteriophage фX174J. Virol.88201450425049 Peres-da-SilvaA.Brandao-MelloC.E.LampeE.Prevalence of" exact="sofosbuvir" post="resistance-associated variants in Brazilian and worldwide NS5B sequences of"/>
   <result pre="helix α18Sci. Rep.620161952626787124 SullivanJ.C.De MeyerS.BartelsD.J.DierynckI.ZhangE.Z.Evolution of treatment-emergent resistant variants in" exact="telaprevir" post="phase 3 clinical trialsClin. Infect. Dis.57201322122923575197 SutharA.B.HarriesA.D.A public health"/>
   <result pre="resistance to genotype 1-6 hepatitis C virus-infected subjects treated with" exact="sofosbuvir" post="in phase 2 and 3 clinical trialsClin. Infect. Dis.5920141666167425266287"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7153320\results\search\drugs\results.xml">
   <result pre="Section 4.4 in Chapter 4). V3 loop mutants associated with" exact="maraviroc" post="resistance may exhibit increase replicative capacity (Garcia-Perez et al.,"/>
   <result pre="the simultaneous administration of inactivated H5N2 vaccine and the inhibitor" exact="amantadine" post="conferred protection against H5N2 influenza virus A/Chick/Pennsylvania/83 in chickens"/>
   <result pre="effect). Then, following the important discovery that the nucleoside analog" exact="ribavirin" post="(1-β- d-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide) is mutagenic for PV (Crotty et al.,"/>
   <result pre="for PV (Crotty et al., 2000) it was observed that" exact="ribavirin" post="decreased PV-specific infectivity (the ratio of infectivity to the"/>
   <result pre="viral RNA (see Section 9.4 for the mutagenic mechanisms of" exact="ribavirin" post="and FU). This result suggested that a class of"/>
   <result pre="amplification of A, U-rich genomic sequences of FMDV subjected to" exact="ribavirin" post="mutagenesis (Perales et al., 2011b). The main effect of"/>
   <result pre="ribavirin mutagenesis (Perales et al., 2011b). The main effect of" exact="ribavirin" post="was to accelerate the occupation of A, U-rich regions"/>
   <result pre="(Sowers et al., 1988, Yu et al., 1993), and of" exact="ribavirin" post="and T-705 (favipiravir) (5-Fluoro-2-oxo-1H-pyrazine-3-carboxamide) in Fig. 9.6 (Crotty et"/>
   <result pre="included. Figure 9.6 Some of the possible base pairs between" exact="ribavirin" post="(Rib) or favipiravir (T-705) and the standard nucleotides U"/>
   <result pre="possible point mutations generated as a consequence of FU or" exact="ribavirin" post="incorporation during viral genome replication are depicted in Figure"/>
   <result pre="spectrum (see text for references). Figure 9.8 Mutations produced by" exact="ribavirin" post="(R) as a result of its incorporation into viral"/>
   <result pre="U (Fig. 9.7). Studies with several viruses have indicated that" exact="ribavirin" post="mutagenesis yields mutant spectra with an excess of G"/>
   <result pre="among other studies; as reviews of the mutagenic activity of" exact="ribavirin" post="see (Crotty et al., 2002, Beaucourt and Vignuzzi, 2014)]."/>
   <result pre="mild mutagenic activities for other analogs, such as shown with" exact="sofosbuvir" post="for Zika virus (Sacramento et al., 2017). The complexities"/>
   <result pre="complications derived from multiple mechanisms of drug action—the case of" exact="ribavirin" post="Most of the investigations summarized in the previous section"/>
   <result pre="Favipiravir and derivatives are interesting compounds because they share with" exact="ribavirin" post="a broad antiviral spectrum of activity. Favipiravir has proven"/>
   <result pre="involved deep sequencing analyses of HCV from patients subjected to" exact="ribavirin" post="monotherapy, and the virus showed the mutational bias expected"/>
   <result pre="monotherapy, and the virus showed the mutational bias expected from" exact="ribavirin" post="mutagenesis. It has been suggested that in cell culture"/>
   <result pre="been suggested that in cell culture experiments, the concentrations of" exact="ribavirin" post="used are not attainable in vivo. Until measurements of"/>
   <result pre="not attainable in vivo. Until measurements of the concentration of" exact="ribavirin" post="nucleotides at the HCV replication complexes are available, it"/>
   <result pre="HCV replication complexes are available, it cannot be concluded that" exact="ribavirin" post="concentrations in vivo are incompatible with mutagenesis; also, a"/>
   <result pre="vivo are incompatible with mutagenesis; also, a broad range of" exact="ribavirin" post="concentration in human serum have been reported during treatment"/>
   <result pre="possible interpretation is that when the mutational load due to" exact="ribavirin" post="mutagenesis surpasses some critical value, increasingly defective genomes cease"/>
   <result pre="9.9 Expansion and compression of an FMDV mutant spectrum following" exact="ribavirin" post="mutagenesis. A biological clone of FMDV (left) was subjected"/>
   <result pre="to serial passages in the presence of increasing concentrations of" exact="ribavirin" post="(200 up to 5000 μM). The size of the"/>
   <result pre="et al., 2011, Palmer et al., 2014). Thus, even during" exact="ribavirin" post="treatment alteration of mutant spectrum complexity may be missed"/>
   <result pre="totally absent and bear no relationship with the activity of" exact="ribavirin" post="in vivo, even though other mechanisms of ribavirin action"/>
   <result pre="activity of ribavirin in vivo, even though other mechanisms of" exact="ribavirin" post="action may also play a role in its overall"/>
   <result pre="role in its overall antiviral activity. A mutagenic activity of" exact="ribavirin" post="has been documented in cell culture with HCV and"/>
   <result pre="main problem to interpret the mechanism of antiHCV activity of" exact="ribavirin" post="in vivo is that this antiviral agent can act"/>
   <result pre="(Streeter et al., 1973), with a mutagenic effect of reduced" exact="inosine" post="triphosphate (ITP) pyrophosphatase activity (which is associated with a"/>
   <result pre="2018). The ongoing studies with favipiravir, and many others on" exact="ribavirin" post="that can now be considered a classic in antiviral"/>
   <result pre="pathways It took more than 1 decade of use of" exact="ribavirin" post="to obtain the first resistant mutants using Sindbis virus"/>
   <result pre="to obtain the first resistant mutants using Sindbis virus and" exact="mycophenolic acid" post="(a nonmutagenic inhibitor of IMPDH); the selected mycophenolic acid-resistant"/>
   <result pre="of IMPDH); the selected mycophenolic acid-resistant mutants displayed cross-resistance to" exact="ribavirin" post="(Scheidel et al., 1987, Scheidel and Stollar, 1991). A"/>
   <result pre="(Pfeiffer and Kirkegaard, 2003), and of HCV from patients under" exact="ribavirin" post="monotherapy were described (Young et al., 2003). Subsequent work"/>
   <result pre="other proteins. The first substitution to be described that conferred" exact="ribavirin" post="resistance was G64S in the PV polymerase (3D) that"/>
   <result pre="of related viruses may have a different phenotypic effect. The" exact="ribavirin" post="resistance, fidelity-enhancing PV substitution G64S in 3D was obtained"/>
   <result pre="may have a very restricted number of mutations to attain" exact="ribavirin" post="resistance, despite ample evidence that viruses generally display alternative"/>
   <result pre="not selected. Instead, 3D substitution M296I became dominant and conferred" exact="ribavirin" post="resistance (Sierra et al., 2007). A mutant FMDV encoding"/>
   <result pre="evoke resistance to multiple mutagenic nucleotides, such as cross-resistance to" exact="ribavirin" post="and the nucleoside derivative of T-1106 of St. Louis"/>
   <result pre="of 800 μM ribavirin, and 0.5 in the absence of" exact="ribavirin" post="[these values represent a selective strength of 7.6 for"/>
   <result pre="one in 3D for the virus to respond to higher" exact="ribavirin" post="concentrations. Passage of the 3D M296I mutant virus in"/>
   <result pre="the triple mutant measured in the presence of 800 μM" exact="ribavirin" post="was 18.3, 2.4-fold higher than the selective strength conferred"/>
   <result pre="advantage only in the presence of very high (5000 μM)" exact="ribavirin" post="concentrations, once the transition-modulating phenotype through P44S had already"/>
   <result pre="standard and SSI 3D in the absence and presence of" exact="ribavirin" post="suggest that a bias in favor of G →"/>
   <result pre="substitutions that in 3D of FMDV can be involved in" exact="ribavirin" post="resistance (Sierra et al., 2007, Agudo et al., 2010,"/>
   <result pre="to standard, nonmutagenic inhibitors. In the case of PV, different" exact="ribavirin" post="resistance substitutions would be expected if independent viral lineages"/>
   <result pre="if independent viral lineages were subjected to a range of" exact="ribavirin" post="concentrations. Modulation of nucleotide incorporation is also a mechanism"/>
   <result pre="al., 2010) was further passaged in the presence of high" exact="ribavirin" post="concentrations, a population that included replacement I248T in nonstructural"/>
   <result pre="protein NS5A of an HCV replicon conferred low-level resistance to" exact="ribavirin" post="(Pfeiffer and Kirkegaard, 2005b). In the case of the"/>
   <result pre="became dominant upon passage of FMDV in the presence of" exact="ribavirin" post="also existed in the standard viral population, albeit at"/>
   <result pre="(Perales et al., 2011b). That is, the main effect of" exact="ribavirin" post="was to shift the dominant part of the mutant"/>
   <result pre="in the presence of the inhibitor guanidinium chloride alone, or" exact="ribavirin" post="alone, or a combination of guanidinium chloride and ribavirin,"/>
   <result pre="of guanidinium chloride, followed by passages in the presence of" exact="ribavirin" post="alone (Fig. 9.10 ). The results of quantification of"/>
   <result pre="alone first, followed by additional passages in the presence of" exact="ribavirin" post="alone was the most effective to reduce progeny production"/>
   <result pre="inhibitor used was guanidine hydrochloride (GU), and the mutagen was" exact="ribavirin" post="(R). (A) The four types of serial passages (p"/>
   <result pre="of guanidine alone (yellow diamond); passages in the presence of" exact="ribavirin" post="(R) alone (red triangle); passages in the presence of"/>
   <result pre="yet with lethal mutagenesis at the clinical level. True, unless" exact="ribavirin" post="has been clearing (or helped the immune system to"/>
   <result pre="(notably inhibitors of pyrimidine biosynthesis) and mutagenic nucleotide analogs (notably" exact="ribavirin" post="and favipiravir as the most relevant examples, likely to"/>
   <result pre="may offer additional possibilities. F. Sobrino and colleagues demonstrated that" exact="valproic acid" post="(2-propylpentanoic acid, VPA) displays a broad antiviral activity against"/>
   <result pre="virus HIV-1 human immunodeficiency virus type 1 IFN interferon IMPDH" exact="inosine" post="monophosphate dehydrogenase ITP inosine triphosphate IV influenza virus LCMV"/>
   <result pre="virus type 1 IFN interferon IMPDH inosine monophosphate dehydrogenase ITP" exact="inosine" post="triphosphate IV influenza virus LCMV lymphocytic choriomeningitis virus MNV"/>
   <result pre="MNV murine norovirus NLS nuclear localization signal PV poliovirus Rib" exact="ribavirin" post="RMP ribavirin-monophosphate RVFV Rift Valley fever virus TMV Tobacco"/>
   <result pre="fever virus TMV Tobacco mosaic virus USUV Usutu virus VPA" exact="valproic acid" post="VSV vesicular stomatitis virus WNV West Nile virus ZIKV"/>
   <result pre="AiraksinenA.ParienteN.Menendez-AriasL.DomingoE.Curing of foot-and-mouth disease virus from persistently infected cells by" exact="ribavirin" post="involves enhanced mutagenesisVirology311200333934912842623 AmselemJ.LebrunM.H.QuesnevilleH.Whole genome comparative analysis of transposable"/>
   <result pre="mutations conferring 5-azacytidine resistance in bacteriophage QbetaVirology417201134335221757215 AsahinaY.IzumiN.EnomotoN.UchiharaM.KurosakiM.Mutagenic effects of" exact="ribavirin" post="and response to interferon/ribavirin combination therapy in chronic hepatitis"/>
   <result pre="multiple effects on virus replication and propagation. Molecular basis of" exact="ribavirin" post="resistanceCurr. Opin. Virol.82014101524846716 BonhoefferS.MayR.M.ShawG.M.NowakM.A.Virus dynamics and drug therapyProc. Natl."/>
   <result pre="Agents Chemother.6382019e00669-19 BougieI.BisaillonM.Initial binding of the broad spectrum antiviral nucleoside" exact="ribavirin" post="to the hepatitis C virus RNA polymeraseJ. Biol. Chem.2782003524715247814563844"/>
   <result pre="the NS5A-cyclophilin A interaction to cyclophilin inhibitorsJ. Hepatol.532010505620451281 ChevaliezS.BrilletR.LazaroE.HezodeC.PawlotskyJ.M.Analysis of" exact="ribavirin" post="mutagenicity in human hepatitis C virus infectionJ. Virol.8120077732774117494069 ChungD.H.SunY.ParkerW.B.ArterburnJ.B.BartolucciA.Ribavirin"/>
   <result pre="Biol.48201130632620854921 ContrerasA.M.HiasaY.HeW.TerellaA.SchmidtE.V.Viral RNA mutations are region specific and increased by" exact="ribavirin" post="in a full-length hepatitis C virus replication systemJ. Virol.7620028505851712163570"/>
   <result pre="hepatitis C virus replication systemJ. Virol.7620028505851712163570 CrottyS.MaagD.ArnoldJ.J.ZhongW.LauJ.Y.The broad-spectrum antiviral ribonucleoside" exact="ribavirin" post="is an RNA virus mutagenNat. Med.620001375137911100123 CrottyS.CameronC.E.AndinoR.RNA virus error"/>
   <result pre="antiviral mechanism of action: lethal mutagenesis?J. Mol. Med.802002869511907645 CuevasJ.M.González-CandelasF.MoyaA.SanjuánR.Effect of" exact="ribavirin" post="on the mutation rate and spectrum of hepatitis C"/>
   <result pre="spectrum of hepatitis C virus in vivoJ. Virol.8320095760576419321623 CummingsK.J.LeeS.M.WestE.S.Cid-RuzafaJ.FeinS.G.Interferon and" exact="ribavirin" post="vs interferon alone in the re-treatment of chronic hepatitis"/>
   <result pre="C virus replicationAntimicrob. Agents Chemother.5520114103411321709100 Di BisceglieA.M.ThompsonJ.Smith-WilkaitisN.BruntE.M.BaconB.R.Combination of interferon and" exact="ribavirin" post="in chronic hepatitis C: re-treatment of nonresponders to interferonHepatology33200170470711230751"/>
   <result pre="via lethal defectionSci. Rep.82018144429362502 DietzJ.SchelhornS.E.FittingD.MihmU.SusserS.Deep sequencing reveals mutagenic effects of" exact="ribavirin" post="during monotherapy of hepatitis C virus genotype 1-infected patientsJ."/>
   <result pre="of hepatitis C virus genotype 1-infected patientsJ. Virol.8720136172618123536652 DixitN.M.Layden-AlmerJ.E.LaydenT.J.PerelsonA.S.Modelling how" exact="ribavirin" post="improves interferon response rates in hepatitis C virus infectionNature432200492292415602565"/>
   <result pre="Natural Self-Organization1979SpringerBerlin ErikssonB.HelgstrandE.JohanssonN.G.LarssonA.MisiornyA.Inhibition of influenza virus ribonucleic acid polymerase by" exact="ribavirin" post="triphosphateAntimicrob. Agents Chemother.111977946951879760 EscarmísC.DávilaM.DomingoE.Multiple molecular pathways for fitness recovery"/>
   <result pre="treatment responseHepatology4620071548156317929300 Fernandez-LarssonR.O'ConnellK.KoumansE.PattersonJ.L.Molecular analysis of the inhibitory effect of phosphorylated" exact="ribavirin" post="on the vesicular stomatitis virus in vitro polymerase reactionAntimicrob."/>
   <result pre="the evolutionary cost of genome defenseTrends Genet.20200441742315313550 GalliA.MensH.GottweinJ.M.GerstoftJ.BukhJ.Antiviral effect of" exact="ribavirin" post="against HCV associated with increased frequency of G-to-A and"/>
   <result pre="Garcia-PerezJ.StaropoliI.AzoulayS.HeinrichJ.T.CascajeroA.A single-residue change in the HIV-1 V3 loop associated with" exact="maraviroc" post="resistance impairs CCR5 binding affinity while increasing replicative capacityRetrovirology1220155026081316"/>
   <result pre="Dev.21200719520517234885 GerottoM.SullivanD.G.PolyakS.J.ChemelloL.CavallettoL.Effect of retreatment with interferon alone or interferon plus" exact="ribavirin" post="on hepatitis C virus quasispecies diversification in nonresponder patients"/>
   <result pre="can interfere with infectivityJ. Virol.7820043319332415016853 GoswamiB.B.BorekE.SharmaO.K.FujitakiJ.SmithR.A.The broad spectrum antiviral agent" exact="ribavirin" post="inhibits capping of mRNABiochem. Biophys. Res. Commun.891979830836226095 GraciJ.D.CameronC.E.Quasispecies, error"/>
   <result pre="by chemical mutagenesisJ. Virol.641990396039621695258 HopkinsS.ScorneauxB.HuangZ.MurrayM.G.WringS.SCY-635, a novel nonimmunosuppressive analog of" exact="cyclosporine" post="that exhibits potent inhibition of hepatitis C virus RNA"/>
   <result pre="ion channels-an emergent anti-viral target?J. Gen. Virol.98201734535128113044 HultgrenC.MilichD.R.WeilandO.SallbergM.The antiviral compound" exact="ribavirin" post="modulates the T helper (Th) 1/Th2 subset balance in"/>
   <result pre="KandaT.YokosukaO.ImazekiF.TanakaM.ShinoY.Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells:" exact="ribavirin" post="induces mutagenesis in HCV RNAJ. Viral Hepat.11200447948715500548 KatoT.DateT.MiyamotoM.SugiyamaM.TanakaY.Detection of"/>
   <result pre="Hepat.11200447948715500548 KatoT.DateT.MiyamotoM.SugiyamaM.TanakaY.Detection of anti-hepatitis C virus effects of interferon and" exact="ribavirin" post="by a sensitive replicon systemJ. Clin. Microbiol.4320055679568416272504 KimY.LeeC.Ribavirin efficiently"/>
   <result pre="RNA dependent RNA polymerases uncover an indirect, mutagenic activity of" exact="amiloride" post="compoundsPLoS Pathog.62010e1001163 LeyssenP.BalzariniJ.De ClercqE.NeytsJ.The predominant mechanism by which ribavirin"/>
   <result pre="of amiloride compoundsPLoS Pathog.62010e1001163 LeyssenP.BalzariniJ.De ClercqE.NeytsJ.The predominant mechanism by which" exact="ribavirin" post="exerts its antiviral activity in vitro against flaviviruses and"/>
   <result pre="IMP dehydrogenaseJ. Virol.7920051943194715650220 LeyssenP.De ClercqE.NeytsJ.The anti-yellow fever virus activity of" exact="ribavirin" post="is independent of error-prone replicationMol. Pharmacol.6920061461146716421290 LiC.WangH.YuanT.WoodmanA.YangD.Foot-and-mouth disease virus"/>
   <result pre="the hepatitis C virus NS5B in patients undergoing treatment with" exact="ribavirin" post="monotherapyGastroenterology13220071757176617484873 MaagD.CastroC.HongZ.CameronC.E.Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as"/>
   <result pre="acid resistanceJ. Virol.8520112733274021177816 McHutchisonJ.G.GordonS.C.SchiffE.R.ShiffmanM.L.LeeW.M.Interferon alfa-2b alone or in combination with" exact="ribavirin" post="as initial treatment for chronic hepatitis C. Hepatitis Interventional"/>
   <result pre="mutagenesis. Prospects for new ribavirin-based interventionsViruses420122786280523202505 MoriK.IkedaM.AriumiY.DansakoH.WakitaT.Mechanism of action of" exact="ribavirin" post="in a novel hepatitis C virus replication cell systemVirus"/>
   <result pre="onset of Muller's ratchetJ. Theor. Biol.13719893753952626057 NyströmK.WanrooijP.H.WaldenströmJ.AdamekL.BrunetS.Inosine triphosphate pyrophosphatase dephosphorylates" exact="ribavirin" post="triphosphate and reduced enzymatic activity potentiates mutagenesis in hepatitis"/>
   <result pre="Natl. Acad. Sci. U.S.A.49196351752113940312 Ortega-PrietoA.M.SheldonJ.Grande-PérezA.TejeroH.GregoriJ.Extinction of hepatitis C virus by" exact="ribavirin" post="in hepatoma cells involves lethal mutagenesisPLoS One82013e71039 Ortiz-RianoE.NgoN.DevitoS.EgginkD.MungerJ.Inhibition of"/>
   <result pre="mutations in the replicon RNAJ. Virol.7920052346235515681435 PolS.CouzigouP.BourliereM.AbergelA.CombisJ.M.A randomized trial of" exact="ribavirin" post="and interferon-alpha vs. interferon-alpha alone in patients with chronic"/>
   <result pre="of hepatitis C virus genome in chronically infected patients receiving" exact="ribavirin" post="monotherapyJ. Viral Hepat.8200112013111264732 RaiD.K.Diaz-San SegundoF.CampagnolaG.KeithA.SchaferE.A.Attenuation of foot-and-mouth disease virus"/>
   <result pre="choriomeningitis virus (LCMV)Virology3082003374712706088 SacramentoC.Q.De MeloG.R.De FreitasC.S.RochaN.HoelzL.V.B.The clinically approved antiviral drug" exact="sofosbuvir" post="inhibits Zika virus replicationSci. Rep.720174092028098253 SadeghipourS.BekE.J.McMinnP.C.Ribavirin-resistant mutants of human"/>
   <result pre="with hepatitis C virus infectionGastroenterology138201044746220006612 ScheidelL.M.StollarV.Mutations that confer resistance to" exact="mycophenolic acid" post="and ribavirin on Sindbis virus map to the nonstructural"/>
   <result pre="virus infectionGastroenterology138201044746220006612 ScheidelL.M.StollarV.Mutations that confer resistance to mycophenolic acid and" exact="ribavirin" post="on Sindbis virus map to the nonstructural protein nsP1Virology18119914904991826574"/>
   <result pre="to the nonstructural protein nsP1Virology18119914904991826574 ScheidelL.M.DurbinR.K.StollarV.Sindbis virus mutants resistant to" exact="mycophenolic acid" post="and ribavirinVirology1581987173033882 SchusterP.Quasispecies on fitness landscapesCurr. Top. Microbiol. Immunol.39220166112026597856"/>
   <result pre="catastrophe in cancer?J. Theor. Biol.2282004475415064082 SookoianS.CastanoG.FriderB.CelloJ.CamposR.Combined therapy with interferon and" exact="ribavirin" post="in chronic hepatitis C does not affect serum quasispecies"/>
   <result pre="SowersL.C.EritjaR.KaplanB.GoodmanM.F.FazakerlyG.V.Equilibrium between a wobble and ionized base pair formed between" exact="fluorouracil" post="and guanine in DNA as studied by proton and"/>
   <result pre="catastrophe to lethal defectionCurr. Top. Microb. Immunol.3922016161179 ToltzisP.O'ConnellK.PattersonJ.L.Effect of phosphorylated" exact="ribavirin" post="on vesicular stomatitis virus transcriptionAntimicrob. Agents Chemother.3219884924972837139 Van de"/>
   <result pre="of a ribavirin-resistant NS5B mutation of hepatitis C virus during" exact="ribavirin" post="monotherapyHepatology38200386987814512874 YuH.EritjaR.BloomL.B.GoodmanM.F.Ionization of bromouracil and fluorouracil stimulates base mispairing"/>
   <result pre="hepatitis C virus during ribavirin monotherapyHepatology38200386987814512874 YuH.EritjaR.BloomL.B.GoodmanM.F.Ionization of bromouracil and" exact="fluorouracil" post="stimulates base mispairing frequencies with guanineJ. Biol. Chem.268199315935159437688001 ZengJ.WangH.XieX.YangD.ZhouG.An"/>
   <result pre="in respiratory syncytial virus-infected epithelial cellsJ. Virol.7720035933594712719586 ZhouS.LiuR.BaroudyB.M.MalcolmB.A.ReyesG.R.The effect of" exact="ribavirin" post="and IMPDH inhibitors on hepatitis C virus subgenomic replicon"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7153330\results\search\drugs\results.xml">
   <result pre="can only be possible by neuraminidase inhibitors. The neuraminidase inhibitors" exact="oseltamivir" post="or Tamiflu derived from shikimic acid pathway have been"/>
   <result pre="not developed any resistance yet within the virus. Oseltamivir and" exact="zanamivir" post="are the drugs that function by affecting the activity"/>
   <result pre="for all influenza A and B viruses. Both the drugs" exact="oseltamivir" post="and zanamivir serve as stable transformation state counterparts of"/>
   <result pre="influenza A and B viruses. Both the drugs oseltamivir and" exact="zanamivir" post="serve as stable transformation state counterparts of the sialosyl"/>
   <result pre="oseltamivir, zanamivir, peramivir, and laninamivir octanoate, matrix 2 inhibitors, e.g.," exact="rimantadine" post="and amantadine, and polymerase inhibitors such as favipiravir and"/>
   <result pre="polymerase inhibitors such as favipiravir and ribavirin. 16.2.3.1.1 Rimantadine and" exact="amantadine" post="Amantadine (1-adamantanamine) approved in 1966 was the first antiviral"/>
   <result pre="disassembling of influenza virus molecule inside the endosomes. Amantadine and" exact="rimantadine" post="were approved for adult patients, but they were not"/>
   <result pre="and older ones. The prevalent resistance also leads to abandon" exact="amantadine" post="in the medication of influenza infections. However, the interest"/>
   <result pre="infections. However, the interest is growing for the application of" exact="amantadine" post="in the evidential therapy of Parkinson disease and levodopa-induced"/>
   <result pre="ingested by the oral route. According to many researches, oral" exact="oseltamivir" post="and inhaled zanamivir have proved to be a net"/>
   <result pre="oral route. According to many researches, oral oseltamivir and inhaled" exact="zanamivir" post="have proved to be a net benefit by controlling"/>
   <result pre="for the therapy of influenza infections after the success of" exact="zanamivir" post="and oseltamivir. First was peramivir, which could be administered"/>
   <result pre="found to be effective if administered in an inhalation. Notably," exact="peramivir" post="has been found to have clinical potency equal to"/>
   <result pre="been found to have clinical potency equal to that of" exact="oseltamivir" post="for curing the severe seasonal influenza, and the efficacy"/>
   <result pre="seasonal influenza, as well as oseltamivir-resistant virus, in adults. Both" exact="peramivir" post="and laninamivir are effectively used as a one-dose therapy"/>
   <result pre="of ribavirin, for the therapy of HCV infestation accompanied with" exact="peginterferon alfa-2a." post="The patients of HCV infection undergoing therapy of telaprevir,"/>
   <result pre="alfa-2a. The patients of HCV infection undergoing therapy of telaprevir," exact="peginterferon alfa-2a," post="and ribavirin are found to have an outstanding level"/>
   <result pre="of HCV infection undergoing therapy of telaprevir, peginterferon alfa-2a, and" exact="ribavirin" post="are found to have an outstanding level of response"/>
   <result pre="of influenza virus in the triphosphate form. Apart from this," exact="ribavirin" post="could also be used in the treatment of &quot;Lassa"/>
   <result pre="the treatment of &quot;Lassa fever�? (hemorrhagic fever virus infection), but" exact="ribavirin" post="has yet not got the formal license for this"/>
   <result pre="got the formal license for this medication. The effect of" exact="ribavirin" post="on RNA viruses has also been found to have"/>
   <result pre="infected cells, hence resulting in safeguarding cell-to-cell transmission. Zanamivir and" exact="oseltamivir" post="are the two most important parts of the approved"/>
   <result pre="many drugs and the mostly related to antiviral agent called" exact="oseltamivir" post="(Tamiflu). 16.2.5.3 Other methods for the synthesis of shikimic"/>
   <result pre="from the Liquidambar genus plants. 16.2.5.6 Mechanism of action of" exact="oseltamivir" post="As discussed above, oseltamivir commercialized under the trade name"/>
   <result pre="plants. 16.2.5.6 Mechanism of action of oseltamivir As discussed above," exact="oseltamivir" post="commercialized under the trade name Tamiflu is an antiviral"/>
   <result pre="antiviral drug, which is being synthesized from shikimic acid. The" exact="oseltamivir" post="help to lower down the rate of spread of"/>
   <result pre="of hydroxylation, it changes to active metabolite—the free carboxylate of" exact="oseltamivir" post="(GS4071). It was the firstly used orally active neuraminidase"/>
   <result pre="normal host cells. By hindering the activity of the enzyme," exact="oseltamivir" post="stops new viral particles from being formed by infected"/>
   <result pre="viruses. In gastrointestinal tract, there is approximately 80% bioavailability of" exact="oseltamivir" post="phosphate, which made it readily absorbed in the cells."/>
   <result pre="which made it readily absorbed in the cells. Consequently, the" exact="oseltamivir" post="is well distributed after ingestion as pill to the"/>
   <result pre="and the tissues of the middle ear. The elimination of" exact="oseltamivir" post="carboxylate from the body follows the route for its"/>
   <result pre="out of which the NA is a primary target of" exact="oseltamivir" post="and zanamivir. 16.2.6 Conclusion Despite the rapid growth of"/>
   <result pre="used as a precursor for industrial production of the antiviral" exact="oseltamivir" post="or Tamiflu, a potent viral neuraminidase inhibitor. Rigorous researches"/>
   <result pre="macrophage colony stimulating factor (GM CSF)Stem Cell.122009229240 15HultgrenC.MilichD.R.WeilandO.SällbergM.The antiviral compound" exact="ribavirin" post="modulates the T helper (Th) 1/Th2 subset balance in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7153345\results\search\drugs\results.xml">
   <result pre="and industrial applications [77]. Brown algae Sargassum wightii species show" exact="alginic acid" post="with antioxidant and antiinflammatory activities, reducing many cyclooxygenase, lipoxygenase,"/>
   <result pre="reduction and enhanced enzyme activity [78]. The antioxidant activity of" exact="alginic acid" post="is because of its metal chelating capacity, scavenging of"/>
   <result pre="derivatives [98]. GAGs in animals include Heparin, heparan sulfate (HS)," exact="chondroitin sulfate" post="(CS), dermatan sulfate (DS), keratan sulfate (KS) and hyaluronan"/>
   <result pre="Geodisterol-3-O-sulfite and 29-demethylgeodisterol-3-O-sulfite, two novel sulfated sterols, exhibited reversal of" exact="fluconazole" post="resistance [156]. Marine endophytic fungus Colletotrichum sp. containing ring"/>
   <result pre="peptides from S. mirabilis with antiviral (HIV-1) potency [48]. •FDA-approved" exact="vidarabine" post="(Ara-A), Vira-A®, is a nucleoside Ara-A from marine sponge"/>
   <result pre="Group PressBoca Raton, FL, USA 78SarithakumariC.H.RenjuG.L.KurupG.M.Anti-inflammatory and antioxidant potential of" exact="alginic acid" post="isolated from the marine algae, Sargassum wightii on adjuvant-induced"/>
   <result pre="algae, Sargassum wightii on adjuvant-induced arthritic ratsInflammopharmacology21201326126823179138 79EndoY.AotaT.TsukuiT.Antioxidant activity of" exact="alginic acid" post="in minced pork meatFood Sci. Technol. Res.212015875878 80NeetooH.YeM.ChenH.Bioactive alginate"/>
   <result pre="selectin binding, and biological activityJ. Biol. Chem.2892014282842829825147180 101HuangN.WuM.Y.ZhengC.B.ZhuL.ZhaoJ.H.ZhengY.T.The depolymerized fucosylated" exact="chondroitin sulfate" post="from sea cucumber potently inhibits HIV replication via interfering"/>
   <result pre="marine sponge of the genus EuryspongiaJ. Nat. Prod.70200784684817378608 156DigirolamoJ.A.LiX.C.JacobM.R.ClarkA.M.FerreiraD.Reversal of" exact="fluconazole" post="resistance by sulphated sterols from the marine sponge Topsentia"/>
   <result pre="with insecticidal and antifungal activityJ. Am. Chem. Soc.108198631233124 181DunbarD.C.RimoldiJ.M.ClarkA.M.KellyM.HamannM.T.Anti-cryptococcal and" exact="nitric oxide" post="synthase inhibitory imidazole alkaloids from the calcareous sponge Leucetta"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7153449\results\search\drugs\results.xml">
   <result pre="Reactive Nitrogen and Oxygen Species The production of superoxide (O2*)," exact="nitric oxide" post="(NO), and peroxynitrite (ONOO−) contribute to elimination of many"/>
   <result pre="are three isoforms of the enzyme responsible for generating NO," exact="nitric oxide" post="synthase (NOS) (Bruckdorfer 2005). In the CNS, NOS-1 is"/>
   <result pre="et al. 2014). Adenosine signaling, through surface A1 and A2A" exact="adenosine" post="receptors, has been shown to be neuroprotective (Perigolo-Vicente et"/>
   <result pre="receptors. There is reciprocal modulation of cannabinoid receptor expression by" exact="adenosine" post="(Carrier et al. 2006), thus signaling by one neurotransmitter"/>
   <result pre="al. 2006). Somewhat unexpectedly, the antinociceptive and anti-pyretic effects of" exact="acetaminophen" post="(Tylenol™) may be due to binding CB1 receptors. Δ9-Tetrahydrocannabinol"/>
   <result pre="the expression of a number of genes including defensins, the" exact="adenosine" post="A2B receptor, Vascular Endothelial Growth Factor (VEGF), COX-2, NOS-2,"/>
   <result pre="HCV disease is more severe in males, and correlated with" exact="testosterone" post="levels (Tian et al. 2012; White et al. 2012)."/>
   <result pre="encephalitis in mice is linked to neutrophil infiltration and inducible" exact="nitric oxide" post="synthase activity in the central nervous systemJ Virol199973108781879010482632 AngeliAMaseraRGStaurenghiAHSolomonSBatemanASartoriMLLazzeroAGriotGThe"/>
   <result pre="virus infection is STAT1 dependentJ Neurovirol2004101576310.1080/1355028049026170714982729 CheslerDAMcCutcheonJAReissCSPosttranscriptional regulation of neuronal" exact="nitric oxide" post="synthase expression by IFN-gammaJ Interferon Cytokine Res200424214114910.1089/10799900432281338114980078 ChoHShresthaBSenGCDiamondMSA role"/>
   <result pre="virusClin Exp Dermatol201237553454310.1111/j.1365-2230.2012.04305.x22639919 CronsteinBNLevinRIPhilipsMHirschhornRAbramsonSBWeissmannGNeutrophil adherence to endothelium is enhanced via" exact="adenosine" post="A1 receptors and inhibited via adenosine A2 receptorsJ Immunol19921487220122061347551"/>
   <result pre="endothelium is enhanced via adenosine A1 receptors and inhibited via" exact="adenosine" post="A2 receptorsJ Immunol19921487220122061347551 CroxfordJLMillerSDImmunoregulation of a viral model of"/>
   <result pre="FurmanDHejblumBPSimonNJojicVDekkerCLThiebautRTibshiraniRJDavisMMSystems analysis of sex differences reveals an immunosuppressive role for" exact="testosterone" post="in the response to influenza vaccinationProc Natl Acad Sci"/>
   <result pre="via RIG-I-mediated recognition of RNA bearing 5′-diphosphatesNature2014514752237237510.1038/nature1359025119032 GowerTLGrahamBSAntiviral activity of" exact="lovastatin" post="against respiratory syncytial virus in vivo and in vitroAntimicrob"/>
   <result pre="multinational settingsJ Infect Dis2014210224425310.1093/infdis/jiu25924799602 HayashiTYamadaKEsakiTMutohEIguchiAEffect of estrogen on isoforms of" exact="nitric oxide" post="synthase: possible mechanism of anti-atherosclerotic effect of estrogenGerontology199743Suppl 124349187936"/>
   <result pre="stress granules by interferon and down-regulation by the cellular RNA" exact="adenosine" post="deaminase ADAR1Virology2014454–45529931010.1016/j.virol.2014.02.02524725957 JohnsonHLJinFPirkoIJohnsonAJTheiler’s murine encephalomyelitis virus as an experimental"/>
   <result pre="on the severity of murine AIDS: murine AIDS alone depletes" exact="norepinephrine" post="levels in infected spleenBrain Behav Immun200216211813910.1006/brbi.2001.062711908922 KhanMMWakadeCde SevillaLBrannDWSelective estrogen"/>
   <result pre="infectionAm J Respir Cell Mol Biol201451450251510.1165/rcmb.2013-0414OC24749674 KomatsuTBiZReissCSInterferon-gamma induced type I" exact="nitric oxide" post="synthase activity inhibits viral replication in neuronsJ Neuroimmunol1996681–210110810.1016/0165-5728(96)00083-58784266 KomatsuTBarnaMReissCSInterleukin-12"/>
   <result pre="encephalitis: roles of IL-12 and NOSNitric Oxide19993432733910.1006/niox.1999.023710444372 KongTWestermanKAFaigleMEltzschigHKColganSPHIF-dependent induction of" exact="adenosine" post="A2B receptor in hypoxiaFASEB J200620132242225010.1096/fj.06-6419com17077301 KoromMWylieKMWangHDavisKLSangabathulaMSDelassusGSMorrisonLAA proautophagic antiviral role"/>
   <result pre="Spring Harb Perspect Biol201025a00066110.1101/cshperspect.a00066120452955 LaneTEBuchmeierMJWatryDDFoxHSExpression of inflammatory cytokines and inducible" exact="nitric oxide" post="synthase in brains of SIV-infected rhesus monkeys: applications to"/>
   <result pre="applications to HIV-induced central nervous system diseaseMol Med19962127378900532 LaneTEFoxHSBuchmeierMJInhibition of" exact="nitric oxide" post="synthase-2 reduces the severity of mouse hepatitis virus-induced demyelination:"/>
   <result pre="and IFN-gamma help protect against Japanese encephalitisEur J Immunol20134371789179810.1002/eji.20124315223568450 LatiniSPazzagliMPepeuGPedataFA2" exact="adenosine" post="receptors: their presence and neuromodulatory role in the central"/>
   <result pre="Pharmacol Toxicol2005458911810.1146/annurev.pharmtox.45.120403.09574815822172 LiaoPHHsuYHYangHHWangMHChenLKInvolvement of extraneural tissues and upregulation of inducible" exact="nitric oxide" post="synthase after experimental infection with rabies virus in BALB/c"/>
   <result pre="U S A2005102248680868510.1073/pnas.050322710215937107 Molina-HolgadoFHernanzADe laFMGuazaCN-Acetyl-cysteine inhibition of encephalomyelitis Theiler’s virus-induced" exact="nitric oxide" post="and tumour necrosis factor-alpha production by murine astrocyte culturesBiofactors1999102–318719310.1002/biof.552010021510609881"/>
   <result pre="cell signaling and drug developmentN Engl J Med2006355192003201110.1056/NEJMsa06390417093251 MurphySProduction of" exact="nitric oxide" post="by glial cells: regulation and potential roles in the"/>
   <result pre="lymphoma by dietary omega 6 fatty acidNutr Cancer199217321722110.1080/016355892095141901437641 ProbascoJCSpudichSSCritchfieldJLeeELolloNDeeksSGPriceRWFailure of" exact="atorvastatin" post="to modulate CSF HIV-1 infection: results of a pilot"/>
   <result pre="RNA virusesJ Interferon Cytokine Res201434964965810.1089/jir.2014.006624956361 ReissCSCannabinoids and viral infectionsPharmaceuticals2010361873188610.3390/ph306187320634917 ReissCSKomatsuTDoes" exact="nitric oxide" post="play a critical role in viral infections?J Virol1998726454745519573217 RempelJDMurraySJMeisnerJBuchmeierMJDifferential"/>
   <result pre="macrophages leading to resolution of lung pathologyMucosal Immunol20147354955710.1038/mi.2013.7124064666 ShuklaDKKaiserCCStebbinsGTFeinsteinDLEffects of" exact="pioglitazone" post="on diffusion tensor imaging indices in multiple sclerosis patientsNeurosci"/>
   <result pre="at the blood-brain barrierJ Neuropathol Exp Neurol200261759760410.1093/jnen/61.7.59712125738 SicilianoRBaroneECalabreseVRispoliVButterfieldDAMancusoCExperimental research on" exact="nitric oxide" post="and the therapy of Alzheimer disease: a challenging bridgeCNS"/>
   <result pre="experimental autoimmune encephalomyelitisArch Biochem Biophys2015567758210.1016/j.abb.2014.12.01725541149 WardSVGeorgeCXWelchMJLiouLYHahmBLewickiHde la TorreJCSamuelCEOldstoneMBRNA editing enzyme" exact="adenosine" post="deaminase is a restriction factor for controlling measles virus"/>
   <result pre="Foxp3+ regulatory T cells are necessary for therapeutic benefit of" exact="atorvastatin" post="in treatment of central nervous system autoimmunityJ Neuroinflammation2014112910.1186/1742-2094-11-2924498870 WeinbergJBJensenDRGralinskiLELakeARStempfleGSSpindlerKRContributions"/>
   <result pre="infectionVet Immunol Immunopathol20111411–216216710.1016/j.vetimm.2011.02.01421419498 WhitacreCCReingoldSCO’LooneyPAA gender gap in autoimmunityScience199928354061277127810.1126/science.283.5406.127710084932 WhiteDLTavakoli-TabasiSKuzniarekJPascuaRRamseyDJEl-SeragHBHigher serum" exact="testosterone" post="is associated with increased risk of advanced hepatitis C-related"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7153514\results\search\drugs\results.xml">
   <result pre="A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of" exact="oseltamivir" post="and zanamivirVirol J720105310.1186/1743-422X-7-5320202225 14NaesensL.StevaertA.VanderlindenE.Antiviral therapies on the horizon for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7156157\results\search\drugs\results.xml">
   <result pre="special interest in COVID-19 is that there are indications that" exact="chloroquine" post="and hydroxychloroquine might be of value.17 Chloroquine is one"/>
   <result pre="in COVID-19 is that there are indications that chloroquine and" exact="hydroxychloroquine" post="might be of value.17 Chloroquine is one of the"/>
   <result pre="investigated as a potential broad-spectrum antiviral drug.18 Among its mechanisms," exact="chloroquine" post="appears to interfere with the terminal glycosylation of ACE2"/>
   <result pre="negatively influence virus-receptor binding and abrogate infection.19, 20, 21 However," exact="chloroquine" post="is closely related to quinidine, and while the latter"/>
   <result pre="with QT interval-related malignant arrhythmias. Luckily, the QT-prolonging effect of" exact="chloroquine" post="is modest, and in general, it does not result"/>
   <result pre="to also efficiently inhibit SARS-CoV-2 infection in vitro.24 However, both" exact="chloroquine" post="and hydroxychloroquine are metabolized by CYP3A4, and COVID-19 treatment"/>
   <result pre="efficiently inhibit SARS-CoV-2 infection in vitro.24 However, both chloroquine and" exact="hydroxychloroquine" post="are metabolized by CYP3A4, and COVID-19 treatment with (hydroxy)chloroquine"/>
   <result pre="(hydroxy)chloroquine can be combined with additional antiviral treatments such as" exact="ritonavir" post="plus lopinavir (both potent CYP3A4-inhibiting drugs; their combination is"/>
   <result pre="be combined with additional antiviral treatments such as ritonavir plus" exact="lopinavir" post="(both potent CYP3A4-inhibiting drugs; their combination is associated with"/>
   <result pre="potent CYP3A4-inhibiting drugs; their combination is associated with QT prolongation)," exact="azithromycin" post="(besides being a macrolide antibiotic, it is investigated for"/>
   <result pre="3.If these higher-risk patients develop a high fever (&amp;gt;38.5°C) despite" exact="paracetamol" post="treatment, they will need to attend the emergency department.∗"/>
   <result pre="first-line treatment comprises intensive β-blocker therapy. In insufficiently responsive cases," exact="flecainide" post="should be added or left sympathetic denervation should be"/>
   <result pre="be used in cases in need of hemodynamic support. Intravenous" exact="epinephrine" post="has been used to unmask ventricular arrhythmias, and initial"/>
   <result pre="used to unmask ventricular arrhythmias, and initial data suggested that" exact="epinephrine" post="was more effective than exercise testing in unmasking ventricular"/>
   <result pre="phosphodiesterase 3 inhibitor, acts by decreasing the degradation of cyclic" exact="adenosine" post="monophosphate. This may potentially stimulate the RyR2 receptor and"/>
   <result pre="diagnosis, should stay on their β-blocker treatment with or without" exact="flecainide" post="as long as it is tolerated hemodynamically. Flecainide does"/>
   <result pre="the basis of the above, we also suggest avoidance of" exact="epinephrine" post="in the setting of a ventricular tachycardia/ventricular fibrillation arrest,"/>
   <result pre="if possible. This is probably the only resuscitation setting where" exact="epinephrine" post="is contraindicated.53 Conclusion Patients with inherited arrhythmia syndromes may"/>
   <result pre="of website statisticsEuropace1520131042104923533266 16GoldenbergI.MossA.J.BradleyJ.Long-QT syndrome after age 40Circulation11720082192220118427134 17WangM.CaoR.ZhangL.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="Infect Dis62006676916439323 19ZhouD.DaiS.-M.TongQ.COVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progression [published online ahead of"/>
   <result pre="of print March 20, 2020]. J Antimicrob Chemotherhttps://doi.org/10.1093/jac/dkaa114 20GautretP.LagierJ.C.ParolaP.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: preliminary results of an"/>
   <result pre="toxicity: an analysis of electrocardiograms in 85 patients treated with" exact="hydroxychloroquine" post="for connective tissue diseasesRheumatology (Oxford)46200780881017202178 24LiuJ.CaoR.XuM.Hydroxychloroquine, a less toxic"/>
   <result pre="and pooled analysisFront Genet102020131232010184 45LuoC.WangK.LiuT.ZhangH.Computational analysis of the action of" exact="chloroquine" post="on short QT syndrome variant 1 and variant 3"/>
   <result pre="IEEE Eng Med Biol Soc201820185462546530441573 46El HarchiA.McPateM.J.ZhangYhZhangH.HancoxJ.C.Action potential clamp and" exact="chloroquine" post="sensitivity of mutant Kir2.1 channels responsible for variant 3"/>
   <result pre="sympathetic stimulationPLoS One132018e0207100 50Krahn AndrewD.GollobM.YeeR.Diagnosis of unexplained cardiac arrestCirculation11220052228223416203906 51MarjamaaA.HiippalaA.ArrheniusB.Intravenous" exact="epinephrine" post="infusion test in diagnosis of catecholaminergic polymorphic ventricular tachycardiaJ"/>
   <result pre="ventricular tachycardiaJ Cardiovasc Electrophysiol23201219419921954897 52KobayashiS.SusaT.IshiguchiH.A low-dose β1-blocker in combination with" exact="milrinone" post="improves intracellular Ca2+ handling in failing cardiomyocytes by inhibition"/>
   <result pre="reticulumPLoS One102015e0114314 53BellamyD.NuthallG.DalzielS.SkinnerJ.R.Catecholaminergic polymorphic ventricular tachycardia: the cardiac arrest where" exact="epinephrine" post="is contraindicatedPediatr Crit Care Med20201926226830640888 Acknowledgments We acknowledge the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7156260\results\search\drugs\results.xml">
   <result pre="treatment protocol for management of COVID-19 patients, which included moxifloxacin," exact="levofloxacin" post="(consider tolerance) and arbidol administration (8). However, the underlying"/>
   <result pre="potentially effective in treating COVID-19, including oseltamivir, ganciclovir, arbidol and" exact="lopinavir" post="/ ritonavir. Many clinical trials are currently underway to"/>
   <result pre="treated with antiviral agents. The most commonly used antivirals were" exact="lopinavir" post="/ ritonavir, oseltamivir, ribavirin and arbidol, respectively. Route and"/>
   <result pre="The most commonly used antivirals were lopinavir / ritonavir, oseltamivir," exact="ribavirin" post="and arbidol, respectively. Route and duration of administration were"/>
   <result pre="COVID-19 patients Oseltamivir 393 NR NR NR Yes Administration of" exact="oseltamivir" post="did not decrease ICU admission and need for ventilator"/>
   <result pre="COVID-19 Lopinavir/ritonavirArbidolLopinavir/ritonavir + Arbidol 25121 Lopinavir 400 mg twice daily" exact="ritonavir" post="100 mg twice dailyArbidol 200 mg three time daily"/>
   <result pre="Z; 2020; China (30) 2 38 1 Symptomatic COVID-19 patients" exact="oseltamivir" post="and Arbidol 2 NR NR NR Yes Both patients"/>
   <result pre="al. studied 1099 patients, 393 of which were treated with" exact="oseltamivir" post="and showed that ICU admission, need for mechanical ventilation,"/>
   <result pre="group that was not treated with oseltamivir. In other words," exact="oseltamivir" post="administration was ineffective in decreasing ICU admission rate, the"/>
   <result pre="was treated with oseltamivir/ganciclovir (14) and two patients treated with" exact="oseltamivir" post="and arbidol (30), respectively. There are also studies available"/>
   <result pre="the MIRACLE trial, was designed to evaluate the efficacy of" exact="lopinavir" post="/ ritonavir and interferon-β1b combination therapy in the treatment"/>
   <result pre="trial, was designed to evaluate the efficacy of lopinavir /" exact="ritonavir" post="and interferon-β1b combination therapy in the treatment of MERS-CoV"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7157827\results\search\drugs\results.xml">
   <result pre="increasing number of patients treated with vitamin K antagonists (VKA:" exact="warfarin" post="or acenocoumarol) or direct oral anticoagulants (DOAC: dabigatran, apixaban,"/>
   <result pre="commonly treated with multiple drugs as antiviral therapies (lopinavir/ritonavir, darunavir)," exact="tocilizumab" post="(humanized monoclonal antibody against the interleukin-6 receptor), chloroquine or"/>
   <result pre="(lopinavir/ritonavir, darunavir), tocilizumab (humanized monoclonal antibody against the interleukin-6 receptor)," exact="chloroquine" post="or hydroxychloroquine, antibiotics (levofloxacin, ceftriaxone, azithromycin, and amoxicillin/clavulanic acid),"/>
   <result pre="clinical practice guidelinesChest20121412 Supple576Se600S10.1378/chest.11-230522315272 6.EikelboomJWConnollySJBrueckmannMGrangerCBKappeteinAPMackMJBlatchfordJDevennyKFriedmanJGuiverKHarperRKhderYLobmeyerMTMaasHVoigtJUSimoonsMLVan de WerfFcollab: RE-ALIGN InvestigatorsDabigatran versus" exact="warfarin" post="in patients with mechanical heart valvesN Engl J Med2013369131206121410.1056/NEJMoa130061523991661"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7157945\results\search\drugs\results.xml">
   <result pre=": Review Challenges and cares to promote rational use of" exact="chloroquine" post="and hydroxychloroquine in the management of coronavirus disease 2019"/>
   <result pre="Challenges and cares to promote rational use of chloroquine and" exact="hydroxychloroquine" post="in the management of coronavirus disease 2019 (COVID-19) pandemic:"/>
   <result pre="infectious diseases, availability, and relatively low cost, the use of" exact="chloroquine" post="(CQ) and hydroxychloroquine (HCQ) has been tested in vivo"/>
   <result pre="and relatively low cost, the use of chloroquine (CQ) and" exact="hydroxychloroquine" post="(HCQ) has been tested in vivo and in vitro"/>
   <result pre="drugs currently tested in vitro and in vivo, remdesivir, ribavirin," exact="chloroquine" post="(CQ) and hydroxychloroquine (HCQ) have shown promising clinical results"/>
   <result pre="in vitro and in vivo, remdesivir, ribavirin, chloroquine (CQ) and" exact="hydroxychloroquine" post="(HCQ) have shown promising clinical results in inhibiting the"/>
   <result pre="after treatment of COVID-19. Pharmacological, therapeutic, and toxicological properties of" exact="chloroquine" post="and hydroxychloroquine General aspects to be considered for prophylaxis"/>
   <result pre="of COVID-19. Pharmacological, therapeutic, and toxicological properties of chloroquine and" exact="hydroxychloroquine" post="General aspects to be considered for prophylaxis or treatment"/>
   <result pre="in Figure 1. Figure 1(a) emphasizes the physicochemical properties of" exact="chloroquine" post="(CQ) and hydroxychloroquine (HCQ). CQ and HCQ are synthetic"/>
   <result pre="Figure 1(a) emphasizes the physicochemical properties of chloroquine (CQ) and" exact="hydroxychloroquine" post="(HCQ). CQ and HCQ are synthetic antimalarials developed from"/>
   <result pre="of COVID-19 using CQ and HCQ. (a) Physicochemical properties of" exact="chloroquine" post="(CQ) and hydroxychloroquine (HCQ); (b) Incidence of side effects"/>
   <result pre="CQ and HCQ. (a) Physicochemical properties of chloroquine (CQ) and" exact="hydroxychloroquine" post="(HCQ); (b) Incidence of side effects in patients on"/>
   <result pre="1B. * In all studies the most important predictor of" exact="hydroxychloroquine" post="retinal toxicity was the duration of use (cumulative dose)."/>
   <result pre="HCQ diminish the activity of antibiotics and immunosuppressants, such as" exact="ampicillin" post="and cyclosporin. Patients who are being treated with mefloquine"/>
   <result pre="as ampicillin and cyclosporin. Patients who are being treated with" exact="mefloquine" post="are at increased risk of convulsions. Current recommendations emphasized"/>
   <result pre="Superior�? (CAPES). References References Al-BariM., and AlimA.2017Targeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
   <result pre="ChatreC., RoubilleF., VernhetH., JorgensenC., and PersY. M.2018Cardiac complications attributed to" exact="chloroquine" post="and hydroxychloroquine: A systematic review of the literature. Drug"/>
   <result pre="S., LiL., ZhangY., XuC., LiQ., SunX., TianH., et al2018Chloroquine and" exact="hydroxychloroquine" post="are associated with reduced cardiovascular risk: A systematic review"/>
   <result pre="MielerW. F., collab: American Academy of Ophthalmology2002Recommendations on screening for" exact="chloroquine" post="and hydroxychloroquine retinopathy: A report by the American Academy"/>
   <result pre="collab: American Academy of Ophthalmology2002Recommendations on screening for chloroquine and" exact="hydroxychloroquine" post="retinopathy: A report by the American Academy of Ophthalmology."/>
   <result pre="MellesR.B., MielerW.F., collab: American Academy of Ophthalmology2016Recommendations on screening for" exact="chloroquine" post="and hydroxychloroquine retinopathy. Ophthalmology123: 1386–94. doi:10.1016/j.ophtha.2016.01.058.26992838 MavrikakisI., SfikakisP. P.,"/>
   <result pre="collab: American Academy of Ophthalmology2016Recommendations on screening for chloroquine and" exact="hydroxychloroquine" post="retinopathy. Ophthalmology123: 1386–94. doi:10.1016/j.ophtha.2016.01.058.26992838 MavrikakisI., SfikakisP. P., MavrikakisE., RougasK.,"/>
   <result pre="MarmorM. F.2014The risk of toxic retinopathy in patients on long-term" exact="hydroxychloroquine" post="therapy. J. Am. Med. Assoc. Ophthalmol.132:1453–60. MellesR. B., and"/>
   <result pre="MellesR. B., and MarmorM. F.2015Pericentral retinopathy and racial differences in" exact="hydroxychloroquine" post="toxicity. Ophthalmology122:110–16. doi:10.1016/j.ophtha.2014.07.018.25182842 PlantoneD., and KoudriavtsevaT.2018Current and future use"/>
   <result pre="toxicity. Ophthalmology122:110–16. doi:10.1016/j.ophtha.2014.07.018.25182842 PlantoneD., and KoudriavtsevaT.2018Current and future use of" exact="chloroquine" post="and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases:"/>
   <result pre="doi:10.1016/j.ophtha.2014.07.018.25182842 PlantoneD., and KoudriavtsevaT.2018Current and future use of chloroquine and" exact="hydroxychloroquine" post="in infectious, immune, neoplastic, and neurological diseases: A mini-review."/>
   <result pre="ParkeA. L., Clifford-RashotteM., and KeanW. F.2015Therapy and pharmacological properties of" exact="hydroxychloroquine" post="and chloroquine in treatment of systemic lupus erythematosus, rheumatoid"/>
   <result pre="Clifford-RashotteM., and KeanW. F.2015Therapy and pharmacological properties of hydroxychloroquine and" exact="chloroquine" post="in treatment of systemic lupus erythematosus, rheumatoid arthritis and"/>
   <result pre="DeD., and MirsalisJ. C.2001Genetic toxicology testing of the antimalarial drugs" exact="chloroquine" post="and a new analog, AQ-13. Environ. Mol. Mutagen.38:69–79. doi:10.1002/em.1052.11473390"/>
   <result pre="Pearls Publishing, LLC10Gen 22; NBK 537086 TouretF., and de LamballerieX.2020Of" exact="chloroquine" post="and COVID-19. Antiviral Res.177:104762. doi:10.1016/j.antiviral.2020.104762.32147496 WolfeF., and MarmorM. F.2010Rates"/>
   <result pre="Antiviral Res.177:104762. doi:10.1016/j.antiviral.2020.104762.32147496 WolfeF., and MarmorM. F.2010Rates and predictors of" exact="hydroxychloroquine" post="retinal toxicity in patients with rheumatoid arthritis and systemic"/>
   <result pre="print. ZhangY., LiaoZ., ZhangL. J., and XiaoH. T.2015The utility of" exact="chloroquine" post="in cancer therapy. Curr. Med. Res. Opin.31:1009–13. doi:10.1185/03007995.2015.1025731.25734693"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7158822\results\search\drugs\results.xml">
   <result pre="the case, for example, for: (i) the FDA-approved antimalarial drugs" exact="chloroquine" post="and hydroxychloroquine, owing to their ability to interfere with"/>
   <result pre="is the case, it could draw the attention on possible" exact="chloroquine" post="off-targets and side effects, in certain patients, that would"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7158837\results\search\drugs\results.xml">
   <result pre="Current guidelines recommend combination treatment with hydroxychloroquine/azithromycin or chloroquine, if" exact="hydroxychloroquine" post="is unavailable, in patients with moderate disease, although these"/>
   <result pre="and ARBs should not be discontinued at this time and" exact="ibuprofen" post="may be used for fever. Conclusion There are several"/>
   <result pre="OR radiographic evidence of pneumonia -hydroxychloroquine + azithromycinb -chloroquine (if" exact="hydroxychloroquine" post="is unavailable)    Severe disease Worsening respiratory function with"/>
   <result pre="an alternative for patients who demonstrate a hypersensitivity reaction to" exact="azithromycin" post="[20]. cHydroxychloroquine must be discontinued prior to initiation of"/>
   <result pre="(Torsades de Pointes) May be used as an alternative when" exact="hydroxychloroquine" post="is unavailable. Hydroxychloroquine Elevates endosomal pH and inhibits pH"/>
   <result pre="-Electrolyte imbalance -Fatal dysrhythmias (Torsades de Pointes) Combination treatment with" exact="azithromycin" post="recommended for patients with moderate to severe disease [20,25]."/>
   <result pre="respiratory failure [8]. It cannot be used in conjunction with" exact="hydroxychloroquine" post="due to an increased risk of QT prolongation and"/>
   <result pre="thereby limiting its clinical use (Table 2) [12,13]. Favipiravir and" exact="ribavirin" post="are not currently recommended for the treatment of patients"/>
   <result pre="United States [14]. The high risk of toxicity due to" exact="ribavirin" post="therapy outweighs its potential benefits and it is no"/>
   <result pre="immunodeficiency virus (HIV) infection; however, it has been noted that" exact="lopinavir" post="has in vitro activity against coronavirus [15]. Ritonavir is"/>
   <result pre="a protease inhibitor, but its primary role is to boost" exact="lopinavir" post="concentrations and prolong its half-life via cytochrome P450 inhibition."/>
   <result pre="there is concern regarding the multiple drug-drug interactions associated with" exact="ritonavir" post="in particular (Table 2) [9]. Due to a lack"/>
   <result pre="treatment of COVID-19 [20]. 3.4 Antimalarials Chloroquine and its derivative" exact="hydroxychloroquine" post="have traditionally been used for the treatment of malaria"/>
   <result pre="leads to rapid deterioration of patients with COVID-19 [1,22]. Furthermore," exact="chloroquine" post="was found to show some efficacy in treating COVID-19"/>
   <result pre="&amp;gt;100 patients in China [23]. Subsequent studies have found that" exact="hydroxychloroquine" post="has increased potency and a more tolerable safety profile"/>
   <result pre="potency and a more tolerable safety profile when compared to" exact="chloroquine" post="[24]. In a recent nonrandomized clinical trial, 14 patients"/>
   <result pre="a recent nonrandomized clinical trial, 14 patients were treated with" exact="hydroxychloroquine" post="alone and 6 patients were treated with a combination"/>
   <result pre="alone and 6 patients were treated with a combination of" exact="hydroxychloroquine" post="and azithromycin [25]. A substantial reduction in viral load"/>
   <result pre="6 patients were treated with a combination of hydroxychloroquine and" exact="azithromycin" post="[25]. A substantial reduction in viral load and more"/>
   <result pre="elimination was seen in patients treated with a combination of" exact="hydroxychloroquine" post="and azithromycin; however, the majority of patients treated with"/>
   <result pre="hydroxychloroquine and azithromycin; however, the majority of patients treated with" exact="hydroxychloroquine" post="alone continued to display symptoms of upper or lower"/>
   <result pre="surrounding this treatment has prompted self-medication with compounds that contain" exact="chloroquine" post="in an effort to prevent COVID-19 infection. It should"/>
   <result pre="COVID-19 infection. It should be noted that when used inappropriately," exact="chloroquine" post="and to a lesser extent hydroxychloroquine, are very toxic"/>
   <result pre="antimalarials, as compared to the aforementioned antivirals, combination treatment with" exact="hydroxychloroquine" post="and azithromycin is now recommended for many hospitalized patients"/>
   <result pre="compared to the aforementioned antivirals, combination treatment with hydroxychloroquine and" exact="azithromycin" post="is now recommended for many hospitalized patients with moderate"/>
   <result pre="to severe COVID-19. The FDA recently granted emergency authorization for" exact="hydroxychloroquine" post="to treat COVID-19 infection [27]. Although chloroquine has not"/>
   <result pre="emergency authorization for hydroxychloroquine to treat COVID-19 infection [27]. Although" exact="chloroquine" post="has not been approved by the FDA, it was"/>
   <result pre="a result, there has been a surge in demand for" exact="chloroquine" post="and hydroxychloroquine, and India, a major exporter of these"/>
   <result pre="A study conducted in China found that the use of" exact="methylprednisolone" post="decreased risk of death in patients with COVID-19 who"/>
   <result pre="limited data supporting the use of monoclonal antibodies such as" exact="tocilizumab" post="and sarilumab. Patients who develop evidence of COVID-19 associated"/>
   <result pre="Interestingly, a study conducted in 2006 found that the NSAID" exact="indomethacin" post="was a potent inhibitor of SARS-CoV-1 replication in dogs,"/>
   <result pre="[40]. However, no evidence exists as to the effects of" exact="indomethacin" post="in patients infected with SARS-CoV-2. The WHO initially recommended"/>
   <result pre="but has since revised its statement and states that either" exact="acetaminophen" post="or ibuprofen may be used [39]. Additional studies are"/>
   <result pre="since revised its statement and states that either acetaminophen or" exact="ibuprofen" post="may be used [39]. Additional studies are required to"/>
   <result pre="lack of alternative treatment options, treatment with a combination of" exact="hydroxychloroquine" post="and azithromycin is often considered for hospitalized patients with"/>
   <result pre="alternative treatment options, treatment with a combination of hydroxychloroquine and" exact="azithromycin" post="is often considered for hospitalized patients with moderate to"/>
   <result pre="were many concerns regarding the use of medications such as" exact="ibuprofen" post="and RAAS antagonists in patients with COVID-19, current guidelines"/>
   <result pre="RAAS antagonists in patients with COVID-19, current guidelines state that" exact="ibuprofen" post="may be used and recommend against the discontinuation of"/>
   <result pre="at increased risk for COVID-19 infection?Lancet Respir Med26002020203011610.1016/S2213-2600(20)30116-8Internet 4WangM.CaoR.ZhangL.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="acute respiratory infection (SARI) when COVID-19 disease is suspectedhttps://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected2020 23GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome main"/>
   <result pre="for the treatment of severe acute respiratory syndrome main point:" exact="hydroxychloroquine" post="was found to be more potent than chloroquine at"/>
   <result pre="main point: hydroxychloroquine was found to be more potent than" exact="chloroquine" post="at inhibiting SARS-CoV-2 in vitClin Infect Dis2202012510.1093/cid/ciaa237 25GautretP.LagieraJ.C.ParolaP.Hydroxychloroquine and"/>
   <result pre="chloroquine at inhibiting SARS-CoV-2 in vitClin Infect Dis2202012510.1093/cid/ciaa237 25GautretP.LagieraJ.C.ParolaP.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-"/>
   <result pre="label non-randomized clinical trial Philippe GautretMediterr Infect2020;(March12410.1016/j.ijantimicag.2020.105949 26de OlanoJ.HowlandM.A.SuM.K.Toxicokinetics of" exact="hydroxychloroquine" post="following a massive overdoseAm J Emerg Med371220192264.e52264.e810.1016/j.ajem.2019.158387 27U.S. Food"/>
   <result pre="Drug Administration. Request for emergency use authorization for use of" exact="chloroquine" post="phosphate or hydroxychloroquine sulfate supplied from the strategic National"/>
   <result pre="for emergency use authorization for use of chloroquine phosphate or" exact="hydroxychloroquine" post="sulfate supplied from the strategic National Stockpile for treatment"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7158903\results\search\drugs\results.xml">
   <result pre="candidates are shown in the table . Baricitinib, fedratinib, and" exact="ruxolitinib" post="are potent and selective JAK inhibitors approved for indications"/>
   <result pre="AI-algorithm-predicted NAK inhibitors include a combination of the oncology drugs" exact="sunitinib" post="and erlotinib, shown to reduce the infectivity of a"/>
   <result pre="dengue virus, Ebola virus, and respiratory syncytial virus.5, 6 However," exact="sunitinib" post="and erlotinib would be difficult for patients to tolerate"/>
   <result pre="Ebola virus, and respiratory syncytial virus.5, 6 However, sunitinib and" exact="erlotinib" post="would be difficult for patients to tolerate at the"/>
   <result pre="JAK inhibitors. Our analysis of the closely related JAK inhibitors" exact="ruxolitinib" post="and fedratinib (table) illustrates that the predicted unbound plasma"/>
   <result pre="potential for combining baricitinib with the direct-acting antivirals (lopinavir or" exact="ritonavir" post="and remdesivir) currently being used in the COVID-19 outbreak,"/>
   <result pre="antiviral effectsJ Clin Invest12720171338135228240606 6PuS-YXiaoFSchorSFeasibility and biological rationale of repurposing" exact="sunitinib" post="and erlotinib for dengue treatmentAntiviral Res1552018677529753658 7collab: European Medicines"/>
   <result pre="Clin Invest12720171338135228240606 6PuS-YXiaoFSchorSFeasibility and biological rationale of repurposing sunitinib and" exact="erlotinib" post="for dengue treatmentAntiviral Res1552018677529753658 7collab: European Medicines AgencyOlumiant: summary"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7159184\results\search\drugs\results.xml">
   <result pre="transmission of A(H1N1)pdm09 virus from infected ferrets treated with baloxavir," exact="oseltamivir" post="or placebo to naïve sentinel ferrets exposed either indirectly"/>
   <result pre="when treatment was delayed until 2 days post-infection. In contrast," exact="oseltamivir" post="treatment did not substantially affect viral shedding or transmission"/>
   <result pre="adjacent cage. In both cases, we found that compared to" exact="oseltamivir" post="or placebo treatment, infected ferrets treated with baloxavir produced"/>
   <result pre="class of influenza antivirals that includes the widely prescribed compound" exact="oseltamivir" post="phosphate (OST), which was licensed in most countries in"/>
   <result pre="containing 5% (w/v) sodium dodecyl sulfate (SDS) and 10% (w/w)" exact="polysorbate" post="80 (Wako Pure Chemical Industries, Osaka, Japan). BXA was"/>
   <result pre="10 mg/5 mL/kg was delivered to fasted ferrets anesthetized by" exact="isoflurane" post="using an intragastric tube to achieve a dose of"/>
   <result pre="turkey erythrocytes [16]. For inoculation, ferrets were lightly anesthetized with" exact="ketamine" post="(22 mg/kg) and xylazine (0.9 mg/kg). All animals were"/>
   <result pre="(DPI), ferrets were injected with a non-reversible anesthetic consisting of" exact="ketamine" post="(≥25 mg/kg) and xylazine (≥5 mg/kg), before sacrifice by"/>
   <result pre="delivery was performed under reversible anesthesia by intramuscular injection of" exact="ketamine" post="(10 mg/kg, Troy Laboratories), midazolam (0.5 mg/kg, Troy Laboratories)"/>
   <result pre="anesthesia by intramuscular injection of ketamine (10 mg/kg, Troy Laboratories)," exact="midazolam" post="(0.5 mg/kg, Troy Laboratories) and medetomidine (0.02 mg/kg, Troy"/>
   <result pre="(10 mg/kg, Troy Laboratories), midazolam (0.5 mg/kg, Troy Laboratories) and" exact="medetomidine" post="(0.02 mg/kg, Troy Laboratories) mixture, which was then antagonized"/>
   <result pre="endpoint, ferrets were injected with a non-reversible anesthetic consisting of" exact="ketamine" post="(≥25 mg/kg) and xylazine (≥5 mg/kg), before sacrifice by"/>
   <result pre="previous pharmacokinetic analysis that showed a 5 mg/kg dose of" exact="oseltamivir" post="every 12 hours for 5 days results in the"/>
   <result pre="necessary to exert greater virus reduction than that seen with" exact="oseltamivir" post="phosphate. However, oral administration of 10 mg/kg BXM in"/>
   <result pre="with the untreated (21.10 ± 5.60, p = 0.014) and" exact="oseltamivir" post="groups (18.87 ± 5.17, p = 0.033). A similar"/>
   <result pre="ferrets. Donor ferrets were either untreated (upper panel), treated with" exact="oseltamivir" post="(OST, middle) or treated with baloxavir (BXA, lower). Virus"/>
   <result pre="ferrets were either treated with placebo (upper panel), treated with" exact="oseltamivir" post="(OST, middle) or treated with baloxavir (BXA, lower). Virus"/>
   <result pre="ferrets were either treated with placebo (upper panel), treated with" exact="oseltamivir" post="(OST, middle) or treated with baloxavir (BXA, lower). Virus"/>
   <result pre="ferrets were either treated with placebo (upper panel), treated with" exact="oseltamivir" post="(OST, middle) or treated with baloxavir (BXA, lower). Virus"/>
   <result pre="24 hours after administration than OST, and other NAIs including" exact="zanamivir" post="and peramivir [24]. The superior antiviral effect of BXA"/>
   <result pre="after administration than OST, and other NAIs including zanamivir and" exact="peramivir" post="[24]. The superior antiviral effect of BXA treatment resulted"/>
   <result pre="laboratory-confirmed influenza amongst household contacts of OST-treated index patients. However," exact="zanamivir" post="and peramivir, which can more effectively limit viral shedding"/>
   <result pre="2008;5(3):e7410.1371/journal.pmed.005007418366252 8NgS, CowlingBJ, FangVJ, ChanKH, IpDK, ChengCK, et al.Effects of" exact="oseltamivir" post="treatment on duration of clinical illness and viral shedding"/>
   <result pre="10.1086/65045820121573 9FryAM, GoswamiD, NaharK, SharminAT, RahmanM, GubarevaL, et al.Effects of" exact="oseltamivir" post="treatment of index patients with influenza on secondary household"/>
   <result pre="in Japan: age-specificity and reduction of household transmission risk by" exact="zanamivir" post="treatment. J Int Med Res. 2011;39(2):619–28. 10.1177/14732300110390023121672367 12BouvierNM, LowenAC."/>
   <result pre="10.1111/irv.1259029989680 30OhDY, LowtherS, McCawJM, SullivanSG, LeangS-K, HainingJ, et al.Evaluation of" exact="oseltamivir" post="prophylaxis regimens for reducing influenza virus infection, transmission and"/>
   <result pre="PaggiaroP, CarewiczO, El SawyA, WatC, et al.Early administration of oral" exact="oseltamivir" post="increases the benefits of influenza treatment. J Antimicrob Chemother."/>
   <result pre="10.1016/S2213-2600(14)70041-424815805 35ViasusD, Pano-PardoJR, PachonJ, RieraM, Lopez-MedranoF, PayerasA, et al.Timing of" exact="oseltamivir" post="administration and outcomes in hospitalized adults with pandemic 2009"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7159849\results\search\drugs\results.xml">
   <result pre="reduce transmission of the virus. In-vitro studies have shown that" exact="chloroquine" post="and hydroxychloroquine can both inhibit SARS-CoV-2 transmission,3, 4, 5"/>
   <result pre="of the virus. In-vitro studies have shown that chloroquine and" exact="hydroxychloroquine" post="can both inhibit SARS-CoV-2 transmission,3, 4, 5 through alkalinisation"/>
   <result pre="Early results from clinical studies conducted in China suggest that" exact="chloroquine" post="use might have been associated with reduced fever, increased"/>
   <result pre="disease progression.6, 7 Results of two French studies suggested that" exact="hydroxychloroquine" post="could reduce the viral load in patients with COVID-19—in"/>
   <result pre="9 (table ). On the basis of these preliminary findings," exact="chloroquine" post="and hydroxychloroquine have been prescribed to patients to reduce"/>
   <result pre="). On the basis of these preliminary findings, chloroquine and" exact="hydroxychloroquine" post="have been prescribed to patients to reduce the length"/>
   <result pre="in the ICU with severe COVID-19? Table Clinical studies of" exact="hydroxychloroquine" post="in patients with COVID-19 Study type (number of patients)"/>
   <result pre="Hydroxychloroquine (200 mg every 8 h) alone (n=14) or with" exact="azithromycin" post="(500 mg on day 1, 250 mg on days"/>
   <result pre="observational study (n=80) Hydroxychloroquine (200 mg every 8 h) and" exact="azithromycin" post="(500 mg on day 1, 250 mg on days"/>
   <result pre="observational study (n=11) Hydroxychloroquine (200 mg every 8 h) and" exact="azithromycin" post="(500 mg on day 1, 250 mg on days"/>
   <result pre="RCT=randomised controlled trial. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. First," exact="hydroxychloroquine" post="is not expensive, is readily available, and seems to"/>
   <result pre="increase the risk of adverse events. Second, clinical data on" exact="hydroxychloroquine" post="are far from convincing. The first study reported by"/>
   <result pre="study reported by Philippe Gautret and colleagues,8 which indicated that" exact="hydroxychloroquine" post="might be effective, had several limitations: a small cohort"/>
   <result pre="small cohort of patients, with only 20 participants who received" exact="hydroxychloroquine" post="(six of whom received azithromycin) and 16 controls included"/>
   <result pre="that reported for untreated patients with COVID-19.11 The combination of" exact="hydroxychloroquine" post="and azithromycin was associated with reduced viral load (83%"/>
   <result pre="for untreated patients with COVID-19.11 The combination of hydroxychloroquine and" exact="azithromycin" post="was associated with reduced viral load (83% and 93%"/>
   <result pre="significant difference in nasopharyngeal viral carriage on day 7 when" exact="hydroxychloroquine" post="was compared with local standard of care; however, concomitant"/>
   <result pre="trial in 62 patients, Zhaowei Chen and colleagues showed that" exact="hydroxychloroquine" post="treatment was associated with a shorter time to clinical"/>
   <result pre="should aim to clarify the precise role, if any, of" exact="chloroquine" post="and hydroxychloroquine in critically ill patients with COVID-19. References"/>
   <result pre="to clarify the precise role, if any, of chloroquine and" exact="hydroxychloroquine" post="in critically ill patients with COVID-19. References References 1YangXYuYXuJClinical"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="effective in inhibiting SARS-CoV-2 infection in vitroCell Discov620201632194981 5WangMCaoRZhangLRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="Trends142020727332074550 7CortegianiAIngogliaGIppolitoMGiarratanoAEinavSA systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J Crit Care2020published online March"/>
   <result pre="treatment of COVID-19J Crit Care2020published online March 10.10.1016/j.jcrc.2020.03.005 8GautretPLagierJCParolaPHydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="March 20.10.1016/j.ijantimicag.2020.105949 9GautretPLagierJCParolaPClinical and microbiological effect of a combination of" exact="hydroxychloroquine" post="and azithromycin in 80 COVID-19 patients with at least"/>
   <result pre="9GautretPLagierJCParolaPClinical and microbiological effect of a combination of hydroxychloroquine and" exact="azithromycin" post="in 80 COVID-19 patients with at least a six-day"/>
   <result pre="Engl J Med2020published online Feb 28.10.1056/NEJMoa2002032 12ChenJLiuDLiuLA pilot study of" exact="hydroxychloroquine" post="in treatment of patients with common coronavirus disease-19 (COVID-19)J"/>
   <result pre="(COVID-19)J Zhejiang Univ (Med Sci)2020published online March 6.10.3785/j.issn.1008-9292.2020.03.03 13ChenZHuJZhangZEfficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
   <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infectionMed Mal"/>
   <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infectionMed Mal Infect2020published online"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7159901\results\search\drugs\results.xml">
   <result pre="A.Editor[], Address correspondence to alakwaaf@med.umich.edu. Citation Alakwaa FM. 2020. Repurposing" exact="didanosine" post="as a potential treatment for COVID-19 using single-cell RNA"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7159988\results\search\drugs\results.xml">
   <result pre="involve drugs used in pediatric rheumatology; two are focused on" exact="tocilizumab" post="(an anti-IL-6R monoclonal antibody approved for juvenile idiopathic arthritis"/>
   <result pre="another investigating intravenous administrations of emapalumab (anti-IFNγ) in combination with" exact="anakinra" post="(an IL-1 receptor antagonist, approved for cryopyrin-associated periodic syndromes"/>
   <result pre="by AIFA. Another drug that is being investigated widely is" exact="hydroxychloroquine" post="(HCQ), an immunomodulatory agent commonly used in autoimmune diseases"/>
   <result pre="4.SIR COVID-19 database. 2020. https://www.reumatologia.it/cmsx.asp?IDPg=1092. 5.ChenJLiuDLiuLLiuPXuQXiaLet al.A pilot study of" exact="hydroxychloroquine" post="in treatment of patients with common coronavirus disease-19 (COVID-19)J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7160056\results\search\drugs\results.xml">
   <result pre="Cyclosporin A as First-line Therapy in COVID-19 Pneumonia☆¿Por qué elegir" exact="ciclosporina" post="A como primera línea terapéutica para la neumonía causada"/>
   <result pre="consequence of a vigorous innate immune response, while effectiveness of" exact="tocilizumab" post="in COVID-19 infected patients also supports the participation of"/>
   <result pre="Exp Biol217Pt 1201413714324353213 7DuS.HiramatsuN.HayakawaK.KasaiA.OkamuraM.HuangT.Suppression of NF-κB by cyclosporin A and" exact="tacrolimus" post="(FK506) via induction of the C/EBP family: implication for"/>
   <result pre="role for mitochondrial permeability transition in cell deathNature434200565866215800627 10PiotC.CroisilleP.StaatP.ThibaultH.RioufolG.MewtonN.Effect of" exact="cyclosporine" post="on reperfusion injury in acute myocardial infarctionN Engl J"/>
   <result pre="myocardial infarctionN Engl J Med359200847348118669426 11GoD.J.ParkJ.K.KangE.H.KwonH.M.LeeY.J.SongY.W.Survival benefit associated with early" exact="cyclosporine" post="treatment for dermatomyositis-associated interstitial lung diseaseRheumatol Int36201612513126223808 12PfefferleS.SchöpfJ.KöglM.FriedelC.C.MüllerM.A.Carbajo-LozoyaJ.The SARS-coronavirus-host"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7160655\results\search\drugs\results.xml">
   <result pre="Exp Immunol2008; 153:117–26.18505432 12VarisliL, CenO, VlahopoulosS. Dissecting pharmacological effects of" exact="chloroquine" post="in cancer treatment: interference with inflammatory signaling pathways. Immunology2020;"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7161506\results\search\drugs\results.xml">
   <result pre="Article Cytokine storm and immunomodulatory therapy in COVID-19: Role of" exact="chloroquine" post="and anti-IL-6 monoclonal antibodies ZhaoMingzhaoming4287@bjhmoh.cnab�?�[a], [b], �?�Address: No.1 Dahua"/>
   <result pre="immunomodulatory agents currently used in the treatment of COVID-19 (chloroquine," exact="hydroxychloroquine" post="and tocilizumab) are discussed. •Other immunomodulatory agents with good"/>
   <result pre="which included 201 patients with COVID-19, found that treatment with" exact="methylprednisolone" post="decreased the risk of death (hazard ratio 0.38, 95%"/>
   <result pre="oxygenation indicators) at low-to-moderate doses (no more than 1–2 mg/kg/day" exact="methylprednisolone" post="or equivalent) for a short duration (3–5 days), as"/>
   <result pre="issued by the National Health Commission of China [7]. Recently," exact="chloroquine" post="and its derivative hydroxychloroquine have been used in the"/>
   <result pre="Health Commission of China [7]. Recently, chloroquine and its derivative" exact="hydroxychloroquine" post="have been used in the treatment of COVID-19. In"/>
   <result pre="from more than 100 Chinese patients with COVID-19 showed that" exact="chloroquine" post="phosphate had good efficacy [8]. French doctors conducted an"/>
   <result pre="this study reported that 20 patients with COVID-19 who received" exact="hydroxychloroquine" post="treatment showed relatively good efficacy [9]. Both chloroquine and"/>
   <result pre="who received hydroxychloroquine treatment showed relatively good efficacy [9]. Both" exact="chloroquine" post="and hydroxychloroquine are weak bases and are able to"/>
   <result pre="hydroxychloroquine treatment showed relatively good efficacy [9]. Both chloroquine and" exact="hydroxychloroquine" post="are weak bases and are able to accumulate in"/>
   <result pre="diseases such as rheumatoid arthritis and lupus erythematosus. Chloroquine and" exact="hydroxychloroquine" post="can inhibit major histocompatibility complex class II expression, antigen"/>
   <result pre="receptor signalling and cGAS stimulation of interferon genes [11]. Thus," exact="chloroquine" post="and hydroxychloroquine can reduce the production of various pro-inflammatory"/>
   <result pre="and cGAS stimulation of interferon genes [11]. Thus, chloroquine and" exact="hydroxychloroquine" post="can reduce the production of various pro-inflammatory cytokines, such"/>
   <result pre="on 20 severe cases of COVID-10 showed that treatment with" exact="tocilizumab" post="led to a reduction in fever and lung lesion"/>
   <result pre="in chimeric antigen receptor T-cell immunotherapy. However, clinical experience with" exact="tocilizumab" post="in viral disease is very limited. In a retrospective"/>
   <result pre="level of C-reactive protein were observed in patients who received" exact="tocilizumab" post="compared with patients who did not receive tocilizumab [16]."/>
   <result pre="who received tocilizumab compared with patients who did not receive" exact="tocilizumab" post="[16]. Meanwhile, IL-6 inhibition by tocilizumab did not exacerbate"/>
   <result pre="who did not receive tocilizumab [16]. Meanwhile, IL-6 inhibition by" exact="tocilizumab" post="did not exacerbate or increase susceptibility to influenza virus"/>
   <result pre="risks may be a barrier for the wide use of" exact="tocilizumab" post="in the treatment of COVID-19. In early March 2020,"/>
   <result pre="COVID-19 (Table 1 ). Table 1 Dosing regimen of chloroquine," exact="hydroxychloroquine" post="and tocilizumab for treatment of COVID-19. [alt-text] Table 1"/>
   <result pre="1 ). Table 1 Dosing regimen of chloroquine, hydroxychloroquine and" exact="tocilizumab" post="for treatment of COVID-19. [alt-text] Table 1 Drug Dosage"/>
   <result pre="to drug–drug interactions and adverse reactions during the use of" exact="chloroquine" post="Hydroxychloroquine sulphateb 200 mg, three times per day 10"/>
   <result pre="such as tuberculosis G6PD, glucose-6-phosphate dehydrogenase. aThis dosing regimen of" exact="chloroquine" post="is provided in the Diagnosis and Treatment Protocol for"/>
   <result pre="the National Health Commission of China. bThis dosing regimen of" exact="hydroxychloroquine" post="was used in an open-label non-randomized clinical trial conducted"/>
   <result pre="clinical trial conducted in France to investigate the efficacy of" exact="hydroxychloroquine" post="and azithromycin therapy in the treatment of COVID-19. Breastfeeding"/>
   <result pre="conducted in France to investigate the efficacy of hydroxychloroquine and" exact="azithromycin" post="therapy in the treatment of COVID-19. Breastfeeding and pregnant"/>
   <result pre="for novel coronavirus pneumonia (Trial Version 7)Chin Med J202013310.3760/cma.j.issn.0366-6999.2020.0027 8GaoJTianZYangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="of COVID-19 associated pneumonia in clinical studiesBiosci Trends142020727332074550 9GautretPLagierJCParolaPHoangVTMeddebLMailheMHydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="Agents2020 Mar 2010.1016/j.ijantimicag.2020.105949 10DevauxCARolainJMColsonPRaoultD.New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int J Antimicrob"/>
   <result pre="COVID-19?Int J Antimicrob Agents2020 Mar 1110.1016/j.ijantimicag.2020.105938 11SchrezenmeierEDörnerT.Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatologyNat Rev Rheumatol2020 Feb 710.1038/s41584-020-0372-x"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7162641\results\search\drugs\results.xml">
   <result pre="These consist of Gilead's RNA polymerase inhibitor remdesivir, the antimalarials" exact="hydroxychloroquine" post="and chloroquine, the HIV protease inhibitors lopinavir and ritonavir,"/>
   <result pre="remdesivir, the antimalarials hydroxychloroquine and chloroquine, the HIV protease inhibitors" exact="lopinavir" post="and ritonavir, and lopinavir and ritonavir in combination with"/>
   <result pre="and chloroquine, the HIV protease inhibitors lopinavir and ritonavir, and" exact="lopinavir" post="and ritonavir in combination with the immunomodulatory agent interferon"/>
   <result pre="the HIV protease inhibitors lopinavir and ritonavir, and lopinavir and" exact="ritonavir" post="in combination with the immunomodulatory agent interferon beta-1a. First"/>
   <result pre="and lopinavir and ritonavir in combination with the immunomodulatory agent" exact="interferon beta-1a." post="First results could be available within 12–16 weeks, insiders"/>
   <result pre="Most likely not�?, she says. A 200-patient trial of the" exact="lopinavir" post="plus ritonavir combination has already failed, Cao and colleagues"/>
   <result pre="not�?, she says. A 200-patient trial of the lopinavir plus" exact="ritonavir" post="combination has already failed, Cao and colleagues reported in"/>
   <result pre="been finding preliminary antiviral efficacy signals with repurposed agents including" exact="hydroxychloroquine" post="for decades, says Bausch. But these rarely translate into"/>
   <result pre="more a day, and an international 40 000-patient prevention trial with" exact="chloroquine" post="and hydroxychloroquine. Industry sponsored trials will also be needed,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7162749\results\search\drugs\results.xml">
   <result pre="clathrin-mediated endocytosis. The drugs which act by clathrin-mediated endocytosis is" exact="chlorpromazine" post="which can inhibit the entry of these CoVs into"/>
   <result pre="entry of these CoVs into the host cells [10]. The" exact="chlorpromazine" post="is widely used anti-psychotic agent and is safe to"/>
   <result pre="more effective results against COVID-19 in vitro[11]. It is an" exact="adenosine" post="analogue, which incorporates into nascent viral RNA chains and"/>
   <result pre="Zika virus and Ebola virus in-vitro[14,15]. The synergistic effects of" exact="azithromycin" post="and hydroxychloroquine combination were also reported to treat COVID-19"/>
   <result pre="and Ebola virus in-vitro[14,15]. The synergistic effects of azithromycin and" exact="hydroxychloroquine" post="combination were also reported to treat COVID-19 patients [16]."/>
   <result pre="Covid-19 patients when compared to patients receiving only hydroxychloroquine. The" exact="hydroxychloroquine" post="increases the pH within acidic organelles and also inhibits"/>
   <result pre="bat originNature2020 Feb 310.1038/s41586-020-2012-7[Epub ahead of print] 2https://www.worldometers.info/coronavirus/#countries. 3RolainJ.M.ColsonP.RaoultD.Recycling of" exact="chloroquine" post="and its hydroxyl analogue to face bacterial, fungal and"/>
   <result pre="expressing ACE2 with the cytoplasmic tail deletedJ Virol8120078722872917522231 11WangManliCaoRuiyuanZhangLeikeYangXinglouLiuJiaXuMingyueShiZhengliHuZhihongZhongWuXiaoGengfuRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="inhibits the replication of Zika virusJ Antivirals Antiretrovirals1012018611 16PhilippeGautretHydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID- 19: results of an"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7162763\results\search\drugs\results.xml">
   <result pre="During hospitalization, most patients received antiviral treatment with interferon inhalation," exact="lopinavir" post="and ritonavir, combined with probiotics. Patients were discharged once"/>
   <result pre="caused by SARS-CoV-2 infection. Antiviral drugs used during hospitalization, including" exact="lopinavir" post="and ritonavir, might aggravate liver injury in patients with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7162768\results\search\drugs\results.xml">
   <result pre="(88%). Corticosteroid treatment was reported most frequently (N=25), followed by" exact="lopinavir" post="(N=21) and oseltamivir (N=16). Conclusions This is the first"/>
   <result pre="was reported most frequently (N=25), followed by lopinavir (N=21) and" exact="oseltamivir" post="(N=16). Conclusions This is the first systematic review to"/>
   <result pre="latest guidelines from the National Health Commission, including interferon, lopinavir/ritonavir," exact="chloroquine" post="phosphate, ribavirin and arbidol [3]. Angiotensin receptor blockers, such"/>
   <result pre="from the National Health Commission, including interferon, lopinavir/ritonavir, chloroquine phosphate," exact="ribavirin" post="and arbidol [3]. Angiotensin receptor blockers, such as losartan,"/>
   <result pre="the treatment protocols across countries are similar, and include hydroxychloroquine," exact="chloroquine" post="phosphate, remedesivir and lopinavir/ritonavir [[5], [6], [7]]. Treatment guidelines"/>
   <result pre="USA United States of America, interferon-β B1 (Betaseron) AntibioticsOseltamivirHydroxychloroquine (or" exact="chloroquine" post="phosphate)Azithromycin Hydrocortisone Therapeutic anticoagulants if D-Dimer Invasive In light"/>
   <result pre="COVID-19, SARS-COV-2, glucocorticoids, chloroquine, convalescent plasma, antiviral, antibacterial, oseltamivir, hydroxychloroquine," exact="chloroquine" post="phosphate and monoclonal antibodies. There were no restrictions on"/>
   <result pre="therapeutics Yes Commentary 3 Wang et al., 2020 Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="vitro Yes Commentary 4 Colson et al., 2020 Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19 Yes Commentary 5"/>
   <result pre="anti-inflammatory treatments Yes Commentary 21 Touret and Lamballerie, 2020 Of" exact="chloroquine" post="and COVID-19 Yes Commentary 22 Porcheddu et al., 2020"/>
   <result pre="Yes No therapeutic data 34 Gao et al., 2020 Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="62 Padmanabhan, 2020 Potential dual therapeutic approach against SARS-CoV-2/COVID-19 with" exact="nitazoxanide" post="and hydroxychloroquine Yes Commentary 63 Hick et al., 2020"/>
   <result pre="2020 Potential dual therapeutic approach against SARS-CoV-2/COVID-19 with nitazoxanide and" exact="hydroxychloroquine" post="Yes Commentary 63 Hick et al., 2020 Duty to"/>
   <result pre="2020 A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19 Yes Review 106 Ryu"/>
   <result pre="et al., 2020 New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19? Yes Review"/>
   <result pre="Yes Review 158 Liu et al., 2020 Therapeutic effects of" exact="dipyridamole" post="on COVID-19 patients with coagulation dysfunction Yes No therapeutic"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="199 58 120 M79 F Randomized clinical trial Lopinavir and" exact="ritonavir" post="Lopinavir and ritonavir: 50%Standard care: 50% In hospitalized adult"/>
   <result pre="Med 2020.https://doi.org/10.1007/s00134-020-05987-7 41 49 30 M11 F Prospective Antibiotics and" exact="oseltamivir" post="(orally 75 mg twice daily)Corticosteroid was given as a"/>
   <result pre="and low-dose glucocorticoid. The patient was first treated with oral" exact="ofloxacin" post="and oseltamivir, but her condition deteriorated. The patient was"/>
   <result pre="61 62 Not mentioned Open labelled clinical trial Oseltamivir or" exact="peramivir" post="(according to standard therapy) and antibiotics were given based"/>
   <result pre="observational study (retrospective) Antiviral drugs, including oseltamivir, ribavirin, lopinavir, ritonavir," exact="ganciclovir" post="and interferonGlucocorticoids, IV immunoglobulins and thymosin preparationsAntibiotic treatment, including"/>
   <result pre="IV immunoglobulins and thymosin preparationsAntibiotic treatment, including cephalosporins, quinolones, carbapenems," exact="linezolid" post="and tigecycline Antiviral: 61 (60.4%) Glucocorticoid: 59 (58.42%)IV immunoglobulin:"/>
   <result pre="and thymosin preparationsAntibiotic treatment, including cephalosporins, quinolones, carbapenems, linezolid and" exact="tigecycline" post="Antiviral: 61 (60.4%) Glucocorticoid: 59 (58.42%)IV immunoglobulin: 63.37%Thymosin: 44.55%Antibiotic:"/>
   <result pre="M32 F Retrospective, single-centre descriptive study Antibiotic: cephalo-sporins, quinolones, carbapenems," exact="tigecycline" post="against meticillin-resistant Staphylococcus aureus, linezolidAntifungalAntiviral: oseltamivir, ganciclovir and lopinavir/ritonavirGlucocorticoid:"/>
   <result pre="cephalo-sporins, quinolones, carbapenems, tigecycline against meticillin-resistant Staphylococcus aureus, linezolidAntifungalAntiviral: oseltamivir," exact="ganciclovir" post="and lopinavir/ritonavirGlucocorticoid: methylprednisolone sodium succinate, methylprednisolone and dexamethasone-Immunoglobulin Antibiotic:"/>
   <result pre="tigecycline against meticillin-resistant Staphylococcus aureus, linezolidAntifungalAntiviral: oseltamivir, ganciclovir and lopinavir/ritonavirGlucocorticoid:" exact="methylprednisolone" post="sodium succinate, methylprednisolone and dexamethasone-Immunoglobulin Antibiotic: 70 (71%)Antifungal: 15"/>
   <result pre="Staphylococcus aureus, linezolidAntifungalAntiviral: oseltamivir, ganciclovir and lopinavir/ritonavirGlucocorticoid: methylprednisolone sodium succinate," exact="methylprednisolone" post="and dexamethasone-Immunoglobulin Antibiotic: 70 (71%)Antifungal: 15 (15%)Antiviral: 75 (76%),"/>
   <result pre="and dexamethasone-Immunoglobulin Antibiotic: 70 (71%)Antifungal: 15 (15%)Antiviral: 75 (76%), including" exact="oseltamivir" post="(75 mg every 12 h, orally), ganciclovir (0.25 g"/>
   <result pre="75 (76%), including oseltamivir (75 mg every 12 h, orally)," exact="ganciclovir" post="(0.25 g every 12 h, intravenously), and lopinavir/ritonavir (500"/>
   <result pre="291 46 145 M146 F Double-centre observational study Antiviral including" exact="lopinavir" post="and ritonavir Recombinant human interferon-α2b Recombinant cytokine gene-derived protein"/>
   <result pre="145 M146 F Double-centre observational study Antiviral including lopinavir and" exact="ritonavir" post="Recombinant human interferon-α2b Recombinant cytokine gene-derived protein Arbidol hydrochloride"/>
   <result pre="55 days F Case report Inhaled interferon-α1b (15 μg, bid);" exact="amoxicillin" post="potassium clavulanate (30 mg/kg, Q8H, ivgtt) NA NA NA"/>
   <result pre="F Case report Inhaled interferon-α1b (15 μg, bid); amoxicillin potassium" exact="clavulanate" post="(30 mg/kg, Q8H, ivgtt) NA NA NA Case report"/>
   <result pre="outcomes in some patients 12 Gautret et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="M21 other Open label non- randomized clinical trial Hydroxychloroquine and" exact="azithromycin" post="Hydroxychloroquine sulfate 200 mg, three times per day for"/>
   <result pre="post inclusion, 100% of patients treated with a combination of" exact="hydroxychloroquine" post="and azithromycin were virologicaly cured, compared with 57.1% of"/>
   <result pre="100% of patients treated with a combination of hydroxychloroquine and" exact="azithromycin" post="were virologicaly cured, compared with 57.1% of patients treated"/>
   <result pre="were virologicaly cured, compared with 57.1% of patients treated with" exact="hydroxychloroquine" post="alone and 12.5% of patients in the control group"/>
   <result pre="2020. https://doi.org/10.1056/NEJMoa2001191 1 35 M Case report Antipyretic consisting of" exact="guaifenesin" post="650 mg600 mg Discharged with no symptoms Not reported"/>
   <result pre="was hospitalized for longer than other patients who continued taking" exact="lopinavir" post="Digestive adverse effect and hypokalaemia Small sample size 23"/>
   <result pre="Retrospective, multi-centre case series AntiviralAntibioticOxygen Oseltamivir: 38 (55.1%)Moxifloxacin, ceftriaxone, azithromycin," exact="tigecycline" post="or linezolid:31 (44.9%)Mechanical ventilation: 2Invasive ventilator: 2 Three patients"/>
   <result pre="with a significant increase in IL6 were also treated with" exact="methylprednisolone" post="Applicable 33 Xu et al. Clinical findings in critical"/>
   <result pre="Antiviral:196 (88.7%)AntibioticCorticosteroid: 115 (52.0%) OseltamivirArbidol hydrochlorideInterferon-α atomization inhalationLopinavir/ritonavirMoxifloxacin hydrochloridePiperacillin sodium" exact="tazobactam" post="sodiumCefoperazone sulbactamGlucocorticoid: 64 (49.6%) 12 (5.4%) patients died Not"/>
   <result pre="study institution)Observation of clinical manifestation Antibiotic: 73 (91.25%)Oseltamivir: 20 (25%)Ribavirin," exact="ganciclovir" post="or peramivir: 47 (58.75%)Arbidol: 49 (61.25%)Antifungal: 10 (12.5%)IV immunoglobin:"/>
   <result pre="review (N=25), using different names and product characteristics (corticosteroid N=21," exact="methylprednisolone" post="N=3, dexamethasone N=1). Use of lopinavir, an antiviral HIV"/>
   <result pre="using different names and product characteristics (corticosteroid N=21, methylprednisolone N=3," exact="dexamethasone" post="N=1). Use of lopinavir, an antiviral HIV medication (N=21)"/>
   <result pre="lopinavir, an antiviral HIV medication (N=21) – in combination with" exact="ritonavir" post="(N=18) or alone (N=3) – oseltamivir (N=16) and arbidol"/>
   <result pre="– in combination with ritonavir (N=18) or alone (N=3) –" exact="oseltamivir" post="(N=16) and arbidol hydrochloride (N=8) was also reported. In"/>
   <result pre="hydrochloride (N=8) was also reported. In terms of antibacterial agents," exact="moxifloxacin" post="(N=4) and tigecycline were reported most frequently. Convalescent plasma"/>
   <result pre="also reported. In terms of antibacterial agents, moxifloxacin (N=4) and" exact="tigecycline" post="were reported most frequently. Convalescent plasma therapy was reported"/>
   <result pre="formulations were reported most frequently, followed by the antivirals lopinavir," exact="oseltamivir" post="and arbidol hydrochloride. Convalescent plasma therapy was reported in"/>
   <result pre="pandemic influenza. A retrospective observational study reported the use of" exact="oseltamivir" post="in 1099 patients with COVID-19; however, the study was"/>
   <result pre="able to provide any solid data on the effectiveness of" exact="oseltamivir" post="in the prevention or treatment of COVID-19. Study limitations"/>
   <result pre="on 15th February 2020 in China [52]. Chloroquine phosphate and" exact="hydroxychloroquine" post="were reported in this review and showed favourable outcomes"/>
   <result pre="antimalarial, has shown positive outcomes in patients with COVID-19. Furthermore," exact="hydroxychloroquine" post="has shown significant effectiveness against intracellular pathogens such as"/>
   <result pre="of these medications in patients with COVID-19. The effect of" exact="hydroxychloroquine" post="was significant because it showed a reduction in the"/>
   <result pre="compared with the control group [22]. Moreover, the effect of" exact="hydroxychloroquine" post="was significantly more potent when given in conjunction with"/>
   <result pre="the morbidity and mortality of COVID-19 [[57], [58], [59]]. Although" exact="chloroquine" post="and hydroxychloroquine have shown promising activity against SARSCoV-2, there"/>
   <result pre="and mortality of COVID-19 [[57], [58], [59]]. Although chloroquine and" exact="hydroxychloroquine" post="have shown promising activity against SARSCoV-2, there is a"/>
   <result pre="and Drug Administration (FDA) issued an emergency use authorization for" exact="chloroquine" post="and hydroxychloroquine to treat patients hospitalized with COVID-19 [60]."/>
   <result pre="Administration (FDA) issued an emergency use authorization for chloroquine and" exact="hydroxychloroquine" post="to treat patients hospitalized with COVID-19 [60]. Convalescent plasma"/>
   <result pre="safety alerts issued by WHO and CDC, followed by lopinavir," exact="oseltamivir" post="and arbidol hydrochloride. Although further research is warranted as"/>
   <result pre="the 2019 novel coronavirus SARS-CoV-2Int J Antimicrob Agents202010592310.1016/j.ijantimicag.2020.10592332070753 7ColsonP.RolainJ.-M.LagierJ.-C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int J Antimicrob Agents55420201310.1016/j.ijantimicag.2020.105932"/>
   <result pre="retrospective observational studyAm J Respir Crit Care Med202010.1164/rccm.202003-0543OC 22GautretP.LagierJ.ParolaP.HoangV.MeddebL.MailheM.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="lopinavir, ritonavir, and interferon beta against MERS-CoVNat Commun11202022231924756 55WelliverR.MontoA.S.CarewiczO.SchattemanE.HassmanM.HedrickJ.Effectiveness of" exact="oseltamivir" post="in preventing influenza in household contacts: a randomized controlled"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis202010.1093/cid/ciaa237 58WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7163137\results\search\drugs\results.xml">
   <result pre="Kd (dissociation constant) of 6 × 10−6 mol/liter. As a broad-spectrum antiviral drug," exact="ribavirin" post="is currently used to treat several RNA virus infections"/>
   <result pre="several RNA virus infections clinically. A previous study showed that" exact="ribavirin" post="effectively reduced EV71 viral yields (EC50, 65 μg/ml [266 mM]) by"/>
   <result pre="assay (27). However, we failed to observe the interaction between" exact="ribavirin" post="and EV71 3Dpol by an ITC assay, suggesting that"/>
   <result pre="by an ITC assay, suggesting that the inhibitory effect of" exact="ribavirin" post="on EV71 is not related to a direct interaction"/>
   <result pre="consistent with previous report by Lohmann et al. showing that" exact="ribavirin" post="inhibition on HCV is not related to a direct"/>
   <result pre="direct inhibition of the RdRp NS5B of HCV (40). Actually," exact="ribavirin" post="is a broad-spectrum antiviral agent and nonselective nucleoside analog,"/>
   <result pre="restrain EV RNA synthesis, especially positive-strand RNA synthesis, than could" exact="ribavirin" post="by binding to EV 3Dpol. FIG 7 FNC inhibits"/>
   <result pre="EV71 3Dpol protein and negative control (buffer) or FNC or" exact="ribavirin" post="at 25°C showed that FNC binds to EV71 3Dpol"/>
   <result pre="Kd of 6 × 10−6 mol/liter. The titrant of 1.0 mM FNC or 3 mM" exact="ribavirin" post="was mixed with 100 μM EV71 3Dpol protein solution. Curves"/>
   <result pre="1-day-old mice, followed by FNC (infected and treated groups) or" exact="dimethyl sulfoxide" post="(DMSO) treatment (infected and untreated groups) (Fig. 9). For"/>
   <result pre="proteins have limited side effects (23). Nucleoside analogs such as" exact="ribavirin" post="and 2′-C-methylcytidine have been studied most extensively as RNA"/>
   <result pre="compounds were synthesized by Chang’s lab (34–39) and dissolved in" exact="dimethyl sulfoxide" post="(DMSO) for in vitro and in vivo studies. FNC"/>
   <result pre="(DMSO) for in vitro and in vivo studies. FNC and" exact="ribavirin" post="were dissolved in buffer (pH 7.5, 25 mM HEPES, 100 mM"/>
   <result pre="h at 37°C, overlay medium containing 2% FBS and 0.8%" exact="methylcellulose" post="was added and incubated at 37°C for 72 h."/>
   <result pre="or three times a week interferon alfa-2b in combination with" exact="ribavirin" post="or interferon alone for the treatment of patients with"/>
   <result pre="drug combination features and better inhibition on drug-resistant strains than" exact="lamivudine" post="in vitro. PLoS One9:e105617. doi:10.1371/journal.pone.0105617.25144636 39.LiuY, LiuB, ZhangY, PengY,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7163356\results\search\drugs\results.xml">
   <result pre="standard treatment for patients with HCV infection is peg-interferon plus" exact="ribavirin" post="(PegIFN/RBV) in 24 to 72 weeks, but only a"/>
   <result pre="ultimately resulting in a decrease in SVR. For example, when" exact="simeprevir" post="(TMC435) is used for the treatment of HCV infection,"/>
   <result pre="of R155 is good for facilitating its interaction with the" exact="simeprevir" post="crystal structure. Moreover, a salt bridge network structure formed"/>
   <result pre="R155K, D168A, and Q80K ultimately contribute to the effect of" exact="simeprevir" post="escaped by NS3 81. NS5A inhibitors are an indispensable"/>
   <result pre="position 282 of polymerase (S282T) conferred a 10-fold resistance against" exact="sofosbuvir" post="86. The in vitro analysis of the S282T variant"/>
   <result pre="failure in two HCV G1a-infected patients treated with ledipasvir (LED)+" exact="sofosbuvir" post="(SOF) 67, 104-106. Thus, the drug resistance of DAA"/>
   <result pre="The role of direct-acting antiviralsAntiviral Res20171428312228238877 4MannsMPMcHutchisonJGGordonSCRustgiVKShiffmanMReindollarRet al.Peginterferon alfa-2b plus" exact="ribavirin" post="compared with interferon alfa-2b plus ribavirin for initial treatment"/>
   <result pre="4MannsMPMcHutchisonJGGordonSCRustgiVKShiffmanMReindollarRet al.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus" exact="ribavirin" post="for initial treatment of chronic hepatitis C: a randomised"/>
   <result pre="2018J Hepatol20186946151129650333 7SullivanJCDe MeyerSBartelsDJDierynckIZhangEZSpanksJet al.Evolution of treatment-emergent resistant variants in" exact="telaprevir" post="phase 3 clinical trialsClin Infect Dis201357221923575197 8ContiFBuonfiglioliFScuteriACrespiCBolondiLCaraceniPet al.Early occurrence"/>
   <result pre="trialLancet HIV20152e3192726423374 26SulkowskiMSEronJJWylesDTrinhRLalezariJWangCet al.Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and" exact="ribavirin" post="for hepatitis C in patients co-infected with HIV-1: a"/>
   <result pre="a randomized trialJAMA201531312233125706092 27OsinusiATownsendKKohliANelsonASeamonCMeissnerEGet al.Virologic response following combined ledipasvir and" exact="sofosbuvir" post="administration in patients with HCV genotype 1 and HIV"/>
   <result pre="of the metabolic milieuEur J Gastroenterol Hepatol201931260630379706 49MeissnerEGLeeYJOsinusiASimsZQinJSturdevantDet al.Effect of" exact="sofosbuvir" post="and ribavirin treatment on peripheral and hepatic lipid metabolism"/>
   <result pre="metabolic milieuEur J Gastroenterol Hepatol201931260630379706 49MeissnerEGLeeYJOsinusiASimsZQinJSturdevantDet al.Effect of sofosbuvir and" exact="ribavirin" post="treatment on peripheral and hepatic lipid metabolism in chronic"/>
   <result pre="changes in intrahepatic immune cell populations during HCV treatment with" exact="sofosbuvir" post="and ribavirinJ Viral Hepat201926323830383918 71ShrivastavaSWilsonEPooniaBTangLOsinusiAKohliAet al.Augmentation of hepatitis C"/>
   <result pre="resistance in genotype 1-6 hepatitis C virus-infected subjects treated with" exact="sofosbuvir" post="in phase 2 and 3 clinical trialsClin Infect Dis20145916667425266287"/>
   <result pre="phase 2 and 3 clinical trialsClin Infect Dis20145916667425266287 86Martel-LaferriereVABT-450/r-ombitasvir and" exact="dasabuvir" post="with ribavirin eliminates viraemia in most patients with HCV"/>
   <result pre="and 3 clinical trialsClin Infect Dis20145916667425266287 86Martel-LaferriereVABT-450/r-ombitasvir and dasabuvir with" exact="ribavirin" post="eliminates viraemia in most patients with HCV infection with"/>
   <result pre="regionAntiviral Res201511610625614456 90JacobsonIMDoreGJFosterGRFriedMWRaduMRafalskyVVet al.Simeprevir with pegylated interferon alfa 2a plus" exact="ribavirin" post="in treatment-naive patients with chronic hepatitis C virus genotype"/>
   <result pre="for Direct-Acting Antiviral Treatment and Drug ResistanceViruses2015750183926389941 92LawitzEMatusowGDeJesusEYoshidaEMFelizartaFGhalibRet al.Simeprevir plus" exact="sofosbuvir" post="in patients with chronic hepatitis C virus genotype 1"/>
   <result pre="Pibrentasvir M28A/G/T, Q30E/H/R, L31F/M/V, P32L/S, H58D, Y93H NS5B inhibitors sofosbuvir," exact="dasabuvir" post="C316N"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7164882\results\search\drugs\results.xml">
   <result pre="rate in patients with SARS who did not respond to" exact="methylprednisolone" post="in uncontrolled non-randomized clinical trials.3, 4 Cheng et al."/>
   <result pre="challengesCrit Care2420209132178711 3SooY.O.ChengY.WongR.HuiD.S.LeeC.K.TsangK.K.Retrospective comparison of convalescent plasma with continuing high-dose" exact="methylprednisolone" post="treatment in SARS patientsClin Microbiol Infect10200467667815214887 4ChengY.WongR.SooY.O.WongW.S.LeeC.K.NgM.H.Use of convalescent"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7165083\results\search\drugs\results.xml">
   <result pre="(Figure 1 ). One study showed no benefit in using" exact="lopinavir" post="plus ritonavir over standard of care for sick hospitalized"/>
   <result pre="). One study showed no benefit in using lopinavir plus" exact="ritonavir" post="over standard of care for sick hospitalized adult patients"/>
   <result pre="arm for comparison.5 There has also been interest in using" exact="azithromycin" post="for COVID-19. It has been included in the ACTION"/>
   <result pre="on SARS-CoV-2 remains speculative.6 Caution is advised in trials evaluating" exact="azithromycin" post="in conjunction with hydroxychloroquine (NCT04335552), due to potential additive"/>
   <result pre="Caution is advised in trials evaluating azithromycin in conjunction with" exact="hydroxychloroquine" post="(NCT04335552), due to potential additive effects on QT interval"/>
   <result pre="ARDS. Also shown are the putative mechanisms of action for" exact="bromhexine" post="and hydroxychloroquine in attenuating upstream SARS-CoV-2 tissue binding, the"/>
   <result pre="shown are the putative mechanisms of action for bromhexine and" exact="hydroxychloroquine" post="in attenuating upstream SARS-CoV-2 tissue binding, the effect of"/>
   <result pre="upstream SARS-CoV-2 tissue binding, the effect of antivirals on replication," exact="azithromycin" post="as an antiviral and immunomudulator, nonspecific cytokine suppression by"/>
   <result pre="together with the selective downstream effect of IL-6 blockade with" exact="tocilizumab" post="or sarilumab and effects of anti-TNF and interferon beta-1-a."/>
   <result pre="2. Blocking viral host cell entry with the antimalarial drugs" exact="hydroxychloroquine" post="or chloroquine is another potential upstream modality (Figure 1)."/>
   <result pre="viral host cell entry with the antimalarial drugs hydroxychloroquine or" exact="chloroquine" post="is another potential upstream modality (Figure 1). Hydroxychloroquine is"/>
   <result pre="one non peer reviewed randomised controlled trial from France with" exact="hydroxychloroquine" post="added to usual care in 181 patients with severe"/>
   <result pre="of more effectively blocking viral host cell entry using combined" exact="hydroxychloroquine" post="and bromhexine (NCT04340349), but at present this only remains"/>
   <result pre="effectively blocking viral host cell entry using combined hydroxychloroquine and" exact="bromhexine" post="(NCT04340349), but at present this only remains speculative. It"/>
   <result pre="an increased pneumonia risk, especially with lipophilic drugs such as" exact="fluticasone" post="furoate,12 due to its prolonged lung retention and associated"/>
   <result pre="microbiome and impaired mucociliary clearance.13 Moreover, suppression of interferon by" exact="fluticasone" post="propionate is associated with an increased bacterial load after"/>
   <result pre="with COPD with blood eosinophils ≥300 cells/μL, the benefit of" exact="fluticasone" post="furoate in reducing severe exacerbations outweighs its risk in"/>
   <result pre="to an excess of 1.44 cases per 1000 patient-years.17 Interestingly," exact="ciclesonide" post="and mometasone, but not budesonide, beclomethasone, or fluticasone, exhibit"/>
   <result pre="replication appears to be nonstructural protein 15 (NSP15). Budesonide and" exact="formoterol" post="independently suppress systemic suppression of IL-6 in relation to"/>
   <result pre="evidence can support switching patients with controlled asthma to inhaled" exact="ciclesonide" post="or mometasone. A study evaluating ciclesonide in South Korea"/>
   <result pre="controlled asthma to inhaled ciclesonide or mometasone. A study evaluating" exact="ciclesonide" post="in South Korea will look at the rate of"/>
   <result pre="with mild COVID-19 infection (NCT04330586). Another study comparing high dose" exact="ciclesonide" post="with usual care from Japan will report on progression"/>
   <result pre="the possibility of therapeutic intervention with anti-IL-6 drugs such as" exact="tocilizumab" post="and sarilumab that are indicated for rheumatoid disease. There"/>
   <result pre="in 21 patients infected with SARS-CoV-2 using the anti-IL-6 agent" exact="tocilizumab" post="showed a rapid reduction in fever, C reactive protein"/>
   <result pre="All patients already had routine treatment for 1 week including" exact="lopinavir" post="and methylprednisolone before receiving tocilizumab. A significant limitation may"/>
   <result pre="already had routine treatment for 1 week including lopinavir and" exact="methylprednisolone" post="before receiving tocilizumab. A significant limitation may therefore be"/>
   <result pre="the anti-IL-6 agent sarilumab, whereas 3 other studies are evaluating" exact="tocilizumab" post="alone: COVACTA (NCT04320615) and TOCOVID (NCT04322773), or in combination"/>
   <result pre="be required to obviate upstream SARS-CoV-2 lung tissue binding with" exact="hydroxychloroquine" post="or bromhexine, or instead with antivirals, together with downstream"/>
   <result pre="with antivirals, together with downstream IL-6 blockade by sarilumab or" exact="tocilizumab" post="(Figure 1). With this in mind we believe studies"/>
   <result pre="such as lopinavir-ritonavir or blocking viral host cell entry with" exact="hydroxychloroquine" post="may not be successful unless used earlier in the"/>
   <result pre="print April 10, 2020]. N Engl J Med10.1056/NEJMoa2007016 6GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="in human monocytes and T cellsJ Rheumatol2019938038088336306 10MahévasM.TranV.-T.RoumierM.ChabrolA.PauleR.GuillaudC.Clinical efficacy of" exact="hydroxychloroquine" post="in patients with covid-19 pneumonia who require oxygen: observational"/>
   <result pre="corticosteroids: a quasi-cohort studyBr J Clin Pharmacol8320172077208628425216 18MatsuyamaS.KawaseM.NaoN.ShiratoK.UjikeM.KamitaniW.The inhaled corticosteroid" exact="ciclesonide" post="blocks coronavirus RNA replication by targeting viral NSP15 [published"/>
   <result pre="hospitalised with influenza A infectionEur Respir J41201382483122903963 21BafadhelM.DaviesL.CalverleyP.M.AaronS.D.BrightlingC.E.PavordI.D.Blood eosinophil guided" exact="prednisolone" post="therapy for exacerbations of COPD: a further analysisEur Respir"/>
   <result pre="Allergy Clin Immunol10.1016/j.jaci.2020.05.008 25XuX.HanM.LiT.SunW.WangD.FuB.Effective treatment of severe COVID-19 patients with" exact="tocilizumab" post="[published online ahead of print April 29, 2020]Proc Natl"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7165104\results\search\drugs\results.xml">
   <result pre="with coronavirus induced lung injury showed improvement when treated with" exact="losartan" post="[5]. As far as CVID-19 infection is concerned, the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7166016\results\search\drugs\results.xml">
   <result pre="resource centre remains active. Beyond their well-known antiparasitic activity, both" exact="chloroquine" post="and hydroxychloroquine (HCQ) have antibacterial, antifungal and antiviral properties,"/>
   <result pre="remains active. Beyond their well-known antiparasitic activity, both chloroquine and" exact="hydroxychloroquine" post="(HCQ) have antibacterial, antifungal and antiviral properties, the latter"/>
   <result pre="a higher rate of relapse of hematological malignancies in the" exact="azithromycin" post="arm [5]. From the perspective of antiviral immunity, a"/>
   <result pre="from the cardiovascular side-effects, the widespread use of HCQ and" exact="azithromycin" post="could be detrimental to patients with minimally symptomatic disease."/>
   <result pre="lockdown strategy (Fig. 1 ). Fig. 1 Scenario on how" exact="hydroxychloroquine" post="with/without azithromycin could be responsible for failure of the"/>
   <result pre="(Fig. 1 ). Fig. 1 Scenario on how hydroxychloroquine with/without" exact="azithromycin" post="could be responsible for failure of the herd immunity,"/>
   <result pre="use in minimally or asymptomatic individuals. References References 1RolainJ.M.ColsonP.RaoultD.Recycling of" exact="chloroquine" post="and its hydroxyl analogue to face bacterial, fungal and"/>
   <result pre="infections in the 21st centuryInt J Antimicrob Agents304200729730817629679 2GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="Agents2020105949 3FavaA.PetriM.Systemic lupus erythematosus: diagnosis and clinical managementJ Autoimmun96201911330448290 4RadhakrishnanS.V.PalaniyandiS.MuellerG.MiklosS.HagerM.SpacenkoE.Preventive" exact="azithromycin" post="treatment reduces noninfectious lung injury and acute graft-versus-host disease"/>
   <result pre="of allogeneic hematopoietic cell transplantationBiol Blood Marrow Transplant2112014303825445642 5BergeronA.ChevretS.GranataA.ChevallierP.VincentL.HuynhA.Effect of" exact="azithromycin" post="on airflow decline-free survival after allogeneic hematopoietic stem cell"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7166223\results\search\drugs\results.xml">
   <result pre="as neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and" exact="ribavirin" post="are not valid for 2019-nCoV [ 9 ]. Some"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7166314\results\search\drugs\results.xml">
   <result pre="before HBeAg seroclearance. A total of 173 (85.2%) patients received" exact="entecavir" post="or tenofovir as the first-line treatment. The remaining 30"/>
   <result pre="seroclearance. A total of 173 (85.2%) patients received entecavir or" exact="tenofovir" post="as the first-line treatment. The remaining 30 (14.8%) patients"/>
   <result pre="as the first-line treatment. The remaining 30 (14.8%) patients received" exact="tenofovir" post="only or tenofovir plus entecavir combination therapy as a"/>
   <result pre="treatment. The remaining 30 (14.8%) patients received tenofovir only or" exact="tenofovir" post="plus entecavir combination therapy as a rescue therapy. One"/>
   <result pre="remaining 30 (14.8%) patients received tenofovir only or tenofovir plus" exact="entecavir" post="combination therapy as a rescue therapy. One hundred seventy-five"/>
   <result pre="HBeAg seroclearance. Choi et al. recently reported the association between" exact="tenofovir" post="treatment and significantly lower risk of HCC as compared"/>
   <result pre="treatment and significantly lower risk of HCC as compared with" exact="entecavir" post="treatment in a population-based cohort study [20]. In our"/>
   <result pre="study [20]. In our study, all patients were treated with" exact="entecavir" post="(n = 152), tenofovir (n = 49), or combination of both (n = 2) as"/>
   <result pre="In our study, all patients were treated with entecavir (n = 152)," exact="tenofovir" post="(n = 49), or combination of both (n = 2) as the first"/>
   <result pre="underwent rescue therapy, 28 had undetectable HBV DNA regardless of" exact="lamivudine" post="or adefovir mutant profiles. There was no difference in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7167223\results\search\drugs\results.xml">
   <result pre="A recent French study on 36 patients indicated that adding" exact="azithromycin" post="to HCQ resulted in further reduction of viral load"/>
   <result pre="of severe COVID-19 patients with tocilizumab. ChinaXiv: 202003.00026v1. 9RolainJ.-M.ColsonP.RaoultD.Recycling of" exact="chloroquine" post="and its hydroxyl analogue to face bacterial, fungal and"/>
   <result pre="inhibitor of SARS coronavirus infection and spreadVirol J220056916115318 11WangM.CaoR.ZhangL.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="pneumonia (7th interim edition). China2020[Available from: http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989/files/ce3e6945832a4 38eaae415350a8ce964.pdf] 15GautretP.LagierJ.C.ParolaP.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an openlabel"/>
   <result pre="Antimicrob Agents202010.1016/j.ijantimicag.2020.105949 16ZhouD.DaiS.M.TongQ.COVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progressionJ Antimicrob Chemother202010.1093/jac/dkaa114 17DiaoB.WangC.TanY.Reduction and"/>
   <result pre="of COVID-19J Pharm Anal202010.1016/j.jpha.2020.03.001 26PuS.-Y.XiaoF.SchorS.Feasibility and biological rationale of repurposing" exact="sunitinib" post="and erlotinib for dengue treatmentAntiviral Res1552018677529753658 27RichardsonP.GriffinI.TuckerC.Baricitinib as potential"/>
   <result pre="Pharm Anal202010.1016/j.jpha.2020.03.001 26PuS.-Y.XiaoF.SchorS.Feasibility and biological rationale of repurposing sunitinib and" exact="erlotinib" post="for dengue treatmentAntiviral Res1552018677529753658 27RichardsonP.GriffinI.TuckerC.Baricitinib as potential treatment for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7167229\results\search\drugs\results.xml">
   <result pre="recently shown activity against MERS in rhesus macaques [13]. Remdesivir," exact="chloroquine" post="and several other drugs were tested in vitro against"/>
   <result pre="for in vitro testing [28]. We identified pyronaridine, tilorone and" exact="quinacrine" post="as having good in vitro activity (nM) against the"/>
   <result pre="348 FDA-approved drugs identified four FDA-approved drugs including chloroquine, chlorpromazine," exact="loperamide" post="and lopinavir [63]. At the same time, a second"/>
   <result pre="drugs identified four FDA-approved drugs including chloroquine, chlorpromazine, loperamide and" exact="lopinavir" post="[63]. At the same time, a second study screened"/>
   <result pre="290 compounds and identified 27 FDA- and non-FDA-approved drugs including" exact="chloroquine" post="among the many hits [64], and the Abl2 kinase"/>
   <result pre="many hits [64], and the Abl2 kinase inhibitors such as" exact="imatinib" post="which impacts the early stages of infection after internalization"/>
   <result pre="viral membrane [65]. Chloroquine is widely used for malaria and" exact="loperamide" post="is used for diarrhea. These represent drugs that are"/>
   <result pre="protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir," exact="saquinavir" post="and tipranavir) and hepatitis C NS3/4A protease inhibitors (asunaprevir,"/>
   <result pre="and hepatitis C NS3/4A protease inhibitors (asunaprevir, boceprevir, grazoprevir, paritaprevir," exact="simeprevir" post="and telaprevir) into the Mpro structure of SARS-CoV-2. The"/>
   <result pre="the results of both docking approaches indicated that azatanavir and" exact="lopinavir" post="may be of most interest for in vitro/and/or in"/>
   <result pre="Cys145 residue of the S1’ pocket. The aromatic ring of" exact="lopinavir" post="also formed hydrophobic interactions with residues Cys44, Met49 (S2"/>
   <result pre="Leu50, Pro52, Tyr54, and Cys145 (S1’ pocket). In relation to" exact="atazanavir" post="(Fig. 4b) (LigandFit score of 175.497), hydrogen bonds were"/>
   <result pre="nitrogen atoms of carbamate groups. Similar hydrophobic interactions observed with" exact="lopinavir" post="occurred also with atazanavir, with residues Met49 (S2 pocket),"/>
   <result pre="Pro52 and Tyr54 (Fig. 4). In China and South Korea" exact="lopinavir" post="200 mg/ritonavir 50 mg has already been used for"/>
   <result pre="titers have been observed since then [11]. Lopinavir, co-formulated with" exact="ritonavir" post="is commercially available and known as Kaletra® around the"/>
   <result pre="around the world–it is on formularies for HIV. By contrast," exact="atazanavir" post="is less commonly used. Kaletra® can be widely produced"/>
   <result pre="testing. Figure 4 Intermolecular 3D and 2D interactions of (a)" exact="lopinavir" post="and (b) atazanavir with the main protease structure of"/>
   <result pre="Intermolecular 3D and 2D interactions of (a) lopinavir and (b)" exact="atazanavir" post="with the main protease structure of SARS-CoV-2 (PDB ID"/>
   <result pre="be seen in Table 3 , docking scores indicated that" exact="rizatriptan" post="(an antimigraine agent, Glide score = −7.49 kcal mol−1),"/>
   <result pre="rizatriptan (an antimigraine agent, Glide score = −7.49 kcal mol−1)," exact="dasabuvir" post="(an antiviral for hepatitis C, Glide score = −7.09"/>
   <result pre="antiviral for hepatitis C, Glide score = −7.09 kcal mol−1)," exact="pravastatin" post="(a lipid-lowering agent, Glide score = −6.17 kcal mol−1)"/>
   <result pre="(a lipid-lowering agent, Glide score = −6.17 kcal mol−1) and" exact="empagliflozin" post="(a hypoglycemic agent, Glide score = −6.37 kcal mol−1)"/>
   <result pre="agent −6.37 Figure 5 3D and 2D intermolecular interactions of" exact="rizatriptan" post="(a), dasabuvir (b) , pravastatin (c) and empagliflozin (d)"/>
   <result pre="Figure 5 3D and 2D intermolecular interactions of rizatriptan (a)," exact="dasabuvir" post="(b) , pravastatin (c) and empagliflozin (d) with the"/>
   <result pre="and 2D intermolecular interactions of rizatriptan (a), dasabuvir (b) ," exact="pravastatin" post="(c) and empagliflozin (d) with the spike–ACE2 interface. In"/>
   <result pre="interactions of rizatriptan (a), dasabuvir (b) , pravastatin (c) and" exact="empagliflozin" post="(d) with the spike–ACE2 interface. In 3D representation (left),"/>
   <result pre="a disease. As an example, we have applied the drugs" exact="ritonavir" post="[9], favipiravir, ribavirin and chloroquine as scaffolds to find"/>
   <result pre="an example, we have applied the drugs ritonavir [9], favipiravir," exact="ribavirin" post="and chloroquine as scaffolds to find new potential molecular"/>
   <result pre="we have applied the drugs ritonavir [9], favipiravir, ribavirin and" exact="chloroquine" post="as scaffolds to find new potential molecular and biological"/>
   <result pre="Table S3 online). Comparing the molecular and biological signature of" exact="ritonavir" post="with other drugs, we found that the drugs cobicistat,"/>
   <result pre="ritonavir with other drugs, we found that the drugs cobicistat," exact="carfilzomib" post="and ombitasvir presented the highest matching scores (81–71%), suggesting"/>
   <result pre="other drugs, we found that the drugs cobicistat, carfilzomib and" exact="ombitasvir" post="presented the highest matching scores (81–71%), suggesting that those"/>
   <result pre="SARS-CoV-2. Figure 6 Molecular and biological signature profiles generated for" exact="ritonavir" post="compared with other drugs, using artificial intelligence to create"/>
   <result pre="and in vitro and in vivo endpoints. The drugs cobicistat," exact="carfilzomib" post="and ombitasvir presented the higher matching scores (81–71%) with"/>
   <result pre="vitro and in vivo endpoints. The drugs cobicistat, carfilzomib and" exact="ombitasvir" post="presented the higher matching scores (81–71%) with ritonavir. Concluding"/>
   <result pre="model of MERS-CoV infectionProc. Natl. Acad. Sci. U.S.A.202010.1073/pnas.1922083117 14WangM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019- nCoV)"/>
   <result pre="of tilorone dihydrochloride against Ebola virus infectionAntimicrob. Agents Chemother.62201810.1128/AAC.01711-17 30LaneT.R.Repurposing" exact="quinacrine" post="against Ebola virus infection in vivoAntimicrob. Agents Chemother.63201910.1128/AAC.01142-19 31LaneT.R.Repurposing"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7167303\results\search\drugs\results.xml">
   <result pre="lead to the drug resistance of the virus. Fabiravir and" exact="ribavirin" post="Nucleoside analogs have a broad-spectrum antiviral effect via the"/>
   <result pre="mutagenesis, chain termination, and inhibition of nucleotide biosynthesis. Fabiravir and" exact="ribavirin" post="are representative drugs of nucleoside analogs and exhibit the"/>
   <result pre="It has been demonstrated that the combination of fabiravir and" exact="oseltamivir" post="in the treatment of severe influenza may accelerate clinical"/>
   <result pre="the treatment of severe influenza may accelerate clinical recovery than" exact="oseltamivir" post="alone [14]. In addition, it has been reported that"/>
   <result pre="In addition, it has been reported that the combination of" exact="ribavirin" post="and interferon alpha (IFN-�?�) significantly reduced the 14-day mortality"/>
   <result pre="IFN-�?� were also used in the treatment for SARS. However," exact="ribavirin" post="might have side effects such as anemia and liver"/>
   <result pre="not improve the patients’ outcome [16]. Therefore, the use of" exact="ribavirin" post="and IFN-�?� in the treatment of COVID-19 needs to"/>
   <result pre="It has been reported that the combination of lopinavir/ritonavir with" exact="ribavirin" post="could lower the risk of ARDS compared with ribavirin"/>
   <result pre="with ribavirin could lower the risk of ARDS compared with" exact="ribavirin" post="alone [17]. Most recently, the randomized clinical trial of"/>
   <result pre="with 2019-nCoV is in progress in China [30]. Chloroquine and" exact="hydroxychloroquine" post="It is known that angiotensin-converting enzyme-2 (ACE2) as a"/>
   <result pre="of oral mucosa via the essential receptor ACE2 [37], and" exact="chloroquine" post="can function at both entry and post-entry stages of"/>
   <result pre="post-entry stages of 2019-nCoV infection [38]. Besides the antiviral activity," exact="chloroquine" post="has an immune-modulating activity, which may synergistically enhance its"/>
   <result pre="effect in vivo. Recently, Wang et al. have demonstrated that" exact="chloroquine" post="is highly effective in the control of 2019-nCoV infection"/>
   <result pre="results from more than 100 COVID-19 patients have indicated that" exact="chloroquine" post="phosphate is superior to the control treatment in inhibiting"/>
   <result pre="attention should be paid to the potential detrimental effects of" exact="chloroquine" post="observed in previous attempts to treat viral diseases. At"/>
   <result pre="the clinical trials to evaluate the efficacy and safety of" exact="chloroquine" post="in the treatment of COVID-19 is ongoing [40]. The"/>
   <result pre="the treatment of COVID-19 is ongoing [40]. The use of" exact="chloroquine" post="in the treatment of COVID-19 should refer to the"/>
   <result pre="refer to the most recent announcements if any. In addition," exact="hydroxychloroquine" post="is a 4-aminoquinoline derivative antimalarial drug. Hydroxychloroquine is an"/>
   <result pre="42]. It has been found to be more potent than" exact="chloroquine" post="in inhibiting 2019-nCoV in vitro. Hydroxychloroquine sulfate 400 mg"/>
   <result pre="the treatment COVID-19 [43]. At present, the clinical evaluation of" exact="hydroxychloroquine" post="in the treatment of COVID-19 is in progress [44],"/>
   <result pre="data in SARS suggest that immunomodulation with regimens of high-dose" exact="methylprednisolone" post="might be helpful in modulating inflammatory responses and lung"/>
   <result pre="a key member of immunophilins is the cellular receptor for" exact="cyclosporine" post="A [63]. The inhibition of cyclophilins by cyclosporine A"/>
   <result pre="receptor for cyclosporine A [63]. The inhibition of cyclophilins by" exact="cyclosporine" post="A could block the replication of coronavirus, including SARS-CoV"/>
   <result pre="replication of coronavirus, including SARS-CoV [64]. Therefore, non-immunosuppressive derivatives of" exact="cyclosporine" post="A might serve as broad-range CoV inhibitors applicable against"/>
   <result pre="patients with severe MERS-CoV infection, the combination of IFN-alpha-2a with" exact="ribavirin" post="was shown to improve survival [66]. Recently, the combination"/>
   <result pre="used in the treatment for rheumatoid arthritis (RA) [71]. Moreover," exact="tocilizumab" post="has been reported to be effective against cytokine release"/>
   <result pre="Diagnosis and Treatment Guidelines of NCP (trial version 7.0) [73]," exact="tocilizumab" post="is recommended for the immunotherapy of patients with extensive"/>
   <result pre="increased level of IL6 in laboratory testing. The efficacy of" exact="tocilizumab" post="in COVID-19 patients still needs to be investigated. Chinese"/>
   <result pre="in Wuhan, ChinaJAMA.202010.1001/jama.2020.158532275295 14.WangYFanGSalamAet al.Comparative effectiveness of combined favipiravir and" exact="oseltamivir" post="therapy versus oseltamivir monotherapy in critically ill patients with"/>
   <result pre="14.WangYFanGSalamAet al.Comparative effectiveness of combined favipiravir and oseltamivir therapy versus" exact="oseltamivir" post="monotherapy in critically ill patients with influenza virus infectionJ"/>
   <result pre="influenza virus infectionJ Infect Dis201910.1093/infdis/jiz65631822885 15.KimUJWonEJKeeSJet al.Combination therapy with lopinavir/ritonavir," exact="ribavirin" post="and interferon-alpha for Middle East respiratory syndromeAntivir Ther.201621545545910.3851/IMP300226492219 16.OmraniASSaadMMBaigKet"/>
   <result pre="cells: opportunities for therapeutic interventionMed Res Rev200626441443310.1002/med.2005516521129 35.YanYZouZSunYet al.Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
   <result pre="cells of oral mucosaInt J Oral Sci.2020121810.1038/s41368-020-0074-x32094336 38.WangMCaoRZhangLet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="the recently emerged novel coronavirus (2019-nCoV) in vitroCell Res202010.1038/s41422-020-0282-032284560 39.GaoJTianZYangXBreakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="lupus erythematosus (SLE)Expert Opin Drug Saf.201716341141910.1080/14740338.2017.126916827927040 42.SchrezenmeierEDornerTMechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatologyNat Rev Rheumatol202016315516610.1038/s41584-020-0372-x32034323 43.YaoXYeFZhangMet al.In"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome Coronavirus"/>
   <result pre="with rheumatoid arthritisInt J Mol Sci.20192018 72.LeRQLiLYuanWet al.FDA approval summary:" exact="tocilizumab" post="for treatment of chimeric antigen receptor T cell-induced severe"/>
   <result pre="75.JiSBaiQWuXet al.Unique synergistic antiviral effects of Shufeng Jiedu Capsule and" exact="oseltamivir" post="in influenza A viral-induced acute exacerbation of chronic obstructive"/>
   <result pre="Med2016374252498250010.1056/NEJMc160228427332914 81.SooYOChengYWongRet al.Retrospective comparison of convalescent plasma with continuing high-dose" exact="methylprednisolone" post="treatment in SARS patientsClin Microbiol Infect200410767667810.1111/j.1469-0691.2004.00956.x15214887 82.ChengYWongRSooYOet al.Use of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7167491\results\search\drugs\results.xml">
   <result pre="development. In this case report, the patient was treated with" exact="vancomycin" post="and cefepime from day 5 of hospitalization (9th day"/>
   <result pre="this case report, the patient was treated with vancomycin and" exact="cefepime" post="from day 5 of hospitalization (9th day of illness)"/>
   <result pre="(Vero E6 cells) study suggested the combination of remdesivir and" exact="chloroquine" post="could be a choice. [19] This study indicates the"/>
   <result pre="or suggested for COVID-19 managements Antiviral Oseltamivir, remdesivir, α-interferon, lopinavir + ritonavir," exact="ribavirin" post="In practice Indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, redcivir, favipiravir"/>
   <result pre="saquinavir, lopinavir, carfilzomib, ritonavir, redcivir, favipiravir Suggestion Antibiotics Moxifloxacin, ceftriaxone," exact="azithromycin" post="In practice Steroids Methylprednisolone, Glucocorticoid In practice TCM Polygonum"/>
   <result pre="In practice TCM Polygonum cuspidatum, shandougen Suggestion Other Cyclosporine*, baricitinib**," exact="chloroquine" post="phosphate#, Cinnamyl amine## Suggestion According to the Chinese clinical"/>
   <result pre="trajectory of this novel CoV outbreak. Broad-spectrum antiviral like remdisivir," exact="chloroquine" post="phosphate, favipiravir, oseltamivir, α-interferon, lopinavir + ritonavir, ribavirin possibly present a"/>
   <result pre="Broad-spectrum antiviral like remdisivir, chloroquine phosphate, favipiravir, oseltamivir, α-interferon, lopinavir + ritonavir," exact="ribavirin" post="possibly present a light of hope on the novel"/>
   <result pre="2019 novel coronavirus-infected pneumonia in Wuhan, ChinaJAMA20192020e20158510.1001/jama.2020.1585 19.WangMCaoRZhangLet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7167494\results\search\drugs\results.xml">
   <result pre="years ago, and disease remission was achieved after treatment with" exact="leflunomide" post="(20 mg per day), hydroxychloroquine (200 mg per day),"/>
   <result pre="was achieved after treatment with leflunomide (20 mg per day)," exact="hydroxychloroquine" post="(200 mg per day), methylprednisolone (2 mg per day),"/>
   <result pre="leflunomide (20 mg per day), hydroxychloroquine (200 mg per day)," exact="methylprednisolone" post="(2 mg per day), meloxicam (7.5 mg per day),"/>
   <result pre="hydroxychloroquine (200 mg per day), methylprednisolone (2 mg per day)," exact="meloxicam" post="(7.5 mg per day), famotidine (20 mg per day),"/>
   <result pre="methylprednisolone (2 mg per day), meloxicam (7.5 mg per day)," exact="famotidine" post="(20 mg per day), and folic acid (1 mg"/>
   <result pre="(7.5 mg per day), famotidine (20 mg per day), and" exact="folic acid" post="(1 mg per day). The patient denied any smoking"/>
   <result pre="given twice per day (Fig. 2). Of the RA medications," exact="leflunomide" post="and methylprednisolone were discontinued; however, the patient continued receiving"/>
   <result pre="per day (Fig. 2). Of the RA medications, leflunomide and" exact="methylprednisolone" post="were discontinued; however, the patient continued receiving hydroxychloroquine, meloxicam,"/>
   <result pre="Syndrome (SARS) [14]. In the presented cases, while we discontinued" exact="leflunomide" post="and steroids to minimize the severity of COVID-19, we"/>
   <result pre="minimize the severity of COVID-19, we continued the administration of" exact="hydroxychloroquine" post="due to its possible antiviral effects [15], as well"/>
   <result pre="case reports showed that the combination of the protease inhibitors" exact="lopinavir" post="and ritonavir, which are widely used in individuals infected"/>
   <result pre="joints, soft tissue, and respiratory tract [9]. Abatacept, rituximab, and" exact="tocilizumab" post="have been associated with pneumonia and pyogenic bacterial infections,"/>
   <result pre="have been associated with pneumonia and pyogenic bacterial infections, while" exact="tofacitinib" post="with herpes zoster infection [9]. Meanwhile, selective cytokine blockade"/>
   <result pre="and monitoring of non-biologic disease-modifying anti-rheumatic drugsRheumatology (Oxford)201756225710.1093/rheumatology/kex38929029272 11.BlumCANigroNBrielMSchuetzPUllmerESuter-WidmerIet al.Adjunct" exact="prednisone" post="therapy for patients with community-acquired pneumonia: a multicentre, double-blind,"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7167497\results\search\drugs\results.xml">
   <result pre="stay in the ICU: a meta-analysisNutrients112019708 12MarikP.E.KhangooraV.RiveraR.HooperM.H.CatravasJ.Hydrocortisone, vitamin C, and" exact="thiamine" post="for the treatment of severe sepsis and septic shock:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7167571\results\search\drugs\results.xml">
   <result pre="on promising preliminary data against a wide range of viruses," exact="chloroquine" post="sulfate (CQ) – a drug used for a long"/>
   <result pre="BID for the treatment of SARS-CoV-2. The other choice was" exact="hydroxychloroquine" post="(HCQ) sulfate. First synthesized in 1946 as the hydroxyl"/>
   <result pre="patient was hospitalized in the COVID19 Unit and treatment with" exact="lopinavir" post="plus HCQ and oxygen support was stared. At 48"/>
   <result pre="and lower panels. Peripheral blood smears. Acute haemolysis induced by" exact="hydroxychloroquine" post="is characterized by marked anisopoikilocytosis with erythrocytes of different"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7169457\results\search\drugs\results.xml">
   <result pre="Distribution of Radiolabeled U18666A in the BrainEpilepsia19822325726810.1111/j.1528-1157.1982.tb06190.x7084137 27.TakanoT.AkiyamaM.DokiT.HohdatsuT.Antiviral activity of" exact="itraconazole" post="against type I feline coronavirus infectionVet. Res.201950510.1186/s13567-019-0625-330658691 28.TakanoT.YamadaS.DokiT.HohdatsuT.Pathogenesis of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7169479\results\search\drugs\results.xml">
   <result pre="proteins, glycyrrhetate and glycyrrhizic acid are used in clinic for" exact="cisplatin" post="resistance reversal in hepatocellular carcinoma cells and reduction in"/>
   <result pre="copolymer.68 Another study has shown that silver nanoparticle�?based codelivery of" exact="oseltamivir" post="could remarkably inhibit the accumulation of ROS and activate"/>
   <result pre="cells, the expressions were downregulated in thioredoxin�?like protein 1 (TXNL1)," exact="nitric oxide" post="synthase (NOS3), and olfactomedin 4 (OLFM4), upregulated in cathepsin"/>
   <result pre="Nitric oxide (NO) regulates the heart by spatial confinement of" exact="nitric oxide" post="synthase (NOS) isoforms.73 NOS3, a dimeric enzyme, is the"/>
   <result pre="formazan crystals were dissolved in 150 µL per well of" exact="dimethyl sulfoxide" post="(DMSO) solution. After shaking on rocking shaker for 10"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7169894\results\search\drugs\results.xml">
   <result pre="2. This article focuses on the vaporization and delivery of" exact="hydroxychloroquine" post="and bryostatin (two compounds with antiviral activity), their bioactive"/>
   <result pre="of the bulk solvent mass. In a typical formulation, the" exact="hydroxychloroquine" post="or bryostatin extract was 2–4% of the bulk solvent"/>
   <result pre="3% of the solvent mass. Hydroxychloroquine can be replaced wth" exact="chloroquine" post="or Remdesivir in the evaporation experiment. In our experiments"/>
   <result pre="medicinal activity. In some of our vaporization experiments we replaced" exact="hydroxychloroquine" post="with bryostatin extracts and found the species with a"/>
   <result pre="rate, subjective effects and puff topographyDrug Alcohol Dependence188201819319929778773 3YazdanyJ.KimA.H.J.Use of" exact="hydroxychloroquine" post="and chloroquine during the COVID-19 pandemic: what every clinician"/>
   <result pre="effects and puff topographyDrug Alcohol Dependence188201819319929778773 3YazdanyJ.KimA.H.J.Use of hydroxychloroquine and" exact="chloroquine" post="during the COVID-19 pandemic: what every clinician should knowAnn."/>
   <result pre="with the respiratory systemFront. Physiol.9201885330038580 8KuG.Y.Phase II trial of sequential" exact="paclitaxel" post="and 1 h infusion of bryostatin-1 in patients with"/>
   <result pre="of a three-component complex that repurposes the front line antibiotic" exact="isoniazid" post="against Mycobacterium tuberculosisTuberculosis107201710.1016/j.tube.2017.08.011 22ManningT.A copper10-paclitaxel crystal: a medicinally active"/>
   <result pre="Chem. Lett.2320134453445823777781 24ManningT.Cell line studies and analytical measurements of three" exact="paclitaxel" post="complex variationsBioorg. Med. Chem. Lett.2720172793279928495086 25ManningT.J.Identifying bryostatins and potential"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7170385\results\search\drugs\results.xml">
   <result pre="pmid: 32228103 doi: 10.1080/14756366.2020.17432821743282 : Research Paper The selenium-containing drug" exact="ebselen" post="potently disrupts LEDGF/p75-HIV-1 integrase interaction by targeting LEDGF/p75 D.-W."/>
   <result pre="the interaction by binding to LEDGF/p75 and the ability of" exact="ebselen" post="to inhibit the interaction could be reversed by dithiothreitol"/>
   <result pre="could be reversed by dithiothreitol (DTT). BLI experiment showed that" exact="ebselen" post="probably formed selenium-sulphur bonds with reduced thiols in LEDGF/p75."/>
   <result pre="knowledge, we showed for the first time that small-molecule compound," exact="ebselen" post="inhibited LEDGF/p75-IN interaction by directly binding to LEDGF/p75. The"/>
   <result pre="there are four approved HIV-1 IN inhibitors, including raltegravir, elvitegravir," exact="dolutegravir" post="and bictegravir, which block the strand-transfer step by binding"/>
   <result pre="LEDGF/p75-IN interaction by screening compound libraries. In a previous study," exact="ebselen" post="was reported as HIV-1 capsid inhibitor, which inhibits the"/>
   <result pre="a half-maximal cytotoxic concentration (CC50) of 25.4 µM. In present study," exact="ebselen" post="was identified as ligand binding to the LEDGF/p75 and"/>
   <result pre="isolated targets (Table 2). Out of these compounds, we selected" exact="ebselen" post="(1), for further investigation of mode of action and/or"/>
   <result pre="investigated against infectious diseases (Table 3). Importantly, in most cases," exact="ebselen" post="was shown to be a covalent inhibitor of these"/>
   <result pre="designed experiments to study the binding mode of ebselen. If" exact="ebselen" post="functions by modifying reduced this in proteins, then adding"/>
   <result pre="adding compounds with reduced thiols should abrogate the ability of" exact="ebselen" post="to inhibit the interaction. To test the hypothesis, we"/>
   <result pre="hypothesis, we repeated the HTRF-based LEDGF/p75 IBD-IN interaction assay with" exact="ebselen" post="in the presence of 50 µM dithiothreitol (DTT). The inhibitory"/>
   <result pre="the presence of 50 µM dithiothreitol (DTT). The inhibitory effect of" exact="ebselen" post="was completely abolished in the presence of DTT (Figure"/>
   <result pre="the following experiment to determine which protein (IN or LEDGF/p75)" exact="ebselen" post="binds to. When IBD was pre-cubated with ebselen, there"/>
   <result pre="obvious signal change was observed when IN was pre-cubated with" exact="ebselen" post="(Figure 4(B)). These results suggested that ebselen probably disrupt"/>
   <result pre="was pre-cubated with ebselen (Figure 4(B)). These results suggested that" exact="ebselen" post="probably disrupt the interaction by binding to LEDGF/p75. Using"/>
   <result pre="Using biolayer interferometry (BLI) by Octet Red, we confirmed that" exact="ebselen" post="binds to LEDGF/p75 with a KD value of 13.3 nM"/>
   <result pre="LEDGF/p75 with a KD value of 13.3 nM (Figure 4(C)). If" exact="ebselen" post="is a covalent inhibitor, it should show apparent increasing"/>
   <result pre="show apparent increasing affinity over time36. The results showed that" exact="ebselen" post="displayed an increase in its affinity over 1 h, consistent"/>
   <result pre="covalent bond formation. (Figure 4(D)). All these data showed that" exact="ebselen" post="probably inhibited the LEDGF/p75-IN interaction by covalently modifying the"/>
   <result pre="in LEDGF/p75. Figure 4. Determination of the inhibition mode of" exact="ebselen" post="on LEDGF/p75-IN interaction. (A) The inhibition of ebselen on"/>
   <result pre="mode of ebselen on LEDGF/p75-IN interaction. (A) The inhibition of" exact="ebselen" post="on LEDGF/p75-IN interaction was abolished in the presence of"/>
   <result pre="LEDGF/p75-IN interaction by binding to LEDGF/p75. (C) Association/dissociation kinetics of" exact="ebselen" post="for LEDGF/p75 determined by Octet. (D) Time-dependent inhibition of"/>
   <result pre="triplicate; error bars show the mean ± SD. Table 3. Activity of" exact="ebselen" post="on targets from pathogen. Target IC50（µM） Covalent Reference Cryptosporidium"/>
   <result pre="Pseudomonas aeruginosa Diguanylate Cyclases 5 Yes Lieberman et al.55 However," exact="ebselen" post="seems to be a promiscuous compound. Data from PubChem"/>
   <result pre="to be a promiscuous compound. Data from PubChem reveals that" exact="ebselen" post="was found to be active in 193 out of"/>
   <result pre="these hits coming from confirmatory screens37. And the promiscuity of" exact="ebselen" post="may be partly attributed to its known ability of"/>
   <result pre="attributed to its known ability of modifying cysteine residues. If" exact="ebselen" post="really bind LEDGF/p75 by modifying reduced thiols, then similar"/>
   <result pre="interaction except for disulphiram (IC50 = 23.2 µM) (Figure 5). Obviously," exact="ebselen" post="is more potent PPI than other thiol-modifying compounds. Moreover,"/>
   <result pre="PPI than other thiol-modifying compounds. Moreover, BLI experiment indicated that" exact="ebselen" post="do not show obvious dissociation from LEDGF/p75 (Figure 4(C))."/>
   <result pre="LEDGF/p75 (Figure 4(C)). Taken together, as a highly active compound," exact="ebselen" post="probably formed selenium-sulphur bonds with reduced thiols in LEDGF/p75."/>
   <result pre="study, we showed for the first time that small-molecule compounds," exact="ebselen" post="inhibited LEDGF/p75-IN interaction by directly binding to LEDGF/p75. Although,"/>
   <result pre="directly binding to LEDGF/p75. Although, a previous research indicated that" exact="ebselen" post="inhibited replication of HIV-1 by targeting capsid39, the compound"/>
   <result pre="drug screening of three compound libraries. The research revealed that" exact="ebselen" post="disrupted the interaction by covalently binding to LEDGF/p75. This"/>
   <result pre="to chiral nonracemic tricyclic ring systems and the discovery of" exact="dolutegravir" post="(S/GSK1349572) and (S/GSK1265744). J Med Chem2013;56:5901–16.23845180 11TsiangM, JonesGS, GoldsmithJ,"/>
   <result pre="leukemia and HIV. Blood2014;124:3730–7.25305204 42LerouxF, BoscD, BeghynT, et al.Identification of" exact="ebselen" post="as a potent inhibitor of insulin degrading enzyme by"/>
   <result pre="discovery. ACS Chem Biol2016;11:2140–8.27219844 46EltahanR, GuoF, ZhangH, et al.Discovery of" exact="ebselen" post="as an inhibitor of Cryptosporidium parvum glucose-6-phosphate isomerase (CpGPI)"/>
   <result pre="Drugs Drug Resist2018;8:43–9.29414105 47GordhanHM, PatrickSL, SwasyMI, et al.Evaluation of substituted" exact="ebselen" post="derivatives as potential trypanocidal agents. Bioorg Med Chem Lett2017;27:537–41.28043795"/>
   <result pre="using the differential radial capillary action of ligand assay identifies" exact="ebselen" post="as an inhibitor of diguanylate cyclases. ACS Chem Biol2014;9:183–92.24134695"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7170387\results\search\drugs\results.xml">
   <result pre="formed by benzylisoquinolines coupled with the isoquinoline N-methyl group after" exact="phenol" post="oxidation (Wang et al. 2019). To date, 41 protoberberine"/>
   <result pre="the striatum/nucleus accumbens-arcuate nucleus-periaqueductal grey pathway through the blockade of" exact="dopamine" post="D2 receptors to regulate nociception. Purified or synthesized l-THP"/>
   <result pre="neuropathic pain, without causing tolerance. In vitro, RC exhibited prominent" exact="dopamine" post="receptor antagonistic properties. In dopamine D2 receptor knockout mice,"/>
   <result pre="In vitro, RC exhibited prominent dopamine receptor antagonistic properties. In" exact="dopamine" post="D2 receptor knockout mice, its antinociceptive effects were attenuated"/>
   <result pre="the central inhibitory transmitter, GABA, and increased the release of" exact="dopamine" post="in the amygdala. They found that injecting picrotoxin (3–4 mg/kg)"/>
   <result pre="in rats. Posture freeze was restrained and amygdaloidal release of" exact="dopamine" post="was increased in anesthetized rats. After pre-treatment with l-THP,"/>
   <result pre="add, l-THP could inhibit seizure by inhibiting the release of" exact="dopamine" post="in the amygdala. In another study, Lin et al."/>
   <result pre="Their results indicate that l-THP can inhibit the release of" exact="dopamine" post="from the amygdala at doses of 20–30 mg/kg, thereby preventing"/>
   <result pre="could significantly reduce anxiety and motor movements. In addition, 3 mg/kg" exact="flumazenil" post="did not completely antagonize the effects of THP. Effect"/>
   <result pre="western blotting (WB) were employed to analyze oxidative stress, inducible" exact="nitric oxide" post="synthase (iNOS), inflammation factors, glial fibrillary acidic protein (GFAP),"/>
   <result pre="anti-oxidation, anti-inflammation, and anti-apoptosis, learning and memory impairment induced by" exact="ketamine" post="in mice can be ameliorated. Cao et al. (2018)"/>
   <result pre="spatial memory impairment induced by low and high doses of" exact="methamphetamine" post="in mice. In earlier studies, Qu et al. (2016)"/>
   <result pre="place preference (CPP) in cocaine-induced mice by receptor binding, cyclic" exact="adenosine" post="monophosphate (cAMP), and GTPγS assays. The metabolites of l-ICP"/>
   <result pre="al. (2006) examined the detoxification effect of l-THP combined with" exact="methadone" post="on heroin. Sixty patients were randomly divided into the"/>
   <result pre="methadone on heroin. Sixty patients were randomly divided into the" exact="methadone" post="plus l-THP treatment group and methadone group. The results"/>
   <result pre="randomly divided into the methadone plus l-THP treatment group and" exact="methadone" post="group. The results showed that the combination group had"/>
   <result pre="group had a 96% success rate in detoxification, while the" exact="methadone" post="group had a 73% success rate in detoxification. Total"/>
   <result pre="methadone group had a 73% success rate in detoxification. Total" exact="methadone" post="use was also significantly reduced in the combination group."/>
   <result pre="decreased. Effect on the myocardium Min et al. (2001) used" exact="isoprenaline" post="(ISO) to create rat models of myocardial ischaemia necrosis"/>
   <result pre="of hypothalamic serotonin and norepinephrine, and increased release of hypothalamic" exact="dopamine" post="in rats. l-THP could induce hypotension and bradycardia by"/>
   <result pre="THP can improve the contractility of rat aorta induced by" exact="phenylephrine" post="(Phe), KCl and U46619. The relaxation effect of THP"/>
   <result pre="that DHC could inhibit platelet aggregation by binding to the" exact="adenosine" post="diphosphate (ADP) receptors, P2Y1 and P2Y12. To add, THB"/>
   <result pre="ulcer, and acetic ulcer in rats, but no effect on" exact="reserpine" post="ulcer. Xu et al. (2015) investigated the protective effects"/>
   <result pre="RC and l-THP could significantly reverse the abnormal decrease in" exact="dopamine" post="transmitter and abnormal increase in D2R in the stomach"/>
   <result pre="that DHC inhibited the elevation of mitochondrial membrane potential and" exact="adenosine" post="triphosphate (ATP) depletion in macrophages stimulated by lipopolysaccharide (LPS)."/>
   <result pre="MCF-7/ADR cancer cell lines, the IC50 values of Adriamycin and" exact="mitoxantrone" post="respectively decreased from 41 and 24.19 µg/mL to 12.6 and"/>
   <result pre="LinMT2001 DL-Tetrahydropalmatine may act through inhibition of amygdaloid release of" exact="dopamine" post="to inhibit an epileptic attack in rats. Neurosci Lett."/>
   <result pre="in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial" exact="nitric oxide" post="synthase phosphorylation. Circulation. 105(12):1497–1502.11914261 GeYC, WangKW2018New analogues of aporphine"/>
   <result pre="34:1917–1920. HuY, QiuYY, ZhongYN, HeHL2006Therapeutic effects of rotundine combined with" exact="methadone" post="in treatment of heroin dependence. Chin J Drug Abuse"/>
   <result pre="isolated from Corydalis yanhusuo and their binding affinities at the" exact="dopamine" post="D1 receptor. Molecules. 13(9):2303–2312.18830156 MantschJR, LiSJ, RisingerR, AwadS, KatzE,"/>
   <result pre="YeEM, LiuS, GongZH, YangHJ, YangZ2016l-Scoulerine attenuates behavioural changes induced by" exact="methamphetamine" post="in zebrafish and mice. Behav Brain Res. 298:97–104.26433144 MinQ,"/>
   <result pre="BaiYT, ShuSJ2001Protective effects of dl-tetrahydropalmatine on experimental myocardial necrosis by" exact="isoprenaline" post="in rat. Acta Chin Med Pharmacol. 4:40–45. MinQ, BaiYT,"/>
   <result pre="overload in rats. J Pharm Pharmacol. 59(8):1159–1165.17725860 WoodPB2008Role of central" exact="dopamine" post="in pain and analgesia. Expert Rev Neurother. 8(5):781–797.18457535 WoolfCJ2010What"/>
   <result pre="TuP, YuSY, LuoSY2015Effect of Corydalis yanhusuo and l-THP on gastrointestinal" exact="dopamine" post="system in morphine-dependent rats. J Chin Med Mater. 38:2568–2572."/>
   <result pre="and rewarding effects of cocaine in mice by acting on" exact="dopamine" post="receptors. Drug Alcohol Depend. 133(2):693–703.24080315 XuZT, ChenXP, FuS, BaoJL,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7170955\results\search\drugs\results.xml">
   <result pre="as indictors to test the anti-HBV effects of EGFR inhibitors" exact="erlotinib" post="and gefitinib. Erlotinib inhibited HBV replication with a half-maximal"/>
   <result pre="these EGFR inhibitors additionally reduced hepatitis B e antigen and" exact="erlotinib" post="also marginally affected the cccDNA reservoir in HBV-infected HepG2-NTCP"/>
   <result pre="future. Highlights •We test the anti-HBV potential of EGFR inhibitors" exact="erlotinib" post="and gefitinib in vitro. •Erlotinib inhibits HBV replication in"/>
   <result pre="•We test the anti-HBV potential of EGFR inhibitors erlotinib and" exact="gefitinib" post="in vitro. •Erlotinib inhibits HBV replication in clinically safe"/>
   <result pre="of rIFN-α by down-regulation of STAT3 phosphorylation [13]. In addition," exact="erlotinib" post="has been found to inhibit the activation of myofibroblastic"/>
   <result pre="models [14]. Since STAT3 is favorable for HBV replication [6]," exact="erlotinib" post="or EGFR inhibition may be of anti-HBV efficacy. Together"/>
   <result pre="expression vector pCDH-CMV-EF1-copGFP-T2A-Puro, infecting HepG2 cells and performing selection using" exact="puromycin" post="(Sigma-Aldrich Corporation, St. Louis, MO, USA). All cells were"/>
   <result pre="HepG2.2.15 and HepG2-NTCP cells, 380 μg/mL geneticin and 2 μg/mL" exact="puromycin" post="cells were added to the culture media, respectively. 2.2"/>
   <result pre="cells near confluent growth (&amp;gt;90%) were treated with 0–12.5 μM" exact="erlotinib" post="(ab141930, Abcam, Cambridge, UK) or 10 and 20 μM"/>
   <result pre="erlotinib (ab141930, Abcam, Cambridge, UK) or 10 and 20 μM" exact="gefitinib" post="(ab142052, Abcam) for 48 h. The media were replaced"/>
   <result pre="phosphorylation, HepG2.2.15 cells were treated with or without 10 μM" exact="erlotinib" post="for 1 h. To study the anti-HBV effects of"/>
   <result pre="before treating with or without 2.5 μM erlotinib, 10 μM" exact="gefitinib" post="or 30 nM ETV (Sigma-Aldrich Corporation) for 48 h"/>
   <result pre="reservoir, HepG2-NCTP cells were treated with or without 2.5 μM" exact="erlotinib" post="for up to 8 days. Erlotinib, gefitinib and ETV"/>
   <result pre="without 2.5 μM erlotinib for up to 8 days. Erlotinib," exact="gefitinib" post="and ETV were all dissolved in dimethylsulfoxide (DMSO). The"/>
   <result pre="HCC and some type of lung cancer for years. Recently," exact="erlotinib" post="has been found to act synergistically with IFN-α by"/>
   <result pre="importance of STAT3 to HBV replication [6], the influence of" exact="erlotinib" post="on HBV was investigated here. HepG2.2.15 is a commonly"/>
   <result pre="cells kept a viability of above 85% when exposed to" exact="erlotinib" post="at a concentration up to 12.5 μM for 48"/>
   <result pre="decreases in intracellular core-associated HBV DNA (Fig. 1C), implying that" exact="erlotinib" post="inhibits HBV replication rather than interferes with virion release."/>
   <result pre="rather than interferes with virion release. Next, we wonder whether" exact="erlotinib" post="cover the fatal shortage of current anti-HBV drugs (NAs)"/>
   <result pre="drugs (NAs) to inhibit viral antigen syntheses. Within 48 h," exact="erlotinib" post="at higher concentrations (2.5 and 12.5 μM) significantly decreased"/>
   <result pre="precore protein (HBeAg precursor) (Fig. 1F). These results showed that" exact="erlotinib" post="inhibited the antigen syntheses of HBV. Fig. 1 Erlotinib"/>
   <result pre="concentration (0.125%) of DMSO and different concentrations (0–12.5 μM) of" exact="erlotinib" post="for 48 h. Error bars indicate the SD for"/>
   <result pre="(A) HepG2.2.15 cells kept viability of 85% when exposed to" exact="erlotinib" post="up to 12.5 μM. Erlotinib inhibited (B) supernatant virions"/>
   <result pre="(E) HBeAg and (F) intracellular core protein were reduced by" exact="erlotinib" post="at higher concentrations (2.5 and 12.5 μM). 3.2 Erlotinib"/>
   <result pre="wondered whether STAT3 was involved in the inhibitory effect of" exact="erlotinib" post="on HBV replication. Compared to HepG2 cells, HepG2.2.15 cells"/>
   <result pre="of STAT3 to HBV replication [6,7], these results suggest that" exact="erlotinib" post="inhibits HBV replication by inhibition of STAT3 phosphorylation and"/>
   <result pre="concentration (0.125%) of DMSO and with or without 10 μM" exact="erlotinib" post="for 1 h. STAT3, p-STAT3 and SOCS3 were detected"/>
   <result pre="cells had much higher levels of STAT3 and p-STAT3 and" exact="erlotinib" post="inhibited STAT3 phosphorylation without affection on STAT3 level. (B)"/>
   <result pre="the transfected HBV cell model, HepG2.2.15. Next, we evaluate whether" exact="erlotinib" post="and another EGFR inhibitor (gefitinib) inhibit HBV replication in"/>
   <result pre="In order to understand the clinical prospect of EGFR inhibitors," exact="entecavir" post="(ETV), the commonest anti-HBV drug nowadays, is used as"/>
   <result pre="is used as positive control. Both EGFR inhibitors (2.5 μM" exact="erlotinib" post="and 10 μM gefitinib for 48 h) inhibited the"/>
   <result pre="control. Both EGFR inhibitors (2.5 μM erlotinib and 10 μM" exact="gefitinib" post="for 48 h) inhibited the supernatant virions (Fig. 3A)."/>
   <result pre="the lack of direct effect on the cccDNA [20]. Excitingly," exact="erlotinib" post="marginally reduced the intracellular level of the cccDNA though"/>
   <result pre="the intracellular level of the cccDNA though the effect of" exact="gefitinib" post="was not statistically significant (Fig. 3C). To some extent,"/>
   <result pre="was not statistically significant (Fig. 3C). To some extent, both" exact="erlotinib" post="and gefitinib demonstrated anti-HBV effects in HBV-infected HepG2-NTCP cells."/>
   <result pre="statistically significant (Fig. 3C). To some extent, both erlotinib and" exact="gefitinib" post="demonstrated anti-HBV effects in HBV-infected HepG2-NTCP cells. Erlotinib seemed"/>
   <result pre="gefitinib, which is in concordance with the stronger efficacy of" exact="erlotinib" post="on EGFR inhibition. Fig. 3 EGFR inhibitors show anti-HBV"/>
   <result pre="with HBV (2✕102 GEq/cells) for 6 days before treating with" exact="erlotinib" post="(ERL, 2.5 μM), gefitinib (GEF, 10 μM) or entecavir"/>
   <result pre="for 6 days before treating with erlotinib (ERL, 2.5 μM)," exact="gefitinib" post="(GEF, 10 μM) or entecavir (ETV, 30 nM) for"/>
   <result pre="with erlotinib (ERL, 2.5 μM), gefitinib (GEF, 10 μM) or" exact="entecavir" post="(ETV, 30 nM) for additional 48 h. The solvent"/>
   <result pre="performed in triplicate.*P &amp;lt; 0.05, **P &amp;lt; 0.01. (A) Erlotinib," exact="gefitinib" post="and entecavir all significantly inhibited the supernatant virions. (B)"/>
   <result pre="triplicate.*P &amp;lt; 0.05, **P &amp;lt; 0.01. (A) Erlotinib, gefitinib and" exact="entecavir" post="all significantly inhibited the supernatant virions. (B) Erlotinib and"/>
   <result pre="Erlotinib and gefitinib, but entecavir, inhibited supernatant HBeAg. (C) Only" exact="erlotinib" post="marginally reduced the level of intracellular HBV cccDNA. Prolonged"/>
   <result pre="reduced the level of intracellular HBV cccDNA. Prolonged treatment of" exact="erlotinib" post="(ERL, 2.5 μM) for 4 and 8 days, respectively,"/>
   <result pre="and 59.3%). 3.4 Prolonged treatment improves the anti-HBV efficacy of" exact="erlotinib" post="Although significantly reduced the supernatant virions, EGFR inhibitors at"/>
   <result pre="the cccDNA. For this reason, re-tests of the stronger inhibitor" exact="erlotinib" post="with prolonged treatments for 4 and 8 days were"/>
   <result pre="cell growth was firstly studied. Prolonged treatments with 2.5 μM" exact="erlotinib" post="for 4 and 8 days inhibited cell growth at"/>
   <result pre="cccDNA reservoir in HBV-infected HepG2-NTCP cells. Furthermore, prolonged treatment let" exact="erlotinib" post="obtain a comprehensive anti-HBV effect including inhibitions to viral"/>
   <result pre="down-regulates SOCS3 expression in mouse embryonic fibroblasts and EGFR inhibitor" exact="erlotinib" post="in hepatocytes unleashing SOCS3 expression that inhibits IFN-α-induced STAT3"/>
   <result pre="that inhibits IFN-α-induced STAT3 activity [13,23]. The cccDNA reduction by" exact="erlotinib" post="was accompanied with HBV replication and viral antigen synthesis"/>
   <result pre="with HBV replication and viral antigen synthesis inhibitions, suggesting that" exact="erlotinib" post="drains the cccDNA reservoir by limitation of the source."/>
   <result pre="no additional effect when used with the currently main drug" exact="sorafenib" post="[31]. One possible explanation for treatment failure could be"/>
   <result pre="is safety concerns in patients with advanced liver diseases. Indeed," exact="erlotinib" post="has shown hepatotoxicity [32]. Fortunately, the IC50 (1.05 μM)"/>
   <result pre="has shown hepatotoxicity [32]. Fortunately, the IC50 (1.05 μM) of" exact="erlotinib" post="to inhibit HBV replication is less than the plasma"/>
   <result pre="of the treated patients (150 mg, daily) and recently approved" exact="afatinib" post="is much safer. In recent, some reports announce that"/>
   <result pre="afatinib is much safer. In recent, some reports announce that" exact="erlotinib" post="or other EGFR inhibitors cause HBV reactivation in patients"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7171434\results\search\drugs\results.xml">
   <result pre="for many years to treat lupus and arthritis that is" exact="hydroxychloroquine" post="[3]. The logic behind application of azithriomycin is that"/>
   <result pre="evaluated. Similarly, more evidence is needed to show effectiveness of" exact="hydroxychloroquine" post="being an immunomodulatory drug as well as other antiviral"/>
   <result pre="CD147 as a target for COVID-19 treatment: Suggested effects of" exact="azithromycin" post="and stem cell engagement (this issue). 3.Broxmeyer, H. E.,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7171523\results\search\drugs\results.xml">
   <result pre="Review on the global epidemiological situation and the efficacy of" exact="chloroquine" post="and hydroxychloroquine for the treatment of COVID-19 SaqraneS.s.saqrane@usms.ma1∗El MhammediM.A.2[1)],"/>
   <result pre="the global epidemiological situation and the efficacy of chloroquine and" exact="hydroxychloroquine" post="for the treatment of COVID-19 SaqraneS.s.saqrane@usms.ma1∗El MhammediM.A.2[1)], [2)], ∗Corresponding"/>
   <result pre="tests are also being conducted to assess the efficacy of" exact="chloroquine" post="and hydroxychloroquine for the treatment of this epidemic, which"/>
   <result pre="also being conducted to assess the efficacy of chloroquine and" exact="hydroxychloroquine" post="for the treatment of this epidemic, which is considered"/>
   <result pre="modification as the epidemic progresses. Keywords Chloroquine coronavirus Covid-19 epidemic" exact="hydroxychloroquine" post="treatment Introduction In mid-December 2019, in the city of"/>
   <result pre="itself, the world epidemiological situation and the effectiveness of using" exact="chloroquine" post="and hydroxychloroquine in the treatment. Answers to these questions"/>
   <result pre="world epidemiological situation and the effectiveness of using chloroquine and" exact="hydroxychloroquine" post="in the treatment. Answers to these questions will be"/>
   <result pre="According to the US Centers for Disease Control and Prevention," exact="hydroxychloroquine" post="and chloroquine are oral prescription drugs that have been"/>
   <result pre="the US Centers for Disease Control and Prevention, hydroxychloroquine and" exact="chloroquine" post="are oral prescription drugs that have been used for"/>
   <result pre="Chloroquine has been used for malaria treatment and chemoprophylaxis, and" exact="hydroxychloroquine" post="is used for treatment of rheumatoid arthritis, systemic lupus"/>
   <result pre="have in-vitro activity against SARS-CoV, SARS-CoV-2, and other coronaviruses, with" exact="hydroxychloroquine" post="having relatively higher potency against SARS-CoV-2 [[7], [8], [9]]."/>
   <result pre="[6,10]. According to Colson et al., 2020 the activity of" exact="hydroxychloroquine" post="on viruses is probably the same as that of"/>
   <result pre="hydroxychloroquine on viruses is probably the same as that of" exact="chloroquine" post="since the mechanism of action of these two molecules"/>
   <result pre="mechanism of action of these two molecules is identical, and" exact="hydroxychloroquine" post="was prescribed for long periods, which would be therefore"/>
   <result pre="carried out by a Chinese group on the effect of" exact="chloroquine" post="in vitro, using Vero E6 cells infected with SARS-CoV-2"/>
   <result pre="multiplicity of infection (MOI) of 0.05. The study demonstrated that" exact="chloroquine" post="was very effective in reducing viral replication, with an"/>
   <result pre="tissues, including in the lungs [7]. The authors described that" exact="chloroquine" post="is known to block viral infection by increasing endosomal"/>
   <result pre="Beijing and Shanghai in particular) to measure the effectiveness of" exact="chloroquine" post="on treatment of pneumonia associated with Covid-19 [13]. In"/>
   <result pre="it was confirmed that the anti-viral and anti-inflammatory activities of" exact="chloroquine" post="may account for its potent efficacy in treating patients"/>
   <result pre="According to Chinese researchers, a treatment of 500 mg of" exact="chloroquine" post="per day for ten days would be sufficient. According"/>
   <result pre="According to Chinese researchers, a treatment of 500 mg of" exact="chloroquine" post="per day for ten days would be sufficient. Chinese"/>
   <result pre="so far on more than 100 patients have shown that" exact="chloroquine" post="phosphate was more effective than the treatment received by"/>
   <result pre="efficacy against the coronavirus. He considers that the use of" exact="chloroquine" post="is a preferred route according to him rather than"/>
   <result pre="diverge and critics on the effectiveness of its treatment with" exact="chloroquine" post="to treat patients with coronavirus, a second study was"/>
   <result pre="coronavirus [14]. The objective of this study is to defend" exact="chloroquine" post="and to prove the effectiveness of the protocol adopted"/>
   <result pre="the protocol adopted and the relevance of the combination of" exact="hydroxychloroquine" post="and azithromycin. According to this study [14], only one"/>
   <result pre="March, 2020 a new article demonstrated that the combination of" exact="hydroxychloroquine" post="and azithromycin has a synergistic effect in vitro on"/>
   <result pre="a new article demonstrated that the combination of hydroxychloroquine and" exact="azithromycin" post="has a synergistic effect in vitro on SARS-CoV-2 at"/>
   <result pre="scientific committee of the Ministry of Health decided to prescribe" exact="chloroquine" post="for all patients, and not only severe cases, with"/>
   <result pre="References 1https://www.pasteur.fr/fr/centre-medical/fiches-maladies/coronavirus-wuhan 2https://www.who.int/fr/emergencies/diseases/novel-coronavirus2019/advice-for-public/q-a-coronaviruses 3https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200402-sitrep-73-covid-19.pdf?sfvrsn=5ae25bc7_4 4http://www.euro.who.int/fr/health-topics/health-emergencies/coronavirus-covid 19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic 5https://www.lemonde.fr/afrique/article/2020/03/16/covid-19-le-tour-d-afrique-des mesures_6033295_3212.html 6SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against today's diseases?Lancet"/>
   <result pre="an old drug against today's diseases?Lancet Infect Dis3200372272714592603 7WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="emerged novel coronavirus (2019-nCoV) in vitroCell Res3032020 Mar26927132020029 8ColsonP.RolainJ.M.LagierJ.C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int J Antimicrob Agents2020"/>
   <result pre="Vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020 Mar 910.1093/cid/ciaa237pii: ciaa237 10YanY.ZouZ.SunY.LiX.XuK.F.WeiY.JinN.JiangC.Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
   <result pre="Res23201330030223208422 11CortegianiA.IngogliaG.IppolitoM.A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J Crit Care2020 March10.1016/j.jcrc.2020.03.005 13GaoJ.TianZ.YangX.Breakthrough:"/>
   <result pre="chloroquine for the treatment of COVID-19J Crit Care2020 March10.1016/j.jcrc.2020.03.005 13GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7171712\results\search\drugs\results.xml">
   <result pre="KYangJ JViral calciomics: Interplays between Ca2+ and virusCell Calcium20094611719535138 31WilsonLGagePEwartGHexamethylene" exact="amiloride" post="blocks E protein ion channels and inhibits coronavirus replicationVirology200635329430616815524"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7172803\results\search\drugs\results.xml">
   <result pre="(Caly et al., 2020). Despite the authors' cautious conclusion that" exact="ivermectin" post="&quot;warrants further investigation for possible benefits in humans,&quot; the"/>
   <result pre="statements led to a warning by the US FDA, that" exact="ivermectin" post="in veterinary products should not be used for human"/>
   <result pre="Editor Recently Caly et al. reported in vitro activity of" exact="ivermectin" post="against SARS-CoV-2 following a single addition to Vero-hSLAM cells,"/>
   <result pre="to Vero-hSLAM cells, and suggest that these data &quot;demonstrate that" exact="ivermectin" post="is worthy of further consideration as a possible SARS-CoV-2"/>
   <result pre="genuine therapeutic options. Caly et al. bathed Vero-hSLAM cells with" exact="ivermectin" post="at a concentration of 5μM from 2 hours post-infection"/>
   <result pre="experiments. The authors noted 93–99.8% reduction in viral RNA for" exact="ivermectin" post="versus DMSO control at 24h in supernatant (released virions)"/>
   <result pre="72 hours. Additional experiments were conducted with serial dilutions of" exact="ivermectin" post="to establish the concentration-response profile, and the authors describe"/>
   <result pre="ivermectin to establish the concentration-response profile, and the authors describe" exact="ivermectin" post="as a potent inhibitor of SARS-CoV-2, with an IC50"/>
   <result pre="in vitro experiments to those that may be achieved with" exact="ivermectin" post="dosing in practice, in order to assist in prioritizing"/>
   <result pre="a standard high-fat meal. Smit et al. (2019) report that" exact="ivermectin" post="600 μg/kg administered orally resulted in a maximum median"/>
   <result pre="Similar to Yao et al. who proposed the potential for" exact="hydroxychloroquine" post="for treating COVID-19, (Yao et al., 2020) we applied"/>
   <result pre="al., 2020) we applied a physiologic-based pharmacokinetic (PBPK) model of" exact="ivermectin" post="using the Simcyp platform to explore the plasma and"/>
   <result pre="to the IC50 values against SARS-CoV-2 determined in vitro. The" exact="ivermectin" post="PBPK model was initially developed to facilitate drug development"/>
   <result pre="been independently verified. The predicted versus observed plasma profiles for" exact="ivermectin" post="across clinical studies in the Mectizan NDA were well"/>
   <result pre="well defined. Furthermore, the PBPK model was able to predict" exact="ivermectin" post="exposures in plasma, adipose and skin to within 1.3-fold"/>
   <result pre="simulated using the Sim-NEurCaucasion population. In the simulation, high dose" exact="ivermectin" post="(600 μg/kg) was administered orally, daily for 3 days"/>
   <result pre="in Fig. 1. Fig. 1 Simulated mean concentration-time profile of" exact="ivermectin" post="in plasma (black line) and lung tissue (blue line)"/>
   <result pre="and lung tissue simulated Cmax respectively, following a high dose" exact="ivermectin" post="regimen of 600 μg/kg dose daily for 3 days."/>
   <result pre="Caly et al. cite the importance of regulatory approval of" exact="ivermectin" post="as a key part of the rationale for further"/>
   <result pre="infected with Onchocerca volvulusEur. J. Clin. Pharmacol.50519964074108839664 CalyL.The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntivir. Res.202010.1016/j.antiviral.2020.104787 CrumpA.OmuraS.Ivermectin,"/>
   <result pre="Sci.87220111328 GuzzoC.A.Safety, tolerability, and pharmacokinetics of escalating high doses of" exact="ivermectin" post="in healthy adult subjectsJ. Clin. Pharmacol.421020021122113312362927 MerckMectizan NDA 0507421996"/>
   <result pre="Clin. Pharmacol.421020021122113312362927 MerckMectizan NDA 0507421996 MerckStromectol USPIhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050742s026lbl.pdf2009 SmitM.R.Pharmacokinetics-pharmacodynamics of high-dose" exact="ivermectin" post="with dihydroartemisinin-piperaquine on mosquitocidal activity and QT-prolongation (IVERMAL)Clin. Pharmacol."/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="Caly et al. (2020) based on their data showing that" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitro. However, this"/>
   <result pre="2019). As we previously showed (Pimenta et al., 2010) that" exact="ivermectin" post="is a nonselective inhibitor of three important mammalian P-type"/>
   <result pre="result, a phase 1 study is absolutely needed before using" exact="ivermectin" post="since a recent meta-analysis concluded that there are not"/>
   <result pre="of mammalian P-type ATPasesNaunyn-Schmied Arch. Pharmacol.3812010147152 SmitM.R.OchomoE.O.WaterhouseD.KwambaiT.K.Abong'oB.O.BousemaT.Pharmacokinetics-pharmacodynamics of high dose" exact="ivermectin" post="with Dihydroartemisinin-piperaquine on mosquitocidal activity and QT-prolongation (IVERMAL)Clin. Pharmacol."/>
   <result pre="point out that published studies show that blood levels of" exact="ivermectin" post="achieved during standard therapy are much lower than the"/>
   <result pre="and Lima (2020) voices concern that if high concentrations of" exact="ivermectin" post="could be achieved, this would likely be toxic. These"/>
   <result pre="they do not address the reported mechanism of action of" exact="ivermectin" post="(Yang et al., 2020), and thereby fail to highlight"/>
   <result pre="further vitally important reason to be very cautious in considering" exact="ivermectin" post="as a therapeutic for viral infection in human patients."/>
   <result pre="administration of long-acting ivermectin, develop aerosol administration, and consider using" exact="ivermectin" post="in combination with other agents to enhance efficacy at"/>
   <result pre="important to urge great caution in approaching the use of" exact="ivermectin" post="in this simplistic way, precisely because ivermectin is a"/>
   <result pre="the use of ivermectin in this simplistic way, precisely because" exact="ivermectin" post="is a HDA. Because it targets a host component,"/>
   <result pre="measured immune response is key to recovery. Clinical testing of" exact="ivermectin" post="at any dose in the fight against viral infection"/>
   <result pre="as possible. Finally, it is critically important to remember that" exact="ivermectin" post="as an antiviral is in a very early phase"/>
   <result pre="by the inhibitor IvermectinAntivir. Res.993201330130610.1016/j2013 Sep23769930 YangS.N.Y.AtkinsonS.C.WangC.LeeA.BogoyevitchM.A.BorgN.A.JansD.A.The broad spectrum antiviral" exact="ivermectin" post="targets the host nuclear transport importin α/β1 heterodimerAntiviral Res.220201047602020"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7172861\results\search\drugs\results.xml">
   <result pre="and adults [[1], [2], [3], [4]]. The antiviral activities of" exact="ascorbic acid" post="was known and it was published almost 80 years"/>
   <result pre="were involved in work on poliomyelitis. Moreover, the use of" exact="ascorbic acid" post="as a medicinally crucial agent against various diseases was"/>
   <result pre="Vit-C deficiency [39]. A review suggested that a high-dose of" exact="ascorbic acid" post="can enhance host resistance. This study also identified the"/>
   <result pre="enhance host resistance. This study also identified the use of" exact="ascorbic acid" post="in cancer therapy [40]. In general, Vit-C is synthesized"/>
   <result pre="humans lack the enzyme l-gulonolactone oxidase which is required for" exact="ascorbic acid" post="synthesis. On this basis, humans need Vit-C through food"/>
   <result pre="50 cancer patients who were taken a high dose of" exact="ascorbic acid" post="[41]. Conventional therapies were applied to these patients, but"/>
   <result pre="successful. On this basis, these patients were recommended to take" exact="ascorbic acid." post="Different doses and schedules were used. For example, some"/>
   <result pre="schedules were used. For example, some patients were given IV" exact="ascorbic acid" post="(10 g/day for 10 successive days), a few were"/>
   <result pre="higher dose amounts, and some were chosen to give oral" exact="ascorbic acid" post="(10 g/day) or a combination of both. A wide"/>
   <result pre="study prevented making any conclusion on the health benefits of" exact="ascorbic acid" post="treatment. From a limited study published in 1975, it"/>
   <result pre="reticulum cell sarcoma exhibited improvement due to the treatment with" exact="ascorbic acid." post="A reduction of the daily dose of ascorbic acid"/>
   <result pre="with ascorbic acid. A reduction of the daily dose of" exact="ascorbic acid" post="was not helpful since symptoms of the disease appeared."/>
   <result pre="the same patient was given a higher initial dose of" exact="ascorbic acid." post="A larger study of terminal cancer patients treated with"/>
   <result pre="efficiency of dual drug therapy by combining IV ascorbate with" exact="gemcitabine" post="and erlotinib in stage IV pancreatic cancer patients. Fourteen"/>
   <result pre="dual drug therapy by combining IV ascorbate with gemcitabine and" exact="erlotinib" post="in stage IV pancreatic cancer patients. Fourteen subjects were"/>
   <result pre="subjects were evaluated in this study. The patients received IV" exact="gemcitabine" post="(1000 mg for 30 min, once a week for"/>
   <result pre="for 30 min, once a week for 7 weeks), oral" exact="erlotinib" post="(100 mg daily for 8 weeks), and IV ascorbate"/>
   <result pre="week for 8 weeks). No adverse effects were observed for" exact="ascorbic acid" post="treatment. Five subjects received fewer than 18 of the"/>
   <result pre="I clinical investigation studied the effects of combining ascorbate with" exact="gemcitabine" post="in the treatment of stage IV pancreatic cancer. During"/>
   <result pre="IV pancreatic cancer. During each 4-week cycle, patients were given" exact="gemcitabine" post="weekly for 3 weeks and ascorbate for 4 weeks"/>
   <result pre="two systems. The first one was combined IV ascorbate with" exact="carboplatin" post="and the second one was ascorbate paclitaxel in stage"/>
   <result pre="IV ascorbate with carboplatin and the second one was ascorbate" exact="paclitaxel" post="in stage III/IV ovarian cancer. More than 24 patients"/>
   <result pre="well-known agents: oxaliplatin, leucovorin, and 5-fluorouracil or leucovorin, 5-fluorouracil and" exact="irinotecan" post="hydrochloride. This study was conducted on 36 patients with"/>
   <result pre="Another goal was to determine the phase II dose of" exact="ascorbic acid" post="with co-administration with mFOLFOX6 or FOLFIRI. Initially, all patients"/>
   <result pre="for 14 days with Vit-C infusions. Later, the concentration of" exact="ascorbic acid" post="was altered for the dose-escalation investigation. This study demonstrated"/>
   <result pre="from this investigation. However, a dose of 1.5 g/kg for" exact="ascorbic acid" post="was recommended for this phase II study. No adverse"/>
   <result pre="of this study is to determine the clinical power of" exact="ascorbic acid" post="against metastatic colorectal cancer in combination with mFOLFOX6 with"/>
   <result pre="metastatic colorectal cancer in combination with mFOLFOX6 with or without" exact="bevacizumab" post="[67]. Several studies were performed small doses of IV"/>
   <result pre="bevacizumab [67]. Several studies were performed small doses of IV" exact="ascorbic acid" post="treatment (1000 mg) with arsenic trioxide regimens, and mixed"/>
   <result pre="small doses of IV ascorbic acid treatment (1000 mg) with" exact="arsenic trioxide" post="regimens, and mixed results were obtained [[68], [69], [70]]."/>
   <result pre="[[68], [69], [70]]. Clinical investigations of ascorbate in combination with" exact="arsenic trioxide" post="were reported [36]. Patients with non-small cell lung carcinoma"/>
   <result pre="clinical trials are focused to identify the efficiency of high-dose" exact="ascorbic acid" post="combined with common anticancer molecules. These studies with ascorbate"/>
   <result pre="cancer therapy under radiation therapy and in the presence of" exact="carboplatin" post="and paclitaxel; metastatic pancreatic adenocarcinoma in the presence of"/>
   <result pre="carboplatin and paclitaxel; metastatic pancreatic adenocarcinoma in the presence of" exact="gemcitabine" post="and nab-paclitaxel; pancreatic adenocarcinoma in the presence of gemcitabine"/>
   <result pre="of gemcitabine and nab-paclitaxel; pancreatic adenocarcinoma in the presence of" exact="gemcitabine" post="and radiation therapy, and glioblastoma in the presence of"/>
   <result pre="gemcitabine and radiation therapy, and glioblastoma in the presence of" exact="temozolomide" post="and radiation therapy. Another phase IB/II trial is investigating"/>
   <result pre="radiation therapy against soft tissue sarcoma. Numerous studies used IV" exact="ascorbic acid" post="at a fixed dose of 1000 mg with various"/>
   <result pre="a fixed dose of 1000 mg with various amounts of" exact="arsenic trioxide" post="as anticancer therapy. It was expected that the pro-oxidant"/>
   <result pre="therapy. It was expected that the pro-oxidant character of IV" exact="ascorbic acid" post="can improve the effects of arsenic trioxide by a"/>
   <result pre="character of IV ascorbic acid can improve the effects of" exact="arsenic trioxide" post="by a sensitization process of the malignant cells to"/>
   <result pre="[77]. Since these trials were not placebo-controlled, the role of" exact="ascorbic acid" post="to the results is unclear. Intravenous (IV) high-dose ascorbic"/>
   <result pre="ascorbic acid to the results is unclear. Intravenous (IV) high-dose" exact="ascorbic acid" post="was well-tolerated in clinical trials [46], [78], [74], [71],"/>
   <result pre="[46], [78], [74], [71], [73], [64]. It was speculated that" exact="ascorbic acid" post="may accelerate renal failure in patients with preexisting renal"/>
   <result pre="investigation examined the feasibility of using high-dose IV ascorbate and" exact="gemcitabine" post="in stage IV pancreatic cancer patients. It was important"/>
   <result pre="alter the mechanism of the drug. For example, ascorbate with" exact="bortezomib" post="altered the action of the medicine as a proteasome"/>
   <result pre="of hypovitaminosis C in malnourished patients. A combination of hydrocortisone," exact="ascorbic acid," post="and thiamine (HAT therapy) worked well in the treatment"/>
   <result pre="in malnourished patients. A combination of hydrocortisone, ascorbic acid, and" exact="thiamine" post="(HAT therapy) worked well in the treatment of patients"/>
   <result pre="cold [82] and other health disorders was questioned [83,84]. The" exact="ascorbic acid" post="therapy for acute inflammatory disorders was based upon numerous"/>
   <result pre="found that a very high-dose of one sodium salt of" exact="ascorbic acid" post="(90 mM) kills Candida albicans in-vitro through an iron-catalyzed"/>
   <result pre="also accelerated [[95], [96], [97]]. The rate-determining last step of" exact="ascorbic acid" post="biosynthesis in animals is l-Gulono-γ-lactone oxidase or the isomeric"/>
   <result pre="These results were corrected in Gulo (-/-) mice repleted with" exact="ascorbic acid" post="before viral exposure occurs. Most probably, an impaired phosphorylation"/>
   <result pre="the loss of cell-induced immunity with age. The concentration of" exact="ascorbic acid" post="in plasma is decreased in post-herpetic neuralgia patients compared"/>
   <result pre="experienced less pain. In a non-blinded RCT, the role of" exact="ascorbic acid" post="on acute herpetic pain and postherpetic neuralgia were evaluated"/>
   <result pre="evaluated [112]. Eighty-seven patients were given 5 g of IV" exact="ascorbic acid" post="on the first, third and fifth days or placebo."/>
   <result pre="people every year. Experimental studies demonstrate a beneficial effect of" exact="ascorbic acid" post="against influenza. Patients with respiratory disorders due to infection"/>
   <result pre="herpes, and other viral illnesses. A large dose of IV" exact="ascorbic acid" post="can be one treatment of choices for Covid19 pneumonia"/>
   <result pre="VC (2000 mg twice daily) [125]. The protective action of" exact="ascorbic acid" post="is shown in [126]. A high dose IV Vit-C"/>
   <result pre="its treatment with vitamin CSouth. Med. Surg.110219483618900646 11KlineA.B.EheartM.S.Variations in the" exact="ascorbic acid" post="requirements for saturation of nine normal young womenJ. Nutr.281944413"/>
   <result pre="sodium bicarbonate and of ammonium chloride on the amount of" exact="ascorbic acid" post="found in the urineJ. Nutr.121936215 18KlennerF.R.Significance of high daily"/>
   <result pre="in the urineJ. Nutr.121936215 18KlennerF.R.Significance of high daily intake of" exact="ascorbic acid" post="in preventive medicineJ. Int. Acad. Prev. Med.119744569 19KlennerF.R.Use of"/>
   <result pre="in laboratory animalsActa Med. Acad. Sci. Hungary2719702329 30GinterE.The effects of" exact="ascorbic acid" post="on cholesterolemia in healthy subjects with seasonal deficit of"/>
   <result pre="the preservation of disc integrityMed. Ann. DC331964614116704 35KyhosE.D.Large doses of" exact="ascorbic acid" post="in treatment of vitamin C deficienciesArch. Int. Med.751945407 36Cancer.govHigh-Dose"/>
   <result pre="Pediatr.764195916617113638066 40CameronE.PaulingL.The orthomolecular treatment of cancer. I. The role of" exact="ascorbic acid" post="in host resistanceChem. Biol. Interact.9419742732834609626 41CameronE.CampbellA.The orthomolecular treatment of"/>
   <result pre="41CameronE.CampbellA.The orthomolecular treatment of cancer. II. Clinical trial of high-dose" exact="ascorbic acid" post="supplements in advanced human cancerChem. Biol. Interact.9419742853154430016 42CameronE.PaulingL.Supplemental ascorbate"/>
   <result pre="intravenous useAnn. Intern. Med.1407200453353715068981 47HofferL.J.LevineM.AssoulineS.Phase I clinical trial of i.v." exact="ascorbic acid" post="in advanced malignancyAnn. Oncol.191120081969197418544557 48VerraxJ.CalderonP.B.Pharmacologic concentrations of ascorbate are"/>
   <result pre="haemolysis in G-6-PD deficiencyLancet33687201990944 52ReesD.C.KelseyH.RichardsJ.D.Acute haemolysis induced by high dose" exact="ascorbic acid" post="in glucose-6-phosphate dehydrogenase deficiencyBMJ306688119938418428490379 53BartonJ.C.McDonnellS.M.AdamsP.C.Management of hemochromatosis. Hemochromatosis management"/>
   <result pre="Hemochromatosis management working groupAnn. Intern. Med.1291119989329399867745 54WelshJ.L.WagnerB.A.van’t ErveT.J.Pharmacological ascorbate with" exact="gemcitabine" post="for the control of metastatic and node-positive pancreatic cancer"/>
   <result pre="endometrial carcinoma cellsAnticancer Drugs192200811512418176107 57PerroneG.HideshimaT.IkedaH.Ascorbic acid inhibits antitumor activity of" exact="bortezomib" post="in vivoLeukemia23920091679168619369963 58BannermanB.XuL.JonesM.Preclinical evaluation of the antitumor activity of"/>
   <result pre="bortezomib in vivoLeukemia23920091679168619369963 58BannermanB.XuL.JonesM.Preclinical evaluation of the antitumor activity of" exact="bortezomib" post="in combination with vitamin C or with epigallocatechin gallate,"/>
   <result pre="III. Reticulum cell sarcoma: double complete regression induced by high-dose" exact="ascorbic acid" post="therapyChem. Biol. Interact.11519753873931104207 61PadayattyS.J.RiordanH.D.HewittS.M.Intravenously administered vitamin C as cancer"/>
   <result pre="C administrationJ. Korean Med. Sci.221200771117297243 64MontiD.A.MitchellE.BazzanA.J.Phase I evaluation of intravenous" exact="ascorbic acid" post="in combination with gemcitabine and erlotinib in patients with"/>
   <result pre="64MontiD.A.MitchellE.BazzanA.J.Phase I evaluation of intravenous ascorbic acid in combination with" exact="gemcitabine" post="and erlotinib in patients with metastatic pancreatic cancerPLoS One712012e29794"/>
   <result pre="evaluation of intravenous ascorbic acid in combination with gemcitabine and" exact="erlotinib" post="in patients with metastatic pancreatic cancerPLoS One712012e29794 65MaY.ChapmanJ.LevineM.High-dose parenteral"/>
   <result pre="phase I-II clinical trialPLoS One1042015e0120228 67WangF.HeM.M.WangZ.X.Phase I study of high-dose" exact="ascorbic acid" post="with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal"/>
   <result pre="metastatic colorectal cancer or gastric cancerBMC Cancer191201946031096937 68QazilbashM.H.SalibaR.M.NietoY.ParikhG.PelosiniM.KhanF.B.JonesR.B.HosingC.MendozaF.WeberD.M.WangM.Arsenic trioxide with" exact="ascorbic acid" post="and high-dose melphalan: results of a phase II randomized"/>
   <result pre="trialBiol. Blood Marrow Transplant.141220081401140719041063 69BerensonJ.R.BocciaR.SiegelD.BozdechM.BessudoA.StadtmauerE.Talisman PomeroyJ.SteisR.FlamM.LutzkyJ.JilaniS.Efficacy and safety of melphalan," exact="arsenic trioxide" post="and ascorbic acid combination therapy in patients with relapsed"/>
   <result pre="Transplant.141220081401140719041063 69BerensonJ.R.BocciaR.SiegelD.BozdechM.BessudoA.StadtmauerE.Talisman PomeroyJ.SteisR.FlamM.LutzkyJ.JilaniS.Efficacy and safety of melphalan, arsenic trioxide and" exact="ascorbic acid" post="combination therapy in patients with relapsed or refractory multiple"/>
   <result pre="2 trial of a preparative regimen of bortezomib, high�?dose melphalan," exact="arsenic trioxide," post="and ascorbic acidCancer118920122507251521887685 71BerensonJ.R.MatousJ.SwiftR.A.A phase I/II study of arsenic"/>
   <result pre="relapsed or refractory multiple myelomaClin. Cancer Res.13620071762176817363530 72CampbellR.A.SanchezE.SteinbergJ.A.Antimyeloma effects of" exact="arsenic trioxide" post="are enhanced by melphalan, bortezomib and ascorbic acidBr. J."/>
   <result pre="Res.13620071762176817363530 72CampbellR.A.SanchezE.SteinbergJ.A.Antimyeloma effects of arsenic trioxide are enhanced by melphalan," exact="bortezomib" post="and ascorbic acidBr. J. Haematol.1384200746747817587338 73QazilbashM.H.SalibaR.M.NietoY.Arsenic trioxide with ascorbic"/>
   <result pre="melphalan, bortezomib and ascorbic acidBr. J. Haematol.1384200746747817587338 73QazilbashM.H.SalibaR.M.NietoY.Arsenic trioxide with" exact="ascorbic acid" post="and high-dose melphalan: results of a phase II randomized"/>
   <result pre="Transplant.141220081401140719041063 74Abou-JawdeR.M.ReedJ.KellyM.Efficacy and safety results with the combination therapy of" exact="arsenic trioxide," post="dexamethasone, and ascorbic acid in multiple myeloma patients: a"/>
   <result pre="results with the combination therapy of arsenic trioxide, dexamethasone, and" exact="ascorbic acid" post="in multiple myeloma patients: a phase 2 trialMed. Oncol.232200626327216720927"/>
   <result pre="a phase 2 trialMed. Oncol.232200626327216720927 75BerensonJ.R.BocciaR.SiegelD.Efficacy and safety of melphalan," exact="arsenic trioxide" post="and ascorbic acid combination therapy in patients with relapsed"/>
   <result pre="trialMed. Oncol.232200626327216720927 75BerensonJ.R.BocciaR.SiegelD.Efficacy and safety of melphalan, arsenic trioxide and" exact="ascorbic acid" post="combination therapy in patients with relapsed or refractory multiple"/>
   <result pre="of vitamin CExpert Rev. Anti. Ther.182202099101 81MarikP.E.KhangooraV.RiveraR.Hydrocortisone, vitamin C and" exact="thiamine" post="for the treatment of severe sepsis and septic shock:"/>
   <result pre="coldCochrane Database Syst. Rev.12013CD000980 83PaulingL.The significance of the evidence about" exact="ascorbic acid" post="and the common coldProc. Natl. Acad. Sci. U. S."/>
   <result pre="reaction: a biochemical perspectiveCrit. Care Resusc.20201817417930153778 87WhileL.A.FreemanC.Y.ForresterB.D.In vitro effect of" exact="ascorbic acid" post="on infectivity of herpesviruses and paramyxovirusesJ. Clin. Microbiol.2419865275313021808 88KleinM.The"/>
   <result pre="88KleinM.The mechanism of the virucidal action of ascorbic acidScience101194558758917739440 89MarikP.E.Hydrocortisone," exact="ascorbic acid" post="and thiamine (HAT therapy) for the treatment of sepsis."/>
   <result pre="the virucidal action of ascorbic acidScience101194558758917739440 89MarikP.E.Hydrocortisone, ascorbic acid and" exact="thiamine" post="(HAT therapy) for the treatment of sepsis. Focus on"/>
   <result pre="cytomegalovirus replication in human foreskin fibroblasts and endothelial cells by" exact="ascorbic acid" post="2-phosphateAntiviral Res.2719954054188540759 93CarrA.C.Vitamin C and immune functionNutrients920171211 94MayJ.M.HarrisonF.E.Role of"/>
   <result pre="Biol.13519811257010958 96DeyS.BishayiB.Killing of S. aureus in murine peritoneal macrophages by" exact="ascorbic acid" post="along with antibiotics chloramphenicol or ofloxacin: correlation with inflammationMicrob."/>
   <result pre="in murine peritoneal macrophages by ascorbic acid along with antibiotics" exact="chloramphenicol" post="or ofloxacin: correlation with inflammationMicrob. Pathog.115201823925029274459 97KimY.KimH.BaeS.Vitamin C is"/>
   <result pre="on A/FM/1/47(H1N1) virus-induced pneumonia in restraint-stressed miceBiomed Res. Int.20152015675149 100ValeroN.MosqueraJ.AlcocerS.Melatonin," exact="minocycline" post="and ascorbic acid reduce oxidative stress and viral titers"/>
   <result pre="virus-induced pneumonia in restraint-stressed miceBiomed Res. Int.20152015675149 100ValeroN.MosqueraJ.AlcocerS.Melatonin, minocycline and" exact="ascorbic acid" post="reduce oxidative stress and viral titers and increase survival"/>
   <result pre="and influenza: a case reportJ. Orthomol. Med.3332018isom.ca/article/high-dose-vitamin-c-influenza-case-report/ 126ZarubaevaV.V.SlitaaA.V.LavrentyevaaI.N.SmirnovbV.S.Protective activity of" exact="ascorbic acid" post="at influenza infectionRuss. J. Infect. Immun.742017319326 127LevyT.E.Primal Panacea2012MedFox PublishingHenderson,"/>
   <result pre="stay in the ICU: a meta-analysisNutrients1142019 129MarikP.E.KhangooraV.RiveraR.HooperM.H.CatravasJ.Hydrocortisone, vitamin C, and" exact="thiamine" post="for the treatment of severe sepsis and septic shock:"/>
   <result pre="genes related to iron metabolismOncotarget820176376639828031527 135ShenoyN.Upregulation of TET activity with" exact="ascorbic acid" post="induces epigenetic modulation of lymphoma cellsBlood Cancer J.72017e58728731456 136XiaJ.Multiple"/>
   <result pre="cancer cells with GLUT1 overexpression and enhances the efficacy of" exact="oxaliplatin" post="through redox modulationTheranostics820181312132629507622 138QuinnJ.Effect of high-dose vitamin C infusion"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7173023\results\search\drugs\results.xml">
   <result pre="the human immunodeficiency virus (HIV) drug lopinavir/ritonavir, the antimalarial drugs" exact="chloroquine" post="and hydroxychloroquine, and remdesivir, an inhibitor of RNA polymerase"/>
   <result pre="was observed beyond standard care.30 While a recent trial using" exact="hydroxychloroquine" post="was more promising and showed that treatment is significantly"/>
   <result pre="clinical efficacy of the antiviral drugs remdesivir, lopinavir/ritonavir (+/−interferon), and" exact="hydroxychloroquine" post="(NCT04315948). DISCLOSURES Name: Stephan Ludwig, PhD. Contribution: This author"/>
   <result pre="2020 March 18 [Epub ahead of print]. 31.GautretPLagierJCParolaPet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7173238\results\search\drugs\results.xml">
   <result pre="HIV-1 (Clouser et al., 2010)HIV-1 – synergy in combination with" exact="gemcitabine" post="(Clouser et al., 2010)HIV-1 – synergy in combination with"/>
   <result pre="(2010); (Clouser et al., 2012)HIV-1 – synergy in combination with" exact="decitabine" post="(Clouser et al., 2010)MuLV (Clouser et al., 2012)HIV-2 (Beach"/>
   <result pre="et al., 2015; Zhang et al., 2017)Enteroviruses – synergy with" exact="ribavirin" post="(Kang et al., 2015)Rhinoviruses (Song et al., 2017)HCV (Beran"/>
   <result pre="anti-inflammatory properties (Van Linthout et al., 2018) Tenofovir disoproxil Acyclic" exact="adenosine" post="nucleotide analogue HIV (2001)HBV (2008) Tenofovir alafenamide Acyclic adenosine"/>
   <result pre="Acyclic adenosine nucleotide analogue HIV (2001)HBV (2008) Tenofovir alafenamide Acyclic" exact="adenosine" post="nucleotide analogue HBV (2016)HIV (several combination, see Table 2)"/>
   <result pre="analogue HSV (1980) Metastatic colorectal cancer (2015) in combination with" exact="tipiracil" post="Mycoplasma pneumonia (Sun and Wang, 2013) Valaciclovir Acyclic guanosine"/>
   <result pre="Approved nucleos(t)ide inhibitors of HBV polymerase include lamivudine, adefovir, telbivudine," exact="entecavir" post="and tenofovir. Two of them, lamivudine and tenofovir, exhibit"/>
   <result pre="include lamivudine, adefovir, telbivudine, entecavir and tenofovir. Two of them," exact="lamivudine" post="and tenofovir, exhibit multi-target activity and are also approved"/>
   <result pre="of the pentose ring. Tenofovir is an acyclic analogue of" exact="adenosine" post="5′-monophosphate and is marketed in the form of two"/>
   <result pre="5′-monophosphate and is marketed in the form of two prodrugs:" exact="tenofovir" post="disoproxil (TDF, Viread) and tenofovir alafenamide (TAF, Vemlidy). The"/>
   <result pre="the form of two prodrugs: tenofovir disoproxil (TDF, Viread) and" exact="tenofovir" post="alafenamide (TAF, Vemlidy). The roles of the two prodrugs"/>
   <result pre="by De Clercq (De Clercq, 2018). The tendency to substitute" exact="tenofovir" post="disoproxil with tenofovir alafenamide in both anti-HIV and anti-HBV"/>
   <result pre="(De Clercq, 2018). The tendency to substitute tenofovir disoproxil with" exact="tenofovir" post="alafenamide in both anti-HIV and anti-HBV treatment has been"/>
   <result pre="have shown that this drug is significantly more effective than" exact="lamivudine" post="and less likely to cause resistance. Moreover, telbivudine has"/>
   <result pre="effective than lamivudine and less likely to cause resistance. Moreover," exact="telbivudine" post="has some pleiotropic immunomodulatory and anti-inflammatory properties (Rehermann and"/>
   <result pre="properties (Rehermann and Bertoletti, 2015). Recently, it was shown that" exact="telbivudine" post="confers endothelial-protective effects on B19V-infected endothelial cells and improves"/>
   <result pre="Clercq, 2018). One of the exceptions is the use of" exact="ribavirin" post="in combination with standard therapy to enhance the current"/>
   <result pre="positively affect HBV treatment. A study on anti-HBV treatment with" exact="ribavirin" post="and tenofovir, compared to tenofovir treatment alone, is currently"/>
   <result pre="study on anti-HBV treatment with ribavirin and tenofovir, compared to" exact="tenofovir" post="treatment alone, is currently in a phase 3 clinical"/>
   <result pre="target multiple stages of the HIV life cycle. Lamivudine and" exact="tenofovir" post="are among the most important drugs used in combination"/>
   <result pre="24 small-molecule combinations most frequently utilized as drug components, anti-HIV" exact="lamivudine" post="occurred 15 times, while tenofovir disoproxil occurred 9 times."/>
   <result pre="utilized as drug components, anti-HIV lamivudine occurred 15 times, while" exact="tenofovir" post="disoproxil occurred 9 times. Lamivudine and tenofovir have been"/>
   <result pre="15 times, while tenofovir disoproxil occurred 9 times. Lamivudine and" exact="tenofovir" post="have been combined with other NRTIs (e.g., abacavir, emtricitabine,"/>
   <result pre="Sciences, 2001 (tenofovir disoproxil fumarate)Truvada, Gilead Sciences, 2004 (emtricitabine +" exact="tenofovir" post="disoproxil fumarate)Atripla, Gilead Sciences, Bristol-Myers Squibb, 2006 (emtricitabine +"/>
   <result pre="tenofovir disoproxil fumarate)Atripla, Gilead Sciences, Bristol-Myers Squibb, 2006 (emtricitabine +" exact="efavirenz" post="+ tenofovir disoproxil fumarate)Complera, Gilead Sciences, 2011 (emtricitabine +"/>
   <result pre="fumarate)Atripla, Gilead Sciences, Bristol-Myers Squibb, 2006 (emtricitabine + efavirenz +" exact="tenofovir" post="disoproxil fumarate)Complera, Gilead Sciences, 2011 (emtricitabine + rilpivirine +"/>
   <result pre="efavirenz + tenofovir disoproxil fumarate)Complera, Gilead Sciences, 2011 (emtricitabine +" exact="rilpivirine" post="+ tenofovir disoproxil fumarate)Stribild, Gilead Sciences, 2012 (elvitegravir +"/>
   <result pre="tenofovir disoproxil fumarate)Complera, Gilead Sciences, 2011 (emtricitabine + rilpivirine +" exact="tenofovir" post="disoproxil fumarate)Stribild, Gilead Sciences, 2012 (elvitegravir + cobicistat +"/>
   <result pre="rilpivirine + tenofovir disoproxil fumarate)Stribild, Gilead Sciences, 2012 (elvitegravir +" exact="cobicistat" post="+ emtricitabine + tenofovir disoproxil fumarate)Delstrigo, Merck, 2018 (doravirine"/>
   <result pre="tenofovir disoproxil fumarate)Stribild, Gilead Sciences, 2012 (elvitegravir + cobicistat +" exact="emtricitabine" post="+ tenofovir disoproxil fumarate)Delstrigo, Merck, 2018 (doravirine + lamivudine"/>
   <result pre="fumarate)Stribild, Gilead Sciences, 2012 (elvitegravir + cobicistat + emtricitabine +" exact="tenofovir" post="disoproxil fumarate)Delstrigo, Merck, 2018 (doravirine + lamivudine +tenofovir disoproxil"/>
   <result pre="+ emtricitabine + tenofovir disoproxil fumarate)Delstrigo, Merck, 2018 (doravirine +" exact="lamivudine" post="+tenofovir disoproxil fumarate)Cimduo, Mylan Pharmaceuticals, 2018 (lamivudine + tenofovir"/>
   <result pre="+ lamivudine +tenofovir disoproxil fumarate)Cimduo, Mylan Pharmaceuticals, 2018 (lamivudine +" exact="tenofovir" post="disoproxil fumarate)Symfi Lo, Mylan Pharmaceuticals, 2018 (efavirenz + lamivudine"/>
   <result pre="+ tenofovir disoproxil fumarate)Symfi Lo, Mylan Pharmaceuticals, 2018 (efavirenz +" exact="lamivudine" post="+ tenofovir disoproxil fumarate) Tenofovir alafenamide fumarate (TAF) Vemlidy,"/>
   <result pre="disoproxil fumarate)Symfi Lo, Mylan Pharmaceuticals, 2018 (efavirenz + lamivudine +" exact="tenofovir" post="disoproxil fumarate) Tenofovir alafenamide fumarate (TAF) Vemlidy, Gilead, 2016"/>
   <result pre="(TAF) Vemlidy, Gilead, 2016 Genvoya, Gilead Sciences 2015 (elvitegravir +" exact="cobicistat" post="+ emtricitabine, + tenofovir alafenamide)Descovy, Gilead Sciences, 2016 (emtricitabine"/>
   <result pre="Genvoya, Gilead Sciences 2015 (elvitegravir + cobicistat + emtricitabine, +" exact="tenofovir" post="alafenamide)Descovy, Gilead Sciences, 2016 (emtricitabine + tenofovir alafenamide)Odefsey, Gilead"/>
   <result pre="+ emtricitabine, + tenofovir alafenamide)Descovy, Gilead Sciences, 2016 (emtricitabine +" exact="tenofovir" post="alafenamide)Odefsey, Gilead Sciences, 2016 (emtricitabine + rilpivirine + tenofovir"/>
   <result pre="2016 (emtricitabine + tenofovir alafenamide)Odefsey, Gilead Sciences, 2016 (emtricitabine +" exact="rilpivirine" post="+ tenofovir alafenamide)Symtuza, Janssen Therapeutics, 2018 (darunavir + cobicistat"/>
   <result pre="+ tenofovir alafenamide)Odefsey, Gilead Sciences, 2016 (emtricitabine + rilpivirine +" exact="tenofovir" post="alafenamide)Symtuza, Janssen Therapeutics, 2018 (darunavir + cobicistat + emtricitabine"/>
   <result pre="+ rilpivirine + tenofovir alafenamide)Symtuza, Janssen Therapeutics, 2018 (darunavir +" exact="cobicistat" post="+ emtricitabine + tenofovir alafenamide)Biktarvy, Gilead Sciences, 2018 (bictegravir"/>
   <result pre="+ tenofovir alafenamide)Symtuza, Janssen Therapeutics, 2018 (darunavir + cobicistat +" exact="emtricitabine" post="+ tenofovir alafenamide)Biktarvy, Gilead Sciences, 2018 (bictegravir + emtricitabine"/>
   <result pre="alafenamide)Symtuza, Janssen Therapeutics, 2018 (darunavir + cobicistat + emtricitabine +" exact="tenofovir" post="alafenamide)Biktarvy, Gilead Sciences, 2018 (bictegravir + emtricitabine + tenofovir"/>
   <result pre="+ emtricitabine + tenofovir alafenamide)Biktarvy, Gilead Sciences, 2018 (bictegravir +" exact="emtricitabine" post="+ tenofovir alafenamide) Lamivudine (3TC) Epivir, Glaxo Wellcome, 1998"/>
   <result pre="+ tenofovir alafenamide)Biktarvy, Gilead Sciences, 2018 (bictegravir + emtricitabine +" exact="tenofovir" post="alafenamide) Lamivudine (3TC) Epivir, Glaxo Wellcome, 1998 Combivir, ViiV"/>
   <result pre="Healthcare, 2000 (lamivudine + zidovudine)Trizivir, ViiV Healthcare, 2000 (abacavir +" exact="lamivudine" post="+ zidovudine)Epzicom, ViiV Healthcare, 2004 (abacavir + lamivudine)Triumeq, ViiV"/>
   <result pre="Healthcare, 2004 (abacavir + lamivudine)Triumeq, ViiV HealthCare, 2014 (abacavir +" exact="dolutegravir" post="+ lamivudine)Dutrebis, Merck, 2015 (lamivudine + raltegravir)Delstrigo, Merck, 2018"/>
   <result pre="lamivudine)Dutrebis, Merck, 2015 (lamivudine + raltegravir)Delstrigo, Merck, 2018 (doravirine +" exact="lamivudine" post="+tenofovir disoproxil fumarate)Cimduo, Mylan Pharmaceuticals, 2018 (lamivudine + tenofovir"/>
   <result pre="+ lamivudine +tenofovir disoproxil fumarate)Cimduo, Mylan Pharmaceuticals, 2018 (lamivudine +" exact="tenofovir" post="disoproxil fumarate)Symfi Lo, Mylan Pharmaceuticals, 2018 (efavirenz + lamivudine"/>
   <result pre="+ tenofovir disoproxil fumarate)Symfi Lo, Mylan Pharmaceuticals, 2018 (efavirenz +" exact="lamivudine" post="+ tenofovir disoproxil fumarate)Dovato, ViiV Healthcare, 2019 (dolutegravir +"/>
   <result pre="disoproxil fumarate)Symfi Lo, Mylan Pharmaceuticals, 2018 (efavirenz + lamivudine +" exact="tenofovir" post="disoproxil fumarate)Dovato, ViiV Healthcare, 2019 (dolutegravir + lamivudine) Fig."/>
   <result pre="Structures of nucleos(t)ide-based and non-nucleoside drugs used in combination with" exact="tenofovir" post="and lamivudine for the treatment of HIV infections. Abbreviations:"/>
   <result pre="nucleos(t)ide-based and non-nucleoside drugs used in combination with tenofovir and" exact="lamivudine" post="for the treatment of HIV infections. Abbreviations: NRTIs -"/>
   <result pre="One of the recently approved anti-HIV combinations, Biktarvy (bictegravir +" exact="emtricitabine" post="+ tenofovir alafenamide), is currently under phase 3 and"/>
   <result pre="the recently approved anti-HIV combinations, Biktarvy (bictegravir + emtricitabine +" exact="tenofovir" post="alafenamide), is currently under phase 3 and 4 clinical"/>
   <result pre="development of anti-HCV drugs. Treatments with pegylated interferon (PEG-IFN) and" exact="ribavirin" post="for HCV eradication have been replaced by the second"/>
   <result pre="the need for co-administration of INF. The high potency of" exact="sofosbuvir" post="is attributable, in part, to the first 5′-phosphate group,"/>
   <result pre="ZIKV RNA polymerases have very similar active sites, confirming that" exact="sofosbuvir" post="could also act on ZIKV-infected cells. It was also"/>
   <result pre="was also demonstrated via cellular assays and animal models that" exact="sofosbuvir" post="inhibits the replication of other flaviviruses, such as dengue"/>
   <result pre="bioavailability of some of the anti-herpesvirus drugs, such as acyclovir," exact="penciclovir" post="or ganciclovir, an amino acid esterification strategy is applied"/>
   <result pre="esterification strategy is applied to obtain compounds such as valaciclovir," exact="famciclovir" post="and valganciclovir, respectively. These &quot;prodrugs�? are rapidly converted into"/>
   <result pre="associated with its systemic use. The mechanism of action of" exact="idoxuridine" post="is not exactly defined, but the triphosphate inhibits viral"/>
   <result pre="both viral and cellular DNA. Currently, in the United States," exact="idoxuridine" post="is approved for only topical treatment of HSV keratitis,"/>
   <result pre="for only topical treatment of HSV keratitis, but in Europe," exact="idoxuridine" post="in DMSO is available for the treatment of herpes"/>
   <result pre="et al., 2010). The results of a comparison of brivudine," exact="famciclovir" post="and valaciclovir treatment in immunocompetent adult patients with herpes"/>
   <result pre="2010). The results of a comparison of brivudine, famciclovir and" exact="valaciclovir" post="treatment in immunocompetent adult patients with herpes zoster indicate"/>
   <result pre="of cancer cell lines. Compared to parent nucleoside, such as" exact="idoxuridine" post="or brivudine, which displayed only weak to moderate activity,"/>
   <result pre="in therapy for HSV-induced epithelial keratitis. After its conversion to" exact="trifluridine" post="monophosphate, it inhibits thymidylate synthetase, which is elevated in"/>
   <result pre="respect to thymidine triphosphate (Aoki, 2015). Trifluridine in combination with" exact="tipiracil" post="(Lonsurf) has been approved in Japan, the United States,"/>
   <result pre="colorectal cancer who were previously subjected to chemotherapy involving fluoropyrimidine," exact="oxaliplatin" post="and irinotecan (Burness and Duggan, 2016; Matsuoka et al.,"/>
   <result pre="who were previously subjected to chemotherapy involving fluoropyrimidine, oxaliplatin and" exact="irinotecan" post="(Burness and Duggan, 2016; Matsuoka et al., 2018). Phase"/>
   <result pre="tested as an antibacterial agent. Specifically, it was found that" exact="trifluridine" post="strongly inhibits Mycoplasma pneumoniae growth in vitro (Sun and"/>
   <result pre="acyclic guanosine analogues, namely, acyclovir, ganciclovir, valaciclovir, valganciclovir, penciclovir, and" exact="famciclovir" post="(Fig. 4). First, acyclovir (ACV, [9-(2-hydroxyethoxy)methyl)guanine]) was originally designed"/>
   <result pre="acyclovir (ACV, [9-(2-hydroxyethoxy)methyl)guanine]) was originally designed as an inhibitor of" exact="adenosine" post="deaminases, but in 1977, it was discovered to be"/>
   <result pre="specific enzymes (Weller et al., 1993). The oral bioavailability of" exact="valaciclovir" post="is much higher than that of acyclovir, reaching almost"/>
   <result pre="than that of acyclovir, reaching almost 50%. In clinical trials," exact="valaciclovir" post="has a similar antiviral activity and safety profile as"/>
   <result pre="the replicative function of the viral DNA polymerase. Unlike acyclovir," exact="penciclovir" post="is not considered a DNA chain terminator due to"/>
   <result pre="acyclic part of PCV, which allows DNA chain elongation. Incorporated" exact="penciclovir" post="probably distorts the DNA conformation and then induces the"/>
   <result pre="higher intracellular concentration compensate for the lower antiviral effect. Phosphorylated" exact="penciclovir" post="concentrations can be as much as 200-fold higher than"/>
   <result pre="acyclovir (Littler and Zhou, 2007; Kimberlin, 2018). The bioavailability of" exact="penciclovir" post="upon oral administration is poor, at approximately 5%; therefore,"/>
   <result pre="oral administration is poor, at approximately 5%; therefore, its prodrug" exact="famciclovir" post="(FCV, 6-deoxypenciclovir diacetate) was designed and approved for clinical"/>
   <result pre="mouse models have shown that the main advantage in using" exact="famciclovir" post="over using other drugs is its ability to prevent"/>
   <result pre="acyclic chain. Due to its highly efficient action against CMV," exact="ganciclovir" post="has been approved for use in the treatment of"/>
   <result pre="after oral administration (Jabs et al., 1986). For this reason," exact="ganciclovir" post="prodrugs have been explored. Valganciclovir (VGCV, 9-[(2-hydroxy-1-valyloxymethyl)ethoxymethyl]guanine), which was"/>
   <result pre="(over 60%). The addition of a valyl ester group to" exact="ganciclovir" post="makes it a good substrate of the two peptide"/>
   <result pre="its absorption. The ester linkage between the valyl group and" exact="ganciclovir" post="is easily hydrolysed by intestinal esterase and hepatic esterase"/>
   <result pre="et al., 2000). Vidarabine (VDR, 9-β-D-arabinofuranosyladenine) is an analogue of" exact="adenosine" post="isolated from Streptomyces antibioticus. Vidarabine, unlike previously discussed drugs,"/>
   <result pre="to generate an active metabolite. When phosphorylated by cellular enzymes," exact="vidarabine" post="is in the active triphosphate form. The lack of"/>
   <result pre="may also contribute to the antiviral and toxic effects of" exact="vidarabine" post="(Aoki, 2015; Theobald, 2016). Vidarabine was initially used as"/>
   <result pre="acyclovir-resistant herpesviruses. Due to its relative insolubility in aqueous media," exact="vidarabine" post="is mainly administered topically (Littler and Zhou, 2007). A"/>
   <result pre="Zhou, 2007). A few years ago, it was proposed that" exact="vidarabine" post="could be applied as a potent and selective inhibitor"/>
   <result pre="methylenecyclopropane nucleoside analogue structurally related to drugs such as acyclovir," exact="ganciclovir" post="and penciclovir. In vitro studies demonstrated its activity against"/>
   <result pre="tested in a phase 2 clinical trial in comparison with" exact="valaciclovir" post="for herpes zoster (NCT00900783) and in a phase 3"/>
   <result pre="and in a phase 3 clinical trial in comparison with" exact="valaciclovir" post="for the prevention of post-herpetic neuralgia (NCT02412917). Brincidofovir (CMX001),"/>
   <result pre="nelarabine, approved in 2005) and pyrimidine analogues (first approved in" exact="cytarabine" post="in 1969, gemcitabine in 1996, azacytidine in 2004, decitabine"/>
   <result pre="2005) and pyrimidine analogues (first approved in cytarabine in 1969," exact="gemcitabine" post="in 1996, azacytidine in 2004, decitabine in 2006, and"/>
   <result pre="in cytarabine in 1969, gemcitabine in 1996, azacytidine in 2004," exact="decitabine" post="in 2006, and floxuridine in 1970), which have had"/>
   <result pre="gemcitabine in 1996, azacytidine in 2004, decitabine in 2006, and" exact="floxuridine" post="in 1970), which have had important roles in several"/>
   <result pre="(Ianevski et al., 2018, 2019). Among them, the cytidine analogue" exact="gemcitabine" post="was reported to be 6th on the list of"/>
   <result pre="2019). Examples of such drugs include gemcitabine, zidovudine, 5-fluorouracil, floxuridine," exact="idoxuridine" post="and thiopurines. The application limitations of some nucleoside analogues"/>
   <result pre="replicating DNA (Cerqueira et al., 2007). Gemzar in combination with" exact="cisplatin" post="was approved in 1998 for the treatment of locally"/>
   <result pre="metastatic non-small cell lung cancer, and Gemzar in combination with" exact="paclitaxel" post="was approved as the first-line therapy for women battling"/>
   <result pre="cancer (at least 6 months after completion of platinum-based therapy)," exact="gemcitabine" post="is used in combination with carboplatin. Another study showed"/>
   <result pre="in combination with carboplatin. Another study showed that co-treatment with" exact="gemcitabine" post="and zidovudine re-sensitized gemcitabine-resistant pancreatic cancer by inhibiting the"/>
   <result pre="with carboplatin. Another study showed that co-treatment with gemcitabine and" exact="zidovudine" post="re-sensitized gemcitabine-resistant pancreatic cancer by inhibiting the key signalling"/>
   <result pre="phase 2 clinical trials have shown that combining brivudine with" exact="gemcitabine" post="or cisplatin enhanced their efficacy as a pancreatic cancer"/>
   <result pre="clinical trials have shown that combining brivudine with gemcitabine or" exact="cisplatin" post="enhanced their efficacy as a pancreatic cancer therapy (Heinrich"/>
   <result pre="been approved. Recently, experimental data on the antiviral activity of" exact="gemcitabine" post="have been widely reported (Shin et al., 2018; Ianevski"/>
   <result pre="et al., 2019). The broad range of viruses against which" exact="gemcitabine" post="has shown activity includes HIV-1 (Rawson et al., 2013;"/>
   <result pre="and FLUAV (Denisova et al., 2012). The synergistic effect of" exact="gemcitabine" post="combined with low doses of other nucleoside analogues was"/>
   <result pre="analogues was also reported. It is applied in combination with" exact="ribavirin" post="for the treatment of enteroviruses or with decitabine for"/>
   <result pre="combination with ribavirin for the treatment of enteroviruses or with" exact="decitabine" post="for the treatment of HIV (Kang et al., 2015;"/>
   <result pre="et al., 2015; Clouser et al., 2010). In most cases," exact="gemcitabine" post="inhibits viruses at low, non-cytotoxic concentrations (Denisova et al.,"/>
   <result pre="al., 2012; Kuivanen et al., 2017). Depending on the virus," exact="gemcitabine" post="was shown to be an inhibitor of viral replication,"/>
   <result pre="viral replication, proliferation, RNA and protein synthesis, or production. The" exact="gemcitabine" post="antiviral effect on enteroviruses was proposed to be based"/>
   <result pre="cellular DNA or RNA synthesis. It is also possible that" exact="gemcitabine" post="can block the RNA polymerase by binding to the"/>
   <result pre="nucleoside available (Song et al., 2017). As a cytidine analogue," exact="gemcitabine" post="was reported to inhibit the salvage pathway of the"/>
   <result pre="the salvage pathway of the pyrimidine biosynthesis. Additionally, treatment with" exact="gemcitabine" post="activates the expression of several IFN-stimulated genes (including CXCL10,"/>
   <result pre="phenomenon could in turn be overcome by the combination of" exact="gemcitabine" post="and gentamicin, which showed synergistic activity and reduced the"/>
   <result pre="silenced (Wolff et al., 2017). Experimental studies have shown that" exact="azacitidine" post="is a potent, broad-spectrum antiviral agent. The range of"/>
   <result pre="rapidly dividing cells by disrupting DNA synthesis. Similar to azacytidine," exact="decitabine" post="also induces immune responses and sensitizes tumours to checkpoint"/>
   <result pre="Additionally, it was shown that in muscle-invasive bladder cancer cells," exact="decitabine" post="treatment (at low non-cytotoxic doses) restored NOTCH1 expression and"/>
   <result pre="CK5 differentiation (Ramakrishnan et al., 2017). The antiviral activity of" exact="decitabine" post="has been shown mostly in HIV treatment. Similar to"/>
   <result pre="described synergistic effect of azacytidine with resveratrol, the combination of" exact="decitabine" post="and resveratrol significantly reduced the levels of HIV-1 reverse"/>
   <result pre="et al., 2016b). Another study indicated that the combination of" exact="gemcitabine" post="and decitabine at concentrations much lower than those used"/>
   <result pre="2016b). Another study indicated that the combination of gemcitabine and" exact="decitabine" post="at concentrations much lower than those used in cancer"/>
   <result pre="et al., 2014). Further study on the anti-HIV-1 activity of" exact="clofarabine" post="revealed its dual inhibitory function in virus replication. It"/>
   <result pre="revealed through an integrated network analysisbioRxiv 1–232019 Bullard-FeibelmanK.M.GoveroJ.ZhuZ.SalazarV.VeselinovicM.DiamondM.S.GeissB.J.The FDA-approved drug" exact="sofosbuvir" post="inhibits Zika virus infectionAntivir. Res.137201713414010.1016/j.antiviral.2016.11.02327902933 BurnessC.B.DugganS.T.Trifluridine/tipiracil: a review in"/>
   <result pre="beyondAntivir. Res.1552018768810.1016/j.antiviral.2018.05.00529758235 ClouserC.L.HoltzC.M.MullettM.CrankshawD.L.BriggsJ.E.O'SullivanM.G.PattersonS.E.ManskyL.M.Activity of a novel combined antiretroviral therapy of" exact="gemcitabine" post="and decitabine in a mouse model for HIV-1Antimicrob. Agents"/>
   <result pre="ClouserC.L.HoltzC.M.MullettM.CrankshawD.L.BriggsJ.E.O'SullivanM.G.PattersonS.E.ManskyL.M.Activity of a novel combined antiretroviral therapy of gemcitabine and" exact="decitabine" post="in a mouse model for HIV-1Antimicrob. Agents Chemother.5620121942194810.1128/aac.06161-1122271861 ClouserC.L.PattersonS.E.ManskyL.M.Exploiting"/>
   <result pre="over the past 50 yearsClin. Microbiol. Rev.29201669574710.1128/CMR.00102-15Address27281742 De ClercqE.Role of" exact="tenofovir" post="alafenamide (TAF) in the treatment and prophylaxis of HIV"/>
   <result pre="zosterBiochem. Pharmacol.6820042301231510.1016/j.bcp.2004.07.03915548377 De FreitasC.S.HigaL.M.SacramentoC.Q.FerreiraA.C.ReisP.A.DelvecchioR.MonteiroF.L.Barbosa-LimaG.James WestgarthH.VieiraY.R.MattosM.RochaN.HoelzL.V.B.LemeR.P.P.BastosM.M.RodriguesG.O.L.LopesC.E.M.Queiroz-JuniorC.M.LimaC.X.CostaV.V.TeixeiraM.M.BozzaF.A.BozzaP.T.BoechatN.TanuriA.SouzaT.M.L.Yellow fever virus is susceptible to" exact="sofosbuvir" post="both in vitro and in vivoPLoS Neglected Trop. Dis.132019e000707210.1371/journal.pntd.0007072"/>
   <result pre="and in vivoPLoS Neglected Trop. Dis.132019e000707210.1371/journal.pntd.0007072 DenisovaO.V.KakkolaL.FengL.StenmanJ.NagarajA.LampeJ.YadavB.AittokallioT.KaukinenP.AholaT.KuivanenS.VapalahtiO.KanteleA.TynellJ.JulkunenI.Kallio-KokkoH.PaavilainenH.HukkanenV.ElliottR.M.De BrabanderJ.K.SaelensX.KainovD.E.Obatoclax, saliphenylhalamide, and" exact="gemcitabine" post="inhibit influenza A virus infectionJ. Biol. Chem.2872012353243533210.1074/jbc.M112.39214222910914 DiamantopoulosP.T.MichaelM.BenopoulouO.BazanisE.TzeletasG.MeletisJ.VayopoulosG.ViniouN.A.Antiretroviral activity"/>
   <result pre="Gouveia PedrosaC.SouzaL.R.Q.LoiolaE.C.TrindadeP.VieiraY.R.Barbosa-LimaG.de Castro Faria NetoH.C.BoechatN.RehenS.K.BrüningK.BozzaF.A.BozzaP.T.SouzaT.M.L.Beyond members of the Flaviviridae family," exact="sofosbuvir" post="also inhibits chikungunya virus replicationAntimicrob. Agents Chemother.63201910.1128/AAC.01389-18e01389-18 FlorescuD.F.PergamS.A.NeelyM.N.QiuF.JohnstonC.WayS.S.SandeJ.LewinsohnD.A.Guzman-CottrillJ.A.GrahamM.L.PapanicolaouG.KurtzbergJ.RigdonJ.PainterW.Mommeja-MarinH.LanierR.AndersonM.van der"/>
   <result pre="Res. Clin. Oncol.13720111349136110.1007/s00432-011-1005-121833720 HertelL.W.BoderG.B.KroinJ.S.RinzelS.M.PooreG. aToddG.C.GrindeyG.B.Evaluation of the antitumor activity of" exact="gemcitabine" post="(2 ′ , 2 ′ evaluation of the antitumor"/>
   <result pre="and in a mouse modelAntivir. Res.1372017142210.1016/j.antiviral.2016.11.00327838352 KaminskasE.FarrellA.T.WangY.-ChSridharaR.PazdurR.FDA drug approval summary:" exact="azacitidine" post="(5-azacytidine, Vidaza) for injectable suspensionThe Oncologist10200517618210.1634/theoncologist.10-3-17615793220 KangH.KimC.KimD.E.SongJ.H.ChoiM.ChoiK.KangM.LeeK.KimH.S.ShinJ.S.KimJ.HanS.B.LeeM.Y.LeeS.U.LeeC.K.KimM.KoH.J.Van KuppeveldF.J.M.ChoS.Synergistic antiviral"/>
   <result pre="Vidaza) for injectable suspensionThe Oncologist10200517618210.1634/theoncologist.10-3-17615793220 KangH.KimC.KimD.E.SongJ.H.ChoiM.ChoiK.KangM.LeeK.KimH.S.ShinJ.S.KimJ.HanS.B.LeeM.Y.LeeS.U.LeeC.K.KimM.KoH.J.Van KuppeveldF.J.M.ChoS.Synergistic antiviral activity of" exact="gemcitabine" post="and ribavirin against enterovirusesAntivir. Res.124201511010.1016/j.antiviral.2015.10.01126526589 KimberlinD.W.Antiviral Agents. Principles and"/>
   <result pre="injectable suspensionThe Oncologist10200517618210.1634/theoncologist.10-3-17615793220 KangH.KimC.KimD.E.SongJ.H.ChoiM.ChoiK.KangM.LeeK.KimH.S.ShinJ.S.KimJ.HanS.B.LeeM.Y.LeeS.U.LeeC.K.KimM.KoH.J.Van KuppeveldF.J.M.ChoS.Synergistic antiviral activity of gemcitabine and" exact="ribavirin" post="against enterovirusesAntivir. Res.124201511010.1016/j.antiviral.2015.10.01126526589 KimberlinD.W.Antiviral Agents. Principles and Practice of"/>
   <result pre="Practice of Pediatric Infectious DiseasesFifth. ed2018 KuivanenS.BespalovM.M.NandaniaJ.IanevskiA.VelagapudiV.De BrabanderJ.K.KainovD.E.VapalahtiO.Obatoclax, saliphenylhalamide and" exact="gemcitabine" post="inhibit Zika virus infection in vitro and differentially affect"/>
   <result pre="NambaT.KodamaR.MoritomoS.HoshinoT.MizushimaT.Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to" exact="gemcitabine" post="by inhibition of the Akt-GSK3β-Snail pathwayCell Death Dis.6201511110.1038/cddis.2015.172 NikkeisA.F.PiérardG.E.Recognition"/>
   <result pre="hepatitis C virusJ. Med. Chem.5320107202721810.1021/jm100863x20845908 SongJ.H.KimS.R.HeoE.Y.LeeJ.Y.KimD. eunChoS.ChangS.Y.YoonB. IlSeongJ.KoH.J.Antiviral activity of" exact="gemcitabine" post="against human rhinovirus in vitro and in vivoAntivir. Res.145201761310.1016/j.antiviral.2017.07.00328705625"/>
   <result pre="inhibitors azacytidine and decitabineInt. J. Cancer123200881310.1002/ijc.2360718425818 SugawaraM.HuangW.FeiY.J.LeibachF.H.GanapathyV.GanapathyM.E.Transport of valganciclovir, a" exact="ganciclovir" post="prodrug, via peptide transporters PEPT1 and PEPT2J. Pharm. Sci.89200078178910.1002/(SICI)1520-6017(200006)89:6&amp;lt;781::AID-JPS10&amp;gt;3.0.CO;2-710824137"/>
   <result pre="anticancer and antiviral nucleoside and nucleobase analogsBMC Microbiol.13201318410.1186/1471-2180-13-18423919755 ThackrayA.M.FieldH.J.Famciclovir and" exact="valaciclovir" post="differ in the prevention of herpes simplex virus type"/>
   <result pre="Physiol. Cell Physiol.3052013H1H810.1152/ajpheart.00080.2013 WellerS.BlumM.R.DoucetteM.BurnetteT.CederbergD.M.MirandaP. DeSmileyM.L.Pharmacolunetics of the acvclovir pro- drug" exact="valaciclovir" post="after iscalati and multiple-dose adrninis tration normal volunteersClin. Pharmacol."/>
   <result pre="nucleoside scaffoldAntivir. Res.162201952110.1016/j.antiviral.2018.11.01630529089 ZhangZ.YangE.HuC.ChengH.ChenC.Y.HuangD.WangR.ZhaoY.RongL.VignuzziM.ShenH.ShenL.ChenZ.W.Cell-based high-throughput screening assay identifies 2′,2′- difluoro-2′-deoxycytidine" exact="gemcitabine" post="as a potential antipoliovirus agentACS Infect. Dis.32017455310.1021/acsinfecdis.6b0011627733043"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7173598\results\search\drugs\results.xml">
   <result pre="immunocompromised/AIDS patients). Oral, intravenous, intraocular/intravitreal implant ▪ Valganciclovir Valcyte® As for" exact="ganciclovir" post="As for ganciclovir Oral ▪ Foscarnet Foscavir® HSV-1, HSV-2, VZV,"/>
   <result pre="intravenous, intraocular/intravitreal implant ▪ Valganciclovir Valcyte® As for ganciclovir As for" exact="ganciclovir" post="Oral ▪ Foscarnet Foscavir® HSV-1, HSV-2, VZV, CMV, HIV CMV"/>
   <result pre="reactivation in stages of immunosuppressionTreatment of HCV in combination with" exact="ribavirin" post="SubcutaneousIntramuscularlyIntravenous ▪ Pegylated interferon alpha Peg-Intron®Pegasys® HBV, HCV, HPV, HHV"/>
   <result pre="drugs Oral ▪ Ritonavir Norvir® HIV 1 and 2 As for" exact="saquinavir" post="Oral ▪ Indinavir Crixivan® HIV 1 and 2 As for"/>
   <result pre="saquinavir Oral ▪ Indinavir Crixivan® HIV 1 and 2 As for" exact="saquinavir" post="Oral ▪ Nelfinavir Viracept® HIV 1 and 2 As for"/>
   <result pre="saquinavir Oral ▪ Nelfinavir Viracept® HIV 1 and 2 As for" exact="saquinavir" post="Oral ▪ Amprenavir Agenerase® HIV 1 and 2 As for"/>
   <result pre="saquinavir Oral ▪ Amprenavir Agenerase® HIV 1 and 2 As for" exact="saquinavir" post="Oral ▪ Lopinavir Kaletra® (combined with ritonavir) HIV 1 and"/>
   <result pre="Kaletra® (combined with ritonavir) HIV 1 and 2 As for" exact="saquinavir" post="Oral ▪ Atazanavir Reyataz® HIV 1 and 2 As for"/>
   <result pre="saquinavir Oral ▪ Atazanavir Reyataz® HIV 1 and 2 As for" exact="saquinavir" post="Oral CCR5 entry inhibitors ▪ Maraviroc Selzentry®/Celsentri® HIV-1 HIV-1 infection,"/>
   <result pre="famcyclovir TK (thymidine kinase) mutation(s) FoscarnetCidofovir HSV and VZV Foscarnet," exact="cidofovir" post="DNA polymerase mutation(s) Possibly acyclovir, if not multidrug resistant"/>
   <result pre="Cytomegalovirus (CMV) Gancyclovir UL 97 (phosphotransferase) mutation(s) FoscarnetCidofovir CMV Foscarnet," exact="cidofovir" post="UL 54/DNA polymerase mutation(s) Possibly gancyclovir, if not multidrug"/>
   <result pre="mutation(s) Possibly gancyclovir, if not multidrug resistant Influenza A Amantadine," exact="rimantadine" post="Mutation(s) in M2 protein channel Neuraminidase inhibitors (zanamivir, oseltamivir),"/>
   <result pre="rimantadine Mutation(s) in M2 protein channel Neuraminidase inhibitors (zanamivir, oseltamivir)," exact="ribavirin" post="Hepatitis B virus (HBV) Lamivudine/3TC Mutation(s) in the YMDD"/>
   <result pre="in the YMDD motif of HBV DNA polymerase Adefovir dipivoxil," exact="entecavir" post="HIV Nucleotide reverse transcriptase inhibitors (NRTIs) ↓ Incorporation of"/>
   <result pre="in DNA chain (e.g. M184V mutation that causes high level" exact="lamivudine" post="resistance)Removal of NRTI from DNA chain (e.g. thymidine analogue"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7174146\results\search\drugs\results.xml">
   <result pre="al. lanzaban la hipótesis de la posible utilidad de la" exact="cloroquina" post="e hidroxicloroquina en el tratamiento del SARS-CoV1, y que"/>
   <result pre="la hipótesis de la posible utilidad de la cloroquina e" exact="hidroxicloroquina" post="en el tratamiento del SARS-CoV1, y que impulsaba la"/>
   <result pre="inmune5, 7, la acción combinada antiviral e inmunomoduladora de la" exact="hidroxicloroquina" post="hace fisiopatológicamente atractivo su uso. El primer estudio que"/>
   <result pre="El primer estudio que se realizó sobre el uso de" exact="cloroquina" post="en la infección por coronavirus-19 tuvo lugar en China"/>
   <result pre="evaluar el efecto, midieron la EC50, la concentración mínima de" exact="cloroquina" post="necesaria para inhibir al 50% del virus, y la"/>
   <result pre="como se vio que ocurría en el caso de la" exact="cloroquina" post="y el remdesivir8. Ya que la cloroquina actúa impidiendo"/>
   <result pre="caso de la cloroquina y el remdesivir8. Ya que la" exact="cloroquina" post="actúa impidiendo la entrada del virus a las células,"/>
   <result pre="pautas de tratamiento que verificaron el potencial inhibitorio de la" exact="cloroquina" post="antes y después de producirse la infección de las"/>
   <result pre="infección ya establecida8. El que la concentración con que la" exact="cloroquina" post="lograba inhibir el 90% del patógeno, de 6,90 μM,"/>
   <result pre="en el propio artículo se aconsejaba el uso de la" exact="cloroquina" post="fosfato en pacientes con COVID-199, recomendación que se añade"/>
   <result pre="el virus. Este estudio reveló que la EC50 de la" exact="hidroxicloroquina" post="era menor que la de la cloroquina, tanto en"/>
   <result pre="como profiláctico, lo que traducía una mayor eficacia de la" exact="hidroxicloroquina" post="frente a su precursora. Asimismo, la eficacia era mayor"/>
   <result pre="57,1% de los pacientes que recibieron 200 mg diarios de" exact="hidroxicloroquina" post="sulfato durante 10 días, y al 100% de los"/>
   <result pre="y al 100% de los que recibieron la combinación de" exact="hidroxicloroquina" post="y azitromicina, esta última, a dosis de 500 mg"/>
   <result pre="la neumonía entre el grupo tratado con 400 mg/día de" exact="hidroxicloroquina" post="durante 5 días (80,6%) frente al grupo control (54,8%),"/>
   <result pre="tratamiento que se les ofrece. Además, el uso de la" exact="hidroxicloroquina" post="tiene el atractivo de su bajo precio con relación"/>
   <result pre="eficacia y seguridad de la administración de 400 mg de" exact="hidroxicloroquina" post="junto con los distintos tratamientos recomendados por el Plan"/>
   <result pre="las dosis a las que se pretende utilizar porque la" exact="cloroquina" post="y/o hidroxicloroquina se emplean a dosis elevadas en el"/>
   <result pre="a las que se pretende utilizar porque la cloroquina y/o" exact="hidroxicloroquina" post="se emplean a dosis elevadas en el ataque agudo"/>
   <result pre="Medicamento8, 12, 14. La evidencia para el uso concomitante de" exact="azitromicina" post="y cloroquina es más limitada. Aunque en un artículo"/>
   <result pre="14. La evidencia para el uso concomitante de azitromicina y" exact="cloroquina" post="es más limitada. Aunque en un artículo del año"/>
   <result pre="un reciente estudio sobre 84 pacientes con COVID-19 tratados con" exact="hidroxicloroquina" post="y azitromicina demuestra la prolongación del intervalo QTc desde"/>
   <result pre="estudio sobre 84 pacientes con COVID-19 tratados con hidroxicloroquina y" exact="azitromicina" post="demuestra la prolongación del intervalo QTc desde 435 ±"/>
   <result pre="estudio multinacional sobre el perfil de la seguridad de la" exact="hidroxicloroquina" post="sola y en combinación con azitromicina sobre más de"/>
   <result pre="la seguridad de la hidroxicloroquina sola y en combinación con" exact="azitromicina" post="sobre más de 130.000 pacientes con neumonía por COVID-19"/>
   <result pre="en que nos encontramos, la generalización del uso de la" exact="hidroxicloroquina" post="es inminente, en la medida que la disponibilidad del"/>
   <result pre="su administración. Conflicto de intereses Ninguno. References Bibliografía 1SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: An old drug against today's diseases?Lancet"/>
   <result pre="An old drug against today's diseases?Lancet Infect Dis.3200372272710.1016/S1473-3099(03)00806-514592603 2ColsonP.RolainJ.-M.LagierJ.-C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int J Antimicrob Agents.202010593210.1016/j.ijantimicag.2020.10593232145363"/>
   <result pre="J Antimicrob Agents.202010593210.1016/j.ijantimicag.2020.10593232145363 3DevauxC.A.RolainJ.M.ColsonP.RaoultD.New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: What to expect for COVID-19?Int J Antimicrob"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="7ShangL.ZhaoJ.HuY.DuR.CaoB.On the use of corticosteroids for 2019-nCoV pneumoniaLancet.395202068368410.1016/S0140-6736(20)30361-532122468 8WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="version 6). 2020:1-17. Disponible en: http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm 11MarmorM.F.KellnerU.LaiT.Y.Y.MellesR.B.MielerW.F.LumF.Recommendations on screening for" exact="chloroquine" post="and hydroxychloroquine retinopathy (2016 revision)Ophthalmology.12320161386139410.1016/j.ophtha.2016.01.05826992838 12Agencia Española de Medicamentos"/>
   <result pre="2020:1-17. Disponible en: http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm 11MarmorM.F.KellnerU.LaiT.Y.Y.MellesR.B.MielerW.F.LumF.Recommendations on screening for chloroquine and" exact="hydroxychloroquine" post="retinopathy (2016 revision)Ophthalmology.12320161386139410.1016/j.ophtha.2016.01.05826992838 12Agencia Española de Medicamentos y Productos"/>
   <result pre="Hidroxicloroquina Ratiopharm 200mg. Octubre 2011 1-11. doi: 10.1017/CBO9781107415324.004. 13GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="Antimicrob Agents.202010594910.1016/j.ijantimicag.2020.10594932205204 14GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.SevestreJ.Clinical and microbiological effect of a combination of" exact="hydroxychloroquine" post="and azithromycin in 80 COVID-19 patients with at least"/>
   <result pre="14GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.SevestreJ.Clinical and microbiological effect of a combination of hydroxychloroquine and" exact="azithromycin" post="in 80 COVID-19 patients with at least a six-day"/>
   <result pre="An observational studyTravel Med Infect Dis2020Disponible en: https://www.groupedeveillecovid.fr/blog/2020/03/28/clinical-and-microbiological-effect-of-a-combination-of-hydroxychloroquine-and-azithromycin-in-80-covid-19-patients-with-at-least-a-six-day-follow-up-an-observational-study/ 15ChenZ.HuJ.ZhangZ.Z.JiangS.HanS.YanD.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: Results of a randomized clinical"/>
   <result pre="Wuhan, China: A retrospective cohort studyLancet.39520201054106210.1016/s0140-6736(20)30566-332171076 17ChenJ.LiuD.LiuL.A pilot study of" exact="hydroxychloroquine" post="in treatment of patients with common coronavirus disease-19 (COVID-19)J"/>
   <result pre="(COVID-19)J Zhehiang Univ.492020Disponible en: http://www.zjujournals.com/med 18MahaseE.Covid-19: six million doses of" exact="hydroxychloroquine" post="donated to US despite lack of evidenceBMJ.3682020m116610.1136/bmj.m116632205321 19Centers for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7174859\results\search\drugs\results.xml">
   <result pre="specific management plan for DM in which premixed insulin and" exact="metformin" post="are the main components. Nondiabetic patients with acute HZ"/>
   <result pre="medication history included metoprolol, 100 mg, atorvastatin, 20 mg, and" exact="acetylsalicylic acid," post="100 mg daily. Over the following 10 days, he"/>
   <result pre="management. We initiated him on insulin Mixtard, 40 IU, and" exact="metformin" post="2,000 mg daily, with an urgent referral to the"/>
   <result pre="result in better healing of the lesions [9]. Valacyclovir or" exact="famciclovir" post="are preferred over acyclovir due to reduced dosing frequency"/>
   <result pre="inhibitors which appear to increase the risk of HZ, whereas" exact="metformin" post="and sulphonylureas did not [3, 14]. Further protection for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7175289\results\search\drugs\results.xml">
   <result pre="fetal calf serum, 100 U of penicillin, 100 µg of" exact="streptomycin" post="per mL in a 5% CO2 atmosphere at 37"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7175848\results\search\drugs\results.xml">
   <result pre="AAK1, adaptor-associated kinase 1; CQ, chloroquine; ER, endoplasmic reticulum; HCQ," exact="hydroxychloroquine" post="sulfate; IFNs, interferons; iNO, inhaled nitric oxide; JAK, janus"/>
   <result pre="ER, endoplasmic reticulum; HCQ, hydroxychloroquine sulfate; IFNs, interferons; iNO, inhaled" exact="nitric oxide;" post="JAK, janus kinase; LHQW, Lianhua Qingwen; rhACE2, recombinant human"/>
   <result pre="CQ, chloroquine; DC, dendritic cell; G-CSF, granulocyte-colony stimulating factor; HCQ," exact="hydroxychloroquine" post="sulfate; IFN-γ, interferon gamma; IL, interleukin; iNO, inhaled nitric"/>
   <result pre="HCQ, hydroxychloroquine sulfate; IFN-γ, interferon gamma; IL, interleukin; iNO, inhaled" exact="nitric oxide;" post="IP-10, interferon-inducible protein-10; IVIG, intravenous gamma globulin; LHQW, Lianhua"/>
   <result pre="human immunodeficiency virus; IFNs, interferons; IL-6, interleukin 6; iNO, inhaled" exact="nitric oxide;" post="IVIG, intravenous gammaglobulin; LHQW, Lianhua Qingwen; mAb, monoclonal antibody;"/>
   <result pre="therapy for HIV (Barragan and Podzamczer, 2008). Concomitant use of" exact="ritonavir" post="could increase the plasma half-life of lopinavir through cytochrome"/>
   <result pre="Concomitant use of ritonavir could increase the plasma half-life of" exact="lopinavir" post="through cytochrome P450 inhibition in the liver. During the"/>
   <result pre="(Chu et al., 2004a), and combination therapy of LPV-r and" exact="ribavirin" post="provided favorable results in treating patients with SARS (Fig."/>
   <result pre="beneficial or harmful for COVID-19 infected patients. 5 Chloroquine and" exact="hydroxychloroquine" post="Chloroquine (CQ), a drug widely used in treating malarial"/>
   <result pre="in COVID-19 patients and that its effect was reinforced by" exact="azithromycin" post="(Gautret et al., 2020). Although this study is an"/>
   <result pre="study using small sample size, the combination of HCQ and" exact="azithromycin" post="could be promising candidate for COVID-19 patients. In contrast,"/>
   <result pre="safe (Lane et al., 2020). However, combination of HCQ and" exact="azithromycin" post="may induce an increased risk of 30 day cardiovascular"/>
   <result pre="therefore be a valuable treatment option for COVID-19. 9 Inhaled" exact="nitric oxide" post="(iNO) Nitric oxide (NO) is a key endogenous molecule"/>
   <result pre="macaques (Haagmans et al., 2004). Combined treatment of IFN-α-2a and" exact="ribavirin" post="was shown to have antiviral effects on MERS-CoV (Falzarano"/>
   <result pre="Non-steroidal anti-inflammatory drugs (NSAIDs) The non-steroidal anti-inflammatory drugs (NSAIDs) including" exact="ibuprofen" post="have been widely used to treat fever or pain."/>
   <result pre="11, 2020, Fang et al. (2020) reported the hypothesis that" exact="ibuprofen" post="can increase the risk of developing severe and fatal"/>
   <result pre="increase the risk of developing severe and fatal COVID-19 since" exact="ibuprofen" post="is known to upregulate ACE2 receptors. However, there is"/>
   <result pre="upregulate ACE2 receptors. However, there is no evidence indicating that" exact="ibuprofen" post="worsens the clinical symptoms of COVID-19 infected patients (FitzGerald,"/>
   <result pre="is not aware of any evidence that NSAIDs such as" exact="ibuprofen" post="could worsen COVID-19. 16 Vaccine There is no specific"/>
   <result pre="vitro study by Australian researchers are notable. They found that" exact="ivermectin" post="(an anti-parasitic drug) could effectively block SARS-CoV-2 growth in"/>
   <result pre="of a promising potential treatment for COVID-19. CalyL.DruceJ.D.CattonM.G.JansD.A.WagstaffK.M.The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntiviral Res.1047872020 CaoB.WangY.WenD.LiuW.WangJ.FanG.RuanL.SongB.CaiY.WeiM.LiX.XiaJ.ChenN.XiangJ.YuT.BaiT.XieX.ZhangL.LiC.YuanY.ChenH.LiH.HuangH.TuS.GongF.LiuY.WeiY.DongC.ZhouF.GuX.XuJ.LiuZ.ZhangY.LiH.ShangL.WangK.LiK.ZhouX.DongX.QuZ.LuS.HuX.RuanS.LuoS.WuJ.PengL.ChengF.PanL.ZouJ.JiaC.WangJ.LiuX.WangS.WuX.GeQ.HeJ.ZhanH.QiuF.GuoL.HuangC.JakiT.HaydenF.G.HorbyP.W.ZhangD.WangC.A"/>
   <result pre="severe and moderate Coronavirus Disease 2019J. Clin Invest.2020137244 ChenL.LiuP.GaoH.SunB.ChaoD.WangF.ZhuY.HedenstiernaG.WangC.G.Inhalation of" exact="nitric oxide" post="in the treatment of severe acute respiratory syndrome: a"/>
   <result pre="drug advice for COVID-19Science36720021434 FowlerA.A.3rdSyedA.A.KnowlsonS.SculthorpeR.FarthingD.DeWildeC.FarthingC.A.LarusT.L.MartinE.BrophyD.F.GuptaS.FisherB.J.NatarajanR.Phase I safety trial of intravenous" exact="ascorbic acid" post="in patients with severe sepsisJ. Transl. Med.1220143224484547 FurutaY.GowenB.B.TakahashiK.ShirakiK.SmeeD.F.BarnardD.L.Favipiravir (T-705),"/>
   <result pre="B., Rolain, J.M., Brouqui, P., Raoult D., 2020. Hydrochloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="remdesivir for patients with severe COVID-19N. Engl. J. Med.202010.1056/NEHMoa2007016 GriffithsM.J.D.EvansT.W.Inhaled" exact="nitric oxide" post="therapy in adultsN. Eng. J. Med.353200526832695 GuanW.J.NiZ.Y.HuY.LiangW.H.OuC.Q.HeJ.X.LiuL.ShanH.LeiC.L.HuiD.DuB.LiL.J.ZengG.YuenK.Y.ChenR.C.TangC.L.WangT.ChenP.Y.XiangJ.LiS.Y.WangJ.L.LiangZ.J.PengY.X.WeiL.LiuY.HuY.H.PengP.WangJ.M.LiuJ.Y.ChenZ.LiG.ZhengZ.J.QiuS.Q.LuoJ.YeC.J.ZhuS.Y.ZhongN.S.Clinical Characteristics of"/>
   <result pre="China dealing with the 2019 novel coronavirusLancet Psychiatry72020e14 KarramT.AbbasiA.KeidarS.GolombE.HochbergI.WinaverJ.HoffmanA.AbassiZ.Effects of" exact="spironolactone" post="and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms"/>
   <result pre="with the 2019 novel coronavirusLancet Psychiatry72020e14 KarramT.AbbasiA.KeidarS.GolombE.HochbergI.WinaverJ.HoffmanA.AbassiZ.Effects of spironolactone and" exact="eprosartan" post="on cardiac remodeling and angiotensin-converting enzyme isoforms in rats"/>
   <result pre="KeyaertsE.VijgenL.ChenL.MaesP.HedenstiernaG.Van RanstM.Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a" exact="nitric oxide" post="donor compoundInt. J. Infect. Dis.8200422322615234326 KeyaertsE.VijgenL.MaesP.NeytsJ.Van RanstM.In vitro inhibition"/>
   <result pre="vaccines: Immunogenicity and rapid translational developmentEBioMedicine102743202010.1016/j.ebiom.2020.102743 KimU.J.WonE.J.KeeS.J.JungS.I.JangH.C.Combination therapy with lopinavir/ritonavir," exact="ribavirin" post="and interferon-α for middle east respiratory syndromeAntivir. Ther.21201645545926492219 KrasnodembskayaA.SamaraniG.SongY.ZhuoH.SuX.LeeJ.W.GuptaN.PetriniM.MatthayM.A.Human"/>
   <result pre="medical teams aiding in COVID-19 controlBrain Behav. Immun.202010.1016/j.bbi.2020.03.007 LimH.S.ImJ.S.ChoJ.Y.BaeK.S.KleinT.A.YeomJ.S.KimT.S.ChoiJ.S.JangI.J.ParkJ.W.Pharmacokinetics of" exact="hydroxychloroquine" post="and its clinical implications in chemoprophylaxis against malaria caused"/>
   <result pre="assessmentN. Engl. J. Med.382202069269431978293 NakanoK.SuzukiS.Stress-induced change in tissue levels of" exact="ascorbic acid" post="and histamine in ratsJ. Nutr.1141984160216086206215 National Health and Family"/>
   <result pre="diseaseNat. Rev. Immunol.18201813414728990587 ParkinJ.CohenB.An overview of the immune systemLancet35720011777178911403834 Pepke-ZabaJ.HigenbottamT.W.Dinh-XuanA.T.StoneD.WallworkJ.Inhaled" exact="nitric oxide" post="as a cause of selective pulmonary vasodilatation in pulmonary"/>
   <result pre="replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV)Virology3292004111715476870 SakkasL.I.Spotlight on" exact="tocilizumab" post="and its potential in the treatment of systemic sclerosisDrug"/>
   <result pre="of nitric oxide: inhibition of a viral proteaseImmunity101999212810023767 SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against today's diseases?"/>
   <result pre="airway epitheliaSci. Transl. Med.112019eaax586631645453 van den BorneB.E.DijkmansB.A.de RooijH.H.le CessieS.VerweijC.L.Chloroquine and" exact="hydroxychloroquine" post="equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma"/>
   <result pre="lymphocyte subset alteration in COVID-19 pneumoniaJ. Infect. Dis.202010.1093/infdis/jiaa150 WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="treatment of taste disordersRecent Pat. Food Nutr. Agric.52013445123305423 YanY.ZouZ.SunY.LiX.XuK.F.WeiY.JinN.JiangC.Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7175862\results\search\drugs\results.xml">
   <result pre="and the virus. An in vitro experiment showed that in" exact="chloroquine" post="treated cells endosomes vesicles were abnormally enlarged. This indicates"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7175881\results\search\drugs\results.xml">
   <result pre="effective treatments such as remdesivir, lopinavir/ritonavir, favipiravir, steroid, plasma transfusion," exact="hydroxychloroquine" post="(HCQ), and chloroquine (CQ) are used to control the"/>
   <result pre="as remdesivir, lopinavir/ritonavir, favipiravir, steroid, plasma transfusion, hydroxychloroquine (HCQ), and" exact="chloroquine" post="(CQ) are used to control the COVID-19 [7], [6]."/>
   <result pre="lumefantrine, etc.), antifolate compounds (such as pyrimethamine, proguanil, etc.) and" exact="artemisinin" post="compounds (such as artemisinin, artesunate, etc.) are common antimalarial"/>
   <result pre="common antimalarial drugs for malaria treatment [18]. Amodiaquine, CQ, and" exact="primaquine" post="(PQ) were the main components of presumptive, Plasmodium falciparum"/>
   <result pre="14 days. For P. falciparum treatment, oral Quinine (QN) +" exact="tetracycline" post="or doxycycline was recommended when the treatment with CQ"/>
   <result pre="For P. falciparum treatment, oral Quinine (QN) + tetracycline or" exact="doxycycline" post="was recommended when the treatment with CQ and AS"/>
   <result pre="chemoprophylaxis, 5 mg/kg body weight (up to 250 mg) weekly" exact="mefloquine" post="is recommended to be continued two weeks before, during,"/>
   <result pre="Immunother. Cancer620185629907163 6ZhouD.DaiS.M.TongQ.COVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progressionJ. Antimicrob. Chemother.202020 7CunninghamA.C.GohH.P.KohD.Treatment of"/>
   <result pre="new challengesCrit. Care2420209132178711 8DevauxC.A.RolainJ.M.ColsonP.New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int. J. Antimicrob."/>
   <result pre="for COVID-19?Int. J. Antimicrob. Agents112020105938 9https://clinicaltrials.gov/ct2/results?cond=hydroxychloroquine+corona. 10SchrezenmeierE.DörnerT.Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatologyNat. Rev. Rheumatol.16202015516632034323 11ThabahM.RavindranV.Antimalarials in"/>
   <result pre="expanding therapeutic ArmamentariumIndian J. Rhuematol.1020155152 12PlantoneD.KoudriavtsevaT.Current and future use of" exact="chloroquine" post="and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases:"/>
   <result pre="ArmamentariumIndian J. Rhuematol.1020155152 12PlantoneD.KoudriavtsevaT.Current and future use of chloroquine and" exact="hydroxychloroquine" post="in infectious, immune, neoplastic, and neurological diseases: a mini-reviewClin."/>
   <result pre="a mini-reviewClin. Drug Investig.382018653671 13CouturierA.Giocanti-AuréganA.DupasB.Update on recommendations for screening for" exact="hydroxychloroquine" post="retinopathyJ. Fr. Ophtalmol.40201779380029054477 14RolainJ.M.ColsonP.RaoultD.Recycling of chloroquine and its hydroxyl"/>
   <result pre="recommendations for screening for hydroxychloroquine retinopathyJ. Fr. Ophtalmol.40201779380029054477 14RolainJ.M.ColsonP.RaoultD.Recycling of" exact="chloroquine" post="and its hydroxyl analogue to face bacterial, fungal and"/>
   <result pre="India: past, present &amp;amp; futureIndian J. Med. Res.139201420521524718394 20SehgalP.N.SharmaM.I.D.SharmaS.L.Resistance to" exact="chloroquine" post="in falciparum malaria in Assam state, IndiaJ. Commun. Dis51973175180"/>
   <result pre="of chloroquine-resistant malaria in sub-Saharan AfricaHealth Policy Plan.162001112 22FroschA.E.VenkatesanM.LauferM.K.Patterns of" exact="chloroquine" post="use and resistance in sub-Saharan Africa: a systematic review"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7175902\results\search\drugs\results.xml">
   <result pre="pmcid: 7175902S2052-2975(20)30036-6 doi: 10.1016/j.nmni.2020.100684100684 : Mini-Review Potential use of hydroxychloroquine," exact="ivermectin" post="and azithromycin drugs in fighting COVID-19: trends, scope and"/>
   <result pre="doi: 10.1016/j.nmni.2020.100684100684 : Mini-Review Potential use of hydroxychloroquine, ivermectin and" exact="azithromycin" post="drugs in fighting COVID-19: trends, scope and relevance ChoudharyR.rc_07@live.in∗SharmaA.K.anibiotech18@gmail.com[],"/>
   <result pre="spread of COVID-19. Towards that initiative, potential drugs like hydroxychloroquine," exact="ivermectin" post="and azithromycin have been tested by diverse group of"/>
   <result pre="COVID-19. Towards that initiative, potential drugs like hydroxychloroquine, ivermectin and" exact="azithromycin" post="have been tested by diverse group of researchers worldwide"/>
   <result pre="of the current health emergency around the world. Hydroxychloroquine and" exact="ivermectin" post="were known to act by creating the acidic environment"/>
   <result pre="viral import. Azithromycin was found to act similar to the" exact="hydroxychloroquine" post="as an acidotropic lipophilic weak base. All the three"/>
   <result pre="in order to combat COVID-19 infection. Keywords Azithromycin coronavirus COVID-19" exact="hydroxychloroquine" post="ivermectin Introduction COVID-19 infection has become pandemic after its"/>
   <result pre="order to combat COVID-19 infection. Keywords Azithromycin coronavirus COVID-19 hydroxychloroquine" exact="ivermectin" post="Introduction COVID-19 infection has become pandemic after its first"/>
   <result pre="first category of drug was Chloroquine and its safer derivative" exact="hydroxychloroquine" post="which may act as a therapeutic agent against COVID-19"/>
   <result pre="antiviral drug. Chang and his colleagues in 2014 revealed that" exact="hydroxychloroquine" post="activates the host anti-viral innate immunity [9]. This drug"/>
   <result pre="recent pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)," exact="hydroxychloroquine" post="was found to act as a potential drug in"/>
   <result pre="2 (SARS–CoV-2) [[2], [3], [4]]. In China, clinical trials of" exact="hydroxychloroquine" post="are further in-progress for the treatment and management of"/>
   <result pre="of action against COVID-19 infection. Ivermectin Another study revealed that" exact="ivermectin" post="which is a broad spectrum anti-parasitic drug demonstrated its"/>
   <result pre="is closely related to SARS coronavirus (SARS-CoV). Recent study on" exact="ivermectin" post="against SARS-CoV-2 under in vitro conditions revealed that it"/>
   <result pre="drug at any point of time [5]. Mechanism by which" exact="ivermectin" post="responded against the CoV-19 virus is not known and"/>
   <result pre="New Mexico University. The researchers were able to prove that" exact="azithromycin" post="acted as an acidotropic lipophilic weak base which modulate"/>
   <result pre="on intracellular organelles similar to the one as conferred by" exact="hydroxychloroquine" post="[6]. This further indicates that this antimicrobial drug has"/>
   <result pre="antiviral response in vitro against many viruses including coronaviruses. However," exact="hydroxychloroquine" post="has been found to be associated with dangerous side-effects"/>
   <result pre="is not carefully controlled. There have been many cases of" exact="chloroquine" post="poisoning reported in Nigeria and the USA as well."/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome Coronavirus"/>
   <result pre="acute respiratory syndrome Coronavirus 2 (SARS-CoV-2)Clin Infect Dis202010.1093/cid/ciaa237ciaa237 4GautretP.LagierJ.C.ParolaP.MeddebL.MailheM.DoudierB.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID19: results of an open-label"/>
   <result pre="replication of SARS-CoV-2 in vitroAntivir Res3 April 202010478732251768 6PoschetJ.F.PerkettE.A.TimminsG.S.DereticVojoAzithromycin and" exact="ciprofloxacin" post="have a chloroquine-like effect on respiratory epithelial cellsbioRxiv329202000863110.1101/2020.03.29.008631 7WenigerH.Review"/>
   <result pre="and toxicity of chloroquineBull World Health791979906 8FoxR.I.Mechanism of action of" exact="hydroxychloroquine" post="as an antirheumatic drugSemin Arthritis Rheum232199382918278823 9ChangT.H.WangL.F.LinY.S.YangC.S.YuC.Y.LinY.L.Hydroxychloroquine activates host"/>
   <result pre="antiviral innate immunityCytokine70120143334 10AzeemS.AshrafM.RasheedM.A.AnjumA.A.HameedR.Evaluation of cytotoxicity and antiviral activity of" exact="ivermectin" post="against Newcastle disease virusPak J Pharm Sci282201559760225730813 11MastrangeloE.PezzulloM.De BurghgraeveT.KapteinS.PastorinoB.DallmeierK.Ivermectin"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7175909\results\search\drugs\results.xml">
   <result pre="analyzed that a combination of antiviral drugs with hydroxyl-chloroquine and" exact="azithromycin" post="(with the consultation of a medical practitioner) may be"/>
   <result pre="be operative to treat COVID-19 (Lu, 2020). A combination of" exact="lopinavir" post="and ritonavir, previously used for SARS-Cov and MERS-Cov, may"/>
   <result pre="et al. (2020) reported that a combination of remdesivir and" exact="chloroquine" post="may be effective to treat COVID-19 disease. Besides, the"/>
   <result pre="Singh (SMS) Hospital, Jaipur India by giving a combination of" exact="lopinavir" post="(200 mg) and ritonavir (50 mg) twice a day."/>
   <result pre="India by giving a combination of lopinavir (200 mg) and" exact="ritonavir" post="(50 mg) twice a day. Besides, the patient was"/>
   <result pre="day. Besides, the patient was also given a combination of" exact="oseltamivir" post="and chloroquine medicine. The patient test was found negative"/>
   <result pre="the patient was also given a combination of oseltamivir and" exact="chloroquine" post="medicine. The patient test was found negative for COVID-19."/>
   <result pre="empty stomach for 3 days. Arsenic Album-30 is highly diluted" exact="arsenic trioxide" post="and work as homeopathic prophylaxis. It is important to"/>
   <result pre="best options. A combination of antiviral drugs with hydroxyl-chloroquine and" exact="azithromycin" post="(with the consultation of a medical practitioner) may be"/>
   <result pre="to evaluate the anti-viral efficacy of Glycyrrhiza glabra extract and" exact="ribavirin" post="against the Newcastle disease virusPharm. Res.62014611 PradityaD.KirchhoffL.BrüningJ.RachmawatiH.SteinmannJ.SteinmannE.Anti-infective properties of"/>
   <result pre="licorice, a widely-used Chinese herbActa Pharm. Sin. B5201531031526579460 WangM.CaoR.ZhangL.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7177554\results\search\drugs\results.xml">
   <result pre="et al. [39] reported a meta-analysis regarding the efficacy of" exact="ganciclovir" post="among UC patients detected with HCMV infection. The result"/>
   <result pre="detected with HCMV infection. The result showed that administration of" exact="ganciclovir" post="did not contribute to surgical resection and death related"/>
   <result pre="complications accompanied by HCMV infection is high when steroids and" exact="cyclosporine" post="are administered due to strong suppression of the immune"/>
   <result pre="for colectomyJ. Crohn’s Colitis2016101205121110.1093/ecco-jcc/jjw07126971053 38.KimY.S.KimY.H.KimJ.S.CheonJ.H.YeB.D.JungS.A.ParkY.S.ChoiC.H.JangB.I.HanD.S.et al.The prevalence and efficacy of" exact="ganciclovir" post="on steroid-refractory ulcerative colitis with cytomegalovirus infection: A prospective"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7177691\results\search\drugs\results.xml">
   <result pre="found out that the businesswoman had suppressed the symptoms with" exact="paracetamol" post="[40], there is yet enough evidence to rule out"/>
   <result pre="6.1. Antiviral Therapy Oxygen therapy, mechanical ventilation, intravenous antibiotics, and" exact="oseltamivir" post="therapy were initiated in 38.0%, 6.1%, 57.5%, and 35.8%"/>
   <result pre="Another type of antiviral medication used for SARS-CoV-2 patients is" exact="ganciclovir" post="[13], normally used to treat cytomegalovirus (CMV) retinitis in"/>
   <result pre="as thymidine kinase (TK) [71]. Monophosphate is then converted into" exact="ganciclovir" post="triphosphate by cellular enzymes which, competitively, inhibits dATP, leading"/>
   <result pre="the formation of ‘faulty’ DNA by replacing many of the" exact="adenosine" post="bases in the DNA strand and preventing DNA synthesis"/>
   <result pre="an antiviral drug to treat COVID-19 patients. In the past," exact="lopinavir" post="and ritonavir have been prescribed to patients suffering from"/>
   <result pre="drug to treat COVID-19 patients. In the past, lopinavir and" exact="ritonavir" post="have been prescribed to patients suffering from SARS-CoV and"/>
   <result pre="SARS-CoV and MERS-CoV to reduce clinical symptoms. A combination of" exact="lopinavir" post="and ritonavir have been administered to patients suffering from"/>
   <result pre="MERS-CoV to reduce clinical symptoms. A combination of lopinavir and" exact="ritonavir" post="have been administered to patients suffering from COVID-19 [31]."/>
   <result pre="to patients suffering from COVID-19 [31]. KALETRA, a co-formulation of" exact="lopinavir" post="and ritonavir, is also tested for activity against SARS-CoV-2"/>
   <result pre="defective, immature, and non-infectious viral particles. By co-formulating in KALETRA," exact="ritonavir" post="increases the half-life and plasma level of lopinavir by"/>
   <result pre="in KALETRA, ritonavir increases the half-life and plasma level of" exact="lopinavir" post="by inhibiting the oxidation caused by cytochrome P450 [77]."/>
   <result pre="is a potential broad-spectrum antiviral drug. Therefore, nafamostat, nitazoxanide, and" exact="chloroquine" post="are of high potential and are recommended for evaluation"/>
   <result pre="use that have been studied [79], oncology drugs such as" exact="sunitinib" post="and erlotinib have shown effective viral infection inhibition. However,"/>
   <result pre="have been studied [79], oncology drugs such as sunitinib and" exact="erlotinib" post="have shown effective viral infection inhibition. However, the side"/>
   <result pre="protease [80]. Valrubicin, icatibant, bepotastine, epirubicin, epoprostenol, vapreotide, aprepitant, and" exact="caspofungin" post="are examined via virtual docking and appeared to exhibit"/>
   <result pre="2019-nCoV [78]. On the contrary, other antiviral drugs, such as" exact="oseltamivir" post="and KALETRA, have been tested over H5N1 and MERS-CoV,"/>
   <result pre="treatment, primarily using oseltamivir, ganciclovir, and KALETRA (a combination of" exact="lopinavir" post="and ritonavir), is prescribed to treat the ARD and"/>
   <result pre="AdministrationKaletraUS Food and Drug AdministrationSilver Spring, MD, USA2000 78.WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhouX.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="the susceptibility of highly pathogenic avian influenza H5N1 viruses to" exact="oseltamivir" post="using embryonated chicken eggsIndian J. Med Res.201915048649131939392 83.WerthB.J.CephalosporinsMerck Manual"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7177898\results\search\drugs\results.xml">
   <result pre="essential role in its replication cycle. The HIV protease inhibitors," exact="lopinavir" post="and ritonavir, are therefore used in combination as HIV"/>
   <result pre="class of protease, the cysteine protease, theoretical evidence exists that" exact="lopinavir" post="and ritonavir also inhibit the coronaviral 3CL1pro protease [53,54,55,56]."/>
   <result pre="protease, the cysteine protease, theoretical evidence exists that lopinavir and" exact="ritonavir" post="also inhibit the coronaviral 3CL1pro protease [53,54,55,56]. More importantly,"/>
   <result pre="evaluated. 7.3.2. Hydroxychloroquine As a well-known antimalarial and anti-autoimmune agent," exact="hydroxychloroquine" post="can also block virus infection by increasing endosomal pH"/>
   <result pre="trials have been quickly conducted in China, which demonstrated that" exact="hydroxychloroquine" post="was to various degree effective in treatment of COVID-19-associated"/>
   <result pre="Similarly, in a small open-label non-randomized clinical trial from France," exact="hydroxychloroquine" post="demonstrated positive effect in combination with azithromycin [62]. In"/>
   <result pre="trial from France, hydroxychloroquine demonstrated positive effect in combination with" exact="azithromycin" post="[62]. In the wake of this evidence, the U.S."/>
   <result pre="FDA issued an Emergency Use Authorization for the use of" exact="hydroxychloroquine" post="to treat COVID-19 in the USA. It is noteworthy"/>
   <result pre="found no evidence of clinical benefit of the combination of" exact="hydroxychloroquine" post="and azithromycin for the treatment of 11 patients with"/>
   <result pre="evidence of clinical benefit of the combination of hydroxychloroquine and" exact="azithromycin" post="for the treatment of 11 patients with severe COVID-19"/>
   <result pre="efficacy in treating SARS-CoV-2 is still unknown. 7.5.6. Thalidomide Recently," exact="thalidomide" post="has re-emerged as an antiangiogenic, anti-inflammatory, and anti-fibrotic agent."/>
   <result pre="anti-inflammatory, and anti-fibrotic agent. Through decreasing the synthesis of TNF-alpha," exact="thalidomide" post="has been used as a treatment for multiple inflammatory"/>
   <result pre="and Behcets disease [80]. In addition, preclinical studies proved that" exact="thalidomide" post="was effective in treating H1N1-infected mice by reducing infiltration"/>
   <result pre="and the excessive immune response from the host. Thus, whether" exact="methylprednisolone" post="administration would help suppress the unwanted immune reactions is"/>
   <result pre="refractory multiple sclerosis. By structurally resembling the lipid sphingosine-1-phosphate (S1P)," exact="fingolimod" post="can act as a highly potent functional antagonist of"/>
   <result pre="by the Viral Polymerase and the Proofreading ExoribonucleasemBio2018910.1128/mBio.00221-18 46.WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="of HIV-1 and dengue virusBiochem. J.201244385185610.1042/BJ2012015022417684 50.YangS.N.Y.AtkinsonS.C.WangC.LeeA.BogoyevitchM.A.BorgN.A.JansD.A.The broad spectrum antiviral" exact="ivermectin" post="targets the host nuclear transport importin alpha/beta1 heterodimerAntivir. Res.202010476010.1016/j.antiviral.2020.10476032135219"/>
   <result pre="enzyme 2 in acute respiratory distress syndromeCrit. Care20172123410.1186/s13054-017-1823-x28877748 60.SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: An old drug against today’s diseasesLancet"/>
   <result pre="of SARS coronavirus infection and spreadVirol. J.200526910.1186/1743-422X-2-6916115318 62.GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.et al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: Results of an open-label"/>
   <result pre="non-randomized clinical trialInt. J. Antimicrob. Agents202010594910.1016/j.ijantimicag.2020.10594932205204 63.MolinaJ.M.DelaugerreC.GoffJ.L.Mela-LimaB.PonscarmeD.GoldwirtL.de CastroN.No benefit of" exact="hydroxychloroquine" post="and azithromycin in people hospitalised with COVID-19Med. Mal. Infect.202010.1016/j.medmal.2020.03.006"/>
   <result pre="trialInt. J. Antimicrob. Agents202010594910.1016/j.ijantimicag.2020.10594932205204 63.MolinaJ.M.DelaugerreC.GoffJ.L.Mela-LimaB.PonscarmeD.GoldwirtL.de CastroN.No benefit of hydroxychloroquine and" exact="azithromycin" post="in people hospitalised with COVID-19Med. Mal. Infect.202010.1016/j.medmal.2020.03.006 64.KadamR.U.WilsonI.A.Structural basis"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7178844\results\search\drugs\results.xml">
   <result pre="and achieved SVR12 [16,17]. Londoño et al. described Ombitasvir/paritaprevir/ritonavir and" exact="dasabuvir" post="or Ombitasvir/paritaprevir/ritonavir with or without ribavirin (RBV) regimens in"/>
   <result pre="al. described Ombitasvir/paritaprevir/ritonavir and dasabuvir or Ombitasvir/paritaprevir/ritonavir with or without" exact="ribavirin" post="(RBV) regimens in CKD patients, included twelve PD patients,"/>
   <result pre="dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and" exact="dasabuvir" post="in patients with chronic hcv infection: Pharmacokinetic analysis of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7178925\results\search\drugs\results.xml">
   <result pre="the maternal respiratory system during pregnancy. Anatomically, the effects of" exact="progesterone" post="and relaxants in the first trimester of pregnancy can"/>
   <result pre="compensated by increased tidal volume and hyperventilation. In addition, elevated" exact="progesterone" post="can be transmitted through estrogen-dependent progesterone receptors in the"/>
   <result pre="hyperventilation. In addition, elevated progesterone can be transmitted through estrogen-dependent" exact="progesterone" post="receptors in the hypothalamus, thus stimulating the respiratory center"/>
   <result pre="means. In addition, the changes of nasal mucosa mediated by" exact="progesterone" post="during pregnancy may lead to the adhesion of the"/>
   <result pre="the blood decreased [32]. Moreover, the surge in estrogen and" exact="progesterone" post="in the first trimester of pregnancy leads to reversible"/>
   <result pre="prohibited during pregnancy because of their proven teratogenicity. For example:" exact="ribavirin" post="is listed as an X-grade drug in the Federal"/>
   <result pre="and cyst of 4th ventricle of the brain (1). Clearly," exact="ribavirin" post="should be banned during pregnancy. In addition, many prescription"/>
   <result pre="to provide convenient evidence for clinicians to choose drugs. Chloroquine," exact="chloroquine" post="phosphate, and hydroxychloroquine Chloroquine was first synthesized in 1934"/>
   <result pre="evidence for clinicians to choose drugs. Chloroquine, chloroquine phosphate, and" exact="hydroxychloroquine" post="Chloroquine was first synthesized in 1934 by Hans Andersag"/>
   <result pre="new antimalarial drug developed by scientists on the basis of" exact="chloroquine" post="in 1944. The difference between the two drugs is"/>
   <result pre="difference between the two drugs is that one ethyl in" exact="chloroquine" post="is replaced by one hydroxyethyl in hydroxychloroquine. Though the"/>
   <result pre="two drugs share similar therapeutic effects, the side effects of" exact="hydroxychloroquine" post="are significantly less than that of chloroquine [60]. At"/>
   <result pre="side effects of hydroxychloroquine are significantly less than that of" exact="chloroquine" post="[60]. At present, the main clinical applications are chloroquine"/>
   <result pre="of chloroquine [60]. At present, the main clinical applications are" exact="chloroquine" post="phosphate and hydroxychloroquine. Previous studies have clearly suggested that"/>
   <result pre="chloroquine phosphate and hydroxychloroquine. Previous studies have clearly suggested that" exact="chloroquine" post="has shown immunomodulatory and broad-spectrum antiviral effects, and such"/>
   <result pre="Evidence and clinical trials have confirmed the inhibitory effect of" exact="chloroquine" post="on HIV/AIDS, MERS-CoV, SARS-CoV, and other viruses. Moreover, the"/>
   <result pre="Martin et al. [62] showed that the inhibitory effect of" exact="chloroquine" post="on cells of SARS-CoV infection can be demonstrated before"/>
   <result pre="the cells are exposed to the virus, which means that" exact="chloroquine" post="shows an effect both on prevention and on treatment"/>
   <result pre="effect both on prevention and on treatment of SARS-CoV. Firstly," exact="chloroquine" post="is an alkaline compound whose non-protonated parts enter cells"/>
   <result pre="inhibited and make the infection invalidated. Last but not least," exact="chloroquine" post="has also been found to have an immunomodulatory effect."/>
   <result pre="the severity of the disease, so the anti-inflammatory effect of" exact="chloroquine" post="can also reduce immune lesions. It has been reported"/>
   <result pre="immune lesions. It has been reported that the use of" exact="hydroxychloroquine" post="in systemic lupus erythematosus leads to defective differentiation in"/>
   <result pre="limited to some extent, which is a potential evidence of" exact="chloroquine" post="in reducing cytokine storm [66]. These trials were sufficient"/>
   <result pre="These trials were sufficient to support the therapeutic effect of" exact="chloroquine" post="on COVID-19. Wang et al. [67] demonstrated that chloroquine"/>
   <result pre="of chloroquine on COVID-19. Wang et al. [67] demonstrated that" exact="chloroquine" post="functioned at both entry and at post-entry stages of"/>
   <result pre="Vero E6 cells by time-of-addition assay. Besides its antiviral activity," exact="chloroquine" post="has an immune-modulating activity, which may synergistically enhance its"/>
   <result pre="in vivo. We collected some evidences for the use of" exact="chloroquine" post="in pregnancy combined with COVID-19. Although chloroquine is classified"/>
   <result pre="the use of chloroquine in pregnancy combined with COVID-19. Although" exact="chloroquine" post="is classified as class C in the FDA for"/>
   <result pre="class C in the FDA for pregnancy, the effect of" exact="chloroquine" post="on pregnancy is proved to be mild. Klumpp et"/>
   <result pre="records in WHO do not show any adverse effects of" exact="chloroquine" post="on pregnancy, childbirth, or newborns. In addition, regarding the"/>
   <result pre="CI 0.95, 3.24). Based on this evidence, we speculate that" exact="hydroxychloroquine" post="has the potential to be an effective drug in"/>
   <result pre="shear the precursor protein of Gag-Pol polymerase. The combination of" exact="lopinavir" post="and litonavir can inhibit the proliferation of HIV virus"/>
   <result pre="and papain-like virus protease through homologous modeling, and then docked" exact="ritonavir" post="and lopinavir with the protease model respectively. Through docking,"/>
   <result pre="virus protease through homologous modeling, and then docked ritonavir and" exact="lopinavir" post="with the protease model respectively. Through docking, 100 poses"/>
   <result pre="model respectively. Through docking, 100 poses were found when docking" exact="ritonavir" post="to CEP_C30, with the libdock score of the optimal"/>
   <result pre="the optimal pose 192.346. Eighty-eight poses were found when docking" exact="lopinavir" post="to CEP_C30, with the libdock score of the optimal"/>
   <result pre="optimal pose. The results suggest that the therapeutic effect of" exact="ritonavir" post="on COVID-19 may be mainly due to its inhibition"/>
   <result pre="SARS, scholars [77] in Hong Kong, China, used lopinavir/ritonavir and" exact="ribavirin" post="to treat 41 patients. The results showed that compared"/>
   <result pre="[79] involved 356 pregnant women infected with HIV. Lopinavir/ritonavir or" exact="efavirenz" post="was randomly administered at 12 to 28 weeks of"/>
   <result pre="to be safe and effective, of which metformin, glitazone, and" exact="atorvastatin" post="are commonly used drugs [84]. The application of HDT"/>
   <result pre="reducing mortality in patients with COVID-19. Studies have shown that" exact="metformin" post="increases the production of mitochondrial ROS and enhances autophagy"/>
   <result pre="JW et al. [86] treated mice exposed to LPS with" exact="metformin" post="and found that metformin inhibited the level of mitochondrial"/>
   <result pre="treated mice exposed to LPS with metformin and found that" exact="metformin" post="inhibited the level of mitochondrial complex I in the"/>
   <result pre="neutrophils. Thus, we concluded that one of the mechanisms that" exact="metformin" post="takes effect in acute inflammation is to inhibit mitochondrial"/>
   <result pre="acute inflammation is to inhibit mitochondrial complex I. So, can" exact="metformin" post="be considered when pregnant women choose an HDT drug?"/>
   <result pre="answer. They included eight studies involving 200 women exposed to" exact="metformin" post="in the first trimester of pregnancy. The results showed"/>
   <result pre="first trimester of pregnancy. The results showed that exposure to" exact="metformin" post="in the first trimester of pregnancy was not associated"/>
   <result pre="involving 2712 women with gestational diabetes. The results showed that" exact="metformin" post="could significantly reduce adverse maternal and neonatal outcomes such"/>
   <result pre="injury diseases [89]. A trial involving 477 cases exposed to" exact="simvastatin" post="or lovastatin during pregnancy showed the incidence of congenital"/>
   <result pre="[89]. A trial involving 477 cases exposed to simvastatin or" exact="lovastatin" post="during pregnancy showed the incidence of congenital abnormalities in"/>
   <result pre="of an increase in congenital deformities in children exposed to" exact="simvastatin" post="or lovastatin before birth, compared with the general population."/>
   <result pre="increase in congenital deformities in children exposed to simvastatin or" exact="lovastatin" post="before birth, compared with the general population. Therefore, such"/>
   <result pre="birth, compared with the general population. Therefore, such drugs as" exact="metformin" post="and statins are much friendlier for pregnancy. Alimuddin Zumla"/>
   <result pre="that can be used in the current COVID-19 treatment, including" exact="chloroquine" post="and its analogues, drugs of HDT (Metformin, statins), lobinavir/ritonavir,"/>
   <result pre="and after vaginal deliveryBr J Anaesth197042121100110410.1093/bja/42.12.11005504452 19.BaylissDAMillhornDECentral neural mechanisms of" exact="progesterone" post="action: application to the respiratory systemJ Appl Physiol199273239340410.1152/jappl.1992.73.2.3931399957 20.Field"/>
   <result pre="therapeutics to control coronavirus and influenza virusDrug Discov Today201924372673610.1016/j.drudis.2019.01.01830711575 57.RobertsSSMillerRKJonesJKLindsayKLGreeneMFMaddreyWCWilliamsITLiuJSpiegelRJThe" exact="ribavirin" post="pregnancy registry: findings after 5 years of enrollment, 2003-2009Birth"/>
   <result pre="in pregnancyCurr Opin Infect Dis201326657558810.1097/QCO.000000000000001724152762 60.PlantoneDKoudriavtsevaTCurrent and future use of" exact="chloroquine" post="and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases:"/>
   <result pre="Opin Infect Dis201326657558810.1097/QCO.000000000000001724152762 60.PlantoneDKoudriavtsevaTCurrent and future use of chloroquine and" exact="hydroxychloroquine" post="in infectious, immune, neoplastic, and neurological diseases: a mini-reviewCLIN"/>
   <result pre="neurological diseases: a mini-reviewCLIN DRUG INVEST201838865367110.1007/s40261-018-0656-y 61.KeyaertsELiSVijgenLRysmanEVerbeeckJVan RanstMMaesPAntiviral activity of" exact="chloroquine" post="against human coronavirus OC43 infection in newborn miceAntimicrob Agents"/>
   <result pre="Z, Hu Z, Zhong W, Xiao G (2020) Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="in vitro. Cell Res 30(3):269–271 68.Klumpp TG (1965) Safety of" exact="chloroquine" post="in pregnancy. JAMA 191 (9):765 69.KaplanYCOzsarfatiJNickelCKorenGReproductive outcomes following hydroxychloroquine"/>
   <result pre="of chloroquine in pregnancy. JAMA 191 (9):765 69.KaplanYCOzsarfatiJNickelCKorenGReproductive outcomes following" exact="hydroxychloroquine" post="use for autoimmune diseases: a systematic review and meta-analysisBr"/>
   <result pre="SARS with human interferonsLANCET20033629390115910.1016/S0140-6736(03)14484-414550718 74.ShalhoubSFarahatFAl-JiffriASimhairiRShammaOSiddiqiNMushtaqAIFN-alpha2a or IFN-beta1a in combination with" exact="ribavirin" post="to treat Middle East respiratory syndrome coronavirus pneumonia: a"/>
   <result pre="VenAKroonFRockstrohJWyenCBaumerAde GrootEKoopmansPStroesEReissPBurgerDPharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and" exact="rosuvastatin" post="in HIV-infected patientsAntivir Ther20071271127113218018771 77.ChuCMChengVCHungIFWongMMChanKHChanKSKaoRYPoonLLWongCLGuanYPeirisJSYuenKYRole of lopinavir/ritonavir in the"/>
   <result pre="X (2020) Molecular modeling evaluation of the binding abilities of" exact="ritonavir" post="and lopinavir to Wuhan pneumonia coronavirus proteases. bioRxiv:2020–2021 79.KossCANatureebaPPlentyALuweddeFMwesigwaJAdesVCharleboisEDClarkTDAchanJRuelTNzarubaraBKamyaMRHavlirDVCohanDRisk"/>
   <result pre="Molecular modeling evaluation of the binding abilities of ritonavir and" exact="lopinavir" post="to Wuhan pneumonia coronavirus proteases. bioRxiv:2020–2021 79.KossCANatureebaPPlentyALuweddeFMwesigwaJAdesVCharleboisEDClarkTDAchanJRuelTNzarubaraBKamyaMRHavlirDVCohanDRisk factors for"/>
   <result pre="first-trimester exposure to metformin: a meta-analysisFertil Steril200686365866310.1016/j.fertnstert.2006.02.09816879826 88.LiGZhaoSCuiSLiLXuYLiYEffect comparison of" exact="metformin" post="with insulin treatment for gestational diabetes: a meta-analysis based"/>
   <result pre="other immunomodulatory agentsAntivir Res201399341743510.1016/j.antiviral.2013.06.01823831494 90.PollackPSShieldsKEBurnettDMOsborneMJCunninghamMLStepanavageMEPregnancy outcomes after maternal exposure to" exact="simvastatin" post="and lovastatinBirth Defects Res A Clin Mol Teratol2005731188889610.1002/bdra.2018116163683 91.ZumlaAAzharEIArabiYAlotaibiBRaoMMcCloskeyBPetersenEMaeurerMHost-directed"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7179937\results\search\drugs\results.xml">
   <result pre="ZhangL., YangX., LiuJ., XuM., ShiZ., HuZ., ZhongW., XiaoG., Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7180238\results\search\drugs\results.xml">
   <result pre="been tested widely for the newly emerged SARS-CoV-2. Remdesivir and" exact="chloroquine" post="were found highly effective in vitro for the control"/>
   <result pre="infection (44). Treatment with remdesivir alone or in combination with" exact="chloroquine" post="or interferon beta was found effective against COVID-19 infection."/>
   <result pre="pathogenic viruses, thus might be used against SARS-CoV-2. (62) Hexamethylene" exact="amiloride" post="Targets viral envelope to inhibit ion channel activity Has"/>
   <result pre="synergistic effects against SARS-CoV-2. In addition, calcineurin inhibitors such as" exact="cyclosporine" post="(53), in combination with antibiotics and traditional Chinese medicines,"/>
   <result pre="scenario of pneumonia in Wuhan, China. Broad-range combinational therapies, including" exact="lopinavir" post="and interferon antiviral peptides, can also be evaluated and"/>
   <result pre="CaoR, ZhangL, YangX, LiuJ, XuM, ShiZ, HuZ, ZhongW, XiaoG2020Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7181215\results\search\drugs\results.xml">
   <result pre="Herpes simplex was demonstrated [10]. A mixture of echinochrome A," exact="ascorbic acid," post="and alpha-tocopherol (5:5:1) showed higher antioxidant and antiviral effects"/>
   <result pre="in modulating the in vivo genotoxicity of the antiviral drug" exact="ribavirin" post="in miceMutat. Res.2013752142010.1016/j.mrgentox.2012.12.01223402882 5.PanchalR.G.ReidS.P.TranJ.P.BergeronA.A.WellsJ.KotaK.P.AmanJ.BavariS.Identification of an antioxidant small-molecule with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7182748\results\search\drugs\results.xml">
   <result pre="7182748S0882-4010(20)30515-5 doi: 10.1016/j.micpath.2020.104228104228 : Article In vitro testing of combined" exact="hydroxychloroquine" post="and azithromycin on SARS-CoV-2 shows synergistic effect AndreaniJulienabLe BideauMarionabDuflotIsabelleabJardotPriscillaabRollandClaraabBoxbergerManonabWurtzNathalieabRolainJean-MarcabColsonPhilippeabLa"/>
   <result pre="10.1016/j.micpath.2020.104228104228 : Article In vitro testing of combined hydroxychloroquine and" exact="azithromycin" post="on SARS-CoV-2 shows synergistic effect AndreaniJulienabLe BideauMarionabDuflotIsabelleabJardotPriscillaabRollandClaraabBoxbergerManonabWurtzNathalieabRolainJean-MarcabColsonPhilippeabLa ScolaBernardbernard.la-scola@univ-amu.frab∗∗RaoultDidierdidier.raoult@gmail.comab∗[a], [b],"/>
   <result pre="vitro. In vivo it showed efficacy, especially when combined with" exact="azithromycin" post="in a preliminary clinical trial. Here we demonstrate that"/>
   <result pre="preliminary clinical trial. Here we demonstrate that the combination of" exact="hydroxychloroquine" post="and azithromycin has a synergistic effect in vitro on"/>
   <result pre="trial. Here we demonstrate that the combination of hydroxychloroquine and" exact="azithromycin" post="has a synergistic effect in vitro on SARS-CoV-2 at"/>
   <result pre="is the best strategy for quick therapeutic response. •Azithromycin and" exact="hydroxychloroquine" post="shows synergistic effect on replication. •Concentrations of drugs are"/>
   <result pre="mg per day over several months [24]. Clinical tests of" exact="chloroquine" post="and hydroxychloroquine to treat COVID-19 are underway in China"/>
   <result pre="day over several months [24]. Clinical tests of chloroquine and" exact="hydroxychloroquine" post="to treat COVID-19 are underway in China [25], with"/>
   <result pre="COVID-19 are underway in China [25], with such trials using" exact="hydroxychloroquine" post="in progress in the US (ClinicalTrials.gov Identifier: NCT04307693) and"/>
   <result pre="treatments for this disease [32]. In a preliminary clinical study," exact="hydroxychloroquine" post="and, with even greater potency, the combination of hydroxychloroquine"/>
   <result pre="study, hydroxychloroquine and, with even greater potency, the combination of" exact="hydroxychloroquine" post="and azithromycin were found effective in reducing the SARS-CoV-2"/>
   <result pre="and, with even greater potency, the combination of hydroxychloroquine and" exact="azithromycin" post="were found effective in reducing the SARS-CoV-2 viral load"/>
   <result pre="one of them, the SARS-CoV-2 IHUMI-3, using different concentrations of" exact="hydroxychloroquine" post="and azithromycin in combination, with Vero E6 cells. 2"/>
   <result pre="them, the SARS-CoV-2 IHUMI-3, using different concentrations of hydroxychloroquine and" exact="azithromycin" post="in combination, with Vero E6 cells. 2 Materials and"/>
   <result pre="per liter (μM), were 1, 2 or 5 μM for" exact="hydroxychloroquine" post="associated with 5 or 10 μM for azithromycin. Each"/>
   <result pre="and repeated two times except conditions with 5 μM for" exact="hydroxychloroquine" post="associated with 5 or 10 μM for azithromycin that"/>
   <result pre="μM for hydroxychloroquine associated with 5 or 10 μM for" exact="azithromycin" post="that were repeated a third time. Four hours before"/>
   <result pre="All others conditions was not significant. Fig. 2 Effect of" exact="hydroxychloroquine" post="and azithromycin association on SARS-CoV 2 replication. 2A. Delta"/>
   <result pre="conditions was not significant. Fig. 2 Effect of hydroxychloroquine and" exact="azithromycin" post="association on SARS-CoV 2 replication. 2A. Delta Ct between"/>
   <result pre="compared to control by the combinations of 5 μM of" exact="hydroxychloroquine" post="associated with 5 or 10 μM for azithromycin. Data"/>
   <result pre="viral production as compared to control (Fig. 1). Combination of" exact="azithromycin" post="and hydroxychloroquine led to significant inhibition of viral replication"/>
   <result pre="as compared to control (Fig. 1). Combination of azithromycin and" exact="hydroxychloroquine" post="led to significant inhibition of viral replication for wells"/>
   <result pre="led to significant inhibition of viral replication for wells containing" exact="hydroxychloroquine" post="at 5 μM in combination with azithromycin at 10"/>
   <result pre="for wells containing hydroxychloroquine at 5 μM in combination with" exact="azithromycin" post="at 10 and 5 μM (P-values at 0,0003 for"/>
   <result pre="we identified a strong synergistic effect of the combination of" exact="hydroxychloroquine" post="and azithromycin. Hydroxychloroquine has been demonstrated in vitro to"/>
   <result pre="effect on microorganisms (50% inhibitory concentration, IC50). With Zika virus," exact="azithromycin" post="showed activity with an IC 50 range from 2.1"/>
   <result pre="50 at high concentration [29]. The observation of efficacy of" exact="azithromycin" post="on RNA viruses is probably shared by some other"/>
   <result pre="on rhinovirus in vitro [[36], [37]]. In vivo sulfate of" exact="hydroxychloroquine" post="could be imply in the modulation of the immune"/>
   <result pre="lung affections was associated with cytokines storm [39]. In parallel" exact="azithromycin" post="was known as inhibit the viral replication of Zika"/>
   <result pre="virus in vitro [29]. And in enlarge viral infection context," exact="azithromycin" post="was associated to up-regulate interferons I and III [30]."/>
   <result pre="the ICAM-1 protein (36). So, in the SARS-CoV 2 context," exact="azithromycin" post="could potentialize the effect of hydroxychloroquine by similar mechanism."/>
   <result pre="the SARS-CoV 2 context, azithromycin could potentialize the effect of" exact="hydroxychloroquine" post="by similar mechanism. On Vero E6 it was shown"/>
   <result pre="tested herein [19]. Against SARS-CoV 2, the IC 50 of" exact="hydroxychloroquine" post="was determined to be 4.51, 4.06, 17.31, and 12.96"/>
   <result pre="effects that would occur at those concentrations. The synergy between" exact="hydroxychloroquine" post="and azithromycin that we observed herein is at concentrations"/>
   <result pre="would occur at those concentrations. The synergy between hydroxychloroquine and" exact="azithromycin" post="that we observed herein is at concentrations achieved in"/>
   <result pre="in agreement with the clinical efficacy of the combination of" exact="hydroxychloroquine" post="and azithromycin observed by Gautret et al. [33]. They"/>
   <result pre="with the clinical efficacy of the combination of hydroxychloroquine and" exact="azithromycin" post="observed by Gautret et al. [33]. They support the"/>
   <result pre="of the monolayer in each well for the condition of" exact="azithromycin" post="5 μM associated with hydroxychloroquine at 5 μM, 3D."/>
   <result pre="well for the condition of azithromycin 5 μM associated with" exact="hydroxychloroquine" post="at 5 μM, 3D. Negative control well and 3E."/>
   <result pre="epidemic and the challengesInt. J. Antimicrob. Agents5532020 Mar10592432081636 9ColsonP.RolainJ.M.LagierJ.C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int. J. Antimicrob. Agents2020"/>
   <result pre="pH various agentsProc. Natl. Acad. Sci. U.S.A.7519783327333128524 11KeyaertsE.LiS.VijgenL.RysmanE.VerbeeckJ.VanR.M.Antiviral activity of" exact="chloroquine" post="against human coronavirus OC43 infection in newborn miceAntimicrob. Agents"/>
   <result pre="SARS coronavirus infection and spreadVirol. J.22005 Aug 226916115318 13SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against today's diseases?Lancet"/>
   <result pre="ERKAntivir. Res.7722008 Feb15015218055026 16DevauxC.A.RolainJ.M.ColsonP.RaoultD.New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int. J. Antimicrob."/>
   <result pre="coronavirus by chloroquineBiochem. Biophys. Res. Commun.32312004 Oct 826426815351731 18WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="of Q fever endocarditis : comparison of two regimens containing" exact="doxycycline" post="and ofloxacin or hydroxychloroquineArch. Intern. Med.159219991671739927100 21RaoultD.DrancourtM.VestrisG.Bactericidal effect of"/>
   <result pre="fever endocarditis : comparison of two regimens containing doxycycline and" exact="ofloxacin" post="or hydroxychloroquineArch. Intern. Med.159219991671739927100 21RaoultD.DrancourtM.VestrisG.Bactericidal effect of Doxycycline associated"/>
   <result pre="Engl. J. Med.35612007 Jan 4556617202456 24ArmstrongN.RichezM.RaoultD.ChabriereE.Simultaneous UHPLC-UV analysis of hydroxychloroquine," exact="minocycline" post="and doxycycline from serum samples for the therapeutic drug"/>
   <result pre="Med.35612007 Jan 4556617202456 24ArmstrongN.RichezM.RaoultD.ChabriereE.Simultaneous UHPLC-UV analysis of hydroxychloroquine, minocycline and" exact="doxycycline" post="from serum samples for the therapeutic drug monitoring of"/>
   <result pre="Chromatogr. B Analyt Technol. Biomed. Life Sci.10602017 Aug 15166172 25GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="Chemother.2019 Sep 1610.1128/AAC.00394-19Epub ahead of print 31Fleming-DutraK.E.DemirjianA.BartocesM.RobertsR.M.TaylorT.H.Jr.HicksL.A.Variations in antibiotic and" exact="azithromycin" post="prescribing for children by geography and specialty-United States, 2013Pediatr."/>
   <result pre="pathways to reposition common approved drugs against COVID-19202010.20944/preprints202003.0302.v1Preprints 33GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="an innovative novel model of rhinovirus infection and impact of" exact="clarithromycin" post="treatment on infection kineticsVirology5232018 Oct273430077071 37LusambaKNNomuraKKawaseTOtaCKuboHSatoTThe non-antibiotic macrolide EM900"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7183928\results\search\drugs\results.xml">
   <result pre="for planned and ongoing clinical trials. The focus is on" exact="chloroquine" post="and hydroxychloroquine- two oral drugs that have been available"/>
   <result pre="Drug Administration (FDA issued) an emergency use authorization (EUA) permitting" exact="chloroquine" post="phosphate (medical grade) and hydroxychloroquine sulfate to be added"/>
   <result pre="emergency use authorization (EUA) permitting chloroquine phosphate (medical grade) and" exact="hydroxychloroquine" post="sulfate to be added to the strategic national stockpile"/>
   <result pre="and Human Services (HHS) and accepted 30 million doses of" exact="hydroxychloroquine" post="sulfate donated by Sandoz™, the Novartis™ generics and biosimilars"/>
   <result pre="Novartis™ generics and biosimilars division, and one million doses of" exact="chloroquine" post="phosphate donated by Bayer Pharmaceuticals™ for potential use in"/>
   <result pre="avoid shortages for patients with autoimmune disease who rely on" exact="hydroxychloroquine" post="sulfate (Plaquenil®) for routine treatment [4]. Fig. 2 Chloroquine"/>
   <result pre="sulfate (Plaquenil®) for routine treatment [4]. Fig. 2 Chloroquine and" exact="hydroxychloroquine" post="compounds. Molecular structures of chloroquine and chloroquine phosphate (upper"/>
   <result pre="[4]. Fig. 2 Chloroquine and hydroxychloroquine compounds. Molecular structures of" exact="chloroquine" post="and chloroquine phosphate (upper panels) and hydroxychloroquine and hydroxychloroquine"/>
   <result pre="2 Chloroquine and hydroxychloroquine compounds. Molecular structures of chloroquine and" exact="chloroquine" post="phosphate (upper panels) and hydroxychloroquine and hydroxychloroquine sulfate The"/>
   <result pre="Molecular structures of chloroquine and chloroquine phosphate (upper panels) and" exact="hydroxychloroquine" post="and hydroxychloroquine sulfate The coordinated use of chloroquine phosphate"/>
   <result pre="of chloroquine and chloroquine phosphate (upper panels) and hydroxychloroquine and" exact="hydroxychloroquine" post="sulfate The coordinated use of chloroquine phosphate and hydroxychloroquine"/>
   <result pre="panels) and hydroxychloroquine and hydroxychloroquine sulfate The coordinated use of" exact="chloroquine" post="phosphate and hydroxychloroquine sulfate is governed by the HHS"/>
   <result pre="and hydroxychloroquine sulfate The coordinated use of chloroquine phosphate and" exact="hydroxychloroquine" post="sulfate is governed by the HHS office of the"/>
   <result pre="of Homeland Security The EUA grants permission to BARDA allowing" exact="chloroquine" post="phosphate and hydroxychloroquine sulfate to be distributed and prescribed"/>
   <result pre="The EUA grants permission to BARDA allowing chloroquine phosphate and" exact="hydroxychloroquine" post="sulfate to be distributed and prescribed by physicians to"/>
   <result pre="may be modest and largely unknown in patients with Covid-19," exact="chloroquine" post="reduces neutrophil extracellular trap (NET) formation, platelet aggregation and"/>
   <result pre="arterial vasodilation in diabetic mice [8]. In humans, it decreases" exact="nitric oxide" post="production in coronary artery endothelial cells. The potential clinical"/>
   <result pre="hypotension, decreased myocardial performance and arrhythmias have been reported following" exact="chloroquine" post="administration at high doses (reviewed in Ben-Zvi [10]). The"/>
   <result pre="doses (reviewed in Ben-Zvi [10]). The potential cardiotoxic effects of" exact="chloroquine" post="have been summarized by several groups. Blignaut and colleagues"/>
   <result pre="Prevention (CDC) posted a warning on their website about non-medicinal" exact="chloroquine" post="phosphate products and their potential risks to humans after"/>
   <result pre="mindful of and attentive to the potential risk of medicinal" exact="chloroquine" post="and hydroxychloroquine (to be discussed) when taken in doses"/>
   <result pre="and attentive to the potential risk of medicinal chloroquine and" exact="hydroxychloroquine" post="(to be discussed) when taken in doses higher that"/>
   <result pre="cause of sudden cardiac death Data supporting the investigation of" exact="chloroquine" post="in Covid-19 There are in vitro data for chloroquine"/>
   <result pre="of chloroquine in Covid-19 There are in vitro data for" exact="chloroquine" post="and SARS-CoV replication [12]. Kayaerts et al. tested its"/>
   <result pre="SARS-CoV-induced cytopathicity in Vero E6 cell culture. The IC50 of" exact="chloroquine" post="for antiviral activity (8.8 ± 1.2 μM) was significantly lower than"/>
   <result pre="rate (98.6%) occurred when mother mice received 15 mg of" exact="chloroquine" post="per kg of body weight daily. Wang and colleagues"/>
   <result pre="and colleagues [14] tested the in vitro antiviral activity of" exact="chloroquine" post="in Vero E6 cells infected with nCoV-2019BetaCoV/Wuhan/WIV04/2019 at a"/>
   <result pre="patients were divided into two groups: one (n = 10) treated with" exact="chloroquine" post="(500 mg, oral administration, twice daily) and another (n = 12)"/>
   <result pre="a result of its lipophilic properties and relatively high pH," exact="hydroxychloroquine" post="enters cell readily and accumulates within lysosomes. There is"/>
   <result pre="[28] performed a systematic review of cardiac complications attributable to" exact="hydroxychloroquine" post="(and chloroquine). There were a total of 127 patients"/>
   <result pre="autoimmune disease. Potential risks The adverse effects associated with taking" exact="hydroxychloroquine" post="are similar to those observed with chloroquine and include"/>
   <result pre="associated with taking hydroxychloroquine are similar to those observed with" exact="chloroquine" post="and include nausea, vomiting, diarrhea, AV conduction defects, a"/>
   <result pre="or calcium). Drug-drug interactions must be considered in patients taking" exact="hydroxychloroquine" post="and include digoxin (increased levels), insulin and oral hypoglycemic"/>
   <result pre="interactions must be considered in patients taking hydroxychloroquine and include" exact="digoxin" post="(increased levels), insulin and oral hypoglycemic agents (heighted responses"/>
   <result pre="oral hypoglycemic agents (heighted responses and hypoglycemia), antiepileptic drugs, methotrexate," exact="cyclosporine" post="and drugs that prolong the QTc. Data supporting the"/>
   <result pre="drugs that prolong the QTc. Data supporting the investigation of" exact="hydroxychloroquine" post="in Covid-19 The antiviral properties of hydroxychloroquine have been"/>
   <result pre="the investigation of hydroxychloroquine in Covid-19 The antiviral properties of" exact="hydroxychloroquine" post="have been summarized and provide a foundation for additional"/>
   <result pre="discussion. Yao and colleagues [29] determined the pharmacological activity of" exact="hydroxychloroquine" post="employing SARS-CoV-2 infected Vero cells. Pharmacokinetic models were constructed"/>
   <result pre="Hydroxychloroquine (EC50 = 0.72 μM) was found to be more potent than" exact="chloroquine" post="(EC50 = 5.47 μM). Based on modeling, a loading dose of"/>
   <result pre="modeling, a loading dose of 400 mg twice daily of" exact="hydroxychloroquine" post="sulfate given orally, followed by a maintenance dose of"/>
   <result pre="be recommended for SARS-CoV-2 infection. The in vitro cytotoxicity of" exact="hydroxychloroquine" post="was determined in VeroE6 cells and showed that the"/>
   <result pre="0.2, and 0.8), the 50% maximal effective concentration (EC50) for" exact="hydroxychloroquine" post="was 4.51, 4.06, 17.31, and 12.96 μM, respectively. The"/>
   <result pre="respiratory tract symptoms and 8 lower respiratory tract symptoms) received" exact="hydroxychloroquine" post="600 mg daily. By day 6, there was decreased"/>
   <result pre="untreated patients derived from the medical literature. The effects of" exact="hydroxychloroquine" post="were reinforced by the addition of azithromycin. More on"/>
   <result pre="of over 12 million patients with greater than 23 million" exact="azithromycin" post="prescriptions, Patel and colleagues [33] identified nearly 25% of"/>
   <result pre="for QTc-prolongation: the RISQ-PATH study [32] The Brazilian study of" exact="chloroquine" post="underscores the importance of cardiovascular safety when using or"/>
   <result pre="Covid-19 confirmed patients of whom approximately half received 450 mg" exact="chloroquine" post="twice daily for five days and the remainder received"/>
   <result pre="CloroCovid-19 study was performed on a background of treatment with" exact="azithromycin" post="and ceftriaxone. Arrhythmias were observed within three days of"/>
   <result pre="study was terminated. While more detailed information is needed, high-dose" exact="chloroquine" post="may not be safe in the treatment of Covid-19."/>
   <result pre="the lay community about the potential risks associated with non-medicinal" exact="chloroquine" post="products. Similarly, patients with Covid-19 for whom a clinician"/>
   <result pre="patients with Covid-19 for whom a clinician believes that either" exact="chloroquine" post="or hydroxychloroquine is indicated must receive information, preferably in"/>
   <result pre="Covid-19 for whom a clinician believes that either chloroquine or" exact="hydroxychloroquine" post="is indicated must receive information, preferably in the form"/>
   <result pre="and drug-drug interactions. Planned and ongoing clinical trials that include" exact="chloroquine" post="or hydroxychloroquine The number of clinical trials in Covid-19"/>
   <result pre="interactions. Planned and ongoing clinical trials that include chloroquine or" exact="hydroxychloroquine" post="The number of clinical trials in Covid-19 patients, either"/>
   <result pre="(New York, NY)20203671412141310.1126/science.367.6485.1412 4.Jakhar D, Kaur I (2020) Potential of" exact="chloroquine" post="and hydroxychloroquine to treat COVID-19 causes fears of shortages"/>
   <result pre="NY)20203671412141310.1126/science.367.6485.1412 4.Jakhar D, Kaur I (2020) Potential of chloroquine and" exact="hydroxychloroquine" post="to treat COVID-19 causes fears of shortages among people"/>
   <result pre="strategies for monitoring and deterrenceCurr Top Microbiol Immunol2005295557916265887 6.SavarinoABoelaertJRCassoneAMajoriGCaudaREffects of" exact="chloroquine" post="on viral infections: an old drug against today's diseasesLancet"/>
   <result pre="coronavirus by chloroquineBiochem Biophys Res Commun200432326426810.1016/j.bbrc.2004.08.08515351731 13.KeyaertsELiSVijgenLRysmanEVerbeeckJVan RanstMMaesPAntiviral activity of" exact="chloroquine" post="against human Coronavirus OC43 infection in newborn miceAntimicrob Agents"/>
   <result pre="Coronavirus OC43 infection in newborn miceAntimicrob Agents Chemother2009533416342110.1128/AAC.01509-0819506054 14.WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="to multifarious diseasesJ Antimicrob Chemother2015701608162125693996 17.PlantoneDKoudriavtsevaTCurrent and future use of" exact="chloroquine" post="and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases:"/>
   <result pre="diseasesJ Antimicrob Chemother2015701608162125693996 17.PlantoneDKoudriavtsevaTCurrent and future use of chloroquine and" exact="hydroxychloroquine" post="in infectious, immune, neoplastic, and neurological diseases: a mini-reviewClin"/>
   <result pre="molecular modeling studies reveal a new mechanism of action of" exact="chloroquine" post="and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents"/>
   <result pre="studies reveal a new mechanism of action of chloroquine and" exact="hydroxychloroquine" post="against SARS-CoV-2 infection. Int J Antimicrob Agents 105960. 22.JacobssonLTTuressonCGulfeAKapetanovicMCPeterssonIFSaxneTGeborekPTreatment"/>
   <result pre="persuasive concept waiting for clinical translationMatrix Biol201544–4615716610.1016/j.matbio.2015.01.015 25.WallaceDJMetzgerALStecherVJTurnbullBAKernPACholesterol-lowering effect of" exact="hydroxychloroquine" post="in patients with rheumatic disease: reversal of deleterious effects"/>
   <result pre="events in systemic lupus erythematosusArthritis Rheum20106286386810.1002/art.2728920131232 28.ChatreCRoubilleFVernhetHJorgensenCPersYMCardiac complications attributed to" exact="chloroquine" post="and hydroxychloroquine: a systematic review of the literatureDrug Saf20184191993110.1007/s40264-018-0689-429858838"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome Coronavirus"/>
   <result pre="Rolain JM, Brouqui P and Raoult D (2020) Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7184439\results\search\drugs\results.xml">
   <result pre="interest the study by Yao et al [1] reporting that" exact="hydroxychloroquine" post="has better antiviral activity than chloroquine against severe acute"/>
   <result pre="al [1] reporting that hydroxychloroquine has better antiviral activity than" exact="chloroquine" post="against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which"/>
   <result pre="concentration ratio and immunomodulatory effects. Moreover, the authors highlighted that" exact="hydroxychloroquine" post="half maximal effective concentration values &quot;tended to decrease with"/>
   <result pre="agents such as human immunodeficiency virus (HIV) [2]. Chloroquine and" exact="hydroxychloroquine" post="are able to inhibit replication at early stages of"/>
   <result pre="or viral genome replication (remdesivir or ribavirin). These effects of" exact="chloroquine" post="on early phases of viral replication permit the attenuation"/>
   <result pre="[6]. On the basis of these investigations, we believe that" exact="hydroxychloroquine" post="can be effective in preventing respiratory tract invasion in"/>
   <result pre="respiratory tract invasion in HCWs exposed to SARS-CoV-2 and that" exact="hydroxychloroquine" post="administration as a prophylactic agent could be particularly useful"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="Clin Infect Dis2020. doi:10.1093/cid/ciaa255. 3.SavarinoA, BoelaertJR, CassoneA, MajoriG, CaudaREffects of" exact="chloroquine" post="on viral infections: an old drug against today’s diseases?Lancet"/>
   <result pre="3:722–7.14592603 4.ShiryaevSA, MesciP, PintoA, et al.Repurposing of the anti-malaria drug" exact="chloroquine" post="for Zika virus treatment and prophylaxis. Sci Rep2017; 7:15771.29150641"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7184499\results\search\drugs\results.xml">
   <result pre="Leading Article COVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progression http://orcid.org/0000-0002-2306-3456ZhouDand1d2DaiSheng-Mingd3TongQiangd3[d1], Institutes of Biomedical"/>
   <result pre="of CQ can cause severe side effects. We propose that" exact="hydroxychloroquine" post="(HCQ), which exhibits an antiviral effect highly similar to"/>
   <result pre="being developed for the treatment of Ebola virus infection; and" exact="chloroquine" post="(CQ), a drug well-known for its effectiveness in treating"/>
   <result pre="bring risks of infectious complications, unlike immunosuppressant drugs such as" exact="methotrexate" post="and leflunomide.19 Gastrointestinal responses, such as vomiting and diarrhoea,"/>
   <result pre="J Immunother Cancer2018; 6: 56.29907163 4WangM, CaoR, ZhangLet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="19: 183.28793932 9van den BorneBE, DijkmansBA, de RooijHHet al.Chloroquine and" exact="hydroxychloroquine" post="equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma"/>
   <result pre="pathogenesis. Virus Res2015; 202: 120–34.25445340 17SchrezenmeierE, DornerT.Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatology. Nat Rev Rheumatol2020; 16:"/>
   <result pre="rheumatology. Nat Rev Rheumatol2020; 16: 155–66.32034323 18Al-BariMAA.Targeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
   <result pre="Rev Rheumatol2018; 14: 693–703.30401979 22IzmirlyPM, Costedoat-ChalumeauN, PisoniCNet al.Maternal use of" exact="hydroxychloroquine" post="is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated"/>
   <result pre="Ann Rheum Dis2017; 76: 1476–80.28501799 24FurstDE, LindsleyH, BaethgeBet al.Dose-loading with" exact="hydroxychloroquine" post="improves the rate of response in early, active rheumatoid"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7184878\results\search\drugs\results.xml">
   <result pre="become available. However, a combination of two HIV-1 protease inhibitors," exact="lopinavir" post="and ritonavir, has been found to be effective against"/>
   <result pre="water accessibility at the 3CLpro active site. In addition, only" exact="ritonavir" post="could interact with the oxyanion hole residues N142 and"/>
   <result pre="A combination of the two approved drugs for HIV infection," exact="lopinavir" post="and ritonavir (KALETRA), has been reported to be active"/>
   <result pre="of the two approved drugs for HIV infection, lopinavir and" exact="ritonavir" post="(KALETRA), has been reported to be active toward SARS"/>
   <result pre="of patients with SARS in a nonrandomized open-label trial.17 Although" exact="ritonavir" post="is a protease inhibitor, it is generally used to"/>
   <result pre="family. Previously, a theoretical study of the molecular interaction of" exact="lopinavir" post="and ritonavir with 3CLpro of SARS-CoV suggested that these"/>
   <result pre="a theoretical study of the molecular interaction of lopinavir and" exact="ritonavir" post="with 3CLpro of SARS-CoV suggested that these two drugs"/>
   <result pre="the three-dimensional structure of SARS-CoV-2 3CLpro in a complex with" exact="lopinavir" post="and ritonavir has not been reported. Thus, in our"/>
   <result pre="structure of SARS-CoV-2 3CLpro in a complex with lopinavir and" exact="ritonavir" post="has not been reported. Thus, in our study, we"/>
   <result pre="our study, we aimed to investigate the binding interactions of" exact="lopinavir" post="and ritonavir with the SARS-CoV-2 proteinase using both molecular"/>
   <result pre="we aimed to investigate the binding interactions of lopinavir and" exact="ritonavir" post="with the SARS-CoV-2 proteinase using both molecular modeling and"/>
   <result pre="(Figure 1A). To generate the models of SARS-CoV-2 3CLpro with" exact="lopinavir" post="and ritonavir bound to protomer A, the positions of"/>
   <result pre="To generate the models of SARS-CoV-2 3CLpro with lopinavir and" exact="ritonavir" post="bound to protomer A, the positions of the original"/>
   <result pre="common reaction mechanism of cysteine protease.23 The chemical structures of" exact="lopinavir" post="(ZINC3951740) and ritonavir (ZINC3944422) were downloaded from the ZINC15"/>
   <result pre="of cysteine protease.23 The chemical structures of lopinavir (ZINC3951740) and" exact="ritonavir" post="(ZINC3944422) were downloaded from the ZINC15 database.24 The electrostatic"/>
   <result pre="an orange ball and stick model. Chemical structures of (B)" exact="lopinavir" post="and (C) ritonavir, where the atomic labels are also"/>
   <result pre="As shown in Figure 2, the RMSD values of both" exact="lopinavir" post="and ritonavir systems continuously increased in the first 40"/>
   <result pre="in Figure 2, the RMSD values of both lopinavir and" exact="ritonavir" post="systems continuously increased in the first 40 ns and"/>
   <result pre="that the # H-bonds and # atom contacts of the" exact="ritonavir" post="system (# H-bonds of 3 ± 1 and #"/>
   <result pre="the last 20 ns) were higher than those of the" exact="lopinavir" post="model (# H-bonds of 2 ± 1 and #"/>
   <result pre="and # atom contacts of 14 ± 4), suggesting that" exact="ritonavir" post="was more susceptible to SARS-CoV-2 3CLpro (discussed in more"/>
   <result pre="further analysis in terms of (i) the binding affinity between" exact="lopinavir" post="or ritonavir and SARS-CoV-2 3CLpro, (ii) key binding residues"/>
   <result pre="in terms of (i) the binding affinity between lopinavir or" exact="ritonavir" post="and SARS-CoV-2 3CLpro, (ii) key binding residues involved in"/>
   <result pre="2 All-atom RMSD, # H-bonds, and # atom contacts of" exact="lopinavir" post="(left) and ritonavir (right) in complex with SARS-CoV-2 3CLpro"/>
   <result pre="# H-bonds, and # atom contacts of lopinavir (left) and" exact="ritonavir" post="(right) in complex with SARS-CoV-2 3CLpro plotted along the"/>
   <result pre="100 ns MD simulation. Predicted Inhibitory Efficiency The susceptibility of" exact="lopinavir" post="and ritonavir to SARS-CoV-2 3CLpro was estimated using the"/>
   <result pre="MD simulation. Predicted Inhibitory Efficiency The susceptibility of lopinavir and" exact="ritonavir" post="to SARS-CoV-2 3CLpro was estimated using the MM/PB(GB)SA approach"/>
   <result pre="with SARS-CoV-2 3CLpro Calculated by the MM/PB(GB)SA Methoda energy component" exact="lopinavir" post="ritonavir Gas Term ΔEvdW –50.29 ± 0.62 –74.09 ±"/>
   <result pre="SARS-CoV-2 3CLpro Calculated by the MM/PB(GB)SA Methoda energy component lopinavir" exact="ritonavir" post="Gas Term ΔEvdW –50.29 ± 0.62 –74.09 ± 0.50"/>
   <result pre="main force inducing molecular complexation with SARS-CoV-2 3CLpro of both" exact="lopinavir" post="(ΔEvdW of −50.29 ± 0.62 kcal/mol) and ritonavir (−74.09"/>
   <result pre="of both lopinavir (ΔEvdW of −50.29 ± 0.62 kcal/mol) and" exact="ritonavir" post="(−74.09 ± 0.50 kcal/mol) and is ∼2–3-fold stronger than"/>
   <result pre="two anti-HIV drugs in complex with SARS-CoV 3CLpro15 and (ii)" exact="darunavir" post="and amprenavir binding to the HIV-1 protease.43 Taken together"/>
   <result pre="drugs in complex with SARS-CoV 3CLpro15 and (ii) darunavir and" exact="amprenavir" post="binding to the HIV-1 protease.43 Taken together with the"/>
   <result pre="solvation effect and entropic term, the binding affinity (ΔGbind) of" exact="ritonavir" post="with SARS-CoV-2 3CLpro (−14.93 ± 1.83 and −27.78 ±"/>
   <result pre="−13.83 ± 1.91 kcal/mol, respectively). The predicted results suggested that" exact="ritonavir" post="may have an ∼1.4–2.0-fold greater inhibitory efficiency than lopinavir"/>
   <result pre="that ritonavir may have an ∼1.4–2.0-fold greater inhibitory efficiency than" exact="lopinavir" post="on the focused target; however, it should be noted"/>
   <result pre="be noted that this drug can clinically also boost the" exact="lopinavir" post="efficacy in the fight against COVID-19. Key Residues for"/>
   <result pre="kcal/mol were taken into account. Figure 3 ΔGbindresidue values of" exact="lopinavir" post="(top) and ritonavir (bottom) in complex with SARS-CoV-2 3CLpro."/>
   <result pre="into account. Figure 3 ΔGbindresidue values of lopinavir (top) and" exact="ritonavir" post="(bottom) in complex with SARS-CoV-2 3CLpro. The contributing residues"/>
   <result pre="M165, and E166) that were important for the binding of" exact="lopinavir" post="and ritonavir, respectively. The more strongly contributing residues found"/>
   <result pre="showed that the phenyl ring at the P1 position of" exact="lopinavir" post="and the thiazole ring at the P2 position of"/>
   <result pre="lopinavir and the thiazole ring at the P2 position of" exact="ritonavir" post="were inserted into the S2 pocket of SARS-CoV-2 3CLpro,"/>
   <result pre="M49 and M165 (Figure 3), and the O1 atom of" exact="ritonavir" post="was stabilized by the -NH group of E166 via"/>
   <result pre="(Figure 6, discussed below). It is of note that only" exact="ritonavir" post="could interact with the catalytic residue H4145 and the"/>
   <result pre="kcal/mol for each residue), suggesting that the molecular structure of" exact="ritonavir" post="fitted well within the active site of SARS-CoV-2 3CLpro."/>
   <result pre="The obtained information was supported by the well-aligned structures of" exact="ritonavir" post="over the last 20 ns simulation (Figure 4), whereas"/>
   <result pre="Figure 4 Superimposed structures over the 20 snapshots of (A)" exact="lopinavir" post="and (B) ritonavir in complex with SARS-CoV-2 3CLpro derived"/>
   <result pre="structures over the 20 snapshots of (A) lopinavir and (B)" exact="ritonavir" post="in complex with SARS-CoV-2 3CLpro derived from the last"/>
   <result pre="the main energy contribution for stabilizing the HIV-1 protease inhibitors" exact="lopinavir" post="and ritonavir was the vdW energy (≲−4.0 kcal/mol), especially"/>
   <result pre="energy contribution for stabilizing the HIV-1 protease inhibitors lopinavir and" exact="ritonavir" post="was the vdW energy (≲−4.0 kcal/mol), especially for residues"/>
   <result pre="and individual residue.40,47,48Figure 6 highlights that residue Q189 dramatically stabilized" exact="lopinavir" post="(−37.3 kcal/mol) mainly through electrostatic, dispersion, and charge transfer"/>
   <result pre="amino acids (i.e., N142, M165, E166, and Q189) contributing to" exact="ritonavir" post="binding with an energy stabilization of approximately −12 to"/>
   <result pre="from each residue of SARS-CoV-2 3CLpro to the binding of" exact="lopinavir" post="(top) and ritonavir (bottom). Figure 6 Pair interaction energy"/>
   <result pre="of SARS-CoV-2 3CLpro to the binding of lopinavir (top) and" exact="ritonavir" post="(bottom). Figure 6 Pair interaction energy decomposition analysis (PIEDA)"/>
   <result pre="(bottom). Figure 6 Pair interaction energy decomposition analysis (PIEDA) of" exact="lopinavir" post="(top) and ritonavir (bottom) interacting with individual residues in"/>
   <result pre="Pair interaction energy decomposition analysis (PIEDA) of lopinavir (top) and" exact="ritonavir" post="(bottom) interacting with individual residues in the binding pocket"/>
   <result pre="α-ketoamide inhibitor (13b) bound to SARS-CoV-2 3CLpro,49 the anti-HIV drugs" exact="lopinavir" post="and ritonavir lack (i) the P3 moiety, (ii) an"/>
   <result pre="(13b) bound to SARS-CoV-2 3CLpro,49 the anti-HIV drugs lopinavir and" exact="ritonavir" post="lack (i) the P3 moiety, (ii) an α-ketoamide group"/>
   <result pre="and P2′ (found only in HIV-1 protease inhibitors) regions of" exact="lopinavir" post="and ritonavir strongly interacted with SARS-CoV-2 3CLpro at the"/>
   <result pre="(found only in HIV-1 protease inhibitors) regions of lopinavir and" exact="ritonavir" post="strongly interacted with SARS-CoV-2 3CLpro at the S2 and"/>
   <result pre="proposed a rational design of novel protease inhibitor(s) derived from" exact="lopinavir" post="and ritonavir to enhance the binding efficiency with SARS-CoV-2"/>
   <result pre="rational design of novel protease inhibitor(s) derived from lopinavir and" exact="ritonavir" post="to enhance the binding efficiency with SARS-CoV-2 3CLpro as"/>
   <result pre="site) at 83.9%. Meanwhile, four H-bonds were detected in the" exact="ritonavir" post="complex: (i) O1(P2 site)···H–N(E166) at 65.6%, (ii) O(H164)···H–N4(P1 site)"/>
   <result pre="reported binding of such HIV-1 protease inhibitors to SARS-CoV.15 Notably," exact="ritonavir" post="showed a slightly higher level of H-bond formation with"/>
   <result pre="occupation of SARS-CoV-2 3CLpro that contributed to the binding of" exact="lopinavir" post="(top) and ritonavir (bottom). Figure 9 Binding patterns of"/>
   <result pre="3CLpro that contributed to the binding of lopinavir (top) and" exact="ritonavir" post="(bottom). Figure 9 Binding patterns of (A) lopinavir and"/>
   <result pre="(top) and ritonavir (bottom). Figure 9 Binding patterns of (A)" exact="lopinavir" post="and (B) ritonavir in complex with SARS-CoV-2 3CLpro demonstrated"/>
   <result pre="(bottom). Figure 9 Binding patterns of (A) lopinavir and (B)" exact="ritonavir" post="in complex with SARS-CoV-2 3CLpro demonstrated from the last"/>
   <result pre="(RDF) (Figure 11) of water oxygens toward all heteroatoms of" exact="lopinavir" post="and ritonavir was used to verify the number of"/>
   <result pre="11) of water oxygens toward all heteroatoms of lopinavir and" exact="ritonavir" post="was used to verify the number of water molecules"/>
   <result pre="time of the two studied systems. (C) Average SASAs of" exact="lopinavir" post="and ritonavir systems. Figure 11 Radial distribution functions, g(r),"/>
   <result pre="the two studied systems. (C) Average SASAs of lopinavir and" exact="ritonavir" post="systems. Figure 11 Radial distribution functions, g(r), of the"/>
   <result pre="up to the first minimum around the heteroatoms of (A)" exact="lopinavir" post="and (B) ritonavir (see Figure 1 for definitions) in"/>
   <result pre="first minimum around the heteroatoms of (A) lopinavir and (B)" exact="ritonavir" post="(see Figure 1 for definitions) in complex with SARS-CoV-2"/>
   <result pre="883.81 ± 75.24 and 918.15 ± 110.03 Å2 for the" exact="lopinavir" post="and ritonavir systems, respectively. Upon molecular complexation in protomer"/>
   <result pre="75.24 and 918.15 ± 110.03 Å2 for the lopinavir and" exact="ritonavir" post="systems, respectively. Upon molecular complexation in protomer A (yellow),"/>
   <result pre="molecular complexation in protomer A (yellow), the SASAs of both" exact="lopinavir" post="(500.21 ± 67.38 Å2) and ritonavir (451.60 ± 61.62"/>
   <result pre="the SASAs of both lopinavir (500.21 ± 67.38 Å2) and" exact="ritonavir" post="(451.60 ± 61.62 Å2) systems dramatically decreased in a"/>
   <result pre="found that the first peak at ∼3 Å of the" exact="lopinavir" post="system (up to ∼2) was slightly higher than that"/>
   <result pre="(up to ∼2) was slightly higher than that of the" exact="ritonavir" post="system (up to ∼1.4), indicating that accessible water molecules"/>
   <result pre="that there was only one bridging water coordinating with (i)" exact="lopinavir" post="(O2) and E166 as well as (ii) ritonavir (O4)"/>
   <result pre="with (i) lopinavir (O2) and E166 as well as (ii)" exact="ritonavir" post="(O4) and N142 with a very low percentage of"/>
   <result pre="binding pattern and susceptibility of the two HIV-1 protease inhibitors" exact="lopinavir" post="and ritonavir in complex with SARS-CoV-2 3CLpro were fully"/>
   <result pre="and susceptibility of the two HIV-1 protease inhibitors lopinavir and" exact="ritonavir" post="in complex with SARS-CoV-2 3CLpro were fully revealed by"/>
   <result pre="According to ΔGbind prediction, the susceptibility against SARS-CoV-2 3CLpro of" exact="ritonavir" post="was somewhat higher than that of lopinavir, supported by"/>
   <result pre="methods: (i) M49, M165, P168, and Q189 from MM/GBSA for" exact="lopinavir" post="and L27, H41, M49, F140, N142, G143, H164, M165,"/>
   <result pre="F140, N142, G143, H164, M165, and E166 from MM/GBSA for" exact="ritonavir" post="and (ii) H41, A46, M49, E166, L167, L187, Q189,"/>
   <result pre="E166, L167, L187, Q189, A191, and A193 from FMO-MP2/PCM/6-31G* for" exact="lopinavir" post="and N142, G143, S144, C145, M165, E166, D187, and"/>
   <result pre="hole residues N142 and G143 were found to interact with" exact="ritonavir" post="via hydrogen bonds. From the FMO-MP2/PCM/6-31G* data, the electrostatics,"/>
   <result pre="AruksakulwongO.; HannongbuaS. (2008) Molecular dynamic simulations analysis of ritronavir and" exact="lopinavir" post="as SARS-CoV 3CLpro inhibitors. J. Theor. Biol.254 (4), 861–867."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7185016\results\search\drugs\results.xml">
   <result pre="the ACE2 receptor has a central function. The antimalarial drugs" exact="chloroquine" post="phosphate (CQ) and hydroxychloroquine (HCQ) impair in vitro the"/>
   <result pre="a central function. The antimalarial drugs chloroquine phosphate (CQ) and" exact="hydroxychloroquine" post="(HCQ) impair in vitro the terminal glycosylation of ACE2"/>
   <result pre="be a more potent inhibitor of infection with SARS-CoV-2 than" exact="chloroquine" post="[14], [15]. Both drugs, taken orally, may cause severe"/>
   <result pre="drugs, e.g. in the treatment of asthma with corticosteroids, e.g." exact="budesonide" post="[23], [24] and beta mimetica, e.g. fenoterol [25], and"/>
   <result pre="with corticosteroids, e.g. budesonide [23], [24] and beta mimetica, e.g." exact="fenoterol" post="[25], and in the early treatment of influenza (during"/>
   <result pre="influenza (during the first 48 h) with neuraminidase blockers like" exact="zanamivir" post="[26]. Moreover, there are reports of undergoing clinical studies"/>
   <result pre="HCQ/CQ in this application form. Evaluation of the hypothesis Why" exact="hydroxychloroquine" post="might be efficacious in COVID-19 It has been demonstrated"/>
   <result pre="0.72 µM for the hydroxy derivative in direct comparison to" exact="chloroquine" post="(5.47 µM) in cell culture experiments with the pathogen"/>
   <result pre="mg twice daily and a subsequent dose of 200 mg" exact="hydroxychloroquine" post="sulfate twice daily there should be significantly higher concentrations"/>
   <result pre="clinical study with more than 100 patients demonstrated superiority of" exact="chloroquine" post="phosphate to controls in inhibiting exacerbation of pneumonia, improving"/>
   <result pre="reactions [11]. In a non-randomized open-label trial in 20 patients," exact="hydroxychloroquine" post="treatment was significantly associated with viral load reduction/disappearance in"/>
   <result pre="a pharmacological standpoint, one major problem of oral treatment with" exact="chloroquine" post="phosphate or hydroxychloroquine is that relatively high concentrations between"/>
   <result pre="one major problem of oral treatment with chloroquine phosphate or" exact="hydroxychloroquine" post="is that relatively high concentrations between 1 and 10"/>
   <result pre="lungs and other organs. 100 to 500 times of the" exact="chloroquine" post="plasma concentration is found in parenchyma cells and 1000"/>
   <result pre="to treat coronavirus disease 2019 (COVID-19)Drug Discover Therapeut14120205860 10ColsonP.RolainJ.M.LagierJ.C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int J Antimicrob Agents1059322020"/>
   <result pre="COVID-19 associated pneumonia in clinical studies. Bioscience trends. 12GautretP.LagierJ.C.ParolaP.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID- 19: results of an"/>
   <result pre="treatment options for the 2019-new coronavirus (2019-nCoV)Biosci Trends1412020697131996494 14WangM.CaoR.ZhangL.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="Controlled Trial. http://www.chictr.org.cn/showproj.aspx?proj=48777 [Accessed 03 April 2020]. 24PauwelsR.A.LöfdahlC.G.PostmaD.S.TattersfieldA.E.O'ByrneP.BarnesP.J.Effect of inhaled" exact="formoterol" post="and budesonide on exacerbations of asthmaN Engl J Med337201997140514119358137"/>
   <result pre="http://www.chictr.org.cn/showproj.aspx?proj=48777 [Accessed 03 April 2020]. 24PauwelsR.A.LöfdahlC.G.PostmaD.S.TattersfieldA.E.O'ByrneP.BarnesP.J.Effect of inhaled formoterol and" exact="budesonide" post="on exacerbations of asthmaN Engl J Med337201997140514119358137 25SalomeC.M.SchoeffelR.E.WoolcockA.J.Effect of"/>
   <result pre="of asthmaN Engl J Med337201997140514119358137 25SalomeC.M.SchoeffelR.E.WoolcockA.J.Effect of aerosol and oral" exact="fenoterol" post="on histamine and methacholine challenge in asthmatic subjectsThorax36819815805847031973 26CassL.M.EfthymiopoulosC.ByeA.Pharmacokinetics"/>
   <result pre="on histamine and methacholine challenge in asthmatic subjectsThorax36819815805847031973 26CassL.M.EfthymiopoulosC.ByeA.Pharmacokinetics of" exact="zanamivir" post="after intravenous, oral, inhaled or intranasal administration to healthy"/>
   <result pre="of human airway epitheliaJ Virol79232005146141462116282461 30Zhang Z. Therapeutic effect of" exact="hydroxychloroquine" post="on novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=48880 [Accessed 14 Feb"/>
   <result pre="Raoult, D. (2020). New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?. Int J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7185795\results\search\drugs\results.xml">
   <result pre="coronavirus: implications for virus origins and receptor bindingLancet39510224202056557432007145 7WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7186114\results\search\drugs\results.xml">
   <result pre="support, and symptomatic treatment. For antiviral therapy, α - interferon," exact="lopinavir" post="/ ritonavir, or abidol can be used. Glucocorticoids in"/>
   <result pre="syndrome in childrenChinese J Pediatr201755729734 2.LiHSKuokDITCheungMCNgMMTNgKCHuiKPYPeirisJSMChanMCWNichollsJMEffect of interferon alpha and" exact="cyclosporine" post="treatment separately and in combination on Middle East respiratory"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7186860\results\search\drugs\results.xml">
   <result pre="Therapy Initial antiviral treatment included lamivudine, entecavir, adefovir dipivoxil, and" exact="tenofovir" post="disoproxil fumarate. In case of drug resistance, another drug,"/>
   <result pre="Therapies Drug Alternative treatment No. of patients Lamivudine Switch to" exact="tenofovir" post="2 Add adefovir when tenofovir is unavailable 0 Adefovir"/>
   <result pre="of patients Lamivudine Switch to tenofovir 2 Add adefovir when" exact="tenofovir" post="is unavailable 0 Adefovir dipivoxil Switch to tenofovir if"/>
   <result pre="adefovir when tenofovir is unavailable 0 Adefovir dipivoxil Switch to" exact="tenofovir" post="if available and add a second drug 6 rtN236T"/>
   <result pre="add a second drug 6 rtN236T substitution is present, add" exact="entecavir" post="1 Without lamivudine resistance detected by sensitive assays for"/>
   <result pre="drug 6 rtN236T substitution is present, add entecavir 1 Without" exact="lamivudine" post="resistance detected by sensitive assays for one with prior"/>
   <result pre="lamivudine resistance detected by sensitive assays for one with prior" exact="lamivudine" post="exposure, switch to entecavir 1 rtA181V/T substitution is present,"/>
   <result pre="sensitive assays for one with prior lamivudine exposure, switch to" exact="entecavir" post="1 rtA181V/T substitution is present, alone or in combination"/>
   <result pre="is present, alone or in combination with rtN236T, switch to" exact="tenofovir" post="plus entecavir 0 Telbivudine Add or switch to tenofovir"/>
   <result pre="alone or in combination with rtN236T, switch to tenofovir plus" exact="entecavir" post="0 Telbivudine Add or switch to tenofovir 1 Entecavir"/>
   <result pre="to tenofovir plus entecavir 0 Telbivudine Add or switch to" exact="tenofovir" post="1 Entecavir Add tenofovir 2 Tenofovir disoproxil fumarate Hepatitis"/>
   <result pre="0 Telbivudine Add or switch to tenofovir 1 Entecavir Add" exact="tenofovir" post="2 Tenofovir disoproxil fumarate Hepatitis B virus genotype and"/>
   <result pre="disoproxil fumarate Hepatitis B virus genotype and phenotyping is required," exact="entecavir" post="may be added 0 Anti-HCC Treatment In the present"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7187825\results\search\drugs\results.xml">
   <result pre="include 3CL protein inhibitors (ribavirin, lopinavir/ritonavir), RNA synthesis inhibitors (remdesivir," exact="tenofovir" post="disoproxil fumarate and 3TC), neuraminidase inhibitors (oseltamivir and peramivir"/>
   <result pre="(remdesivir, tenofovir disoproxil fumarate and 3TC), neuraminidase inhibitors (oseltamivir and" exact="peramivir" post=") [4] and other small molecule drugs which target"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7188521\results\search\drugs\results.xml">
   <result pre="(1/2, 1 and 2 × IC50) of C10, C11 and" exact="digitoxin" post="(positive control) for 24 h at 37 °C. The"/>
   <result pre="Opin Ther Pat2006161463148010.1517/13543776.16.11.1463 4.BaconTHLevinMJLearyJJSariskyRTSuttonDHerpes simplex virus resistance to acyclovir and" exact="penciclovir" post="after two decades of antiviral therapyClin Microbiol Rev20031611412810.1128/CMR.16.1.114-128.200312525428 5.MorfinFThouvenotDHerpes"/>
   <result pre="replication identified via a chemical screening approachVirology200736634034810.1016/j.virol.2007.05.00117544048 28.SuCTHsuJTHsiehHPLinPHChenTCKaoCLLeeCNChangSYAnti-HSV activity of" exact="digitoxin" post="and its possible mechanismsAntiviral Res200879627010.1016/j.antiviral.2008.01.15618353452 29.SinghSShenoySNehetePNYangPNeheteBFontenotDYangGNewmanRASastryKJNerium oleander derived cardiac"/>
   <result pre="Rep2018885010.1038/s41598-018-19298-x29339801 32.Van Der KolkTDillinghMRRijneveldRKlaassenESKoningMNCKouwenhovenSTPGendersREBouwes BavinckJNFeissGRissmannRBurggraafJTopical ionic contra-viral therapy comprised of" exact="digoxin" post="and furosemide as a potential novel treatment approach for"/>
   <result pre="Der KolkTDillinghMRRijneveldRKlaassenESKoningMNCKouwenhovenSTPGendersREBouwes BavinckJNFeissGRissmannRBurggraafJTopical ionic contra-viral therapy comprised of digoxin and" exact="furosemide" post="as a potential novel treatment approach for common wartsJ"/>
   <result pre="substituent of the 1-aminoethyl pharmacophore group on the potency of" exact="rimantadine" post="against influenza virus ABioorg Med Chem Lett20071769269610.1016/j.bmcl.2006.10.09217113287"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7188631\results\search\drugs\results.xml">
   <result pre="very likely to be effectively inhibited by sofosbuvir. More importantly," exact="sofosbuvir" post="is safe and well tolerated at 400 mg daily"/>
   <result pre="is hypothesized that SARS-CoV-2 infection could also be susceptible to" exact="sofosbuvir" post="and we were convinced to design and run a"/>
   <result pre="and run a clinical trial to evaluate the effect of" exact="sofosbuvir" post="400 mg (in combination with velpatasvir 100 mg, as"/>
   <result pre="very likely to be effectively inhibited by sofosbuvir. More importantly," exact="sofosbuvir" post="is safe and well tolerated at 400 mg daily"/>
   <result pre="is hypothesized that SARS-CoV-2 infection could also be susceptible to" exact="sofosbuvir" post="and we were convinced to design and run a"/>
   <result pre="and run a clinical trial to evaluate the effect of" exact="sofosbuvir" post="400 mg (in combination with velpatasvir 100 mg, as"/>
   <result pre="In vitro and limited clinical data suggest potential benefit for" exact="chloroquine" post="and hydroxychloroquine. Nevertheless, FDA on March 27th, 2020, issued"/>
   <result pre="removal of phosphate protection to enter a pathway to yield" exact="sofosbuvir" post="triphosphate, the pharmacologically active antiviral compound. Sofosbuvir is a"/>
   <result pre="with diverse genotypes (11). The acid dissociation constant (pKa) of" exact="sofosbuvir" post="is around 9.3 and as the class 3 compound"/>
   <result pre="3 compound possess high-solubility and low-permeability (12). The phosphorylation of" exact="sofosbuvir" post="within the host cell (hepatocyte) converts it to the"/>
   <result pre="against liver cirrhosis, as well as prior null response to" exact="ribavirin" post="and IFN (13). Moreover, sofosbuvir is fast response and"/>
   <result pre="as prior null response to ribavirin and IFN (13). Moreover," exact="sofosbuvir" post="is fast response and estimated that during the mean"/>
   <result pre="(18). It is reported that the patients receiving combination of" exact="sofosbuvir" post="and ribavirin with or without interferon-α did not express"/>
   <result pre="is reported that the patients receiving combination of sofosbuvir and" exact="ribavirin" post="with or without interferon-α did not express primary sofosbuvir"/>
   <result pre="and ribavirin with or without interferon-α did not express primary" exact="sofosbuvir" post="resistance mutation in NS5B, S282T (15,19). Moreover, sofosbuvir exerts"/>
   <result pre="express primary sofosbuvir resistance mutation in NS5B, S282T (15,19). Moreover," exact="sofosbuvir" post="exerts pan-genotypic antiviral effects against HCV genotypes 1–6 (20)."/>
   <result pre="due to its high efficacy and safety profile (21). Moreover," exact="sofosbuvir" post="can be prescribed in an oral single daily dose"/>
   <result pre="dose due to its promising pharmacokinetic profile. The bioavailability of" exact="sofosbuvir" post="is high with maximum plasma concentrations (Cmax) at ≈"/>
   <result pre="al. (9) observed that, beyond members of the Flaviviridae family," exact="sofosbuvir" post="also inhibits chikungunya virus replication. They found that sofosbuvir"/>
   <result pre="family, sofosbuvir also inhibits chikungunya virus replication. They found that" exact="sofosbuvir" post="was three times more selective in inhibiting Chikungunya virus"/>
   <result pre="Although hepatic cells have the most effective system for removing" exact="sofosbuvir" post="phosphate protection, functional assays have revealed that other cells,"/>
   <result pre="revealed that other cells, relevant to SARS-CoV-2 infection, also activate" exact="sofosbuvir" post="(9,31). One of principle cell types productively infected by"/>
   <result pre="non-human and human epithelial cell lines (32). As mentioned above," exact="sofosbuvir" post="is (metabolized to the active drug and) capable of"/>
   <result pre="of this type of virus inside the epithelial cells. Furthermore," exact="sofosbuvir" post="appears to be highly active against ZIKV in human"/>
   <result pre="ZIKV in human neuroepithelial stem cells (24,26) Antiviral activity of" exact="sofosbuvir" post="against Zika virus or SARS-CoV-2 depends on the (cellular"/>
   <result pre="enzymes (such as NDK), involved in the metabolic activation of" exact="sofosbuvir" post="in the infected cells, are two main determinants. Other"/>
   <result pre="in part, explain the successful uptake and intracellular activation of" exact="sofosbuvir" post="in alveolar epithelial cells, as a viral reservoir. We"/>
   <result pre="of the drug in the disease state. Which feature of" exact="sofosbuvir" post="may give hope? That may be intracellular stability of"/>
   <result pre="also confirmed this observation and evaluated In vitro metabolism of" exact="sofosbuvir" post="and ribavirin in primary human hepatocytes (38). They showed"/>
   <result pre="this observation and evaluated In vitro metabolism of sofosbuvir and" exact="ribavirin" post="in primary human hepatocytes (38). They showed that activation"/>
   <result pre="efficient for two investigated drugs, but the triphosphate metabolite of" exact="sofosbuvir" post="persisted with a half-life of 24 h while ribavirin"/>
   <result pre="of sofosbuvir persisted with a half-life of 24 h while" exact="ribavirin" post="triphosphate had a short initial half-life of approximately 4"/>
   <result pre="above statements demonstrate that the intracellular triphosphate levels achieved following" exact="sofosbuvir" post="administration may equal or exceed the inhibition constant (EC50)"/>
   <result pre="of HCV, may inibit SARS-CoV-2 RdRp enzyme (39). Overall, although" exact="sofosbuvir" post="is not currently listed as potential option of COVID-19"/>
   <result pre="to perform a trial on patients with SARS-CoV-2 infection. Moreover," exact="sofosbuvir" post="is safe and well tolerated at 400 mg daily"/>
   <result pre="in combination with Peg-IFN and RBV or in combination with" exact="ribavirin" post="alone in all-oral regimen, was excellent, even in cirrhotic"/>
   <result pre="regimen, was excellent, even in cirrhotic patients. Also, In vitro," exact="sofosbuvir" post="exhibits no cytotoxicity, mitochondrial toxicity, or bone marrow toxicity"/>
   <result pre="and run a clinical trial to evaluate the effect of" exact="sofosbuvir" post="400 mg (in combination with velpatasvir 100 mg, as"/>
   <result pre="currently in process. In agreement with (9), we advocate generic" exact="sofosbuvir" post="beyond treatment of HCV-infected patients. As it represents a"/>
   <result pre="of SARS-CoV PolymerasebioRxiv202010.1101/2020.03.12.989186 9FerreiraA.C.ReisP.A.de FreitasC.S.Beyond members of the Flaviviridae family," exact="sofosbuvir" post="also inhibits chikungunya virus replicationAntimicrob Agents Chemother63201910.1128/AAC.01389-18 10ElfikyA.A.Anti-HCV, nucleotide"/>
   <result pre="hepatitis C viral kinetics during administration of two nucleotide analogues:" exact="sofosbuvir" post="(GS-7977) and GS-0938Antivir Ther19201421122024464551 15SvarovskaiaE.DvoryH.HebnerC.No Resistance Detected in four"/>
   <result pre="S, Sulkowski M, Lalezari J, et al. All-oral therapy with" exact="sofosbuvir" post="plus ribavirin for the treatment of HCV genotype 1,"/>
   <result pre="M, Lalezari J, et al. All-oral therapy with sofosbuvir plus" exact="ribavirin" post="for the treatment of HCV genotype 1, 2, and"/>
   <result pre="from mortality, preventing short-and long-term sequelaeSci Rep720171928127051 24Bullard-FeibelmanK.M.GoveroJ.ZhuZ.The FDA-approved drug" exact="sofosbuvir" post="inhibits Zika virus infectionAntiviral Res137201713414027902933 25SacramentoC.Q.De MeloG.R.De FreitasC.S.The clinically"/>
   <result pre="virus infectionAntiviral Res137201713414027902933 25SacramentoC.Q.De MeloG.R.De FreitasC.S.The clinically approved antiviral drug" exact="sofosbuvir" post="inhibits Zika virus replicationSci Rep720174092028098253 26OnoratiM.LiZ.LiuF.Zika virus disrupts phospho-TBK1"/>
   <result pre="virus replicationSci Rep7201711128127051 28De FreitasC.S.HigaL.M.SacramentoC.Q.Yellow fever virus is susceptible to" exact="sofosbuvir" post="both in vitro and in vivoPLoS Negl Trop Dis132019e000707230699122"/>
   <result pre="C hikungunya virus infectionCell Microbiol1420121354136322686853 33MumtazN.JimmersonL.C.BushmanL.R.Cell-line dependent antiviral activity of" exact="sofosbuvir" post="against Zika virusAntiviral Res146201716116328912011 34BoissanM.SchlattnerU.LacombeM.-L.The NDPK/NME superfamily: state of"/>
   <result pre="artLab Invest98201816417429451272 35MutchE.NaveR.McCrackenN.The role of esterases in the metabolism of" exact="ciclesonide" post="to desisobutyryl-ciclesonide in human tissueBiochem Pharmacol7320071657166417331475 36McCrackenN.BlainP.WilliamsF.Nature and role"/>
   <result pre="diphosphate and triphosphate prodrugs–An unsolvable task?Antivir Chem Chemother252017698229096525 38BabusisD.CurryM.P.KirbyB.Sofosbuvir and" exact="ribavirin" post="liver pharmacokinetics in patients infected with hepatitis C virusAntimicrob"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7189021\results\search\drugs\results.xml">
   <result pre="(Vincent et al. 2005). In addition to its antiviral function," exact="chloroquine" post="has an immune-modulating role that can improve synergistically its"/>
   <result pre="improve synergistically its antiviral effect in vivo. Upon oral administration," exact="chloroquine" post="is spread extensively throughout the entire body, including the"/>
   <result pre="the entire body, including the lung. The EC90 value of" exact="chloroquine" post="in Vero E6 cells against COVID-19 was 6.90 μM,"/>
   <result pre="The time-of-addition assay demonstrated, in an in vitro analysis, that" exact="chloroquine" post="performed at both entry and post-entry stages of COVID-19"/>
   <result pre="Vero E6 cells (Wang et al. 2020). Hydroxychloroquine Hydroxychloroquine and" exact="chloroquine" post="are cellular autophagy modulators that interact with enveloped viruses,"/>
   <result pre="(Savarino et al. 2003; Byrd and Horwitz 1991). Hydroxychloroquine or" exact="chloroquine" post="anti-HIV-1 activity was demonstrated in conjunction with antiretroviral drugs"/>
   <result pre="in conjunction with antiretroviral drugs such as zidovudine, hydroxyurea, and" exact="didanosine" post="in vitro, or patients (Paton and Aboulhab 2005). Hydroxychloroquine"/>
   <result pre="against COVID-19. There is hope in this high-need scenario that" exact="chloroquine" post="could change the whole history of this pandemic assault."/>
   <result pre="iron. A potential new mechanism for the therapeutic effect of" exact="chloroquine" post="against intracellular pathogensJ Clin Invest19918835135710.1172/JCI1153012056129 Cascella M, Rajnik M,"/>
   <result pre="trial of Ebola virus disease therapeuticsN Engl J Med20193812293230310.1056/NEJMoa191099331774950 PatonNIAboulhabJHydroxychloroquine," exact="hydroxyurea" post="and didanosine as initial therapy for HIV-infected patients with"/>
   <result pre="Ebola virus disease therapeuticsN Engl J Med20193812293230310.1056/NEJMoa191099331774950 PatonNIAboulhabJHydroxychloroquine, hydroxyurea and" exact="didanosine" post="as initial therapy for HIV-infected patients with low viral"/>
   <result pre="efficacy and resistance profile after 144 weeksHIV Med200561132010.1111/j.1468-1293.2005.00259.x15670247 SavarinoABoelaertJRCassoneAMajoriGCaudaREffects of" exact="chloroquine" post="on viral infections: an old drug against today’s diseasesLancet"/>
   <result pre="of SARS coronavirus infection and spreadVirol J200526910.1186/1743-422X-2-6916115318 WangMCaoRZhangLet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7189022\results\search\drugs\results.xml">
   <result pre="efficacy of lopinavir/ritonavir might not be significant. Multiple studies on" exact="hydroxychloroquine" post="sulfate or chloroquine phosphate are currently being conducted in"/>
   <result pre="might not be significant. Multiple studies on hydroxychloroquine sulfate or" exact="chloroquine" post="phosphate are currently being conducted in several countries. An"/>
   <result pre="that in 6 asymptomatic nucleic acid-positive patients, the treatment of" exact="hydroxychloroquine" post="and azithromycin resulted in a 100% negative conversion rate"/>
   <result pre="6 asymptomatic nucleic acid-positive patients, the treatment of hydroxychloroquine and" exact="azithromycin" post="resulted in a 100% negative conversion rate of SARS-CoV-2"/>
   <result pre="France suggested that the disease progression rate of patients using" exact="hydroxychloroquine" post="+ azithromycin was 4.3%, and the mortality rate among"/>
   <result pre="that the disease progression rate of patients using hydroxychloroquine +" exact="azithromycin" post="was 4.3%, and the mortality rate among these patients"/>
   <result pre="the peer review process. More studies on the efficacy of" exact="hydroxychloroquine" post="+ azithromycin will still be needed. Remdesivir is an"/>
   <result pre="review process. More studies on the efficacy of hydroxychloroquine +" exact="azithromycin" post="will still be needed. Remdesivir is an RNA-dependent RNA"/>
   <result pre="experience of treating COVID-19 patients at Shanghai, the dose of" exact="methylprednisolone" post="was 40–80 mg/day for 3 days, which was then tapered"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7189176\results\search\drugs\results.xml">
   <result pre="COVID-19 guidelines and recommended the use of lopinavir/ritonavir tablets or" exact="chloroquine" post="in critically ill older patients. Hydroxychloroquine is also recommended"/>
   <result pre="in critically ill older patients. Hydroxychloroquine is also recommended when" exact="chloroquine" post="is unavailable. The use of other potential drugs reported"/>
   <result pre="of lopinavir/ritonavir tablets (400 mg/100 mg orally twice daily) or" exact="chloroquine" post="(500 mg orally two times daily) in critically ill"/>
   <result pre="Hydroxychloroquine (orally 400 mg once daily) is also recommended when" exact="chloroquine" post="is unavailable [13]. The use of other drugs such"/>
   <result pre="is unavailable [13]. The use of other drugs such as" exact="hydroxychloroquine" post="plus azithromycin [14, 15], ribavirin [16, 17], interferon [18,"/>
   <result pre="[13]. The use of other drugs such as hydroxychloroquine plus" exact="azithromycin" post="[14, 15], ribavirin [16, 17], interferon [18, 19], oseltamivir"/>
   <result pre="of other drugs such as hydroxychloroquine plus azithromycin [14, 15]," exact="ribavirin" post="[16, 17], interferon [18, 19], oseltamivir [20], favipiravir [21],"/>
   <result pre="plus azithromycin [14, 15], ribavirin [16, 17], interferon [18, 19]," exact="oseltamivir" post="[20], favipiravir [21], sofosbuvir [22], ivermectin [23], ozone therapy"/>
   <result pre="ribavirin [16, 17], interferon [18, 19], oseltamivir [20], favipiravir [21]," exact="sofosbuvir" post="[22], ivermectin [23], ozone therapy [24], and tocilizumab [25]"/>
   <result pre="17], interferon [18, 19], oseltamivir [20], favipiravir [21], sofosbuvir [22]," exact="ivermectin" post="[23], ozone therapy [24], and tocilizumab [25] has not"/>
   <result pre="favipiravir [21], sofosbuvir [22], ivermectin [23], ozone therapy [24], and" exact="tocilizumab" post="[25] has not been recommended as first-line therapies; however,"/>
   <result pre="the risk of macular retinopathy [27] and cardiomyopathy due to" exact="chloroquine" post="[28], and cardiotoxicity (prolonged QT syndrome) due to extended"/>
   <result pre="and cardiotoxicity (prolonged QT syndrome) due to extended use of" exact="hydroxychloroquine" post="alone or in combination with azithromycin in hepatic, renal,"/>
   <result pre="to extended use of hydroxychloroquine alone or in combination with" exact="azithromycin" post="in hepatic, renal, and immunocompromised patients [11, 29]. Additionally,"/>
   <result pre="azithromycin in hepatic, renal, and immunocompromised patients [11, 29]. Additionally," exact="hydroxychloroquine" post="in combination with azithromycin has been reported to reduce"/>
   <result pre="and immunocompromised patients [11, 29]. Additionally, hydroxychloroquine in combination with" exact="azithromycin" post="has been reported to reduce the detection of SARS-CoV-2"/>
   <result pre="15.Gautret P, Lagier J, Parola P, et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="against COVID-19. Life Sci. 2020;248:117477. 10.1016/j.lfs.2020.117477. 23.Leon CalyLDruceJDCattonMGJansDAWagstaffKMThe FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntivir Res202010.1016/j.antiviral.2020.10478732251768 24.Zhou"/>
   <result pre="Cancer Network News. FDA approves phase III clinical trial of" exact="tocilizumab" post="for COVID-19 pneumonia. 2020. https://www.cancernetwork.com/news/fda-approves-phase-iii-clinical-trial-tocilizumab-covid-19-pneumonia. Accessed 26 Mar 2020."/>
   <result pre="26 Mar 2020. 27.DevauxCARolainJMColsonPRaoultDNew insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int J Antimicrob"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7189399\results\search\drugs\results.xml">
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7189400\results\search\drugs\results.xml">
   <result pre="Lopinavir 3CLpro Inhibits 3CLpro Ritonavir 3CLpro Inhibits 3CLpro Darunavir and" exact="cobicistat" post="3CLpro Inhibits 3CLpro ASC09F (HIV protease inhibitor) 3CLpro Inhibits"/>
   <result pre="and hypoxia at high doses (Arabi et al. 2019). Similarly," exact="ribavirin" post="was also evaluated against SARS-CoV-2 infection, but the antiviral"/>
   <result pre="to the higher serum level of ribavirin. Similarly, coadministration of" exact="abacavir" post="may increase the hepatotoxicity of ribavirin. Favipiravir (T-705) was"/>
   <result pre="2020). Approved Protease Inhibitors Drugs such as disulfiram, lopinavir, and" exact="ritonavir" post="have antiviral activity against human coronaviruses. Disulfiram was primarily"/>
   <result pre="in cell line models (Agostini et al. 2018). In addition," exact="lopinavir" post="and ritonavir are the HIV protease inhibitors that also"/>
   <result pre="line models (Agostini et al. 2018). In addition, lopinavir and" exact="ritonavir" post="are the HIV protease inhibitors that also have efficacy"/>
   <result pre="action of these protease inhibitors is still controversial. At present," exact="lopinavir" post="and ritonavir are in clinical trial in patients infected"/>
   <result pre="these protease inhibitors is still controversial. At present, lopinavir and" exact="ritonavir" post="are in clinical trial in patients infected with SARS-CoV-2,"/>
   <result pre="Strategies Several immune modulator drugs such as chloroquine, nitazoxanide, and" exact="ribavirin" post="in combination of PEGylated interferon alfa-2a and -2b have"/>
   <result pre="and De Clercq 2020). A recent study has shown that" exact="chloroquine" post="is more effective to prevent SARS-CoV-2 infection in cell"/>
   <result pre="the severity of infection. However, a retrospective analysis reported that" exact="ribavirin" post="alone or in combination with interferon-alpha (IFN-ἀ) or lopinavir"/>
   <result pre="that ribavirin alone or in combination with interferon-alpha (IFN-ἀ) or" exact="lopinavir" post="or ritonavir showed increase in survival compared to patients"/>
   <result pre="alone or in combination with interferon-alpha (IFN-ἀ) or lopinavir or" exact="ritonavir" post="showed increase in survival compared to patients taking supportive"/>
   <result pre="2003). In the same way, several studies have reported that" exact="ribavirin" post="in conjugation with fluoroquinolones and corticosteroids did not demonstrate"/>
   <result pre="2005; Zhao et al. 2003). Nevertheless, it is concluded that" exact="ribavirin" post="alone or in combination with other drugs fails to"/>
   <result pre="Antibiotics ± Corticosteroids ± Immunoglobulin No increased positive outcome with" exact="ribavirin" post="compared to controls Increased risk of anemia, hypomagnesemia, hypoxia,"/>
   <result pre="controls Increased risk of anemia, hypomagnesemia, hypoxia, or bradycardia with" exact="ribavirin" post="compared to ribavirin-naive patients Ribavirin (oral/IV) Lopinavir/ritonavir ± Corticosteroids"/>
   <result pre="Class Mechanism of action Loperamide Antidiarrheal agents Unknown Chloroquine, amodiaquine," exact="mefloquine" post="Antimalarial agents Chloroquine targets the type II transmembrane serine"/>
   <result pre="the type II transmembrane serine protease of MERS-CoV For SARS-CoV," exact="chloroquine" post="has also been attributed to a deficit in glycosylation"/>
   <result pre="Inhibits replication of MERS-CoV and SARS-CoV Imatinib, dasatinib, selumetinib, trametinib," exact="sirolimus" post="Kinase inhibitors Imatinib and dasatinib act as entry inhibitor"/>
   <result pre="SARS-CoV Imatinib, dasatinib, selumetinib, trametinib, sirolimus Kinase inhibitors Imatinib and" exact="dasatinib" post="act as entry inhibitor for both MERS and SARS"/>
   <result pre="as entry inhibitor for both MERS and SARS Selumetinib and" exact="trametinib" post="block the entry and replication of MERS-CoV via targeting"/>
   <result pre="by ~60% via targeting mTOR signaling pathway Chlorpromazine, triflupromazine, thiethylperazine," exact="promethazine" post="fluphenazine, astemizole, chlorphenoxamine, fluspirilene Neurotransmitter inhibitors Chlorpromazine inhibits virus"/>
   <result pre="mTOR signaling pathway Chlorpromazine, triflupromazine, thiethylperazine, promethazine fluphenazine, astemizole, chlorphenoxamine," exact="fluspirilene" post="Neurotransmitter inhibitors Chlorpromazine inhibits virus entry, whereas antiviral mechanism"/>
   <result pre="drugs was still not clearly understood Benztropine Anticholinergic Unknown Ribavirin," exact="mycophenolic acid," post="mizoribine, gemcitabine Nucleic acid synthesis inhibitors Unknown Camostat mesylate,"/>
   <result pre="not clearly understood Benztropine Anticholinergic Unknown Ribavirin, mycophenolic acid, mizoribine," exact="gemcitabine" post="Nucleic acid synthesis inhibitors Unknown Camostat mesylate, K11777, E-64-D,"/>
   <result pre="gemcitabine Nucleic acid synthesis inhibitors Unknown Camostat mesylate, K11777, E-64-D," exact="lopinavir" post="Protease inhibitors Camostat mesylate inhibits TMPSSR2-mediated glycoprotein activation of"/>
   <result pre="to target the main protease (Mpro) of SARS-CoV Emetine, anisomycin," exact="omacetaxine mepesuccinate" post="Protein synthesis inhibitors Unknown Toremifene citrate, tamoxifen citrate Selective"/>
   <result pre="Emetine, anisomycin, omacetaxine mepesuccinate Protein synthesis inhibitors Unknown Toremifene citrate," exact="tamoxifen" post="citrate Selective estrogen receptor modulators Unknown Terconazole and triparanol"/>
   <result pre="the transmission of virus, such as vaccines or drugs. Although," exact="ribavirin" post="along with corticosteroids and interferons has been tested in"/>
   <result pre="coronavirus 229E in vitroClin Exp Pharmacol Physiol200633761261610.1111/j.1440-1681.2006.04415.x16789928 ChengKWChengSCChenWYLinMHChuangSJChengIHSunCYChouCYThiopurine analogs and" exact="mycophenolic acid" post="synergistically inhibit the papain-like protease of Middle East respiratory"/>
   <result pre="of Middle East respiratory syndrome coronavirusAntivir Res201511591610.1016/j.antiviral.2014.12.01125542975 ChiouHELiuCLButtreyMJKuoHPLiuHWKuoHTLuYTAdverse effects of" exact="ribavirin" post="and outcome in severe acute respiratory syndrome: experience in"/>
   <result pre="potential targets for novel therapiesDrugs201777181935196610.1007/s40265-017-0830-129143192 FalzaranoDde WitERasmussenALFeldmannFOkumuraAScottDPBriningDBushmakerTMartellaroCBaselerLBeneckeAGKatzeMGMunsterVJFeldmannHTreatment with interferon-α2b and" exact="ribavirin" post="improves outcome in MERS-CoV-infected rhesus macaquesNat Med201319101313131710.1038/nm.336224013700 HartBJDyallJPostnikovaEZhouHKindrachukJJohnsonRFOlingerGGJrFriemanMBHolbrookMRJahrlingPBHensleyLInterferon-β and"/>
   <result pre="ribavirin improves outcome in MERS-CoV-infected rhesus macaquesNat Med201319101313131710.1038/nm.336224013700 HartBJDyallJPostnikovaEZhouHKindrachukJJohnsonRFOlingerGGJrFriemanMBHolbrookMRJahrlingPBHensleyLInterferon-β and" exact="mycophenolic acid" post="are potent inhibitors of Middle East respiratory syndrome coronavirus"/>
   <result pre="inhibit coronavirus replication in vitroAntivir Ther201015569770910.3851/IMP161520710051 KimUJWonEJKeeSJJungSIJangHCCombination therapy with lopinavir/ritonavir," exact="ribavirin" post="and interferon-α for Middle East respiratory syndromeAntivir Ther201621545545910.3851/IMP300226492219 KindrachukJOrkBHartBJMazurSHolbrookMRFriemanMBTraynorDJohnsonRFDyallJKuhnJHOlingerGGHensleyLEJahrlingPBAntiviral"/>
   <result pre="and SARS coronavirus (SARS-CoV). Virus Dis:1–9. 10.1007/s13337-020-00571-5 LeongHNAngBEarnestATeohCXuWLeoYSInvestigational use of" exact="ribavirin" post="in the treatment of severe acute respiratory syndrome, Singapore,"/>
   <result pre="(MERS). Microbiol Spectr 4(3). 10.1128/microbiolspec.EI10-0020-2016 SaijoMMorikawaSFukushiSMizutaniTHasegawaHNagataNIwataNKuraneIInhibitory effect of mizoribine and" exact="ribavirin" post="on the replication of severe acute respiratory syndrome (SARS)-associated"/>
   <result pre="Z, Hu Z, Zhong W, Xiao G (2020) Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="clinical features and cytokine/chemokine responses in SARS patients treated with" exact="interferon alfacon-1" post="plus corticosteroidsAntivir Ther200510226327515865221 WarrenTKWellsJPanchalRGStuthmanKSGarzaNLVan TongerenSADongLRettererCJEatonBPPegoraroGHonnoldSBantiaSKotianPChenXTaubenheimBRWelchLSMinningDMBabuYSSheridanWPBavariSProtection against filovirus diseases by"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7189412\results\search\drugs\results.xml">
   <result pre="SmallC. B., LombaardJ., GrinsztejnB., DoreyD., … MinS. (2013). Dolutegravir versus" exact="raltegravir" post="in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: Week 48 results"/>
   <result pre="in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and" exact="dasabuvir" post="for 12weeks. Journal of Hepatology, 64(2), 301–307. doi:10.1016/j.jhep.2015.10.00526476290 GimenoA.,"/>
   <result pre="Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor" exact="raltegravir" post="as part of combination therapy in treatment-naive patients with"/>
   <result pre="WhiteK., SenGuptaD., ChengA., &amp;amp; QuirkE. (2017). Coformulated bictegravir, emtricitabine, and" exact="tenofovir" post="alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for"/>
   <result pre="&amp;amp; QuirkE. (2017). Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus" exact="dolutegravir" post="with emtricitabine and tenofovir alafenamide, for initial treatment of"/>
   <result pre="(2017). Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with" exact="emtricitabine" post="and tenofovir alafenamide, for initial treatment of HIV-1 infection"/>
   <result pre="bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and" exact="tenofovir" post="alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): A"/>
   <result pre="… PodsadeckiT. (2015). Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and" exact="ribavirin" post="for hepatitis C in patients co-infected with HIV-1: A"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7189851\results\search\drugs\results.xml">
   <result pre="S protein priming may prevent cell entry of SARS-CoV-2. Further," exact="chloroquine" post="and hydroxychloroquine, and off-label antiviral drugs, such as the"/>
   <result pre="drugs, such as the nucleotide analogue remdesivir, HIV protease inhibitors" exact="lopinavir" post="and ritonavir, broad-spectrum antiviral drugs arbidol and favipiravir as"/>
   <result pre="to limit cell entry of SARS-CoV-2. The established antimalarial drugs" exact="chloroquine" post="and hydroxychloroquine have been shown to inhibit terminal phosphorylation"/>
   <result pre="cell entry of SARS-CoV-2. The established antimalarial drugs chloroquine and" exact="hydroxychloroquine" post="have been shown to inhibit terminal phosphorylation of ACE2"/>
   <result pre="and to elevate the pH in endosomes, respectively. Chloroquine and" exact="hydroxychloroquine" post="constitute candidate drugs against SARS-CoV-2 infection and COVID-19 disease,"/>
   <result pre="have been shown to inhibit ACE2. 2.2.1 Chloroquine phosphate and" exact="hydroxychloroquine" post="Chloroquine phosphate (Resochin™) and its derivative hydroxychloroquine (Quensyl™, Plaquenil™,"/>
   <result pre="Chloroquine phosphate and hydroxychloroquine Chloroquine phosphate (Resochin™) and its derivative" exact="hydroxychloroquine" post="(Quensyl™, Plaquenil™, Hydroquin™, Dolquine™, Quinoric™) have been used for"/>
   <result pre="drugs [42,43]. Chloroquine phosphate inhibits terminal phosphorylation of ACE2, and" exact="hydroxychloroquine" post="elevates the pH in endosomes which are involved in"/>
   <result pre="cell entry [44,45], both mechanisms constitute relevant antiviral mechanisms of" exact="chloroquine" post="and hydroxychloroquine. In vivo, hydroxychloroquine is metabolized into chloroquine."/>
   <result pre="constitute relevant antiviral mechanisms of chloroquine and hydroxychloroquine. In vivo," exact="hydroxychloroquine" post="is metabolized into chloroquine. Chloroquine phosphate has previously been"/>
   <result pre="vitro [44,46], and results from very recent studies reveal that" exact="chloroquine" post="phosphate and, more effectively, hydroxychloroquine also inhibit replication of"/>
   <result pre="very recent studies reveal that chloroquine phosphate and, more effectively," exact="hydroxychloroquine" post="also inhibit replication of SARS-CoV-2 in simian Vero cells"/>
   <result pre="Vero cells [46,47]. By using a physiologically-based pharmacokinetic model for" exact="chloroquine" post="phosphate and hydroxychloroquine in human lung fluid, it was"/>
   <result pre="By using a physiologically-based pharmacokinetic model for chloroquine phosphate and" exact="hydroxychloroquine" post="in human lung fluid, it was demonstrated that the"/>
   <result pre="human lung fluid, it was demonstrated that the concentrations of" exact="hydroxychloroquine" post="recommended for treatment of SARS-CoV-2 infection comprise an oral"/>
   <result pre="in vitro data obtained from SARS-CoV-2-infected Vero cells treated with" exact="hydroxychloroquine" post="[47]. A recent pilot trial conducted in more than"/>
   <result pre="than 100 patients with COVID-19 disease demonstrated that treatment with" exact="chloroquine" post="phosphate is superior to control treatment in inhibiting the"/>
   <result pre="these results and the urgent clinical demand regarding SARS-CoV-2/COVID-19 pandemia," exact="chloroquine" post="phosphate should be recommended to treat COVID-19 associated pneumonia"/>
   <result pre="France with 20 COVID-19 patients treated with daily 600 mg" exact="hydroxychloroquine" post="for 6 days demonstrated at day 6 a negative"/>
   <result pre="COVID-19 patients were randomized to receive either daily 400 mg" exact="hydroxychloroquine" post="for 5 days (n = 31) or no pharmacological"/>
   <result pre="The results from these small studies therefore strongly suggest that" exact="hydroxychloroquine" post="has therapeutic efficacy in COVID-19 disease. Thus, a considerable"/>
   <result pre="a considerable number of clinical trials investigating therapeutic efficacy of" exact="chloroquine" post="phosphate and hydroxychloroquine in patients with SARS-CoV-2 infection and"/>
   <result pre="of clinical trials investigating therapeutic efficacy of chloroquine phosphate and" exact="hydroxychloroquine" post="in patients with SARS-CoV-2 infection and COVID-19 disease have"/>
   <result pre="and parasiticide drug in veterinary medicine), (CAS number. 220119−17-5), and" exact="mefloquine" post="hydrochloride (Lariam™, used for the prophylaxis and treatment of"/>
   <result pre="by GX_P2V, and only the combination of cepharanthine, selamectin and" exact="mefloquine" post="hydrochloride was identified as candidate drug combination against SARS-CoV-2"/>
   <result pre="in 1998 to circumvent HIV resistance towards the protease inhibitor" exact="ritonavir" post="(ABT-538), caused by mutation of valine at position 82"/>
   <result pre="in the active site of HIV protease in response to" exact="ritonavir" post="therapy [92]. Because the metabolism of lopinavir is strongly"/>
   <result pre="in response to ritonavir therapy [92]. Because the metabolism of" exact="lopinavir" post="is strongly inhibited by ritonavir, concomitant oral administration of"/>
   <result pre="lopinavir is strongly inhibited by ritonavir, concomitant oral administration of" exact="lopinavir" post="and ritonavir exceeded the in vitro antiviral EC50 of"/>
   <result pre="strongly inhibited by ritonavir, concomitant oral administration of lopinavir and" exact="ritonavir" post="exceeded the in vitro antiviral EC50 of lopinavir by"/>
   <result pre="lopinavir and ritonavir exceeded the in vitro antiviral EC50 of" exact="lopinavir" post="by &amp;gt;50-fold after 8 h in rat, dog, and"/>
   <result pre="rat, dog, and monkey plasma [92]. Coadministration of 400 mg" exact="lopinavir" post="with 50 mg ritonavir enhanced in healthy human volunteers"/>
   <result pre="plasma [92]. Coadministration of 400 mg lopinavir with 50 mg" exact="ritonavir" post="enhanced in healthy human volunteers the area under the"/>
   <result pre="healthy human volunteers the area under the concentration curve of" exact="lopinavir" post="in plasma by 77-fold over that observed after dosing"/>
   <result pre="in plasma by 77-fold over that observed after dosing with" exact="lopinavir" post="alone, and mean concentrations of lopinavir exceeded the EC50"/>
   <result pre="observed after dosing with lopinavir alone, and mean concentrations of" exact="lopinavir" post="exceeded the EC50 for &amp;gt;24 h [92]. Therefore, the"/>
   <result pre="the EC50 for &amp;gt;24 h [92]. Therefore, the combination of" exact="lopinavir" post="and ritonavir (Kaletra™) has been established as an effective"/>
   <result pre="for &amp;gt;24 h [92]. Therefore, the combination of lopinavir and" exact="ritonavir" post="(Kaletra™) has been established as an effective oral drug"/>
   <result pre="other antiretroviral agents [93,94].An initial study in 2003 demonstrated that" exact="lopinavir" post="at 4 μg/mL inhibited the cytopathic effect in a"/>
   <result pre="patients infected with SARS-CoV were treated with the combination of" exact="lopinavir" post="(400 mg)/ritonavir (100 mg) orally every 12 h for"/>
   <result pre="and COVID-19 pneumonia, oral administration of twice daily 400 mg" exact="lopinavir" post="and 100 mg ritonavir for 14 days revealed rather"/>
   <result pre="administration of twice daily 400 mg lopinavir and 100 mg" exact="ritonavir" post="for 14 days revealed rather disappointing results, compared to"/>
   <result pre="disease received orally 200 mg umifenovir every 8 h plus" exact="lopinavir" post="(400 mg)/ritonavir (100 mg) every 12 h for 5–21"/>
   <result pre="every 12 h for 5–21 days; seventeen COVID-19 patients received" exact="lopinavir" post="(400 mg)/ritonavir (100 mg) every 12 h and served"/>
   <result pre="clinical trials with umifenovir alone or in combination with lopinavir/ritonavir," exact="chloroquine" post="phosphate or carrimycin have been recently initiated in China"/>
   <result pre="combined with a monoclonal antibody against the human interleukin-6 receptor," exact="tocilizumab" post="[123] or favipiravir in combination with chloroquine phosphate and"/>
   <result pre="human interleukin-6 receptor, tocilizumab [123] or favipiravir in combination with" exact="chloroquine" post="phosphate and the viral neuramidase inhibitor oseltamivir [124] have"/>
   <result pre="in combination with chloroquine phosphate and the viral neuramidase inhibitor" exact="oseltamivir" post="[124] have been initiated recently in China. 3.5 Inhibitors"/>
   <result pre="assay with simian Vero cells infected with SARS-CoV-2, N3 and" exact="ebselen" post="displayed antiviral and cell protection efficacy at EC50 values"/>
   <result pre="Union recently and urgently initiated clinical trials to test remdesivir," exact="chloroquine" post="and hydroxychloroquine, lopinavir/ritonavir, and lopinavir/ritonavir plus interferon β-1a in"/>
   <result pre="prevents virus host cell entry by inhibiting TMPRSS2 [8], and" exact="chloroquine" post="phosphate which inhibits terminal phosphorylation of ACE2, or hydroxychloroquine"/>
   <result pre="and chloroquine phosphate which inhibits terminal phosphorylation of ACE2, or" exact="hydroxychloroquine" post="which is metabolized in vivo to chloroquine [44]. For"/>
   <result pre="of ACE2, or hydroxychloroquine which is metabolized in vivo to" exact="chloroquine" post="[44]. For the treatment of ordinary and severe COVID-19"/>
   <result pre="intravenous [36,77,82,83] Lopinavir/ritonavir (KaletraTM) Antiviral drug Viral proteases 400 mg" exact="lopinavir" post="and 100 mg ritonavir twice daily, for 14 days,"/>
   <result pre="Antiviral drug Viral proteases 400 mg lopinavir and 100 mg" exact="ritonavir" post="twice daily, for 14 days, peroral [95,96,98] Umifenovir (ArbidolTM)"/>
   <result pre="non-alcoholic mild pancreatic diseaseJ. Gastroenterol.45320103353411988 98-10419876587 29YamawakiH.FutagamiS.KanetoK.AgawaS.HiguchiK.MurakamiM.Camostat mesilate, pancrelipase, and" exact="rabeprazole" post="combination therapy improves epigastric pain in early chronic pancreatitis"/>
   <result pre="in ratsJpn. J. Pharmacol.41219861551622427760 33HiraishiM.YamazakiZ.IchikawaK.KanaiF.IdezukiY.OnishiK.Plasma collection using nafamostat mesilate and" exact="dipyridamole" post="as an anticoagulantInt. J. Artif. Organs11319882122163403059 34HirotaM.ShimosegawaT.KitamuraK.TakedaK.TakeyamaY.MayumiT.Continuous regional arterial"/>
   <result pre="using the split-protein-based cell-cell fusion assayAntimicrob. Agents Chemother.601120166532653927550352 36WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="into the antiviral effects of chloroquineLancet Infect. Dis.622006676916439323 43YanY.ZouZ.SunY.LiX.XuK.F.WeiY.Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
   <result pre="coronavirus infection and spreadVirol. J.2August 2220056916115318 45Al-BariM.A.A.Targeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="an overview of approaches currently under studyArztebl.117132020213219(2020) 72-73. 50GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and" exact="azithromycin" post="as a tratment of COVID-19: results of an open-label"/>
   <result pre="open-label non-randomized clinical trialInt. J. Antimicrob. AgentsMarch 20202010594910.1016/j.ijantimicag.2020.10594932205204 51ChenZ.HuJ.ZhangZ.JiangS.HanS.YanD.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
   <result pre="28202010.1002/jmv.25733 53CortegianiA.IngogliaG.IppolitoM.GiarratanoA.EinavS.A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J. Crit. CareMarch 10202010.1016/j.jcrc.2020.03.005pii: S0883-9441(20)30390-7"/>
   <result pre="93BensonC.A.DeeksS.G.BrunS.C.GulickR.M.EronJ.J.KesslerH.A.Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus" exact="nevirapine" post="and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus"/>
   <result pre="human endothelial cells exposed to trimethylamine-N-oxideJ. Cardiovasc. Pharmacol.746201955856531815868 133ChoeJ.Y.KimS.K.Quercetin and" exact="ascorbic acid" post="suppress fructose-induced NLRP3 inflammasome activation by blocking intracellular shuttling"/>
   <result pre="(NF-κB) signaling during haemophilus parasuis infectionVet. Res.47120168027502767 136SunY.ZhaoY.YaoJ.ZhaoL.WuZ.WangY.Wogonoside protects against" exact="dextran" post="sulfate sodium-induced experimental colitis in mice by inhibiting NF-κB"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7189871\results\search\drugs\results.xml">
   <result pre="alarm on a possible risk deriving from the use of" exact="ibuprofen" post="for the control of fever and other symptoms during"/>
   <result pre="serious infectious complications that occurred in patients receiving NSAIDs, mainly" exact="ibuprofen" post="and ketoprofen, used in the treatment of fever and"/>
   <result pre="(which led to hospitalization or death) of infectious complications with" exact="ibuprofen" post="and 49 serious cases with ketoprofen (including cases of"/>
   <result pre="of infectious complications with ibuprofen and 49 serious cases with" exact="ketoprofen" post="(including cases of dermohypoderma, necrotizing fasciitis, sepsis, pneumonia complicated"/>
   <result pre="the French Minister of Health has recommended the use of" exact="paracetamol" post="instead of ibuprofen or oral cortisone for the treatment"/>
   <result pre="of Health has recommended the use of paracetamol instead of" exact="ibuprofen" post="or oral cortisone for the treatment of fever in"/>
   <result pre="in models of acute pleural effusion, the treatment with ibuprofen," exact="indomethacin" post="and flurbiprofen have significantly reduced the volume of exudate"/>
   <result pre="of acute pleural effusion, the treatment with ibuprofen, indomethacin and" exact="flurbiprofen" post="have significantly reduced the volume of exudate and the"/>
   <result pre="evaluated in vitro and in vivo the effects of aspirin," exact="indomethacin" post="and celecoxib on the replication of Vesicular Stomatitis Virus"/>
   <result pre="vitro and in vivo the effects of aspirin, indomethacin and" exact="celecoxib" post="on the replication of Vesicular Stomatitis Virus (VSV) induced"/>
   <result pre="infection, respectively [28]. Amici et al. evaluated the effect of" exact="indomethacin" post="on the replication of coronavirus responsible for the development"/>
   <result pre="in vivo the virus titers in infected dogs treated with" exact="indomethacin" post="(1 mg/kg body weight). Indomethacin showed a potent direct"/>
   <result pre="into host cells were observed. Since the antiviral activity of" exact="indomethacin" post="occurred at concentrations higher than those needed for COX"/>
   <result pre="the drug [30]. As regards to viral infections, studies on" exact="celecoxib" post="appear interesting. In a mouse infection model, the combined"/>
   <result pre="treatment with the polymerase basic protein 2 (PB2) oligonucleotides and" exact="celecoxib" post="was associated to a significant reduction in the viral"/>
   <result pre="with CK1 or H5N1 influenza viruses, the combined treatment with" exact="celecoxib" post="and zanamivir ameliorated lung inflammation and significantly improved the"/>
   <result pre="or H5N1 influenza viruses, the combined treatment with celecoxib and" exact="zanamivir" post="ameliorated lung inflammation and significantly improved the survival rate"/>
   <result pre="lung inflammation and significantly improved the survival rate compared to" exact="zanamivir" post="(p &amp;lt; 0.05) or celecoxib alone (p &amp;lt; 0.05)"/>
   <result pre="the survival rate compared to zanamivir (p &amp;lt; 0.05) or" exact="celecoxib" post="alone (p &amp;lt; 0.05) [32]. Nowadays few clinical studies"/>
   <result pre="community-acquired pneumonia from 1995 to 2003. The results showed that" exact="ibuprofen" post="was the only therapy administered before hospitalization to be"/>
   <result pre="et al. suggests that the repeated exposure of infants to" exact="acetaminophen" post="and ibuprofen may induce immune deviations [42]. We could"/>
   <result pre="suggests that the repeated exposure of infants to acetaminophen and" exact="ibuprofen" post="may induce immune deviations [42]. We could then think"/>
   <result pre="levels was higher for the combination of celecoxib-oseltamivir compared to" exact="oseltamivir" post="alone, without increasing adverse effects [45]. In conclusion, inflammation"/>
   <result pre="on the administration of COX-2 in strengthened inhibitors, such as" exact="celecoxib" post="or etoricoxib, during influenza infection which may improve the"/>
   <result pre="elicited by acute non-specific inflammations in the rat–effect of indomethacin," exact="ibuprofen" post="and flurbiprofenBiochem. Pharmacol.3319842239224310.1016/0006-2952(84)90661-06466346 13DayR.O.GrahamG.G.Non-steroidal anti-inflammatory drugs (NSAIDs)BMJ11June (346)2013f319510.1136/bmj.f3195Erratum in:"/>
   <result pre="16RoccaJ.ManinS.HulinA.AissatA.Verbecq-MorlotW.Prulière-EscabasseV.Wohlhuter-HaddadA.EpaudR.FanenP.TarzeA.New use for an old drug: COX-independent anti-inflammatory effects of" exact="sulindac" post="in models of cystic fibrosisBr. J. Pharmacol.17320161728174110.1111/bph.1346426894321 17LevyB.D.ClishC.B.SchmidtB.GronertK.SerhanC.N.Lipid mediator"/>
   <result pre="24AlfajaroM.M.ChoiJ.S.KimD.S.SeoJ.Y.KimJ.Y.ParkJ.G.SolimanM.BaekY.B.ChoE.H.KwonJ.KwonH.J.ParkS.J.LeeW.S.KangM.I.HosmilloM.GoodfellowI.ChoK.O.Activation of COX-2/PGE2 promotes sapovirus replication via the inhibition of" exact="nitric oxide" post="productionJ. Virol.91January (3)201710.1128/JVI.01656-16pii: e01656-16 25KirkbyN.S.ZaissA.K.WrightW.R.Differential COX-2 induction by viral"/>
   <result pre="Ther.118200610211030PubMed PMID: 17302372 30AmiciC.La FraziaS.BrunelliC.BalsamoM.AngeliniM.SantoroM.G.Inhibition of viral protein translation by" exact="indomethacin" post="in vesicular stomatitis virus infection: role of eIF2α kinase"/>
   <result pre="mice without prior adaptation and responds to a combination of" exact="zanamivir" post="and COX-2 inhibitorPLoS One992014e10796610.1371/journal.pone.0107966 33FrançoisP.DesrumauxA.CansC.PinI.PaveseP.LabarèreJ.Prevalence and risk factors of"/>
   <result pre="Jun 3 42LanghendriesJ.P.AllegaertK.Van Den AnkerJ.N.VeyckemansF.SmetsF.Possible effects of repeated exposure to" exact="ibuprofen" post="and acetaminophen on the intestinal immune response in young"/>
   <result pre="42LanghendriesJ.P.AllegaertK.Van Den AnkerJ.N.VeyckemansF.SmetsF.Possible effects of repeated exposure to ibuprofen and" exact="acetaminophen" post="on the intestinal immune response in young infantsMed. Hypotheses87February2016909610.1016/j.mehy.2015.11.012Epub"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7190394\results\search\drugs\results.xml">
   <result pre="Given the tolerability and minimal P450 interactions, antidepressants (i.e., citalopram," exact="escitalopram" post="etc.), antipsychotics (i.e., olanzapine) and valproate can be considered"/>
   <result pre="interactions, antidepressants (i.e., citalopram, escitalopram etc.), antipsychotics (i.e., olanzapine) and" exact="valproate" post="can be considered to be safe in combination with"/>
   <result pre="of stressor events. Because sedative and hypnotic drugs such as" exact="oxazepam" post="and lorazepam are not metabolised by the CYP system,"/>
   <result pre="events. Because sedative and hypnotic drugs such as oxazepam and" exact="lorazepam" post="are not metabolised by the CYP system, these are"/>
   <result pre="minimal P450 interactions, antidepressants (citalopram, escitalopram, etc.), antipsychotics (olanzapine) and" exact="valproate" post="can be considered to be safe in combination with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7190496\results\search\drugs\results.xml">
   <result pre="and cognitive impairment. •All patients were receiving treatments with either" exact="amantadine" post="or memantine on stable registered doses. •In all patients"/>
   <result pre="impairment. •All patients were receiving treatments with either amantadine or" exact="memantine" post="on stable registered doses. •In all patients infection with"/>
   <result pre="rtPCR of nasopharyngeal swabs. They were receiving treatment with either" exact="amantadine" post="(n=15) or memantine (n=7) in stable registered doses. All"/>
   <result pre="swabs. They were receiving treatment with either amantadine (n=15) or" exact="memantine" post="(n=7) in stable registered doses. All of them had"/>
   <result pre="tested positive for SARS-CoV-2 and were receiving treatment with either" exact="amantadine" post="or memantine on stable registered doses (100mg q.d. and"/>
   <result pre="for SARS-CoV-2 and were receiving treatment with either amantadine or" exact="memantine" post="on stable registered doses (100mg q.d. and 10mg b.i.d,"/>
   <result pre="treatment (n, %) 10 (100%) 5 (100%) 7 (100%) -" exact="amantadine" post="(n) 10 5 0 - memantine (n) 0 0"/>
   <result pre="(100%) 7 (100%) - amantadine (n) 10 5 0 -" exact="memantine" post="(n) 0 0 7 SARS-Cov-2 positive (n, %) 10"/>
   <result pre="adamantanes could be repurposed for COVID-19 (Cimolai, 2020). Among adamantanes," exact="amantadine" post="and memantine are commonly used as symptomatic treatment to"/>
   <result pre="be repurposed for COVID-19 (Cimolai, 2020). Among adamantanes, amantadine and" exact="memantine" post="are commonly used as symptomatic treatment to alleviate fatigue,"/>
   <result pre="by amantadine. Based on this result it was hypothesized that" exact="amantadine" post="could serve as a potent therapeutic decreasing the replication"/>
   <result pre="respiratory failure of COVID-19 patientsJ Med Virol202010.1002/jmv.25728Feb 27 TorresJMaheswariUParthasarathyKConductance and" exact="amantadine" post="binding of a pore formed by a lysine-flanked transmembrane"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7190528\results\search\drugs\results.xml">
   <result pre="available and investigational immunomodulators, such as the interleukin 6 inhibitors" exact="tocilizumab" post="and sarilumab and the anti–granulocyte-macrophage colony-stimulating factor lenzilumab, are"/>
   <result pre="immunodeficiency viruses IFN-α, interferon-alpha IFN-β, interferon-beta IL-6, interleukin 6 LPV," exact="lopinavir" post="LPV/r, lopinavir/ritonavir MERS-CoV, Middle East respiratory syndrome–related coronavirus SARS,"/>
   <result pre="mechanism of action Evidence for SARS-CoV-2 Clinical trials7 Hydroxychloroquine and" exact="chloroquine" post="Blocks viral entry by increasing endosomal pH and inhibiting"/>
   <result pre="and post-entry stages of infection. 500 mg per day of" exact="chloroquine" post="would achieve EC50.8Yao et al: Hydroxychloroquine was more potent"/>
   <result pre="al: Hydroxychloroquine was more potent (EC50 of 0.72 μM) than" exact="chloroquine" post="(EC50 of 5.47 μM).9Liu et al: Chloroquine had lower"/>
   <result pre="with hydroxychloroquine.10Gao et al: Preliminary data from 100 patients demonstrated" exact="chloroquine" post="was better than control (peer review data not available).11Gautret"/>
   <result pre="in the study analysis.12Gautret et al: Confirmed the efficacy of" exact="hydroxychloroquine" post="and azithromycin combination but the study did not have"/>
   <result pre="study analysis.12Gautret et al: Confirmed the efficacy of hydroxychloroquine and" exact="azithromycin" post="combination but the study did not have a control"/>
   <result pre="PCR on days 5-6 after treatment with a combination of" exact="hydroxychloroquine" post="and azithromycin. The study did not have a control"/>
   <result pre="that blocks viral replicationRitonavir blocks CYP3A4 thereby boosting concentration of" exact="lopinavir" post="Clinical Bhatnagar et al, Young et al, Han et"/>
   <result pre="and reduction in supplemental oxygen requirement in 21 patients after" exact="tocilizumab" post="use.27 NCT04315298NCT04320615NCT04317092NCT04306705NCT04322188 Anti–GM-CSF Reduce severity of cytokine release syndrome"/>
   <result pre="benefit in clinical or animal models.32 Paton et al33 tested" exact="chloroquine" post="as a prophylactic agent against influenza. In this randomized"/>
   <result pre="prophylactic agent against influenza. In this randomized double-blind placebo-controlled trial," exact="chloroquine" post="failed to prevent influenza infection. Similarly, after showing a"/>
   <result pre="influenza infection. Similarly, after showing a promising in vitro effect," exact="chloroquine" post="failed to reduce the duration of dengue viremia and"/>
   <result pre="duration of dengue viremia and nonstructural protein 1 antigenemia.34 Moreover," exact="chloroquine" post="did not improve acute disease and was associated with"/>
   <result pre="al8 showed, in in vitro studies on Vero cells, that" exact="chloroquine" post="affected the entry and post-entry stages of infection. They"/>
   <result pre="They suggested that a daily dose of 500 mg of" exact="chloroquine" post="would achieve the half-maximal effective concentration (EC50) in clinical"/>
   <result pre="et al11 reported their preliminary finding on the use of" exact="chloroquine" post="in 100 patients in Wuhan, China, which concluded that"/>
   <result pre="chloroquine in 100 patients in Wuhan, China, which concluded that" exact="chloroquine" post="prevented exacerbation of pneumonia, improved findings on lung imaging,"/>
   <result pre="clinical trial is not available. Because of a shortage of" exact="chloroquine" post="and a superior safety profile, hydroxychloroquine has been proposed"/>
   <result pre="of a shortage of chloroquine and a superior safety profile," exact="hydroxychloroquine" post="has been proposed as an alternative for the treatment"/>
   <result pre="treatment of COVID-19. Yao et al9 compared the EC50 for" exact="hydroxychloroquine" post="and chloroquine and found that hydroxychloroquine was more potent"/>
   <result pre="COVID-19. Yao et al9 compared the EC50 for hydroxychloroquine and" exact="chloroquine" post="and found that hydroxychloroquine was more potent (EC50 of"/>
   <result pre="compared the EC50 for hydroxychloroquine and chloroquine and found that" exact="hydroxychloroquine" post="was more potent (EC50 of 0.72 μM) than chloroquine"/>
   <result pre="that hydroxychloroquine was more potent (EC50 of 0.72 μM) than" exact="chloroquine" post="(EC50 of 5.47 μM). However, in a subsequent analysis,"/>
   <result pre="μM). However, in a subsequent analysis, Liu et al10 found" exact="chloroquine" post="to show a lower EC50 across four different multiplicities"/>
   <result pre="across four different multiplicities of infection. The antiviral effects of" exact="hydroxychloroquine" post="were tested in a small open-label non-randomized trial by"/>
   <result pre="al.12 In this study, viral eradication was faster in the" exact="hydroxychloroquine" post="group compared with the untreated control group; this finding"/>
   <result pre="this finding was further magnified in six patients who received" exact="azithromycin" post="for prevention of bacterial infection. However, there are major"/>
   <result pre="Society’s expected standards.37 Only 20 of 26 patients treated with" exact="hydroxychloroquine" post="were included in the final analysis. The SARS-CoV-2 polymerase"/>
   <result pre="to the viral load) was higher in patients treated with" exact="hydroxychloroquine" post="and azithromycin combination (therefore, they have lower viral load"/>
   <result pre="viral load) was higher in patients treated with hydroxychloroquine and" exact="azithromycin" post="combination (therefore, they have lower viral load and expected"/>
   <result pre="to clear sooner). The majority of the patients treated with" exact="hydroxychloroquine" post="had milder disease (only 22% patients had lower respiratory"/>
   <result pre="virologic outcomes of 80 patients managed with the combination of" exact="hydroxychloroquine" post="and azithromycin. Although the authors confirmed the efficacy of"/>
   <result pre="their conclusion.13 Molina et al14 also investigated the use of" exact="hydroxychloroquine" post="and azithromycin and reported that 8 of 10 (80.0%)"/>
   <result pre="Molina et al14 also investigated the use of hydroxychloroquine and" exact="azithromycin" post="and reported that 8 of 10 (80.0%) patients remain"/>
   <result pre="observed in 25 of 31 (80.6%) of patients treated with" exact="hydroxychloroquine" post="as compared to 17 of 31 (54.8%) in the"/>
   <result pre="Collectively, the suggestion of clinical benefit for the use of" exact="chloroquine" post="and hydroxychloroquine for SARS-CoV-2 should be interpreted with caution,"/>
   <result pre="suggestion of clinical benefit for the use of chloroquine and" exact="hydroxychloroquine" post="for SARS-CoV-2 should be interpreted with caution, as it"/>
   <result pre="and often times conflicting, clinical data. Accordingly, the use of" exact="chloroquine" post="or hydroxychloroquine for COVID-19 should be under clinical trials"/>
   <result pre="times conflicting, clinical data. Accordingly, the use of chloroquine or" exact="hydroxychloroquine" post="for COVID-19 should be under clinical trials or treatment"/>
   <result pre="outside of these trials is not currently recommended. Before starting" exact="hydroxychloroquine" post="or chloroquine, patients should have corrected QT measured.39 Certain"/>
   <result pre="glucose-6-phosphate dehydrogenase deficiency, which is associated with hemolytic anemia with" exact="chloroquine" post="use. Although chloroquine and hydroxychloroquine are considered safe, the"/>
   <result pre="which is associated with hemolytic anemia with chloroquine use. Although" exact="chloroquine" post="and hydroxychloroquine are considered safe, the therapeutic index for"/>
   <result pre="associated with hemolytic anemia with chloroquine use. Although chloroquine and" exact="hydroxychloroquine" post="are considered safe, the therapeutic index for chloroquine is"/>
   <result pre="chloroquine and hydroxychloroquine are considered safe, the therapeutic index for" exact="chloroquine" post="is narrow, and it has been associated with gastrointestinal"/>
   <result pre="underway to provide real-world clinical data on the efficacy of" exact="chloroquine" post="and hydroxychloroquine for the treatment of COVID-19 (Supplemental Table).11"/>
   <result pre="provide real-world clinical data on the efficacy of chloroquine and" exact="hydroxychloroquine" post="for the treatment of COVID-19 (Supplemental Table).11 Based on"/>
   <result pre="and Drug Administration (FDA) has issued an emergency-use authorization of" exact="chloroquine" post="and hydroxychloroquine to treat hospitalized patients with COVID-19.42 Clinicians"/>
   <result pre="Administration (FDA) has issued an emergency-use authorization of chloroquine and" exact="hydroxychloroquine" post="to treat hospitalized patients with COVID-19.42 Clinicians considering the"/>
   <result pre="of LPV/r use was independently associated with worse outcomes. Notably," exact="ribavirin" post="was used concurrently with LPV/r because of its known"/>
   <result pre="intubation rate (0% versus 11%, P&amp;lt;.05), and the proportion requiring" exact="methylprednisolone" post="rescue (27.3% versus 55.4%, P&amp;lt;.05). However, in the rescue-therapy"/>
   <result pre="RNA-dependent viral RNA polymerase. It is a monophosphoramidate prodrug of" exact="adenosine" post="C-nucleoside,57 and its structure is similar to tenofovir alafenamide,"/>
   <result pre="prodrug of adenosine C-nucleoside,57 and its structure is similar to" exact="tenofovir" post="alafenamide, which is active against HIV and hepatitis B"/>
   <result pre="and EC50) when compared with ribavirin, penciclovir, favipiravir, nafamostat, and" exact="nitazoxanide" post="(&amp;gt;129.87 and &amp;gt;88.50 versus &amp;gt;3.65, &amp;gt;4.17, &amp;gt;6.46, &amp;gt;4.44, and"/>
   <result pre="but with much more limited experimental or clinical data, are" exact="nitazoxanide" post="(an antiparasitic drug with broad-spectrum antiviral activity), ribavirin (a"/>
   <result pre="data, are nitazoxanide (an antiparasitic drug with broad-spectrum antiviral activity)," exact="ribavirin" post="(a broad-spectrum antiviral drug), baloxavir (an anti-influenza drug that"/>
   <result pre="febrile patients (including 17 severe and 4 critical patients) received" exact="tocilizumab" post="(including 3 patients who received a second dose), and"/>
   <result pre="underway to evaluate the efficacy and safety of sarilumab and" exact="tocilizumab" post="for IL-6 inhibition in the management of COVID-19 (Table)."/>
   <result pre="that will compare the clinical outcome of patients treated with" exact="chloroquine" post="or hydroxychloroquine, LPV/r, and remdesivir. Second, there are numerous"/>
   <result pre="clinical studies related to the coronavirus disease (COVID-19)https://clinicaltrials.gov/ct2/results?cond=COVID-19 8WangM.CaoR.ZhangL.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="is effective in inhibiting SARS-CoV-2 infection in vitroCell Discov620201431934347 11GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="of COVID-19 associated pneumonia in clinical studiesBiosci Trends1412020727332074550 12GautretP.LagierJ.C.ParolaP.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="Antimicrob Agents202010594932205204 13GautretP.LagierJ.-C.ParolaP.Clinical and microbiological effect of a combination of" exact="hydroxychloroquine" post="and azithromycin in 80 COVID-19 patients with at least"/>
   <result pre="13GautretP.LagierJ.-C.ParolaP.Clinical and microbiological effect of a combination of hydroxychloroquine and" exact="azithromycin" post="in 80 COVID-19 patients with at least a six-day"/>
   <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infection [published"/>
   <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infection [published online ahead"/>
   <result pre="infection [published online ahead of print]Méd Mal Infect202010.1016/j.medmal.2020.03.006 15ChenZ.HuJ.ZhangZ.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
   <result pre="critically ill patients with COVID-19 with convalescent plasmaJAMA32316202015821589 29SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against today's diseases?Lancet"/>
   <result pre="an old drug against today's diseases?Lancet Infect Dis311200372272714592603 30ColsonP.RolainJ.M.LagierJ.C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int J Antimicrob Agents554202010593232145363"/>
   <result pre="Coronavirus OC43 Infection in Newborn MiceAntimicrob Agents Chemother53820093416342119506054 32TouretF.de LamballerieX.Of" exact="chloroquine" post="and COVID-19Antiviral Res177202010476232147496 33PatonN.I.LeeL.XuY.Chloroquine for influenza prevention: a randomised,"/>
   <result pre="placebo controlled trialLancet Infect Dis119201167768321550310 34TricouV.MinhN.N.VanT.P.A randomized controlled trial of" exact="chloroquine" post="for the treatment of dengue in Vietnamese adultsPLoS Negl"/>
   <result pre="dengue in Vietnamese adultsPLoS Negl Trop Dis482010e78520706626 35RoquesP.ThibervilleS.D.Dupuis-MaguiragaL.Paradoxical effect of" exact="chloroquine" post="treatment in enhancing chikungunya virus infectionViruses1052018268 36De LamballerieX.BoissonV.ReynierJ.C.On chikungunya"/>
   <result pre="enhancing chikungunya virus infectionViruses1052018268 36De LamballerieX.BoissonV.ReynierJ.C.On chikungunya acute infection and" exact="chloroquine" post="treatmentVector Borne Zoonotic Dis86200883783918620511 37Official Statement from International Society"/>
   <result pre="41Fearing coronavirus, Arizona man dies after taking a form of" exact="chloroquine" post="used to treat aquariumshttps://www.cnn.com/2020/03/23/health/arizona-coronavirus-chloroquine-death/index.html 42Request for Emergency Use Authorization"/>
   <result pre="Agents Chemother6112016e01305e0131627736754 45OestereichL.RiegerT.LudtkeA.Efficacy of favipiravir alone and in combination with" exact="ribavirin" post="in a lethal, immunocompetent mouse model of lassa feverJ"/>
   <result pre="virus disease: an update on post-exposure prophylaxisLancet Infect Dis1862018e183e192 47WestoverJ.B.SefingE.J.BaileyK.W.Low-dose" exact="ribavirin" post="potentiates the antiviral activity of favipiravir against hemorrhagic fever"/>
   <result pre="Razonable serves as the principal investigator on clinical trials for" exact="tocilizumab" post="and sarilumab. The remaining authors report no competing interests."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7190535\results\search\drugs\results.xml">
   <result pre="al., 2020). However, several synthetic compounds have shown promise, including" exact="hydroxychloroquine" post="and choloroquine phosphate (Cortegiani et al., 2020; Gao et"/>
   <result pre="of the host cell phagolysosomes. Newer antiviral medications such as" exact="lopinavir" post="(Yao et al., 2020), remdesivir (Holshue et al., 2020;"/>
   <result pre="agents tested for comparison purposes. For example, the protease inhibitor" exact="nelfinavir" post="displayed an EC50 of 8.19 μM and a selectivity"/>
   <result pre="Medicinehttps://clinicaltrials.gov/ct2/results?cond=COVID-19 CortegianiA.IngogliaG.IppolitoM.GiarratanoA.EinavS.A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J. Crit. Care202010.1016/j.jcrc.2020.03.005 Covés-DatsonE.M.DyallJ.DeWaldL.E.KingS.R.DubeD.LegendreM.NelsonE.DrewsK.C.GrossR.GerhardtD.M.Inhibition of"/>
   <result pre="and plant preparations as remedial approach for viral diseasesVirusDisease.264201522523626645032 GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="J. Med.382202092993632004427 HsiehL.E.LinC.N.SuB.L.JanT.R.ChenC.M.WangC.H.LinD.S.LinC.T.ChuehL.L.Synergistic antiviral effect of Galanthus nivalis agglutinin and" exact="nelfinavir" post="against feline coronavirusAntiviral Res.8812010253020603153 HuangI.C.BoschB.J.LiF.LiW.LeeK.H.GhiranS.VasilievaN.DermodyT.S.HarrisonS.C.DormitzerP.R.FarzanM.SARS coronavirus, but not human"/>
   <result pre="caffeic acid in vivo and in vitroAntiviral Res.832200918619019463857 WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="novel coronavirus epidemic in ChinaJ. Autoimmun.1092020102434 YaoT.T.QianJ.D.ZhuW.Y.WangY.WangG.Q.A systematic review of" exact="lopinavir" post="therapy for SARS coronavirus and MERS coronavirus–A possible reference"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7191282\results\search\drugs\results.xml">
   <result pre="on being treated with limited scientific evidence. Oseltamivir, umifenovir and" exact="ribavirin" post="have safer cardiovascular profiles, whereas chloroquine or hydroxychloroquine, lopinavir/ritonavir"/>
   <result pre="evidence. Oseltamivir, umifenovir and ribavirin have safer cardiovascular profiles, whereas" exact="chloroquine" post="or hydroxychloroquine, lopinavir/ritonavir and azithromycin have certain toxicity potentials"/>
   <result pre="have safer cardiovascular profiles, whereas chloroquine or hydroxychloroquine, lopinavir/ritonavir and" exact="azithromycin" post="have certain toxicity potentials [4]. Vascular inflammation and myocarditis"/>
   <result pre="elevated troponin levels was as high as 71%. Treatment with" exact="hydroxychloroquine" post="in those vulnerable patients may further hinder cardiac reserves"/>
   <result pre="monitored with ECG during their hospitalization for COVID-19. Given that" exact="hydroxychloroquine" post="has a long half-life (about one month), hydroxychloroquine-related retinopathy"/>
   <result pre="hospital-discharge. We suggest follow-up ECG evaluations for people who receive" exact="hydroxychloroquine" post="and/or azithromycin. Telemedicine fueled with ECG monitoring could be"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7191300\results\search\drugs\results.xml">
   <result pre="that would down regulate the expression of CTSL/CTSB and found" exact="amantadine" post="to be one of the top inhibitors. •Amantadine may"/>
   <result pre="shown to downregulate the expression of the CTSL gene is" exact="amantadine" post="(10uM). Amantadine was approved by the US Food and"/>
   <result pre="lysosomotropic agent altering the CTSL functional environment. We hypothesize that" exact="amantadine" post="could decrease the viral load in SARS-CoV-2 positive patients"/>
   <result pre="studies will be needed to examine the therapeutic utility of" exact="amantadine" post="in COVID-19 infection. 1 Introduction Recently a novel type"/>
   <result pre="compounds. Further clinical studies should be conducted to examine whether" exact="amantadine" post="could be useful in treating patients with COVID-19 infection."/>
   <result pre="of well known, neuronal, cell surface receptors that include the" exact="dopamine" post="receptor D2, the serotonin receptors 1A, 2A, and 2C,"/>
   <result pre="and enzyme activity inhibition or storage material accumulation [16]. Since" exact="amantadine" post="behaves as a lysosomotropic substance that passes easily through"/>
   <result pre="pH of lysosome thus inhibit the protease activities [17]. Moreover" exact="amantadine" post="may directly affect viral entry bydown-modulating CTSL and other"/>
   <result pre="twice daily [18]. Human cells in tissue culture readily tolerated" exact="amantadine" post="up to a concentration of 100 ug/mL (~657uM). Since"/>
   <result pre="lysosome pathway genes. Black columns represent average expression levels of" exact="amantadine" post="treated samples, gray columns represent average expression levels of"/>
   <result pre="amantadine. [alt-text] Table 3 Gene Name Affymetrix Probe ID Mean" exact="amantadine" post="treated expression (log2) Mean control expression (log2) Mean expression"/>
   <result pre="virus or decrease the severity of the symptoms. Given that" exact="amantadine" post="does not only down-regulate CTSL expression, but a number"/>
   <result pre="enzymes, we can now hypothesize that lysosomal dysfunction induced by" exact="amantadine" post="administration can be protective against viral entry and ultimately"/>
   <result pre="would be required in order to examine the role of" exact="amantadine" post="administration as a treatment for COVID-19. 4 Materials and"/>
   <result pre="fresh media with a drug, or the drug vehicle (water," exact="dimethyl sulfoxide," post="ethanol, methanol, or phosphate-buffered saline solution). Drugs were diluted"/>
   <result pre="Tools to Study Lysosomal FunctionCurr. Drug Metab.18201811471158 17DuffK.C.CudmoreA.J.BradshawJ.P.The location of" exact="amantadine" post="hydrochloride and free base within phospholipid multilayers: a neutron"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7191631\results\search\drugs\results.xml">
   <result pre="LiuQ, ZhaoY, ZhangY, QinY, LiX, LiC, ZhouC, JinN, JiangCIdentification of" exact="amitriptyline" post="HCl, flavin adenine dinucleotide, azacitidine and calcitriol as repurposing"/>
   <result pre="LiC, ZhouC, JinN, JiangCIdentification of amitriptyline HCl, flavin adenine dinucleotide," exact="azacitidine" post="and calcitriol as repurposing drugs for influenza A H5N1"/>
   <result pre="JinN, JiangCIdentification of amitriptyline HCl, flavin adenine dinucleotide, azacitidine and" exact="calcitriol" post="as repurposing drugs for influenza A H5N1 virus-induced lung"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7191900\results\search\drugs\results.xml">
   <result pre="group on an aromatic hydrocarbon and is classified into monohydric" exact="phenol" post="and polyhydric phenol. This review summarises phenolic compounds isolated"/>
   <result pre="belongs to Moniliaceae and has important medical value. The antibiotic" exact="fusidic acid" post="extracted from Fusidium sp. has been used for disease"/>
   <result pre="Soc1997;119:1594–8. 90EfferthTFrom ancient herb to modern drug: artemisia annua and" exact="artemisinin" post="for cancer therapy. Semin Cancer Biol2017;46:65–83.28254675 91Megdiche-KsouriW, TrabelsiN, MkadminiK,"/>
   <result pre="the biosynthesis of moenomycin family antibiotics in the genome of" exact="teicoplanin" post="producer Actinoplanes teichomyceticus. Appl Microbiol Biotechnol2016;100:7629–38.27344593 114SilvermanKC, CascalesC, GenilloudO,"/>
   <result pre="antibiotic. Nature1962;193:987.13899435 119WuP-P, HeH, HongWD, et al.The biological evaluation of" exact="fusidic acid" post="and its hydrogenation derivative as antimicrobial and anti-inflammatory agents."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7192075\results\search\drugs\results.xml">
   <result pre="notes are from Guo et al. [83]. 2.2 Chloroquine and" exact="hydroxychloroquine" post="Chloroquine is a drug widely used in the treatment"/>
   <result pre="broad-spectrum antiviral potential in2006 [11]. In a recent study [8]," exact="chloroquine" post="was found to inhibit SARS-COV-2 at low-micromolar (EC50 ="/>
   <result pre="rheumatoid arthritis [12]. In addition, time-of-addition assay [8] demonstrated that" exact="chloroquine" post="functioned at both entry and post-entry stages of the"/>
   <result pre="2019-nCoV infection in Vero E6 cells. The antiviral activity of" exact="chloroquine" post="may be due to the following three ways (Fig."/>
   <result pre="press released from the State Council of China indicated that" exact="chloroquine" post="phosphate had demonstrated marked efficacy in preventing the deterioration"/>
   <result pre="cardiotoxicity. There are currently more than 20 clinical trials of" exact="chloroquine" post="registered in the China Clinical Trial Registry. Fig. 2"/>
   <result pre="Fig. 2 A graphical illustration of the antiviral mechanisms of" exact="chloroquine" post="(CQ) and hydroxychloroquine (HCQ). The picture is come from"/>
   <result pre="graphical illustration of the antiviral mechanisms of chloroquine (CQ) and" exact="hydroxychloroquine" post="(HCQ). The picture is come from Zhou et al."/>
   <result pre="from Zhou et al. [84]. Hydroxychloroquine is an analogue of" exact="chloroquine" post="with similar therapeutic effects and significantly reduced toxic side"/>
   <result pre="and significantly reduced toxic side effects [18]. Besides, in vitro," exact="hydroxychloroquine" post="exhibited better anti-SARS-CoV-2 activity than chloroquine [19]. Comprehensive treatment"/>
   <result pre="[18]. Besides, in vitro, hydroxychloroquine exhibited better anti-SARS-CoV-2 activity than" exact="chloroquine" post="[19]. Comprehensive treatment and management of coronavirus disease 2019:"/>
   <result pre="disease 2019: an expert consensus statement from Shanghai [20] recommended" exact="hydroxychloroquine" post="in an attempt of antiviral treatment; however, no dosage"/>
   <result pre="physiology-based pharmacokinetic PBPK model based on the data of the" exact="hydroxychloroquine" post="and chloroquine in vitro to simulate the distribution concentration"/>
   <result pre="PBPK model based on the data of the hydroxychloroquine and" exact="chloroquine" post="in vitro to simulate the distribution concentration of the"/>
   <result pre="model, it is recommended that the oral loading dose of" exact="hydroxychloroquine" post="400 mg bid on the first day and the"/>
   <result pre="lung titer can reach more than three times the oral" exact="chloroquine" post="phosphate (500 mg twice daily) [19]. This dose was"/>
   <result pre="confirmed in the first randomized controlled clinical trial (ChiCTR2000029559) of" exact="hydroxychloroquine" post="for COVID-19, which enroll 62 patients with COVID-19 (31"/>
   <result pre="that after 5 days, the clinical recovery time of the" exact="hydroxychloroquine" post="group was significantly shortened, and the symptoms of fever"/>
   <result pre="faster (p &amp;lt; 0.05). 81 % of patients in the" exact="hydroxychloroquine" post="group had significantly improved pneumonia, compared with 55 %"/>
   <result pre="the control group. This study affirmed the therapeutic effect of" exact="hydroxychloroquine" post="[21]. Recently, in a clinical trial [22] involving 36"/>
   <result pre="[22] involving 36 patients with COVID-19 shown the combination of" exact="hydroxychloroquine" post="and azithromycin has a full and rapid viral clearance,"/>
   <result pre="36 patients with COVID-19 shown the combination of hydroxychloroquine and" exact="azithromycin" post="has a full and rapid viral clearance, the effects"/>
   <result pre="rapid viral clearance, the effects of which is better than" exact="hydroxychloroquine" post="alone. The mechanism by which azithromycin enhances the efficacy"/>
   <result pre="which is better than hydroxychloroquine alone. The mechanism by which" exact="azithromycin" post="enhances the efficacy of COVID-19 is unclear, but azithromycin"/>
   <result pre="which azithromycin enhances the efficacy of COVID-19 is unclear, but" exact="azithromycin" post="has previously been shown to prevent severe respiratory infections"/>
   <result pre="11 COVID-19 patients who have received the combination therapy of" exact="hydroxychloroquine" post="and azithromycin. Given the trial is not an RCT,"/>
   <result pre="is needed to confirm. In addition, the simultaneous use of" exact="hydroxychloroquine" post="and azithromycin can lead to a prolonged QT interval"/>
   <result pre="to confirm. In addition, the simultaneous use of hydroxychloroquine and" exact="azithromycin" post="can lead to a prolonged QT interval and increase"/>
   <result pre="to the cardiac and retinal toxicity, acute lethal risk of" exact="chloroquine" post="and hydroxychloroquine, when chloroquine or hydroxychloroquine is used, electrocardiogram"/>
   <result pre="retinal toxicity, acute lethal risk of chloroquine and hydroxychloroquine, when" exact="chloroquine" post="or hydroxychloroquine is used, electrocardiogram monitoring should be performed,"/>
   <result pre="acute lethal risk of chloroquine and hydroxychloroquine, when chloroquine or" exact="hydroxychloroquine" post="is used, electrocardiogram monitoring should be performed, and attention"/>
   <result pre="(91.43 % vs. 62.22 %) than control group treated with" exact="lopinavir" post="and ritonavir (45 cases) with significant differences between the"/>
   <result pre="vs. 62.22 %) than control group treated with lopinavir and" exact="ritonavir" post="(45 cases) with significant differences between the two groups,"/>
   <result pre="(FDA) to treat HIV infection as a protease inhibitor, with" exact="ritonavir" post="as a booster by inhibiting cytochrome P450 to increase"/>
   <result pre="A non-randomized clinical trial showed that SARS patients treated with" exact="ribavirin" post="combined with LPV/r had a lower risk of ARDS"/>
   <result pre="LPV/r had a lower risk of ARDS and death than" exact="ribavirin" post="monotherapy [34]. A Korean COVID-19 patient has been found"/>
   <result pre="the early stages of the SARS epidemic. However, the role" exact="ribavirin" post="play is controversial; on the one hand, severe side"/>
   <result pre="decreased hemoglobin levels are related to the use of high-dose" exact="ribavirin" post="[41], the other hand contradictory results from clinical observation"/>
   <result pre="[[42], [43], [44], [45], [46], [47], [48]]. In cell culture," exact="ribavirin" post="has an inhibitory effect on SARA-CoV-2, but requires higher"/>
   <result pre="of Novel Coronavirus-induced Pneumonia (Trial Version 7), which recommend low-dose" exact="ribavirin" post="(500 mg each time, 2–3 times/day) combined with lopinavir/ritonavir"/>
   <result pre="instead of monotherapy. A trial comparing effectiveness and safety of" exact="ribavirin" post="plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir"/>
   <result pre="and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and" exact="ribavirin" post="plus lopinavir/ritonavir plus interferon-alpha in patients with mild to"/>
   <result pre="coronavirus pneumonia is in progress (ChiCTR2000029387). The antiviral effect of" exact="ribavirin" post="in the combination of multiple drugs is not clear,"/>
   <result pre="mouse model [52]. Effect of IFN monotherapy or combined with" exact="ribavirin" post="was observed in vitro and animal models if given"/>
   <result pre="Wuhan Red Cross Hospital with the treatment of low dose" exact="methylprednisolone" post="when mild and common cases became severe and critical,"/>
   <result pre="and found that the optimal window period for low dose" exact="methylprednisolone" post="treatment of COVID-19 is within 48 h after switching"/>
   <result pre="to severe or critical. The early administration of low dose" exact="methylprednisolone" post="within the window period for these patients could significantly"/>
   <result pre="in China [66] recommends low-to-moderate corticosteroid (≤0.5−1 mg/kg per day" exact="methylprednisolone" post="or equivalent) should be used carefully in critically ill"/>
   <result pre="multicenter, randomized controlled trial for the efficacy and safety of" exact="tocilizumab" post="in the treatment of COVID-19 (ChiCTR2000029765), in the first"/>
   <result pre="persistent fever. After treatment with the new treatment regimen of" exact="tocilizumab" post="combined conventional therapy, the temperature of 11 patients with"/>
   <result pre="for patients with severe conditions caused by a cytokine storm," exact="tocilizumab" post="is a drug worthy of clinical research. There have"/>
   <result pre="five clinical trials in addition to that mentioned above on" exact="trastuzumab" post="in progress. For patients with extensive infiltrating lesions of"/>
   <result pre="lesions of the lungs and severe patients with elevated IL-6," exact="tocilizumab" post="treatment can be tried (the recommended dose is 400"/>
   <result pre="are the following: interferon (IFN) + LPV/r, IFN + arbidol," exact="oseltamivir" post="+ arbiodol, IFN + LPV/r + arbidol. A multicenter,"/>
   <result pre="caused by inflammatory storms. Cardioprotective drugs such as coenzyme Q10," exact="trimetazidine" post="hydrochloride, and creatine phosphate, and vitamin C could be"/>
   <result pre="the antiviral effect. In critically ill patients, low-to-moderate corticosteroid and" exact="tocilizumab" post="should be used to combat cytokine storms and reduce"/>
   <result pre="of Ebola virus disease therapeuticsN. Engl. J. Med.3812420192293230331774950 8WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="for patients with severe Covid-19N. Engl. J. Med.2020 10SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against today’s diseases?Lancet"/>
   <result pre="of coronavirus tropism and pathogenesisVirus Res.202201512013425445340 14SchrezenmeierE.DornerT.Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatologyNat. Rev. Rheumatol.163202015516632034323 15Al-BariM.A.A.Targeting endosomal"/>
   <result pre="chloroquine: implications for rheumatologyNat. Rev. Rheumatol.163202015516632034323 15Al-BariM.A.A.Targeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="comprehensive treatment expert consensusChin. J. Infect. Dis. Committee2020E016 21ChenZ.HuJ.ZhangZ.JiangS.HanS.YanD.ZhuangR.HuB.ZhangZ.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
   <result pre="of an Openlabel Non Randomized Clinical Trial2020 23KawamuraK.IchikadoK.TakakiM.EguchiY.AnanK.SugaM.Adjunctive therapy with" exact="azithromycin" post="for moderate and severe acute respiratory distress syndrome: a"/>
   <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infectionMédecine et"/>
   <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infectionMédecine et Maladies Infectieuses2020"/>
   <result pre="as a broad-spectrum antiviral: an updateAntiviral Res.1072014849424769245 30News: Abidol and" exact="darunavir" post="can effectively inhibit coronavirus http://www.sd.chinanews.com/2/2020/0205/70145.html (Accessed February 21, 2020)."/>
   <result pre="respiratory syndrome coronavirusJ. Infect.676201360661624096239 57ShalhoubS.FarahatF.Al-JiffriA.SimhairiR.ShammaO.SiddiqiN.MushtaqA.IFN-alpha2a or IFN-beta1a in combination with" exact="ribavirin" post="to treat Middle East respiratory syndrome coronavirus pneumonia: a"/>
   <result pre="research group, a multi-center, prospective study of early Abidor +" exact="lopinavir" post="/ ritonavir + recombinant interferon α-2b combined antiviral therapy"/>
   <result pre="a multi-center, prospective study of early Abidor + lopinavir /" exact="ritonavir" post="+ recombinant interferon α-2b combined antiviral therapy in patients"/>
   <result pre="Med. Res.7120201132169119 84ZhouD.DaiS.M.TongQ.COVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progressionJ. Antimicrob. Chemother.2020 Acknowledgements This"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7192107\results\search\drugs\results.xml">
   <result pre="a clinical efficacy against severe acute respiratory syndrome coronavirus 2;" exact="ivermectin" post="has also demonstrated a remarkable experimental efficacy with a"/>
   <result pre="but unfortunately widely ignored, to be tested in combination with" exact="azithromycin" post="for their potential activity against SARS CoV-2, soonest. The"/>
   <result pre="2019 (COVID-19) at 48 h of its single addition [4]. Interestingly," exact="ivermectin" post="therapy has been shown to reverse onchocerciasis-associated immunosuppression through"/>
   <result pre="advanced HIV disease [6]. Similarly, another macrolide macrocyclic lactone antibiotic;" exact="azithromycin" post="(Fig. 2 ) has been reported to have an"/>
   <result pre="chronic obstructive pulmonary disease, 24 h post infection [7,8]. Noteworthy, only" exact="azithromycin" post="which is a synthetic derivative of erythromycin; the prototype"/>
   <result pre="first isolated from the soil bacterium Streptomyces erythraeus, but not" exact="erythromycin" post="or telithromycin, has been shown to significantly increase rhinovirus"/>
   <result pre="in bronchial epithelial cells [9]. This differential peculiarity associated with" exact="azithromycin" post="should be properly investigated as regards to its potential"/>
   <result pre="activity relationship. Further, it’s also been recently reported that when" exact="azithromycin" post="was added to hydroxychloroquine, the efficiency of SARS CoV-2"/>
   <result pre="increased overall mortality that was identified in patients treated with" exact="hydroxychloroquine" post="without azithromycin as compared to the standard care alone"/>
   <result pre="mortality that was identified in patients treated with hydroxychloroquine without" exact="azithromycin" post="as compared to the standard care alone and it’s"/>
   <result pre="previous reported beneficial effects might be more properly attributed to" exact="azithromycin" post="alone; further studies might explore this potential and hopefully"/>
   <result pre="help other colleagues in their search for answers. Taken together," exact="ivermectin" post="and azithromycin share a potential structural similarity and more"/>
   <result pre="colleagues in their search for answers. Taken together, ivermectin and" exact="azithromycin" post="share a potential structural similarity and more importantly both"/>
   <result pre="the placebo group [11]. Taken together, the author agrees that" exact="ivermectin" post="deserves its enrollment for clinical trials to explore its"/>
   <result pre="and immunocompetent children, antidiarrhea drug; nitazoxanide, [17] in combination with" exact="azithromycin" post="[18], soonest. Nitazoxanide (Fig. 3 ), is an orally"/>
   <result pre="to be safer and free of mutagenic effects [19]. Similarly," exact="nitazoxanide" post="is also known to potentiate interferon alfa and interferon"/>
   <result pre="vitro activity against MERS-CoV and other coronaviruses [20]. Moreover, when" exact="nitazoxanide" post="was given as 600 mg twice daily for 5 days,"/>
   <result pre="regimen might be reasonably considered to be used combined with" exact="azithromycin" post="in a suggested new COVID-19 protocol aiming to test"/>
   <result pre="like to stress that on the 9th of March, 2020," exact="nitazoxanide" post="was previously suggested, among other drugs, by French colleagues"/>
   <result pre="been published on the 15th of March, 2020 to recommend" exact="nitazoxanide" post="to be used with hydroxychloroquine for COVID-19 patients pointing"/>
   <result pre="of March, 2020 to recommend nitazoxanide to be used with" exact="hydroxychloroquine" post="for COVID-19 patients pointing to some links with the"/>
   <result pre="To date, the 30 th of April, 2020, only eight" exact="nitazoxanide" post="clinical trials are undergoing worldwide [24] with remarkable difficulties"/>
   <result pre="of patients, who might have also doubted the potential of" exact="nitazoxanide" post="for COVID-19, and only two of them are currently"/>
   <result pre="start date on the 12th of April, 2020 to compare" exact="nitazoxanide" post="600 mg, without any added drugs, against placebo for"/>
   <result pre="patients in their clinical trials. Similarly, the second currently recruiting" exact="nitazoxanide" post="trial is wishing to enroll 86 participants with an"/>
   <result pre="start date on the 6th of April, 2020 to compare" exact="nitazoxanide" post="alone to nitazoxanide/hydroxychloroquine combination in patients with COVID-19 risk"/>
   <result pre="suggested in this manuscipt. Interestingly 4 out of the 8" exact="nitazoxanide" post="clinical trials for COVID-19 are undergoing in Egypt and"/>
   <result pre="the very small number with their difficulties in recruitment, of" exact="nitazoxanide" post="clinical trials which have been only adopted countries like"/>
   <result pre="the progressively increasing 150 COVID-19 registered and undergoing studies for" exact="hydroxychloroquine" post="all over the world [26], we might eventually consider"/>
   <result pre="especially after the recent report that showed no evidence for" exact="hydroxychloroquine" post="to decrease the risk of mechanical ventilation in patients"/>
   <result pre="suggested protocol, the reasons for this potentially misfortunate underestimation of" exact="nitazoxanide" post="should be properly investigated, and to stress that all"/>
   <result pre="and supported by the recent release of clinical data disputing" exact="hydroxychloroquine" post="efficacy, the author suggests that nitazoxanide/azithromycin combination might eventually"/>
   <result pre="COVID-19, especially if the preliminary data regarding the inefficacy of" exact="hydroxychloroquine" post="has been confirmed or as soon as nitazoxanide/azithromycin combination"/>
   <result pre="None. Declaration of Competing Interest None. References References 1CoscioneS.EsauT.KekeubataE.Impact of" exact="ivermectin" post="administered for scabies treatment on the prevalence of head"/>
   <result pre="Online First: 2018/09/27] 2KandeelM.ElgazarW.KitadeY.The binding interactions of the macrolide endectocide" exact="ivermectin" post="with the antibiotics ampicillin, chloramphenicol and tetracycline HCLIndian J."/>
   <result pre="interactions of the macrolide endectocide ivermectin with the antibiotics ampicillin," exact="chloramphenicol" post="and tetracycline HCLIndian J. Pharm. Sci.746201259259610.4103/0250-474X.11063523798790 3SmitM.R.OchomoE.O.AljayyoussiG.Safety and mosquitocidal"/>
   <result pre="the macrolide endectocide ivermectin with the antibiotics ampicillin, chloramphenicol and" exact="tetracycline" post="HCLIndian J. Pharm. Sci.746201259259610.4103/0250-474X.11063523798790 3SmitM.R.OchomoE.O.AljayyoussiG.Safety and mosquitocidal efficacy of"/>
   <result pre="HCLIndian J. Pharm. Sci.746201259259610.4103/0250-474X.11063523798790 3SmitM.R.OchomoE.O.AljayyoussiG.Safety and mosquitocidal efficacy of high-dose" exact="ivermectin" post="when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated"/>
   <result pre="HIV diseaseAIDS Res. Hum. Retroviruses179200178979710.1089/088922201750251981[published Online First: 2001/06/29]11429120 7GautretP.LagierJ.C.ParolaP.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="Middle East respiratory syndrome coronavirusJ. Infect. Public Health93201622723010.1016/j.jiph.2016.04.00127095301 21HaffizullaJ.HartmanA.HoppersM.Effect of" exact="nitazoxanide" post="in adults and adolescents with acute uncomplicated influenza: a"/>
   <result pre="Approach against SARS-CoV-2/COVID-19 with Nitazoxanide and Hydroxychloroquine2020 24https://clinicaltrials.gov/ct2/results?cond=COVID-19&amp;amp;term=Nitazoxanide&amp;amp;cntry=&amp;amp;state=&amp;amp;city=&amp;amp;dist= 25GautretHydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7192111\results\search\drugs\results.xml">
   <result pre="treatment of COVID-19 mainly include antiviral drugs (such as interferon," exact="ribavirin" post="and lopinavir/ritonavir), antibiotics (e.g. moxifloxacin and azithromycin) and steroidal"/>
   <result pre="antiviral drugs (such as interferon, ribavirin and lopinavir/ritonavir), antibiotics (e.g." exact="moxifloxacin" post="and azithromycin) and steroidal drugs such as glucocorticoids. In"/>
   <result pre="issued by the National Health Commission of China, interferon-alpha, and" exact="ribavirin" post="(combined with interferon or lopinavir/ritonavir), Arbidol (umifenovir) and chloroquine"/>
   <result pre="and ribavirin (combined with interferon or lopinavir/ritonavir), Arbidol (umifenovir) and" exact="chloroquine" post="phosphate have been recommended for use. Ribavirin is a"/>
   <result pre="a broad-spectrum antiviral drug. Animal experiments reported that ingestion of" exact="ribavirin" post="decreased testosterone concentrations and impaired spermatogenesis (Almasry et al.,"/>
   <result pre="antiviral drug. Animal experiments reported that ingestion of ribavirin decreased" exact="testosterone" post="concentrations and impaired spermatogenesis (Almasry et al., 2017), and"/>
   <result pre="2002a; Narayana et al., 2005). Clinical studies have shown that" exact="ribavirin" post="combined with interferon treatment could affect male fertility, manifested"/>
   <result pre="recommended during the medication period (Hofer et al., 2010). Moreover," exact="ribavirin" post="was able to cause sperm DNA fragmentation for up"/>
   <result pre="There have been relatively few studies on the effects of" exact="ribavirin" post="on the female reproductive system, but a clinical case"/>
   <result pre="case was reported that involved a 36-year-old woman injected with" exact="ribavirin" post="intramuscularly due to a suspected SARS infection during the"/>
   <result pre="disinfectants, biguanide and quaternary ammonium disinfectants, iodine disinfectants, aldehyde disinfectants," exact="phenol" post="disinfectants, peroxide disinfectants and ethylene oxide. Alcohol 75% is"/>
   <result pre="indicated that psychological stress can lead to an increase in" exact="nitric oxide" post="concentration and a decrease in arginase activity in the"/>
   <result pre="of histological and histometric changes in rats testes treated with" exact="chloroquine" post="phosphateNigerian journal of physiological sciences: official publication of the"/>
   <result pre="psychological effects of quarantine, Toronto, CanadaEmerg. Infect. Dis.1020041206121215324539 HoferH.DonnererJ.SatorK.StauferK.ScherzerT.-M.DejacoC.SatorM.KesslerH.FerenciP.Seminal fluid" exact="ribavirin" post="level and functional semen parameters in patients with chronic"/>
   <result pre="an individual participant data meta-analysisBMC Infect. Dis.19201968331375073 NarayanaK.D'souzaU.J.A.NarayanP.KumarG.The antiviral drug" exact="ribavirin" post="reversibly affects the reproductive parameters in the male Wistar"/>
   <result pre="reproductive parameters in the male Wistar ratFolia morphologica642005657116121321 NarayanaK.D'souzaU.J.A.RaoK.P.S.Effect of" exact="ribavirin" post="on epididymal sperm count in ratIndian journal of physiology"/>
   <result pre="the human ovaryFertil. Steril.95201117618120674894 RezvaniM.KorenG.Pregnancy outcome after exposure to injectable" exact="ribavirin" post="during embryogenesisReproductive toxicology (Elmsford, N Y)212006113115 SakamotoK.Q.IshizukaM.KazusakaA.FujitaS.Iodine intake as"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7192119\results\search\drugs\results.xml">
   <result pre="reaction COVID-19, 2019 coronavirus disease MOI, multiplicity of infection DMSO," exact="dimethyl sulfoxide" post="Keywords Liu Shen capsule SARS-CoV-2 Antiviral Anti-inflammatory 1 Introduction"/>
   <result pre="and regulate immune function and achieved similar therapeutic effectiveness with" exact="oseltamivir" post="in reducing the course of H1N1 virus infection. Notably,"/>
   <result pre="LS was triturated, 50 mg was prepared in 10 mL" exact="dimethyl sulfoxide" post="(DMSO). The mixture was ultrasonicated for 4 h and"/>
   <result pre="% bufalin, 0.70 % resibufogenin, 0.68 % cinobufagin, 1.81 %" exact="cholic acid," post="0.27 % anserine deoxycholic acid, and 0.23 % deoxycholic"/>
   <result pre="and the formed formazan crystals were dissolved in 200 μL" exact="dimethyl sulfoxide" post="(DMSO). The absorbance at 570 nm was determined using"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7192209\results\search\drugs\results.xml">
   <result pre="Publishing Ltd pmcid: 7192209 doi: 10.7573/dic.2020-4-5dic-2020-4-5 : Review Chloroquine and" exact="hydroxychloroquine" post="in the context of COVID-19 ShuklaAshutosh MMD12ArchibaldLennox KMD12Wagle ShuklaAparnaMD3MehtaHiren"/>
   <result pre="to each patient who may require treatment. anti-inflammatory antimalarial antiviral" exact="chloroquine" post="COVID-19 hydroxychloroquine immunomodulatory pandemic SARS-CoV-2 Chloroquine and related drugs"/>
   <result pre="patient who may require treatment. anti-inflammatory antimalarial antiviral chloroquine COVID-19" exact="hydroxychloroquine" post="immunomodulatory pandemic SARS-CoV-2 Chloroquine and related drugs were initially"/>
   <result pre="to large populations increasingly affected with COVID-19. Mechanistic rationale Both" exact="chloroquine" post="and hydroxychloroquine (HCQ) are weak bases that exist in"/>
   <result pre="populations increasingly affected with COVID-19. Mechanistic rationale Both chloroquine and" exact="hydroxychloroquine" post="(HCQ) are weak bases that exist in the extracellular"/>
   <result pre="Thus, neutralization of the acidic pH of the endosome by" exact="chloroquine" post="or HCQ may prevent the fusion of SARS-CoV-2 with"/>
   <result pre="into the host cell is based on the ability of" exact="chloroquine" post="to be a broad inhibitor of nanoparticle endocytosis by"/>
   <result pre="resident macrophages.20 At the concentrations achieved in routine clinical dosing," exact="chloroquine" post="reduces in vitro and in vivo accumulation of synthetic"/>
   <result pre="the Centers for Disease Control (CDC) studied the effects of" exact="chloroquine" post="in primate Vero E6 cells (African green monkey kidney"/>
   <result pre="cells (African green monkey kidney cells). The investigators found that" exact="chloroquine" post="was effective against SARS-CoV-1, and the inhibitory effects were"/>
   <result pre="found that among the two, HCQ was more potent than" exact="chloroquine" post="as the effective concentration for a half-maximal response (EC50)"/>
   <result pre="(EC50) was much lower (0.72 μM) for HCQ than for" exact="chloroquine" post="(5.47 μM). Based on these experiments, the investigators suggested"/>
   <result pre="study from China,29 the investigators found the EC90 value of" exact="chloroquine" post="against the SARS-CoV-2 in Vero E6 cells was 6.90"/>
   <result pre="performed in the plasma of rheumatoid arthritis patients who received" exact="chloroquine" post="at 500 mg per day dose, were clinically achievable.30"/>
   <result pre="colleagues from China drew attention to the potential role of" exact="chloroquine" post="for treating COVID-19. Based on the clinical data collected"/>
   <result pre="Chongqing, and Ningbo) involving &amp;gt;100 patients, the authors proposed that" exact="chloroquine" post="was a promising therapeutic drug. They reported that the"/>
   <result pre="promising therapeutic drug. They reported that the patients who received" exact="chloroquine" post="phosphate had lower rates of pneumonia exacerbation, greater improvement"/>
   <result pre="10 days) of which six received it in conjunction with" exact="azithromycin" post="(500 mg on day 1 followed by 250 mg"/>
   <result pre="by 250 mg daily for 4 days). The inclusion of" exact="azithromycin" post="was rationalized on the basis of its in vitro"/>
   <result pre="that patients treated with HCQ alone or in combination with" exact="azithromycin" post="had significantly greater virological clearance (p=0.001) at day 6"/>
   <result pre="Furthermore, the criteria for the selection of patients receiving additional" exact="azithromycin" post="were not specified. Finally, the study had a very"/>
   <result pre="is well established. HCQ is the structural analog of the" exact="chloroquine" post="molecule with the addition of a β-hydroxyl moiety at"/>
   <result pre="obtain a routine electrocardiogram prior to initiating HCQ therapy. As" exact="azithromycin" post="is also known to prolong the QTc interval, patients"/>
   <result pre="Antimicrob Chemother20157061608162110.1093/jac/dkv01825693996 3WallaceDJThe history of antimalarialsLupus19965Suppl 1S238803902 4WallaceDJThe use of" exact="chloroquine" post="and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis"/>
   <result pre="3WallaceDJThe history of antimalarialsLupus19965Suppl 1S238803902 4WallaceDJThe use of chloroquine and" exact="hydroxychloroquine" post="for non-infectious conditions other than rheumatoid arthritis or lupus:"/>
   <result pre="rheumatoid arthritis or lupus: a critical reviewLupus19965Suppl 1S596410.1177/09612033960050011318803913 5SavarinoABoelaertJRCassoneAMajoriGCaudaREffects of" exact="chloroquine" post="on viral infections: an old drug against today’s diseases?Lancet"/>
   <result pre="drug against today’s diseases?Lancet Infect Dis200331172272710.1016/s1473-3099(03)00806-514592603 6FoxRIMechanism of action of" exact="hydroxychloroquine" post="as an antirheumatic drugSemin Arthritis Rheum1993232 Suppl 1829110.1016/s0049-0172(10)80012-58278823 7RainsfordKDParkeALClifford-RashotteMKeanWFTherapy"/>
   <result pre="drugSemin Arthritis Rheum1993232 Suppl 1829110.1016/s0049-0172(10)80012-58278823 7RainsfordKDParkeALClifford-RashotteMKeanWFTherapy and pharmacological properties of" exact="hydroxychloroquine" post="and chloroquine in treatment of systemic lupus erythematosus, rheumatoid"/>
   <result pre="Rheum1993232 Suppl 1829110.1016/s0049-0172(10)80012-58278823 7RainsfordKDParkeALClifford-RashotteMKeanWFTherapy and pharmacological properties of hydroxychloroquine and" exact="chloroquine" post="in treatment of systemic lupus erythematosus, rheumatoid arthritis and"/>
   <result pre="vivo guinea pig modelJ Gen Virol201596123484349210.1099/jgv.0.00030926459826 11BoelaertJRPietteJSperberKThe potential place of" exact="chloroquine" post="in the treatment of HIV-1-infected patientsJ Clin Virol200120313714010.1016/s1386-6532(00)00140-211166662 12TsaiWPNaraPLKungHFOroszlanSInhibition"/>
   <result pre="replication in cell cultureAntimicrob Agents Chemother20145884875488410.1128/aac.03011-1424841269 14KeyaertsELiSVijgenLet al.Antiviral activity of" exact="chloroquine" post="against human coronavirus oc43 infection in newborn miceAntimicrob Agents"/>
   <result pre="miceAntimicrob Agents Chemother20095383416342110.1128/aac.01509-0819506054 15DevauxCARolainJMColsonPRaoultDNew insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int J Antimicrob"/>
   <result pre="antiviral effects of chloroquineLancet Infect Dis200662676910.1016/s1473-3099(06)70361-916439323 20HuTYFriemanMWolframJInsights from nanomedicine into" exact="chloroquine" post="efficacy against COVID-19Nat Nanotechnol202010.1038/s41565-020-0674-9 21PeltJBusattoSFerrariMThompsonEAModyKWolframJChloroquine and nanoparticle drug delivery:"/>
   <result pre="Today201925859810.1016/j.nantod.2019.02.00531360214 24GentileECilurzoFDi MarzioLet al.Liposomal chemotherapeuticsFuture Oncol (London, England)20139121849185910.2217/fon.13.146 25SinghAKSinghAShaikhASinghRMisraAChloroquine and" exact="hydroxychloroquine" post="in the treatment of COVID-19 with or without diabetes:"/>
   <result pre="coronavirus (SARS-CoV)J Biol Chem2016291179218923210.1074/jbc.M116.71610026953343 27van den BorneBEDijkmansBAde RooijHHle CessieSVerweijCLChloroquine and" exact="hydroxychloroquine" post="equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis202010.1093/cid/ciaa237 29WangMCaoRZhangLet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-ncov) in"/>
   <result pre="long-term therapy of rheumatoid arthritis with antimalarialsAm J Med1983751a404510.1016/0002-9343(83)91269-x 31GaoJTianZYangXBreakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="COVID-19 associated pneumonia in clinical studiesBiosci Trends2020141727310.5582/bst.2020.0104732074550 32GautretPLagierJCParolaPet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="inhibitors for drug repurposingACS Infect Dis20151731732610.1021/acsinfecdis.5b0003027622822 35BacharierLBGuilbertTWMaugerDTet al.Early administration of" exact="azithromycin" post="and prevention of severe lower respiratory tract illnesses in"/>
   <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infectionMéd Mal"/>
   <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infectionMéd Mal Infect202010.1016/j.medmal.2020.03.006 37Zhaowei"/>
   <result pre="with severe COVID-19 infectionMéd Mal Infect202010.1016/j.medmal.2020.03.006 37Zhaowei ChenJHZhangZJiangSet al.Efficacy of" exact="hydroxychloroquine" post="in patients with covid-19: results of a randomized clinical"/>
   <result pre="of a randomized clinical trialmedRxiv preprint202010.1101/2020.03.22.20040758 38ChenJLiuDLiuLet al.Pilot study of" exact="hydroxychloroquine" post="in treatment of patients with common coronavirus disease-19 (COVID-19)J"/>
   <result pre="common coronavirus disease-19 (COVID-19)J Zhejiang Univ (Med Sci)202010.3785/j.issn.1008-9292.2020.03.03 39McLachlanAJTettSECutlerDJDayROBioavailability of" exact="hydroxychloroquine" post="tablets in patients with rheumatoid arthritisBr J Rheumatol199433323523910.1093/rheumatology/33.3.2358156285 40MullerFKonigJGlaeserHet"/>
   <result pre="the antimalarial drug chloroquineAntimicrob Agents Chemother20115573091309810.1128/aac.01835-1021518836 41MarmorMFKellnerULaiTYMellesRBMielerWFRecommendations on screening for" exact="chloroquine" post="and hydroxychloroquine retinopathy (2016 revision)Ophthalmology201612361386139410.1016/j.ophtha.2016.01.05826992838 42CotroneoJSleikKMRene RodriguezEKleinALHydroxychloroquine-induced restrictive cardiomyopathyEur"/>
   <result pre="drug chloroquineAntimicrob Agents Chemother20115573091309810.1128/aac.01835-1021518836 41MarmorMFKellnerULaiTYMellesRBMielerWFRecommendations on screening for chloroquine and" exact="hydroxychloroquine" post="retinopathy (2016 revision)Ophthalmology201612361386139410.1016/j.ophtha.2016.01.05826992838 42CotroneoJSleikKMRene RodriguezEKleinALHydroxychloroquine-induced restrictive cardiomyopathyEur J Echocardiogr20078424725110.1016/j.euje.2006.02.00216600690"/>
   <result pre="toxicity: an analysis of electrocardiograms in 85 patients treated with" exact="hydroxychloroquine" post="for connective tissue diseasesRheumatology (Oxford, England)200746580881010.1093/rheumatology/kel402 44BonowROFonarowGCO’GaraPTYancyCWAssociation of coronavirus"/>
   <result pre="Cardiol202010.1001/jamacardio.2020.1105 45TeixeiraRABorbaEFPedrosaAet al.Evidence for cardiac safety and antiarrhythmic potential of" exact="chloroquine" post="in systemic lupus erythematosusEuropace201416688789210.1093/europace/eut29024050965 46GuptaNAgrawalSIshPChloroquine in COVID-19: the evidenceMonaldi"/>
   <result pre="2020 48PCORI funds registry and large-scale study of effectiveness of" exact="hydroxychloroquine" post="to prevent COVID-19 infection in U.S. healthcare workers2020https://www.pcori.org/news-release/pcori-funds-registry-study-effectiveness-hydroxychloroquine-prevent-covid-19-healthcare-workersAccessed April"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7192425\results\search\drugs\results.xml">
   <result pre="= 16.1 mg/L [9]. We also added 20 mg/L of" exact="antipyrine" post="(Merck, Germany) in the maternal compartment. This is an"/>
   <result pre="collected every 5 minutes to determine the antiviral drug and" exact="antipyrine" post="concentrations in the fetal vein side and in the"/>
   <result pre="drug to the FTR of the control (= antipyrine). An" exact="antipyrine" post="FTR over 20% was required to validate each experiment"/>
   <result pre="5 were validated with a mean ± standard deviation (SD)" exact="antipyrine" post="FTR of 31 ± 2%. In these validated procedures,"/>
   <result pre="3 were validated with a mean ± standard deviation (SD)" exact="antipyrine" post="FTR of 21 ± 1%. The system reached steady"/>
   <result pre="challenging procedure: half of our experiments were validated by an" exact="antipyrine" post="FTR &amp;gt; 20%, which is a standard success rate"/>
   <result pre="47 no. 41334–1342 10ChallierJC, D’AthisP, Guerre-MilloM, NandakumaranM. Flow-dependent transfer of" exact="antipyrine" post="in the human placenta in vitro. Reprod Nutr Dév."/>
   <result pre="10.1016/j.ajog.2006.01.01716678781 24Faure-BardonV, MandelbrotL, DuroD, DussauxC, LeM, PeytavinG. Placental transfer of" exact="elvitegravir" post="and cobicistat in an ex-vivo human cotyledon double perfusion"/>
   <result pre="MandelbrotL, DuroD, DussauxC, LeM, PeytavinG. Placental transfer of elvitegravir and" exact="cobicistat" post="in an ex-vivo human cotyledon double perfusion model. AIDS"/>
   <result pre="1Mai2016; 60(5):3112–4. 10.1128/AAC.00007-1626833154 30MandelbrotL, DuroD, BelissaE, PeytavinG. Placental transfer of" exact="darunavir" post="in an ex vivo human cotyledon perfusion model. Antimicrob"/>
   <result pre="31BerveillerP, MirO, VinotC, BonatiC, DucheneP, GiraudC, et al.Transplacental transfer of" exact="oseltamivir" post="and its metabolite using the human perfused placental cotyledon"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7193140\results\search\drugs\results.xml">
   <result pre="an excessive cytokine response. Indeed, cytokine blockers, such as infliximab," exact="adalimumab" post="(anti-tumor necrosis factor [TNF]), and ustekinumab (anti-interleukin [IL]-12/IL-23 [p40"/>
   <result pre="blockers, such as infliximab, adalimumab (anti-tumor necrosis factor [TNF]), and" exact="ustekinumab" post="(anti-interleukin [IL]-12/IL-23 [p40 subunit]), used for the treatment of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7193267\results\search\drugs\results.xml">
   <result pre="permitted which does not comply with these terms. COVID-19 SARS-CoV-2" exact="chloroquine" post="antiviral 2019-nCoV fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction"/>
   <result pre="publications have discussed the possible efficacy of the antimalarial drug" exact="chloroquine" post="(CQ) and its derivatives as a possible treatment against"/>
   <result pre="in vivo response to a standard (25 mg/kg) dosage of" exact="chloroquine" post="in a group of semi-immunized children from Tanzania. The"/>
   <result pre="of influenza. For Ebola virus, the replication was inhibited by" exact="chloroquine" post="in vitro but failed to protect Guinea pigs, mice,"/>
   <result pre="arrest. Nevertheless, a randomized double-blind trial was performed to establish" exact="epinephrine" post="effectiveness in out-of-hospital arrest (35). As reminded by Kalil"/>
   <result pre="Med. (1987) 317:710–1. 10.1056/NEJM1987091031711143627179 3.Don MichaelTAAiwazzadehS. The effects of acute" exact="chloroquine" post="poisoning with special reference to the heart. Am Heart"/>
   <result pre="to cardiac arrest. Circulation. (1991) 83:1888–94. 10.1161/01.CIR.83.6.18882040041 6.SinghAKSinghAShaikhASinghRMisraA. Chloroquine and" exact="hydroxychloroquine" post="in the treatment of COVID-19 with or without diabetes:"/>
   <result pre="drugs. J Gen Virol. (1969) 4:203–14. 10.1099/0022-1317-4-2-2034306296 14.ShimizuYYamamotoSHommaMIshidaN. Effect of" exact="chloroquine" post="on the growth of animal viruses. Arch Gesamte Virusforsch."/>
   <result pre="Virusforsch. (1972) 36:93–104. 10.1007/BF012502994335025 15.HellgrenUKihamiaCMMahikwanoLFBjörkmanAErikssonORomboL. Response of plasmodium falciparum to" exact="chloroquine" post="treatment: relation to whole blood concentrations of chloroquine and"/>
   <result pre="falciparum to chloroquine treatment: relation to whole blood concentrations of" exact="chloroquine" post="and desethylchloroquine. Bull World Health Organ. (1989) 67:197–202. 2663218"/>
   <result pre="Bull World Health Organ. (1989) 67:197–202. 2663218 16.GeraldesAValdeiraML. Effect of" exact="chloroquine" post="on African swine fever virus infection. J Gen Virol."/>
   <result pre="1:189–92. 10.1111/j.1750-2659.2007.00027.x19453426 21.De LamballerieXBoissonVReynierJCEnaultSCharrelRNFlahaultAet al.. On chikungunya acute infection and" exact="chloroquine" post="treatment. Vector Borne Zoonotic Dis. (2008) 8:837–9. 10.1089/vbz.2008.004918620511 22.DowallSDBosworthAWatsonRBewleyKTaylorIRaynerEet"/>
   <result pre="96:3484–92. 10.1099/jgv.0.00030926459826 23.FalzaranoDSafronetzDPrescottJMarziAFeldmannFFeldmannH. Lack of protection against ebola virus from" exact="chloroquine" post="in mice and hamsters. Emerg Infect Dis. (2015) 21:1065–7."/>
   <result pre="in different cell models. Viruses. (2016) 8:322. 10.3390/v812032227916837 25.GaoJTianZYangX. Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="clinical studies. Biosci Trends. (2020) 14:72–310.5582/bst.2020.0104732074550 26.WangMCaoRZhangLYangXLiuJXuMet al.. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="Antimicrob Agents. (2020) 55:105923. 10.1016/j.ijantimicag.2020.10592332070753 28.RoquesPThibervilleSDDupuis-MaguiragaLLumFMLabadieKMartinonFet al.. Paradoxical effect of" exact="chloroquine" post="treatment in enhancing chikungunya virus infection. Viruses. (2018) 10:268."/>
   <result pre="of Guangdong, and p. Health Commission of Guangdong Province for" exact="chloroquine" post="in the treatment of novel coronavirus. [Expert consensus on"/>
   <result pre="chloroquine in the treatment of novel coronavirus. [Expert consensus on" exact="chloroquine" post="phosphate for the treatment of novel coronavirus pneumonia]. Zhonghua"/>
   <result pre="Xi Za Zhi. (2020) 43:185–8. 10.3760/cma.j.issn.1001-0939.2020.03.00932164085 30.GautretPLagierJCParolaPHoangVTMeddebLMailheMet al.. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="dissemination of results and its consequences regarding the use of" exact="hydroxychloroquine" post="for COVID-19. Annal Internal Med. (2020) M20-1223. 10.7326/M20-1223. [Epub"/>
   <result pre="ahead of print]. 32227189 32.Chen JunLDLiLPingLQingnianXLuXYunLet al.A pilot study of" exact="hydroxychloroquine" post="in treatment of patients with common coronavirus disease-19 (COVID-19)."/>
   <result pre="Med. (1991) 324:781–8. 10.1056/NEJM1991032132412011900101 35.PerkinsGDJiCDeakinCDQuinnTNolanJPScomparinCet al.. A randomized trial of" exact="epinephrine" post="in out-of-hospital cardiac arrest. N Eng J Med. (2018)"/>
   <result pre="Exp Stroke Translat Med. (2010) 3:19–27. 10.6030/1939-067X-3.1.1921533012 40.TouretFde LamballerieX. Of" exact="chloroquine" post="and COVID-19. Antiviral Res. (2020) 177:104762. 10.1016/j.antiviral.2020.10476232147496"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7193273\results\search\drugs\results.xml">
   <result pre="rare species. 2.2. Reagents Ethanol, methanol, DMSO, growth media (components)," exact="ciprofloxacin" post="hydrochloride, and miconazole were obtained from Sigma-Aldrich (Belgium). Water"/>
   <result pre="Reagents Ethanol, methanol, DMSO, growth media (components), ciprofloxacin hydrochloride, and" exact="miconazole" post="were obtained from Sigma-Aldrich (Belgium). Water was obtained from"/>
   <result pre="DMSO using sterile 96-well microdilution plates with flat-bottom wells. Antibiotics" exact="ciprofloxacin" post="and miconazole were used as positive control for bacteria"/>
   <result pre="sterile 96-well microdilution plates with flat-bottom wells. Antibiotics ciprofloxacin and" exact="miconazole" post="were used as positive control for bacteria and fungi,"/>
   <result pre="0.70 mg/L, respectively. These were more potent than the positive control," exact="mebendazole" post="(EC50 value = 1.25 mg/L). Wabo et al. [22] evaluated ethanolic extracts"/>
   <result pre="of Crude Drug Research1990281172510.3109/13880209009082768 20MorikawaT.Abdel-HalimO. B.MatsudaH.AndoS.MuraokaO.YoshikawaM.Pseudoguaiane-type sesquiterpenes and inhibitors on" exact="nitric oxide" post="production from Dichrocephala integrifoliaTetrahedron200662266435644210.1016/j.tet.2006.03.091 21WandaG. J. M. K.DjiogueS.GamoF. Z.NgitedemS."/>
   <result pre="found to be comparable to that of the standard drug" exact="metronidazole" post="[24]. Cynoglossum zeylanicum (Vahl) Brand Boraginaceae 6053 Used for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7193980\results\search\drugs\results.xml">
   <result pre="is permitted which does not comply with these terms. COVID-19" exact="hydroxychloroquine" post="dose efficacy side-effects coronavirus fig-count: table-count: equation-count: ref-count: page-count:"/>
   <result pre="prolongation. In vitro studies have shown strong anti-viral activity of" exact="chloroquine" post="(1, 3, 4). Chloroquine blocked virus infection at low-micromolar"/>
   <result pre="&amp;gt; 88.50) (4). Besides its antiviral activity, immunomodulatory properties of" exact="chloroquine" post="might have synergistically enhanced its antiviral effect in vivo."/>
   <result pre="impact of timing on its immunomodulatory effect, authors demonstrated that" exact="chloroquine" post="was effective both at entry and post-entry stages of"/>
   <result pre="to humans and reported that an initial- loading dose of" exact="hydroxychloroquine" post="400 mg twice a day followed by 200 mg"/>
   <result pre="4 days could be effective in humans. Authors reported that" exact="hydroxychloroquine" post="was more effective than chloroquine (lower EC50-0.72 vs. 5.47μM)"/>
   <result pre="in humans. Authors reported that hydroxychloroquine was more effective than" exact="chloroquine" post="(lower EC50-0.72 vs. 5.47μM) (1). In China, a panel"/>
   <result pre="vs. 5.47μM) (1). In China, a panel of experts recommended" exact="chloroquine" post="phosphate, administered orally at a dose of 500 mg"/>
   <result pre="severe cases of novel coronavirus pneumonia and without contraindications to" exact="chloroquine" post="(6). Regarding hydroxychloroquine, the first non-randomized, single-center clinical trial"/>
   <result pre="(6). Regarding hydroxychloroquine, the first non-randomized, single-center clinical trial of" exact="hydroxychloroquine" post="in humans was recently published by the French group"/>
   <result pre="for 6 days (7). Authors enrolled 42 patients−26 were given" exact="hydroxychloroquine" post="200 mg tid (overall 600 mg) and 16 were"/>
   <result pre="group (p = 0.001). Interestingly, its effects were enhanced by" exact="azithromycin" post="which was co-administered in 6 patients to prevent bacterial"/>
   <result pre="one patient who was still positive following 6 days of" exact="hydroxychloroquine" post="administration of azithromycin resulted in negative PCR 3 days"/>
   <result pre="was still positive following 6 days of hydroxychloroquine administration of" exact="azithromycin" post="resulted in negative PCR 3 days after. Notably, two"/>
   <result pre="in negative PCR 3 days after. Notably, two patients receiving" exact="hydroxychloroquine" post="were asymptomatic. The study was underpowered and included non-severe"/>
   <result pre="the same group enrolling 1,061 patients with COVID-19. Combination of" exact="hydroxychloroquine" post="and azithromycin, started immediately after diagnosis, led to a"/>
   <result pre="Results are encouraging but should be treated with caution. Perhaps" exact="hydroxychloroquine" post="could be effective in combination with other drugs (i.e.,"/>
   <result pre="hydroxychloroquine could be effective in combination with other drugs (i.e.," exact="azithromycin" post="or other immunomodulatory or anti-viral agents) in most moderate"/>
   <result pre="in most moderate and severe cases. The1 concept of using" exact="hydroxychloroquine" post="as a preventive strategy in the general population is"/>
   <result pre="and potentially hazardous. Our approach in Greece is to administer" exact="hydroxychloroquine" post="in all hospitalized patients including those intubated in ICU,"/>
   <result pre="hospitalized patients including those intubated in ICU, in combination with" exact="azithromycin" post="as well as anti-viral agents depending on disease severity."/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome Coronavirus"/>
   <result pre="2 (SARS-CoV-2). Clin Infect Dis. (2020) 9:ciaa23710.1093/cid/ciaa237 2.GautretPLJParollaPHoangVTMeddebLMailheMDoudierBet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an openlabel"/>
   <result pre="spread. Virol J. (2005). 2:69. 10.1186/1743-422X-2-6916115318 4.WangMCaoRZhangLYangXLiuJXuMet al.. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="Cell Res. (2020). 30:269–71. 10.1038/s41422-020-0282-032020029 5.SchrezenmeierEDornerT. Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatology. Nat Rev Rheumatol. (2020)"/>
   <result pre="of Guangdong Province and Health Commission of Guangdong Province for" exact="chloroquine" post="in the treatment of novel coronavirus pneumonia. [Expert consensus"/>
   <result pre="in the treatment of novel coronavirus pneumonia. [Expert consensus on" exact="chloroquine" post="phosphate for the treatment of novel coronavirus pneumonia]. Zhonghua"/>
   <result pre="(2020) 43:185–8. 10.3760/cma.j.issn.1001-0939.2020.03.00932164085 7.DevauxCARolainJ-MColsonPRaoultDNew insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int J Antimicrob"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7194068\results\search\drugs\results.xml">
   <result pre="Ltd. pmcid: 7194068S1359-6446(20)30167-7 doi: 10.1016/j.drudis.2020.04.021 : Article Chiral switches of" exact="chloroquine" post="and hydroxychloroquine: potential drugs to treat COVID-19 D’AcquaricaIlariailaria.dacquarica@uniroma1.it�?�[], AgranatIsraelisri.agranat@mail.huji.ac.il�?��?�[],"/>
   <result pre="as long as the COVID-19 resource centre remains active. Repurposing" exact="chloroquine" post="and hydroxychloroquine against COVID-19 Therapeutic options in response to"/>
   <result pre="as the COVID-19 resource centre remains active. Repurposing chloroquine and" exact="hydroxychloroquine" post="against COVID-19 Therapeutic options in response to the COVID-19"/>
   <result pre="as candidates for COVID-19. Chloroquine (CQ) and its hydroxyl analog" exact="hydroxychloroquine" post="(HCQ) are showing preliminary inhibitory effects against COVID-19 and"/>
   <result pre="COVID-19. Chloroquine phosphate (CQ phosphate), IUPAC name: N4-(7-chloro-4-quinolinyl)-N1,N1-diethylpentane-1,4-diamine diphosphate, and" exact="hydroxychloroquine" post="sulfate (HCQ sulfate), IUPAC name: 2-[[4-[(7-chloro-4-quinolinyl)amino]pentyl]ethylamino]ethanol sulfate, are old"/>
   <result pre="Chemical structures of the paired (S)-(+) and (R)-(–) enantiomers of" exact="chloroquine" post="(CQ) and hydroxychloroquine (HCQ). CAS Numbers: (S)-(+)-CQ: [58175-86-3]; (R)-(–)-CQ:"/>
   <result pre="the paired (S)-(+) and (R)-(–) enantiomers of chloroquine (CQ) and" exact="hydroxychloroquine" post="(HCQ). CAS Numbers: (S)-(+)-CQ: [58175-86-3]; (R)-(–)-CQ: [58175-87-4]; (S)-(+)-HCQ: [137433-24-0];"/>
   <result pre="for the 2019 novel coronavirus (2019-nCoV)Nat. Rev. Drug Discov19202014915032127666 2GaoJ.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="of COVID-19 associated pneumonia in clinical studiesBiosci. Trends142020727332074550 3WangM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="recently emerged novel coronavirus (2019-nCoV) in vitroCell Res.30202026927132020029 4ColsonP.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int. J. Antimicrob. Agents55202010593232145363"/>
   <result pre="2019 novel coronavirus SARS-CoV-2Int. J. Antimicrob. Agents55202010592332070753 10DucharmeJ.Enantioselective disposition of" exact="hydroxychloroquine" post="after a single oral dose of the racemate to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7194111\results\search\drugs\results.xml">
   <result pre="have indicated that many drugs can effectively suppress ZIKV, including" exact="candesartan" post="cilexetil (Loe et al., 2019), pinocembrin (Lee et al.,"/>
   <result pre="(Lee et al., 2019), aurintricarboxylic acid (Park et al. 2019)," exact="ribavirin" post="and sofosbuvir. However, how to protect pregnant women safely"/>
   <result pre="a substantial challenge for the development of small-molecule drugs. Although" exact="ribavirin" post="can effectively inhibit ZIKV replication (Kim et al., 2018),"/>
   <result pre="long term (Russmann et al., 2006). Research has reported that" exact="sofosbuvir" post="can also inhibit ZIKV infection (Reznik and Ashby, 2017),"/>
   <result pre="cells were immediately replenished with plaque medium supplemented with 1%" exact="methylcellulose" post="(Sigma, Saint Louis, USA). Infected cells were incubated for"/>
   <result pre="and 15.7 in Huh7 cells) (Julander et al., 2017), and" exact="sofosbuvir" post="(SI &amp;gt; 52.63 in Huh7) (Bullard-Feibelman et al., 2017),"/>
   <result pre="the literature and proposed guidelines for the use of oral" exact="ribavirin" post="as postexposure prophylaxis for Lassa feverClin. Infect. Dis.5120101435144121058912 Bullard-FeibelmanK.M.GoveroJ.ZhuZ.SalazarV.VeselinovicM.DiamondM.S.GeissB.J.The"/>
   <result pre="postexposure prophylaxis for Lassa feverClin. Infect. Dis.5120101435144121058912 Bullard-FeibelmanK.M.GoveroJ.ZhuZ.SalazarV.VeselinovicM.DiamondM.S.GeissB.J.The FDA-approved drug" exact="sofosbuvir" post="inhibits Zika virus infectionAntivir. Res.137201713414027902933 CedronJ.C.GutierrezD.FloresN.RaveloA.G.Estevez-BraunA.Synthesis and antiplasmodial activity"/>
   <result pre="cell culture and in a mouse modelAntivir. Res.1372017142227838352 KimJ.A.SeongR.K.KumarM.ShinO.S.Favipiravir and" exact="ribavirin" post="inhibit replication of asian and african strains of Zika"/>
   <result pre="inhibiting virus replicationVirol. J.8201148322029605 LoeM.LeeR.ChuJ.Antiviral activity of the FDA-approved drug" exact="candesartan" post="cilexetil against Zika virus infectionAntivir. Res.172201910463731669333 LuG.BluemlingG.R.CollopP.HagerM.KuiperD.GuraleB.P.PainterG.R.De La RosaA.KolykhalovA.A.Analysis"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7194516\results\search\drugs\results.xml">
   <result pre="and its hydroxyl analogue, hydroxychloroquine, inhibit SARS-CoV-2 in vitro with" exact="hydroxychloroquine" post="(EC50 = 0.72%μM) found to be more potent than"/>
   <result pre="hydroxychloroquine (EC50 = 0.72%μM) found to be more potent than" exact="chloroquine" post="(EC50 = 5.47%μM) [3]. A French paper reporting on"/>
   <result pre="of drug combinations in infected patients highlighted the possibility that" exact="hydroxychloroquine" post="is effective in the treatment of COVID-19 patients [4]"/>
   <result pre="azithromycin. In this study, with a limited number of patients," exact="hydroxychloroquine" post="with azithromycin was shown to clear viral nasopharyngeal carriage"/>
   <result pre="this study, with a limited number of patients, hydroxychloroquine with" exact="azithromycin" post="was shown to clear viral nasopharyngeal carriage of SARS-CoV-2"/>
   <result pre="There are a variety of classes of antimalarial medications, including" exact="artemisinin" post="derivatives (derived from the plant Artemisia annua), quinine and"/>
   <result pre="sulfonamides). The story of the rediscovery of the sesquiterpene lactone," exact="artemisinin" post="in China, an active principle derived from plants described"/>
   <result pre="evidence on a number of potential COVID-19 therapeutics. Chloroquine and" exact="hydroxychloroquine" post="are included in the panel of drugs under investigation."/>
   <result pre="showed that remdesivir and interferon beta were superior to lopinavir," exact="ritonavir" post="and interferon beta both in vitro and in a"/>
   <result pre="MERS-CoV mouse model. Remdesivir, administered alone or in combination with" exact="chloroquine" post="[10] is also considered to be effective and has"/>
   <result pre="that must be considered for use against SARS-CoV-2. For instance," exact="teicoplanin" post="was proposed as a potential treatment in COVID-19 patients"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of Severe Acute Respiratory Syndrome coronavirus"/>
   <result pre="2 (SARS-CoV-2)Clin Infect Dis2020 Mar 910.1093/cid/ciaa237pii: ciaa237 4GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.HonoréS.ColsonP.ChabrièreE.La ScolaB.RolainJ.M.BrouquiP.RaoultD.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID�?19: results of an open�?label"/>
   <result pre="for the COVID_19Trav Med Infect Dis2020 Mar 510161510.1016/j.tmaid.2020.101615 10WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7194560\results\search\drugs\results.xml">
   <result pre="nicotinamide) and other miscellaneous systemically acting drugs. Of special interest," exact="ribavirin" post="had been used in treating cases of SARS CoV."/>
   <result pre="repurposing against the viral Mpro. Ribavirin, telbivudine, vitamin B12 and" exact="nicotinamide" post="can be combined and used for COVID treatment. This"/>
   <result pre="1 anticancer and other miscellaneous systemically acting drugs. Among antivirals," exact="ribavirin" post="and telbivudine were ranked at the second and third"/>
   <result pre="and other miscellaneous systemically acting drugs. Among antivirals, ribavirin and" exact="telbivudine" post="were ranked at the second and third positions. They"/>
   <result pre="in the docking scores, compared with curcumin. Vitamin B12 and" exact="nicotinamide" post="were ranked at the 4th and 6th positions. Table"/>
   <result pre="Cysteamine HCl C2H8ClNS 114 1.77 12.01 0.00 2.00 Nephropathic cystinosis" exact="methoxamine" post="hydrochloride C11H18ClNO3 248 1.77 3.20 0.10 5.09 Alpha-adrenergic agonist"/>
   <result pre="[25]. Given the high similarity of SARS and COVID-19 Mpros," exact="ribavirin" post="might be of a value in treating COVID-19. Telbivudine"/>
   <result pre="and best fits the viral polymerase. The high rank of" exact="telbivudine" post="in this study suggests its repurposing for COVID-19 treatment"/>
   <result pre="into the Mpro binding site. B) The docking site of" exact="ribavirin" post="C) The ligand interactions of ribavirin with Mpro D)"/>
   <result pre="The docking site of ribavirin C) The ligand interactions of" exact="ribavirin" post="with Mpro D) The site of docking of telbivudine"/>
   <result pre="of ribavirin with Mpro D) The site of docking of" exact="telbivudine" post="E) The ligand interactions of telbivudine with Mpro. Hydrogen"/>
   <result pre="site of docking of telbivudine E) The ligand interactions of" exact="telbivudine" post="with Mpro. Hydrogen bonds are shown in purple arrows,"/>
   <result pre="Mpro inhibitor). The repurposing of ribavirin, telbivudine, vitamin B12 and" exact="nicotinamide" post="is suggested. The following is the supplementary data related"/>
   <result pre="docking studiesInterdiscip. Sci. Comput. Life Sci.82016132141 24CrottyS.MaagD.ArnoldJ.J.ZhongW.LauJ.Y.HongZ.The broad-spectrum antiviral ribonucleoside" exact="ribavirin" post="is an RNA virus mutagenNat. Med.620001375137911100123 25KorenG.KingS.KnowlesS.PhillipsE.Ribavirin in the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7194583\results\search\drugs\results.xml">
   <result pre="long as the COVID-19 resource centre remains active. Hydroxychloroquine and" exact="azithromycin" post="have been touted for potential prophylaxis or treatment for"/>
   <result pre="that are required for viral entry.5 The widely used antibiotic" exact="azithromycin" post="is increasingly recognized as a rare cause of QT"/>
   <result pre="and female sex have been implicated as risk factors. Interestingly," exact="azithromycin" post="can also provoke non-pause-dependent polymorphic ventricular tachycardia.11,12 A U.S."/>
   <result pre="U.S. Food and Drug Administration perspective supported the observations that" exact="azithromycin" post="administration leaves the patient vulnerable to corrected QT (QTc)"/>
   <result pre="agents 5 whenever feasible Safety considerations for the use of" exact="hydroxychloroquine" post="and azithromycin in clinical practice have been described.18 Some"/>
   <result pre="whenever feasible Safety considerations for the use of hydroxychloroquine and" exact="azithromycin" post="in clinical practice have been described.18 Some of the"/>
   <result pre="long-QT syndrome; TdP = torsade de pointes. References References 1ChenC.Y.WangF.L.LinC.C.Chronic" exact="hydroxychloroquine" post="use associated with QT prolongation and refractory ventricular arrhythmiaClin"/>
   <result pre="erythematosus due to hydroxychloroquineCase Reports in Cardiology20162016462627927478650 4de OlanoJ.HowlandM.A.SuM.K.HoffmanR.S.BiaryR.Toxicokinetics of" exact="hydroxychloroquine" post="following a massive overdoseAm J Emerg Med3720192264.e5–e8 5GiudicessiJ.R.NoseworthyP.A.FriedmanP.A.AckermanM.J.Urgent guidance"/>
   <result pre="causes a novel proarrhythmic syndromeCirc Arrhythm Electrophysiol102017e003560 13MosholderA.D.MathewJ.AlexanderJ.J.SmithH.NambiarS.Cardiovascular risks with" exact="azithromycin" post="and other antibacterial drugsN Engl J Med36820131665166823635046 14ZhangM.XieM.LiS.Electrophysiologic studies"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7194665\results\search\drugs\results.xml">
   <result pre="in line with a study published in 2005 reporting that" exact="chloroquine" post="tends to be an effective antiviral agent pre- and"/>
   <result pre="for COVID-19. However, the use of malarial drugs such as" exact="chloroquine" post="and hydroxychloroquine shown great promise in treating COVID-19, specifically"/>
   <result pre="However, the use of malarial drugs such as chloroquine and" exact="hydroxychloroquine" post="shown great promise in treating COVID-19, specifically in China"/>
   <result pre="world. Another study in France investigated the effectiveness of both" exact="hydroxychloroquine" post="and azithromycin with COVID-19, 97.5% of 80 patients improved"/>
   <result pre="study in France investigated the effectiveness of both hydroxychloroquine and" exact="azithromycin" post="with COVID-19, 97.5% of 80 patients improved clinically at"/>
   <result pre="inhibiting SARS-CoV-2 infection in vitroCell Discov612020 Mar 181431934347 6ColsonP.RolainJ.M.LagierJ.C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int J Antimicrob Agents2020"/>
   <result pre="Mar 410593232145363 7GautretP.LagierJ.C.ParolaP.MeddebL.SevestreJ.MailheM.DoudierB.AubryC.AmraneS.SengP.HocquartM.Clinical and microbiological effect of a combination of" exact="hydroxychloroquine" post="and azithromycin in 80 COVID-19 patients with at least"/>
   <result pre="7GautretP.LagierJ.C.ParolaP.MeddebL.SevestreJ.MailheM.DoudierB.AubryC.AmraneS.SengP.HocquartM.Clinical and microbiological effect of a combination of hydroxychloroquine and" exact="azithromycin" post="in 80 COVID-19 patients with at least a six-day"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7194727\results\search\drugs\results.xml">
   <result pre="that neutralize the eosinophil growth and activating factor IL-5 (eg," exact="mepolizumab" post="and reslizumab) and drugs that directly induce eosinophil depletion"/>
   <result pre="in human eosinophils triggers eosinophil cytokine production, degranulation, superoxide and" exact="nitric oxide" post="(NO) generation, and prolonged cellular survival.21, 22, 23 Eosinophil-derived"/>
   <result pre="human subjects with asthma were treated with the antieosinophil drug" exact="mepolizumab" post="(an anti–IL-5 humanized mAb) or placebo and subsequently challenged"/>
   <result pre="double-blind studyAm J Respir Crit Care Med199201950851730192638 35BjerregaardA.LaingI.A.BackerV.SverrildA.KhooS.K.ChidlowG.High fractional exhaled" exact="nitric oxide" post="and sputum eosinophils are associated with an increased risk"/>
   <result pre="asthma: focus on benralizumabDrug Saf43202040942532242310 42LugogoN.DomingoC.ChanezP.LeighR.GilsonM.J.PriceR.G.Long-term efficacy and safety of" exact="mepolizumab" post="in patients with severe eosinophilic asthma: a multi-center, open-label,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7194813\results\search\drugs\results.xml">
   <result pre="in the latest 6th edition, recommend: interferon (IFN)-α, lopinavir/ritonavir, ribavirin," exact="chloroquine" post="phosphate, arbidol [5], [6], [7], [8]. In addition, tocilizumab"/>
   <result pre="ribavirin, chloroquine phosphate, arbidol [5], [6], [7], [8]. In addition," exact="tocilizumab" post="has been used as a new therapeutic opportunity results"/>
   <result pre="(H7N9) virus infection initially treated with empirical antibacterial therapy and" exact="oseltamivir" post="with progression to acute respiratory distress syndrome and mechanical"/>
   <result pre="progression to acute respiratory distress syndrome and mechanical ventilation. After" exact="bosentan" post="administration patient’s right ventricular systolic pressure improved rapidly with"/>
   <result pre="lopinavir, given together to suppress HIV-replication, have been associated with" exact="bosentan" post="to treat PAH in HIV-infected patients without dosage adjustment"/>
   <result pre="protease inhibitors with good tolerability [14]. In conclusion, we think" exact="bosentan" post="could be considered, in association with other approved drugs,"/>
   <result pre="coronavirus in the United StatesN Engl J Med.2020 6WangM.CaoR.ZhangL.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="Mar 21]. Oral Oncol. 2020;104659. 10BellisaiF.MorozziG.ScacciaF.Evaluation of the effect of" exact="bosentan" post="treatment on proinflammatory cytokine serum levels in patients affected"/>
   <result pre="and H7N9 influenza virus infectionLung1925201463563624898108 14DingemanseJ.van GiersbergenP.L.PatatA.NilssonP.N.Mutual pharmacokinetic interactions between" exact="bosentan" post="and lopinavir/ritonavir in healthy participantsAntivir Ther152201015716320386070 Acknowledgement The authors"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7194824\results\search\drugs\results.xml">
   <result pre="pH-dependent viral fusion with lysosomal enzymes and replication [20]. Furthermore," exact="chloroquine" post="can block clathrin-mediated endocytosis by SARS-CoV-2 [21]. Interferon-α is"/>
   <result pre="infection include Type II Transmembrane Serine Protease (TMSPSS2) inhibitor and" exact="imatinib" post="(Tyrosine kinase inhibitor) [26], [27]. The summary of the"/>
   <result pre="Yang X, Liu J, Xu M, et al. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="10.1038/s41422-020-0282-0. PubMed PMID: 32020029; PubMed Central PMCID: PMCPMC7054408. 20SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against today's diseases?Lancet"/>
   <result pre="21Hu TY, Frieman M, Wolfram J. Insights from nanomedicine into" exact="chloroquine" post="efficacy against COVID-19. Nat Nanotechnol. 2020. Epub 2020/03/24. doi:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7194845\results\search\drugs\results.xml">
   <result pre="of COVID-19. Lopinavir is more potent HIV protease inhibitor than" exact="ritonavir" post="but it showed poor bioavalibility in vivo. Therefore a"/>
   <result pre="in clinical studies of COVID-19 patients [[28], [29], [30]]. An" exact="adenosine" post="analog known as Remdesivir is a prodrug of Remdesivir-triphosphate."/>
   <result pre="(COVID-19)Int. J. Surg.762020717632112977 9ChristianA.D.Jean-MarcR.PhilippeC.New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus:what to expect for COVID-19?Int. J. Antimicrob. Agents202010.1016/j.ijantimicag.2020.105938"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7194856\results\search\drugs\results.xml">
   <result pre="English version It has been known for a while that" exact="chloroquine" post="(C) and its derivative hydroxychloroquine (HC) inhibit in vitro"/>
   <result pre="known for a while that chloroquine (C) and its derivative" exact="hydroxychloroquine" post="(HC) inhibit in vitro the replication of viruses which"/>
   <result pre="a top-tier scientific journal, just like the recent article evaluating" exact="lopinavir" post="and ritonavir published in the New England Journal of"/>
   <result pre="scientific journal, just like the recent article evaluating lopinavir and" exact="ritonavir" post="published in the New England Journal of Medicine. This"/>
   <result pre="be dangerous to use it without careful clinical supervision. Besides," exact="azithromycin" post="−suggested to act in combination with C/HC against SArs-CoV-2"/>
   <result pre="Version française Il est connu depuis bien longtemps que la" exact="chloroquine" post="(C) et son dérivé l’hydroxychloroquine (HC) inhibent in vitro"/>
   <result pre="l’être), comme cela vient d’être le cas pour l’article sur" exact="lopinavir" post="et ritonavir dans le New England Journal of Medicine"/>
   <result pre="cela vient d’être le cas pour l’article sur lopinavir et" exact="ritonavir" post="dans le New England Journal of Medicine . Cet"/>
   <result pre="that he has no competing interest. References References 1WangM.CaoR.ZhangL.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="effective in inhibiting SARS-CoV-2 infection in vitroCell Discov620201632194981 3TouretF.de LamballerieX.Of" exact="chloroquine" post="and COVID- 19Antiviral research177202010476232147496 4Jianjun GaoZhenxue TianXuYang.Breakthrough: chloroquine phosphate"/>
   <result pre="3TouretF.de LamballerieX.Of chloroquine and COVID- 19Antiviral research177202010476232147496 4Jianjun GaoZhenxue TianXuYang.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="adults hospitalized with severe Covid-19N Engl J Med202010.1056/NEJMoa2001282 6GautretHydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7194865\results\search\drugs\results.xml">
   <result pre="with antiviral and antipyretic drugs. However, both antiviral drugs and" exact="acetaminophen" post="have adverse reactions, including liver injury.22, 23, 24 In"/>
   <result pre="cell death mechanisms in drug-induced liver injury: lessons learned from" exact="acetaminophen" post="hepatotoxicityDrug Metab Rev4420128810622229890 24ShermanK.E.ShireN.J.CernohousP.Liver injury and changes in hepatitis"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7194918\results\search\drugs\results.xml">
   <result pre="to patients suffering from Covid-19. These are Chloroquine phosphate and" exact="hydroxychloroquine" post="sulphate (also known as anti-malarial drugs), arbidol, Remdesivir (GS-5734),"/>
   <result pre="(also known as anti-malarial drugs), arbidol, Remdesivir (GS-5734), Favipitavir and" exact="ribavirin" post="(a complex structure but best viewed as ribosyl purine"/>
   <result pre="the same principle, except that instead of deoxyadenosine we used" exact="adenosine" post="in the selective medium [21]. Deoxyadenosine + Pi →"/>
   <result pre="4DongL.HuS.GaoJ.Discovering drugs to treat coronavirus disease 2019 (COVID-19)Drug Discov14120204860 5GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="pneumonia monitored by quantitative RT-PCRJ Korean Med Sci3562020e7910.3346/jkms.2020.35.e7932056407 9TouretF.de LamballerieOf" exact="chloroquine" post="and COVID-19Antiviral Res177202010476210.101016/j.antiviral.2020.104762[Epub ahead of print]32147496 10SmithE.C.CaseJ.B.BlancH.Mutation in Coronavirus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7194941\results\search\drugs\results.xml">
   <result pre="address drug repositioning against SARS-CoV-2; the target drugs were chloroquine," exact="hydroxychloroquine" post="associated with azithromycin, teicoplanin, remdesivir, nitazoxanide and metformin. Several"/>
   <result pre="target drugs were chloroquine, hydroxychloroquine associated with azithromycin, teicoplanin, remdesivir," exact="nitazoxanide" post="and metformin. Several authors report the potential of chloroquine"/>
   <result pre="remdesivir, nitazoxanide and metformin. Several authors report the potential of" exact="chloroquine" post="as a therapeutic option against this virus: in vitro"/>
   <result pre="in vitro study performed by Liu et al. (2020), both" exact="chloroquine" post="and hydroxychloroquine inhibited the virus from entering the cell"/>
   <result pre="study performed by Liu et al. (2020), both chloroquine and" exact="hydroxychloroquine" post="inhibited the virus from entering the cell and, at"/>
   <result pre="viral genome in cells in the case of SARS-CoV-2. However," exact="chloroquine" post="was observed to have a higher efficacy [9]. Teicoplanin,"/>
   <result pre="[10]. Gautret et al. (2020) conducted a clinical trial using" exact="hydroxychloroquine" post="in patients infected with SARS-CoV-2. The initial results show"/>
   <result pre="a significant reduction in viral carriage and the use of" exact="hydroxychloroquine" post="in conjunction with azithromycin was more efficient in eliminating"/>
   <result pre="viral carriage and the use of hydroxychloroquine in conjunction with" exact="azithromycin" post="was more efficient in eliminating the virus [11]. There"/>
   <result pre="to simultaneously research the efficacy of four drugs, including remdesivir," exact="chloroquine" post="and hydroxychloroquine, for the treatment of patients affected with"/>
   <result pre="alternative in infectious diseasesBraz J Infec Dis223201825225610.1016/j.bjid.2018.05.00729963991 5FolettoV.S.SerafinM.B.BottegaA.da RosaT.F.deS.MachadoC.CoelhoS.S.Repositioning of" exact="fluoxetine" post="and paroxetine: study of potential antibacterial activity and its"/>
   <result pre="diseasesBr J Pharmacol1752201818119110.1111/bph.1389528685814 7Wang M., Cao R., Zhang L.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="novel coronavirus (2019-nCoV) in vitro. Cell Research 2020;30:269–71. https://doi.org/10.1038/s41422-020-0282-0 8GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="10ZhangJ.MaX.YuF.LiuJ.ZouF.PanT.Teicoplanin potently blocks the cell entry of 2019-nCoVBioRxiv202010.1101/2020.02.05.935387 11GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of Severe Acute Respiratory Syndrome Coronavirus"/>
   <result pre="reveals drug targets and potential drug-repurposingBioRxiv202010.1101/2020.03.22.002386 19KeyaertsE.LiS.VijgenL.RysmanE.VerbeeckJ.Van RanstM.Antiviral activity of" exact="chloroquine" post="against human coronavirus OC43 infection in newborn miceAntimicrob Agents"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7195027\results\search\drugs\results.xml">
   <result pre="and rutin, showed a better affinity for the MPro than" exact="nelfinavir" post="[4]. Bioflavonoids are well known for many biological and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7195088\results\search\drugs\results.xml">
   <result pre="where they are not approved for other indications. Oseltamivir or" exact="zanamivir" post="should be provided only in the presence of suspected/proven"/>
   <result pre="chloroquine/hydroxychloroquine be administered? Pending results of RCT, the use of" exact="hydroxychloroquine" post="may be considered for treating worsening patients with COVID-19"/>
   <result pre="hard clinical endpoints such as crude mortality. For these reasons," exact="hydroxychloroquine" post="should be preferentially administered within the framework of investigational"/>
   <result pre="evidence, we are currently unable to support the use of" exact="hydroxychloroquine" post="in asymptomatic or mildly symptomatic nonhospitalized patients outside investigational"/>
   <result pre="administered? Owing to the lack of high-level evidence, administration of" exact="tocilizumab" post="to patients with COVID-19 should preferentially occur within the"/>
   <result pre="our opinion, this could be a reasonable off-label use of" exact="tocilizumab" post="in these early phases of the COVID-19 pandemic, although"/>
   <result pre="outside RCT or compassionate-use programmes (with the exception of early" exact="oseltamivir" post="initiation in patients with suspected concomitant influenza). Corticosteroids should"/>
   <result pre="low-level evidence and pending RCT results, in our opinion, early" exact="hydroxychloroquine" post="administration may be considered in COVID-19 patients manifesting moderate"/>
   <result pre="the true balance between possible favourable effects and toxicity of" exact="hydroxychloroquine" post="in mildly symptomatic and asymptomatic patients. Question 8. What"/>
   <result pre="1 protease inhibitor. Ritonavir is a CYP3A4 inhibitor that boosts" exact="lopinavir" post="concentrations •Open-label RCT comparing lopinavir/ritonavir (99 patients) vs. standard"/>
   <result pre="was 13 days (IQR 11–16) [22] •Comparison of lopinavir/ritonavir vs." exact="hydroxychloroquine" post="in patients with mild COVID-19. Open-label RCT (NCT04307693, recruiting)."/>
   <result pre="10, 14 and 21. •Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus" exact="ribavirin" post="plus interferon beta 1b in patients with COVID-19. Open-label"/>
   <result pre="30 days). •Comparison of only supportive treatment vs. lopinavir/ritonavir vs." exact="oseltamivir" post="vs. umifenovir in patients with confirmed COVID-19 pneumonia. Open-label"/>
   <result pre="2.5 months). •Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or" exact="chloroquine" post="in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not"/>
   <result pre="remission of symptoms (follow-up 28 days). •Comparison of lopinavir/ritonavir plus" exact="hydroxychloroquine" post="vs. lopinavir/ritonavir plus hydroxychloroquine plus levamisole pill plus budesonide"/>
   <result pre="28 days). •Comparison of lopinavir/ritonavir plus hydroxychloroquine vs. lopinavir/ritonavir plus" exact="hydroxychloroquine" post="plus levamisole pill plus budesonide plus formoterol inhaler in"/>
   <result pre="•Comparison of lopinavir/ritonavir plus hydroxychloroquine vs. lopinavir/ritonavir plus hydroxychloroquine plus" exact="levamisole" post="pill plus budesonide plus formoterol inhaler in patients with"/>
   <result pre="plus hydroxychloroquine vs. lopinavir/ritonavir plus hydroxychloroquine plus levamisole pill plus" exact="budesonide" post="plus formoterol inhaler in patients with nonsevere COVID-19 pneumonia."/>
   <result pre="vs. lopinavir/ritonavir plus hydroxychloroquine plus levamisole pill plus budesonide plus" exact="formoterol" post="inhaler in patients with nonsevere COVID-19 pneumonia. Partly blinded"/>
   <result pre="(b) negative RT-PCR at 3–7 days. •Comparison of lopinavir/ritonavir vs." exact="hydroxychloroquine" post="vs. losartan vs. placebos in patients with COVID-19. Double-blind,"/>
   <result pre="RT-PCR at 3–7 days. •Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs." exact="losartan" post="vs. placebos in patients with COVID-19. Double-blind, adaptive RCT"/>
   <result pre="ordinal severity scale (follow-up 60 days). •Comparison of lopinavir/ritonavir vs." exact="hydroxychloroquine" post="vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs."/>
   <result pre="scale at day 15. •Comparison of lopinavir/ritonavir or umifenovir or" exact="chloroquine" post="or hydroxychloroquine or oseltamivir (with or without azithromycin) vs."/>
   <result pre="day 15. •Comparison of lopinavir/ritonavir or umifenovir or chloroquine or" exact="hydroxychloroquine" post="or oseltamivir (with or without azithromycin) vs. natural honey"/>
   <result pre="•Comparison of lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or" exact="oseltamivir" post="(with or without azithromycin) vs. natural honey plus lopinavir/ritonavir"/>
   <result pre="without azithromycin) vs. natural honey plus lopinavir/ritonavir or umifenovir or" exact="chloroquine" post="or hydroxychloroquine or oseltamivir (with or without azithromycin) in"/>
   <result pre="vs. natural honey plus lopinavir/ritonavir or umifenovir or chloroquine or" exact="hydroxychloroquine" post="or oseltamivir (with or without azithromycin) in patients with"/>
   <result pre="honey plus lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or" exact="oseltamivir" post="(with or without azithromycin) in patients with COVID-19. Single-blind"/>
   <result pre="recruiting). Primary endpoint: all-cause mortality (follow-up 30 days). •Comparison of" exact="oseltamivir" post="plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with"/>
   <result pre="endpoint: all-cause mortality (follow-up 30 days). •Comparison of oseltamivir plus" exact="chloroquine" post="vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19"/>
   <result pre="mortality (follow-up 30 days). •Comparison of oseltamivir plus chloroquine vs." exact="oseltamivir" post="plus lopinavir/ritonavir in patients with mild COVID-19 and of"/>
   <result pre="lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus" exact="oseltamivir" post="vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs."/>
   <result pre="mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus" exact="oseltamivir" post="vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus"/>
   <result pre="darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus" exact="oseltamivir" post="plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in"/>
   <result pre="oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus" exact="chloroquine" post="vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with"/>
   <result pre="darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus" exact="oseltamivir" post="in patients with moderate to severe COVID-19. Open-label RCT"/>
   <result pre="8-point ordinal scale at day 15. •Comparison of remdesivir vs." exact="hydroxychloroquine" post="vs. remdesivir plus hydroxychloroquine in patients with COVID-19. Open-label"/>
   <result pre="day 15. •Comparison of remdesivir vs. hydroxychloroquine vs. remdesivir plus" exact="hydroxychloroquine" post="in patients with COVID-19. Open-label adaptive RCT (NCT04321616, not"/>
   <result pre="all-cause in-hospital mortality (follow-up 3 weeks). •Comparison of lopinavir/ritonavir vs." exact="hydroxychloroquine" post="vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs."/>
   <result pre="1 protease inhibitor. Cobicistat is a CYP3A4 inhibitor that boosts" exact="darunavir" post="concentrations •Not available •Comparison of darunavir/cobicistat vs. standard of"/>
   <result pre="still to be peer reviewed [30] •Comparison of favipiravir vs." exact="tocilizumab" post="vs. favipiravir plus tocilizumab in patients with COVID-19. Open-label"/>
   <result pre="reviewed [30] •Comparison of favipiravir vs. tocilizumab vs. favipiravir plus" exact="tocilizumab" post="in patients with COVID-19. Open-label RCT (NCT04310228, recruiting). Primary"/>
   <result pre="recruiting). Primary endpoint: clinical cure (follow-up 3 months). •Comparison of" exact="oseltamivir" post="plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with"/>
   <result pre="endpoint: clinical cure (follow-up 3 months). •Comparison of oseltamivir plus" exact="chloroquine" post="vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19"/>
   <result pre="cure (follow-up 3 months). •Comparison of oseltamivir plus chloroquine vs." exact="oseltamivir" post="plus lopinavir/ritonavir in patients with mild COVID-19 and of"/>
   <result pre="lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus" exact="oseltamivir" post="vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs."/>
   <result pre="mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus" exact="oseltamivir" post="vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus"/>
   <result pre="darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus" exact="oseltamivir" post="plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in"/>
   <result pre="oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus" exact="chloroquine" post="vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with"/>
   <result pre="darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus" exact="oseltamivir" post="in patients with moderate to severe COVID-19. Open-label RCT"/>
   <result pre="Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks). •Comparison of" exact="hydroxychloroquine" post="plus darunavir/cobicistat vs. standard of care in patients with"/>
   <result pre="case and contacts of contacts (follow-up 14 days). •Comparison of" exact="chloroquine" post="plus favipiravir vs. favipiravir vs. placebo in patients with"/>
   <result pre="conversion rate in nasopharyngeal swabs (follow-up 5 months). •Comparison of" exact="oseltamivir" post="plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with"/>
   <result pre="in nasopharyngeal swabs (follow-up 5 months). •Comparison of oseltamivir plus" exact="chloroquine" post="vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19"/>
   <result pre="swabs (follow-up 5 months). •Comparison of oseltamivir plus chloroquine vs." exact="oseltamivir" post="plus lopinavir/ritonavir in patients with mild COVID-19 and of"/>
   <result pre="lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus" exact="oseltamivir" post="vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs."/>
   <result pre="mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus" exact="oseltamivir" post="vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus"/>
   <result pre="darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus" exact="oseltamivir" post="plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in"/>
   <result pre="oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus" exact="chloroquine" post="vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with"/>
   <result pre="darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus" exact="oseltamivir" post="in patients with moderate to severe COVID-19. Open-label RCT"/>
   <result pre="Primary endpoint: virus negative conversion rate (follow-up 7 days). Chloroquine," exact="hydroxychloroquine" post="Some proposed mechanisms are the following: increase in the"/>
   <result pre="of cell receptors; immunomodulatory activity •Not available •Comparison of different" exact="hydroxychloroquine" post="dosages vs. placebo in three cohorts (outpatients, inpatients, healthcare"/>
   <result pre="development of COVID-19 (healthcare workers, follow-up 2 months). •Comparison of" exact="hydroxychloroquine" post="vs. ascorbic acid in contacts of COVID-19 patients. Double-blind"/>
   <result pre="COVID-19 (healthcare workers, follow-up 2 months). •Comparison of hydroxychloroquine vs." exact="ascorbic acid" post="in contacts of COVID-19 patients. Double-blind RCT (NCT04328961, not"/>
   <result pre="recruiting). Primary endpoint: laboratory-confirmed COVID-19 (follow-up 14 days). •Comparison of" exact="tocilizumab" post="plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in"/>
   <result pre="endpoint: laboratory-confirmed COVID-19 (follow-up 14 days). •Comparison of tocilizumab plus" exact="hydroxychloroquine" post="plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with"/>
   <result pre="COVID-19 (follow-up 14 days). •Comparison of tocilizumab plus hydroxychloroquine plus" exact="azithromycin" post="vs. tocilizumab plus hydroxychloroquine in patients with COVID-19. Open-label"/>
   <result pre="14 days). •Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs." exact="tocilizumab" post="plus hydroxychloroquine in patients with COVID-19. Open-label RCT (NCT04332094,"/>
   <result pre="•Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus" exact="hydroxychloroquine" post="in patients with COVID-19. Open-label RCT (NCT04332094, not yet"/>
   <result pre="mechanical ventilation in the ICU (follow-up 2 weeks).• Comparison of" exact="ciclesonide" post="plus hydroxychloroquine vs. ciclesonide in patients with COVID-19. Open-label"/>
   <result pre="in the ICU (follow-up 2 weeks).• Comparison of ciclesonide plus" exact="hydroxychloroquine" post="vs. ciclesonide in patients with COVID-19. Open-label RCT (NCT04330586,"/>
   <result pre="ICU (follow-up 2 weeks).• Comparison of ciclesonide plus hydroxychloroquine vs." exact="ciclesonide" post="in patients with COVID-19. Open-label RCT (NCT04330586, not yet"/>
   <result pre="eradication (based on virus load) at day 14. •Comparison of" exact="hydroxychloroquine" post="vs. placebo in patients with COVID-19 and under biological"/>
   <result pre="weeks); (d) ICU admission rate (follow-up 27 weeks). •Comparison of" exact="hydroxychloroquine" post="vs. placebo for the prevention of COVID-19 in healthcare"/>
   <result pre="symptomatic or asymptomatic SARS-CoV-2 infection (follow-up 2.5 months). •Comparison of" exact="hydroxychloroquine" post="vs. placebo in symptomatic COVID-19 patients or exposed healthcare"/>
   <result pre="3-point ordinal scale at day 14. •Comparison of remdesivir vs." exact="hydroxychloroquine" post="vs. remdesivir plus hydroxychloroquine in patients with COVID-19. Open-label"/>
   <result pre="day 14. •Comparison of remdesivir vs. hydroxychloroquine vs. remdesivir plus" exact="hydroxychloroquine" post="in patients with COVID-19. Open-label adaptive RCT (NCT04321616, not"/>
   <result pre="all-cause in-hospital mortality (follow-up 3 weeks). •Comparison of lopinavir/ritonavir vs." exact="hydroxychloroquine" post="vs. losartan vs. placebos in patients with COVID-19. Double-blind,"/>
   <result pre="mortality (follow-up 3 weeks). •Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs." exact="losartan" post="vs. placebos in patients with COVID-19. Double-blind, adaptive RCT"/>
   <result pre="Severity Scale (follow-up 60 days). •Comparison of convalescent plasma plus" exact="hydroxychloroquine" post="plus azithromycin vs. hydroxychloroquine plus azithromycin in hospitalized patients"/>
   <result pre="(follow-up 60 days). •Comparison of convalescent plasma plus hydroxychloroquine plus" exact="azithromycin" post="vs. hydroxychloroquine plus azithromycin in hospitalized patients with COVID-19."/>
   <result pre="days). •Comparison of convalescent plasma plus hydroxychloroquine plus azithromycin vs." exact="hydroxychloroquine" post="plus azithromycin in hospitalized patients with COVID-19. Open-label RCT"/>
   <result pre="of convalescent plasma plus hydroxychloroquine plus azithromycin vs. hydroxychloroquine plus" exact="azithromycin" post="in hospitalized patients with COVID-19. Open-label RCT (NCT04332835, not"/>
   <result pre="0, 4, 7, 14 and 28. •Comparison of lopinavir/ritonavir vs." exact="hydroxychloroquine" post="vs. lopinavir/ritonavir plus interferon beta-1a vs. remdesivir vs. standard"/>
   <result pre="and 28. •Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus" exact="interferon beta-1a" post="vs. remdesivir vs. standard of care in patients with"/>
   <result pre="may halt the dysregulated cytokine release •Not available •Comparison of" exact="methylprednisolone" post="vs. standard of care in patients with severe COVID-19."/>
   <result pre="lung injury score at days 7 and 14. •Comparison of" exact="methylprednisolone" post="vs. standard of care in patients with COVID-19. Open-label"/>
   <result pre="failure (follow-up 14 days). •Comparison of inhaled alpha interferon plus" exact="methylprednisolone" post="plus umifenovir vs. thalidomide plus inhaled alpha interferon plus"/>
   <result pre="•Comparison of inhaled alpha interferon plus methylprednisolone plus umifenovir vs." exact="thalidomide" post="plus inhaled alpha interferon plus methylprednisolone plus umifenovir in"/>
   <result pre="methylprednisolone plus umifenovir vs. thalidomide plus inhaled alpha interferon plus" exact="methylprednisolone" post="plus umifenovir in patients with severe COVID-19. Double-blind RCT"/>
   <result pre="clinical improvement (follow-up 28 days). •Comparison of different dosages of" exact="methylprednisolone" post="in patients with COVID-19. Open-label RCT (NCT04263402, recruiting). Primary"/>
   <result pre="day 7; (b) critical stage at day 7. •Comparison of" exact="siltuximab" post="(anti–IL-6 monoclonal antibody) vs. methylprednisolone in patients with COVID-19."/>
   <result pre="at day 7. •Comparison of siltuximab (anti–IL-6 monoclonal antibody) vs." exact="methylprednisolone" post="in patients with COVID-19. Open-label RCT (NCT04329650, not yet"/>
   <result pre="ICU admission (follow-up 29 days) Tocilizumab Humanized monoclonal IgG1 antibody," exact="tocilizumab" post="inhibits both membrane-bound and soluble IL-6 receptors. IL-6, is"/>
   <result pre="has been observed in severe COVID-19 •Not available •Comparison of" exact="tocilizumab" post="vs. standard of care in patients with COVID-19. Open-label"/>
   <result pre="rating on a 10-point ordinal scale). •Comparison of favipiravir vs." exact="tocilizumab" post="vs. favipiravir plus tocilizumab in patients with COVID-19. Open-label"/>
   <result pre="ordinal scale). •Comparison of favipiravir vs. tocilizumab vs. favipiravir plus" exact="tocilizumab" post="in patients with COVID-19. Open-label RCT (NCT04310228, recruiting). Primary"/>
   <result pre="recruiting). Primary endpoint: clinical cure (follow-up 3 months). •Comparison of" exact="tocilizumab" post="vs. placebo in hospitalized patients with COVID-19. Double-blind RCT"/>
   <result pre="on a 7-point ordinal scale at day 28. •Comparison of" exact="tocilizumab" post="plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in"/>
   <result pre="7-point ordinal scale at day 28. •Comparison of tocilizumab plus" exact="hydroxychloroquine" post="plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with"/>
   <result pre="scale at day 28. •Comparison of tocilizumab plus hydroxychloroquine plus" exact="azithromycin" post="vs. tocilizumab plus hydroxychloroquine in patients with COVID-19. Open-label"/>
   <result pre="day 28. •Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs." exact="tocilizumab" post="plus hydroxychloroquine in patients with COVID-19. Open-label RCT (NCT04332094,"/>
   <result pre="•Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus" exact="hydroxychloroquine" post="in patients with COVID-19. Open-label RCT (NCT04332094, not yet"/>
   <result pre="mechanical ventilation in the ICU (follow-up 2 weeks). •Comparison of" exact="chloroquine" post="analog (GNS651) vs. tocilizumab vs. nivolumab vs. standard of"/>
   <result pre="ICU (follow-up 2 weeks). •Comparison of chloroquine analog (GNS651) vs." exact="tocilizumab" post="vs. nivolumab vs. standard of care in patients with"/>
   <result pre="2 weeks). •Comparison of chloroquine analog (GNS651) vs. tocilizumab vs." exact="nivolumab" post="vs. standard of care in patients with advanced or"/>
   <result pre="(NCT04333914, not yet recruiting). Primary endpoint: 28-day survival. •Comparison of" exact="tocilizumab" post="intravenously vs. tocilizumab subcutaneously vs. sarilumab (anti-interleukin 6 receptor"/>
   <result pre="recruiting). Primary endpoint: 28-day survival. •Comparison of tocilizumab intravenously vs." exact="tocilizumab" post="subcutaneously vs. sarilumab (anti-interleukin 6 receptor α monoclonal antibody)"/>
   <result pre="independence from supplementary oxygen therapy (follow-up 28 days). •Comparison of" exact="tocilizumab" post="vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs."/>
   <result pre="supplementary oxygen therapy (follow-up 28 days). •Comparison of tocilizumab vs." exact="anakinra" post="(recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus"/>
   <result pre="•Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs." exact="siltuximab" post="vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs."/>
   <result pre="tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs." exact="anakinra" post="plus siltuximab vs. anakinra plus tocilizumab vs. standard of"/>
   <result pre="anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus" exact="siltuximab" post="vs. anakinra plus tocilizumab vs. standard of care in"/>
   <result pre="IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs." exact="anakinra" post="plus tocilizumab vs. standard of care in patients with"/>
   <result pre="antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus" exact="tocilizumab" post="vs. standard of care in patients with COVID-19. Open-label"/>
   <result pre="15 days). •Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or" exact="chloroquine" post="in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not"/>
   <result pre="symptoms in patients with cytokine-release syndrome. •Not available •Comparison of" exact="anakinra" post="vs. emapalumab (anti–interferon γ monoclonal antibody) vs. standard of"/>
   <result pre="recruiting). Primary endpoint: treatment success at day 15. •Comparison of" exact="tocilizumab" post="vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs."/>
   <result pre="endpoint: treatment success at day 15. •Comparison of tocilizumab vs." exact="anakinra" post="(recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus"/>
   <result pre="•Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs." exact="siltuximab" post="vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs."/>
   <result pre="tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs." exact="anakinra" post="plus siltuximab vs. anakinra plus tocilizumab vs. standard of"/>
   <result pre="anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus" exact="siltuximab" post="vs. anakinra plus tocilizumab vs. standard of care in"/>
   <result pre="IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs." exact="anakinra" post="plus tocilizumab vs. standard of care in patients with"/>
   <result pre="antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus" exact="tocilizumab" post="vs. standard of care in patients with COVID-19. Open-label"/>
   <result pre="for the treatment of HIV patients, administered in combination with" exact="ritonavir" post="to improve its serum half-life. On the basis of"/>
   <result pre="prolonged QT interval, further increased when administered with fluoroquinolones or" exact="azithromycin" post="Tocilizumab •Increased serum ALT (≤36%) and AST (≤22%) •Increased"/>
   <result pre="only within strictly regulated and limited compassionate-use/expanded-access frameworks. Oseltamivir and" exact="zanamivir" post="are neuraminidase inhibitors used for treating influenza which are"/>
   <result pre="treating COVID-19 patients (Table 2). However, no apparent activity of" exact="oseltamivir" post="and zanamivir has previously been observed against SARS-CoV-1 in"/>
   <result pre="patients (Table 2). However, no apparent activity of oseltamivir and" exact="zanamivir" post="has previously been observed against SARS-CoV-1 in vitro [27],"/>
   <result pre="76% of the first critically ill patients with COVID-19 received" exact="oseltamivir" post="may also be related to the suspicion of infection"/>
   <result pre="where they are not approved for other indications. Oseltamivir or" exact="zanamivir" post="should be provided only in the presence of suspected/proven"/>
   <result pre="Question 3. should chloroquine/hydroxychloroquine be administered? The rationale of using" exact="chloroquine" post="for treating COVID-19 patients is based on two potential"/>
   <result pre="antiviral activity and immunomodulatory effects. With regard to antiviral activity," exact="chloroquine" post="has been shown to inhibit various viruses in cell"/>
   <result pre="alpha, interleukin (IL)-6 and interferons that follows the administration of" exact="chloroquine" post="might help counteract an exaggerated proinflammatory response, which is"/>
   <result pre="a reduced T helper 2 differentiation [38]. In our opinion," exact="hydroxychloroquine" post="should be preferred over chloroquine because of its less"/>
   <result pre="differentiation [38]. In our opinion, hydroxychloroquine should be preferred over" exact="chloroquine" post="because of its less toxic profile (reduced ocular toxicity"/>
   <result pre="series, comparative observational studies and RCT evaluating the use of" exact="chloroquine" post="or hydroxychloroquine in patients with COVID-19 and registered in"/>
   <result pre="observational studies and RCT evaluating the use of chloroquine or" exact="hydroxychloroquine" post="in patients with COVID-19 and registered in Chinese or"/>
   <result pre="a small controlled nonrandomized study of COVID-19 patients treated with" exact="hydroxychloroquine" post="has been recently published [41]. In this study, Gautret"/>
   <result pre="al. enrolled 26 COVID-19 patients to receive 200 mg of" exact="hydroxychloroquine" post="every 8 hours for 10 days, whereas a total"/>
   <result pre="were included as controls. Of note, six patients treated with" exact="hydroxychloroquine" post="also received azithromycin. The primary endpoint was virologic clearance"/>
   <result pre="results, thereby biasing results towards observing a favourable effect of" exact="hydroxychloroquine" post="administration [42]. Furthermore, the opposite results (apparent absence of"/>
   <result pre="(albeit in a tiny sample size of 11 patients receiving" exact="hydroxychloroquine" post="plus azithromycin) [43]. Uncertainty also surrounds the more marked"/>
   <result pre="surrounds the more marked positive effect observed in patients receiving" exact="azithromycin" post="in addition to hydroxychloroquine in the study by Gautret"/>
   <result pre="positive effect observed in patients receiving azithromycin in addition to" exact="hydroxychloroquine" post="in the study by Gautret et al., especially because"/>
   <result pre="Question 3 statement Pending results of RCT, the use of" exact="hydroxychloroquine" post="may be considered for treating worsening patients with COVID-19"/>
   <result pre="hard clinical endpoints such as crude mortality. For these reasons," exact="hydroxychloroquine" post="should be preferentially administered within the framework of investigational"/>
   <result pre="evidence, we are currently unable to support the use of" exact="hydroxychloroquine" post="in asymptomatic or mildly symptomatic nonhospitalized patients outside investigational"/>
   <result pre="of azithromycin. Furthermore, the small experiences of the administration of" exact="azithromycin" post="in COVID-19 patients have provided conflicting results. Question 4"/>
   <result pre="with acute respiratory distress syndrome (ARDS) in China, administration of" exact="methylprednisolone" post="was associated with reduced progression to death (hazard ratio"/>
   <result pre="patients with SARS-CoV-1 did not report a beneficial effect of" exact="hydrocortisone" post="administration. Of note, higher viraemia was observed in the"/>
   <result pre="in the second and third weeks after infection in the" exact="hydrocortisone" post="group compared to the control group [56]. Moreover, as"/>
   <result pre="included 277 patients with ARDS to assess the effects of" exact="dexamethasone" post="treatment. Patients in the study arm received dexamethasone 20"/>
   <result pre="effects of dexamethasone treatment. Patients in the study arm received" exact="dexamethasone" post="20 mg once daily from day 1 to day"/>
   <result pre="a significant reduction in duration of mechanical ventilation in the" exact="dexamethasone" post="group than in the control group (between-group difference 4.8"/>
   <result pre="proportion of adverse events did not differ significantly between the" exact="dexamethasone" post="group and the control group [63]. Data on the"/>
   <result pre="critically ill patients with MERS-CoV, the administration of a median" exact="hydrocortisone" post="equivalent dose of 300 mg per day was not"/>
   <result pre="severe or life-threatening cytokine release syndrome [68,69]. In this regard," exact="tocilizumab" post="may help mitigate the cytokine release syndrome by decreasing"/>
   <result pre="In their still-to-be-peer-reviewed case series, the following were observed after" exact="tocilizumab" post="administration: (a) reduction in body temperature (21/21, 100%); (b)"/>
   <result pre="tomography (19/21, 90.5%). Interestingly, no adverse reactions were observed after" exact="tocilizumab" post="administration, but long-term follow-up was not available. Tocilizumab has"/>
   <result pre="it should be noted that the optimal time for administering" exact="tocilizumab" post="has not yet been fully elucidated; nor is there"/>
   <result pre="least eight ongoing RCT evaluating the efficacy and safety of" exact="tocilizumab" post="in COVID-19 patients (Table 2). Other immune-modulatory drugs including"/>
   <result pre="tocilizumab in COVID-19 patients (Table 2). Other immune-modulatory drugs including" exact="anakinra" post="(interleukin 1 receptor antagonist) or Janus kinase family enzyme"/>
   <result pre="statement Owing to the lack of high-level evidence, administration of" exact="tocilizumab" post="in patients with COVID-19 should preferentially occur within the"/>
   <result pre="our opinion, this could be a reasonable off-label use of" exact="tocilizumab" post="in these early phases of the COVID-19 pandemic, although"/>
   <result pre="subjects, which overall may support a positive effect of early" exact="hydroxychloroquine" post="initiation in non-ICU settings (although information on the exact"/>
   <result pre="outside RCT or compassionate-use programmes (with the exception of early" exact="oseltamivir" post="initiation in patients with suspected concomitant influenza). Corticosteroids should"/>
   <result pre="low-level evidence and pending RCT results, in our opinion, early" exact="hydroxychloroquine" post="administration may be considered in COVID-19 patients who have"/>
   <result pre="the true balance between possible favourable effects and toxicity of" exact="hydroxychloroquine" post="in mildly symptomatic and asymptomatic patients. Question 8. what"/>
   <result pre="adults hospitalized with severe COVID-19N Engl J Med38220201787179932187464 23WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="arbidol for COVID-19: a randomized clinical trialmedRxiv2020202010.1101/2020.03.17.20037432 31CalyL.DruceJ.D.CattonM.G.JansD.A.WagstaffK.M.The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntivir Res202010478732251768 32KeyaertsE.VijgenL.MaesP.NeytsJ.Van"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="(SARS-CoV-2)Clin Infect Dis202010.1093/cid/ciaa237 34DevauxC.A.RolainJ.M.ColsonP.RaoultD.New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int J Antimicrob"/>
   <result pre="expect for COVID-19?Int J Antimicrob Agents202010.1016/j.ijantimicag.2020.105938 35HuT.Y.FriemanM.WolframJ.Insights from nanomedicine into" exact="chloroquine" post="efficacy against COVID-19Nat Nanotechnol15202024724932203437 36van den BorneB.E.DijkmansB.A.de RooijH.H.le CessieS.VerweijC.L.Chloroquine"/>
   <result pre="efficacy against COVID-19Nat Nanotechnol15202024724932203437 36van den BorneB.E.DijkmansB.A.de RooijH.H.le CessieS.VerweijC.L.Chloroquine and" exact="hydroxychloroquine" post="equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma"/>
   <result pre="cellsJ Rheumatol24199755609002011 37ZhouD.DaiS.M.TongQ.COVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progressionJ Antimicrob Chemother202010.1093/jac/dkaa114 38GuastalegnameM.ValloneA.Could chloroquine/hydroxychloroquine"/>
   <result pre="(COVID-19) treatment?Clin Infect Dis202010.1093/cid/ciaa321 39SahraeiZ.ShabaniM.ShokouhiS.SaffaeiA.Aminoquinolines against coronavirus disease 2019 (COVID-19):" exact="chloroquine" post="or hydroxychloroquineInt J Antimicrob Agents55202010594532194152 40CortegianiA.IngogliaG.IppolitoM.GiarratanoA.EinavS.A systematic review on"/>
   <result pre="Agents55202010594532194152 40CortegianiA.IngogliaG.IppolitoM.GiarratanoA.EinavS.A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J Crit Care202010.1016/j.jcrc.2020.03.005 41GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and"/>
   <result pre="chloroquine for the treatment of COVID-19J Crit Care202010.1016/j.jcrc.2020.03.005 41GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="dissemination of results and its consequences regarding the use of" exact="hydroxychloroquine" post="for COVID-19Ann Intern Med202010.7326/M20-1223 43MolinaJ.M.DelaugerreC.GoffJ.L.Mela-LimaB.PonscarmeD.GoldwirtL.No evidence of rapid antiviral"/>
   <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infectionMed Mal"/>
   <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infectionMed Mal Infect202010.1016/j.medmal.2020.03.006 44HuangC.WangY.LiX.RenL.ZhaoJ.HuY.Clinical"/>
   <result pre="cytokine response to corticosteroid rescue treatment in late ARDSChest1081995131513257587435 60GuMeduriTolleyE.A.ChrousosG.P.StentzF.Prolonged" exact="methylprednisolone" post="treatment suppresses systemic inflammation in patients with unresolving acute"/>
   <result pre="resistance to glucocorticoidsAm J Respir Crit Care Med165200298399111934726 61SeamN.GuMeduriWangH.NylenE.S.SunJ.SchultzM.J.Effects of" exact="methylprednisolone" post="infusion on markers of inflammation, coagulation, and angiogenesis in"/>
   <result pre="consider cytokine storm syndromes and immunosuppressionLancet39520201033103432192578 68BrunnerH.I.RupertoN.ZuberZ.KeaneC.HarariO.KenwrightA.Efficacy and safety of" exact="tocilizumab" post="in patients with polyarticular-course juvenile idiopathic arthritis: results from"/>
   <result pre="randomised, double-blind withdrawal trialAnn Rheum Dis7420151110111724834925 69YokotaS.ImagawaT.MoriM.MiyamaeT.AiharaY.TakeiS.Efficacy and safety of" exact="tocilizumab" post="in patients with systemic-onset juvenile idiopathic arthritis: a randomised,"/>
   <result pre="a multicentre retrospective matched cohort studyHong Kong Med J9200339940614660806 80KatzenJ.KohnR.HoukJ.L.IsonM.G.Early" exact="oseltamivir" post="after hospital admission is associated with shortened hospitalization: a"/>
   <result pre="admission is associated with shortened hospitalization: a 5-year analysis of" exact="oseltamivir" post="timing and clinical outcomesClin Infect Dis692019525830304487 81LouieJ.K.YangS.AcostaM.YenC.SamuelM.C.SchechterR.Treatment with neuraminidase"/>
   <result pre="technology of guangdong province; Health commission of guangdong province for" exact="chloroquine" post="in the treatment of novel coronavirus P. [Expert consensus"/>
   <result pre="in the treatment of novel coronavirus P. [Expert consensus on" exact="chloroquine" post="phosphate for the treatment of novel coronavirus pneumonia]Zhonghua Jie"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7195091\results\search\drugs\results.xml">
   <result pre="pmcid: 7195091S0190-9622(20)30728-3 doi: 10.1016/j.jaad.2020.04.112 : Article Response to: &quot;Risks of" exact="hydroxychloroquine" post="use for COVID-19 prophylaxis�? Grant-KelsJane M.MDgrant@uchc.edu∗[], [], ∗Correspondence to:"/>
   <result pre="Sachdeva et al1 for their interest in our letter, &quot;Does" exact="hydroxychloroquine" post="combat COVID-19? A timeline of evidence.�?2 As they noted,"/>
   <result pre="supporting the preliminary evidence regarding the efficacy and safety of" exact="hydroxychloroquine" post="(HCQ) as a treatment or prophylaxis for COVID-19. What"/>
   <result pre="rheumatologic literature has demonstrated that HCQ is less toxic than" exact="chloroquine" post="and a very safe medication, prolonged use and overdosing"/>
   <result pre="rheumatologists); they reported that more than 5 dozen &quot;people taking" exact="hydroxychloroquine" post="and other treatments for chronic rheumatologic diseases have become"/>
   <result pre="on the effectiveness of HCQ prophylaxis. References References 1SachdevaM.ShahM.ZivM.LeshemE.Dodiuk-GadR.P.Risks of" exact="hydroxychloroquine" post="use for COVID-19 prophylaxisJ Am Acad Dermatol8312020e73e74 2AliaE.Grant-KelsJ.M.Does hydroxychloroquine"/>
   <result pre="of hydroxychloroquine use for COVID-19 prophylaxisJ Am Acad Dermatol8312020e73e74 2AliaE.Grant-KelsJ.M.Does" exact="hydroxychloroquine" post="combat COVID-19? A timeline of evidenceJ Am Acad Dermatol8312020e33e34"/>
   <result pre="the need for an evidence baseLancet Respir Med202010.1016/S2213-2600(20)30172-7 4GautretP.LagierJ.C.ParolaP.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="Antimicrob Agents202010.1016/j.ijantimicag.2020.105949 5GautretP.LagierJ.C.ParolaP.Clinical and microbiological effect of a combination of" exact="hydroxychloroquine" post="and azithromycin in 80 COVID-19 patients with at least"/>
   <result pre="5GautretP.LagierJ.C.ParolaP.Clinical and microbiological effect of a combination of hydroxychloroquine and" exact="azithromycin" post="in 80 COVID-19 patients with at least a six-day"/>
   <result pre="a six-day follow up: an observational studyAvailable at:https://www.mediterranee-infection.com/wp-content/uploads/2020/03/COVID-IHU-2-1.pdf 6ChenZ.HuJ.ZhangZ.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7195146\results\search\drugs\results.xml">
   <result pre="Zhu et al. have prepared an anti-influenza A virus drug" exact="zanamivir" post="loaded by silver nanoparticles (Ag@ZNV) to inhibit H1N1 influenza"/>
   <result pre="investigated the viral suppression mechanism and found both AgNPs and" exact="zanamivir" post="had relatively high antiviral efficacy, but with synergistic virus"/>
   <result pre="that Kim's group has developed a kind of novel liver-targeted" exact="cyclosporine" post="A-encapsulated poly (lactic-co-glycolic) acid (PLGA) nanoparticles, which could inhibit"/>
   <result pre="has developed a triple combination of carbosilane dendrimers, tenofovir, and" exact="maraviroc" post="as a potential microbicide to prevent HIV-1 sexual transmission"/>
   <result pre="dendrimers as camptothecin carriers with antiviral activityEuro. Polym. J.902017136149 107JyothiK.R.BeloorJ.JoA.NguyenM.N.ChoiT.G.KimJ.H.AkterS.LeeS.K.MaengC.H.BaikH.H.KangI.HaJ.KimS.S.Liver-targeted" exact="cyclosporine" post="A-encapsulated poly(lactic-co-glycolic) acid nanoparticles inhibit hepatitis C virus replicationInt."/>
   <result pre="C virus replicationInt. J. Nanomedicine10201590392125673987 108Sepúlveda-CrespoD.Sánchez-RodríguezJ.SerramíaM.J.GómezR.MataF.J.D.L.JiménezJ.L.Muñoz-FernándezM.�?.Triple combination of carbosilane dendrimers," exact="tenofovir" post="and maraviroc as potential microbicide to prevent HIV-1 sexual"/>
   <result pre="replicationInt. J. Nanomedicine10201590392125673987 108Sepúlveda-CrespoD.Sánchez-RodríguezJ.SerramíaM.J.GómezR.MataF.J.D.L.JiménezJ.L.Muñoz-FernándezM.�?.Triple combination of carbosilane dendrimers, tenofovir and" exact="maraviroc" post="as potential microbicide to prevent HIV-1 sexual transmissionNanomedicine10201589991425867856 109ZhangX.C.ZhaoP.J.WuK.X.ZhangY.L.PengM.LiuZ.X.Compositional"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7195149\results\search\drugs\results.xml">
   <result pre="shelf. More than 90 have been approved since 1963, when" exact="idoxuridine" post="was authorised for the treatment of herpes simplex, but"/>
   <result pre="groups are now evaluating the use of long-standing malaria drug" exact="chloroquine" post="and its close cousin hydroxychloroquine. Although the drugs are"/>
   <result pre="a trial in which 26 people with covid-19 were given" exact="hydroxychloroquine" post="three times a day, in some cases alongside the"/>
   <result pre="to self-medicate with the drug. Now several clinical trials of" exact="hydroxychloroquine" post="are in the works, including one that began on"/>
   <result pre="efficacy be proven, the low cost and ready availability of" exact="hydroxychloroquine" post="should make it easy to mass produce for widespread"/>
   <result pre="– Trump's enthusiasm notwithstanding. At this point, the hype around" exact="hydroxychloroquine" post="says more about our desperation than its genuine promise,"/>
   <result pre="pharmaceutical giant Roche began investigating whether its rheumatoid arthritis drug" exact="tocilizumab" post="could interrupt this process. The drug works by inactivating"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7195335\results\search\drugs\results.xml">
   <result pre="(200 mg three times daily), lopinavir-ritonavir (400 mg twice daily)," exact="oseltamivir" post="(75 mg twice daily), and ribavirin and interferon alpha-2b"/>
   <result pre="(400 mg twice daily), oseltamivir (75 mg twice daily), and" exact="ribavirin" post="and interferon alpha-2b (5 million units twice daily). On"/>
   <result pre="sputum suggested Aspergillus infection. The patient was therefore treated with" exact="caspofungin" post="and voriconazole. Eight transfusions of B-compatible convalescent plasma (2,400"/>
   <result pre="and CRRT. Treatment with lopinavir-ritonavir (400 mg twice daily) and" exact="ribavirin" post="(500 mg every 12 h) was started on February"/>
   <result pre="February 2. Gram-positive bacteria were detected by blood culture, and" exact="imipenem" post="and vancomycin were given to the patient. A chest"/>
   <result pre="Gram-positive bacteria were detected by blood culture, and imipenem and" exact="vancomycin" post="were given to the patient. A chest radiograph showed"/>
   <result pre="Dis. https://doi.org/10.1016/S1473-3099(20)30141-9. 5SooY.O.ChengY.WongR.Retrospective comparison of convalescent plasma with continuing high-dose" exact="methylprednisolone" post="treatment in SARS patientsClin Microbiol Infect107200467667815214887 6ChengY.WongR.SooY.O.Use of convalescent"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7195336\results\search\drugs\results.xml">
   <result pre="Chloroquine and Hydroxychloroquine The current data supporting the use of" exact="chloroquine" post="or hydroxychloroquine for treatment of infection with SARS-CoV-2 includes"/>
   <result pre="Hydroxychloroquine The current data supporting the use of chloroquine or" exact="hydroxychloroquine" post="for treatment of infection with SARS-CoV-2 includes evidence of"/>
   <result pre="pneumonia. In the French series,3 6 patients were treated with" exact="azithromycin" post="in addition to hydroxychloroquine and had further reductions in"/>
   <result pre="series,3 6 patients were treated with azithromycin in addition to" exact="hydroxychloroquine" post="and had further reductions in detectable viral load. Azithromycin"/>
   <result pre="the COVID-19 pandemicAvailable at:https://www.ccs.ca/images/Images_2020/NEW_CCS_RRT_Inhoptial_infection_reduction_30Mar.pdfMarch 30, 2020Accessed March 31, 2020 2GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="of COVID-19 associated pneumonia in clinical studiesBiosci Trends142020727332074550 3GautretP.LagierJ.C.ParolaP.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7195609\results\search\drugs\results.xml">
   <result pre="drug most likely to penetrate the brain is the anti-malarial" exact="hydroxychloroquine" post="which, as of 13th April, was in 71 clinical"/>
   <result pre="eight trials, but shows low brain penetrance. Finally, the antibiotic" exact="azithromycin" post="which is in 17 clinical trials shows good brain"/>
   <result pre="vitroJ Neuroinflamm201916118210.1186/s12974-019-1565-6 13.JacksonKMHansenRJGustafsonDLPharmacokinetic and pharmacodynamic assessment of autophagy inhibition following" exact="hydroxychloroquine" post="in miceCancer Res201610.1158/1538-7445.AM2016-208426659574 14.ZhangQZhangYDiamondSBoerJHarrisJJLiYRuparMet al.The Janus kinase 2 inhibitor"/>
   <result pre="miceCancer Res201610.1158/1538-7445.AM2016-208426659574 14.ZhangQZhangYDiamondSBoerJHarrisJJLiYRuparMet al.The Janus kinase 2 inhibitor fedratinib inhibits" exact="thiamine" post="uptake: a putative mechanism for the onset of Wernicke’s"/>
   <result pre="Ebola virus in rhesus monkeysNature2016531759438138510.1038/nature1718026934220 16.NellanAMcCullyCMLCruz GarciaRJayaprakashNWidemannBCLeeDWWarrenKEImproved CNS exposure to" exact="tocilizumab" post="after cerebrospinal fluid compared to intravenous administration in rhesus"/>
   <result pre="(T-705) in rodents infected with Ebola virusAntiviral Res2018151505410.1016/j.antiviral.2017.12.02029289664 19.JaruratanasirikulSHortiwakulRTantisarasartTPhuenpathomNTussanasunthornwongSDistribution of" exact="azithromycin" post="into brain tissue, cerebrospinal fluid, and aqueous humor of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7195821\results\search\drugs\results.xml">
   <result pre="(MOI) of 0.05 in the presence of either compound or" exact="dimethyl sulfoxide" post="(DMSO) control. The dose–response curves were determined by quantification"/>
   <result pre="of 50 μM (Fig. 1a). In contrast, laninamivir, oseltamivir, peramivir, and" exact="zanamivir" post="did not exhibit anti-SARS-CoV-2 activity even at the highest"/>
   <result pre="vesicles (ELs). Among the drugs tested, laninamivir, oseltamivir, peramivir, and" exact="zanamivir" post="are neuraminidase (NA) inhibitors, which are most widely prescribed"/>
   <result pre="no NA analog exists in SARS-CoV-2, NA inhibitors such as" exact="oseltamivir" post="nevertheless are being used clinically in treating COVID-19 patients1,2."/>
   <result pre="SARS-CoV-2 (Fig. 1a), which is consistent with the finding that" exact="oseltamivir" post="and zanamivir were ineffective in inhibiting SARS-CoV9. Baloxavir marboxil"/>
   <result pre="1a), which is consistent with the finding that oseltamivir and" exact="zanamivir" post="were ineffective in inhibiting SARS-CoV9. Baloxavir marboxil is a"/>
   <result pre="process of this study, Choy et al. also showed that" exact="oseltamivir" post="and baloxavir failed to inhibit SARS-CoV-2 in vitro11. Arbidol,"/>
   <result pre="with 2019 novel coronavirus in Wuhan, ChinaLancet202039549750610.1016/S0140-6736(20)30183-531986264 3.WangMet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7195910\results\search\drugs\results.xml">
   <result pre="target for protease inhibitor drugs such as remdesivir, nelfinavir, lopinavir," exact="ritonavir" post="and α-ketoamide. While the 3D structure of protease was"/>
   <result pre="the potential protease inhibitors, the antivirals remdesivir, nelfinavir, lopinavir, and" exact="ritonavir" post="along with α-ketoamide are particularly attractive as therapeutics to"/>
   <result pre="syncytial virus, Nipah virus and Hendra virus [18]. Similarly, nelfinavir," exact="lopinavir" post="and ritonavir are protease inhibitors recommended for the treatment"/>
   <result pre="Nipah virus and Hendra virus [18]. Similarly, nelfinavir, lopinavir and" exact="ritonavir" post="are protease inhibitors recommended for the treatment of SARS"/>
   <result pre="Using Vero cell lines infected with SARS-CoV, antiviral effects of" exact="nelfinavir" post="has been studied [9, 25]. A separate investigation performed"/>
   <result pre="separate investigation performed by Xu et al. [24] indicated that" exact="nelfinavir" post="was identified as a potential inhibitor against COVID-19 main"/>
   <result pre="(MM/GBSA) model and solvated interaction energy methods. Other protease inhibitors," exact="lopinavir" post="and ritonavir are currently available in both first and"/>
   <result pre="and solvated interaction energy methods. Other protease inhibitors, lopinavir and" exact="ritonavir" post="are currently available in both first and second-line antiretroviral"/>
   <result pre="with protease inhibitors available in DrugBank such as remdesivir, nelfinavir," exact="lopinavir" post="and ritonavir along with ketoamide. This was followed by"/>
   <result pre="inhibitors available in DrugBank such as remdesivir, nelfinavir, lopinavir and" exact="ritonavir" post="along with ketoamide. This was followed by molecular interaction"/>
   <result pre="of 4 potential protease inhibitors namely: remdesivir (accession no: DB14761)," exact="nelfinavir" post="(accession no: DB00220), lopinavir (accession no: DB01601) and ritonavir"/>
   <result pre="inhibitors namely: remdesivir (accession no: DB14761), nelfinavir (accession no: DB00220)," exact="lopinavir" post="(accession no: DB01601) and ritonavir (accession no: DB00503) were"/>
   <result pre="DB14761), nelfinavir (accession no: DB00220), lopinavir (accession no: DB01601) and" exact="ritonavir" post="(accession no: DB00503) were downloaded from the DrugBank database"/>
   <result pre="1. The best recorded binding energy value was obtained for" exact="nelfinavir" post="(− 7.54 kcal mol−1) (Fig. 1). Further, molecular interaction studies"/>
   <result pre="protease inhibitors of COVID-19 using AUTODOCK software. Among the 5," exact="nelfinavir" post="has got docked with highest biding affinity (panel A).The"/>
   <result pre="target for protease inhibitor drugs such as remdesivir, nelfinavir, lopinavir," exact="ritonavir" post="and ketoamide. Homology modeling is a useful tool for"/>
   <result pre="suggests the 5 potential protease inhibitors namely nelfinavir, remdesivir, lopinavir," exact="ritonavir" post="and ketoamide got docked onto the predicted 3D model"/>
   <result pre="nelfinavir. Based on the lowest dock energy value scored by" exact="nelfinavir" post="in relation to remaining ligands, this appears to be"/>
   <result pre="in vitro and a clinical study indicate that remdesivir, an" exact="adenosine" post="analogue that acts as a viral protein inhibitor, has"/>
   <result pre="one patient [8, 22]. A combination of the anti-retroviral drugs" exact="lopinavir" post="and ritonavir significantly improved the clinical condition of SARS�?CoV"/>
   <result pre="[8, 22]. A combination of the anti-retroviral drugs lopinavir and" exact="ritonavir" post="significantly improved the clinical condition of SARS�?CoV patients [2]"/>
   <result pre="J Med20203821092993610.1056/NEJMoa200119132004427 9.HsiehLELinCNSuBLJanTRChenCMWangCHLinDSLinCTChuehLLSynergistic antiviral effect of Galanthus nivalis agglutinin and" exact="nelfinavir" post="against feline coronavirusAntiviral Res201088253010.1016/j.antiviral.2010.06.01020603153 10.JohanssonMUZoeteVMichielinOGuexNDefining and searching for structural"/>
   <result pre="the futureMicrobes Infect202022808510.1016/j.micinf.2020.02.00232087334 14.NukoolkarnVLeeVSMalaisreeMAruksakulwongOHannongbuaSMolecular dynamic simulations analysis of ritronavir and" exact="lopinavir" post="as SARS-CoV 3CLpro inhibitorsJ Theor Biol200825486186710.1016/j.jtbi.2008.07.03018706430 15.QamarMTAlqahtaniSMAlamriMAChenLLStructural basis of"/>
   <result pre="insights for wide spectrum anti-coronavirus drug designSci Rep201662267710.1038/srep2267726948040 21.WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="recently emerged novel coronavirus (2019-nCoV) in vitroCell Res202030326927110.1038/s41422-020-0282-032020029 22.WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="molecular docking and binding free energy calculationBioRxiv202010.1101/2020.01.27.921627v1 25.YamamotoNYangRYoshinakaYAmariSNakanoTCinatlJRabenauHDoerrHWHunsmannGOtakaATamamuraHHIV protease inhibitor" exact="nelfinavir" post="inhibits replication of SARS-associated coronavirusBiochem Biophys Res Commun200431871972510.1016/j.bbrc.2004.04.08315144898 26.ZhangLLinDKusovYNianYMaQWangJvon"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7195979\results\search\drugs\results.xml">
   <result pre="lopinavir/ritonavir, favipiravir and remdesivir will be reviewed here .Nitazoxanide and" exact="ivermectin" post="were also included in this review as they have"/>
   <result pre="Website https://www.nebraskamed. com/sites/default/files/documents/covid-19/covid19-antiviral-pharmacotherapy-recommendations.pdf [accessed 12 April 2020]. . Nitazoxanide and" exact="ivermectin" post="were also included in this review as they have"/>
   <result pre="Website www.covidreference. com�? 1.1. Hydroxychloroquine and Chloroquine Chloroquine (CQ) and" exact="hydroxychloroquine" post="(HCQ) are aminoquinolines, which have been used to treat"/>
   <result pre="such as systemic lupus erythematosus and rheumatoid arthritis. Hydroxychloroquine and" exact="chloroquine" post="can inhibit certain cellular functions and molecular pathways involved"/>
   <result pre="is quite scare. An early report from China suggested that" exact="chloroquine" post="usage was associated with reduced progression of the disease"/>
   <result pre="%, (P &amp;lt; 0.001). While the combination of HCQ with" exact="azithromycin" post="resulted in 100% viral clearance in 6 patients, HCQ"/>
   <result pre="drug induced-sudden cardiac death [16]1010Chang R, Sun WZ (2020). Repositioning" exact="chloroquine" post="as an ideal antiviral prophylaxis against COVID-19-time is now"/>
   <result pre="nucleotide analog that is intracellularly metabolized to an analog of" exact="adenosine" post="triphosphate that inhibits viral RNA polymerases. Remdesivir has broadspectrum"/>
   <result pre="is a protease inhibitor used to treat HIV infection, with" exact="ritonavir" post="as a booster. Protease is a key enzyme in"/>
   <result pre="Protease is a key enzyme in coronavirus polyprotein processing and" exact="lopinavir" post="and/or ritonavir has anti coronavirus activity in vitro. Most"/>
   <result pre="a key enzyme in coronavirus polyprotein processing and lopinavir and/or" exact="ritonavir" post="has anti coronavirus activity in vitro. Most in vitro"/>
   <result pre="vitro studies have shown that SARS�?CoV could be inhibited by" exact="lopinavir" post="and that the EC50 of lopinavir is acceptable. Lopinavir"/>
   <result pre="could be inhibited by lopinavir and that the EC50 of" exact="lopinavir" post="is acceptable. Lopinavir showed an antiviral effect against SARS-CoV-2"/>
   <result pre="the early stage. In a study from Hong-Kong, compared with" exact="ribavirin" post="alone, patients treated with lopinavir/ritonavir plus ribavirin had a"/>
   <result pre="Hong-Kong, compared with ribavirin alone, patients treated with lopinavir/ritonavir plus" exact="ribavirin" post="had a lower risk of acute respiratory distress syndrome"/>
   <result pre="host cellular defenses [36]. Due to its broad-spectrum antiviral activity," exact="nitazoxanide" post="is being investigated in clinical trials including randomized controlled"/>
   <result pre="encouraging or unavailable yet. Although the in vitro activity of" exact="nitazoxanide" post="against SARS-CoV-2 is encouraging, more data are clearly needed"/>
   <result pre="importin (IMP) 1 heterodimer responsible for integrase protein nuclear import," exact="ivermectin" post="has since been confirmed to inhibit integrase protein nuclear"/>
   <result pre="integrase protein nuclear import and HIV-1 replication. Other actions of" exact="ivermectin" post="have been reported, but ivermectin has been shown to"/>
   <result pre="HIV-1 replication. Other actions of ivermectin have been reported, but" exact="ivermectin" post="has been shown to inhibit the nuclear import of"/>
   <result pre="pseudorabies virus (PRV) both in vitro and in vivo, with" exact="ivermectin" post="treatment shown to increase survival in PRV-infected mice [37]."/>
   <result pre="survival in PRV-infected mice [37]. Efficacy was not observed for" exact="ivermectin" post="against Zikavirus in mice, but the authors acknowledged that"/>
   <result pre="justified the reevaluation of ivermectin’s anti-Zika virus activity [38]. Finally," exact="ivermectin" post="was the focus of a phase III clinical trial"/>
   <result pre="S, Suputtamongkol Y et al. (2018). Efficacy and safety of" exact="ivermectin" post="against dengue infection: a Phase III, randomized, double-blind, placebo-controlled"/>
   <result pre="[accessed 12 April 2020]. . In an in vitro study," exact="ivermectin" post="was found to be an inhibitor of the SARS-CoV-2,"/>
   <result pre="studyHong Kong Medical Journal939940614660806 Schrezenmeie EDörner T2020Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatologyNature Reviews Rheumatology1615516632034323 Liu JCao"/>
   <result pre="in vitroCell Discovery2020 Wang MCao RZhang LYang XLiu J2020Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="pneumonia in clinical studiesBioscience Trends14727232074550 Chen J2020A pilot study of" exact="hydroxychloroquine" post="in treatment of patients with common coronavirus disease-19 (COVID-1910"/>
   <result pre="patients with common coronavirus disease-19 (COVID-1910 Gautret PHoang VT2020Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="PParola PHoang VT2020Clinical and microbiological effect of a combination of" exact="hydroxychloroquine" post="and azithromycin in 80 COVID-19 patients with at least"/>
   <result pre="VT2020Clinical and microbiological effect of a combination of hydroxychloroquine and" exact="azithromycin" post="in 80 COVID-19 patients with at least a six-day"/>
   <result pre="observational studyTravel Medicine and Infectious Disease10 Chen CYWang FLLin CC2006Chronic" exact="hydroxychloroquine" post="use associated with QT prolongation and refractory ventricular arrhythmiaClinical"/>
   <result pre="findingsThorax5925225614985565 Yao TTQian JDZhu YWang YWang GQ2020A systematic review of" exact="lopinavir" post="therapy for SARS coronavirus and MERS coronavirus–A possible reference"/>
   <result pre="Jasenosky L DCadena CMire CEBorisevich VHaridas V2019The FDA-approved oral drug" exact="nitazoxanide" post="amplifies host antiviral responses and inhibits Ebola virusiScience191279129031402258 Caly"/>
   <result pre="virusiScience191279129031402258 Caly LDruce JDCatton MGJans DAWagstaff KM2020The FDA approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntiviral Research10 Ketkar"/>
   <result pre="vitroAntiviral Research10 Ketkar HYang LWormser GPWang P2019Lack of efficacy of" exact="ivermectin" post="for prevention of a lethal Zika virus infection in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7195984\results\search\drugs\results.xml">
   <result pre="included 16 non-ICU SARS patients, &quot;early�? (&amp;lt;7 days of illness)" exact="hydrocortisone" post="therapy was associated with a higher subsequent plasma viral"/>
   <result pre="assess the efficacy of corticosteroids in COVID-19. 4.2. Chloroquine and" exact="hydroxychloroquine" post="Chloroquine (CQ) and hydroxychloroquine (HCQ) are 4-aminoquinoline derivatives that"/>
   <result pre="corticosteroids in COVID-19. 4.2. Chloroquine and hydroxychloroquine Chloroquine (CQ) and" exact="hydroxychloroquine" post="(HCQ) are 4-aminoquinoline derivatives that are approved by the"/>
   <result pre="use (five or more years). Elders with kidney failure or" exact="tamoxifen" post="users have an increased risk of retinal toxicity. CQ"/>
   <result pre="receptor, or its postreceptor downstream signaling pathways (JAK/STAT). Tocilizumab, sarilumab," exact="siltuximab" post="are IL-6 antagonists with different pharmacologic properties. Tocilizumab is"/>
   <result pre="cytokine release syndrome, and idiopathic multicentric Castleman’s disease (iMCD), whereas" exact="siltuximab" post="received approval for iMCD and sarilumab for RA only"/>
   <result pre="A small clinical trial in China examined the effectiveness of" exact="tocilizumab" post="in 21 patients who met the criteria for severe"/>
   <result pre="et al. (2020). Effective treatment of severe COVID-19 patients with" exact="tocilizumab" post="[online]. Website https://www.ser.es/wp-content/uploads/2020/03/TCZ-and-COVID-19.pdf [accessed 06 April 2020]. . Recently,"/>
   <result pre="a patient with limited cutaneous systemic sclerosis under treatment with" exact="tocilizumab" post="was reported [82]. Since there is an urgent need"/>
   <result pre="for the severe COVID-19 treatments, based on these limited data," exact="tocilizumab" post="is included in the treatment algorithms of many countries."/>
   <result pre="and siltixumab in several countries. Current practice is to give" exact="tocilizumab" post="4–8 mg/kg (maximum 800 mg) as single infusion. After"/>
   <result pre="for cytokine storm and COVID-19. Currently, baricitinib (NCT04320277, NCT04340232, NCT04321993)," exact="tofacitinib" post="(NCT04332042) and ruxolitinib (NCT04331665) studies are ongoing. 4.6. Anakinra"/>
   <result pre="and COVID-19. Currently, baricitinib (NCT04320277, NCT04340232, NCT04321993), tofacitinib (NCT04332042) and" exact="ruxolitinib" post="(NCT04331665) studies are ongoing. 4.6. Anakinra Nod-like receptor family"/>
   <result pre="and IL-1 cytokines (except IL-18) can be successfully inhibited by" exact="anakinra" post="[88]. Anakinra is a recombinant antagonist of human IL-1"/>
   <result pre="sepsis and MAS, a previous, highly cited phase III trial," exact="anakinra" post="did not improve 28-day survival rate in sepsis patients"/>
   <result pre="in rheumatology routine which warrants careful monitoring. There are several" exact="anakinra" post="studies registered for COVID-19, testing 100 mg daily subcutaneous"/>
   <result pre="COVID-19 patients. 4.12. Nonsteroidal antiinflammatory drugs (NSAIDs) An association between" exact="ibuprofen" post="and worse outcome in COVID-19 patients was speculated, with"/>
   <result pre="A registered trial, currently recruiting patients to determine efficacy of" exact="naproxen" post="for its potential interaction with viral nucleoproteins (NCT04325633). Therefore,"/>
   <result pre="interaction with viral nucleoproteins (NCT04325633). Therefore, although evidence is limited," exact="indomethacin" post="or naproxen could be preferred over other NSAIDs when"/>
   <result pre="viral nucleoproteins (NCT04325633). Therefore, although evidence is limited, indomethacin or" exact="naproxen" post="could be preferred over other NSAIDs when indicated [101]."/>
   <result pre="toxicity: an analysis of electrocardiograms in 85 patients treated with" exact="hydroxychloroquine" post="for connective tissue diseasesRheumatology4680881017202178 Varan OKucuk HTufan A2015Myasthenia gravis"/>
   <result pre="and Immunotoxicology3543444223635029 Chhonker YSSleightholm RLLi JOupicky DMurry DJ2018Simultaneous quantitation of" exact="hydroxychloroquine" post="and its metabolites in mouse blood and tissues using"/>
   <result pre="Journal of Biological Chemistry26725744257471464591 Schrezenmeier EDorner T2020Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatologyNature Reviews Rheumatology1615516632034323 Aruoma OIHalliwell"/>
   <result pre="of anti-inflammatory drugsXenobiotica184594703135672 Wang MCao RZhang LYang XLiu J2020Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe aAcute respiratory syndrome coronavirus"/>
   <result pre="Infectious Diseases Society of America 202010 Gao JTian ZYang X2020Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="clinical studiesBioscience Trends14727332074550 Gautret PLagier JCParola PHoang VTMeddeb L2020Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="MTran V-TRoumier MChabrol APaule R2020No evidence of clinical efficacy of" exact="hydroxychloroquine" post="in patients hospitalized for COVID-19 infection with oxygen requirement:"/>
   <result pre="AJordan SCOVID-19 in a patient with systemic sclerosis treated with" exact="tocilizumab" post="for SSc-ILDAnnals of the Rheumatic Diseases10 A TVHaikarainen TRaivola"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7196557\results\search\drugs\results.xml">
   <result pre="reported that patients with diabetes, hypertension, or patients treated with" exact="ibuprofen" post="are at higher risk of contracting severe COVID-19 [[9],"/>
   <result pre="lymphopenia (including CD4+ and NK cells). Interestingly, IL-6 blockade with" exact="tocilizumab" post="partially restored HLA-DR expression on CD14 monocytes and increased"/>
   <result pre="antiviral drugs, such as lopinavir/ritonavir [[96], [97], [98], [99]] or" exact="ribavirin" post="[[100], [101], [102]]. In vitro, IFN-α and -β have"/>
   <result pre="have reported on 21 severe or critical patients treated with" exact="tocilizumab" post="although there was no control group [123]. This first"/>
   <result pre="were enrolled into a compassionate-use program [125]. All patients received" exact="siltuximab" post="at doses ranging from 700 to 1,200 mg. Clinical"/>
   <result pre="not mentioned. Finally, Roumier et al. reported their experience regarding" exact="tocilizumab" post="in 30 selected patients (23% in ICU) [127]. Patients"/>
   <result pre="NCT04321993, NCT04335071, NCT04348500, NCT04329650, NCT04330638, NCT04345289, NCT04327388, NCT04341870). In China," exact="tocilizumab" post="is also being evaluated either alone or in combination"/>
   <result pre="ChiCTR2000030796, ChiCTR2000030442, ChiCTR2000030894). It is noteworthy that since March 2020" exact="tocilizumab" post="has been formally included in the National Health Commission"/>
   <result pre="patients who have been admitted to the hospital with COVID-19," exact="tocilizumab" post="should be used only in the context of a"/>
   <result pre="In a reanalysis of data from a phase-III randomized trial," exact="anakinra" post="was associated with significant survival improvement in patients with"/>
   <result pre="of reHLH, without triggering any serious adverse events [141]. Today," exact="anakinra" post="is being evaluated in this context in the PROVIDE"/>
   <result pre="context in the PROVIDE study (NCT03332225). Often efficacious within hours," exact="anakinra" post="has a short half-life and is considered safe. It"/>
   <result pre="data are available but clinical trials are ongoing to test" exact="anakinra" post="in COVID-19 (NCT04330638, NCT04341584, NCT04339712, NCT04324021). Canakinumab, a monoclonal"/>
   <result pre="which was refractory to corticosteroids, IL-1 blockade, anti-TNF, cyclosporine, and" exact="vedolizumab" post="[147]. Although blocking IL-18 could be of interest in"/>
   <result pre="Indeed, while a few case reports described the benefits of" exact="etanercept" post="[[158], [159], [160]], other studies have shown that it"/>
   <result pre="to hospital [157]. To date, only a single RCT evaluating" exact="adalimumab" post="in COVID-19 has been registered (ChiCTR2000030089). 4.5 Non-targeted therapies"/>
   <result pre="that, among patients who developed ARDS (n=84, 41.8%), treatment with" exact="methylprednisolone" post="decreased the risk of death (HR, 0.38; 95% CI,"/>
   <result pre="prolonged viral shedding and secondary bacterial infections. 4.5.2 Chloroquine and" exact="hydroxychloroquine" post="There has been tremendous debate about chloroquine or its"/>
   <result pre="4.5.2 Chloroquine and hydroxychloroquine There has been tremendous debate about" exact="chloroquine" post="or its derivative, hydroxychloroquine, as potentially effective treatments in"/>
   <result pre="inhibiting prostaglandin synthesis or lipid peroxidation [[186], [187], [188]]. Altogether," exact="chloroquine" post="and hydroxychloroquine are thought to be able to reduce"/>
   <result pre="synthesis or lipid peroxidation [[186], [187], [188]]. Altogether, chloroquine and" exact="hydroxychloroquine" post="are thought to be able to reduce viral load"/>
   <result pre="conclusion, it is noteworthy that several national guidelines already include" exact="chloroquine" post="or hydroxychloroquine whereas the IDSA recommends reserving its use"/>
   <result pre="is noteworthy that several national guidelines already include chloroquine or" exact="hydroxychloroquine" post="whereas the IDSA recommends reserving its use (in combination"/>
   <result pre="whereas the IDSA recommends reserving its use (in combination with" exact="azithromycin" post="or not) for clinical trials. 4.5.3 JAK inhibitors and"/>
   <result pre="of common marmosetJ Infect Dis21220151904191310.1093/infdis/jiv39226198719 98ZengY.-M.XuX.-L.HeX.-Q.TangS.-Q.LiY.HuangY.-Q.Comparative effectiveness and safety of" exact="ribavirin" post="plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir"/>
   <result pre="and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and" exact="ribavirin" post="plus lopinavir/ritonavir plus interferon-alphain in patients with mild to"/>
   <result pre="patientsMedRxiv20202202010.1101/2020.02.29.2002952029.20029520 119CoomesE.A.HaghbayanH.Interleukin-6 in COVID-19: a systematic review and meta-analysisMedRxiv20203202010.1101/2020.03.30.2004805830.20048058 120WatanabeE.SugawaraH.YamashitaT.IshiiA.OdaA.TeraiC.Successful" exact="tocilizumab" post="therapy for macrophage activation syndrome associated with adult-onset still’s"/>
   <result pre="in COVID-19: a single center experienceJ Med Virol202010.1002/jmv.25801 125GrittiG.RaimondiF.RipamontiD.RivaI.LandiF.AlborghettiL.Use of" exact="siltuximab" post="in patients with COVID-19 pneumonia requiring ventilatory supportMedRxiv20204202010.1101/2020.04.01.2004856101.20048561 126MichotJ.-M.AlbigesL.ChaputN.SaadaV.PommeretF.GriscelliF.Tocilizumab,"/>
   <result pre="Pract Res Clin Rheumatol28201427729210.1016/j.berh.2014.03.00224974063 134Gerfaud-ValentinM.JamillouxY.IwazJ.SèveP.Adult-onset Still’s diseaseAutoimmun Rev13201470872210.1016/j.autrev.2014.01.05824657513 135MonteagudoL.A.BoothbyA.GertnerE.Continuous intravenous" exact="anakinra" post="infusion to calm the cytokine storm in macrophage activation"/>
   <result pre="Rheumatol202010.1002/acr2.11135[published online ahead of print, 2020 Apr 8] 136Wampler MuskardinT.L.IV" exact="anakinra" post="for macrophage activation syndrome may hold lessons for treatment"/>
   <result pre="the treatment of relapsed/refractory hemophagocytic lymphohistiocytosisBlood13420191783178610.1182/blood.201900228931537529 154AlbeituniS.VerbistK.C.TedrickP.E.TillmanH.PicarsicJ.BassettR.Mechanisms of action of" exact="ruxolitinib" post="in murine models of hemophagocytic lymphohistiocytosisBlood134201914715910.1182/blood.201900076131015190 155DasR.GuanP.SpragueL.VerbistK.TedrickP.AnQ.A.Janus kinase inhibition"/>
   <result pre="macrophage activation syndromePediatr Blood Cancer50200841942110.1002/pbc.2101916900487 161SterbaG.SterbaY.StempelC.BlankJ.AzorE.GomezL.Macrophage activation syndrome induced by" exact="etanercept" post="in a patient with systemic sclerosisIsr Med Assoc J"/>
   <result pre="Med Assoc J IMAJ12201044344520862830 162RamananA.V.SchneiderR.Macrophage activation syndrome following initiation of" exact="etanercept" post="in a child with systemic onset juvenile rheumatoid arthritisJ"/>
   <result pre="a patient with adult onset Still’s disease after initiation of" exact="etanercept" post="therapyJ Clin Rheumatol Pract Rep Rheum Musculoskelet Dis7200125225610.1097/00124743-200108000-00013 164McDermottJ.E.MitchellH.D.GralinskiL.E.EisfeldA.J.JossetL.BankheadA.The"/>
   <result pre="inhibitor of SARS coronavirus infection and spreadVirol J220056910.1186/1743-422X-2-6916115318 180WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="molecular modeling studies reveal a new mechanism of action of" exact="chloroquine" post="and hydroxychloroquine against SARS-CoV-2 infectionInt J Antimicrob Agents105960202010.1016/j.ijantimicag.2020.105960 182KaliaS.DutzJ.P.New"/>
   <result pre="studies reveal a new mechanism of action of chloroquine and" exact="hydroxychloroquine" post="against SARS-CoV-2 infectionInt J Antimicrob Agents105960202010.1016/j.ijantimicag.2020.105960 182KaliaS.DutzJ.P.New concepts in"/>
   <result pre="Ther20200716017410.1111/j.1529-8019.2007.00131.x17970883 183ZieglerH.K.UnanueE.R.Decrease in macrophage antigen catabolism caused by ammonia and" exact="chloroquine" post="is associated with inhibition of antigen presentation to T"/>
   <result pre="Sci U S A79198217517810.1073/pnas.79.1.1756798568 184van den BorneB.E.DijkmansB.A.de RooijH.H.le CessieS.VerweijC.L.Chloroquine and" exact="hydroxychloroquine" post="equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma"/>
   <result pre="in patients with COVID-19: an open-label, randomized, controlled trialMedRxiv20204202010.1101/2020.04.10.2006055810.20060558 190GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="of COVID-19 associated pneumonia in clinical studiesBiosci Trends142020727310.5582/bst.2020.0104732074550 191ChenZ.HuJ.ZhangZ.JiangS.HanS.YanD.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
   <result pre="open-label non-randomized clinical trialMedRxiv20203202010.1101/2020.03.16.2003713516.20037135 193Chen JunL.D.Chen JunL.D.A pilot study of" exact="hydroxychloroquine" post="in treatment of patients with common coronavirus disease-19 (COVID-19)J"/>
   <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infectionMed Mal"/>
   <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infectionMed Mal Infect202010.1016/j.medmal.2020.03.006 195BorbaM.G.S.de"/>
   <result pre="clinical trial (CloroCovid-19 Study)MedRxiv20204202010.1101/2020.04.07.2005642407.20056424 196MahevasM.TranV.-T.RoumierM.ChabrolA.PauleR.GuillaudC.No evidence of clinical efficacy of" exact="hydroxychloroquine" post="in patients hospitalized for COVID-19 infection with oxygen requirement:"/>
   <result pre="the treatment of autoimmune and inflammatory diseasesAutoimmun Rev18201910239010.1016/j.autrev.2019.10239031520803 199FDA issues" exact="tofacitinib" post="safety alert. RheumatologyMedicinemattersComhttps://rheumatology.medicinematters.com/rheumatoid-arthritis-/tofacitinib/fda-issues-tofacitinib-safety-alert/165271342019(accessed April 20, 2020) 200FavalliE.G.IngegnoliF.De LuciaO.CincinelliG.CimazR.CaporaliR.COVID-19 infection"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7196623\results\search\drugs\results.xml">
   <result pre="(Group 1) and 4 patients received an antiviral regimen without" exact="sofosbuvir" post="(Group 2). Eleven (91.7%) patients achieved a sustained virological"/>
   <result pre="CHC in KT recipients, as interferon-based therapy, with or without" exact="ribavirin" post="(RBV), was usually not recommended, or was even contraindicated"/>
   <result pre="current DAAs are eliminated mainly through the liver, except for" exact="sofosbuvir" post="eliminated through the kidney and may be associated with"/>
   <result pre="Study of Liver Diseases (AASLD), a daily fixed-dose combination of" exact="sofosbuvir" post="(400 mg)/velpatasvir (100 mg) is considered as an option"/>
   <result pre="and DAAs in the KT setting, since calcineurin inhibitors (CNIs:" exact="tacrolimus" post="and cyclosporine) and mammalian target of rapamycin inhibitors (sirolimus"/>
   <result pre="drugs (e.g., protease inhibitors with cyclosporine, given the elevations in" exact="cyclosporine" post="concentrations) [6]. The aim of the present study was"/>
   <result pre="KT, and another patient with CHC genotype 4 had received" exact="sofosbuvir" post="plus RBV after KT. Both cases had discontinued antiviral"/>
   <result pre="and methylprednisolone, 2 (16.7%) patients were under a combination of" exact="everolimus" post="and methylprednisolone (1 with tacrolimus and 1 with MMF),"/>
   <result pre="2 (16.7%) patients were under a combination of everolimus and" exact="methylprednisolone" post="(1 with tacrolimus and 1 with MMF), while 1"/>
   <result pre="were under a combination of everolimus and methylprednisolone (1 with" exact="tacrolimus" post="and 1 with MMF), while 1 (8.3%) patient was"/>
   <result pre="(Group 1) and 4 patients received an antiviral regimen without" exact="sofosbuvir" post="(Group 2). In Group 1 patients, sofosbuvir was given"/>
   <result pre="antiviral regimen without sofosbuvir (Group 2). In Group 1 patients," exact="sofosbuvir" post="was given with ledipasvir (n=3; 1 patient had received"/>
   <result pre="sofosbuvir was given with ledipasvir (n=3; 1 patient had received" exact="sofosbuvir" post="plus RBV after KT), velpatasvir (n=2) and daclatasvir (n=3;"/>
   <result pre="had received sofosbuvir plus RBV after KT), velpatasvir (n=2) and" exact="daclatasvir" post="(n=3; 1 patient had received pegylated interferon plus RBV"/>
   <result pre="was added in 1 patient with genotype 3 treated with" exact="sofosbuvir" post="plus daclatasvir. In Group 2, 2 patients received the"/>
   <result pre="combination of elbasvir/grazoprevir and 2 the combination of ombitasvir/paritaprevir/ritonavir plus" exact="dasabuvir" post="(3D regimen; together with RBV in 1 patient). Eleven"/>
   <result pre="had to decrease the dosage of cyclosporine. Otherwise, CNIs and" exact="everolimus" post="trough levels were measured more frequently during DAAs therapy,"/>
   <result pre="1), compared to those (n=4) who received a regimen without" exact="sofosbuvir" post="(Group 2), were more frequently under CNI-based immunosuppression (7/8"/>
   <result pre="only 1 KT recipient. In that patient, high levels of" exact="cyclosporine" post="were measured during antiviral therapy with the 3D combination"/>
   <result pre="measured during antiviral therapy with the 3D combination and the" exact="cyclosporine" post="dosage was reduced, with no further consequences for patient"/>
   <result pre="different sofosbuvir-containing regimens. In addition, literature studies have shown that" exact="sofosbuvir" post="might have a negative impact on eGFR, particularly in"/>
   <result pre="sofosbuvir-containing regimen was 0 (range: -13 – 15) indicating that" exact="sofosbuvir" post="had an overall neutral renal safety profile in these"/>
   <result pre="in these patients. On the other hand, antiviral regimens without" exact="sofosbuvir" post="were given to recipients with renal dysfunction at baseline"/>
   <result pre="kidney transplant recipientsExp Clin Transplant201917525830719954 12DuerrMSchrezenmeierEVLehnerLJet al.A prospective study of" exact="daclatasvir" post="and sofosbuvir in chronic HCV-infected kidney transplant recipientsBMC Nephrol2019203630717681"/>
   <result pre="recipientsExp Clin Transplant201917525830719954 12DuerrMSchrezenmeierEVLehnerLJet al.A prospective study of daclatasvir and" exact="sofosbuvir" post="in chronic HCV-infected kidney transplant recipientsBMC Nephrol2019203630717681 13WeigertAQueridoSCarvalhoLet al.Hepatitis"/>
   <result pre="recipients:a single-center experience in PortugalTransplant Proc20185074374529661427 14XueYZhangLXWangLLiTQuYDLiuFEfficacy and safety of" exact="sofosbuvir" post="and daclatasvir in treatment of kidney transplantation recipients with"/>
   <result pre="experience in PortugalTransplant Proc20185074374529661427 14XueYZhangLXWangLLiTQuYDLiuFEfficacy and safety of sofosbuvir and" exact="daclatasvir" post="in treatment of kidney transplantation recipients with hepatitis C"/>
   <result pre="Hepatol20176671872328039098 20HuangHTangHDengHet al.Treatment of chronic hepatitis C viral infection with" exact="sofosbuvir" post="and daclatasvir in kidney transplant recipientsTranspl Infect Dis201921e1301830369001 21ZhangJSunWLinJet"/>
   <result pre="al.Treatment of chronic hepatitis C viral infection with sofosbuvir and" exact="daclatasvir" post="in kidney transplant recipientsTranspl Infect Dis201921e1301830369001 21ZhangJSunWLinJet al.Long-term follow-up"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7196837\results\search\drugs\results.xml">
   <result pre="clinical trial), or ribavirin, or peramivir, while one patient received" exact="ribavirin" post="monotherapy (Table 2). Antibacterial or antifungal treatment was used"/>
   <result pre="used when patients had coinfection. Six patients received intravenous (i.v.)" exact="methylprednisolone" post="(20 mg every 24 h). Table 1. Clinical characteristics"/>
   <result pre="coronavirus (2019-nCoV). Biosci. Trends14, 69–71 (2020).31996494 5WangM.et al., Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7196844\results\search\drugs\results.xml">
   <result pre="patient’s cells (5). According to preliminary reports, the antimalarial drug" exact="chloroquine" post="prevents the terminal glycosylation of ACE2. Moreover, chloroquine—or its"/>
   <result pre="cell cultures, the replication of SARS-CoV-2 was inhibited at a" exact="chloroquine" post="concentration (EC50 = concentration with half-maximal effect) of 1.13"/>
   <result pre="Several clinical trials are investigating the efficacy and tolerability of" exact="chloroquine" post="in the prevention and treatment of COVID-19 (table 1)."/>
   <result pre="also not recommended for COVID-19 (9– 11). The nucleoside analog" exact="ribavirin" post="was used at the beginning of the SARS epidemic"/>
   <result pre="is similar for the administration of some antiretrovirals, such as" exact="lopinavir" post="and nelfinavir, that were developed for the treatment of"/>
   <result pre="developed for the treatment of HIV infection. The protease inhibitor" exact="lopinavir" post="has been used—together with a small booster dose of"/>
   <result pre="but yielded no clear evidence for the potential efficacy of" exact="lopinavir" post="(12). In Wuhan, 41 (21%) of 181 patients were"/>
   <result pre="hospital. The initial treatment was unspecific, with antipyretics such as" exact="ibuprofen" post="and paracetamol. Chest radiography then indicated pneumonia, upon which"/>
   <result pre="paracetamol. Chest radiography then indicated pneumonia, upon which the antibiotics" exact="vancomycin" post="and cefepime were given. They were discontinued a day"/>
   <result pre="radiography then indicated pneumonia, upon which the antibiotics vancomycin and" exact="cefepime" post="were given. They were discontinued a day later, however,"/>
   <result pre="Drugs are also available for acute viral infections. Treatment with" exact="aciclovir" post="can save the life of a patient with herpes"/>
   <result pre="the &quot;nucleoside era,�? in the 1970s, it was recognized that" exact="cytarabine" post="could not be used as a virustatic in disseminated"/>
   <result pre="&amp;gt;100 µM. As shown in table 2, the nucleoside analog" exact="penciclovir" post="had a relatively weak effect (EC50: 96 µM). Favipiravir,"/>
   <result pre="mechanisms and potential therapeutic targetIntensive Care Med2020 6WangMCaoRZhangLet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="e.g., relatives of patients with COVID-19Treatment: Placebo or 10 mg" exact="chloroquine" post="base/kg, thereafter 250 mg chloroquine phosphate daily for 3"/>
   <result pre="COVID-19Treatment: Placebo or 10 mg chloroquine base/kg, thereafter 250 mg" exact="chloroquine" post="phosphate daily for 3 months 10 000 University of"/>
   <result pre="Open trialParticipants: Patients with positive COVID-19 test resultTreatment: 800 mg" exact="darunavir" post="(plus 150 mg cobicistat as booster) for 7 days"/>
   <result pre="positive COVID-19 test resultTreatment: 800 mg darunavir (plus 150 mg" exact="cobicistat" post="as booster) for 7 days together with chloroquine; contacts"/>
   <result pre="for 7 days together with chloroquine; contacts receive 1 g" exact="chloroquine" post="phosphate on days 1 and 2, 0.5 g on"/>
   <result pre="trial, pilot studyParticipants: Patients with pneumonia from SARS-CoV-2Treatment: 400 mg" exact="hydroxychloroquine" post="daily for 5 days 30 Shanghai Public Health Clinical"/>
   <result pre="umifenovir* 2 3 × 200 mg/day for 2 weeksc) Plus" exact="oseltamivir" post="2 × 75 mg/day for 2 weeksd) Plus lopinavir/ritonavir"/>
   <result pre="since diagnosis); pulmonary findings on imagingTreatment: 1 × 100 mg" exact="thalidomide" post="or placebo daily for 14 days 100 Second Affiliated"/>
   <result pre="Nucleoside analog, guanosine derivative, inhibits viral DNA polymerase; its prodrug" exact="famciclovir" post="is licensed for treatment of herpes zoster 96 Ribavirin"/>
   <result pre="of herpes zoster 96 Ribavirin Nucleoside analog, guanosine derivative, inhibits" exact="inosine" post="monophosphate dehydrogenase and inhibits DNA and RNA viruses; also"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7196921\results\search\drugs\results.xml">
   <result pre="viruses, such as the human immunodeficiency virus-1 (HIV-1) protease inhibitors" exact="lopinavir" post="and ritonavir [17], disulfiram, which is known to inhibit"/>
   <result pre="as the human immunodeficiency virus-1 (HIV-1) protease inhibitors lopinavir and" exact="ritonavir" post="[17], disulfiram, which is known to inhibit SARS-CoV proteases"/>
   <result pre="Microbiol. 2017;66:1261–1274.28855003 17.YaoTT, QianJD, ZhuWY, et ala systematic review of" exact="lopinavir" post="therapy for SARS coronavirus and MERS coronavirus-a possible reference"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7196923\results\search\drugs\results.xml">
   <result pre="medical and health care (CPAM) recommend using anti-SARS properties of" exact="lopinavir" post="and ritonavir capsule for older age COVID-19 patients with"/>
   <result pre="health care (CPAM) recommend using anti-SARS properties of lopinavir and" exact="ritonavir" post="capsule for older age COVID-19 patients with the underlying"/>
   <result pre="inhibitors, tipranavir, saquinavir, ritonavir, nelfinavir, lopinavir, indinavir, darunavir, atazanavir, and" exact="amprenavir" post="are widely reported to be able to deactivate Mpro"/>
   <result pre="production. In this respect, Wilson et al., showed that hexamethylene" exact="amiloride" post="inhibitor has shown to block the E-protein ion channel"/>
   <result pre="sun allergies for more than sixty years. The activity of" exact="hydroxychloroquine" post="on viruses is probably same as that of chloroquine"/>
   <result pre="of hydroxychloroquine on viruses is probably same as that of" exact="chloroquine" post="since the mechanism of the action of these two"/>
   <result pre="cell culture has been prevented (Vincent et al., 2005). The" exact="hydroxychloroquine" post="has shown a potent efficacy in treating patients with"/>
   <result pre="COVID-19 pneumonia. More than hundred patients showed the superiority of" exact="chloroquine" post="compared with treatment of standard care in terms of"/>
   <result pre="n.d.; Gao et al., 2020). Colson group have suggested that" exact="chloroquine" post="and hydroxychloroquine as available weapons to fight COVID-19 (Colson"/>
   <result pre="et al., 2020). Colson group have suggested that chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19 (Colson et al.,"/>
   <result pre="weapons to fight COVID-19 (Colson et al., 2020). In 2014-2017," exact="ivermectin" post="antiviral drug used for phase 3 treatment of dengue"/>
   <result pre="M. Wang et al. (2020) study reported that remdesivir and" exact="chloroquine" post="are highly effective in the control of COVID-19 infection"/>
   <result pre="Gautret group have treated successfully chronic disease patients with long-term" exact="hydroxychloroquine" post="medicines with 600 mg per day for 12 to 18 months."/>
   <result pre="and 16 control patients. Among hydroxychloroquine-treated patients, six patients received" exact="azithromycin" post="with 500 mg on day 1 followed by 250 mg per"/>
   <result pre="next four days. At day 6, 100% patients treated with" exact="hydroxychloroquine" post="and azithromycin combination have cured comparing with 57.1% in"/>
   <result pre="days. At day 6, 100% patients treated with hydroxychloroquine and" exact="azithromycin" post="combination have cured comparing with 57.1% in patients treated"/>
   <result pre="combination have cured comparing with 57.1% in patients treated with" exact="hydroxychloroquine" post="only, and 12.5% in the control group. Finally, they"/>
   <result pre="and 12.5% in the control group. Finally, they found that" exact="hydroxychloroquine" post="and azithromycin combination have cured the COVID-19 patients but"/>
   <result pre="in the control group. Finally, they found that hydroxychloroquine and" exact="azithromycin" post="combination have cured the COVID-19 patients but the drawback"/>
   <result pre="Doctor’s team reported, a large doses of the flu drug" exact="oseltamivir" post="combined with HIV drugs lopinavir and ritonavir could improve"/>
   <result pre="doses of the flu drug oseltamivir combined with HIV drugs" exact="lopinavir" post="and ritonavir could improve the conditions of several COVID-19"/>
   <result pre="the flu drug oseltamivir combined with HIV drugs lopinavir and" exact="ritonavir" post="could improve the conditions of several COVID-19 patients at"/>
   <result pre="protease. They found that the combination of three drugs, lopinavir," exact="oseltamivir" post="and ritonavir, showed a better binding energy than that"/>
   <result pre="promotive association for medical and health care) recommends to take" exact="lopinavir" post="400 mg, ritonavir 100 mg (two tablets by mouth twice in"/>
   <result pre="for medical and health care) recommends to take lopinavir 400 mg," exact="ritonavir" post="100 mg (two tablets by mouth twice in daily) or"/>
   <result pre="ritonavir 100 mg (two tablets by mouth twice in daily) or" exact="chloroquine" post="(500 mg tablet by mouth twice in daily) for older"/>
   <result pre="patients with under underlying conditions and serious symptoms. In case" exact="chloroquine" post="is unavailable, consider to use of hydroxychloroquine (400 mg by"/>
   <result pre="symptoms. In case chloroquine is unavailable, consider to use of" exact="hydroxychloroquine" post="(400 mg by mouth once daily). It cannot be recommended"/>
   <result pre="by mouth once daily). It cannot be recommended to take" exact="ribavirin" post="and interferon drug because of the high risk for"/>
   <result pre="these drugs may be considered if treatment with lopinavir, ritonavir," exact="chloroquine" post="or hydroxychloroquine are ineffective (Chu et al., 2004; Gao"/>
   <result pre="may be considered if treatment with lopinavir, ritonavir, chloroquine or" exact="hydroxychloroquine" post="are ineffective (Chu et al., 2004; Gao et al.,"/>
   <result pre="drugs have become promises, other are being ruled out including" exact="lopinavir" post="and ritonavir, mix of two drugs used to treat"/>
   <result pre="Mpro with each inhibitor of ritonavir, lopinavir, Azithromycin, hydroxychloroquine, N3," exact="ribavirin" post="and new inhibitors based on free energy calculations. 4."/>
   <result pre="Heart, Lung, and Blood Institute’s AsthmaNet (2015). Early Administration of" exact="azithromycin" post="and prevention of severe lower respiratory tract illnesses in"/>
   <result pre="10.1136/thorax.2003.01265814985565 ColsonP., RolainJ.-M., LagierJ.-C., BrouquiP., &amp;amp; RaoultD. (2020). Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19. International Journal of"/>
   <result pre="ChabrièreE., La ScolaB., RolainJ.-M., BrouquiP., &amp;amp; RaoultD. (2020). Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: Results of an open-label"/>
   <result pre="(2020). Computational studies of drug repurposing and synergism of lopinavir," exact="oseltamivir" post="and ritonavir binding with SARS-CoV-2 Protease against COVID-19. Journal"/>
   <result pre="studies of drug repurposing and synergism of lopinavir, oseltamivir and" exact="ritonavir" post="binding with SARS-CoV-2 Protease against COVID-19. Journal of Biomolecular"/>
   <result pre="MaheswariU., ParthasarathyK., NgL., LiuD. X., &amp;amp; GongX. (2007). Conductance and" exact="amantadine" post="binding of a pore formed by a lysine-flanked transmembrane"/>
   <result pre="LiuJ., XuM., ShiZ., HuZ., ZhongW., &amp;amp; XiaoG. (2020). Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="(n.d). Retrieved from https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 WilsonL., GageP., &amp;amp; EwartG. (2006). Hexamethylene" exact="amiloride" post="blocks E protein ion channels and inhibits coronavirus replication."/>
   <result pre="SunY., LiX., XuK.-F., WeiY., JinN., &amp;amp; JiangC. (2013). Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7197554\results\search\drugs\results.xml">
   <result pre="University Press pmcid: 7197554 doi: 10.1093/ehjcvp/pvaa041pvaa041 : Correspondence Chloroquine and" exact="hydroxychloroquine" post="for COVID-19: implications for cardiac safety http://orcid.org/0000-0002-6232-388XJeevaratnamKamalanp1p2[p1], Faculty of"/>
   <result pre="pharmacology of these drugs are known. With regards to COVID-19," exact="chloroquine" post="(CQ) and hydroxychloroquine (HCQ) have been identified as possible"/>
   <result pre="drugs are known. With regards to COVID-19, chloroquine (CQ) and" exact="hydroxychloroquine" post="(HCQ) have been identified as possible therapeutic agents potentially"/>
   <result pre="CaoR, ZhangL, YangX, LiuJ, XuM, ShiZ, HuZ, ZhongW, XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="Pflugers Arch2007;454:209–222.17295037 8WozniackaA, CygankiewiczI, ChudzikM, Sysa-JedrzejowskaA, WraniczJK.The cardiac safety of" exact="chloroquine" post="phosphate treatment in patients with systemic lupus erythematosus: the"/>
   <result pre="DupontHT, HonoreS, ColsonP, ChabriereE, La ScolaB, RolainJM, BrouquiP, RaoultD.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7197622\results\search\drugs\results.xml">
   <result pre="by reducing reactive oxygen species and increasing antioxidants, and ameliorate" exact="nitric oxide" post="bioavailability, endothelial function, and integrity. Most of these effects"/>
   <result pre="of symptoms in statin-naïve patients hospitalized for seasonal influenza receiving" exact="atorvastatin" post="40 mg compared with placebo. An association between outpatient"/>
   <result pre="a proinflammatory trigger such as hypoxia.8 Moreover, in murine cells," exact="atorvastatin" post="0.1 μM (corresponding to the plasma concentration obtained with"/>
   <result pre="protease inhibitor treatment10 and in patients with rheumatoid arthritis receiving" exact="tocilizumab" post="(Figure 1).2 Most statins undergo hepatic metabolism through CYP3A4,"/>
   <result pre="administration of CYP3A4 inhibitors currently used in COVID-19, such as" exact="ritonavir" post="and cobicistat, could increase the risk of muscle and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7199242\results\search\drugs\results.xml">
   <result pre="have recovered. Preliminary reports suggest that certain drugs, such as" exact="chloroquine" post="and antiviral nucleotide analogues such as remdesivir, which inhibit"/>
   <result pre="identified as a possible broad spectrum antiviral drug44,45. In vitro," exact="chloroquine" post="is reported to be a variable bioactive agent that"/>
   <result pre="The China National Center for Biotechnology Development recently reported that" exact="chloroquine" post="is one of the three drugs with a promising"/>
   <result pre="side effects caused by long term use of chloroquine54-56. Evidently," exact="chloroquine" post="could be used for the treatment of COVID-19 because"/>
   <result pre="term use57. A narrative letter by Chinese authors reported that" exact="chloroquine" post="phosphate used in many clinical trials has marked efficacy"/>
   <result pre="clinical trials has marked efficacy against COVID-19. After oral administration," exact="chloroquine" post="is distributed widely across the body, including the lung."/>
   <result pre="regarding the use of Chloroquine against the COVID-19 Administration of" exact="chloroquine" post="against COVID-19 is experimental. Therefore, ethical trial approval is"/>
   <result pre="tend to agree with this viewpoint of WHO to view" exact="chloroquine" post="as experimental. The outbreak is not the perfect environment"/>
   <result pre="perfect environment for doing so, but even the use of" exact="chloroquine" post="off-label can be followed by many concerns; the first"/>
   <result pre="could cause severe medication shortages when needed for malaria, since" exact="chloroquine" post="remains a crucial medication in the treatment of malaria"/>
   <result pre="many parts of the world60. 7.1.3 Specific precautions before using" exact="chloroquine" post="against COVID-19 For the use of chloroquine phosphate an"/>
   <result pre="precautions before using chloroquine against COVID-19 For the use of" exact="chloroquine" post="phosphate an expert consensus was published on February 20,"/>
   <result pre="and/or mental disturbance. Electrocardiography was routinely recommended and quinolones, macrolides," exact="ondansetron" post="as well as various antiarrhythmic, antidepressant and antipsychotic drugs"/>
   <result pre="shown that favipiravir has a more potent antiviral effect than" exact="lopinavir" post="/ ritonavir43. 7.4. Convalescent plasma and monoclonal antibodies Convalescent"/>
   <result pre="patients with SARS, whose condition continued to deteriorate after pulsed" exact="methylprednisolone" post="therapy69. In addition, some studies found a shorter hospital"/>
   <result pre="in Thailand, the infectious disease team used a combination of" exact="oseltamivir" post="(anti-influenza agent) and lopinavir/ritonavir to successfully improve the status"/>
   <result pre="drugs, such as immunoglobulins, arbidol hydrochloride combined with interferon atomization," exact="ritonavir" post="plus oseltamivir, ASC09F plus oseltamivir, mesenchymal stem cell treatment,"/>
   <result pre="ritonavir plus oseltamivir, ASC09F plus oseltamivir, mesenchymal stem cell treatment," exact="lopinavir" post="plus ritonavir, hydroxychloroquine, darunavir plus cobicistat, methylprednisolone and washed"/>
   <result pre="plus oseltamivir, mesenchymal stem cell treatment, lopinavir plus ritonavir, hydroxychloroquine," exact="darunavir" post="plus cobicistat, methylprednisolone and washed microbiota transplantation65,77. Repurposing these"/>
   <result pre="stem cell treatment, lopinavir plus ritonavir, hydroxychloroquine, darunavir plus cobicistat," exact="methylprednisolone" post="and washed microbiota transplantation65,77. Repurposing these available drugs for"/>
   <result pre="clinical management78. Study of Xiaoling Xu et al. suggests that" exact="tocilizumab" post="is an important therapy in serious COVID-19 patients, which"/>
   <result pre="the treatment of other pathologies, including ribavirin, penciclovir, nitazoxanide, nafamostat," exact="chloroquine" post="and two well-known drugs having broad spectrum activity i.e."/>
   <result pre="monoclonal antibody (CCR5 antagonist) arbidol hydrochloride combined with interferon atomisation," exact="lopinavir" post="plus ritonavir, ritonavir plus oseltamivir, ASC09F plus oseltamivir, mesenchymal"/>
   <result pre="antagonist) arbidol hydrochloride combined with interferon atomisation, lopinavir plus ritonavir," exact="ritonavir" post="plus oseltamivir, ASC09F plus oseltamivir, mesenchymal stem cell treatment"/>
   <result pre="antiviral effects of chloroquine267-69SavarinoAndreaDi TraniLiviaDonatelliIsabellaCaudaRobertoCassoneAntonioThe Lancet Infectious Diseases6200616439323 45Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
   <result pre="virus infection in an animal model2300-302YanYiwuZouZhenSunYangLiXiaoXuKai-FengWeiYuquanJinNingyiJiangChengyuCell Research23201223208422 46Ammonium chloride and" exact="chloroquine" post="inhibit rabies virus infection in neuroblastoma cells3-4377-382TsiangH.SupertiF.Archives of Virology8119846148053"/>
   <result pre="Activity212643-2648RomanelliFrankSmithKellyHovenArdisCurrent Pharmaceutical Design10200415320751 50Inhibition of hepatitis C virus replication by" exact="chloroquine" post="targeting virus-associated autophagy2195-203MizuiTomokazuYamashinaShunheiTanidaIseiTakeiYoshiyukiUenoTakashiSakamotoNaoyaIkejimaKenichiKitamuraTsuneoEnomotoNobuyukiSakaiTatsuoKominamiEikiWatanabeSumioJournal of Gastroenterology45200919760134 51Chloroquine is a potent"/>
   <result pre="JBergeronEricBenjannetSuzanneEricksonBobbie RRollinPierre EKsiazekThomas GSeidahNabil GNicholStuart TVirology journal2200516115318 52[Expert consensus on" exact="chloroquine" post="phosphate for the treatment of novel coronavirus pneumonia].E019Zhonghua jie"/>
   <result pre="of COVID-19 associated pneumonia in clinical studies.17273GaoJianjunTianZhenxueYangXuBioscience trends14202032074550 54Diagnosis of" exact="chloroquine" post="cardiomyopathy by endomyocardial biopsy.41913RatliffN BEstesM LMylesJ LShireyE KMcMahonJ TThe"/>
   <result pre="off-label use: European perspective.53746LenkChristianDuttgeGunnarTherapeutics and clinical risk management10201425050064 60Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="EstevesDupontHervé TissotHonoréStéphaneColsonPhilippeChabrièreEricLa ScolaBernardRolainJean-MarcBrouquiPhilippeRaoultDidierInternational journal of antimicrobial agents202032205204 61[Expert consensus on" exact="chloroquine" post="phosphate for the treatment of novel coronavirus pneumonia].3185188Zhonghua jie"/>
   <result pre="medicine9201728659436 64Emerging Therapeutic Strategies for COVID-19 patients.1e105ZhuShudongGuoXialingGearyKylaZhangDianzhengDiscoveries (Craiova)8202032309622 65Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7199282\results\search\drugs\results.xml">
   <result pre="reducing the autophagy-inhibitory effects of CoVs. The FDA-approved anti-malarial drugs" exact="chloroquine" post="and hydroxychloroquine have been suggested to be repurposed for"/>
   <result pre="autophagy-inhibitory effects of CoVs. The FDA-approved anti-malarial drugs chloroquine and" exact="hydroxychloroquine" post="have been suggested to be repurposed for the treatment"/>
   <result pre="of COVID-19 [68–70], but this remains widely controversial [71–73]. Although" exact="chloroquine" post="is a lysosomotropic agent that blocks autophagic degradation, possibly"/>
   <result pre="acidification after endocytosis is critical for SARS-CoV-2 entry [75], and" exact="chloroquine" post="inhibits this acidification [76]. In addition, chloroquine limits terminal"/>
   <result pre="entry [75], and chloroquine inhibits this acidification [76]. In addition," exact="chloroquine" post="limits terminal glycosylation of the metallopeptidase ACE2, the functional"/>
   <result pre="it unlikely that autophagy modulation contributes to the outcome of" exact="chloroquine" post="treatment at that point. Additionally, chloroquine has been shown"/>
   <result pre="to the outcome of chloroquine treatment at that point. Additionally," exact="chloroquine" post="has been shown to induce autophagy-independent effects, for instance,"/>
   <result pre="TFE3 [80, 81]. Altogether, further clinical work must clarify if" exact="chloroquine" post="and hydroxychloroquine have major effects on COVID-19 and at"/>
   <result pre="81]. Altogether, further clinical work must clarify if chloroquine and" exact="hydroxychloroquine" post="have major effects on COVID-19 and at which (early?)"/>
   <result pre="phase of the disease these drugs should be administered. If" exact="chloroquine" post="or its derivative turned out to be clinically useful"/>
   <result pre="of SARS coronavirus infection and spread.Virol J200526910.1186/1743-422X-2-6916115318 69GautretPLagierJ-CParolaPHoangVTMeddebLMailheMDoudierBCourjonJGiordanengoVVieiraVEDupontHTHonoréSColsonPChabrièreELa ScolaBRolainJ-MBrouquiPRaoultDHydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="an open-label non-randomized clinical trial.Int J Antimicrob Agents202010594910.1016/j.ijantimicag.2020.105949 70WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="Res202030326927110.1038/s41422-020-0282-032020029 71JaffeSRegulators split on antimalarials for COVID-19.The Lancet202039510231117910.1016/S0140-6736(20)30817-5 72FernerREAronsonJKChloroquine and" exact="hydroxychloroquine" post="in covid-19.BMJ2020369m143210.1136/bmj.m143232269046 73GbinigieKFrieKShould chloroquine and hydroxychloroquine be used to"/>
   <result pre="antimalarials for COVID-19.The Lancet202039510231117910.1016/S0140-6736(20)30817-5 72FernerREAronsonJKChloroquine and hydroxychloroquine in covid-19.BMJ2020369m143210.1136/bmj.m143232269046 73GbinigieKFrieKShould" exact="chloroquine" post="and hydroxychloroquine be used to treat COVID-19? A rapid"/>
   <result pre="COVID-19.The Lancet202039510231117910.1016/S0140-6736(20)30817-5 72FernerREAronsonJKChloroquine and hydroxychloroquine in covid-19.BMJ2020369m143210.1136/bmj.m143232269046 73GbinigieKFrieKShould chloroquine and" exact="hydroxychloroquine" post="be used to treat COVID-19? A rapid review.BJGP Open.202010.3399/bjgpopen20X101069"/>
   <result pre="by a Clinically Proven Protease Inhibitor.Cell20201812271280.e810.1016/j.cell.2020.02.05232142651 76Al-BariMdAATargeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
   <result pre="Influenza Virus.EBioMedicine20183214216310.1016/j.ebiom.2018.05.02729866590 85GassenNCPapiesJBajajTDethloffFEmanuelJWeckmannKHeinzDEHeinemannNLennarzMRichterANiemeyerDCormanVMGiavaliscoPDrostenCMullerMAAnalysis of SARS-CoV-2-controlled autophagy reveals spermidine, MK-2206, and" exact="niclosamide" post="as putative antiviral therapeutics.bioRxiv [Preprint]. Version 12020posted April 15,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7199295\results\search\drugs\results.xml">
   <result pre="appear to be old drugs, the antimalarial and immunomodulatory medication," exact="chloroquine" post="and its hydroxy analog, hydroxychloroquine. Chloroquine and hydroxychloroquine are"/>
   <result pre="immunomodulatory medication, chloroquine and its hydroxy analog, hydroxychloroquine. Chloroquine and" exact="hydroxychloroquine" post="are by far the most popular drugs proposed for"/>
   <result pre="have well-known pharmacokinetic and pharmacodynamic properties. The antiviral mechanisms of" exact="chloroquine" post="are based on its capacity to increase the endosomal"/>
   <result pre="by the President of Brazil recommending the indiscriminate use of" exact="chloroquine" post="resulted in a shortage of the drug in several"/>
   <result pre="president's action hampered the treatment of patients who truly need" exact="chloroquine" post="for systemic lupus erythematosus and rheumatoid arthritis. Pronouncements by"/>
   <result pre="in the United States (USA); the country's president has endorsed" exact="chloroquine" post="in a highly politicized debate over its use 10."/>
   <result pre="Interventional Studies | COVID19 - List Results -ClinicalTrials.govhttps://clinicaltrials.gov/ct2/results?cond=COVID19&amp;amp;age_v=&amp;amp;gndr=&amp;amp;type=Intr&amp;amp;rslt=&amp;amp;Search=Apply 4SavarinoABoelaertJCassoneAMajoriGCaudaREffects of" exact="chloroquine" post="on viral infections: an old drug against today's diseases?Lancet"/>
   <result pre="an old drug against today's diseases?Lancet Infect Dis20033(11)722710.1016/S1473-3099(03)00806-514592603 5SchroederRLGerberJPChloroquine and" exact="hydroxychloroquine" post="binding to melanin: Some possible consequences for pathologiesToxicol Rep2014196396810.1016/j.toxrep.2014.10.01928962308"/>
   <result pre="2020]Available from: https://www.medrxiv.org/content/10.1101/2020.04.07.20056424v1 8collab: BBC News BrasilBolsonaro volta a defender" exact="cloroquina" post="em novo pronunciamento em rede nacional [Internet]BBC News Brasil2020[cited"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7199731\results\search\drugs\results.xml">
   <result pre="virus IVIg, intravenous gammaglobulin PLP, papain-like protease LPV, Lopinavir RTV," exact="ritonavir" post="RDV, Remdesivir NO, Nitric oxide Mpro, Main protease HLA,"/>
   <result pre="viral mutations [86]. 6.2 Immunoenhancers A combination of interferon-α-2a with" exact="ribavirin" post="was administered to patients with severe MERS-CoV infection and"/>
   <result pre="been shown to restore antibody production in old mice [92]." exact="levamisole" post="can act as either an immunostimulant agent or an"/>
   <result pre="treatment of HIV infection. Lopinavir (LPV) is usually combined with" exact="ritonavir" post="(RTV) to increase and Polygonum and it is also"/>
   <result pre="inhibiting the replication of SARS-CoV [107]. As compared to emodin," exact="promazine" post="exhibited potent inhibition of the binding of S protein"/>
   <result pre="S protein to ACE2. These findings suggested that emodin and" exact="promazine" post="might be able to inhibit SARS-CoV infectivity by blocking"/>
   <result pre="and ACE2. Therefore, the monoclonal antibody (scFv80R), chloroquine, emodin, and" exact="promazine" post="could be used as choices for the treatment of"/>
   <result pre="hepatitis C [110]. Morgenstern et al. [111] had reported that" exact="ribavirin" post="and interferon-β synergistically inhibited the replication of SARS-associated coronavirus"/>
   <result pre="and the lack of in vitro efficacy, the use of" exact="ribavirin" post="should be seriously considered for the treatment of COVID-19,"/>
   <result pre="even in combination with other antiviral drugs. The combination of" exact="lopinavir" post="(LPV) with ritonavir (RTV) is widely used as a"/>
   <result pre="with other antiviral drugs. The combination of lopinavir (LPV) with" exact="ritonavir" post="(RTV) is widely used as a boosted protease inhibitor"/>
   <result pre="efficacy of remdesivir. Yamamoto et al. [116] had found that" exact="nelfinavir" post="could strongly inhibit the replication of SARS-CoV. Arbidol and"/>
   <result pre="a riboflavin�?based and ultraviolet light�?based photochemical treatmentTransfusion5620162948295227805261 80AthertonJ.KratzingC.FisherA.The effect of" exact="ascorbic acid" post="on infection of chick-embryo ciliated tracheal organ cultures by"/>
   <result pre="ill patients with severe acute respiratory syndromeJAMA290200337438012865379 89BaumannC.A.BadamchianM.GoldsteinA.L.Thymosin α1 antagonizes" exact="dexamethasone" post="and CD3-induced apoptosis of CD4+ CD8+ thymocytes through the"/>
   <result pre="measles. Depressed helper/inducer subpopulation reversed by in vitro treatment with" exact="levamisole" post="and ascorbic acidJ. Clin. Invest.7219839719806604071 94LuoC.LuoH.ZhengS.GuiC.YueL.YuC.Nucleocapsid protein of SARS"/>
   <result pre="receptor associationProc. Natl. Acad. Sci. Unit. States Am.101200425362541 104SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against today's diseasesLancet"/>
   <result pre="Res. Commun.326200590590815607755 112TsangK.ZhongN.S.SARS: pharmacotherapyRespirology82003S25S3015018130 113KimU.J.WonE.-J.KeeS.-J.JungS.-I.JangH.-C.Case report Combination therapy with lopinavir/ritonavir," exact="ribavirin" post="and interferon-α for Middle East respiratory syndromeAntivir. Ther.21201645545926492219 114AgostiniM.L.AndresE.L.SimsA.C.GrahamR.L.SheahanT.P.LuX.Coronavirus"/>
   <result pre="ritonavir, and interferon beta against MERS-CoVNat. Commun.11202011431911652 116YamamotoN.YangR.YoshinakaY.AmariS.NakanoT.CinatlJ.HIV protease inhibitor" exact="nelfinavir" post="inhibits replication of SARS-associated coronavirusBiochem. Biophys. Res. Commun.318200471972515144898 117KhamitovR.LoginovaS.ShchukinaV.BorisevichS.MaksimovV.ShusterA.Antiviral"/>
   <result pre="122MohanasundaramN.SekharT.Computational studies of molecular targets regarding the adverse effects of" exact="isoniazid" post="drug for tuberculosisCurr. Pharmacogenom. Pers. Med. (Former. Curr. Pharmacogenom.)162018210218"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7199908\results\search\drugs\results.xml">
   <result pre="RNA polymerization activity on a poly-U template upon addition of" exact="adenosine" post="triphosphate (ATP) (Fig. 1, B and C). This RNA"/>
   <result pre="center of the catalytic active site (Fig. 3D). As an" exact="adenosine" post="monophosphate analog, RMP forms base-stacking interactions with an upstream"/>
   <result pre="ZhangL., YangX., LiuJ., XuM., ShiZ., HuZ., ZhongW., XiaoG., Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7200131\results\search\drugs\results.xml">
   <result pre="a 25-year-old male with moderately active UC being treated with" exact="infliximab" post="300 mg every eight weeks and methotrexate 15 mg/week."/>
   <result pre="being treated with infliximab 300 mg every eight weeks and" exact="methotrexate" post="15 mg/week. Although not confirmed in a large series"/>
   <result pre="2 Flow chart to manage rheumatic patients. MTX Methotrexate HCQ" exact="hydroxychloroquine" post="RTX rituximab LFN leflunomide bDMARDS Biologic disease- modifying anti-rheumatic"/>
   <result pre="chart to manage rheumatic patients. MTX Methotrexate HCQ hydroxychloroquine RTX" exact="rituximab" post="LFN leflunomide bDMARDS Biologic disease- modifying anti-rheumatic drugs NSAIDs"/>
   <result pre="manage rheumatic patients. MTX Methotrexate HCQ hydroxychloroquine RTX rituximab LFN" exact="leflunomide" post="bDMARDS Biologic disease- modifying anti-rheumatic drugs NSAIDs Non-steroidal anti-inflammatory"/>
   <result pre="data supporting it, we prefer to discontinue the use of" exact="rituximab" post="(RTX) infusions because of the related risk of infections."/>
   <result pre="the minimum effective dose, but not below 5–10 mg of" exact="prednisone" post="per day. 7.4 NSAIDs A great tumult arose about"/>
   <result pre="French Minister of Health»s statement advising against the use of" exact="ibuprofen" post="in patients with COVID-19. The European Medicines Agency (EMA)"/>
   <result pre="now there is no scientific evidence of a link between" exact="ibuprofen" post="and the worsening of COVID-19, although the situation will"/>
   <result pre="although it may be necessary to favour domiciliary treatment with" exact="adalimumab" post="injections if infliximab infusions are not accessible [39]. It"/>
   <result pre="be necessary to favour domiciliary treatment with adalimumab injections if" exact="infliximab" post="infusions are not accessible [39]. It is generally not"/>
   <result pre="a positive test, immunosuppressive treatment with traditional DMARDs other than" exact="chloroquine" post="or hydroxychloroquine, biological DMARDs (bDMARDs), small molecules, and biological"/>
   <result pre="patients with COVID-19 infection? Some recent studies have reported that" exact="chloroquine" post="has an antiviral effect on COVID-19 assays, and chloroquine"/>
   <result pre="that chloroquine has an antiviral effect on COVID-19 assays, and" exact="chloroquine" post="and its analogue hydroxychloroquine are well known to rheumatologists."/>
   <result pre="antiviral effect on COVID-19 assays, and chloroquine and its analogue" exact="hydroxychloroquine" post="are well known to rheumatologists. The repositioning of old"/>
   <result pre="schedules and drug interactions [37,47]. Recent findings have shown that" exact="hydroxychloroquine" post="is three times more potent than chloroquine [48]. This"/>
   <result pre="have shown that hydroxychloroquine is three times more potent than" exact="chloroquine" post="[48]. This in vitro antiviral effect is related to"/>
   <result pre="disease (Lombardy section) recommend the use of 500 mg of" exact="chloroquine" post="twice a day for ten days, or 200 mg"/>
   <result pre="twice a day for ten days, or 200 mg of" exact="hydroxychloroquine" post="200 mg per day [3][. However, we would like"/>
   <result pre="protective role against Sars -COV- 2? Can drugs such as" exact="tocilizumab" post="also be used chronically or only in the acute"/>
   <result pre="European drugs agency to review safety of ibuprofenBMJ.3682020m116832205306 37WangM.CaoR.ZhangL.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="the recently emerged novel coronavirus (2019-nCoV) in vitroCell Res30202026927132020029 38GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="Patients Dying in Relation to COVID-19 in ItalyJAMA.202010.1001/jama.2020.4683 47GautretP.LagierJ.C.ParolaP.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-"/>
   <result pre="Co3232004264268 50CortegianiAndreaIngogliaGiuliaIppolitoMariachiaraA systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J Crit Care2020pii: S0883-9441(20)30390-7 51ScuccimarriR.SuttonE.FitzcharlesM.A.Hydroxychloroquine:"/>
   <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 InfectionMed Mal"/>
   <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 InfectionMed Mal Infect.202010.1016/j.medmal.2020.03.006 53BaglivoM.BaronioM.NataliniG.BeccariT.Natural"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7200354\results\search\drugs\results.xml">
   <result pre="well as the treatments currently in use and future approaches;" exact="nitazoxanide" post="may be our dream drug. We hope that this"/>
   <result pre="eventually clear wheezing indications are recommended. Certain drugs such as" exact="methylprednisolone" post="intravenously (1–2 mg/kg/d) are suggested for 3–5 d, but"/>
   <result pre="It is worth noting that J.-F. Rossignol at 2016 presented" exact="nitazoxanide" post="as a broad-spectrum antiviral agent for Flu and other"/>
   <result pre="this drug is undergoing clinical progress. In vitro studies on" exact="nitazoxanide" post="showed its efficient function against MERS-CoV and other coronaviruses"/>
   <result pre="also declared that the clinical trials and post-marketing experience approve" exact="nitazoxanide" post="as an attractive drug candidate for treatment of MERS-CoV"/>
   <result pre="for treatment of MERS-CoV (58). There is a hope that" exact="nitazoxanide" post="may be effective for treatment of 2019-nCoV through similar"/>
   <result pre="clinical trial Therapeutics Approved for Other Indications Hydroxychloroquine (Plaquenil) and" exact="chloroquine" post="(Aralen) Quinoline Sanofi; Mylan, Teva, Novartis, Bayer, Rising Pharmaceuticals"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7200986\results\search\drugs\results.xml">
   <result pre="mmol/L L-glutamine, non-essential amino acids, 100 U/ml penicillin, 100 μg/ml" exact="streptomycin" post="and 10% fetal calf serum). Kinetics Experiments (120830 and"/>
   <result pre="E.CotlerS. J.et al.. (2013). Modeling shows that the NS5A inhibitor" exact="daclatasvir" post="has two modes of action and yields a shorter"/>
   <result pre="123–126. 10.1038/373123a07816094 KatoF.IshidaY.OishiS.FujiiN.WatanabeS.VasudevanS. G.et al.. (2016). Novel antiviral activity of" exact="bromocriptine" post="against dengue virus replication. Antiviral Res.131, 141–147. 10.1016/j.antiviral.2016.04.01427181378 KreutzC.RaueA.KaschekD.TimmerJ."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7201615\results\search\drugs\results.xml">
   <result pre="and were followed in the clinic. Clinic patients treated with" exact="ribavirin" post="or PEGylated interferon-based regimens were excluded from the study."/>
   <result pre="ago demonstrated that a SVR achieved with interferon alpha plus" exact="ribavirin" post="in patients with chronic hepatitis C could improve glycemic"/>
   <result pre="medications used to achieve a SVR, including hemolytic anemia from" exact="ribavirin" post="which can falsely lower HbA1C levels and interferon-mediated nausea,"/>
   <result pre="Gastrointestinal and Liver Diseases201827328128910.15403/jgld.2014.1121.273.daa30240472 10MoralesA. L.JungaZ.SinglaM. B.SjogrenM.TorresD.Hepatitis C eradication with" exact="sofosbuvir" post="leads to significant metabolic changesWorld Journal of Hepatology20168351557156310.4254/wjh.v8.i35.155728050236 11IkedaA.IkedaK.TakaiA.et"/>
   <result pre="metabolic changesWorld Journal of Hepatology20168351557156310.4254/wjh.v8.i35.155728050236 11IkedaA.IkedaK.TakaiA.et al.Hepatitis c treatment with" exact="sofosbuvir" post="and ledipasvir accompanied by immediate improvement in hemoglobin a1cDigestion201796422823010.1159/00048423729084399"/>
   <result pre="diabetes in type 2 diabetic patient treated with IFN-?? and" exact="ribavirin" post="for hepatitis CEuropean journal of gastroenterology &amp;amp; hepatology200618329129310.1097/00042737-200603000-0001116462544 20AraseY.SuzukiF.SuzukiY.et"/>
   <result pre="C.WoodY. A.Falsely low hemoglobin A1c levels in a patient receiving" exact="ribavirin" post="and peginterferon alfa-2b for hepatitis CPharmacotherapy200929112112310.1592/phco.29.1.12119113800 22GreenbergP. D.RosmanA. S.EldeiryL."/>
   <result pre="low hemoglobin A1c levels in a patient receiving ribavirin and" exact="peginterferon alfa-2b" post="for hepatitis CPharmacotherapy200929112112310.1592/phco.29.1.12119113800 22GreenbergP. D.RosmanA. S.EldeiryL. S.NaqviZ.BräuN.Decline in haemoglobin"/>
   <result pre="in haemoglobin A1c values in diabetic patients receiving interferon-alpha and" exact="ribavirin" post="for chronic hepatitis CJournal of Viral Hepatitis200613961361710.1111/j.1365-2893.2006.00729.x16907848 23StineJ. G.WynterJ."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7201855\results\search\drugs\results.xml">
   <result pre="immunomodulatory therapy (bacterial lysates, β-glucans, probiotics, prebiotics, Echinacea, enzyme therapy," exact="inosine" post="pranobex, azoximer bromide, etc.) in the prior 28 days"/>
   <result pre="and prevention of labial herpes simplex with various efficacies, including" exact="inosine" post="pranobex [34], transfer factors [35–38], topical honey [39], lysine"/>
   <result pre="of NK cells and T lymphocytes, and increased production of" exact="nitric oxide" post="should be pointed out [50–56]. Another important mechanism could"/>
   <result pre="lips)Cochrane Database of Systematic Reviews2015CD01009510.1002/14651858.cd010095.pub2 34YouY.WangL.LiY.et al.Multicenter randomized study of" exact="inosine" post="pranobex versus acyclovir in the treatment of recurrent herpes"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7202120\results\search\drugs\results.xml">
   <result pre="cortisone disappeared). At the same time, the preference given to" exact="paracetamol" post="became quite a strong recommendation [2]. The British Medical"/>
   <result pre="in patients with COVID-19-related acute respiratory distress syndrome treated with" exact="methylprednisolone" post="[5]. Still, our Facebook contacts, mostly non-doctors, continued to"/>
   <result pre="Informations sur le coronavirus COVID-19.https://www.chuv.ch/fr/chuv-home/en-bref/informations-sur-le-coronavirus-covid-19/. [Accessed 17 March 2020] 3DayM.COVID-19:" exact="ibuprofen" post="should not be used for managing symptoms, say doctors"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7202249\results\search\drugs\results.xml">
   <result pre="(and convalescent plasma therapy) or recombinant ACE2 protein; use of" exact="hydroxychloroquine" post="(based on in vitro data) to inhibit endosome maturation;"/>
   <result pre="does not appear to have been disclosed, a 1′-CN modified" exact="adenosine" post="C-nucleoside hit (GS-441524), along with a prodrug form of"/>
   <result pre="virus particles with deleterious mutations. Furthermore, treatment with concentrations of" exact="ribavirin" post="that caused a 9.7-fold increase in mutations was sufficient"/>
   <result pre="a number of FDA-approved antiviral drugs including the Gilead products" exact="sofosbuvir" post="(for treating HCV) and tenofovir alafenamide (first approved for"/>
   <result pre="drugs including the Gilead products sofosbuvir (for treating HCV) and" exact="tenofovir" post="alafenamide (first approved for treating HIV).64 Figure 3 Remdesivir"/>
   <result pre="a four-arm trial comparing remdesivir, lopinavir/ritonavir, lopinavir/ritonavir with interferon-β1a, and" exact="chloroquine" post="or hydroxychloroquine (ISRCTN83971151). With the goal of reducing trial"/>
   <result pre="trial comparing remdesivir, lopinavir/ritonavir, lopinavir/ritonavir with interferon-β1a, and chloroquine or" exact="hydroxychloroquine" post="(ISRCTN83971151). With the goal of reducing trial design time"/>
   <result pre="2020-001052-18).87 The comparative arms of the study are daily remdesivir," exact="hydroxychloroquine" post="loading dose of 800 mg × 2 followed by"/>
   <result pre="alone or standard of care plus the following: remdesivir, hydroxychloroquine," exact="lopinavir" post="and ritonavir, or lopinavir, ritonavir, and interferon-β1a.89 The remdesivir"/>
   <result pre="with maintenance dosing continuing up to 10 days. Lopinavir and" exact="ritonavir" post="tablets are to be administered every 12 h for"/>
   <result pre="administered every 12 h for 14 days (400 mg of" exact="lopinavir" post="/100 mg of ritonavir). In combination with the lopinavir/ritonavir"/>
   <result pre="clinically approved nucleoside/nucleotide analogues, such as the hepatitis C drug" exact="sofosbuvir" post="and HIV drugs alovudine and zidovudine, have also been"/>
   <result pre="S. A.2020, 117, 6771–6776. 10.1073/pnas.1922083117.32054787 WangM.; et al. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="Characterization of the activation pathway of phosphoramidate triester prodrugs of" exact="stavudine" post="and zidovudine. Mol. Pharmacol.1999, 56 (4), 693–704.10496951 TobiasS. C.;"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7202352\results\search\drugs\results.xml">
   <result pre="are the most commonly used for HBV suppression. Entecavir and" exact="tenofovir" post="are preferred over lamivudine due to the possibility of"/>
   <result pre="used for HBV suppression. Entecavir and tenofovir are preferred over" exact="lamivudine" post="due to the possibility of lamivudine resistance. Prophylaxis is"/>
   <result pre="tenofovir are preferred over lamivudine due to the possibility of" exact="lamivudine" post="resistance. Prophylaxis is started at least one week prior"/>
   <result pre="steroid-refractory acute GVHD are available, including rabbit/equine antithymocyte globulin (ATG)," exact="alemtuzumab" post="(Campath), interleukin-2 receptor antibodies as daclizumab and basiliximab, anti-TNFα"/>
   <result pre="rabbit/equine antithymocyte globulin (ATG), alemtuzumab (Campath), interleukin-2 receptor antibodies as" exact="daclizumab" post="and basiliximab, anti-TNFα drugs (such as infliximab), and extracorporeal"/>
   <result pre="mg/kg per day on days 3 and 4 post-transplantation, and" exact="cyclosporine" post="was started on day 5. The cumulative 1-year incidence"/>
   <result pre="with post-transplant cyclophosphamideRinsho Ketsueki201758102124213428978857 10MoiseevISet al.Risk-adapted GVHD prophylaxis with post-transplantation" exact="cyclophosphamide" post="in adults after related, unrelated, and haploidentical transplantationsEur J"/>
   <result pre="Immunotherapy for Graft-Versus-Host DiseaseFront Immunol20189108710.3389/fimmu.2018.0108729868032 27SainiNNathRCernyJCalcineurin inhibitor-free GVHD prophylaxis with" exact="sirolimus" post="and mycophenolate mofetil combinationAnn Hematol20179691563156810.1007/s00277-017-3062-228710649 28SaleemMSet al.Challenges in managing"/>
   <result pre="With No Immunosuppression but C5 InhibitionTransplantation20191032e48e5110.1097/TP.000000000000250530365467 37RichardsonPet al.Systematic review of" exact="defibrotide" post="studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7202545\results\search\drugs\results.xml">
   <result pre="have limitations. Previous studies showed that postulated geroprotectors, such as" exact="sirolimus" post="(rapamycin) and its close derivative rapalog everolimus (RAD001), decreased"/>
   <result pre="geroprotectors, such as sirolimus (rapamycin) and its close derivative rapalog" exact="everolimus" post="(RAD001), decreased infection rates in a small sample of"/>
   <result pre="undergone clinical evaluation for this purpose. Keywords: COVID-19 SARS-CoV-2 coronavirus" exact="sirolimus" post="rapalog INTRODUCTION Aging is a complex, multifactorial process [1]"/>
   <result pre="strategy against viral disease [31]. For influenza, the neuraminidase inhibitors" exact="oseltamivir" post="and zanamivir are occasionally given prophylactically to high-risk individuals"/>
   <result pre="viral disease [31]. For influenza, the neuraminidase inhibitors oseltamivir and" exact="zanamivir" post="are occasionally given prophylactically to high-risk individuals in long-term"/>
   <result pre="cost and may be associated with side effects; for example," exact="zanamivir" post="can induce bronchospasms in patients with chronic respiratory disease"/>
   <result pre="transmission risk. Other anti-influenza medications licensed for treatment, aside from" exact="oseltamivir" post="and zanamivir, consist of an intravenous neuraminidase inhibitor, peravamir,"/>
   <result pre="efficacy, neurological side effects, and widespread resistance, adamantanes (M2 inhibitors," exact="amantadine" post="and rimantadine), are only active against influenza A [31]."/>
   <result pre="still limited by a lack of large clinical trials, are" exact="sirolimus" post="(rapamycin) and everolimus. These may be used as single"/>
   <result pre="rapamycin (TOR) pathway. Everolimus (RAD001), another close structural derivative of" exact="sirolimus" post="developed by Novartis, acts as an immunosuppressant; but like"/>
   <result pre="the cyclical secretion that occurs physiologically, which normally indirectly increases" exact="testosterone" post="levels, actually reduces hormone levels. Therefore, it might be"/>
   <result pre="following transplantation [74, 80]. In 2009, two seminal studies of" exact="sirolimus" post="demonstrated the immunostimulatory effects of rapamycin on the CD8+"/>
   <result pre="[74, 80]. Later studies also showed that monkeys treated with" exact="sirolimus" post="exhibited increased recall responses and enhanced differentiation of memory"/>
   <result pre="role of rapalogs in the elderly using the Novartis rapalog" exact="everolimus" post="(RAD001), a close structural analog of sirolimus (rapamycin). Administration"/>
   <result pre="the Novartis rapalog everolimus (RAD001), a close structural analog of" exact="sirolimus" post="(rapamycin). Administration of everolimus ameliorated immunosenescence in healthy elderly"/>
   <result pre="(RAD001), a close structural analog of sirolimus (rapamycin). Administration of" exact="everolimus" post="ameliorated immunosenescence in healthy elderly volunteers and enhanced the"/>
   <result pre="which demonstrated that a low-dose combination of dactolisib (BEZ235) and" exact="everolimus" post="in an elderly population was safe and associated with"/>
   <result pre="(BEZ235), a PI3K inhibitor [84] and catalytic mTOR inhibitor, and" exact="everolimus" post="in an elderly population was safe and associated with"/>
   <result pre="endpoint and further trials were withdrawn [85]. In prior studies," exact="everolimus" post="(RAD001) was used as a standalone agent or in"/>
   <result pre="shown, several clinical trials are in progress [88–91]. Supplementation with" exact="nicotinamide" post="riboside (NR) in one human study produced an improvement"/>
   <result pre="by the enzymes NAPRT, NMNAT, and NADS. Large-scale trials of" exact="nicotinic acid" post="for cardiovascular disease [94, 95] showed some efficacy, but"/>
   <result pre="or intravenous supplementation with NAD donors, such as NR and" exact="nicotinic acid," post="will increase NAD levels and exert a clinical benefit"/>
   <result pre="human data have been reported with the tyrosine kinase inhibitor" exact="dasatinib" post="in combination with the plant flavonol quercetin in a"/>
   <result pre="with supplementation and no improvement in immune function.Side effects of" exact="nicotinic acid" post="include headache, skin flushing and dizziness. Uncertain effects on"/>
   <result pre="that several geroprotective and senoremediative interventions, such as treatment with" exact="sirolimus" post="and rapalogs, can induce immunopotentiation, increase resistance to infection,"/>
   <result pre="of this article, another group utilizing computational approaches proposed using" exact="melatonin" post="and sirolimus (rapamycin) in combination to treat the COVID-19"/>
   <result pre="article, another group utilizing computational approaches proposed using melatonin and" exact="sirolimus" post="(rapamycin) in combination to treat the COVID-19 infection outside"/>
   <result pre="speculative aging reversal treatments, such as experimental geroprotective strategies using" exact="everolimus" post="(RAD001) and sirolimus (rapamycin). We summarize the current possible"/>
   <result pre="treatments, such as experimental geroprotective strategies using everolimus (RAD001) and" exact="sirolimus" post="(rapamycin). We summarize the current possible interventions and identify"/>
   <result pre="BockV, Van CouterA, GibbensM, von PlantaTA, WardP. Long-term use of" exact="oseltamivir" post="for the prophylaxis of influenza in a vaccinated frail"/>
   <result pre="CorteseF, ArtemovA, Karpinsky-SemperD, MoskalevA, SwickAG, ZhavoronkovA. Towards natural mimetics of" exact="metformin" post="and rapamycin.Aging (Albany NY). 2017; 9:2245–68. 10.18632/aging.10131929165314 52AspinallR, LangPO."/>
   <result pre="RostaingL, KreisH, BurkeJT, BraultY, et al.. Sirolimus therapy after early" exact="cyclosporine" post="withdrawal reduces the risk for cancer in adult renal"/>
   <result pre="92DolopikouCF, KourtzidisIA, MargaritelisNV, VrabasIS, KoidouI, KyparosA, TheodorouAA, PaschalisV, NikolaidisMG. Acute" exact="nicotinamide" post="riboside supplementation improves redox homeostasis and exercise performance in"/>
   <result pre="10.1007/s00394-019-01919-430725213 93MartensCR, DenmanBA, MazzoMR, ArmstrongML, ReisdorphN, McQueenMB, ChoncholM, SealsDR. Chronic" exact="nicotinamide" post="riboside supplementation is well-tolerated and elevates NAD+ in healthy"/>
   <result pre="Van GoolF, GalliM, LeoO, SoA, De SmedtT. Pharmacological inhibition of" exact="nicotinamide" post="phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7202831\results\search\drugs\results.xml">
   <result pre="likely to be an important driver of pathogenesis. For example," exact="oseltamivir" post="has shown benefits over placebo in patients with influenza"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7202847\results\search\drugs\results.xml">
   <result pre="development for the treatment of COVID-19 patients. The antimalarial drug" exact="chloroquine" post="(CQ) and its metabolite hydroxychloroquine (HCQ) are currently being"/>
   <result pre="COVID-19 patients. The antimalarial drug chloroquine (CQ) and its metabolite" exact="hydroxychloroquine" post="(HCQ) are currently being tested in several clinical studies"/>
   <result pre="might be the clinical use of the oral prescription drugs" exact="chloroquine" post="(CQ) and hydroxychloroquine (HCQ) used for the treatment of"/>
   <result pre="clinical use of the oral prescription drugs chloroquine (CQ) and" exact="hydroxychloroquine" post="(HCQ) used for the treatment of malaria and certain"/>
   <result pre="of an open label non-randomized clinical trial with HCQ and" exact="azithromycin" post="in France support these findings [7]. Based on these"/>
   <result pre="of malaria –Remdesivir, developed for treatment of Ebola –Lopinavir and" exact="ritonavir" post="used in combination for treatment of HIV –Lopinavir and"/>
   <result pre="ritonavir used in combination for treatment of HIV –Lopinavir and" exact="ritonavir" post="with interferon beta The antiviral nucleoside analogue, remdesivir has"/>
   <result pre="outbreaks (SARS-CoV in 2002/2003 and MERS-CoV in 2012) and include" exact="lopinavir" post="and ritonavir with or without interferon beta [4]. However,"/>
   <result pre="in 2002/2003 and MERS-CoV in 2012) and include lopinavir and" exact="ritonavir" post="with or without interferon beta [4]. However, it is"/>
   <result pre="in the treatment of SARS-CoV-2 infected COVID-19 patients. For example," exact="lopinavir" post="and ritonavir already failed to show beneficial clinical effects"/>
   <result pre="treatment of SARS-CoV-2 infected COVID-19 patients. For example, lopinavir and" exact="ritonavir" post="already failed to show beneficial clinical effects versus standard"/>
   <result pre="200 mg twice daily, zinc sulfate 220 mg once-daily, and" exact="azithromycin" post="500 mg once-daily, each for 5 days. Detailed analysis"/>
   <result pre="drug information, clinical solutions. https://www.elsevier.com/__data/assets/pdf_file/0007/988648/COVID-19-Drug-Therapy_Mar-2020.pdf [consulted on 2020-03-28]. 5ColsonP.RolainJ.M.LagierJ.C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int J Antimicrob Agents202010.1016/j.ijantimicag.2020.105932published"/>
   <result pre="to fight COVID-19Int J Antimicrob Agents202010.1016/j.ijantimicag.2020.105932published online Mar 4 6GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="of COVID-19 associated pneumonia in clinical studiesBiosci Trends1412020727332074550 7GautretP.LagierJ.C.ParolaP.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="severe Covid-19N Engl J Med202010.1056/NEJMoa2001282published online Mar 18 11RolainJ.M.ColsonP.RaoultD.Recycling of" exact="chloroquine" post="and its hydroxyl analogue to face bacterial, fungal and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7202851\results\search\drugs\results.xml">
   <result pre="Ltd. pmcid: 7202851S1477-8939(20)30214-3 doi: 10.1016/j.tmaid.2020.101735101735 : Article Therapeutic use of" exact="chloroquine" post="and hydroxychloroquine in COVID-19 and other viral infections: A"/>
   <result pre="7202851S1477-8939(20)30214-3 doi: 10.1016/j.tmaid.2020.101735101735 : Article Therapeutic use of chloroquine and" exact="hydroxychloroquine" post="in COVID-19 and other viral infections: A narrative review"/>
   <result pre="efficacy and safety considerations [19]. Recent publications have suggested using" exact="chloroquine" post="(CQ), a broadly used antimalarial drug, and its derivative"/>
   <result pre="chloroquine (CQ), a broadly used antimalarial drug, and its derivative" exact="hydroxychloroquine" post="(HCQ) as a treatment for COVID-19 patients [[20], [21],"/>
   <result pre="mouse hepatitis virus (MHV4) [116,117]. Other CQ derivatives such as" exact="amodiaquine" post="(AMD), ferroquine (FQ), hydroxy ferroquine (HFQ) have been also"/>
   <result pre="toxicity was indicated if available). aEither alone or combined with" exact="hydroxyurea" post="(HU1) + didanosine (ddI). bIn combination with hydroxyurea (HU1)"/>
   <result pre="if available). aEither alone or combined with hydroxyurea (HU1) +" exact="didanosine" post="(ddI). bIn combination with hydroxyurea (HU1) + didanosine (ddI)."/>
   <result pre="combined with hydroxyurea (HU1) + didanosine (ddI). bIn combination with" exact="hydroxyurea" post="(HU1) + didanosine (ddI). cIn combination with hydroxyurea (HU1)"/>
   <result pre="(HU1) + didanosine (ddI). bIn combination with hydroxyurea (HU1) +" exact="didanosine" post="(ddI). cIn combination with hydroxyurea (HU1) + didanosine (ddI)"/>
   <result pre="combination with hydroxyurea (HU1) + didanosine (ddI). cIn combination with" exact="hydroxyurea" post="(HU1) + didanosine (ddI) or with hydroxyurea (HU1) +"/>
   <result pre="(HU1) + didanosine (ddI). cIn combination with hydroxyurea (HU1) +" exact="didanosine" post="(ddI) or with hydroxyurea (HU1) + zidovudine (ZDV). dEnhanced"/>
   <result pre="cIn combination with hydroxyurea (HU1) + didanosine (ddI) or with" exact="hydroxyurea" post="(HU1) + zidovudine (ZDV). dEnhanced inhibition against HIV-1 and"/>
   <result pre="hydroxyurea (HU1) + didanosine (ddI) or with hydroxyurea (HU1) +" exact="zidovudine" post="(ZDV). dEnhanced inhibition against HIV-1 and HIV-2 in combination"/>
   <result pre="H9 and MT-4 cells; and against HIV-1 in combination with" exact="indinavir" post="(IDV), saquinavir (SQV) or ritonavir (RTV) in MT-4 cells"/>
   <result pre="MT-4 cells; and against HIV-1 in combination with indinavir (IDV)," exact="saquinavir" post="(SQV) or ritonavir (RTV) in MT-4 cells or peripheral"/>
   <result pre="against HIV-1 in combination with indinavir (IDV), saquinavir (SQV) or" exact="ritonavir" post="(RTV) in MT-4 cells or peripheral blood mononuclear cells"/>
   <result pre="be inhibited by CQ alone or in combination with HCQ," exact="hydroxyurea" post="(HU1), didanosine (ddI), zidovudine (ZDV), indinavir (IDV), saquinavir (SQV)"/>
   <result pre="by CQ alone or in combination with HCQ, hydroxyurea (HU1)," exact="didanosine" post="(ddI), zidovudine (ZDV), indinavir (IDV), saquinavir (SQV) or ritonavir"/>
   <result pre="alone or in combination with HCQ, hydroxyurea (HU1), didanosine (ddI)," exact="zidovudine" post="(ZDV), indinavir (IDV), saquinavir (SQV) or ritonavir (RTV) [106,[118],"/>
   <result pre="in combination with HCQ, hydroxyurea (HU1), didanosine (ddI), zidovudine (ZDV)," exact="indinavir" post="(IDV), saquinavir (SQV) or ritonavir (RTV) [106,[118], [119], [120],"/>
   <result pre="with HCQ, hydroxyurea (HU1), didanosine (ddI), zidovudine (ZDV), indinavir (IDV)," exact="saquinavir" post="(SQV) or ritonavir (RTV) [106,[118], [119], [120], [121], [122]]."/>
   <result pre="(HU1), didanosine (ddI), zidovudine (ZDV), indinavir (IDV), saquinavir (SQV) or" exact="ritonavir" post="(RTV) [106,[118], [119], [120], [121], [122]]. While other derivatives"/>
   <result pre="s.c.: subcutaneous; i.t: intratracheal; i.v: intravenous; i.g: intragastric. aCombined with" exact="doxycycline" post="(2.5 mg/kg) and azithromycin (50 mg/kg). bEither alone or"/>
   <result pre="i.v: intravenous; i.g: intragastric. aCombined with doxycycline (2.5 mg/kg) and" exact="azithromycin" post="(50 mg/kg). bEither alone or combined with ribavirin. cDose-dependent"/>
   <result pre="have suggested that the use of HCQ alone or with" exact="azithromycin" post="(AZT) could be beneficial for COVID-19 patients as it"/>
   <result pre="19LuH.Drug treatment options for the 2019-new coronavirus (2019-nCoV)Biosci Trends142020697110.5582/bst.2020.0102031996494 20GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="of COVID-19 associated pneumonia in clinical studiesBiosci Trends142020727310.5582/bst.2020.0104732074550 21ColsonP.RolainJ.M.LagierJ.C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int J Antimicrob Agents202010593210.1016/j.ijantimicag.2020.10593232145363"/>
   <result pre="Antimicrob Agents202010593210.1016/j.ijantimicag.2020.10593232145363 22ZhouD.DaiS.M.TongQ.COVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progressionJ Antimicrob Chemother202010.1093/jac/dkaa114dkaa114 23InglotA.D.Comparison of"/>
   <result pre="antiviral agentsProc Natl Acad Sci U S A7819813605360910.1073/pnas.78.6.36056115382 25ShimizuY.YamamotoS.HommaM.IshidaN.Effect of" exact="chloroquine" post="on the growth of animal virusesArch Gesamte Virusforsch3619729310410.1007/BF012502994335025 26SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects"/>
   <result pre="on the growth of animal virusesArch Gesamte Virusforsch3619729310410.1007/BF012502994335025 26SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against today's diseases?Lancet"/>
   <result pre="an old drug against today's diseases?Lancet Infect Dis3200372272710.1016/S1473-3099(03)00806-514592603 27RomanelliF.SmithK.M.HovenA.D.Chloroquine and" exact="hydroxychloroquine" post="as inhibitors of human immunodeficiency virus (HIV-1) activityCurr Pharmaceut"/>
   <result pre="into the antiviral effects of chloroquineLancet Infect Dis62006676910.1016/S1473-3099(06)70361-916439323 29YanY.ZouZ.SunY.LiX.XuK.F.WeiY.Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
   <result pre="41KhanM.SanthoshS.R.TiwariM.Lakshmana RaoP.V.ParidaM.Assessment of in vitro prophylactic and therapeutic efficacy of" exact="chloroquine" post="against Chikungunya virus in vero cellsJ Med Virol82201081782410.1002/jmv.2166320336760 42YangZ.Y.HuangY.GaneshL.LeungK.KongW.P.SchwartzO.pH-dependent"/>
   <result pre="autophagy that induces cathepsin D-mediated apoptosisJ Biol Chem28620116602661310.1074/jbc.M110.15132421148553 45SavarinoA.Use of" exact="chloroquine" post="in viral diseasesLancet Infect Dis11201165365410.1016/S1473-3099(11)70092-521550312 46WangH.JiangC.Influenza A virus H5N1"/>
   <result pre="STAT5, signalingArthritis Res Ther19201718310.1186/s13075-017-1393-y28793932 49van den BorneB.E.DijkmansB.A.de RooijH.H.le CessieS.VerweijC.L.Chloroquine and" exact="hydroxychloroquine" post="equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma"/>
   <result pre="55AlbertD.A.DeboisL.K.LuK.F.Antimalarial ocular toxicity a critical appraisalJ Clin Rheumatol419985762https://scite.ai/reports/10.1097/00124743-199804000-0000419078251 56GustafssonL.L.WalkerO.AlvanG.BeermannB.EstevezF.GleisnerL.Disposition of" exact="chloroquine" post="in man after single intravenous and oral dosesBr J"/>
   <result pre="single intravenous and oral dosesBr J Clin Pharmacol15198347147910.1111/j.1365-2125.1983.tb01532.x6849784 57FurstD.E.Pharmacokinetics of" exact="hydroxychloroquine" post="and chloroquine during treatment of rheumatic diseasesLupus51996111510.1177/09612033960050010418646219 58TettS.E.CutlerD.J.DayR.O.BrownK.F.Bioavailability of"/>
   <result pre="and oral dosesBr J Clin Pharmacol15198347147910.1111/j.1365-2125.1983.tb01532.x6849784 57FurstD.E.Pharmacokinetics of hydroxychloroquine and" exact="chloroquine" post="during treatment of rheumatic diseasesLupus51996111510.1177/09612033960050010418646219 58TettS.E.CutlerD.J.DayR.O.BrownK.F.Bioavailability of hydroxychloroquine tablets"/>
   <result pre="hydroxychloroquine and chloroquine during treatment of rheumatic diseasesLupus51996111510.1177/09612033960050010418646219 58TettS.E.CutlerD.J.DayR.O.BrownK.F.Bioavailability of" exact="hydroxychloroquine" post="tablets in healthy volunteersBr J Clin Pharmacol27198977177910.1111/j.1365-2125.1989.tb03439.x2757893 59BothwellB.FurstD.E.HydroxychloroquineAntirheumatic therapy:"/>
   <result pre="4-aminoquinoline antimalarialsAgents Actions Suppl24198814215710.1007/978-3-0348-9160-8_133263755 63RainsfordK.D.Parke AnnL.Clifford-RashotteM.KeanW.F.Therapy and pharmacological properties of" exact="hydroxychloroquine" post="and chloroquine in treatment of systemic lupus erythematosus, rheumatoid"/>
   <result pre="Actions Suppl24198814215710.1007/978-3-0348-9160-8_133263755 63RainsfordK.D.Parke AnnL.Clifford-RashotteM.KeanW.F.Therapy and pharmacological properties of hydroxychloroquine and" exact="chloroquine" post="in treatment of systemic lupus erythematosus, rheumatoid arthritis and"/>
   <result pre="related diseasesInflammopharmacology23201523126910.1007/s10787-015-0239-y26246395 64BanksC.N.Melanin: blackguard or red herring? Another look at" exact="chloroquine" post="retinopathyAust N Z J Ophthalmol15198736537010.1111/j.1442-9071.1987.tb00097.x3325085 65Frisk-HolmbergM.BergqvistY.TermondE.Domeij-NybergB.The single dose kinetics"/>
   <result pre="retinopathyAust N Z J Ophthalmol15198736537010.1111/j.1442-9071.1987.tb00097.x3325085 65Frisk-HolmbergM.BergqvistY.TermondE.Domeij-NybergB.The single dose kinetics of" exact="chloroquine" post="and its major metabolite desethylchloroquine in healthy subjectsEur J"/>
   <result pre="of insulin kinetics and its use to investigate action of" exact="chloroquine" post="in NIDDMAm J Physiol2651993E162E17510.1152/ajpendo.1993.265.1.E1628338148 68YamadaY.HidefumiK.ShionH.OshikataM.HaramakiY.Distribution of chloroquine in ocular"/>
   <result pre="investigate action of chloroquine in NIDDMAm J Physiol2651993E162E17510.1152/ajpendo.1993.265.1.E1628338148 68YamadaY.HidefumiK.ShionH.OshikataM.HaramakiY.Distribution of" exact="chloroquine" post="in ocular tissue of pigmented rat using matrix-assisted laser"/>
   <result pre="arthritis with antimalarialsAm J Med751983404510.1016/0002-9343(83)91269-X 74McChesneyE.W.Animal toxicity and pharmacokinetics of" exact="hydroxychloroquine" post="sulfateAm J Med751983111810.1016/0002-9343(83)91265-26408923 75IredaleJ.FiegerH.WainerI.W.Determination of the stereoisomers of hydroxychloroquine"/>
   <result pre="of hydroxychloroquine sulfateAm J Med751983111810.1016/0002-9343(83)91265-26408923 75IredaleJ.FiegerH.WainerI.W.Determination of the stereoisomers of" exact="hydroxychloroquine" post="and its major metabolites in plasma and urine following"/>
   <result pre="80MurphyM.CarmichaelA.J.Fatal toxic epidermal necrolysis associated with hydroxychloroquineClin Exp Dermatol26200145745810.1046/j.1365-2230.2001.00857-3.x11488840 81ChenC.Y.WangF.L.LinC.C.Chronic" exact="hydroxychloroquine" post="use associated with QT prolongation and refractory ventricular arrhythmiaClin"/>
   <result pre="in patients with SARS-CoV-2 infection treated with hydroxychloroquine/azithromycinmedRxiv202010.1101/2020.04.02.200470502020.04.02.20047050 84GoldmanL.PrestonR.H.Reactions to" exact="chloroquine" post="observed during the treatment of various dermatologic disordersAm J"/>
   <result pre="patients treated with hydroxychloroquine: a reappraisalOphthalmology11020031321132610.1016/S0161-6420(03)00409-312867385 90MichaelidesM.StoverN.B.FrancisP.J.WeleberR.G.Retinal toxicity associated with" exact="hydroxychloroquine" post="and chloroquine: risk factors, screening, and progression despite cessation"/>
   <result pre="progression despite cessation of therapyArch Ophthalmol1292011303910.1001/archophthalmol.2010.32121220626 91WolfeF.MarmorM.F.Rates and predictors of" exact="hydroxychloroquine" post="retinal toxicity in patients with rheumatoid arthritis and systemic"/>
   <result pre="toxic myopathy causing respiratory failureChest131200758859010.1378/chest.06-114617296665 93KwonJ.B.KleinerA.IshidaK.GodownJ.CiafaloniE.LooneyR.J.Hydroxychloroquine-Induced myopathyJ Clin Rheumatol162010283110.1097/RHU.0b013e3181c47ec820051753 94Abdel-HamidH.OddisC.V.LacomisD.Severe" exact="hydroxychloroquine" post="myopathyMuscle Nerve3820081206121010.1002/mus.2109118720511 95Becerra-CuñatJ.L.Coll-CantíJ.Gelpí-MantiusE.Ferrer-AvellíX.Lozano-SánchezM.Millán-TornéM.[Chloroquine-induced myopathy and neuropathy: progressive tetraparesis with"/>
   <result pre="replication in cell cultureAntimicrob Agents Chemother5820144875488410.1128/AAC.03011-1424841269 108KeyaertsE.LiS.VijgenL.RysmanE.VerbeeckJ.Van RanstM.Antiviral activity of" exact="chloroquine" post="against human coronavirus OC43 infection in newborn miceAntimicrob Agents"/>
   <result pre="chloroquine: involvement of p38 MAPK and ERKAntivir Res77200815015210.1016/j.antiviral.2007.10.01118055026 110TakanoT.KatohY.DokiT.HohdatsuT.Effect of" exact="chloroquine" post="on feline infectious peritonitis virus infection in vitro and"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis202010.1093/cid/ciaa237ciaa237 113WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="effective in inhibiting SARS-CoV-2 infection in vitroCell discov620201410.1038/s41421-020-0156-031934347 115MallucciL.Effect of" exact="chloroquine" post="on lysosomes and on growth of mouse hepatitis virus"/>
   <result pre="additive in vitro anti-HIV type 1 effect when associated with" exact="didanosine" post="and hydroxyureaAIDS Res Hum Retrovir1519991241124710.1089/08892229931013310505672 121BoelaertJ.R.SperberK.PietteJ.The additive in vitro"/>
   <result pre="additive in vitro anti-HIV-1 effect of chloroquine, when combined with" exact="zidovudine" post="and hydroxyureaBiochem Pharmacol6120011531153510.1016/S0006-2952(01)00576-711377382 122SavarinoA.LuciaM.B.RastrelliE.RutellaS.GolottaC.MorraE.Anti-HIV effects of chloroquine: inhibition of"/>
   <result pre="Syndr35200422323210.1097/00126334-200403010-0000215076236 123SperberK.KalbT.H.StecherV.J.BanerjeeR.MayerL.Inhibition of human immunodeficiency virus type 1 replication by" exact="hydroxychloroquine" post="in T cells and monocytesAIDS Res Hum Retrovir91993919810.1089/aid.1993.9.918427717 124ChiangG.SassaroliM.LouieM.ChenH.StecherV.J.SperberK.Inhibition"/>
   <result pre="TraniL.SavarinoA.CampitelliL.NorelliS.PuzelliS.D'OstilioD.Different pH requirements are associated with divergent inhibitory effects of" exact="chloroquine" post="on human and avian influenza A virusesVirol J420073910.1186/1743-422X-4-3917477867 131ShibataM.AokiH.TsurumiT.SugiuraY.NishiyamaY.SuzukiS.Mechanism"/>
   <result pre="Virol6419831149115610.1099/0022-1317-64-5-11496842189 132SourisseauM.SchilteC.CasartelliN.TrouilletC.Guivel-BenhassineF.RudnickaD.Characterization of reemerging chikungunya virusPLoS Pathog32007e8910.1371/journal.ppat.003008917604450 133RoquesP.ThibervilleS.D.Dupuis-MaguiragaL.LumF.M.LabadieK.MartinonF.Paradoxical effect of" exact="chloroquine" post="treatment in enhancing chikungunya virus infectionViruses10201826810.3390/v10050268 134LiC.ZhuX.JiX.QuanquinN.DengY.-Q.TianM.Chloroquine, a FDA-approved"/>
   <result pre="infection in different cell modelsViruses8201632210.3390/v8120322 136ShiryaevS.A.MesciP.PintoA.FernandesI.SheetsN.ShrestaS.Repurposing of the anti-malaria drug" exact="chloroquine" post="for Zika Virus treatment and prophylaxisSci Rep720171577110.1038/s41598-017-15467-629150641 137DowallS.D.BosworthA.WatsonR.BewleyK.TaylorI.RaynerE.Chloroquine inhibited"/>
   <result pre="modelJ Gen Virol9620153484349210.1099/jgv.0.00030926459826 138FalzaranoD.SafronetzD.PrescottJ.MarziA.FeldmannF.FeldmannH.Lack of protection against ebola virus from" exact="chloroquine" post="in mice and hamstersEmerg Infect Dis2120151065106710.3201/eid2106.15017625988934 139MadridP.B.ChopraS.MangerI.D.GilfillanL.KeepersT.R.ShurtleffA.C.A systematic screen"/>
   <result pre="cells but not in C6/36 cellsSci World J201320132827283410.1155/2013/282734 142CoombsK.MannE.EdwardsJ.BrownD.T.Effects of" exact="chloroquine" post="and cytochalasin B on the infection of cells by"/>
   <result pre="Sindbis virus and vesicular stomatitis virusJ Virol371981106010656262524 143TsiangH.SupertiF.Ammonium chloride and" exact="chloroquine" post="inhibit rabies virus infection in neuroblastoma cells. Brief reportArch"/>
   <result pre="Brief reportArch Virol81198437738210.1007/bf013100106148053 144MizuiT.YamashinaS.TanidaI.TakeiY.UenoT.SakamotoN.Inhibition of hepatitis C virus replication by" exact="chloroquine" post="targeting virus-associated autophagyJ Gastroenterol45201019520310.1007/s00535-009-0132-919760134 145CiviticoG.WangY.Y.LuscombeC.BishopN.TachedjianG.GustI.Antiviral strategies in chronic hepatitis"/>
   <result pre="in arenavirus replication are sensitive to lysosomotropic compoundsArch Virol104198915716110.1007/bf013138172923547 148FreibergA.N.WorthyM.N.LeeB.HolbrookM.R.Combined" exact="chloroquine" post="and ribavirin treatment does not prevent death in a"/>
   <result pre="replication are sensitive to lysosomotropic compoundsArch Virol104198915716110.1007/bf013138172923547 148FreibergA.N.WorthyM.N.LeeB.HolbrookM.R.Combined chloroquine and" exact="ribavirin" post="treatment does not prevent death in a hamster model"/>
   <result pre="RembertA.Paranhos-BaccalaG.Evaluation of Crimean-Congo hemorrhagic fever virus in vitro inhibition by" exact="chloroquine" post="and chlorpromazine, two FDA approved moleculesAntivir Res1182015758110.1016/j.antiviral.2015.03.00525796972 151KronenbergerP.VrijsenR.BoeyeA.Chloroquine induces"/>
   <result pre="placebo controlled trialLancet Infect Dis11201167768310.1016/s1473-3099(11)70065-221550310 156TricouV.MinhN.N.VanT.P.LeeS.J.FarrarJ.WillsB.A randomized controlled trial of" exact="chloroquine" post="for the treatment of dengue in Vietnamese adultsPLoS Neglected"/>
   <result pre="adultsPLoS Neglected Trop Dis42010e78510.1371/journal.pntd.0000785 157De LamballerieX.BoissonV.ReynierJ.C.EnaultS.CharrelR.N.FlahaultA.On chikungunya acute infection and" exact="chloroquine" post="treatmentVector Borne Zoonotic Dis8200883783910.1089/vbz.2008.004918620511 158BorgesM.C.CastroL.A.FonsecaB.A.Chloroquine use improves dengue-related symptomsMem"/>
   <result pre="158BorgesM.C.CastroL.A.FonsecaB.A.Chloroquine use improves dengue-related symptomsMem Inst Oswaldo Cruz108201359659910.1590/s0074-0276201300050001023903975 159SperberK.ChiangG.ChenH.RossW.ChusidE.GoncharM.Comparison of" exact="hydroxychloroquine" post="with zidovudine in asymptomatic patients infected with human immunodeficiency"/>
   <result pre="improves dengue-related symptomsMem Inst Oswaldo Cruz108201359659910.1590/s0074-0276201300050001023903975 159SperberK.ChiangG.ChenH.RossW.ChusidE.GoncharM.Comparison of hydroxychloroquine with" exact="zidovudine" post="in asymptomatic patients infected with human immunodeficiency virus type"/>
   <result pre="with human immunodeficiency virus type 1Clin Therapeut19199791392310.1016/s0149-2918(97)80045-8 160JacobsonJ.M.BosingerS.E.KangM.Belaunzaran-ZamudioP.MatiningR.M.WilsonC.C.The effect of" exact="chloroquine" post="on immune activation and interferon signatures associated with HIV-1AIDS"/>
   <result pre="interferon signatures associated with HIV-1AIDS Res Hum Retrovir32201663664710.1089/AID.2015.033626935044 161PatonN.I.GoodallR.L.DunnD.T.FranzenS.Collaco-MoraesY.GazzardB.G.Effects of" exact="hydroxychloroquine" post="on immune activation and disease progression among HIV-infected patients"/>
   <result pre="not receiving antiretroviral therapy: a randomized controlled trialJAMA308201235336110.1001/jama.2012.693622820788 162GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="an open-label non-randomized clinical trialInt J Antimicrob Agents105949202010.1016/j.ijantimicag.2020.105949 163ChenZ.HuJ.ZhangZ.JiangS.HanS.YanD.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
   <result pre="clinical trialmedRxiv20202004075810.1101/2020.03.22.20040758 164GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.SevestreJ.Clinical and microbiological effect of a combination of" exact="hydroxychloroquine" post="and azithromycin in 80 COVID-19 patients with at least"/>
   <result pre="164GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.SevestreJ.Clinical and microbiological effect of a combination of hydroxychloroquine and" exact="azithromycin" post="in 80 COVID-19 patients with at least a six-day"/>
   <result pre="pilot observational studyTrav Med Infect Dis202010166310.1016/j.tmaid.2020.101663 165ChenJ.LiuD.LiuL.LiuP.XuQ.XiaL.A pilot study of" exact="hydroxychloroquine" post="in treatment of patients with common coronavirus disease-19 (COVID-19)J"/>
   <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infectionMed Maladies"/>
   <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infectionMed Maladies Infect202010.1016/j.medmal.2020.03.006 167LenzerJ.Covid-19:"/>
   <result pre="COVID-19 infectionMed Maladies Infect202010.1016/j.medmal.2020.03.006 167LenzerJ.Covid-19: US gives emergency approval to" exact="hydroxychloroquine" post="despite lack of evidenceBMJ3692020m133510.1136/bmj.m133532238355 168Indian Council for Medical ResearchRecommendation"/>
   <result pre="evidenceBMJ3692020m133510.1136/bmj.m133532238355 168Indian Council for Medical ResearchRecommendation for empiric use of" exact="hydroxychloroquine" post="for prophylaxis of SARS-CoV-2 infectionhttps://www.icmr.gov.in/index.htmlAccessed 9 April 2020 169OrnsteinM.H.SperberK.The"/>
   <result pre="infectionhttps://www.icmr.gov.in/index.htmlAccessed 9 April 2020 169OrnsteinM.H.SperberK.The antiinflammatory and antiviral effects of" exact="hydroxychloroquine" post="in two patients with acquired immunodeficiency syndrome and active"/>
   <result pre="with human immunodeficiency virus type 1Clin Therapeut17199562263610.1016/0149-2918(95)80039-5 171JacobsonJ.M.BosingerS.E.KangM.Belaunzaran-ZamudioP.MatiningR.M.WilsonC.C.The effect of" exact="chloroquine" post="on immune activation and interferon signatures associated with HIV-1AIDS"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7203058\results\search\drugs\results.xml">
   <result pre="fluid management, and treatments with multiple drugs as antiviral therapies," exact="chloroquine" post="or hydroxyichloroquine, antibiotics, steroids, nonsteroidal anti-inflammatory drugs, bronchodilators and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7203261\results\search\drugs\results.xml">
   <result pre="treatment of HIV in combination with a low dose of" exact="ritonavir" post="to increase its plasma half-life, has been used to"/>
   <result pre="11]. However, despite the use of lopinavir/ritonavir in combination with" exact="ribavirin" post="was initially considered a promising therapy for treating COVID-19"/>
   <result pre="Pneumonia [14] included as useful therapy, together with the antimalarial" exact="chloroquine" post="and the antiviral treatment for influenza arbidol, the broad-spectrum"/>
   <result pre="for its undesiderable side effect like anemia, the use of" exact="ribavirin" post="may not be convenient in patients who are already"/>
   <result pre="performed on 20 COVID-19 patients shows that the use of" exact="hydroxychloroquine" post="also by adding the antibacterial drug azithromycin is efficient"/>
   <result pre="the use of hydroxychloroquine also by adding the antibacterial drug" exact="azithromycin" post="is efficient in viral load reduction/disappearance [16]. Hydroxychloroquine and"/>
   <result pre="report on the use of a combination of hydroxicloroquine and" exact="azithromycin" post="to treat COVID-19 patients showed no evidence of a"/>
   <result pre="authors hypothesize that angiotensin receptor 1 (AT1R) blockers such as" exact="losartan" post="or telmisartan, could have some beneficial in patients infected"/>
   <result pre="2019-nCoV therapy registered in ChinaJ Med Virol20209254054510.1002/jmv.25733 16.GautretPLagierJCParolaPet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="chloroquineLancet Infect Dis200662676910.1016/S1473-3099(06)70361-916439323 18.DevauxCARolainJMColsonPRaoultDNew insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int J Antimicrob"/>
   <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infectionMed Mal"/>
   <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infectionMed Mal Infect202010.1016/j.medmal.2020.03.00632240719 22.CalyLDruceJDCattonMGJansDAWagstaffKMThe"/>
   <result pre="patients with severe COVID-19 infectionMed Mal Infect202010.1016/j.medmal.2020.03.00632240719 22.CalyLDruceJDCattonMGJansDAWagstaffKMThe FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntivir Res202010.1016/j.antiviral.2020.10478732251768 23.https://clinicaltrials.gov/ct2/show/NCT04304053?term=cobicistat&amp;amp;cond=covid-19&amp;amp;phase=2&amp;amp;draw=2&amp;amp;rank=1."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7203797\results\search\drugs\results.xml">
   <result pre="can be achieved by using recommended first line antiviral agents" exact="entecavir" post="or tenofovir, which are well tolerated, have high barriers"/>
   <result pre="living with CHB are receiving treatment with oral antivirals, predominantly" exact="entecavir" post="(45%) and tenofovir (28%) [20, 21]. Antiviral medication has"/>
   <result pre="are receiving treatment with oral antivirals, predominantly entecavir (45%) and" exact="tenofovir" post="(28%) [20, 21]. Antiviral medication has primarily been dispensed"/>
   <result pre="550 patients (85.7%) were on first-line oral antiviral therapies (either" exact="entecavir" post="0.5 mg or tenofovir 300 mg). Table 2 Patient characteristics Number(%)"/>
   <result pre="were on first-line oral antiviral therapies (either entecavir 0.5 mg or" exact="tenofovir" post="300 mg). Table 2 Patient characteristics Number(%) Median age (IQR)"/>
   <result pre="2), with no evidence of difference in the proportion for" exact="entecavir" post="vs. tenofovir (p = 0.30) or for first line therapy vs."/>
   <result pre="no evidence of difference in the proportion for entecavir vs." exact="tenofovir" post="(p = 0.30) or for first line therapy vs. older drugs"/>
   <result pre="[7, 13, 19, 25–27], with a small study that examined" exact="entecavir" post="and viral outcomes with a proposed cut-off of less"/>
   <result pre="to viral breakthrough in chronic hepatitis B patients treated with" exact="entecavir" post="than in those with lamivudineInt J Med Sci201310556757423533048 8.KardasPLewekPMatyjaszczykMDeterminants"/>
   <result pre="of breakthrough?J Hepatol20115561468146921703170 24.PolSLamperticoPFirst-line treatment of chronic hepatitis B with" exact="entecavir" post="or tenofovir in ‘real-life’ settings: from clinical trials to"/>
   <result pre="Hepatol20115561468146921703170 24.PolSLamperticoPFirst-line treatment of chronic hepatitis B with entecavir or" exact="tenofovir" post="in ‘real-life’ settings: from clinical trials to clinical practiceJ"/>
   <result pre="breakthroughsJ Viral Hepat201219320521222329375 26.BergTMarcellinPZoulimFMollerBTrinhHChanSet al.Tenofovir is effective alone or with" exact="emtricitabine" post="in adefovir-treated patients with chronic-hepatitis B virus infectionGastroenterology.201013941207121720600025 27.van"/>
   <result pre="VlerkenLGArendsPLieveldFIArendsJEBrouwerWPSiersemaPDet al.Real life adherence of chronic hepatitis B patients to" exact="entecavir" post="treatmentDig Liver Dis201547757758325936691 28.HaynesRBAcklooESahotaNMcDonaldHPYaoXInterventions for enhancing medication adherenceCochrane Database"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7204199\results\search\drugs\results.xml">
   <result pre="China) were heavily anesthetized by intraperitoneal injection (IP) of 100 mg/kg" exact="ketamine" post="hydrochloride, 20 mg/kg xylazine; for a 20 g mouse, inject 0.2 ml"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7204586\results\search\drugs\results.xml">
   <result pre="immunomodulatory agents for the treatment of COVID-19. Chloroquine (CQ) and" exact="hydroxychloroquine" post="(HCQ) have been used to treat malaria for 70"/>
   <result pre="in France who received HCQ alone or in combination with" exact="azithromycin" post="showed that, compared with untreated controls, HCQ reduced nasopharyngeal"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="Virol96: 3484–3492.26459826 4.De LamballerieXBoissonVReynierJCEnaultSCharrelRNFlahaultARoquesPLe GrandR, 2008On chikungunya acute infection and" exact="chloroquine" post="treatment. Vector Borne Zoonotic Dis8: 837–839.18620511 5.PatonNILeeLXuYOoiEECheungYBArchuletaSWongGWilder-SmithA, 2011Chloroquine for"/>
   <result pre="1. Clin Ther17: 622–636.8565026 7.TricouVMinhNNVanTPLeeSJFarrarJWillsBTranHTSimmonsCP, 2010A randomized controlled trial of" exact="chloroquine" post="for the treatment of dengue in Vietnamese adults. PLoS"/>
   <result pre="Vietnamese adults. PLoS Negl Trop Dis4: e785.20706626 8.GautretPet al.2020Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="non-randomized clinical trial. Int J Antimicrob Agents. 10.1016/j.ijantimicag.2020.105949. 9.GaoJTianZYangX, 2020Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7204663\results\search\drugs\results.xml">
   <result pre="pmcid: 7204663S0924-8579(20)30165-5 doi: 10.1016/j.ijantimicag.2020.106007106007 : Article Excessive lysosomal ion-trapping of" exact="hydroxychloroquine" post="and azithromycin DerendorfHartmuthartmut@ufl.edu[], pmc-release: 2020-5-5ppub: 2020-6epub: 2020-5-5556106007106007received: 2020-3-22accepted: 2020-4-28(C)"/>
   <result pre="doi: 10.1016/j.ijantimicag.2020.106007106007 : Article Excessive lysosomal ion-trapping of hydroxychloroquine and" exact="azithromycin" post="DerendorfHartmuthartmut@ufl.edu[], pmc-release: 2020-5-5ppub: 2020-6epub: 2020-5-5556106007106007received: 2020-3-22accepted: 2020-4-28(C) Elsevier Ltd,"/>
   <result pre="of viral load in COVID-19 patients given a combination of" exact="hydroxychloroquine" post="and azithromycin. The present communication discusses some common pharmacokinetic"/>
   <result pre="action for these antiviral effects. The physicochemical properties of both" exact="hydroxychloroquine" post="and azithromycin are consistent with particularly high affinity for"/>
   <result pre="these antiviral effects. The physicochemical properties of both hydroxychloroquine and" exact="azithromycin" post="are consistent with particularly high affinity for the intracellular"/>
   <result pre="highest of all drugs currently in use. The combination of" exact="hydroxychloroquine" post="and azithromycin produces very high local concentrations in lysosomes."/>
   <result pre="all drugs currently in use. The combination of hydroxychloroquine and" exact="azithromycin" post="produces very high local concentrations in lysosomes. The clinical"/>
   <result pre="of viral load in COVID-19 patients given a combination of" exact="hydroxychloroquine" post="and azithromycin [1,2]. However, other clinical studies could not"/>
   <result pre="load in COVID-19 patients given a combination of hydroxychloroquine and" exact="azithromycin" post="[1,2]. However, other clinical studies could not confirm these"/>
   <result pre="1 Chemical structures Fig. 1 shows the chemical structures of" exact="hydroxychloroquine" post="and azithromycin. Although the two compounds are from two"/>
   <result pre="are protonated under physiological conditions. Fig. 1 Chemical structures of" exact="hydroxychloroquine" post="and azithromycin. The circles indicate the pH-sensitive basic nitrogens."/>
   <result pre="lysosomes. This is confirmed by the known pharmacokinetic parameters for" exact="hydroxychloroquine" post="derived from plasma concentrations. After intravenous administration to healthy"/>
   <result pre="volunteers (average weight 63.5 kg), the volume of distribution of" exact="hydroxychloroquine" post="was reported to be over 44 000 L, which"/>
   <result pre="40 days) reported in the same study. In this study," exact="hydroxychloroquine" post="could still be detected in blood more than 6"/>
   <result pre="acidic phospholipids [10], [11], [12], [13]. A clinical study supports" exact="azithromycin" post="lysosomal accumulation [14]. In this study, the experimentally measured"/>
   <result pre="accumulation [14]. In this study, the experimentally measured average total" exact="azithromycin" post="concentrations in polymorphonuclear white blood cells (PMLs) was over"/>
   <result pre="(PMLs) was over 14 000 ng/mL. However, the model-predicted unionized" exact="azithromycin" post="concentration of 6.0 ng/mL in the cytosol of PMLs"/>
   <result pre="cellular concentrations. Just as for hydroxychloroquine, the pharmacokinetic parameters of" exact="azithromycin" post="confirm these extreme distribution properties. The volume of distribution"/>
   <result pre="confirm these extreme distribution properties. The volume of distribution of" exact="azithromycin" post="was reported to be 31 L/kg and the half-life"/>
   <result pre="rapid clearance of 630 mL/min [18]. Furthermore, the pharmacokinetics of" exact="azithromycin" post="have been shown to be affected by the disease"/>
   <result pre="affected by the disease state [19]. In a preclinical investigation," exact="azithromycin" post="was injected into rats and interstitial concentrations were measured"/>
   <result pre="The results can be explained by macrophages loaded with lysosomal" exact="azithromycin" post="migrating to and releasing drug at the infection site."/>
   <result pre="the present paper is focused on the pharmacokinetic properties of" exact="hydroxychloroquine" post="and azithromycin, a similar intracellular accumulation in the lysosomal"/>
   <result pre="lysosomal space can be expected and has been reported for" exact="chloroquine" post="as early as 1974 [20,21]. The pharmacokinetics of chloroquine"/>
   <result pre="for chloroquine as early as 1974 [20,21]. The pharmacokinetics of" exact="chloroquine" post="and hydroxychloroquine have been described to be similar [9]."/>
   <result pre="as early as 1974 [20,21]. The pharmacokinetics of chloroquine and" exact="hydroxychloroquine" post="have been described to be similar [9]. The very"/>
   <result pre="pumps that function to maintain low pH. The combination of" exact="chloroquine" post="and azithromycin is not new, and synergistic effect against"/>
   <result pre="function to maintain low pH. The combination of chloroquine and" exact="azithromycin" post="is not new, and synergistic effect against malaria has"/>
   <result pre="synergistic effect against malaria has been reported [23,24]. Hydroxychloroquine and" exact="chloroquine" post="have similar efficacy against malaria. Although hydroxychloroquine has a"/>
   <result pre="[23,24]. Hydroxychloroquine and chloroquine have similar efficacy against malaria. Although" exact="hydroxychloroquine" post="has a preferred safety profile, more pharmacodynamic information is"/>
   <result pre="a preferred safety profile, more pharmacodynamic information is available for" exact="chloroquine" post="[25], [26], [27]. Several studies point to mechanisms for"/>
   <result pre="studies point to mechanisms for the potential antiviral action of" exact="chloroquine" post="and azithromycin. Chloroquine was shown to impair early stages"/>
   <result pre="several different viruses [28]. Due to the alkalization of endosomes," exact="chloroquine" post="was an effective in vitro treatment against Chikungunya virus"/>
   <result pre="major target site to tackle SARS-CoV-2 [30]. Macrolides such as" exact="azithromycin" post="are very commonly used antibacterial agents; however, they have"/>
   <result pre="with other arrhythmogenic drugs [4]. Most relevant interaction data with" exact="azithromycin" post="is available for chloroquine. QTc interval prolongation was studied"/>
   <result pre="placebo-controlled parallel trial in 116 healthy subjects who received either" exact="chloroquine" post="(1000 mg) alone or in combination with oral azithromycin"/>
   <result pre="either chloroquine (1000 mg) alone or in combination with oral" exact="azithromycin" post="(500 mg, 1000 mg, and 1500 mg once daily)"/>
   <result pre="1000 mg, and 1500 mg once daily) [18]. Co-administration of" exact="azithromycin" post="increased the QTc interval in a dose- and concentration-dependent"/>
   <result pre="QTc interval in a dose- and concentration-dependent manner. Compared with" exact="chloroquine" post="alone, the maximum mean (95% upper confidence bound) increases"/>
   <result pre="increase cardiac instability [34]. In a clinical interaction study between" exact="azithromycin" post="and chloroquine, no clinically relevant pharmacokinetic changes were observed"/>
   <result pre="were noted. Although mean increases were numerically greater for the" exact="azithromycin" post="plus chloroquine group compared with the chloroquine alone group,"/>
   <result pre="Although mean increases were numerically greater for the azithromycin plus" exact="chloroquine" post="group compared with the chloroquine alone group, these differences"/>
   <result pre="greater for the azithromycin plus chloroquine group compared with the" exact="chloroquine" post="alone group, these differences were not statistically significant. Administered"/>
   <result pre="these differences were not statistically significant. Administered alone and together," exact="chloroquine" post="and azithromycin were well tolerated overall in this study."/>
   <result pre="were not statistically significant. Administered alone and together, chloroquine and" exact="azithromycin" post="were well tolerated overall in this study. More investigations"/>
   <result pre="were well tolerated overall in this study. More investigations with" exact="hydroxychloroquine" post="are needed as well as finetuning the optimum dosing"/>
   <result pre="list of pharmacokinetic properties of the most commonly used drugs," exact="chloroquine" post="and azithromycin have the largest volumes of distribution (hydroxychloroquine"/>
   <result pre="pharmacokinetic properties of the most commonly used drugs, chloroquine and" exact="azithromycin" post="have the largest volumes of distribution (hydroxychloroquine is not"/>
   <result pre="of distribution (hydroxychloroquine is not listed) [36]. Short-term use of" exact="hydroxychloroquine" post="with azithromycin may have clinical impact early in the"/>
   <result pre="(hydroxychloroquine is not listed) [36]. Short-term use of hydroxychloroquine with" exact="azithromycin" post="may have clinical impact early in the progress of"/>
   <result pre="ongoing and will provide solid guidance. References References 1GautretPLagierJCParolaPHoangVTMeddebLMailheMHydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="Mar 2010594910.1016/j.ijantimicag.2020.105949 2GautretPLagierJCParolaPHoangVTMeddebLSevestreJClinical and microbiological effect of a combination of" exact="hydroxychloroquine" post="and azithromycin in 80 COVID-19 patients with at least"/>
   <result pre="2GautretPLagierJCParolaPHoangVTMeddebLSevestreJClinical and microbiological effect of a combination of hydroxychloroquine and" exact="azithromycin" post="in 80 COVID-19 patients with at least a six-day"/>
   <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infectionMed Mal"/>
   <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infectionMed Mal Infect2020 Mar"/>
   <result pre="infectionMed Mal Infect2020 Mar 3010.1016/j.medmal.2020.03.006pii: S0399-077X(20)30085-8 4JuurlinkDN.Safety considerations with chloroquine," exact="hydroxychloroquine" post="and azithromycin in the management of SARS-CoV-2 infectionCMAJ2020 Apr"/>
   <result pre="Infect2020 Mar 3010.1016/j.medmal.2020.03.006pii: S0399-077X(20)30085-8 4JuurlinkDN.Safety considerations with chloroquine, hydroxychloroquine and" exact="azithromycin" post="in the management of SARS-CoV-2 infectionCMAJ2020 Apr 810.1503/cmaj.200528pii: cmaj.200528"/>
   <result pre="studies with macrophages and polymorphonuclear neutrophilsAntimicrob Agents Chemother54620102540254820385873 6SchroederRLGerberJPChloroquine and" exact="hydroxychloroquine" post="binding to melanin: Some possible consequences for pathologiesToxicol Rep1201496396828962308"/>
   <result pre="volunteersBr J Clin Pharmacol26319883033133179169 10CarlierMBGarcia-LuqueIMontenezJPTulkensPMPiretJAccumulation, release and subcellular localization of" exact="azithromycin" post="in phagocytic and non-phagocytic cells in cultureInt J Tissue"/>
   <result pre="cultured fibroblastsEur J Cell Biol807200146647811499789 13Van BambekeFMontenezJPPiretJTulkensPMCourtoyPJMingeot-LeclerqMPInteraction of the macrolide" exact="azithromycin" post="with phospholipids. I. Inhibition of lysosomal phospholipase A1 activityEur"/>
   <result pre="of a population pharmacokinetic model characterizing the tissue distribution of" exact="azithromycin" post="in healthy subjectsAntimicrob Agents Chemother581120146675668425155592 15Aubert-TulkensGVan HoofFTulkensPGentamicin-induced lysosomal phospholipidosis"/>
   <result pre="Sci77319881961993373422 21WiboMPooleB.Protein degradation in cultured cells. II. The uptake of" exact="chloroquine" post="by rat fibroblasts and the inhibition of cellular protein"/>
   <result pre="peritoneal macrophagesJ Cell Biol90319816656696169733 23CookJARandinitisEJBramsonCRWescheDLLack of a pharmacokinetic interaction between" exact="azithromycin" post="and chloroquineAm J Trop Med Hyg743200640741216525098 24OhrtCWillingmyreGDLeePKnirschCMihousWAssessment of azithromycin"/>
   <result pre="between azithromycin and chloroquineAm J Trop Med Hyg743200640741216525098 24OhrtCWillingmyreGDLeePKnirschCMihousWAssessment of" exact="azithromycin" post="in combination with other antimalarial drugs against Plasmodium falciparum"/>
   <result pre="drugs against Plasmodium falciparum in vitroAntimicrob Agents Chemother46820022518252412121927 25ColsonPRolainJMLagierJCBrouquiPRaoultDChloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int J Antimicrob Agents5542020105932"/>
   <result pre="the 2019 novel coronavirus SARS-CoV-2Int J Antimicrob Agents5532020105923 27RolainJMColsonPRaoultDRecycling of" exact="chloroquine" post="and its hydroxyl analogue to face bacterial, fungal and"/>
   <result pre="P, Raoult D. New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int J Antimicrob"/>
   <result pre="for cell-cell and virus-cell fusionVirology4132201126527421435673 31KakeyaHSekiMIzumikawaKKosaiKMorinagaYKuriharaSEfficacy of combination therapy with" exact="oseltamivir" post="phosphate and azithromycin for influenza: a multicenter, open-label, randomized"/>
   <result pre="virus-cell fusionVirology4132201126527421435673 31KakeyaHSekiMIzumikawaKKosaiKMorinagaYKuriharaSEfficacy of combination therapy with oseltamivir phosphate and" exact="azithromycin" post="for influenza: a multicenter, open-label, randomized studyPLoS One932014e9129324632748 32MinJYJangYJ.Macrolide"/>
   <result pre="One932014e9129324632748 32MinJYJangYJ.Macrolide therapy in respiratory viral infectionsMediators Inflamm20122012649570 33collab: ConcordiaPLAQUENIL®" exact="hydroxychloroquine" post="sulfate tabletsProduct Information2015Available from:https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009768s037s045s047lbl.pdf 34FossaAAWisialowskiTDuncanJNDengSDunneMAzithromycin/chloroquine combination does not increase"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of Severe Acute Respiratory Syndrome Coronavirus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7204669\results\search\drugs\results.xml">
   <result pre="IFNbeta revealed superior antiviral activity, compared to the effect of" exact="lopinavir" post="and ritonavir [20]. Treatment of these patients with oral"/>
   <result pre="superior antiviral activity, compared to the effect of lopinavir and" exact="ritonavir" post="[20]. Treatment of these patients with oral ribavirin and"/>
   <result pre="lopinavir and ritonavir [20]. Treatment of these patients with oral" exact="ribavirin" post="and subcutaneous pegylated IFN alpha-2a demonstrated significant improvement in"/>
   <result pre="treatment [17,23]. In patients with MERS infection, a combination of" exact="ritonavir" post="plus IFN α2a or IFN α-2b resulted in significantly"/>
   <result pre="improved survival after 14 days of treatment. The combination of" exact="ritonavir" post="and IFNβhad no significant effect on clinical outcome in"/>
   <result pre="outcome in patients infected with MERS, but the combination of" exact="ribavirin" post="(1), ritonavir (2) and IFN α-2a inhibited viremia within"/>
   <result pre="patients infected with MERS, but the combination of ribavirin (1)," exact="ritonavir" post="(2) and IFN α-2a inhibited viremia within 48h of"/>
   <result pre="HIV, MERS-CoV and SARS-CoV-2 Protease inhibitor, inhibits 3CLpro [13] Lopinavir," exact="oseltamivir" post="and ritonavir SARS-CoV-2 Targetiviral protease [32] Lopinavir, ritonavir, and"/>
   <result pre="and SARS-CoV-2 Protease inhibitor, inhibits 3CLpro [13] Lopinavir, oseltamivir and" exact="ritonavir" post="SARS-CoV-2 Targetiviral protease [32] Lopinavir, ritonavir, and interferon beta"/>
   <result pre="and SARS coronavirus replicationEmerg. Infect. Dis.102200431731915030704 24FalzaranoD.WitE.RasmussenA.L.FeldmannF.FeldmannH.Treatment with interferon-α2b and" exact="ribavirin" post="improves outcome in MERS-CoV-infected rhesus macaquesNat. Med.191020131313131724013700 25LiC.C.WangX.J.WangH.R.Repurposing host-based"/>
   <result pre="reviewJAMA202010.1001/jama.2020.6019 32MuralidharanM.SakthivelR.VelmuruganD.GromihaM.M.Computational studies of drug repurposing and synergism of lopinavir," exact="oseltamivir" post="and ritonavir binding with SARS-CoV-2 Protease against COVID-19J. Biomol."/>
   <result pre="studies of drug repurposing and synergism of lopinavir, oseltamivir and" exact="ritonavir" post="binding with SARS-CoV-2 Protease against COVID-19J. Biomol. Struct. Dyn.202010.1080/07391102.2020.1752802"/>
   <result pre="with SARS-CoV-2 Protease against COVID-19J. Biomol. Struct. Dyn.202010.1080/07391102.2020.1752802 33GautretP.LagierJ.C.ParolaP.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7204753\results\search\drugs\results.xml">
   <result pre="the world, causing thousand of deaths. Several drugs such as" exact="chloroquine" post="or remdesivir are currently undergoing clinical studies to test"/>
   <result pre="of them are members of coronavide family. Hong-Jie reported that" exact="lithium" post="inhibited in vitro the entry and replication of the"/>
   <result pre="cells was suppressed in a dose-dependent manner by lithium. Moreover" exact="lithium" post="inhibited early and late apoptosis induced by PEDV. Sally"/>
   <result pre="induced by PEDV. Sally M Harrison reported the effectiveness of" exact="lithium" post="inhibiting in two model of cell types, the coronavirus"/>
   <result pre="this drug, and in the case of favorable results, considerer" exact="lithium" post="as a possible treatment for new outbreak. Declaration of"/>
   <result pre="work reported in this paper. References References 1Hong-JieAntiviral effect of" exact="lithium" post="chloride on porcine epidemic diarrhoea virus in vitroRes Vet"/>
   <result pre="Pathol2007 3LiJingComparative analysis of the effect of glycyrrhizin diammonium and" exact="lithium" post="chloride on infectious bronchitis virus infectionAvian Pathol2009 Appendix A"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7205603\results\search\drugs\results.xml">
   <result pre="• Anti-TNFα Anti gout Colchicine • Tubulin disruption Antibiotics Azithromycin," exact="clarithromycin" post="• Protease inhibitors (?) Reduce organ failure Losartan •"/>
   <result pre="and favipiravir plus baloxavir marboxil (ChiCTR2000029544). Antiparasitic compounds Hydroxychloroquine and" exact="chloroquine" post="are oral prescription drugs that have been used for"/>
   <result pre="for the treatment of malaria and certain inflammatory conditions. Mainly" exact="hydroxychloroquine" post="is under investigation in clinical trials for pre-exposure or"/>
   <result pre="benefit–risk balance, without any choice of valid therapeutic options left," exact="chloroquine" post="and hydroxychloroquine could be applicable for the management of"/>
   <result pre="without any choice of valid therapeutic options left, chloroquine and" exact="hydroxychloroquine" post="could be applicable for the management of COVID-19 in"/>
   <result pre="3 clinical trial [49]. Macrolides such as erythromycin, clarithromycin, and" exact="azithromycin" post="not only have antibacterial activity but also have immunomodulatory"/>
   <result pre="considerable attention [50]. In an open-label, nonrandomized clinical trial using" exact="hydroxychloroquine" post="and azithromycin for COVID-19 treatment, all 6 patients receiving"/>
   <result pre="[50]. In an open-label, nonrandomized clinical trial using hydroxychloroquine and" exact="azithromycin" post="for COVID-19 treatment, all 6 patients receiving combination therapy"/>
   <result pre="cure. In comparison, only 57.1% of the patients treated with" exact="hydroxychloroquine" post="as a single drug and 12.5% in the control"/>
   <result pre="virological cure (P &amp;lt; 0.001). Furthermore, one patient, who was treated with" exact="hydroxychloroquine" post="as a single drug and still PCR-positive at day"/>
   <result pre="received azithromycin, resulting in virological cure. The authors propose that" exact="hydroxychloroquine" post="in combination with azithromycin treatment might be an efficient"/>
   <result pre="virological cure. The authors propose that hydroxychloroquine in combination with" exact="azithromycin" post="treatment might be an efficient antiviral therapy for COVID-19"/>
   <result pre="heme molecule of the globin. It has been speculated that" exact="hydroxychloroquine" post="and favipiravir work through inhibiting the attachment of the"/>
   <result pre="syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist" exact="tocilizumab" post="may be the key to reduce the mortality. Int"/>
   <result pre="Chen C, et al. Comparative effectiveness of combined favipiravir and" exact="oseltamivir" post="therapy versus oseltamivir monotherapy in critically ill patients with"/>
   <result pre="al. Comparative effectiveness of combined favipiravir and oseltamivir therapy versus" exact="oseltamivir" post="monotherapy in critically ill patients with influenza virus infection."/>
   <result pre="Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="Antimicrob Agents. 2020;105949. 47.•Rana DR, Dulal S. Therapeutic application of" exact="chloroquine" post="and hydroxychloroquine in clinical trials for COVID-19: a systematic"/>
   <result pre="2020;105949. 47.•Rana DR, Dulal S. Therapeutic application of chloroquine and" exact="hydroxychloroquine" post="in clinical trials for COVID-19: a systematic review. medRxiv."/>
   <result pre="a systematic review of the first published clinical trials on" exact="hydroxychloroquine" post="for COVID-19 treatment. This article clearly describes what a"/>
   <result pre="JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitro. Antivir Res."/>
   <result pre="of the 2019-nCoV spike in the prefusion conformationScience.20203671260126310.1126/science.abb250732075877 58.Search of:" exact="losartan" post="| COVID - list results [Internet]. ClinicalTrials.gov. [cited 2020"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7205718\results\search\drugs\results.xml">
   <result pre="as the COVID-19 resource centre remains active. Highlights •Luteolin and" exact="chloroquine" post="bind to the main protease of SARS-CoV-2 •The binding"/>
   <result pre="sites of new coronavirus. Ribavirin, a common antiviral drug, remdesivir," exact="chloroquine" post="and luteolin were studied. Honeysuckle is generally believed to"/>
   <result pre="potential antiviral molecule worthy of attention. Keywords 2019-nCoV AutoDock Vina" exact="chloroquine" post="remdesivir ribavirin luteolin Editor: Jean-Marc Rolain 1 Introduction The"/>
   <result pre="molecule worthy of attention. Keywords 2019-nCoV AutoDock Vina chloroquine remdesivir" exact="ribavirin" post="luteolin Editor: Jean-Marc Rolain 1 Introduction The novel coronavirus,"/>
   <result pre="in the biosynthesis of sialic acids. The possible interference by" exact="chloroquine" post="of sialic acid biosynthesis could account for the broad"/>
   <result pre="of viral proteins. However, the mechanism of antiviral action of" exact="chloroquine" post="against 2019-nCoV is not clear. Ribavirin is a traditional"/>
   <result pre="outbreak [34]. In this study, the binding of chloroquine, remdesivir," exact="ribavirin" post="and luteolin with the main proteins of 2019-nCoV (3CLpro,"/>
   <result pre="molecular dynamics simulation has not been carried out. Remdesivir and" exact="ribavirin" post="are RdRp antagonists. Remdesivir may be effective against the"/>
   <result pre="antagonists. Remdesivir may be effective against the new coronavirus; however," exact="ribavirin" post="is invalid. Molecular docking was used to study the"/>
   <result pre="VAL-3 and ASN-142. There is a hydrogen bond interaction between" exact="chloroquine" post="and GLN-110 at the binding site, hydrophobic reactions with"/>
   <result pre="ASN-180, ARG-105 and PHE-185 in the sites. The interactions between" exact="ribavirin" post="and ASP-38 were hydrogen bonds. The binding sites of"/>
   <result pre="ASP-38 were hydrogen bonds. The binding sites of luteolin and" exact="ribavirin" post="are inconsistent with those of the control molecule. 3.3"/>
   <result pre="with LEU-329 and PRO-328. The binding sites of luteolin and" exact="ribavirin" post="are inconsistent with those of remdesivir; however, the binding"/>
   <result pre="inconsistent with those of remdesivir; however, the binding sites of" exact="ribavirin" post="and luteolin are close, indicating another active site. 3.4"/>
   <result pre="of COVID-19 associated pneumonia in clinical studiesBioSci Trends142020727332074550 18GautretPLagierJ-CParolaPHoangVTMeddebLMailheMHydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="J Antimicrob Agents2020105949 19DevauxCARolainJ-MColsonPRaoultDNew insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int J Antimicrob"/>
   <result pre="coronavirus SARS-CoV-2Int J Antimicrob Agents552020105923 22RibavirinElfiky AA.remdesivir, sofosbuvir, galidesivir, and" exact="tenofovir" post="against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7205730\results\search\drugs\results.xml">
   <result pre="as the COVID-19 resource centre remains active. Chloroquine (CQ) and" exact="hydroxychloroquine" post="(HCQ) are generic antiviral agents that have shown effectiveness"/>
   <result pre="to those of controls and dropped to nearly zero if" exact="azithromycin" post="was added. The HCQ dosage of 600 mg/day is"/>
   <result pre="coronavirus. References References 1DevauxC.A.RolainJ.-M.ColsonP.RaoultD.New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int J Antimicrob"/>
   <result pre="coronavirus: what to expect for COVID-19?Int J Antimicrob Agents202010.1016/j.ijantimicag.2020.105938 2GaoJ.ZhenxueT.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="repurposing on the fast trackNat Biotechnol38202037938132205870 4MarmorM.KellnerU.LaiT.Y.MellesR.B.MielerW.F.Recommendations on screening for" exact="chloroquine" post="and hydroxychloroquine retinopathy (2016 revision)Ophthalmology12320161386139426992838 5FurstD.E.LindsleyH.BaethgeB.Dose-loading with hydroxychloroquine improves"/>
   <result pre="the fast trackNat Biotechnol38202037938132205870 4MarmorM.KellnerU.LaiT.Y.MellesR.B.MielerW.F.Recommendations on screening for chloroquine and" exact="hydroxychloroquine" post="retinopathy (2016 revision)Ophthalmology12320161386139426992838 5FurstD.E.LindsleyH.BaethgeB.Dose-loading with hydroxychloroquine improves the rate"/>
   <result pre="screening for chloroquine and hydroxychloroquine retinopathy (2016 revision)Ophthalmology12320161386139426992838 5FurstD.E.LindsleyH.BaethgeB.Dose-loading with" exact="hydroxychloroquine" post="improves the rate of response in early, active rheumatoid"/>
   <result pre="7VoglD.T.StadtmauerE.A.TanK.S.Combined autophagy and proteasome inhibition: a phase 1 trial of" exact="hydroxychloroquine" post="and bortezomib in patients with relapsed/refractory myelomaAutophagy1020141380139024991834 8RangwalaR.ChangY.C.HuJ.Combined MTOR"/>
   <result pre="and proteasome inhibition: a phase 1 trial of hydroxychloroquine and" exact="bortezomib" post="in patients with relapsed/refractory myelomaAutophagy1020141380139024991834 8RangwalaR.ChangY.C.HuJ.Combined MTOR and autophagy"/>
   <result pre="myelomaAutophagy1020141380139024991834 8RangwalaR.ChangY.C.HuJ.Combined MTOR and autophagy inhibition: phase I trial of" exact="hydroxychloroquine" post="and temsirolimus in patients with advanced solid tumors and"/>
   <result pre="MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and" exact="temsirolimus" post="in patients with advanced solid tumors and melanomaAutophagy1020141391140224991838 9LeungL.B.NealJ.W.WakeleeH.A.SequistL.V.MarmorM.F.Rapid"/>
   <result pre="tumors and melanomaAutophagy1020141391140224991838 9LeungL.B.NealJ.W.WakeleeH.A.SequistL.V.MarmorM.F.Rapid onset of retinal toxicity from high-dose" exact="hydroxychloroquine" post="given for cancer therapyAm J Ophthalmol160201579980526189086 10GautretP.LagierJ.-C.ParolaP.Hydroxychloroquine and azithromycin"/>
   <result pre="high-dose hydroxychloroquine given for cancer therapyAm J Ophthalmol160201579980526189086 10GautretP.LagierJ.-C.ParolaP.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="Agents202010.1016/j.tmaid.2020.101663 11MellesR.G.MarmorM.F.The risk of toxic retinopathy in patients on long-term" exact="hydroxychloroquine" post="therapyJAMA Ophthalmol13220141453146025275721"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7205908\results\search\drugs\results.xml">
   <result pre="known side effects, safety and dosing regimens.1 Although remdesivir and" exact="chloroquine" post="could effectively inhibit the replication of SARS-CoV-2 in vitro,2"/>
   <result pre="Rev. Drug Discov.10.1038/d41573-41020-00016-41570 (2020). 2.Wang, M. et al. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7207108\results\search\drugs\results.xml">
   <result pre="[73]. 10 Antimalarial drugs inhibit the SARS-CoV-2 infections Chloroquine and" exact="hydroxychloroquine" post="are the class of quinoline derivatives and widely used"/>
   <result pre="[76] and lupus erythematosus syndrome [77]. Chloroquine and its derivative" exact="hydroxychloroquine" post="inhibit the heme polymerase in malarial trophozoites, preventing the"/>
   <result pre="and exhibits antimalarial activity [78]. Whereas the antiviral activity of" exact="chloroquine" post="is exerted by diffusing into the host cells and"/>
   <result pre="target receptor for SARS-CoV and SARS-CoV-2 for viral fusion, however," exact="chloroquine" post="does not affect the ACE2 levels but downregulated the"/>
   <result pre="by Chloroquine [83]. The combination of Chloroquine or its derivative" exact="hydroxychloroquine" post="with drugs like Remdesivir or Azithromycin demonstrated to produce"/>
   <result pre="induced alterations in fetal brain [93]. Also, the combination of" exact="hydroxychloroquine" post="and azithromycin was found to be effective in SARS-CoV-2"/>
   <result pre="in fetal brain [93]. Also, the combination of hydroxychloroquine and" exact="azithromycin" post="was found to be effective in SARS-CoV-2 associated pneumonia,"/>
   <result pre="spike-ACE2 complex. Recently Pfizer has reported the necessary data of" exact="azithromycin" post="for SARS-CoV-2 clinical trials (NCT04321278) [95]. Another antibiotic and"/>
   <result pre="monoclonal antibodies are tried to treat SARS-CoV-2 infections such as" exact="bevacizumab" post="(NCT04305106), tocilizumab (NCT04317092), and meplazumab (NCT04275245) etc. Xiaolong Tian"/>
   <result pre="are tried to treat SARS-CoV-2 infections such as bevacizumab (NCT04305106)," exact="tocilizumab" post="(NCT04317092), and meplazumab (NCT04275245) etc. Xiaolong Tian et al."/>
   <result pre="SARS-CoV [206] 6. Glycyrrhizin (Liquorice roots; Glycyrrhiza glabra) Induces the" exact="nitric oxide" post="synthase and produces the nitrosative stress in macrophages and"/>
   <result pre="for one yearAnn. Rheum. Dis.1931960243250Sep13701598 77RainsfordK.D.ParkeA.L.Clifford-RashotteM.KeanW.F.Therapy and pharmacological properties of" exact="hydroxychloroquine" post="and chloroquine in treatment of systemic lupus erythematosus, rheumatoid"/>
   <result pre="yearAnn. Rheum. Dis.1931960243250Sep13701598 77RainsfordK.D.ParkeA.L.Clifford-RashotteM.KeanW.F.Therapy and pharmacological properties of hydroxychloroquine and" exact="chloroquine" post="in treatment of systemic lupus erythematosus, rheumatoid arthritis and"/>
   <result pre="target to toolBiochimica et Biophysica Acta (BBA)-General Subjects18406201420322041Jun24556123 79WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="coronavirus infection and spreadVirol. J.21200569Dec 116115318 83HuT.Y.FriemanM.WolframJ.Insights from nanomedicine into" exact="chloroquine" post="efficacy against COVID-19Nat. Nanotechnol.23202013Mar 84BragaC.B.MartinsA.C.CayotopaA.D.KleinW.W.SchlosserA.R.da SilvaA.F.de SouzaM.N.AndradeB.W.Filgueira-JúniorJ.A.PintoW.da Silva-NunesM.Side effects"/>
   <result pre="efficacy against COVID-19Nat. Nanotechnol.23202013Mar 84BragaC.B.MartinsA.C.CayotopaA.D.KleinW.W.SchlosserA.R.da SilvaA.F.de SouzaM.N.AndradeB.W.Filgueira-JúniorJ.A.PintoW.da Silva-NunesM.Side effects of" exact="chloroquine" post="and primaquine and symptom reduction in malaria endemic area"/>
   <result pre="COVID-19Nat. Nanotechnol.23202013Mar 84BragaC.B.MartinsA.C.CayotopaA.D.KleinW.W.SchlosserA.R.da SilvaA.F.de SouzaM.N.AndradeB.W.Filgueira-JúniorJ.A.PintoW.da Silva-NunesM.Side effects of chloroquine and" exact="primaquine" post="and symptom reduction in malaria endemic area (Mâncio Lima,"/>
   <result pre="Brazil)Interdisciplinary Perspectives on Infectious Diseases2015201534685326357512 85KhobragadeS.B.GuptaP.GuravP.ChaudhariG.GatneM.M.ShingatgeriV.M.Assessment of proarrhythmic activity of" exact="chloroquine" post="in in vivo and ex vivo rabbit modelsJ. Pharmacol."/>
   <result pre="vivo and ex vivo rabbit modelsJ. Pharmacol. Pharmacother.422013116Apr23759957 86KaziM.S.SaurabhK.RishiP.RishiE.Delayed onset" exact="chloroquine" post="retinopathy presenting 10 years after long-term usage of chloroquineMiddle"/>
   <result pre="of chloroquineMiddle East African Journal of Ophthalmology2012013899123580861 87LiuA.C.Hepatotoxic reaction to" exact="chloroquine" post="phosphate in a patient with previously unrecognized porphyria cutanea"/>
   <result pre="with previously unrecognized porphyria cutanea tardaWest. J. Med.16261995548551Jun7618323 88SinghA.K.SinghA.ShaikhA.SinghR.MisraA.Chloroquine and" exact="hydroxychloroquine" post="in the treatment of COVID-19 with or without diabetes:"/>
   <result pre="Syndrome: Clinical Research &amp;amp; Reviews1432020241246 89ChouS.MarousekG.AuerochsS.StammingerT.MilbradtJ.MarschallM.The unique antiviral activity of" exact="artesunate" post="is broadly effective against human cytomegaloviruses including therapy-resistant mutantsAntivir."/>
   <result pre="broadly effective against human cytomegaloviruses including therapy-resistant mutantsAntivir. Res.9222011364368Nov21843554 90Oiknine-DjianE.WeisblumY.PanetA.WongH.N.HaynesR.K.WolfD.G.The" exact="artemisinin" post="derivative artemisone is a potent inhibitor of human cytomegalovirus"/>
   <result pre="in human glial cellsAntimicrob. Agents Chemother.6192017Sep 1. (e01152-17) 94GautretP.LagierJ.C.ParolaP.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.HonoréS.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="trialInt. J. Antimicrob. Agents2020105949Mar 2032205204 95Pfizer reports safety data of" exact="azithromycin" post="in Covid-19 trialClinical Trials ArenaMarch 28 2020https://www.clinicaltrialsarena.com/news/pfizer-data-azithromycin-covid-19-trial 96RandhawaP.S.Anti-BK virus"/>
   <result pre="Covid-19 trialClinical Trials ArenaMarch 28 2020https://www.clinicaltrialsarena.com/news/pfizer-data-azithromycin-covid-19-trial 96RandhawaP.S.Anti-BK virus activity of" exact="ciprofloxacin" post="and related antibioticsClin. Infect. Dis.419200513661367Nov 116206122 97GopinathS.KimM.V.RakibT.WongP.W.van ZandtM.BarryN.A.Topical application"/>
   <result pre="Shi PY, Li H, Zhou J. Broad spectrum antiviral agent" exact="niclosamide" post="and its therapeutic potential. ACS Infectious Diseases. 2020 Mar"/>
   <result pre="DrugsbioRxiv. 2020 Mar 232020 102G CangaA.G.PrietoA.M.LiébanaM.J.MartínezN.F.VegaM.S.VieitezJ.J.The pharmacokinetics and interactions of" exact="ivermectin" post="in humans—a mini-reviewAAPS J.10120084246Mar 118446504 103CalyL.DruceJ.D.CattonM.G.JansD.A.WagstaffK.M.The FDA-approved drug ivermectin"/>
   <result pre="of ivermectin in humans—a mini-reviewAAPS J.10120084246Mar 118446504 103CalyL.DruceJ.D.CattonM.G.JansD.A.WagstaffK.M.The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntivir. Res.2020 Apr"/>
   <result pre="effective for COVID-19NEJM Journal WatchMar 24 2020https://www.jwatch.org/NA51172/2020/03/24/lopinavir-ritonavir-was-not-effective-covid-19 114RothanH.A.BahraniH.MohamedZ.TeohT.C.ShankarE.M.RahmanN.A.A combination of" exact="doxycycline" post="and ribavirin alleviated chikungunya infectionPLoS One1052015e0126360May 1325970853 115KorenG.KingS.KnowlesS.PhillipsE.Ribavirin in"/>
   <result pre="COVID-19NEJM Journal WatchMar 24 2020https://www.jwatch.org/NA51172/2020/03/24/lopinavir-ritonavir-was-not-effective-covid-19 114RothanH.A.BahraniH.MohamedZ.TeohT.C.ShankarE.M.RahmanN.A.A combination of doxycycline and" exact="ribavirin" post="alleviated chikungunya infectionPLoS One1052015e0126360May 1325970853 115KorenG.KingS.KnowlesS.PhillipsE.Ribavirin in the treatment"/>
   <result pre="suppressing neuroinflammation and oxidative stressInt. Immunopharmacol.652018438447Dec30388518 157SilvaM.R. daSchapochnikA.LealM.P.EstevesJ.HebedaC.B.SandriS.Beneficial effects of" exact="ascorbic acid" post="to treat lung fibrosis induced by paraquatPLoS One13112018e0205535Nov 530395570"/>
   <result pre="(SARS-CoV)J. Biol. Chem.29117201692189232Apr 2226953343 201MoshkowitzA.GoldblumN.HellerE.Studies on the antiviral effect of" exact="rifampicin" post="in volunteersNature22952841971422424Feb4323457 202WeberN.D.AndersenD.O.NorthJ.A.MurrayB.K.LawsonL.D.HughesB.G.In vitro virucidal effects of Allium sativum"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7207128\results\search\drugs\results.xml">
   <result pre="or Ebola frizzled drug) as well as promising malaria drugs" exact="chloroquine" post="and hydroxychloroquine. COVID-19 and haemophagocytic lymphohistiocytosis (HLH) The development"/>
   <result pre="aims at dampening the cytokine storm and is based on" exact="etoposide" post="and dexamethasone with intrathecal methotrexate in case of central"/>
   <result pre="dampening the cytokine storm and is based on etoposide and" exact="dexamethasone" post="with intrathecal methotrexate in case of central nervous system"/>
   <result pre="storm and is based on etoposide and dexamethasone with intrathecal" exact="methotrexate" post="in case of central nervous system involvement [14], [15]."/>
   <result pre="progressing with a non-neglectable mortality. The expected therapeutic mechanism of" exact="etoposide" post="Etoposide is a topoisomerase II inhibitor. It has been"/>
   <result pre="hamper antiviral response in human since the combined therapy with" exact="dexamethasone" post="increased the survival of patients with EBV associated HLH"/>
   <result pre="and severe sHLH is the use of the combination of" exact="etoposide" post="and dexamethasone for eight weeks. Age-adjusted doses of Etoposide"/>
   <result pre="sHLH is the use of the combination of etoposide and" exact="dexamethasone" post="for eight weeks. Age-adjusted doses of Etoposide are administered"/>
   <result pre="once a week with weekly decisions on whether to continue" exact="etoposide" post="treatment or not, following the clinical and laboratory response"/>
   <result pre="with 2009 influenza A (H1N1) infectionCrit Care152011R8021366922 14BergstenE.HorneA.AricoM.Confirmed efficacy of" exact="etoposide" post="and dexamethasone in HLH treatment: long-term results of the"/>
   <result pre="influenza A (H1N1) infectionCrit Care152011R8021366922 14BergstenE.HorneA.AricoM.Confirmed efficacy of etoposide and" exact="dexamethasone" post="in HLH treatment: long-term results of the cooperative HLH-2004"/>
   <result pre="report from the HLH study centerMed Pediatr Oncol41200310310912825212 18ImashukuS.KuriyamaK.TeramuraT.Requirement for" exact="etoposide" post="in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosisJ Clin"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7207983\results\search\drugs\results.xml">
   <result pre="72079834727 doi: 10.1007/s00417-020-04727-3 : Letter to the Editor Hydroxychloroquine and" exact="ritonavir" post="for COVID-19 infection: a possible synergic toxicity for retinal"/>
   <result pre="risks of combining drugs with established macular toxicity that are" exact="hydroxychloroquine" post="and ritonavir, as actually performed in our Lombardia region,"/>
   <result pre="of COVID-19 Italian break-out [2]. Chloroquine and his hydroxylated analog" exact="hydroxychloroquine" post="were initially used as antimalarial agents and then extended"/>
   <result pre="and then extended to rheumatic disorders [3]. Long-term toxicity of" exact="chloroquine" post="and hydroxychloroquine has been widely demonstrated, and recommended protocols"/>
   <result pre="extended to rheumatic disorders [3]. Long-term toxicity of chloroquine and" exact="hydroxychloroquine" post="has been widely demonstrated, and recommended protocols as the"/>
   <result pre="5]. Risk factors include a preexisting maculopathy, renal disease, and" exact="tamoxifen" post="use. Tamoxifen use increased the risk of toxicity by"/>
   <result pre="a bull’s eye pattern that resembles the one observed with" exact="hydroxychloroquine" post="[6]. Therefore, we alert for a possible synergic toxicity"/>
   <result pre="synergic toxicity for the retina, just like what happens with" exact="hydroxychloroquine" post="and tamoxifen and postulate the need for an ophthalmologic"/>
   <result pre="for the retina, just like what happens with hydroxychloroquine and" exact="tamoxifen" post="and postulate the need for an ophthalmologic follow-up program"/>
   <result pre="Italy. 1–15 3.Costedoat-ChalumeauNDunoguéBLerouxGet al.A critical review of the effects of" exact="hydroxychloroquine" post="and chloroquine on the eyeClin Rev Allergy Immunol20154931732610.1007/s12016-015-8469-825672591 4.MarmorMFKellnerULaiTYYet"/>
   <result pre="3.Costedoat-ChalumeauNDunoguéBLerouxGet al.A critical review of the effects of hydroxychloroquine and" exact="chloroquine" post="on the eyeClin Rev Allergy Immunol20154931732610.1007/s12016-015-8469-825672591 4.MarmorMFKellnerULaiTYYet al.Recommendations on"/>
   <result pre="the eyeClin Rev Allergy Immunol20154931732610.1007/s12016-015-8469-825672591 4.MarmorMFKellnerULaiTYYet al.Recommendations on screening for" exact="chloroquine" post="and hydroxychloroquine retinopathy (2016 revision)Ophthalmology20161231386139410.1016/j.ophtha.2016.01.05826992838 5.Pasaoglu Isil OFE (2019)"/>
   <result pre="Rev Allergy Immunol20154931732610.1007/s12016-015-8469-825672591 4.MarmorMFKellnerULaiTYYet al.Recommendations on screening for chloroquine and" exact="hydroxychloroquine" post="retinopathy (2016 revision)Ophthalmology20161231386139410.1016/j.ophtha.2016.01.05826992838 5.Pasaoglu Isil OFE (2019) Macular toxicity"/>
   <result pre="(2016 revision)Ophthalmology20161231386139410.1016/j.ophtha.2016.01.05826992838 5.Pasaoglu Isil OFE (2019) Macular toxicity after short-term" exact="hydroxychloroquine" post="therapy. Indian J Ophthalmol 6.LouieAKJonesHNCase report: retinal toxicity secondary"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7209974\results\search\drugs\results.xml">
   <result pre="Several mechanisms have been proposed to assume that CQ or" exact="hydroxychloroquine" post="(HCQ) may be effective against SARS-CoV-2 (Fig. 1) [1,"/>
   <result pre="assembly and viral protein synthesis. Fig. 1 Proposed mechanisms for" exact="chloroquine" post="and hydroxychloroquine effectiveness on SARS-CoV-2 infection. The mechanisms proposed"/>
   <result pre="viral protein synthesis. Fig. 1 Proposed mechanisms for chloroquine and" exact="hydroxychloroquine" post="effectiveness on SARS-CoV-2 infection. The mechanisms proposed as responsible"/>
   <result pre="infection. The mechanisms proposed as responsible for the effects of" exact="chloroquine" post="and hydroxychloroquine: (a) the drugs interfere with the terminal"/>
   <result pre="effect seemed more evident in the six patients who received" exact="azithromycin" post="in addition to HCQ. The small number of participants"/>
   <result pre="an &quot;old drug�? (as the recent case of the anti-parasitic" exact="ivermectin" post="[15]), drawing huge media attention and incentivizing early publication"/>
   <result pre="the authors declare no competing interests. References References 1.SavarinoABoelaertJRCassoneAMajoriGCaudaREffects of" exact="chloroquine" post="on viral infections: an old drug against today’s diseases?Lancet"/>
   <result pre="S. A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19. J Crit Care. 2020."/>
   <result pre="immune responses. Cell Death Differ. 2020. 10.1038/s41418-020-0530-3. 4.WangMCaoRZhangLYangXLiuJXuMet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="Hoang VT, Meddeb L, Giordanengo V, et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="trial. Int J Antimicrob Agents. 2020. 10.1016/j.ijantimicag.2020.105949. 8.ISAC. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7211497\results\search\drugs\results.xml">
   <result pre="that examined the effect of a triple combination regimen of" exact="interferon beta-1b" post="8 million international units (0·25 mg) on alternate days,"/>
   <result pre="beta-1b 8 million international units (0·25 mg) on alternate days," exact="lopinavir" post="400 mg plus ritonavir 100 mg every 12 h,"/>
   <result pre="units (0·25 mg) on alternate days, lopinavir 400 mg plus" exact="ritonavir" post="100 mg every 12 h, and ribavirin 400 mg"/>
   <result pre="400 mg plus ritonavir 100 mg every 12 h, and" exact="ribavirin" post="400 mg every 12 h, compared with lopinavir 400"/>
   <result pre="h, and ribavirin 400 mg every 12 h, compared with" exact="lopinavir" post="400 mg plus ritonavir 100 mg every 12 h"/>
   <result pre="mg every 12 h, compared with lopinavir 400 mg plus" exact="ritonavir" post="100 mg every 12 h alone. The investigators enrolled"/>
   <result pre="symptom onset (52 patients in the combination group, who received" exact="interferon beta-1b," post="vs 24 in the control group) but not in"/>
   <result pre="Additionally, despite the relatively small number of patients in the" exact="interferon beta-1b" post="subgroup, significant differences in outcomes were demonstrated. Therefore, this"/>
   <result pre="therefore ideal. Additionally, earlier enrolment to standardise the number of" exact="interferon beta-1b" post="doses is important but might be impractical, particularly because"/>
   <result pre="the authors acknowledge, future studies to examine the efficacy of" exact="interferon beta-1b" post="alone or in combination with other drugs to treat"/>
   <result pre="type I interferon pretreatmentbioRxiv2020published online March 9.10.1101/2020.03.07.982264(preprint). 9HungIF-NLungK-CTsoEY-KTriple combination of" exact="interferon beta-1b," post="lopinavir–ritonavir, and ribavirin in the treatment of patients admitted"/>
   <result pre="online March 9.10.1101/2020.03.07.982264(preprint). 9HungIF-NLungK-CTsoEY-KTriple combination of interferon beta-1b, lopinavir–ritonavir, and" exact="ribavirin" post="in the treatment of patients admitted to hospital with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7211506\results\search\drugs\results.xml">
   <result pre="viral replication stage. Moreover, its combination with the acyclovir and" exact="ganciclovir" post="proved to be effective with the reduction of effective"/>
   <result pre="restricts its export. Moreover, the synergistic effects of dendrobine and" exact="zanamivir" post="(a medication used to treat and prevent influenza) were"/>
   <result pre="interferon-α (IFN-α), an HCV NS5B polymerase inhibitor (2’-C-methylcytidine; NM-107), or" exact="telaprevir" post="(an HCV NS3/4A protease inhibitor) reduced the viral infection"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7211516\results\search\drugs\results.xml">
   <result pre="justify the empirical use of HIV protease inhibitors, such as" exact="lopinavir" post="and ritonavir, that proved effective in some COVID-19 patients.21"/>
   <result pre="(25 g/day for 5 days) combined with antivirals (lopinavir/ritonavir) and" exact="methylprednisolone" post="in severe COVID-19 in Wuhan, China demonstrated elevation of"/>
   <result pre="gp120 and GagUpdated 2020Accessed May 1, 2020https://www.biorxiv.org/content/10.1101/2020.01.30.927871v110.1101/2020.01.30.927871 21NuthoBMahalapbutrPHengphasatpornKPattaranggoonNCSimanonNShigetaYet al.Why are" exact="lopinavir" post="and ritonavir effective against the newly emerged coronavirus 2019?:"/>
   <result pre="GagUpdated 2020Accessed May 1, 2020https://www.biorxiv.org/content/10.1101/2020.01.30.927871v110.1101/2020.01.30.927871 21NuthoBMahalapbutrPHengphasatpornKPattaranggoonNCSimanonNShigetaYet al.Why are lopinavir and" exact="ritonavir" post="effective against the newly emerged coronavirus 2019?: atomistic insights"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7211565\results\search\drugs\results.xml">
   <result pre="pandemic, the world is facing a public health emergency. Repositioning" exact="hydroxychloroquine" post="(HQ) seems to be a promising option. Many emerging"/>
   <result pre="Recently, India has adopted an anti-viral prophylaxis protocol based on" exact="hydroxychloroquine" post="for health professionals [23]. These recommendations are empiric and"/>
   <result pre="participants, called PrEP Covid, to access both of HQ and" exact="azithromycine" post="in Covid-19 prophylaxis, the trial will access a 200"/>
   <result pre="research in the post-genomic eraNature455200875175618843360 2ParhizgarA.R.TahghighiA.Introducing new antimalarial analogues of" exact="chloroquine" post="and amodiaquine: a narrative reviewIran J Med Sci42201711512828360437 3ColsonP.RolainJ.M.LagierJ.C.BrouquiP.RaoultD.Chloroquine"/>
   <result pre="and amodiaquine: a narrative reviewIran J Med Sci42201711512828360437 3ColsonP.RolainJ.M.LagierJ.C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int J Antimicrob Agents202010.1016/j.ijantimicag.2020.105932[published"/>
   <result pre="J Antimicrob Agents55202010592332070753 5DevauxC.A.RolainJ.M.ColsonP.RaoultD.New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int J Antimicrob"/>
   <result pre="for COVID-19?Int J Antimicrob Agents202010.1016/j.ijantimicag.2020.105938[published online 11 March] 6WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="the recently emerged novel coronavirus (2019-nCoV) in vitroCell Res30202026927132020029 7GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="of Guangdong Province and Health Commission of Guangdong Province for" exact="chloroquine" post="in the treatment of novel coronavirus pneumonia. Expert consensus"/>
   <result pre="in the treatment of novel coronavirus pneumonia. Expert consensus on" exact="chloroquine" post="phosphate for the treatment of novel coronavirus pneumonia [in"/>
   <result pre="Chinese]Zhonghua Jie He He Hu Xi Za Zhi43202018518832164085 9GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="https://www.ft.com/content/9418125e-6839-11ea-800d-da70cff6e4d3 [Updated 23 March 2020]. 21Chang R, Sun W. Repositioning" exact="chloroquine" post="as ideal antiviral prophylactic against COVID-19 – time is"/>
   <result pre="erythematosus: a systematic reviewAnn Rheum Dis692010202819103632 27MarmorM.F.KellnerU.LaiT.Y.MellesR.B.MielerW.F.Recommendations on screening for" exact="chloroquine" post="and hydroxychloroquine retinopathy (2016 revision)Ophthalmology12320161386139426992838 ☆Comment on: Gautret et"/>
   <result pre="systematic reviewAnn Rheum Dis692010202819103632 27MarmorM.F.KellnerU.LaiT.Y.MellesR.B.MielerW.F.Recommendations on screening for chloroquine and" exact="hydroxychloroquine" post="retinopathy (2016 revision)Ophthalmology12320161386139426992838 ☆Comment on: Gautret et al. (2020)."/>
   <result pre="(2016 revision)Ophthalmology12320161386139426992838 ☆Comment on: Gautret et al. (2020). Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7211657\results\search\drugs\results.xml">
   <result pre="COVID-19, have tried their hands on the age-old antimalarial drug," exact="chloroquine" post="in the treatment of COVID-19 [4]. Recently, the doctors"/>
   <result pre="using the already available drugs like lopinavir, ritonavir, oseltamivir, and" exact="chloroquine" post="would be the best choice. On 13th March 2020,"/>
   <result pre="has released a protocol for public health emergency which includes" exact="lopinavir" post="and ritonavir [6]. They have given a set of"/>
   <result pre="a protocol for public health emergency which includes lopinavir and" exact="ritonavir" post="[6]. They have given a set of inclusion criteria"/>
   <result pre="scientific evidence. The antiviral properties of ritonavir, lopinavir, oseltamivir, and" exact="chloroquine" post="are already known with scientific evidences. The antiviral properties"/>
   <result pre="and in vivo studies have shown various mechanisms by which" exact="chloroquine" post="exerts antiviral activity on various viruses like the Zika"/>
   <result pre="Keyaerts et al. in 2004 (7), it was observed that" exact="chloroquine" post="inhibits the replication of SARS-CoV in Vero E6 cells."/>
   <result pre="Waals and electrostatic properties. Vincent et al. [13] stresses that" exact="chloroquine" post="can even be considered as prophylaxis for people traveling"/>
   <result pre="affected area due to the easy availability and cost-effectiveness of" exact="chloroquine" post="and may be considered to treat and prevent coronavirus"/>
   <result pre="and prevent coronavirus infection. In addition to the anti-viral activity," exact="chloroquine" post="also possesses an anti-inflammatory property which can be used"/>
   <result pre="and other parts of world to prove the efficacy of" exact="chloroquine" post="in the treatment of COVID-19 [15]. A recent study"/>
   <result pre="non-randomized study conducted by Gautret et al., a combination of" exact="hydroxychloroquine" post="and Azithromycin has caused a significant reduction or disappearance"/>
   <result pre="prospective study from china with 30 patients randomly allocated to" exact="hydroxychloroquine" post="with 400 mg daily for 5 days in addition"/>
   <result pre="statistical difference in virologic clearance a trend was seen in" exact="hydroxychloroquine" post="with support with &quot;86.7% vs. 93.3% viral clearance�? [19]."/>
   <result pre="and other parts of world to prove the efficacy of" exact="hydroxychloroquine" post="in the treatment of COVID-19 and its complication [20]."/>
   <result pre="tomorrow's alternate drug of choice. Thes drugs, the chloroquine, and" exact="hydroxychloroquine" post="are not without their own adverse effects. Hence, vigilance"/>
   <result pre="of New Coronavirus Pneumonia Multi-center Collaboration Group. Expert consensus for" exact="chloroquine" post="phosphate for the treatment of new coronavirus pneumoniaChin J"/>
   <result pre="by chloroquineBiochem Biophys Res Commun32312004 826426815351731 8KeyaertsE.LiS.VijgenL.RysmanE.VerbeeckJ.Van RanstM.Antiviral activity of" exact="chloroquine" post="against human coronavirus OC43 infection in newborn miceAntimicrob Agents"/>
   <result pre="infection and its associated congenital microcephaly in miceEBioMedicine24201718919410.1016/j.ebiom.2017.09.03429033372 11YanY.ZouZ.SunY.LiX.XuK.F.WeiY.Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
   <result pre="Actions251–21988941053142230 15Chloroquine clinical trials in COVID-19. https://clinicaltrials.gov/ct2/results?cond=COVID19&amp;amp;term=chloroquine&amp;amp;cntry=&amp;amp;state=&amp;amp;city=&amp;amp;dist= [Retreived 13.04.20]. 16GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="17Coronavirus (COVID-19) Update: Daily Roundup. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-march-30-2020 [Retreived 30.03.20]. 18GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="non-randomized clinical trialInt J Antimicrob AgentsMarch202010594910.1016/j.ijantimicag.2020.10594932205204 19ChenJ.LiuD.LiuL.PingP.L.I.U.XuQ.XiaL.A pilot study of" exact="hydroxychloroquine" post="in treatment of patients with common coronavirus disease-19 (COVID-19)J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7211740\results\search\drugs\results.xml">
   <result pre="effects, adverse effects, toxicity) and details of clinical trials for" exact="chloroquine" post="and hydroxychloroquine to benefit the clinicians, medicinal chemist, pharmacologist"/>
   <result pre="effects, toxicity) and details of clinical trials for chloroquine and" exact="hydroxychloroquine" post="to benefit the clinicians, medicinal chemist, pharmacologist actively involved"/>
   <result pre="Clinical trials details for studies going on for use of" exact="chloroquine" post="(CQ) and hydroxychloroquine (HCQ) in the treatment of COVID-19"/>
   <result pre="for studies going on for use of chloroquine (CQ) and" exact="hydroxychloroquine" post="(HCQ) in the treatment of COVID-19 infection [5]. [alt-text]"/>
   <result pre="360 HCQ NCT04328961 University of Washington, US 2000 HCQ sulfate," exact="ascorbic acid" post="NCT04318444 Columbia University Irving Medical Centre, US 1600 HCQ,"/>
   <result pre="oral tablet NCT04329832 Intermountain Health Care Inc. US 300 HCQ," exact="azithromycin" post="NCT04334382 Intermountain Health Care Inc. US 1550 HCQ, azithromycin"/>
   <result pre="HCQ, azithromycin NCT04334382 Intermountain Health Care Inc. US 1550 HCQ," exact="azithromycin" post="NCT04332991 Massachusetts General Hospital, US 510 HCQ, placebo NCT04328467"/>
   <result pre="diphosphate, placebo oral tablet NCT04329572 Azidus Brasil 400 HCQ sulfate," exact="azithromycin" post="tablets NCT04321278 Hospital Israelita Albert Einstein, Brazil 440 HCQ"/>
   <result pre="Hospital do Coracao. Brazil 630 HCQ oral product, HCQ _" exact="azithromycin" post="NCT04333628 HaEmek Medical Center, Israel 210 CQ, standard care"/>
   <result pre="Clinical, Spain 1530 HCQ sulfate NCT04332094 Spain 276 Tocilizumab, HCQ," exact="azithromycin" post="NCT04331834 Barcelona Institute for Global Health, Spain 440 HCQ,"/>
   <result pre="group will receive the national corona treatment recommendation (HCQ +" exact="oseltamivir" post="+ lopinavir/ritonavir) for at least 5 days IRCT20100228003449N29 Tehran"/>
   <result pre="Intervention group: tab HCQ 400 mg single dose + cap" exact="oseltamivir" post="75 mg, twice daily + tab lopinavir/ritonavir 200/50 mg"/>
   <result pre="(control group): tab HCQ 400 mg single dose + cap" exact="oseltamivir" post="75 mg, twice daily + tab lopinavir/ritonavir 200/50 mg"/>
   <result pre="400 mg P.O. twice daily for 5 days + tab" exact="oseltamivir" post="75 mg P.O. twice daily for 5 days +"/>
   <result pre="mg P.O. two tablets twice daily for 5 days +" exact="interferon beta-1a" post="44 mg every other day S.C. for 10 days"/>
   <result pre="1: concomitant with the national corona treatment recommendation (HCQ +" exact="oseltamivir" post="+ lopinavir/ritonavir), patients will receive Interferon beta-1b with dose"/>
   <result pre="group will receive the national corona treatment recommendation (HCQ +" exact="oseltamivir" post="+ lopinavir/ritonavir) for at least 5 days NCT04343768 Shahid"/>
   <result pre="of Respiratory Diseases-Mexico 400 HCQ NCT04340349 Mexico 100 HCQ sulfate," exact="bromhexine" post="(8 mg) NCT04342221 University Hospital Tubingen, Germany 220 HCQ"/>
   <result pre="Universitaire de Bordeaux, Etablissement Public, France 1057 HCQ (200 mg)," exact="imatinib" post="(400 mg), favipiravir EUCTR2020-001281-11-FR France 50 HCQ NCT04315948 Hospital"/>
   <result pre="University Hospital, Japan 50 Lopinavir, ritonavir, HCQ with or without" exact="oseltamivir" post="(oral) NCT04328272 Khyber Medical University, Peshawar, Pakistan 75 Drug:"/>
   <result pre="Peshawar, Pakistan 75 Drug: HCQ (200 mg oral tablet), drug:" exact="azithromycin" post="(500 mg oral tablet), dietary supplement: glucose tablet NCT04338698"/>
   <result pre="tablet NCT04338698 University of Health Sciences, Lahore 500 HCQ, oseltamivir," exact="azithromycin" post="ChiCTR2000031454 The Fifth Affiliated Hospital of Sun Yat-Sen University,"/>
   <result pre="University, China Experimental group: 28; Control group: 28 Experimental group:" exact="rabeprazole" post="+ CQControl group: lopinavir + rabeprazole ChiCTR2000030417 Harbin Peiyou"/>
   <result pre="28; Control group: 28 Experimental group: rabeprazole + CQControl group:" exact="lopinavir" post="+ rabeprazole ChiCTR2000030417 Harbin Peiyou Jiandi Biotechnology Co Ltd.,"/>
   <result pre="group: 28 Experimental group: rabeprazole + CQControl group: lopinavir +" exact="rabeprazole" post="ChiCTR2000030417 Harbin Peiyou Jiandi Biotechnology Co Ltd., China Experimental"/>
   <result pre="HCQ sulfate NCT04332835 Universidad del Rosario, Cambodia 80 Plasma, HCQ," exact="azithromycin" post="NCT04338906 – 334 Camostat mesilate, placebo, HCQ NCT04336748 –"/>
   <result pre="is drug repurposing of the traditional anti-malarial drugs aminoquinolines namely," exact="chloroquine" post="(CQ) and hydroxychloroquine (HCQ) (Fig. 3 ). Both are"/>
   <result pre="of the traditional anti-malarial drugs aminoquinolines namely, chloroquine (CQ) and" exact="hydroxychloroquine" post="(HCQ) (Fig. 3 ). Both are synthetic anti-malarial drugs"/>
   <result pre="Both are synthetic anti-malarial drugs with rapid absorption. Chloroquine and" exact="hydroxychloroquine" post="are water soluble; the latter is more soluble due"/>
   <result pre="coronavirus (CoV) and MERS-CoV [[97], [98], [99], [100]]. Chloroquine and" exact="hydroxychloroquine" post="has shown inhibition of SARS-CoV-2 replication [101]. Clinical trials"/>
   <result pre="replication [101]. Clinical trials have demonstrated the effective role of" exact="chloroquine" post="phosphate (dose 500 mg/day) against COVID-19 [102]. The N-hydroxyethyl"/>
   <result pre="mg/day) against COVID-19 [102]. The N-hydroxyethyl substituted derivative of chloroquine," exact="hydroxychloroquine" post="is less toxic, more soluble and has similar activity"/>
   <result pre="systematic review of mechanism of action, efficacy, and safety of" exact="chloroquine" post="and hydroxychloroquine which are being used as therapeutic measure"/>
   <result pre="of mechanism of action, efficacy, and safety of chloroquine and" exact="hydroxychloroquine" post="which are being used as therapeutic measure to cure"/>
   <result pre="pH and interferes with the viral fusion process. In coronavirus," exact="chloroquine" post="binds to the cellular receptors and changes the glycosylation"/>
   <result pre="review helps to propose the possible mechanism of action of" exact="chloroquine" post="and hydroxychloroquine through three ways i.e. immunomodulatory effect, zinc"/>
   <result pre="to propose the possible mechanism of action of chloroquine and" exact="hydroxychloroquine" post="through three ways i.e. immunomodulatory effect, zinc ionophore effect"/>
   <result pre="to the web version of this article.) 3 Chloroquine vs." exact="hydroxychloroquine" post="When compared for pharmacological profile, chloroquine and hydroxychloroquine possess"/>
   <result pre="article.) 3 Chloroquine vs. hydroxychloroquine When compared for pharmacological profile," exact="chloroquine" post="and hydroxychloroquine possess equivalent anti-malarial activity. The latter is"/>
   <result pre="Chloroquine vs. hydroxychloroquine When compared for pharmacological profile, chloroquine and" exact="hydroxychloroquine" post="possess equivalent anti-malarial activity. The latter is preferred due"/>
   <result pre="ocular toxicity [115]. Theoretically, the antiviral activity for chloroqunie and" exact="hydroxychloroquine" post="are similar but the reported clinical details for chloroquine"/>
   <result pre="and hydroxychloroquine are similar but the reported clinical details for" exact="chloroquine" post="are more in number [116]. Use of chloroquine is"/>
   <result pre="details for chloroquine are more in number [116]. Use of" exact="chloroquine" post="is less due to some associated adverse effects and"/>
   <result pre="of availability in some countries. In patients with COVID-19 infection" exact="hydroxychloroquine" post="is preferred as chloroquine when used in combination with"/>
   <result pre="countries. In patients with COVID-19 infection hydroxychloroquine is preferred as" exact="chloroquine" post="when used in combination with lopinavir or ritonavir shows"/>
   <result pre="hydroxychloroquine is preferred as chloroquine when used in combination with" exact="lopinavir" post="or ritonavir shows prolongation of the QT interval. Some"/>
   <result pre="preferred as chloroquine when used in combination with lopinavir or" exact="ritonavir" post="shows prolongation of the QT interval. Some of the"/>
   <result pre="of the other antiviral therapeutics that does not interfere with" exact="hydroxychloroquine" post="is oseltamivir, lopinavir/ritonavir, robavirin, interferons, and immunoglobulins (intravenous) [117]."/>
   <result pre="and adverse effects The toxicological properties reported with use of" exact="chloroquine" post="and hydroxychloroquine are retinopathy, neuromyopathy and cardiomyopathy. Both these"/>
   <result pre="effects The toxicological properties reported with use of chloroquine and" exact="hydroxychloroquine" post="are retinopathy, neuromyopathy and cardiomyopathy. Both these drugs possess"/>
   <result pre="atrophy and irreversible alterations in photoreceptors [106]. In the lysosomes," exact="hydroxychloroquine" post="is protonated and accumulated due to its basic nature."/>
   <result pre="of cardiac and skeletal muscle cells [118]. Prolong use of" exact="hydroxychloroquine" post="produces – i) toxicity to retina tissue which may"/>
   <result pre="even after discontinuation of treatment due to prolong half-life of" exact="chloroquine" post="and hydroxychloroquine. The side effects (keratopathy, maculopathy) may be"/>
   <result pre="current anti-COVID-19 therapeutic regimen suggests longer duration of treatment with" exact="chloroquine" post="than that as anti-malarial drug. Thus close monitoring of"/>
   <result pre="reported to WHO. The essential ethical requirement is use of" exact="chloroquine" post="in COVID-19 patients with ethical trial approval or off-label."/>
   <result pre="with availability of any specific licensed drug. The use of" exact="chloroquine" post="in the treatment of COVID-19 infection is considered by"/>
   <result pre="considered by WHO as experimental. In this regard use of" exact="chloroquine" post="is associated with various concerns such as patient safety,"/>
   <result pre="ease of access to medical fraternity. •In vitro study of" exact="chloroquine" post="were performed in Vero E6 cells infected with SARS-CoV"/>
   <result pre="a multicentric collaborative in vitro and clinical study, use of" exact="chloroquine" post="phosphate (dose 500 mg twice a day for 10"/>
   <result pre="of Infectious and Tropical disease, Lombardy section suggests administration of" exact="chloroquine" post="(500 mg, twice a day) or hydroxychloroquine (200 mg"/>
   <result pre="suggests administration of chloroquine (500 mg, twice a day) or" exact="hydroxychloroquine" post="(200 mg per day for 10 days) (5 to"/>
   <result pre="the Dutch Center of Disease Control (CDC) recommended use of" exact="chloroquine" post="to treat severe infections with requirement of oxygen therapy"/>
   <result pre="therapy and optimal supportive care [134]. The recommended dose for" exact="chloroquine" post="base is 600 mg followed by 300 mg after"/>
   <result pre="side effects (30 h half-life of chloroquine) (500 mg of" exact="chloroquine" post="phosphate = 300 mg of chloroquine base). •In China,"/>
   <result pre="chloroquine) (500 mg of chloroquine phosphate = 300 mg of" exact="chloroquine" post="base). •In China, more than two dozen clinical trials"/>
   <result pre="of COVID-19 infected patients but no details on use of" exact="chloroquine" post="[[136], [137], [138], [139], [140]]. 6 Conclusion For therapeutic"/>
   <result pre="COVID-19 infection – i)History of previous or ongoing use of" exact="chloroquine" post="and hydroxychloroquine in malaria, amebiasis, rheumatoid arthritis, and systemic"/>
   <result pre="– i)History of previous or ongoing use of chloroquine and" exact="hydroxychloroquine" post="in malaria, amebiasis, rheumatoid arthritis, and systemic lupus; ii)Higher"/>
   <result pre="TraniL.SavarinoA.CampitelliL.NorelliS.PuzelliS.D’OstilioD.VignoloE.DonatelliI.CassoneA.Different pH requirements are associated with divergent inhibitory effects of" exact="chloroquine" post="on human and avian influenza A virusesVirol. J.420073917477867 27OoiE.E.ChewJ.S.LohJ.P.ChuaR.C.In"/>
   <result pre="human influenza A virus replication by chloroquineVirol. J.320063916729896 28YanY.ZouZ.SunY.LiX.XuK.F.WeiY.JinN.JiangC.Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
   <result pre="RembertA.Paranhos-BaccalaG.PeyrefitteC.N.Evaluation of crimean-Congo hemorrhagic fever virus in vitro inhibition by" exact="chloroquine" post="and chlorpromazine two FDA approved moleculesAntivir. Res.1182015758125796972 30DelvecchioR.HigaL.M.PezzutoP.ValadaoA.L.GarcezP.P.MonteiroF.L.LoiolaE.C.DiasA.A.SilvaF.J.AliotaM.T.CaineE.A.OsorioJ.E.BellioM.O’ConnorD.H.RehenS.de AguiarR.S.SavarinoA.CampanatiL.TanuriA.Chloroquine,"/>
   <result pre="crimean-Congo hemorrhagic fever virus in vitro inhibition by chloroquine and" exact="chlorpromazine" post="two FDA approved moleculesAntivir. Res.1182015758125796972 30DelvecchioR.HigaL.M.PezzutoP.ValadaoA.L.GarcezP.P.MonteiroF.L.LoiolaE.C.DiasA.A.SilvaF.J.AliotaM.T.CaineE.A.OsorioJ.E.BellioM.O’ConnorD.H.RehenS.de AguiarR.S.SavarinoA.CampanatiL.TanuriA.Chloroquine, an endocytosis"/>
   <result pre="associated congenital microcephaly in miceEBioMedicine24201718919429033372 33ShiryaevS.A.MesciP.PintoA.FernandesI.SheetsN.ShrestaS.FarhyC.HuangC.T.StronginA.Y.MuotriA.R.TerskikhA.V.Repurposing of the antimalaria drug" exact="chloroquine" post="for zika virus treatment and prophylaxisSci. Rep.7201715771 34SperberK.KalbT.H.StecherV.J.BanerjeeR.MayerL.Inhibition of"/>
   <result pre="Rep.7201715771 34SperberK.KalbT.H.StecherV.J.BanerjeeR.MayerL.Inhibition of human immunodeficiency virus type 1 replication by" exact="hydroxychloroquine" post="in T cells and monocytesAIDS Res. Hum. Retrovir.9199391988427717 35TsaiW.P.NaraP.L.KungH.F.OroszlanS.Inhibition"/>
   <result pre="association of cyclophilin A with HIV-1 virionNature37219943633657969495 40WainbergM.A.DascalA.BlainN.Fitz-GibbonL.BoulericeF.NumazakiK.TremblayM.The effect of" exact="cyclosporine" post="A on infection of susceptible cells by human immunodeficiency"/>
   <result pre="kineticsPLoS Pathog.52009e1000546 44NakagawaM.SakamotoN.EnomotoN.TanabeY.KanazawaN.KoyamaT.KurosakiM.MaekawaS.YamashiroT.ChenC.H.ItsuiY.KakinumaS.WatanabeM.Specific inhibition of hepatitis C virus replication by" exact="cyclosporine" post="ABiochem. Biophys. Res. Commun.3132004424714672695 45YangF.RobothamJ.M.NelsonH.B.IrsiglerA.KenworthyR.TangH.Cyclophilin A is an essential"/>
   <result pre="for hepatitis C virus infection and the principal mediator of" exact="cyclosporine" post="resistance in vitroJ. Virol.8220085269527818385230 46BoseS.MathurM.BatesP.JoshiN.BanerjeeA.K.Requirement for cyclophilin A for"/>
   <result pre="Jersey serotypeJ. Gen. Virol.8420031687169912810862 47DamasoC.R.MoussatcheN.Inhibition of vaccinia virus replication by" exact="cyclosporine" post="A analogues correlates with their affinity for cellular cyclophilinsJ."/>
   <result pre="replication through degradation of the M1 proteinPLoS One72012e31063 52MaC.LiF.MusharrafiehR.G.WangJ.Discovery of" exact="cyclosporine" post="A and its analogs as broad-spectrum anti-influenza drugs with"/>
   <result pre="genetic barrier of drug resistanceAntivir. Res.1332016627227478032 53SchiltknechtE.AdaG.L.In vivo effects of" exact="cyclosporine" post="on influenza A virus-infected miceCell. Immunol.9119852272392982505 54de WildeA.H.Zevenhoven-DobbeJ.C.van der"/>
   <result pre="of silver nanoparticles with Tacaribe virusJ. Nanobiotechnology820101920718972 74ChapuisA.G.Paolo RizzardiG.D’AgostinoC.AttingerA.KnabenhansC.FleuryS.Acha-OrbeaH.PantaleoG.Effects of" exact="mycophenolic acid" post="on human immunodeficiency virus infection in vitro and in"/>
   <result pre="in vivoNat. Med.6200076276810888924 75KaurR.KlichkoV.MargolisD.Ex vivo modeling of the effects of" exact="mycophenolic acid" post="on HIV infection: considerations for antiviral therapyAIDS Res. Hum."/>
   <result pre="infection: considerations for antiviral therapyAIDS Res. Hum. Retrovir.21200511612415725750 76MargolisD.HerediaA.GayweeJ.OldachD.DrusanoG.RedfieldR.Abacavir and" exact="mycophenolic acid" post="an inhibitor of inosine monophosphate dehydrogenase have profound and"/>
   <result pre="Res. Hum. Retrovir.21200511612415725750 76MargolisD.HerediaA.GayweeJ.OldachD.DrusanoG.RedfieldR.Abacavir and mycophenolic acid an inhibitor of" exact="inosine" post="monophosphate dehydrogenase have profound and synergistic anti-HIV activityJ. Acquir."/>
   <result pre="replication of viral RNAVirology304200221122112504563 81TakhampunyaR.UbolS.HoungH.S.CameronC.E.PadmanabhanR.Inhibition of dengue virus replication by" exact="mycophenolic acid" post="and ribavirinJ. Gen. Virol.8720061947195216760396 82LemaitreM.GuetardD.HeninY.MontagnierL.ZerialA.Protective activity of tetracycline analogs"/>
   <result pre="by mycophenolic acid and ribavirinJ. Gen. Virol.8720061947195216760396 82LemaitreM.GuetardD.HeninY.MontagnierL.ZerialA.Protective activity of" exact="tetracycline" post="analogs against the cytopathic effect of the human immunodeficiency"/>
   <result pre="of macrophage migration inhibitory factor-induced autophagyAntivir. Res.1552018283829752950 87LeelaS.L.SrisawatC.SreekanthG.P.NoisakranS.YenchitsomanusP.T.LimjindapornT.Drug repurposing of" exact="minocycline" post="against dengue virus infectionBiochem. Biophys. Res. Commun.478201641041627396621 88MishraM.K.BasuA.Minocycline neuroprotects,"/>
   <result pre="LLC(10. Gen 22; NBK 537086) 96RainsfordK.D.ParkeA.L.Clifford-RashotteM.KeanW.F.Therapy and pharmacological properties of" exact="hydroxychloroquine" post="and chloroquine in treatment of systemic lupus erythematosus, rheumatoid"/>
   <result pre="22; NBK 537086) 96RainsfordK.D.ParkeA.L.Clifford-RashotteM.KeanW.F.Therapy and pharmacological properties of hydroxychloroquine and" exact="chloroquine" post="in treatment of systemic lupus erythematosus, rheumatoid arthritis and"/>
   <result pre="systemic lupus erythematosus, rheumatoid arthritis and related diseasesInflammopharmacology23201523126926246395 97SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against today’s diseasesThe"/>
   <result pre="coronavirus SARSCoV-2Int. J. Antimicrob. Agents552020105923 99https://www.who.int/blueprint/priority-diseases/keyaction/Table_of_therapeutics_Appendix_17022020.pdf?ua=1 100RoquesP.ThibervilleS.D.Dupuis-MaguiragaL.LumF.M.LabadieK.MartinonF.GrasG.LebonP.NgL.F.P.de LamballerieX.GrandR.L.Paradoxical effect of" exact="chloroquine" post="treatment in enhancing chikungunya virus infectionViruses102018268 101C. Zhang, S."/>
   <result pre="2019, J. Med. Virol. doi:10.1002/jmv.25788. (Epub ahead of print). 102GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="106YamJ.C.KwokA.K.Ocular toxicity of hydroxychloroquineHong Kong Med. J.12200629430416912357 107ZhangY.LiaoZ.ZhangL.J.XiaoH.T.The utility of" exact="chloroquine" post="in cancer therapyCurr. Med. Res. Opin.31201510091101325734693 108PlantoneD.KoudriavtsevaT.Current and future"/>
   <result pre="cancer therapyCurr. Med. Res. Opin.31201510091101325734693 108PlantoneD.KoudriavtsevaT.Current and future use of" exact="chloroquine" post="and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases:"/>
   <result pre="Med. Res. Opin.31201510091101325734693 108PlantoneD.KoudriavtsevaT.Current and future use of chloroquine and" exact="hydroxychloroquine" post="in infectious, immune, neoplastic, and neurological diseases: a mini-reviewClin."/>
   <result pre="T-cell activation by AP-1 signaling modulationSci. Rep.42191201710.1038/srep42191 110DuanY.J.LiuQ.ZhaoS.Q.HuangF.RenL.LiuL.ZhouY.W.The trial of" exact="chloroquine" post="in the treatment of corona virus disease 2019 (COVID-19)"/>
   <result pre="forensic toxicologyFa Yi Xue Za Zhi36202010.12116/j.issn.1004-5619.2020.02.001 111Al-BariM.AlimA.Targeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
   <result pre="molecular modelling studies reveal a new mechanism of action of" exact="chloroquine" post="and hydroxychloroquine against SARS-CoV-2 infectionInt. J. Antimicrob. Agents142020105960 115LimH.S.ImJ.S.ChoJ.Y.BaeK.S.KleinT.A.YeomJ.S.KimT.S.ChoiJ.S.JangI.J.ParkJ.W.Pharmacokinetics"/>
   <result pre="studies reveal a new mechanism of action of chloroquine and" exact="hydroxychloroquine" post="against SARS-CoV-2 infectionInt. J. Antimicrob. Agents142020105960 115LimH.S.ImJ.S.ChoJ.Y.BaeK.S.KleinT.A.YeomJ.S.KimT.S.ChoiJ.S.JangI.J.ParkJ.W.Pharmacokinetics of hydroxychloroquine"/>
   <result pre="and hydroxychloroquine against SARS-CoV-2 infectionInt. J. Antimicrob. Agents142020105960 115LimH.S.ImJ.S.ChoJ.Y.BaeK.S.KleinT.A.YeomJ.S.KimT.S.ChoiJ.S.JangI.J.ParkJ.W.Pharmacokinetics of" exact="hydroxychloroquine" post="and its clinical implications in chemoprophylaxis against malaria caused"/>
   <result pre="malaria caused by plasmodium vivaxAntimicrob. Agents aChemother53200914681475 116TanY.W.YamW.K.SunJ.ChuJ.J.H.An evaluation of" exact="chloroquine" post="as a broad-acting antiviral against hand, foot and mouth"/>
   <result pre="and mouth diseaseAntivir. Res.149201814314929175128 117SahraeiZ.ShabaniM.ShokouhiS.SaffaeiA.Aminoquinolines against coronavirus disease 2019 (COVID-19):" exact="chloroquine" post="or hydroxychloroquineInt. J. Antimicrob. Agents202010594510.1016/j.ijantimicag.2020.105945 118YogasundaramH.PutkoB.N.TienJ.PatersonD.I.CujecB.RingroseJ.OuditG.Y.Hydroxychloroquine-induced cardiomyopathy: case report,"/>
   <result pre="pathophysiology, diagnosis, and treatmentCan. J. Cardiol.3020141706171525475472 119MarmorM.F.CarrR.E.EasterbrookM.MielerW.F.Recommendations on screening for" exact="chloroquine" post="and hydroxychloroquine retinopathy: a report by the American Academy"/>
   <result pre="and treatmentCan. J. Cardiol.3020141706171525475472 119MarmorM.F.CarrR.E.EasterbrookM.MielerW.F.Recommendations on screening for chloroquine and" exact="hydroxychloroquine" post="retinopathy: a report by the American Academy of OphthalmologyOphthalmology10920021377138212093666"/>
   <result pre="by the American Academy of OphthalmologyOphthalmology10920021377138212093666 120WolfeF.MarmorM.F.Rates and predictors of" exact="hydroxychloroquine" post="retinal toxicity in patients with rheumatoid arthritis and systemic"/>
   <result pre="Health Part B2320202750 123RiccioE.S.LeeP.S.WinegarR.A.KrogstadD.J.DeD.MirsalisJ.C.Genetic toxicology testing of the antimalarial drugs" exact="chloroquine" post="and a new analog, AQ-13Environ. Mol. Mutagen.382001697911473390 124MellesR.B.MarmorM.F.The risk"/>
   <result pre="Mutagen.382001697911473390 124MellesR.B.MarmorM.F.The risk of toxic retinopathy in patients on long-term" exact="hydroxychloroquine" post="therapyJ. Am. Med. Assoc. Ophthalmol.132201414531460 125PereiraB.B.Challenges and cares to"/>
   <result pre="Assoc. Ophthalmol.132201414531460 125PereiraB.B.Challenges and cares to promote rational use of" exact="chloroquine" post="and hydroxychloroquine in the management of coronavirus disease 2019"/>
   <result pre="125PereiraB.B.Challenges and cares to promote rational use of chloroquine and" exact="hydroxychloroquine" post="in the management of coronavirus disease 2019 (COVID-19) pandemic:"/>
   <result pre="with hydroxychloroquine: a reappraisalOphthalmology11020031321132612867385 127MarmorM.F.MellesR.B.Hydroxychloroquine and the retinaJAMA313201584784825710661 128LiuD.LiX.ZhangY.KwongJ.S.W.LiL.ZhangY.XuC.LiQ.SunX.TianH.LiS.Chloroquine and" exact="hydroxychloroquine" post="are associated with reduced cardiovascular risk: a systematic review"/>
   <result pre="review and meta-analysisDrug Des. Dev. Ther.11201816851695 129ChatreC.RoubilleF.VernhetH.JorgensenC.PersY.M.Cardiac complications attributed to" exact="chloroquine" post="and hydroxychloroquine: a systematic review of the literatureDrug Saf.41201891993129858838"/>
   <result pre="a systematic review of the literatureDrug Saf.41201891993129858838 130https://www.who.int/blueprint/priority-diseases/key-action/multicenter-adaptive-RCT-of-investigational-therapeutics-for-COVID-19.pdf?ua=1 131WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="of Guangdong Province and Health Commission of Guangdong Province for" exact="chloroquine" post="in the treatment of novel coronavirus pneumoniaExpert consensus on"/>
   <result pre="chloroquine in the treatment of novel coronavirus pneumoniaExpert consensus on" exact="chloroquine" post="phosphate for the treatment of novel coronavirus pneumoniaChin. J."/>
   <result pre="infected with 2019 novel coronavirus in Wuhan, ChinaLancet395202049750631986264 141TouretF.de LamballerieX.Of" exact="chloroquine" post="and COVID-19Antivir. Res.1772020104762 142MarmorM.F.KellnerU.LaiT.Y.MellesR.B.MielerW.F.American Academy of ophthalmology, recommendations on"/>
   <result pre="COVID-19Antivir. Res.1772020104762 142MarmorM.F.KellnerU.LaiT.Y.MellesR.B.MielerW.F.American Academy of ophthalmology, recommendations on screening for" exact="chloroquine" post="and hydroxychloroquine retinopathyOphthalmology12320161386139426992838 Acknowledgment Authors acknowledge the resources provided"/>
   <result pre="142MarmorM.F.KellnerU.LaiT.Y.MellesR.B.MielerW.F.American Academy of ophthalmology, recommendations on screening for chloroquine and" exact="hydroxychloroquine" post="retinopathyOphthalmology12320161386139426992838 Acknowledgment Authors acknowledge the resources provided by KIET"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7211761\results\search\drugs\results.xml">
   <result pre="-10.722 and glide e-model −135.584 (Table 2 ). The ligand" exact="amodiaquine" post="shares four hydrogen bond interactions with Leu 141, ARG"/>
   <result pre="amaodiquine was stabilized after 5 ns and in case of" exact="lopinavir" post="and theaflavin digallate, the values were decreased initially and"/>
   <result pre="on HIV-1 protease and inhibitors complex and they found that" exact="lopinavir" post="was possible drug candidate with a significant binding energy"/>
   <result pre="HIV-drug, amodiquine, an antimalarial drug, and Theaflavin digallate, a plant-based" exact="phenol" post="derivative, were selected as SARS�?CoV�?2 therapeutics due to their"/>
   <result pre="on the observations of docking score, we believed that the" exact="phenol" post="derivative and anti-HIV drug, could aid in COVID�?19 drug"/>
   <result pre="Clin Infect Dis1242017e13823 11NukoolkarnV.LeeV.S.MalaisreeM.AruksakulwongO.HannongbuaS.Molecular dynamic simulations analysis of ritronavir and" exact="lopinavir" post="as SARS-CoV 3CLpro inhibitorsJ Theor Biol2544200886186718706430 Appendix A Supplementary"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7211915\results\search\drugs\results.xml">
   <result pre="treatment of COVID-19. It is a phosphoramidate prodrug of an" exact="adenosine" post="C-nucleoside and a broad-spectrum antiviral agent synthesized and developed"/>
   <result pre="therapeutic effect of remdesivir [34]. Hydroxychloroquine and Chloroquine Chloroquine and" exact="hydroxychloroquine" post="are drugs with a long history of clinical use"/>
   <result pre="lupus erythematosus, rheumatoid arthritis, and malaria [35]. Compared with chloroquine," exact="hydroxychloroquine" post="has a hydroxyl group, which makes it less toxic"/>
   <result pre="toxic while maintaining similar activity. One mechanism of action of" exact="chloroquine" post="and hydroxychloroquine is targeting lysosome which may be useful"/>
   <result pre="maintaining similar activity. One mechanism of action of chloroquine and" exact="hydroxychloroquine" post="is targeting lysosome which may be useful to control"/>
   <result pre="control graft-versus-host disease in humans [36]. With the accumulation of" exact="chloroquine" post="in lysosomes, the pH of lysosomes is significantly changed"/>
   <result pre="ACE2 receptor and its binding with spike protein, suggesting that" exact="chloroquine" post="treatment might be more effective in the early stage"/>
   <result pre="rheumatoid arthritis (RA) patients [40]. There is some evidence that" exact="chloroquine" post="and hydroxychloroquine can reduce cytokine storm. According to one"/>
   <result pre="(RA) patients [40]. There is some evidence that chloroquine and" exact="hydroxychloroquine" post="can reduce cytokine storm. According to one analysis, the"/>
   <result pre="to acute respiratory distress [41]. It has been reported that" exact="hydroxychloroquine" post="is effective in inhibiting SARS-CoV-2 infection in vitro [1,"/>
   <result pre="cell culture [43]. There is also evidence that zinc enhances" exact="chloroquine" post="intracellular uptake [44]. As such, combining zinc with chloroquine"/>
   <result pre="enhances chloroquine intracellular uptake [44]. As such, combining zinc with" exact="chloroquine" post="or hydroxychloroquine is intriguing and is currently under investigation."/>
   <result pre="intracellular uptake [44]. As such, combining zinc with chloroquine or" exact="hydroxychloroquine" post="is intriguing and is currently under investigation. Overall, more"/>
   <result pre="trials are underway to evaluate the safety and efficacy of" exact="hydroxychloroquine" post="as a prophylactic and treatment for COVID-19. The US"/>
   <result pre="US FDA has issued emergency authorization for the use of" exact="chloroquine" post="and hydroxychloroquine for the treatment of COVID-19. A recent"/>
   <result pre="has issued emergency authorization for the use of chloroquine and" exact="hydroxychloroquine" post="for the treatment of COVID-19. A recent study by"/>
   <result pre="COVID-19. A recent study by Tang et al. reported that" exact="hydroxychloroquine" post="did not lead to higher negative conversion rates, but"/>
   <result pre="[45•]. It has also been reported that high doses of" exact="chloroquine" post="(600 mg twice daily for 10 days or total"/>
   <result pre="poor oral bioavailability and extensive biotransformation, it is co-formulated with" exact="ritonavir" post="to enhance its exposure. Ritonavir is a potent inhibitor"/>
   <result pre="a potent inhibitor of the enzymes that are responsible for" exact="lopinavir" post="metabolism, and its co-administration &quot;boosts�? lopinavir exposure and improves"/>
   <result pre="that are responsible for lopinavir metabolism, and its co-administration &quot;boosts�?" exact="lopinavir" post="exposure and improves antiviral activity [48]. Lopinavir is a"/>
   <result pre="favipiravir, nafamostat, nitazoxanide, remdesivir, and chloroquine, showing that remdesivir and" exact="chloroquine" post="have favorable selectivity index [30]. In addition, the study"/>
   <result pre="or in conjunction with interferon-α (ChiCTR2000029600), baloxavir marboxil (ChiCTR2000029544, ChiCTR2000029548)," exact="tocilizumab" post="(ChiCTR2000030894, NCT04310228), or chloroquine phosphate (ChiCTR2000030987, NCT04319900). Oseltamivir (Tamiflu)"/>
   <result pre="interferon-α (ChiCTR2000029600), baloxavir marboxil (ChiCTR2000029544, ChiCTR2000029548), tocilizumab (ChiCTR2000030894, NCT04310228), or" exact="chloroquine" post="phosphate (ChiCTR2000030987, NCT04319900). Oseltamivir (Tamiflu) Oseltamivir(branded as Tamiflu) is"/>
   <result pre="no positive outcomes were observed after receiving antiviral treatment with" exact="oseltamivir" post="[65]. Several clinical trials are still evaluating the effectiveness"/>
   <result pre="[65]. Several clinical trials are still evaluating the effectiveness of" exact="oseltamivir" post="in treating SARS-CoV-2 infection. Oseltamivir is also used in"/>
   <result pre="used in clinical trials in several combinations, such as with" exact="chloroquine" post="and favipiravir [66]. Supporting Agents In the absence of"/>
   <result pre="supportive care for COVID-19 patients. The adjunctive therapies including azithromycin," exact="ascorbic acid," post="corticosteroids, epoprostenol, sirolimus, tocilizumab, sarilumab, and anakinra are highlighted"/>
   <result pre="including azithromycin, ascorbic acid, corticosteroids, epoprostenol, sirolimus, tocilizumab, sarilumab, and" exact="anakinra" post="are highlighted below. Several of these therapies (i.e., tocilizumab"/>
   <result pre="and anakinra are highlighted below. Several of these therapies (i.e.," exact="tocilizumab" post="and other interleukin-directed therapies) are administered in an effort"/>
   <result pre="patients suffering viral infection [69–71]. For the mechanism of action," exact="azithromycin" post="prevents bacteria from growing by interfering with their protein"/>
   <result pre="the bacterial ribosome, thus inhibiting translation of mRNA [72]. Previously," exact="azithromycin" post="has been used as adjunctive therapy to provide antibacterial"/>
   <result pre="[73, 74]. Currently, many trials are testing the effect of" exact="azithromycin" post="conjunction with hydroxychloroquine on the course of disease in"/>
   <result pre="many trials are testing the effect of azithromycin conjunction with" exact="hydroxychloroquine" post="on the course of disease in people with SARS-CoV-2."/>
   <result pre="Pfizer has announced positive data for the use of its" exact="azithromycin" post="(Zithromax) drug, along with hydroxychloroquine, in a COVID-19 clinical"/>
   <result pre="France. In brief, the clinical trial was conducted to assess" exact="hydroxychloroquine" post="in 20 patients, 6 of which were co-administered with"/>
   <result pre="were co-administered with azithromycin. Compared with 16 controls and 14" exact="hydroxychloroquine" post="alone group, the 6 patients treated with hydroxychloroquine +"/>
   <result pre="and 14 hydroxychloroquine alone group, the 6 patients treated with" exact="hydroxychloroquine" post="+ azithromycin presented with highest virologic cure rate following"/>
   <result pre="hydroxychloroquine alone group, the 6 patients treated with hydroxychloroquine +" exact="azithromycin" post="presented with highest virologic cure rate following 6-day treatment"/>
   <result pre="rate following 6-day treatment [73]. Three other clinical studies used" exact="azithromycin" post="(500 mg on day 1, then 250 mg daily"/>
   <result pre="mg daily on days 2–5) co-treated with 10-day regimen of" exact="hydroxychloroquine" post="(600 mg daily) in an open-label non-randomized study in"/>
   <result pre="in nasopharyngeal swabs in their 6 patients after co-treated of" exact="hydroxychloroquine" post="and azithromycin [73]. But the findings reported by Molina"/>
   <result pre="swabs in their 6 patients after co-treated of hydroxychloroquine and" exact="azithromycin" post="[73]. But the findings reported by Molina et al."/>
   <result pre="to date are insufficient to evaluate possible clinical benefits of" exact="azithromycin" post="in patients with COVID-19 [76]. Furthermore, one must consider"/>
   <result pre="[76]. Furthermore, one must consider the additive cardiac toxicity of" exact="hydroxychloroquine" post="and azithromycin. Both agents are known to prolong the"/>
   <result pre="As a potent anti-inflammatory and anti-fibrotic drug, low doses of" exact="methylprednisolone" post="(DEPO-Medrol or SOLU-Medrol) have the potential to prevent an"/>
   <result pre="patients with confirmed COVID-19 who developed ARDS were treated with" exact="methylprednisolone" post="(1–2 mg/kg daily IV for 5–7 days) and the"/>
   <result pre="for 5–7 days) and the results showed that treatment with" exact="methylprednisolone" post="may be beneficial for patients who develop ARDS in"/>
   <result pre="of death. Briefly, of those patients with ARDS who received" exact="methylprednisolone" post="treatment, 23 of 50 (46%) patients died, while those"/>
   <result pre="severe COVID-19 that progressed to acute respiratory failure, use of" exact="methylprednisolone" post="was associated with improvement in clinical symptoms (i.e., fever,"/>
   <result pre="expert consensus statement from Chinese Thoracic Society, dosage regimen of" exact="methylprednisolone" post="should be low to moderate (i.e., ≤ 0.5 to 1"/>
   <result pre="daily or equivalent) [88] and the most common regimens of" exact="methylprednisolone" post="applied in China were typically 40–80 mg IV daily"/>
   <result pre="and hypoxemia despite optimized ventilation and other rescue strategies. Inhaled" exact="nitric oxide" post="(iNO) and inhaled epoprostenol (iEPO, a naturally occurring prostaglandin)"/>
   <result pre="key role in viral replication. In an in vitro experiment," exact="sirolimus" post="has been shown to affect PI3K/AKT/mTOR pathway which inhibited"/>
   <result pre="between April and September 2020 to test the effect of" exact="sirolimus" post="on progression of patients hospitalized with COVID-19 to advanced"/>
   <result pre="support, a group treated with corticosteroids and 2 mg/day of" exact="sirolimus" post="for 14 days (N = 19) showed significantly better clinical outcomes"/>
   <result pre="only, including shorter median duration of ventilator used [105]. Delayed" exact="oseltamivir" post="plus sirolimus treatment in pH1N1-infected mouse model further suggested"/>
   <result pre="shorter median duration of ventilator used [105]. Delayed oseltamivir plus" exact="sirolimus" post="treatment in pH1N1-infected mouse model further suggested a significant"/>
   <result pre="pH1N1-infected mouse model further suggested a significant association between the" exact="sirolimus" post="treatment and improved outcomes [106]. Additionally, a new trial"/>
   <result pre="to begin in August 2020 to investigate the effect of" exact="sirolimus" post="and oseltamivir on normalization of respiratory status and changes"/>
   <result pre="in August 2020 to investigate the effect of sirolimus and" exact="oseltamivir" post="on normalization of respiratory status and changes in biomarkers"/>
   <result pre="influenza patients [107]. At least one in silico study identified" exact="sirolimus" post="as one of the 16 potential candidates for treating"/>
   <result pre="publishing this article, ClinicalTrials.gov listed 20 planned studies that included" exact="tocilizumab" post="treatment arm, all of them at the recruiting stage"/>
   <result pre="was launched (ChiCTR2000029765) and had about 500 patients treated with" exact="tocilizumab" post="already enrolled [109, 110]. Sarilumab Sarilumab, (branded as Kefraza),"/>
   <result pre="damaging inflammation [112]. Out of 5 approved clinical trials involving" exact="anakinra" post="treatment, 2 also have tocilizumab as a comparison: one"/>
   <result pre="5 approved clinical trials involving anakinra treatment, 2 also have" exact="tocilizumab" post="as a comparison: one multicenter open-label non-randomized trial in"/>
   <result pre="II type 1 receptor (AT1R) antagonists like losartan, lisinopril, or" exact="olmesartan" post="facilitates cardiac and renal ACE2 overexpression according to some"/>
   <result pre="SARS-CoV infections may be controlled by blocking renin-angiotensin pathway [123]," exact="ibuprofen" post="may not be harmful. However, there is no strong"/>
   <result pre="symptoms due to infection caused by SARS-CoV-2. The FDA considers" exact="ibuprofen" post="and the likes as a potentially promising therapeutic agent"/>
   <result pre="SARS-CoV and canine coronavirus (CCoV). In vitro studies suggest that" exact="indomethacin" post="exhibits dose-dependent response in Canine A72 cell monolayers infected"/>
   <result pre="were non-toxic for uninfected cells is also observed. In addition," exact="indomethacin" post="significantly blocks viral RNA synthesis in dogs infected with"/>
   <result pre="the drug (1 mg/kg) [127]. This suggests probable efficacy of" exact="indomethacin" post="against SARS-CoV-2 [127]. Colchicine Colchicine is an anti-inflammatory drug"/>
   <result pre="onto the cells [130]. Another study reveals the efficacy of" exact="niclosamide" post="in inhibiting MERS-CoV replication in VeroB4 cells via reduction"/>
   <result pre="determined to be 0.3 uM [131]. Thus, the possibility of" exact="niclosamide" post="to inhibit SARS-CoV-2 cannot be neglected. Ivermectin, a potent"/>
   <result pre="viruses, including dengue virus, flavivirus, and influenza [133–135] .Very recently," exact="ivermectin" post="has shown inhibition against SARS-CoV-2 up to 5000-fold at"/>
   <result pre="inhibition effect against SARS-CoV-2 in vivo. Nitazoxanide and Tizoxanide Both" exact="nitazoxanide" post="and its metabolite and tizoxanide have shown inhibitory effects"/>
   <result pre="L9 (BCoV-L9), and human enteric corona virus 4408 (HECoV-4408) by" exact="nitazoxanide" post="is reported via suppression of viral N protein [137]."/>
   <result pre="ritonavir, and interferon beta against MERS-CoVNat Commun202011122210.1038/s41467-019-13940-631924756 30.WangMCaoRZhangLYangXLiuJXuMet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="drugs in the treatment of rheumatological diseasesRheumatology.199736779980510.1093/rheumatology/36.7.799 36.SchultzKRGilmanALThe lysosomotropic amines," exact="chloroquine" post="and hydroxychloroquine: a potentially novel therapy for graft-versus-host diseaseLeuk"/>
   <result pre="Rolain J-M, Lagier J-C, Brouqui P, Raoult D. Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19. Int J Antimicrob"/>
   <result pre="randomized, controlled trial. medRxiv. 2020:2020.04.10.20060558. 10.1101/2020.04.10.20060558. This paper revealed that" exact="hydroxychloroquine" post="did not benefit COVID-19 patients in terms of negative"/>
   <result pre="toxicity of a high dose (600 mg twice daily) of" exact="chloroquine" post="in treating COVID-19 patients. 47.Juurlink DN. Safety considerations with"/>
   <result pre="in treating COVID-19 patients. 47.Juurlink DN. Safety considerations with chloroquine," exact="hydroxychloroquine" post="and azithromycin in the management of SARS-CoV-2 infection. CMAJ."/>
   <result pre="COVID-19 patients. 47.Juurlink DN. Safety considerations with chloroquine, hydroxychloroquine and" exact="azithromycin" post="in the management of SARS-CoV-2 infection. CMAJ. 2020. 48.https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021251s058"/>
   <result pre="of hemorrhagic fever virus infectionsChem Asian J201914223962396810.1002/asia.20190084131389664 63.McClellanKPerryCMOseltamivirDrugs200161226328310.2165/00003495-200161020-0001111270942 64.WhitleyRJHaydenFGReisingerKSYoungNDutkowskiRIpeDet al.Oral" exact="oseltamivir" post="treatment of influenza in childrenPediatr Infect Dis J200120212713310.1097/00006454-200102000-0000211224828 65.WangDHuBHuCZhuFLiuXZhangJWangBXiangHChengZXiongYZhaoYLiYWangXPengZClinical"/>
   <result pre="virus inhibitors for drug repurposingACS Infect Dis20151731732610.1021/acsinfecdis.5b0003027622822 72.label Ua. US" exact="azithromycin" post="label. US azithromycin label. 2016 February Archived from the"/>
   <result pre="drug repurposingACS Infect Dis20151731732610.1021/acsinfecdis.5b0003027622822 72.label Ua. US azithromycin label. US" exact="azithromycin" post="label. 2016 February Archived from the original on 23"/>
   <result pre="from the original on 23 November 2016. 73.GautretPLagierJCParolaPHoangVTMeddebLMailheMDoudierBCourjonJGiordanengoVVieiraVEDupontHTHonoréSColsonPChabrièreEla ScolaBRolainJMBrouquiPRaoultDHydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infection. Med"/>
   <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infection. Med Mal Infect."/>
   <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infection Med"/>
   <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infection Med Mal Infect"/>
   <result pre="treatment for 2019-nCoV lung injuryLancet20203951022347347510.1016/S0140-6736(20)30317-232043983 84.VillarJBeldaJAnonJMBlancoJPerez-MendezLFerrandoCet al.Evaluating the efficacy of" exact="dexamethasone" post="in the treatment of patients with persistent acute respiratory"/>
   <result pre="ARDSRespir Med201814115015810.1016/j.rmed.2018.06.03030053961 95.KhanTASchnickelGRossDBastaniSLaksHEsmailianFMarelliDBeyguiRSheminRWatsonLVartapetianIArdehaliAA prospective, randomized, crossover pilot study of inhaled" exact="nitric oxide" post="versus inhaled prostacyclin in heart transplant and lung transplant"/>
   <result pre="treating acute respiratory distress syndromeTher Adv Respir Dis20159630231210.1177/175346581559934526294418 99.ChenLLiuPGaoHSunBChaoDWangFZhuYHedenstiernaGWangCGInhalation of" exact="nitric oxide" post="in the treatment of severe acute respiratory syndrome: a"/>
   <result pre="doi: https://clinicaltrials.gov. 101.Biospace. Mallinckrodt evaluates the potential role for inhaled" exact="nitric oxide" post="to treat COVID-19 associated lung complications, engages with scientific,"/>
   <result pre="H1N1 pneumonia and acute respiratory failureCrit Care Med201442231332110.1097/CCM.0b013e3182a2727d24105455 106.JiaXLiuBBaoLLvQLiFLiHet al.Delayed" exact="oseltamivir" post="plus sirolimus treatment attenuates H1N1 virus-induced severe lung injury"/>
   <result pre="and acute respiratory failureCrit Care Med201442231332110.1097/CCM.0b013e3182a2727d24105455 106.JiaXLiuBBaoLLvQLiFLiHet al.Delayed oseltamivir plus" exact="sirolimus" post="treatment attenuates H1N1 virus-induced severe lung injury correlated with"/>
   <result pre="repressed NLRP3 inflammasome activation and inflammatory cell infiltrationPLoS Pathog20181411e100742810.1371/journal.ppat.100742830422993 107.Adjunctive" exact="sirolimus" post="and oseltamivir versus oseltamivir alone for treatment of influenza."/>
   <result pre="inflammasome activation and inflammatory cell infiltrationPLoS Pathog20181411e100742810.1371/journal.ppat.100742830422993 107.Adjunctive sirolimus and" exact="oseltamivir" post="versus oseltamivir alone for treatment of influenza. https://ClinicalTrials.gov/show/NCT03901001. 108.ZhouYHouYShenJHuangYMartinWChengFNetwork-based"/>
   <result pre="and inflammatory cell infiltrationPLoS Pathog20181411e100742810.1371/journal.ppat.100742830422993 107.Adjunctive sirolimus and oseltamivir versus" exact="oseltamivir" post="alone for treatment of influenza. https://ClinicalTrials.gov/show/NCT03901001. 108.ZhouYHouYShenJHuangYMartinWChengFNetwork-based drug repurposing"/>
   <result pre="multicenter, randomized controlled trial for the efficacy and safety of" exact="tocilizumab" post="in the treatment of new coronavirus pneumonia (COVID-19). Chinese"/>
   <result pre="Registry. http://www.chictr.org.cn/showprojen.aspx?proj=49409. Accessed 04/16/2020. 110.Fu BX, Xiaoling, Wei, Haiming. Why" exact="tocilizumab" post="could be an effective treatment for severe COVID-19? J"/>
   <result pre="for an old drugJ Antimicrob Chemother20126781884189410.1093/jac/dks14722535622 135.YangSNYAtkinsonSCWangCLeeABogoyevitchMABorgNAJansDAThe broad spectrum antiviral" exact="ivermectin" post="targets the host nuclear transport importin alpha/beta1 heterodimerAntivir Res202017710476010.1016/j.antiviral.2020.10476032135219"/>
   <result pre="host nuclear transport importin alpha/beta1 heterodimerAntivir Res202017710476010.1016/j.antiviral.2020.10476032135219 136.CalyLDruceJDCattonMGJansDAWagstaffKMThe FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntivir Res202010478710478710.1016/j.antiviral.2020.104787 137.CaoJForrestJCZhangXA"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7212214\results\search\drugs\results.xml">
   <result pre="[4]. The combination of well-known HIV protease inhibitors, such as" exact="ritonavir" post="with lopinavir, has also been a common approach to"/>
   <result pre="is a reasonable strategy. Abelson tyrosine-protein kinase 2 (Abl2), the" exact="imatinib" post="target, was required for efficient SARS-CoV and MERS-CoV replication"/>
   <result pre="in vitro [6]. Coleman et al. have shown that the" exact="imatinib" post="target Abl2 is indispensable for efficient replication of SARS-CoV"/>
   <result pre="occurs late in infection [7]. The authors have shown that" exact="imatinib" post="and two specific Abl kinase inhibitors (GNF2 and GNF5)"/>
   <result pre="the 2020 pandemic. Taken together, repurposing the FDA-approved Abl2 inhibitors" exact="imatinib" post="and saracatinib should be clinically tested for their antiviral"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7212226\results\search\drugs\results.xml">
   <result pre="statins, while antiviral and antiretroviral drugs – favipiravir, nelfinavir, and" exact="lopinavir" post="– were used as standards for comparison. Results The"/>
   <result pre="favipiravir, nelfinavir, lopinavir, simvastatin, rosuvastatin, pravastatin, pitavastatin, lovastatin, fluvastatin, and" exact="atorvastatin" post="were –6.8, –5.8, –7.9, –7.9, –7.0, –7.7, –6.6, –8.2,"/>
   <result pre="the disease and organ damage are available. Although antimalarial drugs" exact="chloroquine" post="and hydroxychloroquine are used in some countries for the"/>
   <result pre="and organ damage are available. Although antimalarial drugs chloroquine and" exact="hydroxychloroquine" post="are used in some countries for the treatment of"/>
   <result pre="favipiravir, nelfinavir, lopinavir, simvastatin, rosuvastatin, pravastatin, pitavastatin, lovastatin, fluvastatin, and" exact="atorvastatin" post="were: –6.8, –5.8, –7.9, –7.9, –7.0, –7.7, –6.6, –8.2,"/>
   <result pre="based on the binding energy of pitavastatin, rosuvastatin, lovastatin, and" exact="fluvastatin" post="suggest that these statins might be potential COVID-19 Mpro"/>
   <result pre="1. Figure 1 Docking analysis visualisation of 6LU7 binding with" exact="atorvastatin" post="(A), fluvastatin (B), lovastatin (C), pitavastatin (D), pravastatin (E),"/>
   <result pre="1 Docking analysis visualisation of 6LU7 binding with atorvastatin (A)," exact="fluvastatin" post="(B), lovastatin (C), pitavastatin (D), pravastatin (E), rosuvastatin (F),"/>
   <result pre="analysis visualisation of 6LU7 binding with atorvastatin (A), fluvastatin (B)," exact="lovastatin" post="(C), pitavastatin (D), pravastatin (E), rosuvastatin (F), simvastatin (G),"/>
   <result pre="of 6LU7 binding with atorvastatin (A), fluvastatin (B), lovastatin (C)," exact="pitavastatin" post="(D), pravastatin (E), rosuvastatin (F), simvastatin (G), standard ligand"/>
   <result pre="binding with atorvastatin (A), fluvastatin (B), lovastatin (C), pitavastatin (D)," exact="pravastatin" post="(E), rosuvastatin (F), simvastatin (G), standard ligand (H), lopinavir"/>
   <result pre="atorvastatin (A), fluvastatin (B), lovastatin (C), pitavastatin (D), pravastatin (E)," exact="rosuvastatin" post="(F), simvastatin (G), standard ligand (H), lopinavir (I), favipiravir"/>
   <result pre="fluvastatin (B), lovastatin (C), pitavastatin (D), pravastatin (E), rosuvastatin (F)," exact="simvastatin" post="(G), standard ligand (H), lopinavir (I), favipiravir (J), and"/>
   <result pre="(D), pravastatin (E), rosuvastatin (F), simvastatin (G), standard ligand (H)," exact="lopinavir" post="(I), favipiravir (J), and nelfinavir (K) Discussion We performed"/>
   <result pre="simvastatin (G), standard ligand (H), lopinavir (I), favipiravir (J), and" exact="nelfinavir" post="(K) Discussion We performed an in silico molecular docking"/>
   <result pre="of statins on the main protease enzyme of SARS-CoV-2. Because" exact="pitavastatin" post="has already been shown to have a potent antiviral"/>
   <result pre="SARS-CoV-2 as well. Based upon our results, rosuvastatin, lovastatin, and" exact="fluvastatin" post="might also be useful in COVID-19 treatment. The limitation"/>
   <result pre="2 inhibitors may help us combat SARS-CoV-2Arch Med Sci20201651921 5GbinigieKFrieKShould" exact="chloroquine" post="and hydroxychloroquine be used to treat COVID-19? A rapid"/>
   <result pre="may help us combat SARS-CoV-2Arch Med Sci20201651921 5GbinigieKFrieKShould chloroquine and" exact="hydroxychloroquine" post="be used to treat COVID-19? A rapid reviewBJGP Open202010.3399/bjgpopen20X101069"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7212361\results\search\drugs\results.xml">
   <result pre="profile. In the context of HIV-1, Roy et al. complexed" exact="efavirenz" post="(EFV), an effective non-nucleoside RTI, to a nanodiamond to"/>
   <result pre="HIV-1 infection but requires daily oral administration (106). PrEP comprises" exact="tenofovir" post="disoproxil fumarate (TDF) and emtricitabine (FTC), two nucleoside RTIs"/>
   <result pre="oral administration (106). PrEP comprises tenofovir disoproxil fumarate (TDF) and" exact="emtricitabine" post="(FTC), two nucleoside RTIs that have low half-lives and"/>
   <result pre="prevent HIV-1 infection. In another study, Mandal et al. encapsulated" exact="dolutegravir" post="(DTG), an integrase strand transfer inhibitor, within nanoparticles made"/>
   <result pre="Invest. (2017) 127:857–73. 10.1172/JCI9002528134625 39.SmithNBadeANSoniDGautamNAlnoutiYHerskovitzJet al.. A long acting nanoformulated" exact="lamivudine" post="ProTide. Biomaterials. (2019) 223:119476. 10.1016/j.biomaterials.2019.11947631525692 40.GuoDZhouTAraingaMPalandriDGautamNBronichTet al.. Creation of"/>
   <result pre="10.1097/QAD.000000000000042125102089 42.PrathipatiPKMandalSPonGVivekanandanRDestacheCJ. Pharmacokinetic and tissue distribution profile of long acting" exact="tenofovir" post="alafenamide and elvitegravir loaded nanoparticles in humanized mice model."/>
   <result pre="and tissue distribution profile of long acting tenofovir alafenamide and" exact="elvitegravir" post="loaded nanoparticles in humanized mice model. Pharm Res. (2017)"/>
   <result pre="Res. (2017) 34:2749–55. 10.1007/s11095-017-2255-728905173 43.KumarPLakshmiYSKondapiAK. Triple drug combination of zidovudine," exact="efavirenz" post="and lamivudine loaded lactoferrin nanoparticles: an effective nano first-line"/>
   <result pre="34:2749–55. 10.1007/s11095-017-2255-728905173 43.KumarPLakshmiYSKondapiAK. Triple drug combination of zidovudine, efavirenz and" exact="lamivudine" post="loaded lactoferrin nanoparticles: an effective nano first-line regimen for"/>
   <result pre="infection. Antimicrob Agents Chemother. (2017) 61:e01475-16. 10.1128/AAC.01475-1627821449 71.DestacheCJMandalSYuanZKangGBDateAALuWXet al.. Topical" exact="tenofovir" post="disoproxil fumarate nanoparticles prevent HIV-1 vaginal transmission in a"/>
   <result pre="Trans Med. (2012) 4:151ra125. 10.1126/scitranslmed.300400622972843 107.ValadeETreluyerJMBouazzaNGhosnJFoissacFBenaboudSet al.. Population pharmacokinetics of" exact="emtricitabine" post="in HIV-1-infected adult patients. Antimicrob Agents Chemother. (2014) 58:2256–61."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7212536\results\search\drugs\results.xml">
   <result pre="being used by clinicians and recent recommended combination therapy of" exact="hydroxychloroquine" post="and azithromycin was studied and its results of open"/>
   <result pre="by clinicians and recent recommended combination therapy of hydroxychloroquine and" exact="azithromycin" post="was studied and its results of open labelled non"/>
   <result pre="COVID-19. And upon certain ​in vitro and some clinical data" exact="chloroquine" post="phosphate and hydroxychloroquine sulphate was advised to be the"/>
   <result pre="certain ​in vitro and some clinical data chloroquine phosphate and" exact="hydroxychloroquine" post="sulphate was advised to be the treatment for COVID-19"/>
   <result pre="09 March 2020). But recent studies have shown that the" exact="hydroxychloroquine" post="can also cause drug poisoning and severe or moderate"/>
   <result pre="are found to be affected severely by COVID-19. Administration of" exact="hydroxychloroquine" post="has found to inhibit pro-inflammatory cytokines which finally leads"/>
   <result pre="that adverse neuropsychiatric condition was seen in post treatment of" exact="hydroxychloroquine" post="which is hypothesized that it specifies the lysosomal dysfunction"/>
   <result pre="seen in patient with acute renal impairment when administered with" exact="hydroxychloroquine" post="(Tailor et al., 2012). A study of high doses"/>
   <result pre="(Tailor et al., 2012). A study of high doses of" exact="hydroxychloroquine" post="along with atorvastatin in diabetic patients showed highest decline"/>
   <result pre="2012). A study of high doses of hydroxychloroquine along with" exact="atorvastatin" post="in diabetic patients showed highest decline of blood glucose"/>
   <result pre="glucose in patients (Wondafrash et al., 2020). When Antimalarial drug," exact="hydroxychloroquine" post="when administered to patients with dermatomyosis, non-life threatening cutaneous"/>
   <result pre="to provide cure for this dreadful viral outbreak. Hydroxychloroquine and" exact="azithromycin" post="complex is being advised to be given for the"/>
   <result pre="&amp;amp; Gallagher, 2012; Vincent et al., 2005). The Hydroxychloroquine and" exact="azithromycin" post="complex mentioned above may be potent, but the adverse"/>
   <result pre="recently proposed combination of three drugs namely, lopinavir, ostelmivir and" exact="ritonavir" post="whose binding scores are -4.1Kcal/mol,-4.65 Kcal/mol and -5.11 Kcal/mol (Muralidharan et"/>
   <result pre="ChabrièreE., La ScolaB., RolainJ., BrouquiP., &amp;amp; RaoultD. (2020). Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: Results of an open-label"/>
   <result pre="(2020). Computational studies of drug repurposing and synergism of lopinavir," exact="oseltamivir" post="and ritonavir binding with SARS-Cov-2 protease against COVID-19. Journal"/>
   <result pre="studies of drug repurposing and synergism of lopinavir, oseltamivir and" exact="ritonavir" post="binding with SARS-Cov-2 protease against COVID-19. Journal of Biomolecular"/>
   <result pre="LiuJ., XuM., ShiZ., HuZ., ZhongW., &amp;amp; XiaoG. (2020). Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="antiviral2\PMC7212541\results\search\drugs\results.xml">
   <result pre="based on Chinese patients. KEYWORDS COVID-19 asymptomatic adverse drug reaction" exact="lopinavir" post="ritonavir arbidol IFN-α Funding This paper was not funded."/>
   <result pre="on Chinese patients. KEYWORDS COVID-19 asymptomatic adverse drug reaction lopinavir" exact="ritonavir" post="arbidol IFN-α Funding This paper was not funded. fig-count:"/>
   <result pre="the HIV gag-pol polyprotein from splitting. The action site of" exact="ritonavir" post="is aspartyl protease of the virus, blocking the precursor"/>
   <result pre="together, resulting in immature virus particles without regeneration capability. Moreover," exact="ritonavir" post="is also an enhancer of lopinavir, which can inhibit"/>
   <result pre="enhancer of lopinavir, which can inhibit the CYP3A-mediated degradation of" exact="lopinavir" post="in the liver [4]. Two SARS-based clinical studies [5,6]"/>
   <result pre="hospitalization or death for reasons other than COVID-19 infection. Besides," exact="lopinavir" post="and ritonavir, both inhibitors of CYP3A, may increase the"/>
   <result pre="the occurrence of adverse drug reactions may increase. Lopinavir and" exact="ritonavir" post="also have certain inhibition effects on ATP-binding cassette subfamily"/>
   <result pre="insufficiency, it should be noted that blood drug concentration of" exact="lopinavir" post="showed a rapid increase in the patients with liver"/>
   <result pre="necessity of therapeutic drug monitoring of lopinavir. Therapeutic concentration of" exact="lopinavir" post="was 3–8 mg/L, and toxic concentration was above 8"/>
   <result pre="at the conventional dosage because the renal clearance rate of" exact="lopinavir" post="and ritonavir is extremely low. Moreover, both lopinavir and"/>
   <result pre="conventional dosage because the renal clearance rate of lopinavir and" exact="ritonavir" post="is extremely low. Moreover, both lopinavir and ritonavir have"/>
   <result pre="rate of lopinavir and ritonavir is extremely low. Moreover, both" exact="lopinavir" post="and ritonavir have strong protein﻿-binding capacity, so hemodialysis will"/>
   <result pre="lopinavir and ritonavir is extremely low. Moreover, both lopinavir and" exact="ritonavir" post="have strong protein﻿-binding capacity, so hemodialysis will not affect"/>
   <result pre="few reports of old people treated with lopinavir/ritonavir, yet the" exact="lopinavir" post="plasma level in the elderly seems to be higher"/>
   <result pre="of Omrani et al. demonstrated that the combination therapy of" exact="ribavirin" post="and IFN-α2a inhalation can improve the early and intermediate"/>
   <result pre="antipyretic effect, and anti-inflammatory effect and is even superior to" exact="oseltamivir" post="in improving the symptoms of influenza infection [36,37]. Lianhuaqingwen"/>
   <result pre="of patients. Whether the western medicine lopinavir/ritonavir, remdesivir, arbidol, and" exact="chloroquine" post="or traditional Chinese medicine with antiviral activity has caused"/>
   <result pre="2020 28]Available from: http://www.gov.cn/zhengce/zhengceku/2020-02/09/5476407/files/765d1e65b7d1443081053c29ad37fb07.pdf 4.The instruction of Alltera (lopinavir and" exact="ritonavir" post="tablets). •• The drug interactions and adverse reactions of"/>
   <result pre="Thorax. 2004;59(3):252–256.14985565 7.KimUJ, WonEJ, KeeSJ, et alCombination therapy with lopinavir/ritonavir," exact="ribavirin" post="and interferon-α for Middle East respiratory syndrome. Antivir Ther."/>
   <result pre="11.WatebaMI, BillaudE, DaillyE, et alLow initial trough plasma concentrations of" exact="lopinavir" post="are associated with an impairment of virological response in"/>
   <result pre="2006;7(3):197–199.16494635 12.GuptaSK, RosenkranzSL, CramerYS, et alThe pharmacokinetics and pharmacogenomics of" exact="efavirenz" post="and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis. AIDS. 2008;22(15):1911–1927."/>
   <result pre="1991;337(8737):371. 20.FalzaranoD, de WitE, RasmussenAL, et alTreatment with interferon-α2b and" exact="ribavirin" post="improves outcome in MERS-CoV-infected rhesus macaques. Nat Med. 2013;19(10):1313–1317.24013700"/>
   <result pre="36.ZhaoP, YangHZ, LvHY, et alEfficacy of Lianhuaqingwen capsule compared with" exact="oseltamivir" post="for influenza A virus infection: a meta-analysis of randomized,"/>
  </snippets>
 </snippetsTree>
</projectSnippetsTree>
